FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Kasckow, J Brown, C Morse, J Begley, A Bensasi, S Reynolds, C AF Kasckow, John Brown, Charlotte Morse, Jennifer Begley, Amy Bensasi, Salem Reynolds, Charles TI Comorbidity in Older Subsyndromally Depressed Participants Presenting for a Depression Prevention SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 18-21, 2011 CL San Antonio, TX SP Amer Assoc Geriat Psychiat C1 [Kasckow, John] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Kasckow, John; Brown, Charlotte; Morse, Jennifer; Begley, Amy; Bensasi, Salem; Reynolds, Charles] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2011 VL 19 IS 3 SU 1 BP S106 EP S107 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 753PD UT WOS:000289791000119 ER PT J AU Kasckow, J Cohen, CI Vahia, I Jeste, DV AF Kasckow, John Cohen, Carl I. Vahia, Ipsit Jeste, Dilip V. TI LATE LIFE SCHIZOPHRENIA: RECENT ADVANCES SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 18-21, 2011 CL San Antonio, TX SP Amer Assoc Geriat Psychiat C1 [Kasckow, John] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Kasckow, John] UPMC Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Vahia, Ipsit; Jeste, Dilip V.] Univ Calif San Diego, San Diego, CA 92103 USA. [Cohen, Carl I.] Suny Downstate Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2011 VL 19 IS 3 SU 1 BP S26 EP S27 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 753PD UT WOS:000289791000028 ER PT J AU Lewis, MS Huege, S Boyle, LL Harmon, AA AF Lewis, Monica S. Huege, Steven Boyle, Lisa L. Harmon, Ashley A. TI THE NEW FRONTIER: MOVING GERIATRIC PSYCHIATRY FELLOWSHIP TRAINING INTO COMMUNITY INTERDISCIPLINARY SETTINGS SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 18-21, 2011 CL San Antonio, TX SP Amer Assoc Geriat Psychiat C1 [Lewis, Monica S.; Huege, Steven] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Boyle, Lisa L.; Harmon, Ashley A.] Univ Rochester, Sch Med & Dent, Rochester, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2011 VL 19 IS 3 SU 1 BP S13 EP S13 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 753PD UT WOS:000289791000009 ER PT J AU Peters, ME Vaidya, V Drye, LT Rosenberg, P Martin, BK Porsteinsson, AP Frangakis, CE Mintzer, J Weintraub, D Schneider, LS Rabins, PV Munro, CA Meinert, CL Lyketsos, C Avramopoulos, D AF Peters, Matthew E. Vaidya, Vijay Drye, Lea T. Rosenberg, Paul Martin, Barbara K. Porsteinsson, Anton P. Frangakis, Constantine E. Mintzer, Jacobo Weintraub, Daniel Schneider, Lon S. Rabins, Peter V. Munro, Cynthia A. Meinert, Curtis L. Lyketsos, Constantine Avramopoulos, Dimitrios TI Sertraline for the Treatment of Depression in Alzheimer's Disease: Genetic Influences SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 18-21, 2011 CL San Antonio, TX SP Amer Assoc Geriat Psychiat C1 [Peters, Matthew E.; Vaidya, Vijay; Drye, Lea T.; Rosenberg, Paul; Martin, Barbara K.; Frangakis, Constantine E.; Rabins, Peter V.; Munro, Cynthia A.; Meinert, Curtis L.; Lyketsos, Constantine; Avramopoulos, Dimitrios] Johns Hopkins Univ, Baltimore, MD USA. [Porsteinsson, Anton P.] Univ Rochester, Rochester, NY USA. [Mintzer, Jacobo] Med Univ S Carolina, Charleston, SC 29425 USA. [Weintraub, Daniel] Philadelphia Veteran Affairs Med Ctr, Philadelphia, PA USA. [Schneider, Lon S.] Univ So Calif, Los Angeles, CA USA. RI Avramopoulos, Dimitrios/J-4392-2012 NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2011 VL 19 IS 3 SU 1 BP S67 EP S68 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 753PD UT WOS:000289791000066 ER PT J AU Ravven, S Schultz, SK Driver, JA AF Ravven, Simha Schultz, Susan K. Driver, Jane A. TI Cancer Treatment for People with Mental Illness: A Systematic Review of the Literature SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 18-21, 2011 CL San Antonio, TX SP Amer Assoc Geriat Psychiat C1 [Ravven, Simha] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Schultz, Susan K.] Univ Iowa Hosp & Clin, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA. [Driver, Jane A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Aging,Dept Med, Boston, MA 02115 USA. [Driver, Jane A.] VA Boston Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2011 VL 19 IS 3 SU 1 BP S97 EP S98 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 753PD UT WOS:000289791000109 ER PT J AU Royall, DR Cordes, JA AF Royall, Donald R. Cordes, Jeffrey A. TI LEWY BODY DISEASE: THE UNDISCOVERED COUNTRY SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 18-21, 2011 CL San Antonio, TX SP Amer Assoc Geriat Psychiat C1 [Royall, Donald R.] UTHSCSA, San Antonio, TX USA. [Cordes, Jeffrey A.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2011 VL 19 IS 3 SU 1 BP S39 EP S39 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 753PD UT WOS:000289791000045 ER PT J AU Seney, M Devlin, B Ferrell, R Klei, L Lopez, OL Seltman, H Sibille, E Sweet, RA AF Seney, Marianne Devlin, Bernie Ferrell, Robert Klei, Lambertus Lopez, Oscar L. Seltman, Howard Sibille, Etienne Sweet, Robert A. TI Association of NRG1 Genetic Variants with Psychosis in Alzheimer Disease and with Brain Expression of Neuregulin Isoforms SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 18-21, 2011 CL San Antonio, TX SP Amer Assoc Geriat Psychiat C1 [Seney, Marianne; Devlin, Bernie; Ferrell, Robert; Klei, Lambertus; Lopez, Oscar L.; Sibille, Etienne; Sweet, Robert A.] Univ Pittsburgh, Pittsburgh, PA USA. [Sweet, Robert A.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Seltman, Howard] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2011 VL 19 IS 3 SU 1 BP S125 EP S126 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 753PD UT WOS:000289791000150 ER PT J AU Spira, AP Rebok, GW Stone, KL Kramer, JH Yaffe, K AF Spira, Adam P. Rebok, George W. Stone, Katie L. Kramer, Joel H. Yaffe, Kristine TI Depressive Symptoms in Oldest-Old Women: Risk of Mild Cognitive Impairment and Dementia SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 18-21, 2011 CL San Antonio, TX SP Amer Assoc Geriat Psychiat C1 [Spira, Adam P.; Rebok, George W.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Stone, Katie L.] Calif Pacific Med Ctr Res Inst, San Francisco, CA USA. [Kramer, Joel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2011 VL 19 IS 3 SU 1 BP S56 EP S57 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 753PD UT WOS:000289791000055 ER PT J AU Sultzer, D Melrose, RJ Harwood, DG Campa, O Walston, A Narvaez, T Ando, T Leskin, LS Mandelkern, MA AF Sultzer, David Melrose, Rebecca J. Harwood, Dylan G. Campa, Olivia Walston, Amy Narvaez, Theresa Ando, Timothy Leskin, Lorraine S. Mandelkern, Mark A. TI Donepezil Treatment Effects on Regional Cortical Metabolism in Alzheimer's Disease: FDG-PET Findings SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 18-21, 2011 CL San Antonio, TX SP Amer Assoc Geriat Psychiat C1 [Sultzer, David; Melrose, Rebecca J.; Harwood, Dylan G.; Campa, Olivia; Walston, Amy; Narvaez, Theresa; Ando, Timothy; Leskin, Lorraine S.; Mandelkern, Mark A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Sultzer, David; Melrose, Rebecca J.; Harwood, Dylan G.; Walston, Amy] UCLA Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2011 VL 19 IS 3 SU 1 BP S124 EP S125 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 753PD UT WOS:000289791000148 ER PT J AU Threlfall, AW Nie, PH Moreno, A Young, JQ Nelson, C AF Threlfall, Alexander W. Nie, Pei-Huey Moreno, Arnaldo Young, John Q. Nelson, Craig TI From Academia to the Community: a Proposed Library for Use in Disseminating Evidenced Based Medicine into Underserved Areas of Geriatric Psychiatry SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 18-21, 2011 CL San Antonio, TX SP Amer Assoc Geriat Psychiat C1 [Threlfall, Alexander W.; Nie, Pei-Huey; Moreno, Arnaldo; Young, John Q.; Nelson, Craig] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Moreno, Arnaldo] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2011 VL 19 IS 3 SU 1 BP S81 EP S82 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 753PD UT WOS:000289791000086 ER PT J AU Long, AA AF Long, Aidan A. TI The Burden of Asthma and Improving Patient Outcomes SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID RISK-FACTORS; ADULTS; VALIDATION AB Asthma is a significant national burden owing to patient morbidity and mortality, rising healthcare costs, and employee absenteeism. The National Asthma Education and Prevention Program (NAEPP) guidelines were created to improve the diagnosis and treatment of asthma, and stress 4 central components for the management of asthma:(1) measures of assessment and monitoring (obtained by patient history and patient reports; physical examinations and objective tests to confirm, diagnose, and assess severity of asthma initially, and to monitor asthma control subsequently); (2) education for a partnership in asthma care; (3) a focus on control of environmental factors and comorbid conditions that affect asthma; and (4) evidence-based decision making about pharmacologic therapy. The NAEPP guidelines recommend step-up and step-down programs for pharmacologic therapy. There are several barriers to effective asthma control. Treatment adherence in patients with asthma is suboptimal. Moreover, clinicians may not completely adhere to treatment guidelines. Finally, insurance companies may indirectly contribute to poor guideline adherence by failing to adequately recognize the time required to educate patients on asthma and develop a partnership for success, as requested by the guidelines. Successful asthma management requires effort by all parties involved, with the ultimate goal of improved outcomes, including reduced medical complications and costs. (Am J Manag Care. 2011;17:S75-S81) C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Long, AA (reprint author), Massachusetts Gen Hosp, Cox 201,55 Fruit St, Boston, MA 02114 USA. EM aalong@partners.org FU Merck Co, Inc. FX Financial support for this work was provided by Merck & Co, Inc. NR 21 TC 9 Z9 10 U1 0 U2 1 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD MAR PY 2011 VL 17 IS 3 SU S BP S75 EP S81 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 755GM UT WOS:000289915900001 PM 21761957 ER PT J AU Li, JQ Feng, RQ Yan, WJ Jiang, JM Chen, JT Guo, J Bringhurst, FR Yang, DH AF Li, Junqing Feng, Ruiqiang Yan, Wenjuan Jiang, Jianming Chen, Jianting Guo, Jun Bringhurst, F. Richard Yang, Dehong TI PTH ACTIVATES PKC VIA PLC-INDEPENDENT SIGNALING PATHWAY: FRET ANALYSIS SO OSTEOPOROSIS INTERNATIONAL LA English DT Meeting Abstract CT 1st IOF-ESCEO Pre-Clinical Symposium CY MAR 23-26, 2011 CL Valencia, SPAIN C1 [Li, Junqing; Feng, Ruiqiang; Jiang, Jianming; Chen, Jianting; Yang, Dehong] So Med Univ, Nanfang Hosp, Dept Spinal & Orthoped Surg, Guangzhou, Guangdong, Peoples R China. [Yan, Wenjuan] So Med Univ, Nanfang Hosp, Dept Stomatol, Guangzhou, Guangdong, Peoples R China. [Guo, Jun; Bringhurst, F. Richard] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. NR 0 TC 31 Z9 31 U1 0 U2 2 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD MAR PY 2011 VL 22 SU 1 BP 22 EP 23 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 738SI UT WOS:000288662000035 ER PT J AU Simic, P Zainabadi, K Gong, JJ Bell, E Adams, E Schipani, E Lotinun, S Baron, R Guarente, L AF Simic, Petra Zainabadi, Kayvan Gong, Jing Jing Bell, Eric Adams, Elisabeth Schipani, Erestina Lotinun, Sutada Baron, Roland Guarente, Leonard TI THE ROLE OF SIRT-1 IN MESENCHYMAL STEM CELLS SO OSTEOPOROSIS INTERNATIONAL LA English DT Meeting Abstract CT 1st IOF-ESCEO Pre-Clinical Symposium CY MAR 23-26, 2011 CL Valencia, SPAIN C1 [Simic, Petra; Zainabadi, Kayvan; Gong, Jing Jing; Bell, Eric; Adams, Elisabeth; Guarente, Leonard] MIT, Dept Biol, Cambridge, MA USA. [Schipani, Erestina] Massachusetts Gen Hosp, Dept Endocrinol, Boston, MA 02114 USA. [Lotinun, Sutada; Baron, Roland] Harvard Univ, Sch Dent Med Oral Med Infect & Immun, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD MAR PY 2011 VL 22 SU 1 BP 48 EP 48 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 738SI UT WOS:000288662000082 ER PT J AU Li, JQ Feng, RQ Yan, WJ Jiang, JM Chen, JT Guo, J Bringhurst, FR Yang, DH AF Li, Junqing Feng, Ruiqiang Yan, Wenjuan Jiang, Jianming Chen, Jianting Guo, Jun Bringhurst, F. Richard Yang, Dehong TI PTH ACTIVATES PKC VIA PLC-INDEPENDENT SIGNALING PATHWAY: FRET ANALYSIS SO OSTEOPOROSIS INTERNATIONAL LA English DT Meeting Abstract CT 1st IOF-ESCEO Pre-Clinical Symposium CY MAR 23-26, 2011 CL Valencia, SPAIN C1 [Li, Junqing; Feng, Ruiqiang; Jiang, Jianming; Chen, Jianting; Yang, Dehong] So Med Univ, Dept Spinal & Orthoped Surg, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China. [Yan, Wenjuan] So Med Univ, Dept Stomatol, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China. [Guo, Jun; Bringhurst, F. Richard] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD MAR PY 2011 VL 22 SU 1 BP 190 EP 190 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 738SI UT WOS:000288662000318 ER PT J AU Simic, P Zainabadi, K Gong, JJ Bell, E Schipani, E Lotinun, S Baron, R Guarente, L AF Simic, Petra Zainabadi, Kayvan Gong, Jing Jing Bell, Eric Schipani, Erestina Lotinun, Sutada Baron, Roland Guarente, Leonard TI THE ROLE OF SIRT-1 IN MESENCHYMAL STEM CELLS SO OSTEOPOROSIS INTERNATIONAL LA English DT Meeting Abstract CT 1st IOF-ESCEO Pre-Clinical Symposium CY MAR 23-26, 2011 CL Valencia, SPAIN C1 [Simic, Petra; Zainabadi, Kayvan; Gong, Jing Jing; Bell, Eric; Guarente, Leonard] MIT, Dept Biol, Cambridge, MA USA. [Schipani, Erestina] Massachusetts Gen Hosp, Dept Endocrinol, Boston, MA 02114 USA. [Lotinun, Sutada; Baron, Roland] Harvard Univ, Sch Dent Med Oral Med Infect & Immun, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD MAR PY 2011 VL 22 SU 1 BP 297 EP 298 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 738SI UT WOS:000288662000532 ER PT J AU Simic, P Zainabadi, K Gong, JJ Bell, E Adams, E Schipani, E Lotinun, S Baron, R Guarente, L AF Simic, Petra Zainabadi, Kayvan Gong, Jing Jing Bell, Eric Adams, Elisabeth Schipani, Erestina Lotinun, Sutada Baron, Roland Guarente, Leonard TI THE ROLE OF SIRT-1 IN MESENCHYMAL STEM CELLS SO OSTEOPOROSIS INTERNATIONAL LA English DT Meeting Abstract CT 1st IOF-ESCEO Pre-Clinical Symposium CY MAR 23-26, 2011 CL Valencia, SPAIN C1 [Simic, Petra; Zainabadi, Kayvan; Gong, Jing Jing; Bell, Eric; Adams, Elisabeth; Guarente, Leonard] MIT, Dept Biol, Cambridge, MA USA. [Schipani, Erestina] Massachusetts Gen Hosp, Dept Endocrinol, Boston, MA 02114 USA. [Lotinun, Sutada; Baron, Roland] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD MAR PY 2011 VL 22 SU 1 BP 330 EP 330 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 738SI UT WOS:000288662000596 ER PT J AU Sharp, ZD Richardson, A AF Sharp, Zelton Dave Richardson, Arlan TI Aging and cancer: can mTOR inhibitors kill two birds with one drug? SO TARGETED ONCOLOGY LA English DT Review DE mTORC1; Aging and cancer; Health span ID LIFE-SPAN EXTENSION; MESSENGER-RNA TRANSLATION; AMES DWARF MICE; FATAL NEOPLASTIC DISEASES; EIF2-ALPHA KINASE GCN2; CALORIE RESTRICTION; DIETARY RESTRICTION; GROWTH-HORMONE; C-ELEGANS; SACCHAROMYCES-CEREVISIAE AB The main risk factor for a number of diseases, including cancer, is aging. By delaying the effects of aging, many years of research indicate that diseases associated with aging are reduced by prolongevity interventions such as reductions in caloric intake and mice genetically deficient for growth factors. Although studies of dietary and growth factor restriction have been highly informative regarding the aging process, they are both unrealistic for human application. Recent preclinical results with a pharmacological prolongevity agent (rapamycin) provide a proof-of-concept that such an approach is feasible in human populations. Exactly how rapamycin works to extend lifespan is under increasingly intense investigation. In addition, these studies underscore the critical role that the intracellular target of rapamycin (TOR) plays in one of the deepest mysteries of life, aging. How age-associated diseases interface with TOR and its signaling systems, and the tremendous opportunities for discovery of new drugs that target both aging and its associated diseases is one of the most exciting areas of research currently being conducted in this new era of aging research. C1 [Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA. [Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Richardson, Arlan] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Sharp, ZD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA. EM sharp@uthscsa.edu FU National Institutes of Health (NIH) [AG036613, AG13319]; Glenn Foundation; Department of Veterans Affairs FX Work in Z. D. Sharp's laboratory is supported by a RC2 Grand Opportunity grant (AG036613) from the National Institutes of Health (NIH) and by the Glenn Foundation, and work in A. Richardson's laboratory supported by a RC2 Grand Opportunity (AG036613) and a P30-Shock Center of Excellence in Basic Biology of Aging (AG13319) grants from the NIH and a Research Enhancement Award Program grant from the Department of Veterans Affairs. NR 121 TC 15 Z9 15 U1 0 U2 8 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1776-2596 J9 TARGET ONCOL JI Target. Oncol. PD MAR PY 2011 VL 6 IS 1 BP 41 EP 51 DI 10.1007/s11523-011-0168-7 PG 11 WC Oncology SC Oncology GA 760KQ UT WOS:000290323600005 PM 21394528 ER PT J AU Chen, K Chen, KH Muller, HG Wang, JL AF Chen, Kun Chen, Kehui Mueller, Hans-Georg Wang, Jane-Ling TI Stringing High-Dimensional Data for Functional Analysis SO JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION LA English DT Article DE Functional Cox model; Functional data analysis; Gene expression; High-dimensional predictors; Multidimensional scaling; Prediction; Tree rings ID LONGITUDINAL DATA; SURVIVAL; CLASSIFICATION; REDUCTION; CURVES; GROWTH AB We propose stringing, a class of methods where one views high-dimensional observations as functional data. Stringing takes advantage of the high dimension by representing such data as discretized and noisy observations that originate from a hidden smooth stochastic process. Assuming that the observations result from scrambling the original ordering of the observations of the process, stringing reorders the components of the high-dimensional vectors, followed by transforming the high-dimensional vector observations into functional data. Established techniques from functional data analysis can be applied for further statistical analysis once an underlying stochastic process and the corresponding random trajectory for each subject have been identified. Stringing of high-dimensional data is implemented with distance based metric multidimensional scaling, mapping high-dimensional data to locations on a real interval, such that predictors that are close in a suitable sample metric also are located close to each other on the interval. We provide some theoretical support, showing that under certain assumptions, an underlying stochastic process can be constructed asymptotically, as the dimension p of the data tends to infinity. Stringing is illustrated for the analysis of tree ring data and for the prediction of survival time from high-dimensional gene expression data and is shown to lead to new insights. In regression applications involving high-dimensional predictors, stringing compares favorably with existing methods. The theoretical results and proofs and also additional simulation results are provided in online Supplemental Material. C1 [Chen, Kun] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chen, Kehui; Mueller, Hans-Georg; Wang, Jane-Ling] Univ Calif Davis, Dept Stat, Davis, CA 95616 USA. RP Chen, K (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM kellychenk@gmail.com; kehchen@ucdavis.edu; mueller@wald.ucdavis.edu; wang@wald.ucdavis.edu FU NSF [DMS-05-05537, DMS-08-06199, DMS-09-06813]; Statistical and Mathematical Sciences Institute (SAMSI), Triangle Park, NC FX Kun Chen is Research Associate Biostatistician, Dana-Farber Cancer Institute, 44 Binney Street Boston, MA 02115 (E-mail: kellychenk@gmail.com). Kehui Chen is Ph.D. Candidate (E-mail: kehchen@ucdavis.edu), Hans-Georg Muller is Professor (E-mail: mueller@wald.ucdavis.edu), and Jane-Ling Wang is Professor (E-mail: wang@wald.ucdavis.edu), Department of Statistics, University of California, Davis, One Shields Avenue, Davis, CA 95616. We thank the Editor, art Associate Editor, and two referees for constructive critiques which led to many improvements in the article and to the Editor for pointing out connections with Andrew's plots. This research was supported by NSF grants DMS-05-05537, DMS-08-06199, and DMS-09-06813. H.G.M. and J.L.W. gratefully acknowledge support from the Statistical and Mathematical Sciences Institute (SAMSI), Triangle Park, NC, during the revision of this article. NR 30 TC 7 Z9 7 U1 2 U2 8 PU AMER STATISTICAL ASSOC PI ALEXANDRIA PA 732 N WASHINGTON ST, ALEXANDRIA, VA 22314-1943 USA SN 0162-1459 J9 J AM STAT ASSOC JI J. Am. Stat. Assoc. PD MAR PY 2011 VL 106 IS 493 BP 275 EP 284 DI 10.1198/jasa.2011.tm10314 PG 10 WC Statistics & Probability SC Mathematics GA 754QI UT WOS:000289871200024 ER PT J AU Walther, K Bendlin, BB Glisky, EL Trouard, TP Lisse, JR Posever, JO Ryan, L AF Walther, K. Bendlin, B. B. Glisky, E. L. Trouard, T. P. Lisse, J. R. Posever, J. O. Ryan, L. TI Anti-inflammatory drugs reduce age-related decreases in brain volume in cognitively normal older adults SO NEUROBIOLOGY OF AGING LA English DT Article DE Aging; Alzheimer's disease; Voxel-based morphometry; Magnetic resonance imaging; Anti-inflammatory agents ID RANDOMIZED CONTROLLED-TRIAL; VOXEL-BASED MORPHOMETRY; ALZHEIMERS-DISEASE; NSAID USE; RISK; MRI; DEMENTIA; ATROPHY; APOE; INFLAMMATION AB Previous studies have indicated a decreased risk for developing Alzheimer's disease in anti-inflammatory (AI) drug users. Yet few studies have determined whether AT drug use provides a protective effect against normal age-related changes in the brains of older adults. Regional volume changes in gray and white matter were assessed cross-sectionally using optimized voxel-based morphometry in 36 females taking AT drugs as arthritis or pain medication and 36 age- and education-matched female controls. Although mean gray and white matter volume differences between AT drug users and the non-AI group were small, AT drug use interacted with age, such that the non-AI group showed significantly greater age-related volume changes in regions of both gray and white matter compared to the AT drug users. These regions included the superior and medial frontal gyri, middle and inferior temporal gyri, fusiform and parahippocampal gyri, and occipital gray matter as well as temporal, parietal, and midbrain white matter. The results are consistent with the notion that AT drugs provide protection against age-related changes in brain volume. It is possible that inflammation plays a role in volume decreases associated with normal aging, and that suppressing the inflammatory response moderates this decrease. (C) 2009 Elsevier Inc. All rights reserved. C1 [Walther, K.; Glisky, E. L.; Ryan, L.] Univ Arizona, Dept Psychol, Cognit Lab, Tucson, AZ 85721 USA. [Walther, K.; Glisky, E. L.; Ryan, L.] Univ Arizona, Dept Psychol, Neuroimaging Lab, Tucson, AZ 85721 USA. [Bendlin, B. B.] Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53705 USA. [Bendlin, B. B.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. [Trouard, T. P.] Univ Arizona, Biomed Engn Program, Tucson, AZ 85721 USA. [Lisse, J. R.] Univ Arizona, Coll Med, Arizona Arthrit Ctr, Tucson, AZ 85724 USA. [Posever, J. O.] Phoenix Indian Med Ctr, Phoenix, AZ 85016 USA. RP Ryan, L (reprint author), Univ Arizona, Dept Psychol, Cognit Lab, POB 210068, Tucson, AZ 85721 USA. EM ryant@email.arizona.edu OI Bendlin, Barbara/0000-0002-0580-9875 FU Arizona Biomedical Research Commission; Arizona Alzheimer's Research Consortium [HB 2354]; Evelyn F. McKnight Brain Institute FX The project was supported by the Arizona Biomedical Research Commission, the Arizona Alzheimer's Research Consortium (HB 2354, Dept. of Health Services, Arizona), and the Evelyn F. McKnight Brain Institute. We would like to thank the Arizona Arthritis Center at the University Medical Center in Tucson, Arizona for their cooperation and support. We thank Ms. Kristina Irwin for coordinating and administering neuropsychological testing. NR 43 TC 15 Z9 15 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD MAR PY 2011 VL 32 IS 3 BP 497 EP 505 DI 10.1016/j.neurobiolaging.2009.03.006 PG 9 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 755PE UT WOS:000289944800013 PM 19386384 ER PT J AU Bekris, LM Galloway, NM Millard, S Lockhart, D Li, G Galasko, DR Farlow, MR Clark, CM Quinn, JF Kaye, JA Schellenberg, GD Leverenz, JB Seubert, P Tsuang, DW Peskind, ER Yu, CE AF Bekris, L. M. Galloway, N. M. Millard, S. Lockhart, D. Li, G. Galasko, D. R. Farlow, M. R. Clark, C. M. Quinn, J. F. Kaye, J. A. Schellenberg, G. D. Leverenz, J. B. Seubert, P. Tsuang, D. W. Peskind, E. R. Yu, C. E. TI Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease SO NEUROBIOLOGY OF AGING LA English DT Article DE APP; ADAM10; BACE1; BACE2; PSEN1; PSEN2; PEN2; NCSTN; APH1B; Alzheimer's; Cerebrospinal fluid ID MILD COGNITIVE IMPAIRMENT; GAMMA-SECRETASE COMPLEX; ALPHA-SECRETASE; MOUSE MODEL; CLINICAL-DIAGNOSIS; PLAQUE-FORMATION; SENILE PLAQUES; DOWN-SYNDROME; TAU PROTEINS; IN-VIVO AB The aim of this exploratory investigation was to determine if genetic variation within amyloid precursor protein (APP) or its processing enzymes correlates with APP cleavage product levels: APP alpha, APP beta or A beta 42, in cerebrospinal fluid (CSF) of cognitively normal subjects or Alzheimer's disease (AD) patients. Cognitively normal control subjects (n = 170) and AD patients (n = 92) were genotyped for 19 putative regulatory tagging SNPs within 9 genes (APP, ADAM10, BACE1, BACE2, PSEN1, PSEN2, PEN2, NCSTN and APH1B) involved in the APP processing pathway. SNP genotypes were tested for their association with CSF APP alpha, APP beta, and A beta 42. AD risk and age-at-onset while taking into account age, gender, race and APOE epsilon 4. After adjusting for multiple comparisons, a significant association was found between ADAM10 SNP rs514049 and APP alpha levels. In controls, the rs514049 CC genotype had higher APP alpha levels than the CA, AA collapsed genotype, whereas the opposite effect was seen in AD patients. These results suggest that genetic variation within ADAM10, an APP processing gene, influences CSF APP alpha levels in an AD specific manner. (C) 2011 Elsevier Inc. All rights reserved. C1 [Bekris, L. M.; Galloway, N. M.; Yu, C. E.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Bekris, L. M.; Yu, C. E.] Univ Washington, Dept Med, Seattle, WA USA. [Millard, S.; Lockhart, D.; Leverenz, J. B.; Tsuang, D. W.; Peskind, E. R.] VA Puget Sound Hlth Care Syst, MIRECC, NW Network VISN 20, Seattle, WA USA. [Li, G.; Leverenz, J. B.; Tsuang, D. W.; Peskind, E. R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Galasko, D. R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Galasko, D. R.] VA Med Ctr, San Diego, CA USA. [Farlow, M. R.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN USA. [Clark, C. M.] Univ Penn, Dept Neurol, Inst Aging, Philadelphia, PA 19104 USA. [Quinn, J. F.; Kaye, J. A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Leverenz, J. B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Seubert, P.] Elan Pharmaceut, San Francisco, CA USA. [Schellenberg, G. D.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. RP Bekris, LM (reprint author), VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. EM lbekris@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Kaye, Jeffrey/0000-0002-9971-3478; Tsuang, Debby/0000-0002-4716-1894 FU US Department of Veterans Affairs; Biomedical Laboratory; NIH [1K99AGO34214-01A1, 2P50AG005136-27, 1P50NS062684-01A1]; University of Washington Alzheimer's Disease Research Center NIH [NIH P50-AG005136]; University of California, San Diego Alzheimer's disease Research Center [P50AGOO5131-27] FX This work is supported in part by the US Department of Veterans Affairs, Office of Research and Development Clinical Research and Development Program, the Biomedical Laboratory Research Program and NIH grants 1K99AGO34214-01A1, 2P50AG005136-27 and 1P50NS062684-01A1. Additional support includes University of Washington Alzheimer's Disease Research Center NIH P50-AG005136 and University of California, San Diego Alzheimer's disease Research Center P50AGOO5131-27. NR 74 TC 4 Z9 4 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD MAR PY 2011 VL 32 IS 3 AR 556.e13 DI 10.1016/j.neurobiolaging.2010.10.020 PG 11 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 755PE UT WOS:000289944800048 PM 21196064 ER PT J AU DeMichele-Sweet, MAA Klei, L Devlin, B Ferrell, RE Weamer, EA Emanuel, JE Lopez, OL Sweet, RA AF DeMichele-Sweet, Mary Ann A. Klei, Lambertus Devlin, Bernie Ferrell, Robert E. Weamer, Elise A. Emanuel, James E. Lopez, Oscar L. Sweet, Robert A. TI No association of psychosis in Alzheimer disease with neurodegenerative pathway genes SO NEUROBIOLOGY OF AGING LA English DT Article DE Alzheimer's disease; Psychosis; Amyloid precursor protein (APP); Beta-site amyloid precursor protein cleaving enzyme (BACE1); Sortilin-related receptor (SORL1); Microtubule-associated protein tau (MAPT); Apolipoprotein E e4 (APOE e4) AB Psychotic symptoms occur in approximately 40% of subjects with Alzheimer disease (AD with psychosis; AD + P) and identify a subgroup with more rapid cognitive decline. We evaluated in 867 AD subjects the association of AD + P with genes which may modify the pathological process via effects on the accumulation of amyloid beta (A beta) protein and/or hyperphosphorylated microtubule-associated protein tau (MAPT): amyloid precursor protein (APP), beta-site amyloid precursor protein cleaving enzyme (BACE1), sortilin-related receptor (SORL1), and MAPT. Each gene was thoroughly interrogated with tag single-nucleotide polymorphisms (SNPs), and gene-based tests were used to enhance power. We found no association of these genes with AD + P. (C) 2011 Elsevier Inc. All rights reserved. C1 [DeMichele-Sweet, Mary Ann A.; Klei, Lambertus; Devlin, Bernie; Weamer, Elise A.; Emanuel, James E.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. [Ferrell, Robert E.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15213 USA. [Weamer, Elise A.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res 4, Educ & Clin Ctr MIRECC, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Univ Pittsburgh, Dept Psychiat, 3811 Ohara St, Pittsburgh, PA 15213 USA. EM SweetRA@upmc.edu FU National Institute of Aging [AG027224, AG05133] FX Supported in part by USPHS grants AG027224 and AG05133 from the National Institute of Aging. NR 0 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD MAR PY 2011 VL 32 IS 3 AR 555.e9 DI 10.1016/j.neurobiolaging.2010.10.003 PG 3 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 755PE UT WOS:000289944800044 PM 21093110 ER PT J AU Unger, CA Weinstein, MM Pretorius, DH AF Unger, Cecile A. Weinstein, Milena M. Pretorius, Dolores H. TI Pelvic Floor Imaging SO OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Pelvic floor disorders; Pelvic floor imaging; Pelvic floor ultrasound; Transperineal ultrasound ID STRESS URINARY-INCONTINENCE; ANAL-SPHINCTER DEFECTS; 2-YEAR FOLLOW-UP; 3-DIMENSIONAL ULTRASOUND; FECAL INCONTINENCE; TRANSANAL ULTRASOUND; PERINEAL ULTRASOUND; VAGINAL DELIVERY; PUBOVISCERAL MUSCLE; URETHRAL SPHINCTER AB Pelvic floor disorders including urinary incontinence, pelvic organ prolapse, and anal incontinence have high prevalence in women of all ages,(1) can significantly decrease quality of life, and produce an economic effect. Proper evaluation of pelvic floor muscle function, strength, and integrity is an important component of diagnosis and treatment of pelvic floor disorders. In addition, the pelvic floor muscle training used to change the structural support and strength of muscle contraction requires clinicians to be able to conduct high-quality measurements of pelvic floor muscle function and strength. Studies have shown that up to one-third of women do not know how to contract their pelvic floor muscles correctly.(2) Therefore, it is also important to be able to assess pelvic muscle function and strength to document a patient's progress during interventions designed to improve their strength.(3) Approximately 1 in 10 women undergo surgery for pelvic organ prolapse by the time they reach the age of 70 years.(4) In addition, urinary incontinence often coexists with pelvic organ prolapse.(1) Urinary incontinence is defined by the International Continence Society as a complaint of any involuntary leakage of urine.(5) The most common type of incontinence is involuntary leaking in response to increased intra-abdominal pressures during exertion, cough, or sneeze. This type of incontinence is called stress urinary incontinence.(6) Urinary incontinence is more common in women than it is in men, and it affects women of all ages. The prevalence ranges from 9% to 72%, with an incidence that rises steeply with age.(7) Several studies have documented the effects that urinary incontinence have on quality of life; it is a debilitating disorder that affects women socially and physically.(6) The International Consultation on Incontinence defines anal incontinence as the involuntary loss of gas, liquid, or stool that causes a social or hygienic problem.(8) The prevalence of anal incontinence has been documented in several studies to range from 20% to 54%.(9,10) The underlying cause of this type of incontinence is often related to anal sphincter defects following vaginal deliveries.(11) Because these disorders are so prevalent and severely affect a woman's quality of life, it is important to understand normal pelvic anatomy and function to treat pelvic floor disorders appropriately.(12) C1 [Weinstein, Milena M.] Massachusetts Gen Hosp, Dept Vincent Obstet & Gynecol, Div Female Pelv Med & Reconstruct Surg, Boston, MA 02114 USA. [Pretorius, Dolores H.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA. RP Weinstein, MM (reprint author), Massachusetts Gen Hosp, Dept Vincent Obstet & Gynecol, Div Female Pelv Med & Reconstruct Surg, 55 Fruit St,FND 5, Boston, MA 02114 USA. EM mweinstein2@partners.org NR 75 TC 6 Z9 8 U1 4 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8545 EI 1558-0474 J9 OBSTET GYN CLIN N AM JI Obstet. Gynecol. Clin. N. Am. PD MAR PY 2011 VL 38 IS 1 BP 23 EP + DI 10.1016/j.ogc.2011.02.002 PG 22 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 754SB UT WOS:000289876100003 PM 21419326 ER PT J AU Yeh, ED AF Yeh, Eren D. TI Breast Magnetic Resonance Imaging: Current Clinical Indications SO OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Breast; Magnetic resonance; Indications; Breast cancer ID EXTENSIVE INTRADUCTAL COMPONENT; INVASIVE LOBULAR CARCINOMA; NEOADJUVANT CHEMOTHERAPY; IMPLANT RUPTURE; PREOPERATIVE CHEMOTHERAPY; MAMMOGRAPHIC FINDINGS; HODGKINS LYMPHOMA; RESIDUAL DISEASE; MR MAMMOGRAPHY; HIGH-RISK AB Breast cancer is the most common cancer among women. In 2009, approximately 192,370 new cases of invasive breast cancer, and an additional 62,280 in situ breast cancers, will be diagnosed. An estimated 40,170 women are expected to die from breast cancer in 2009. Because of early detection of breast cancers from widespread screening mammography and improvements in treatment, the mortality from breast cancer has decreased almost 30% since 1990.(1) Mammography is the mainstay of breast imaging. Other imaging technologies such as ultrasound and magnetic resonance (MR) have been found to be useful adjuncts to mammography. Breast MR is highly sensitive in the detection of invasive malignancies, with reported rates of 89% to 100%, although it is somewhat limited with variable specificity, reported at 37% to 97%.(2) As technology improves, as interpretations and reporting by radiologists become standardized through the development of guidelines by expert consortiums, and as scientific investigation continues, the indications and uses of breast MR as an adjunct to mammography continue to evolve. The specificity of breast MR has gradually improved, likely because of improved technology and increased reader experience. To standardize interpretation among radiologists and to facilitate outcome monitoring, the American College of Radiology (ACR) has developed guidelines for interpretation: the ACR BI-RADS (Breast Imaging Reporting and Data System) MR Imaging Lexicon, the first edition of the MR Imaging Lexicon, in 2003.(3) The BI-RADS MR Imaging Lexicon provides common terminology for describing findings and allows radiologists to communicate findings to referring physicians and with each other in a standardized fashion. It also facilitates comparison of findings across scientific investigations. C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Radiol,Div Breast Imag, Boston, MA 02115 USA. RP Yeh, ED (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Radiol,Div Breast Imag, 75 Francis St,RA Bldg 014, Boston, MA 02115 USA. EM eyeh@partners.org NR 56 TC 2 Z9 3 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8545 J9 OBSTET GYN CLIN N AM JI Obstet. Gynecol. Clin. N. Am. PD MAR PY 2011 VL 38 IS 1 BP 159 EP + DI 10.1016/j.ogc.2011.02.008 PG 20 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 754SB UT WOS:000289876100009 PM 21419332 ER PT J AU Albright, KC Savitz, SI Raman, R Ernstrom, K Broderick, J Ford, A Marshall, R Martin-Schild, S Merino, J Meyer, D Liebeskind, D Rost, N Meyer, B AF Albright, Karen C. Savitz, Sean I. Raman, Rema Ernstrom, Karin Broderick, Joseph Ford, Andria Marshall, Randolph Martin-Schild, Sheryl Merino, Jose Meyer, Dawn Liebeskind, David Rost, Natalia Meyer, Brett CA SPOTRIA Investigators TI Comprehensive Stroke Centers & the Weekend Effect: the SPOTRIAS Experience SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Albright, Karen C.] Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA. [Savitz, Sean I.; Liebeskind, David] Univ Texas Houston, Houston, TX USA. [Raman, Rema; Ernstrom, Karin; Meyer, Dawn; Meyer, Brett] Univ Calif & Endash, San Diego, CA USA. [Raman, Rema; Ernstrom, Karin] Dept Family & Prevent Med, Div Biostat & Bioinformat, San Diego, CA USA. [Broderick, Joseph] Univ Cincinnati, Med Ctr, Dept Neurol, Cincinnati, OH 45267 USA. [Ford, Andria] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA. [Marshall, Randolph] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10016 USA. [Martin-Schild, Sheryl] Tulane Univ, Sch Med, Dept Neurol, New Orleans, LA 70112 USA. [Merino, Jose] Suburban Hosp Stroke Program, Bethesda, MD USA. [Meyer, Dawn; Meyer, Brett] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Liebeskind, David] Stroke Ctr, Los Angeles, CA USA. [Rost, Natalia] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E106 EP E107 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400220 ER PT J AU Almandoz, JED Schaefer, PW Goldstein, JN Rosand, J Lev, MH Gonzalez, RG Romero, JM AF Almandoz, Josser E. Delgado Schaefer, Pamela W. Goldstein, Joshua N. Rosand, Jonathan Lev, Michael H. Gonzalez, R. Gilberto Romero, Javier M. TI Volumetric Analysis of the CT Angiography Spot Sign Enables Calculation of the Rate of On-Going Hemorrhage in Patients with Primary Intracerebral Hemorrhage SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Almandoz, Josser E. Delgado] Massachusetts Gen Hosp, Mallinckrodt Inst Radiol, St Louis, MO USA. [Schaefer, Pamela W.; Goldstein, Joshua N.; Rosand, Jonathan; Lev, Michael H.; Gonzalez, R. Gilberto; Romero, Javier M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Goldstein, Joshua/H-8953-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E149 EP E150 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400356 ER PT J AU Amatangelo, MP Lima, FO Birch, AK Green, RE Rodriguez, AR Thankachan, T Furie, KL AF Amatangelo, Mary P. Lima, Fabricio O. Birch, Ashley K. Green, Rebecca E. Rodriguez, Aaron R. Thankachan, Tijy Furie, Karen L. TI Risk Factor Profiles Differ in Very Elderly Stroke Patients SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Amatangelo, Mary P.; Lima, Fabricio O.; Birch, Ashley K.; Green, Rebecca E.; Rodriguez, Aaron R.; Thankachan, Tijy; Furie, Karen L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Lima, Fabricio/E-6507-2015 OI Lima, Fabricio/0000-0002-0383-4145 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E330 EP E330 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401361 ER PT J AU Anderson, CD Nalls, MA Biffi, A Rost, NS Greenberg, SM Singleton, AB Meschia, JF Rosand, J AF Anderson, Christopher D. Nalls, Michael A. Biffi, Alessandro Rost, Natalia S. Greenberg, Steven M. Singleton, Andrew B. Meschia, James F. Rosand, Jonathan TI The Effect of Survivorship Bias on Cross-Sectional Case-Control Genetic Studies of Highly Lethal Diseases SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Greenberg, Steven M.; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nalls, Michael A.; Singleton, Andrew B.] NIH, Bethesda, MD 20892 USA. [Meschia, James F.] Mayo Clin, Jacksonville, FL 32224 USA. RI Singleton, Andrew/C-3010-2009 NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E186 EP E186 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400491 ER PT J AU Anderson, CD Biffi, A Rahman, R Ross, OA Jagiella, JM Kissela, B Cole, JW Cortellini, L Rost, NS Cheng, YC Greenberg, SM deBakker, PI Brown, RD Brott, TG Mitchell, BD Broderick, JP Worrall, BB Furie, KL Kittner, SJ Woo, D Slowik, A Meschia, JF Saxena, R Rosand, J AF Anderson, Christopher D. Biffi, Alessandro Rahman, Rosanna Ross, Owen A. Jagiella, Jeremiasz M. Kissela, Brett Cole, John W. Cortellini, Lynelle Rost, Natalia S. Cheng, Yu-Ching Greenberg, Steven M. deBakker, Paul I. Brown, Robert D., Jr. Brott, Thomas G. Mitchell, Braxton D. Broderick, Joseph P. Worrall, Bradford B. Furie, Karen L. Kittner, Steven J. Woo, Daniel Slowik, Agnieszka Meschia, James F. Saxena, Richa Rosand, Jonathan CA Int Stroke Genetics Consortium TI Common Mitochondrial Sequence Variants in Ischemic Stroke SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Anderson, Christopher D.; Biffi, Alessandro; Rahman, Rosanna; Cortellini, Lynelle; Rost, Natalia S.; Greenberg, Steven M.; Furie, Karen L.; Saxena, Richa; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ross, Owen A.; Brott, Thomas G.; Meschia, James F.] Mayo Clin, Jacksonville, FL 32224 USA. [Jagiella, Jeremiasz M.; Slowik, Agnieszka] Jagiellonian Univ, Coll Med, Krakow, Poland. [Kissela, Brett; Broderick, Joseph P.; Woo, Daniel] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Cole, John W.; Cheng, Yu-Ching; Mitchell, Braxton D.; Kittner, Steven J.] Univ Maryland, Baltimore, MD 21201 USA. [deBakker, Paul I.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Brown, Robert D., Jr.] Mayo Clin, Rochester, MN USA. [Worrall, Bradford B.] Univ Virginia Hlth Syst, Charlottesville, VA USA. RI Ross, Owen/D-7573-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E102 EP E103 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400211 ER PT J AU Biffi, A Sonni, A Anderson, CD Kissela, B Jagiella, JM Schmidt, H Jimenez-Conde, J Hansen, BM Fernandez-Cadenas, I Brown, DL Silliman, SL Selim, MB Worrall, BB Meschia, JF Montaner, J Lindgren, A Roquer, J Schmidt, R Greenberg, SM Slowik, A Broderick, JP Woo, D Rosand, J AF Biffi, Alessandro Sonni, Akshata Anderson, Christopher D. Kissela, Brett Jagiella, Jeremiasz M. Schmidt, Helena Jimenez-Conde, Jordi Hansen, Bjorn M. Fernandez-Cadenas, Israel Brown, Devin L. Silliman, Scott L. Selim, Magdy B. Worrall, Bradford B. Meschia, James F. Montaner, Joan Lindgren, Arne Roquer, Jaume Schmidt, Reinhold Greenberg, Steven M. Slowik, Agnieszka Broderick, Joseph P. Woo, Daniel Rosand, Jonathan CA International Stroke Genetics Cons TI Variants at APOE Influence Risk of Deep and Lobar Intracerebral Hemorrhage SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Biffi, Alessandro; Sonni, Akshata; Anderson, Christopher D.; Greenberg, Steven M.; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kissela, Brett; Broderick, Joseph P.; Woo, Daniel] Univ Cincinnati, Cincinnati, OH USA. [Jagiella, Jeremiasz M.; Slowik, Agnieszka] Jagiellonian Univ, Krakow, Poland. [Schmidt, Helena; Schmidt, Reinhold] Med Univ Gratz, Grazt, Austria. [Jimenez-Conde, Jordi; Roquer, Jaume] Hosp del Mar, Barcelona, Spain. [Hansen, Bjorn M.; Lindgren, Arne] Lund Univ, Lund, Sweden. [Fernandez-Cadenas, Israel; Montaner, Joan] Vall dHebron Hosp, Barcelona, Spain. [Brown, Devin L.] Univ Michigan, Ann Arbor, MI USA. [Silliman, Scott L.] Univ Florida, Jacksonville, FL USA. [Selim, Magdy B.] Beth Israel Deaconess Med Cntr, Boston, MA USA. [Worrall, Bradford B.] Univ Virginisa, Charlottesville, VA USA. [Meschia, James F.] Mayo Clin Jacksonville, Jacksonville, FL 32224 USA. RI JIMENEZ-CONDE, JORDI/C-1941-2012; Montaner, Joan/D-3063-2015; IBIS, NEUROVASCULAR/O-1855-2015 NR 0 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E185 EP E185 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400486 ER PT J AU Biffi, A Devan, WJ Anderson, CD Ayres, AM Schwab, K Cortellini, L Viswanathan, A Rost, NS Smith, EE Goldstein, JN Greenberg, SM Rosand, J AF Biffi, Alessandro Devan, William J. Anderson, Christopher D. Ayres, Alison M. Schwab, Kristin Cortellini, Lynelle Viswanathan, Anand Rost, Natalia S. Smith, Eric E. Goldstein, Joshua N. Greenberg, Steven M. Rosand, Jonathan TI Statin Use and Outcome after Intracerebral Hemorrhage: Case-control Study and Meta-analysis SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Biffi, Alessandro; Devan, William J.; Anderson, Christopher D.; Ayres, Alison M.; Schwab, Kristin; Cortellini, Lynelle; Viswanathan, Anand; Rost, Natalia S.; Goldstein, Joshua N.; Greenberg, Steven M.; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Smith, Eric E.] Univ Calgary, Calgary, AB, Canada. RI Goldstein, Joshua/H-8953-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E150 EP E151 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400359 ER PT J AU Biffi, A Kissela, B Ayres, AM Sonni, A Gilson, AJ Schwab, K Cortellini, L Pires, CR Hansen, BM Rost, NS Goldstein, JN Viswanathan, A Lindgren, A Slowik, A Schmidt, R Tirschwell, DL Selim, M Brown, DL Silliman, SL Worrall, BB Meschia, JF Broderick, JP Greenberg, SM Woo, D Rosand, J AF Biffi, Alessandro Kissela, Brett Ayres, Alison M. Sonni, Akshata Gilson, Aaron J. Schwab, Kristin Cortellini, Lynelle Pires, Caroline R. Hansen, Bjorn M. Rost, Natalia S. Goldstein, Joshua N. Viswanathan, Anand Lindgren, Arne Slowik, Agnieszka Schmidt, Reinhold Tirschwell, David L. Selim, Magdy Brown, Devin L. Silliman, Scott L. Worrall, Bradford B. Meschia, James F. Broderick, Joseph P. Greenberg, Steven M. Woo, Daniel Rosand, Jonathan CA Int Stroke Genetics Consortium TI APOE Genotype Predicts Hematoma Volume and Expansion in Intracerebral Hemorrhage SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Biffi, Alessandro; Ayres, Alison M.; Sonni, Akshata; Gilson, Aaron J.; Schwab, Kristin; Cortellini, Lynelle; Pires, Caroline R.; Rost, Natalia S.; Goldstein, Joshua N.; Viswanathan, Anand; Greenberg, Steven M.; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kissela, Brett; Broderick, Joseph P.; Woo, Daniel] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Hansen, Bjorn M.; Lindgren, Arne] Univ Lund Hosp, S-22185 Lund, Sweden. [Slowik, Agnieszka] Jagiellonian Univ, Coll Med, Krakow, Poland. [Schmidt, Reinhold] Graz Med Univ, Graz, Austria. [Tirschwell, David L.] Univ Washington, Sch Med, Seattle, WA USA. [Selim, Magdy] Beth Israel Deaconess Med Cntr, Boston, MA USA. [Brown, Devin L.] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Silliman, Scott L.] Univ Florida, Coll Med, Jacksonville, FL USA. [Worrall, Bradford B.] Univ Virigina, Charlottesville, VA USA. [Meschia, James F.] Mayo Clin Jacksonville, Jacksonville, FL 32224 USA. RI Goldstein, Joshua/H-8953-2016 NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E102 EP E102 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400210 ER PT J AU Biffi, A Ayres, AM Cortellini, L Schwab, K Battey, TW Gilson, AJ Rost, NS Goldstein, JN Viswanathan, A Greenberg, SM Rosand, J AF Biffi, Alessandro Ayres, Alison M. Cortellini, Lynelle Schwab, Kristin Battey, Thomas W. Gilson, Aaron J. Rost, Natalia S. Goldstein, Joshua N. Viswanathan, Anand Greenberg, Steven M. Rosand, Jonathan CA Genetics Cerebral Hemorrhage TI Warrfarin, Small Vessel Disease and Outcome after Intracerebral Hemorrhage SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Biffi, Alessandro; Ayres, Alison M.; Cortellini, Lynelle; Schwab, Kristin; Battey, Thomas W.; Gilson, Aaron J.; Rost, Natalia S.; Goldstein, Joshua N.; Viswanathan, Anand; Greenberg, Steven M.; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Goldstein, Joshua/H-8953-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E59 EP E59 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400062 ER PT J AU Brown, WM Biffi, A Jagiella, J Comeau, M Cortellini, L Woo, JG Martin, L Flaherty, ML Broderick, JP Deka, R Slowik, A Tirschwell, D Selim, M Brown, DL Silliman, SS Worrall, BB Meschia, JF Schwab, K Ayres, AM Greenberg, SM Langefeld, CD Woo, D Rosand, J AF Brown, W. Mark Biffi, Alessandro Jagiella, Jeremiasz Comeau, Mary Cortellini, Lynelle Woo, Jessica G. Martin, Lisa Flaherty, Matthew L. Broderick, Joseph P. Deka, Ranjan Slowik, Agnieszka Tirschwell, David Selim, Magdy Brown, Devin L. Silliman, Scott Silliman Worrall, Bradford B. Meschia, James F. Schwab, Kristin Ayres, Alison M. Greenberg, Steven M. Langefeld, Carl D. Woo, Daniel Rosand, Jonathan TI Genome Wide Association Study of Intracerebral Hemorrhage SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Brown, W. Mark; Comeau, Mary; Langefeld, Carl D.] Wake Forest Univ Hlth Sci, Winston Salem, NC 02114 USA. [Biffi, Alessandro; Cortellini, Lynelle; Schwab, Kristin; Ayres, Alison M.; Greenberg, Steven M.; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA USA. [Jagiella, Jeremiasz] Jagiellonian Univ Botaniczna 3, Krakow, Poland. [Woo, Jessica G.; Martin, Lisa] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Flaherty, Matthew L.; Broderick, Joseph P.; Deka, Ranjan; Woo, Daniel] Univ Cincinnati, Cincinnati, OH USA. [Slowik, Agnieszka] Jagiellonian Univ, Krakow, 98195, Poland. [Tirschwell, David] Univ Washington, Seattle, WA USA. [Selim, Magdy] Harvard Univ, Sch Med, Boston, MA USA. [Brown, Devin L.] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [Silliman, Scott Silliman] Univ Florida, Coll Med, Jacksonville, FL USA. [Worrall, Bradford B.] Univ Virginia Hlth Syst, Charlottesville, VA 32224 USA. [Meschia, James F.] Mayo Clin, Jacksonville, FL USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E218 EP E219 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400603 ER PT J AU Busl, K Nogueira, RG Yoo, AJ Hirsch, JA Schwamm, LH Rost, NS AF Busl, Katharina Nogueira, Raul G. Yoo, Albert J. Hirsch, Joshua A. Schwamm, Lee H. Rost, Natalia S. TI Pre-stroke Dementia Is Associated With Poor Outcomes After Thrombolysis Among The Elderly SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Busl, Katharina; Nogueira, Raul G.; Yoo, Albert J.; Hirsch, Joshua A.; Schwamm, Lee H.; Rost, Natalia S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E322 EP E323 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401334 ER PT J AU Chou, SH Lee, PS Konigsberg, RG Gallachi, D Arai, K Simmons, S Loesch, E Bauer, D Stossel, TP Feske, S Lo, EH Ning, MM AF Chou, Sherry H. Lee, Po-Shun Konigsberg, Rachael G. Gallachi, Dana Arai, Ken Simmons, Suzanne Loesch, Eric Bauer, David Stossel, Thomas P. Feske, Steven Lo, Eng H. Ning, MingMing TI Plasma-type gelsolin (pGSN) is reduced in Human Blood and Cerebrospinal Fluid following Subarachnoid Hemorrhage SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Chou, Sherry H.; Lee, Po-Shun; Konigsberg, Rachael G.; Gallachi, Dana; Simmons, Suzanne; Bauer, David; Stossel, Thomas P.; Feske, Steven] Brigham & Womens Hosp, Boston, MA 02115 USA. [Arai, Ken; Loesch, Eric; Lo, Eng H.; Ning, MingMing] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Chou, Sherry/G-5779-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E160 EP E160 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400392 ER PT J AU Chou, SH Ning, MM Konigsberg, RG Simmons, S Bauer, D Loesch, E Feske, SK Lo, EH AF Chou, Sherry H. Ning, MingMing Konigsberg, Rachael G. Simmons, Suzanne Bauer, David Loesch, Eric Feske, Steven K. Lo, Eng H. TI Elevated blood TNF-alpha and IL-6 are Associated with Poor 3-month Outcome following Subarachnoid Hemorrhage SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Chou, Sherry H.; Konigsberg, Rachael G.; Simmons, Suzanne; Bauer, David; Feske, Steven K.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Ning, MingMing; Loesch, Eric; Lo, Eng H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E160 EP E160 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400391 ER PT J AU Chutinet, A Biffi, A Fitzpatrick, KM Kanakis, A Furie, KL Rost, NS AF Chutinet, Aurauma Biffi, Alessandro Fitzpatrick, Kaitlin M. Kanakis, Allison Furie, Karen L. Rost, Natalia S. TI Severity of Leukoaraiosis in Large Vessel Atherosclerotic Disease SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Chutinet, Aurauma; Biffi, Alessandro; Fitzpatrick, Kaitlin M.; Kanakis, Allison; Furie, Karen L.; Rost, Natalia S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E272 EP E273 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401152 ER PT J AU Chutinet, A Rost, NS Muzikansky, A Betensky, RA Parides, MK Lima, FO Batista, L Bayrlee, A Nentwich, LM Maas, MB Feske, SK Furie, KL AF Chutinet, Aurauma Rost, Natalia S. Muzikansky, Alona Betensky, Rebecca A. Parides, Michael K. Lima, Fabricio O. Batista, Leonardo Bayrlee, Ahmad Nentwich, Lauren M. Maas, Matthew B. Feske, Steven K. Furie, Karen L. TI SPOTRIAS: Hyperacute C-Reactive Protein Levels Predict Stroke Outcome in Mild Stroke SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Chutinet, Aurauma; Rost, Natalia S.; Muzikansky, Alona; Lima, Fabricio O.; Batista, Leonardo; Bayrlee, Ahmad; Nentwich, Lauren M.; Maas, Matthew B.; Furie, Karen L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Betensky, Rebecca A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Parides, Michael K.] Mt Sinai Sch Med, New York, NY USA. [Feske, Steven K.] Brigham & Womens Hosp, Boston, MA 02115 USA. RI Lima, Fabricio/E-6507-2015 OI Lima, Fabricio/0000-0002-0383-4145 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E196 EP E196 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400523 ER PT J AU Coe, LJ D'Amore, K Magdon-Ismail, Z Schwamm, LH AF Coe, Laura J. D'Amore, Katrina Magdon-Ismail, Zainab Schwamm, Lee H. TI Hospital Participation in a Voluntary Stroke Quality Improvement (QI) Collaborative in Massachusetts SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Coe, Laura J.; D'Amore, Katrina] Massachusetts Dept Publ Hlth, Boston, MA USA. [Magdon-Ismail, Zainab] Amer Heart Assoc, Founders Affiliate, Albany, NY USA. [Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E332 EP E332 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401370 ER PT J AU Cortellini, L Biffi, A Nearnberg, CM Ayres, AM Schwab, K Gilson, AJ Rost, NS Goldstein, JN Viswanathan, A Greenberg, SM Rosand, J AF Cortellini, Lynelle Biffi, Alessandro Nearnberg, Caryn M. Ayres, Alison M. Schwab, Kristin Gilson, Aaron J. Rost, Natalia S. Goldstein, Joshua N. Viswanathan, Anand Greenberg, Steven M. Rosand, Jonathan TI Extremes of Body Mass Index and Risk of Intracerebral Hemorrhage by Etiology SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Cortellini, Lynelle; Biffi, Alessandro; Nearnberg, Caryn M.; Ayres, Alison M.; Schwab, Kristin; Gilson, Aaron J.; Rost, Natalia S.; Goldstein, Joshua N.; Viswanathan, Anand; Greenberg, Steven M.; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Goldstein, Joshua/H-8953-2016 NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E58 EP E59 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400061 ER PT J AU Damush, TM Anderson, J Nicholas, G Kimmel, B Kent, T Williams, LS AF Damush, Teresa M. Anderson, Jane Nicholas, Gloria Kimmel, Barbara Kent, Thomas Williams, Linda S. TI Implementation of the American Stroke Association Sharegiver Program (Peer Support) SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Damush, Teresa M.; Nicholas, Gloria] Indiana Univ, Sch Med, VA Stroke QUERI, Indianapolis, IN 46204 USA. [Kent, Thomas] Baylor Coll Med, Houston VAMC, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E239 EP E239 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401034 ER PT J AU De Meyer, SF Stoll, G Kleinschnitz, C AF De Meyer, Simon F. Stoll, Guido Kleinschnitz, Christoph TI Letter by De Meyer et al Regarding Article "High von Willebrand Factor Levels Increase the Risk of Stroke: The Rotterdam Study" SO STROKE LA English DT Letter ID ISCHEMIC-STROKE; MICE C1 [De Meyer, Simon F.] Childrens Hosp, Immune Dis Inst, Program Cellular & Mol Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Wurzburg, Dept Neurol, D-8700 Wurzburg, Germany. RP De Meyer, SF (reprint author), Childrens Hosp, Immune Dis Inst, Program Cellular & Mol Med, 300 Longwood Ave, Boston, MA 02115 USA. NR 5 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E41 EP E41 DI 10.1161/STROKEAHA.110.604777 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400010 PM 21293019 ER PT J AU Dierksen, GA Halpin, A Dumas, A Gurol, ME Kahn, MA Rosand, J Viswanathan, A Salat, DH Polimeini, J Greenberg, SM AF Dierksen, Gregory A. Halpin, Amy Dumas, Andrew Gurol, Mahmut E. Kahn, Muhammad A. Rosand, Jonathan Viswanathan, Anand Salat, David H. Polimeini, Jonathan Greenberg, Steve M. TI Functional MRI Detection of Vessel Reactivity in CAA SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Dierksen, Gregory A.; Halpin, Amy; Dumas, Andrew; Gurol, Mahmut E.; Kahn, Muhammad A.; Rosand, Jonathan; Viswanathan, Anand; Salat, David H.; Polimeini, Jonathan; Greenberg, Steve M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E122 EP E122 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400258 ER PT J AU Fang, MC Go, AS Chang, YC Borowsky, LH Pomernacki, NK Udaltsova, N Singer, DE AF Fang, Margaret C. Go, Alan S. Chang, Yuchiao Borowsky, Leila H. Pomernacki, Niela K. Udaltsova, Natalia Singer, Daniel E. TI The Comparative Mortality of Ischemic Stroke vs. Intracranial Hemorrhage On and Off Warfarin: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Fang, Margaret C.] UCSF, San Francisco, CA USA. [Go, Alan S.; Pomernacki, Niela K.; Udaltsova, Natalia] Kaiser Permanente No Calif Div Rsch, Oakland, CA USA. [Chang, Yuchiao; Borowsky, Leila H.; Singer, Daniel E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E155 EP E155 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400375 ER PT J AU Fang, MC Go, AS Chang, YC Borowsky, LH Pomernacki, NK Udaltsova, N Singer, DE AF Fang, Margaret C. Go, Alan S. Chang, Yuchiao Borowsky, Leila H. Pomernacki, Niela K. Udaltsova, Natalia Singer, Daniel E. TI The Long-Term Impact of Ischemic Stroke on Mortality Among Patients with Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Fang, Margaret C.] UCSF, San Francisco, CA USA. [Go, Alan S.; Pomernacki, Niela K.; Udaltsova, Natalia] Kaiser Permanente No Calif, Div Rsch, Oakland, CA USA. [Chang, Yuchiao; Borowsky, Leila H.; Singer, Daniel E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E80 EP E81 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400136 ER PT J AU Fonarow, GC Smith, EE Saver, JL Reeves, MJ Bhatt, DL Grau-Sepulveda, MV Olson, DM Hernandez, AF Peterson, ED Schwamm, LH AF Fonarow, Gregg C. Smith, Eric E. Saver, Jeffrey L. Reeves, Mathew J. Bhatt, Deepak L. Grau-Sepulveda, Maria V. Olson, DaiWai M. Hernandez, Adrian F. Peterson, Eric D. Schwamm, Lee H. TI Characteristics, Hospital Factors, and Temporal Trends in Door-to-Needle Times within 60 Minutes for Acute Ischemic Stroke SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Fonarow, Gregg C.; Saver, Jeffrey L.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. [Smith, Eric E.] Univ Calgary, Calgary, AB, Canada. [Reeves, Mathew J.] Michigan State Univ, E Lansing, MI 48824 USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Grau-Sepulveda, Maria V.; Olson, DaiWai M.; Hernandez, Adrian F.; Peterson, Eric D.] Duke Clin Rsch Inst, Durham, NC USA. [Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Smith, Eric/C-5443-2012 OI Smith, Eric/0000-0003-3956-1668 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E104 EP E105 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400215 ER PT J AU Fonarow, GC Smith, EE Saver, JL Reeves, MJ Bhatt, DL Grau-Sepulveda, MV Olson, DM Hernandez, AF Peterson, ED Schwamm, LH AF Fonarow, Gregg C. Smith, Eric E. Saver, Jeffrey L. Reeves, Mathew J. Bhatt, Deepak L. Grau-Sepulveda, Maria V. Olson, DaiWai M. Hernandez, Adrian F. Peterson, Eric D. Schwamm, Lee H. TI Relationship between Door-to-Needle Times for Tissue Plasminogen Activator and In-Hospital Clinical Outcomes in Acute Ischemic Stroke SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Fonarow, Gregg C.; Saver, Jeffrey L.] UCLA Med Cntr, Los Angeles, CA USA. [Smith, Eric E.] Univ Calgary, Calgary, AB, Canada. [Reeves, Mathew J.] Michigan State Univ, Lansing, MI USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Grau-Sepulveda, Maria V.; Olson, DaiWai M.; Hernandez, Adrian F.; Peterson, Eric D.] Duke Clin Rsch Inst, Durham, NC USA. [Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Smith, Eric/C-5443-2012 OI Smith, Eric/0000-0003-3956-1668 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E86 EP E87 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400156 ER PT J AU Green, RE Rista, B Milbury, PE Blumberg, JB Zampariello, CA Muzikansky, A Parides, MK Betensky, RA Chutinet, A Lima, FO Batista, L Bayrlee, A Nentwich, LM Maas, MB Kelly, PJ Feske, SK Furie, KL AF Green, Rebecca E. Rista, Blerina Milbury, Paul E. Blumberg, Jeffrey B. Zampariello, Carly A. Muzikansky, Alona Parides, Michael K. Betensky, Rebecca A. Chutinet, Aurauma Lima, Fabricio O. Batista, Leonardo Bayrlee, Ahmad Nentwich, Lauren M. Maas, Matthew B. Kelly, Peter J. Feske, Steven K. Furie, Karen L. TI Effects of Glycemic Control and Oxidative Stress on Stroke Outcome SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Green, Rebecca E.; Rista, Blerina; Muzikansky, Alona; Chutinet, Aurauma; Lima, Fabricio O.; Batista, Leonardo; Bayrlee, Ahmad; Nentwich, Lauren M.; Maas, Matthew B.; Kelly, Peter J.; Furie, Karen L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Milbury, Paul E.; Blumberg, Jeffrey B.; Zampariello, Carly A.] Tufts Univ, Jean Mayer USDA Human Nutr Rsch Cntr Aging, Boston, MA 02111 USA. [Parides, Michael K.] Mt Sinai Sch Med, New York, NY USA. [Betensky, Rebecca A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Feske, Steven K.] Brigham & Womens Hosp, Boston, MA 02115 USA. RI Lima, Fabricio/E-6507-2015 OI Lima, Fabricio/0000-0002-0383-4145 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E51 EP E52 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400041 ER PT J AU Gurol, ME Dierksen, GA Betensky, RA Halpin, A Ayres, A Rosand, J Viswanathan, A Salat, DH Johnson, K Greenberg, SM AF Gurol, Mahmut E. Dierksen, Gregory A. Betensky, Rebecca A. Halpin, Amy Ayres, Alison Rosand, Jonathan Viswanathan, Anand Salat, David H. Johnson, Keith Greenberg, Steven M. TI New Cerebral Hemorrhages Occur at Brain Regions with Higher Amyloid Deposition in Cerebral Amyloid Angiopathy: A longitudinal PET/MRI Study SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Gurol, Mahmut E.; Dierksen, Gregory A.; Halpin, Amy; Ayres, Alison; Rosand, Jonathan; Viswanathan, Anand; Greenberg, Steven M.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Betensky, Rebecca A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Salat, David H.; Johnson, Keith] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E59 EP E60 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400064 ER PT J AU Hoh, B Chi, YY Waters, M Mocco, J Barker, F AF Hoh, Brian Chi, Yueh-Yun Waters, Michael Mocco, J. Barker, Fred, II TI Effect of Weekend Compared to Weekday Stroke Admission on Thrombolytic Use, In-Hospital Mortality, Discharge Disposition, Hospital Charges, and Length of Stay in the Nationwide Inpatient Sample Database: 2002-2007 SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Hoh, Brian; Chi, Yueh-Yun; Waters, Michael; Mocco, J.] Univ Florida, Gainesville, FL USA. [Barker, Fred, II] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E158 EP E158 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400384 ER PT J AU Ji, RJ Schwamm, LH Pervez, MA Singhal, AB AF Ji, Ruijun Schwamm, Lee H. Pervez, M. Ahsan Singhal, Aneesh B. TI PFO Risk Factors and Onset Age of First-Ever Stroke in Young Adults SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Ji, Ruijun; Schwamm, Lee H.; Pervez, M. Ahsan; Singhal, Aneesh B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E190 EP E190 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400501 ER PT J AU Ji, RJ Ay, H Arsava, M Zhu, MW Garg, P Tiglias, V Kimberly, WT Wu, O Schwamm, LH Sorensen, AG Singhal, AB AF Ji, Ruijun Ay, Hakan Arsava, Murat Zhu, Mingwang Garg, Priya Tiglias, Vicky Kimberly, W. Taylor Wu, Ona Schwamm, Lee H. Sorensen, A. Gregory Singhal, Aneesh B. TI Factors Related To Ischemic Lesion Growth In Thrombolysed and Non-Thrombolysed Stroke Patients SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Ji, Ruijun; Ay, Hakan; Arsava, Murat; Zhu, Mingwang; Garg, Priya; Tiglias, Vicky; Kimberly, W. Taylor; Wu, Ona; Schwamm, Lee H.; Sorensen, A. Gregory; Singhal, Aneesh B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E123 EP E124 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400264 ER PT J AU Ji, RJ Schwamm, LH Pervez, MA Singhal, AB AF Ji, Ruijun Schwamm, Lee H. Pervez, M. Ahsan Singhal, Aneesh B. TI Modern-Day Profile of Young Adults with Ischemic Stroke SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Ji, Ruijun; Schwamm, Lee H.; Pervez, M. Ahsan; Singhal, Aneesh B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E123 EP E123 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400262 ER PT J AU Kang, DW Fan, X Shim, WH Baek, KY Yun, SC Kwon, SJ Jeong, IK Kim, JK Jeong, J Wang, XY Kim, YR AF Kang, Dong-Wha Fan, Xiang Shim, Woo-Hyun Baek, Kwang-Yeol Yun, Sung-Cheol Kwon, Seon J. Jeong, In-Kyong Kim, Jeong-Kon Jeong, Jaeseung Wang, Xiaoying Kim, Young R. TI Tissue Plasminogen Activator Induces Vasoconstriction in Acute Ischemic Stroke Rat Model SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Kang, Dong-Wha; Shim, Woo-Hyun; Baek, Kwang-Yeol; Kwon, Seon J.; Jeong, In-Kyong; Kim, Jeong-Kon; Kim, Young R.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Fan, Xiang; Wang, Xiaoying] Massachusetts Gen Hosp, Neuroprotect Rsch Lab, Charlestown, MA USA. [Yun, Sung-Cheol] Asan Med Ctr, Seoul, South Korea. [Jeong, Jaeseung] Korea Adv Inst Sci & Technol, Taejon 305701, South Korea. RI Jeong, Jaeseung /C-1620-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E298 EP E298 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401243 ER PT J AU Kernan, WN Viscoli, CM Brass, LM Amatangelo, MP Birch, A Clark, W Conwit, R Furie, KL Gorman, M Hinnau, E Kleindorfer, D Lovejoy, AM Osborne, J Silliman, S Zweifler, RM Horwitz, RI AF Kernan, Walter N. Viscoli, Catherine M. Brass, Lawrence M. Amatangelo, Mary P. Birch, Ashley Clark, Wayne Conwit, Robin Furie, Karen L. Gorman, Mark Hinnau, Elizabeth Kleindorfer, Dawn Lovejoy, Anne M. Osborne, Jenny Silliman, Scott Zweifler, Richard M. Horwitz, Ralph I. CA IRIS Trial Investigators TI Local Hospital Networks for Clinical Trials in Stroke SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Kernan, Walter N.; Viscoli, Catherine M.; Brass, Lawrence M.; Hinnau, Elizabeth; Lovejoy, Anne M.] Yale Univ, Sch Med, New Haven, CT USA. [Amatangelo, Mary P.; Birch, Ashley; Furie, Karen L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Clark, Wayne] Oregon Hlth & Sci Univ, Portland, OR USA. [Conwit, Robin] Natl Inst Neurol Disorders & Stroke, Bethesda, MD USA. [Gorman, Mark] Univ Vermont, Burlington, VT USA. [Kleindorfer, Dawn; Osborne, Jenny] Univ Cincinnati, Cincinnati, OH USA. [Silliman, Scott] Univ Florida, Coll Med Jacksonville, Jacksonville, FL USA. [Zweifler, Richard M.] Eastern Virginia Med Sch, Norfold, VA USA. [Horwitz, Ralph I.] Stanford Univ, Palo Alto, CA 94304 USA. RI Zweifler, Richard/K-1314-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E158 EP E159 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400386 ER PT J AU Khan, MA Dierksen, GA Halpin, A Gurol, ME Rosand, J Viswanathan, A Salat, DS Greenberg, SM AF Khan, M. Ayaz Dierksen, Gregory A. Halpin, Amy Gurol, Mahmut E. Rosand, Jonathan Viswanathan, Anand Salat, David S. Greenberg, Steven M. TI Lobar Tissue Loss in Cerebral Amyloid Angiopathy SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Khan, M. Ayaz; Dierksen, Gregory A.; Halpin, Amy; Gurol, Mahmut E.; Rosand, Jonathan; Viswanathan, Anand; Salat, David S.; Greenberg, Steven M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E253 EP E253 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401084 ER PT J AU Kimberly, WT Wu, O Arsava, EM Garg, P Ji, RJ Vangel, M Singhal, A Ay, H Sorensen, AG AF Kimberly, W. Taylor Wu, Ona Arsava, E. Murat Garg, Priya Ji, Ruijin Vangel, Mark Singhal, Aneesh Ay, Hakan Sorensen, A. Gregory TI Lower Admission Hemoglobin Levels are Associated with Larger Stroke Volumes and Greater Infarct Expansion SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Kimberly, W. Taylor; Wu, Ona; Arsava, E. Murat; Garg, Priya; Ji, Ruijin; Vangel, Mark; Singhal, Aneesh; Ay, Hakan; Sorensen, A. Gregory] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E309 EP E309 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401287 ER PT J AU Lau, BC Baheti, AR Smith, RS Powell, KM Salinas, CL Brott, TG Brown, RD Kissela, BM Wintermark, M Meschia, JF Rost, NS Worrall, BB AF Lau, Benison C. Baheti, Aparna R. Smith, Rodney S. Powell, Kathryn M. Salinas, Carlos Leiva Brott, Thomas G. Brown, Robert D., Jr. Kissela, Brett M. Wintermark, Max Meschia, James F. Rost, Natalia S. Worrall, Bradford B. TI Image analysis of participants in the Siblings With Ischemic Stroke Study (SWISS) SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Lau, Benison C.; Baheti, Aparna R.; Smith, Rodney S.; Salinas, Carlos Leiva; Wintermark, Max; Worrall, Bradford B.] UVA Hlth Syst, Charlottesville, VA USA. [Powell, Kathryn M.] Univ S Florida, Tallahassee, FL USA. [Brott, Thomas G.; Meschia, James F.] Mayo Clin, Jacksonville, FL 32224 USA. [Brown, Robert D., Jr.] Mayo Clin, Rochester, MN USA. [Kissela, Brett M.] Univ Cincinnati, Cincinnati, OH USA. [Rost, Natalia S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E270 EP E270 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401142 ER PT J AU Lindenberg, R Nair, D Zhu, LL Renga, V Schlaug, G AF Lindenberg, Robert Nair, Dinesh Zhu, Lin L. Renga, Vijay Schlaug, Gottfried TI Non-invasive Motor Cortex Stimulation after Stroke: The Effect of Number of Sessions on Outcome SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Lindenberg, Robert; Nair, Dinesh; Zhu, Lin L.; Renga, Vijay; Schlaug, Gottfried] Harvard Univ, Sch Med, BIDMC, Boston, MA USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E72 EP E72 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400108 ER PT J AU Lorenzano, S Rost, NS Li, H Arai, K Hartdegen, S Muzikansky, A Parides, MK Betensky, R Wu, O Lima, FO Batista, L Bayrlee, A Nentwich, LM Maas, MB Chutinet, A Som, AT Pham, LDD Toni, D Harris, GJ Lev, MH Feske, SK Kelly, PJ Lo, EH Furie, KL AF Lorenzano, Svetlana Rost, Natalia S. Li, Hua Arai, Ken Hartdegen, Sophia Muzikansky, Alona Parides, Michael K. Betensky, Rebecca Wu, Ona Lima, Fabricio O. Batista, Leonardo Bayrlee, Ahmad Nentwich, Lauren M. Maas, Matthew B. Chutinet, Aurauma Som, Angel T. Pham, Loc-Duyen D. Toni, Danilo Harris, Gordon J. Lev, Michael H. Feske, Steven K. Kelly, Peter J. Lo, Eng H. Furie, Karen L. TI Hyperacute Matrix Metalloproteinase-9 Levels Predicts Infarct Volume and Stroke Outcome SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Lorenzano, Svetlana; Rost, Natalia S.; Li, Hua; Arai, Ken; Hartdegen, Sophia; Muzikansky, Alona; Wu, Ona; Lima, Fabricio O.; Batista, Leonardo; Bayrlee, Ahmad; Nentwich, Lauren M.; Maas, Matthew B.; Chutinet, Aurauma; Som, Angel T.; Pham, Loc-Duyen D.; Harris, Gordon J.; Lev, Michael H.; Lo, Eng H.; Furie, Karen L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Parides, Michael K.] Mt Sinai Sch Med, New York, NY USA. [Betensky, Rebecca] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Toni, Danilo] Univ Roma La Sapienza, Rome, Italy. [Feske, Steven K.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Kelly, Peter J.] Mater Misericordiae Univ Hosp, Dublin 7, Ireland. RI Lima, Fabricio/E-6507-2015 OI Lima, Fabricio/0000-0002-0383-4145 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E145 EP E146 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400342 ER PT J AU Lorenzano, S Rost, NS Li, H Muzikansky, A Harris, GJ Lev, MH Feske, SK Parides, MK Betensky, R Wu, O Lima, FO Batista, L Bayrlee, A Nentwich, LM Maas, MB Chutinet, A Toni, D Furie, KL AF Lorenzano, Svetlana Rost, Natalia S. Li, Hua Muzikansky, Alona Harris, Gordon J. Lev, Michael H. Feske, Steven K. Parides, Michael K. Betensky, Rebecca Wu, Ona Lima, Fabricio O. Batista, Leonardo Bayrlee, Ahmad Nentwich, Lauren M. Maas, Matthew B. Chutinet, Aurauma Toni, Danilo Furie, Karen L. TI Hyperacute Levels of High Sensitivity C-Reactive Protein are Associated with Mean Transit Time and Diffusion-Weighted Imaging Volumes and Improve Outcome Prediction in Acute Ischemic Stroke SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Lorenzano, Svetlana; Rost, Natalia S.; Li, Hua; Muzikansky, Alona; Harris, Gordon J.; Lev, Michael H.; Wu, Ona; Lima, Fabricio O.; Batista, Leonardo; Bayrlee, Ahmad; Nentwich, Lauren M.; Maas, Matthew B.; Chutinet, Aurauma; Furie, Karen L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Feske, Steven K.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Parides, Michael K.] Mt Sinai Sch Med, New York, NY USA. [Betensky, Rebecca] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Toni, Danilo] Univ Roma La Sapienza, Rome, Italy. RI Lima, Fabricio/E-6507-2015 OI Lima, Fabricio/0000-0002-0383-4145 NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E145 EP E145 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400340 ER PT J AU Maas, MB Singhal, AB AF Maas, Matthew B. Singhal, Aneesh B. TI Un-witnessed Stroke: Impact of Different Onset Times on Eligibility into Stroke Trials SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Maas, Matthew B.; Singhal, Aneesh B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E295 EP E296 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401233 ER PT J AU Masrur, S Smith, EE Saver, JL Reeves, M Bhatt, DL Zhao, X Olson, D Pan, WQ Hernandez, AF Fonarow, GC Schwamm, LH AF Masrur, Shihab Smith, Eric E. Saver, Jeffrey L. Reeves, Mathew Bhatt, Deepak L. Zhao, Xin Olson, DaiWai Pan, Wenqin Hernandez, Adrian F. Fonarow, Gregg C. Schwamm, Lee H. TI Predictors of the Use of Dysphagia Screening in Patients with Acute Ischemic Stroke SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Masrur, Shihab] Berkshire Med Ctr, Pittsfield, MA USA. [Smith, Eric E.] Univ Calgary, Calgary, AB T2N 1N4, Canada. [Saver, Jeffrey L.] Univ Calif Los Angeles, Stroke Ctr, Los Angeles, CA USA. [Reeves, Mathew] Michigan State Univ, E Lansing, MI 48824 USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Zhao, Xin; Pan, Wenqin; Hernandez, Adrian F.] Duke Clin Rsch Inst, Durham, NC USA. [Olson, DaiWai] Duke Univ, Med Ctr, Durham, NC USA. [Fonarow, Gregg C.] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA. [Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Smith, Eric/C-5443-2012 OI Smith, Eric/0000-0003-3956-1668 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E342 EP E343 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401403 ER PT J AU Mazza, M Magdon-Ismail, Z Melluzzo, S Coe, L Schwamm, L Gropen, T AF Mazza, Megan Magdon-Ismail, Zainab Melluzzo, Shannon Coe, Laura Schwamm, Lee Gropen, Toby TI National Institutes of Health Stroke Scale (NIHSS) Use in the Northeastern United States SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Mazza, Megan] Amer Heart Assoc, Framingham, MA USA. [Magdon-Ismail, Zainab] Amer Heart Assoc, Albany, NY USA. [Melluzzo, Shannon] Amer Heart Assoc, Springfield, MA USA. [Coe, Laura] Massachussets Dept Hlth, Boston, MA USA. [Schwamm, Lee] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Gropen, Toby] Long Isl Coll Hosp, Brooklyn, NY 11201 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E329 EP E329 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401356 ER PT J AU Messe, SR Fonarow, GC Smith, EE Kaltenbach, L Olson, D Kasner, SE Schwamm, LH AF Messe, Steven R. Fonarow, Gregg C. Smith, Eric E. Kaltenbach, Lisa Olson, Daiwai Kasner, Scott E. Schwamm, Lee H. CA Get Guidelines Stroke Steering Com TI Use of tPA After Publication of ECASS 3 in the Get With The Guidelines-Stroke Registry SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Messe, Steven R.; Kasner, Scott E.] Univ Penn, Philadelphia, PA 19104 USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Smith, Eric E.] Univ Calgary, Calgary, AB, Canada. [Kaltenbach, Lisa; Olson, Daiwai] Duke Univ, Durham, NC USA. [Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Smith, Eric/C-5443-2012 OI Smith, Eric/0000-0003-3956-1668 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E105 EP E105 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400216 ER PT J AU Muehlschlegel, S Barton, BA Topcuoglu, MA Fok, J Singhal, AB AF Muehlschlegel, Susanne Barton, Bruce A. Topcuoglu, Mehmet A. Fok, Joshua Singhal, Aneesh B. TI Identification of Predictors Differentiating Reversible Cerebral Vasoconstriction Syndrome with Subarachnoid Hemorrhage from Aneurysmal Subarachnoid Hemorrhage SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Muehlschlegel, Susanne; Barton, Bruce A.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Topcuoglu, Mehmet A.] Haceteppe Univ, Ankara, Turkey. [Fok, Joshua] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. [Singhal, Aneesh B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E349 EP E349 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401426 ER PT J AU Nguyen, VHV Poon, J Tokuda, L Sayers, J Wallis, RA Dergalust, S AF Nguyen, Viet-Huong V. Poon, John Tokuda, Lisa Sayers, Jeffrey Wallis, Roi-Ann Dergalust, Sunita TI Pharmacist Telephone Interventions Improve Adherence to Stroke Preventive Medications and Reduce Stroke Risk Factors: A Randomized Controlled Trial SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Nguyen, Viet-Huong V.; Poon, John; Tokuda, Lisa; Sayers, Jeffrey; Wallis, Roi-Ann; Dergalust, Sunita] VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 3 Z9 3 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E244 EP E244 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401052 ER PT J AU Ning, MM Buonanno, F Athenas, M Sarracino, D Krastins, B Demirjian, Z Inglessis-Azuaje, I McMullin, D Dec, GW Palacios, I Lopez, M Lo, EH AF Ning, MingMing Buonanno, Ferdinando Athenas, Michael Sarracino, Dave Krastins, Bryan Demirjian, Zareh Inglessis-Azuaje, Ignacio McMullin, David Dec, G. William Palacios, Igor Lopez, Mary Lo, Eng H. TI Effect of PFO Physiology on Circulatory Proteomic Profile in Ischemic Stroke Patients SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Ning, MingMing; Buonanno, Ferdinando] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp,CardioNeurol Clin,Clin Pro, Boston, MA 02115 USA. [Demirjian, Zareh] Harvard Univ, Sch Med, Dept Hematol, Massachusetts Gen Hosp, Boston, MA USA. [Inglessis-Azuaje, Ignacio; Dec, G. William; Palacios, Igor] Harvard Univ, Sch Med, Dept Cardiol, Massachusetts Gen Hosp, Boston, MA USA. [McMullin, David] NYU, New York, NY USA. [Lo, Eng H.] Harvard Univ, Sch Med, Dept Radiol, Neuroprotect Rsch Lab, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E255 EP E255 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401090 ER PT J AU Ning, MM Navaratna, D Demirjian, Z Inglessis-Azuaje, I McMullin, D Dec, GW Palacios, I Buonanno, F Lo, EH AF Ning, MingMing Navaratna, Deepti Demirjian, Zareh Inglessis-Azuaje, Ignacio McMullin, David Dec, G. William Palacios, Igor Buonanno, Ferdinando Lo, Eng H. TI How the Heart Whispers to the Brain: Serotonin as Neurovascular Mediator in Patent Foramen Ovale Related Stroke SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Ning, MingMing; Buonanno, Ferdinando] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Neurol, CardioNeurol Clin,Clin Prote Rsch Cntr, Boston, MA USA. [Navaratna, Deepti; Lo, Eng H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroprotect Rsch Lab,Dept Radiol, Boston, MA USA. [Demirjian, Zareh] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Hematol, Boston, MA USA. [Inglessis-Azuaje, Ignacio; Dec, G. William; Palacios, Igor] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Cardiol, Boston, MA USA. [McMullin, David] NYU, New York, NY USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E108 EP E109 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400224 ER PT J AU Nogueira, RG Kemmling, A Souza, LM Payabvash, S Yoo, AJ Lev, MH AF Nogueira, Raul G. Kemmling, Andre Souza, Leticia M. Payabvash, Seyedmehdi Yoo, Albert J. Lev, Michael H. TI Clinical-Diffusion Mismatch Better Discriminates Infarct Growth than MTT-DWI Mismatch in Patients with MCA-M1 Occlusion and Limited Infarct Core SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Nogueira, Raul G.; Kemmling, Andre; Souza, Leticia M.; Payabvash, Seyedmehdi; Yoo, Albert J.; Lev, Michael H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E235 EP E235 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401015 ER PT J AU Nogueira, RG Rymer, M Smith, WS Lutsep, H Walker, G Liebeskind, DS Budzik, R Devlin, T Jovin, TG AF Nogueira, Raul G. Rymer, Marilyn Smith, Wade S. Lutsep, Helmi Walker, Gary Liebeskind, David S. Budzik, Ronald Devlin, Thomas Jovin, Tudor G. TI Endovascular Therapy for Acute Ischemic Stroke Due to Proximal Intracranial Anterior Circulation Occlusion Treated Beyond 8 Hours from Times Last Seen Well: A Subset Analysis of the Merci Registry SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Nogueira, Raul G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rymer, Marilyn] St Lukes Hosp, Kansas City, MO USA. [Smith, Wade S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lutsep, Helmi] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Walker, Gary] Concentr Med Inc, Mountain View, CA USA. [Liebeskind, David S.] Univ Calif Los Angeles, Los Angeles, CA USA. [Budzik, Ronald] Riverside Methodist Hosp, Columbus, OH 43214 USA. [Devlin, Thomas] Erlanger SE Stroke Cntr, Chattanooga, TN USA. [Jovin, Tudor G.] UPMC, Stroke Inst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E48 EP E48 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400029 ER PT J AU Olson, D Bushnell, C Cox, M Zimmer, LO Pan, WQ Sacco, R Fonarow, GC Zorowitz, R LaBresh, KA Schwamm, LH Peterson, ED AF Olson, DaiWai Bushnell, Cheryl Cox, Margueritte Zimmer, Louise O. Pan, Wenqin Sacco, Ralph Fonarow, Gregg C. Zorowitz, Richard LaBresh, Kenneth A. Schwamm, Lee H. Peterson, Eric D. TI Death and Rehospitalization Following Hospitalization for Stroke/TIA: One Year Findings from AVAIL SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Olson, DaiWai; Cox, Margueritte; Zimmer, Louise O.; Pan, Wenqin; Peterson, Eric D.] Duke Clin Rsch Inst, Durham, NC 02114 USA. [Bushnell, Cheryl] Wake Forest Univ Hlth Sci, Winston Salem, NC USA. [Sacco, Ralph] Univ Miami, Miami, FL USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Zorowitz, Richard] Johns Hopkins Bayview Med Cntr, Baltimore, MD USA. [LaBresh, Kenneth A.] Rsch Triangle Inst, Res Triangle Pk, NC USA. [Schwamm, Lee H.] Massachusetts Gen Hosp, Stroke Serv, Boston, MA USA. RI LaBresh, Kenneth/A-6995-2017 OI LaBresh, Kenneth/0000-0001-9040-1956 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E80 EP E80 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400135 ER PT J AU Pervez, M Smith, E Siddique, KA Hellkamp, A Saver, J Bhatt, D Fonarow, G Peterson, E Schwamm, LH AF Pervez, Muhammad Smith, Eric Siddique, Khawaja A. Hellkamp, Ann Saver, Jeffrey Bhatt, Deepak Fonarow, Gregg Peterson, Eric Schwamm, Lee H. TI Lower Triglyceride Levels are Associated with Increased Incidence of Symptomatic Intracranial Hemorrhage after Acute Stroke Thrombolysis SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Pervez, Muhammad; Siddique, Khawaja A.; Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Smith, Eric] Univ Calgary, Calgary, AB, Canada. [Hellkamp, Ann; Peterson, Eric] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA. [Saver, Jeffrey] Univ Calif Neurol, Los Angeles, CA USA. [Bhatt, Deepak] Brigham & Womens Hosp, Boston, MA 02115 USA. [Fonarow, Gregg] Univ Calif Cardiol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E57 EP E58 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400059 ER PT J AU Pulli, B Papini, GD Chaudhry, ZA Gonzalez, RG Yoo, AJ Schaefer, PW AF Pulli, Benjamin Papini, Giacomo D. Chaudhry, Zeshan A. Gonzalez, R. G. Yoo, Albert J. Schaefer, Pamela W. TI Combined Magnetic Resonance Imaging and Clinical Thresholds to Predict Outcome in Acute Ischemic Stroke are Higher in Patients Treated with Reperfusion Therapy SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Pulli, Benjamin; Chaudhry, Zeshan A.; Gonzalez, R. G.; Yoo, Albert J.; Schaefer, Pamela W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Papini, Giacomo D.] Univ Milan, Scuola Specializzaz Radiodiagnost, Milan, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E70 EP E70 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400099 ER PT J AU Pulli, B Chaudhry, ZA Papini, GD Nogueira, RG Hirsch, JA Lev, MH Gonzalez, RG Schaefer, PW Yoo, AJ AF Pulli, Benjamin Chaudhry, Zeshan A. Papini, Giacomo D. Nogueira, Raul G. Hirsch, Joshua A. Lev, Michael H. Gonzalez, R. G. Schaefer, Pamela W. Yoo, Albert J. TI Decreased Acquisition Delay in Optimized CTA Protocols is Associated with Infarct Core Overestimation on CTA Source Images in Patients with Acute Ischemic Stroke SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Pulli, Benjamin; Chaudhry, Zeshan A.; Nogueira, Raul G.; Hirsch, Joshua A.; Lev, Michael H.; Gonzalez, R. G.; Schaefer, Pamela W.; Yoo, Albert J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Papini, Giacomo D.] Univ Milan, Scuola Specializzaz Radiodiagnost, Milan, Italy. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E53 EP E54 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400046 ER PT J AU Rost, NS Nogueira, RG Yoo, AJ Hirsch, JA Schwamm, LH AF Rost, Natalia S. Nogueira, Raul G. Yoo, Albert J. Hirsch, Joshua A. Schwamm, Lee H. TI Implementation Of A Patient Selection Protocol For Intra-arterial Therapy Increases Treatment Rates In Acute Ischemic Stroke SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Rost, Natalia S.; Nogueira, Raul G.; Yoo, Albert J.; Hirsch, Joshua A.; Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E321 EP E322 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401331 ER PT J AU Rost, NS Smith, EE Pervez, MA Mello, P Dreyer, P Schwamm, LH AF Rost, Natalia S. Smith, Eric E. Pervez, Muhammad A. Mello, Philip Dreyer, Paul Schwamm, Lee H. TI Improving Rates Of IV tPA For Acute Ischemic Stroke: The Massachusetts Primary Stroke Service Experience, 2004-2008 SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Rost, Natalia S.; Pervez, Muhammad A.; Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Smith, Eric E.] Univ Calgary, Calgary, AB, Canada. [Mello, Philip] Massachusetts Dept Publ Hlth, Boston, MA USA. [Dreyer, Paul] Dept Publ Hlth, Boston, MA USA. RI Smith, Eric/C-5443-2012 OI Smith, Eric/0000-0003-3956-1668 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E157 EP E158 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400382 ER PT J AU Rost, NS Biffi, A Cloonan, L Kelly, PJ Greer, D Ellinor, PT Furie, KL AF Rost, Natalia S. Biffi, Alessandro Cloonan, Lisa Kelly, Peter J. Greer, David Ellinor, Patrick T. Furie, Karen L. TI Brain Natriuretic Peptide Predicts Functional Outcome In Ischemic Stroke SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Rost, Natalia S.; Biffi, Alessandro; Cloonan, Lisa; Ellinor, Patrick T.; Furie, Karen L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kelly, Peter J.] Mater Univ Hosp, Dublin, Ireland. [Greer, David] Yale Univ, New Haven Med Cntr, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E144 EP E144 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400338 ER PT J AU Rost, NS Biffi, A Opherk, C Fitzpatrick, KM Kanakis, AS Viswanathan, A Chabriat, H Furie, KL Greenberg, SM Rosand, J Dichgans, M AF Rost, Natalia S. Biffi, Alessandro Opherk, Christian Fitzpatrick, Kaitlin M. Kanakis, Allison S. Viswanathan, Anand Chabriat, Hugues Furie, Karen L. Greenberg, Steven M. Rosand, Jonathan Dichgans, Martin TI White Matter Hyperintensity Burden Accumulation Is Accelerated In Inherited vs. Sporadic Disorders Of Small Cerebral Vasculature SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Rost, Natalia S.; Biffi, Alessandro; Fitzpatrick, Kaitlin M.; Kanakis, Allison S.; Viswanathan, Anand; Furie, Karen L.; Greenberg, Steven M.; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Opherk, Christian; Dichgans, Martin] Univ Munich, Munich, Germany. [Chabriat, Hugues] Univ Paris 07, Paris, France. RI Chabriat, Hugues/G-5699-2010 OI Chabriat, Hugues/0000-0001-8436-6074 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E134 EP E135 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400306 ER PT J AU Schwamm, LH Smith, E Saver, J Reeves, M Bhatt, D Grau-Sepulveda, M Olson, DW Hernandez, A Peterson, E Fonarow, G AF Schwamm, Lee H. Smith, Eric Saver, Jeffrey Reeves, Matthew Bhatt, Deepak Grau-Sepulveda, Maria Olson, Dai Wai Hernandez, Andrian Peterson, Eric Fonarow, Gregg TI Patient and Hospital Characteristics Associated with Use of IV tPA among Acute Ischemic Stroke Patients Arriving within 2 hours of Symptom Onset SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Smith, Eric] Univ Calgary, Carlgary, AB, Canada. [Saver, Jeffrey] Univ Calif Neurol, Los Angeles, CA USA. [Reeves, Matthew] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA. [Bhatt, Deepak] Brigham & Womens Hosp, Boston, MA 02115 USA. [Grau-Sepulveda, Maria; Olson, Dai Wai; Hernandez, Andrian; Peterson, Eric] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA. [Fonarow, Gregg] Univ Calif Cardiol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E113 EP E114 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400232 ER PT J AU Schwamm, LH Smith, E Saver, J Reeves, M Messe, S Bhatt, D Grau-Sepulveda, M Olson, DW Peterson, E Fonarow, G AF Schwamm, Lee H. Smith, Eric Saver, Jeffrey Reeves, Matthew Messe, Steven Bhatt, Deepak Grau-Sepulveda, Maria Olson, Dai Wai Peterson, Eric Fonarow, Gregg TI Temporal Trends in the Use of IV tPA among All Ischemic Stroke Patients Presenting to GWTG-Stroke Hospitals SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Smith, Eric] Univ Calgary, Calgary, AB, Canada. [Saver, Jeffrey] Univ Calif Neurol, Los Angeles, CA USA. [Reeves, Matthew] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA. [Messe, Steven] Univ Penn, Philadelphia, PA 19104 USA. [Bhatt, Deepak] Brigham & Womens Hosp, Boston, MA 02115 USA. [Grau-Sepulveda, Maria; Olson, Dai Wai; Peterson, Eric] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA. [Fonarow, Gregg] Univ Calif Cardiol, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E104 EP E104 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400214 ER PT J AU Selim, M Goldstein, J Gomes, J Greenberg, S Morgenstern, L Palesch, Y Schlaug, G Torbey, M Waldman, B Xi, GH Yeatts, S AF Selim, Magdy Goldstein, Joshua Gomes, Joao Greenberg, Steven Morgenstern, Lewis Palesch, Yuko Schlaug, Gottfried Torbey, Michel Waldman, Bonnie Xi, Guohua Yeatts, Sharon TI Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage: DFO in ICH Study SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Selim, Magdy; Schlaug, Gottfried] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Goldstein, Joshua; Greenberg, Steven] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Gomes, Joao] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Morgenstern, Lewis; Xi, Guohua] Univ Michigan, Ann Arbor, MI 48109 USA. [Palesch, Yuko; Waldman, Bonnie; Yeatts, Sharon] Med Univ S Carolina, Charleston, SC 29425 USA. [Torbey, Michel] Med Coll Wisconsin, Milwaukee, WI 53226 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E60 EP E61 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400067 ER PT J AU Silva, GS Viswanathan, A Shandra, E Schwamm, LH AF Silva, Gisele S. Viswanathan, Anand Shandra, Emma Schwamm, Lee H. TI TeleStroke 2010: A Survey of Currently Active Stroke Telemedicine Programs in the US SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Silva, Gisele S.] Univ Fed Sao Paulo, Sao Paulo, Brazil. [Viswanathan, Anand; Shandra, Emma; Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E292 EP E293 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401223 ER PT J AU Singhal, AB Fujiwara, N Mandeville, ET Arai, K Lo, EH AF Singhal, Aneesh B. Fujiwara, Norio Mandeville, Emiri T. Arai, Ken Lo, Eng H. TI Effect of Normobaric Oxygen Therapy in a Rat Model of Intracerebral Hemorrhage SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Singhal, Aneesh B.; Fujiwara, Norio; Mandeville, Emiri T.; Arai, Ken; Lo, Eng H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E296 EP E296 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401236 ER PT J AU Singhal, AB Ji, RJ Arsava, MM Zhu, MW Ay, H Wu, O Garg, P Tiglias, V Kimberly, WT Schwamm, LH Sorensen, AG AF Singhal, Aneesh B. Ji, Ruijun Arsava, Murat M. Zhu, Mingwang Ay, Hakan Wu, Ona Garg, Priya Tiglias, Vicky Kimberly, W. Taylor Schwamm, Lee H. Sorensen, A. Gregory TI Presence of MRI 'Mismatch' and Infarct Growth in Different Time Windows After Stroke Onset: a cross-sectional study SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Singhal, Aneesh B.; Ji, Ruijun; Arsava, Murat M.; Zhu, Mingwang; Ay, Hakan; Wu, Ona; Garg, Priya; Tiglias, Vicky; Kimberly, W. Taylor; Schwamm, Lee H.; Sorensen, A. Gregory] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E167 EP E167 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400415 ER PT J AU Singhal, AB Hajj-Ali, RA Topcuoglu, MA Fok, JW Calabrese, LH AF Singhal, Aneesh B. Hajj-Ali, Rula A. Topcuoglu, Mehmet A. Fok, Joshua W. Calabrese, Leonard H. TI Reversible Cerebral Vasoconstriction Syndromes (RCVS): A comparison of Hemorrhagic and Non-Hemorrhagic forms SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Singhal, Aneesh B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hajj-Ali, Rula A.; Calabrese, Leonard H.] Cleveland Clin, Cleveland, OH 44106 USA. [Topcuoglu, Mehmet A.] Hacettepe Univ Hosp, Ankara, Turkey. [Fok, Joshua W.] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E150 EP E150 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400358 ER PT J AU Smith, EE Fonarow, GC Reeves, MJ Cox, M Olson, D Hernandez, A Schwamm, LH AF Smith, Eric E. Fonarow, Gregg C. Reeves, Mathew J. Cox, Margueritte Olson, DaiWai Hernandez, Adrian Schwamm, Lee H. TI Hospital Discharge Outcomes in Mild Stroke Patients Not Treated With tPA: Findings from Get With The Guidelines-Stroke SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Smith, Eric E.] Univ Calgary, Calgary, AB, Canada. [Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Reeves, Mathew J.] Michigan State Univ, E Lansing, MI 48824 USA. [Cox, Margueritte; Olson, DaiWai; Hernandez, Adrian] Duke Univ, Durham, NC USA. [Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Smith, Eric/C-5443-2012 OI Smith, Eric/0000-0003-3956-1668 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E105 EP E106 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400217 ER PT J AU Sohn, JA Broderick, JP Spilker, JA Tomsick, TA Hill, MD Jauch, EC Mitchell, P Yan, B Abou-Chebl, A Cockroft, KM Brown, DM Panagos, PD Nogueira, RG Keller, P Khatri, P AF Sohn, Jonathan A. Broderick, Joseph P. Spilker, Judith A. Tomsick, Thomas A. Hill, Michael D. Jauch, Edward C. Mitchell, Peter Yan, Bernard Abou-Chebl, Alex Cockroft, Kevin M. Brown, David M. Panagos, Peter D. Nogueira, Raul G. Keller, Peter Khatri, Pooja CA IMS III Investigators TI Sedation Practice Patterns in Acute Stroke Endovascular Therapy: The IMS III Trial Experience SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Sohn, Jonathan A.; Broderick, Joseph P.; Spilker, Judith A.; Tomsick, Thomas A.; Khatri, Pooja] Univ Cincinnati, Acad Hlth Cntr, Cincinnati, OH USA. [Hill, Michael D.] Univ Calgary, Calgary, AB, Canada. [Jauch, Edward C.] Med Univ S Carolina, Charleston, SC 29425 USA. [Mitchell, Peter; Yan, Bernard] Royal Melbourne Hosp, Melbourne, Vic, Australia. [Abou-Chebl, Alex] Univ Louisville, Louisville, KY 40292 USA. [Cockroft, Kevin M.] Penn State Med Sch, Hershey, PA USA. [Brown, David M.] Hoag Mem Hosp, Newport Beach, CA USA. [Panagos, Peter D.] Washington Univ, St Louis, MO USA. [Nogueira, Raul G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Keller, Peter] Neurosci Trials Australia, Heidelberg Hts, Vic, Australia. RI Hill, Michael/C-9073-2012 OI Hill, Michael/0000-0002-6269-1543 NR 0 TC 1 Z9 1 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E229 EP E230 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400640 ER PT J AU Song, SS Latour, LL Luby, M Wu, O Chalela, JA Butman, JA Demchuk, AM Hill, MD Patronas, N Warach, S AF Song, Shlee S. Latour, Lawrence L. Luby, Marie Wu, Ona Chalela, Julio A. Butman, John A. Demchuk, Andrew M. Hill, Michael D. Patronas, Nicholas Warach, Steven TI Negative CT in Witnessed Onset Acute Ischemic Stroke Patients is Not a Reliable Indicator for Early Stroke Onset SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Song, Shlee S.; Latour, Lawrence L.; Luby, Marie; Warach, Steven] NIH, Stroke Branch, Bethesda, MD 20892 USA. [Wu, Ona] Massachusetts Gen Hosp, Athinoula A Martinos Cntr, Dept Radiol, Charlestown, MA USA. [Chalela, Julio A.] Med Univ S Carolina, Charleston, SC 29425 USA. [Butman, John A.; Patronas, Nicholas] NIH Clin Cntr, Bethesda, MD USA. [Demchuk, Andrew M.; Hill, Michael D.] Univ Calgary, Calgary, AB T2N 1N4, Canada. RI Demchuk, Andrew/E-1103-2012; Hill, Michael/C-9073-2012 OI Demchuk, Andrew/0000-0002-4930-7789; Hill, Michael/0000-0002-6269-1543 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E137 EP E138 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400316 ER PT J AU Souza, LM Payabvash, S Esfahani, SA Gonzalez, RG Lev, MH Nogueira, R AF Souza, Leticia M. Payabvash, Seyedmehdi Esfahani, Shadi A. Gonzalez, R. Gilberto Lev, Michael H. Nogueira, Raul TI Admission DWI Infarct Volume May Be A Stronger Predictor of Clinical Outcome than The Presence of Proximal Arterial Occlusion in Acute Stroke Patients Undergoing Reperfusion Therapy SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Souza, Leticia M.; Payabvash, Seyedmehdi; Esfahani, Shadi A.; Gonzalez, R. Gilberto; Lev, Michael H.; Nogueira, Raul] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E235 EP E236 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401018 ER PT J AU Souza, LM Payabvash, S Kemmling, A Gonzalez, RG Nogueira, R Lev, MH AF Souza, Leticia M. Payabvash, Seyedmehdi Kemmling, Andre Gonzalez, R. Gilberto Nogueira, Raul Lev, Michael H. TI Robust Collateral Circulation on CT Angiography of Acute Stroke Patients with Proximal MCA Occlusion is a Strong Predictor of Small Admission MR Diffusion/MTT Infarct Size SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Souza, Leticia M.; Payabvash, Seyedmehdi; Kemmling, Andre; Gonzalez, R. Gilberto; Nogueira, Raul; Lev, Michael H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E152 EP E153 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400366 ER PT J AU Thomas, LE Viswanathan, A Cochrane, T Johnson, J McMahon, M Santimauro, JM Schwamm, L AF Thomas, Lisa E. Viswanathan, Anand Cochrane, Thomas Johnson, John McMahon, Marilyn Santimauro, Janine M. Schwamm, Lee TI Variability in the Quality of TeleStroke Informed Consent for IV-TPA SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Thomas, Lisa E.; Viswanathan, Anand; Johnson, John; McMahon, Marilyn; Santimauro, Janine M.; Schwamm, Lee] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cochrane, Thomas] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E293 EP E293 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401225 ER PT J AU Tong, D Zhao, X Olson, D Reeves, M Fonarow, G Schwamm, L Smith, E AF Tong, David Zhao, Xin Olson, DaiWai Reeves, Matthew Fonarow, Gregg Schwamm, Lee Smith, Eric TI Trends in Acute Ischemic Stroke Presentation in the GWTG Stroke Database 2004-2009: Opportunities for Improvement and Implications of Longer Treatment Time Windows SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Tong, David] Calif Pacific Med Ctr, San Francisco, CA USA. [Zhao, Xin] Duke Clin Rsch Inst, Durham, NC USA. [Olson, DaiWai] Duke Univ, Med Cntr, Durham, NC USA. [Reeves, Matthew] Michigan State Univ, E Lansing, MI 48824 USA. [Fonarow, Gregg] Univ Calif Los Angeles, Los Angeles, CA USA. [Schwamm, Lee] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Smith, Eric] Univ Calgary, Calgary, AB, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E339 EP E339 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401392 ER PT J AU Westover, MB Bianchi, MT Eckman, MH Greenberg, SM AF Westover, M. Brandon Bianchi, Matt T. Eckman, Mark H. Greenberg, Steven M. TI Should Statins Be Avoided After Intracerebral Hemorrhage? SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Westover, M. Brandon; Bianchi, Matt T.; Greenberg, Steven M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Eckman, Mark H.] Univ Cincinnati, Cincinnati, OH USA. NR 0 TC 0 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E303 EP E303 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401263 ER PT J AU Wu, O Song, SS Ritter, C Latour, LL Yoo, AJ Lorenzano, S Chaudhry, ZA Sorensen, AG Schwamm, LH Warach, S AF Wu, Ona Song, Shlee S. Ritter, Carsten Latour, Lawrence L. Yoo, Albert J. Lorenzano, Svetlana Chaudhry, Zeshan A. Sorensen, A. G. Schwamm, Lee H. Warach, Steven CA MR WITNESS Investigators TI MRI As Witness: Ready For Prime-time? SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Wu, Ona; Yoo, Albert J.; Lorenzano, Svetlana; Chaudhry, Zeshan A.; Sorensen, A. G.; Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Song, Shlee S.; Ritter, Carsten; Latour, Lawrence L.; Warach, Steven] NINDS, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E285 EP E285 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479401197 ER PT J AU Yigitkanli, K Pekcec, A Pallast, S Antipenko, A Nikolov, D Lo, EH Van Leyen, K AF Yigitkanli, Kazim Pekcec, Anton Pallast, Stefanie Antipenko, Alexander Nikolov, Dimitar Lo, Eng H. Van Leyen, Klaus TI A Role for Semaphorin 3A in Stroke Recovery SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Yigitkanli, Kazim; Pekcec, Anton; Pallast, Stefanie; Lo, Eng H.; Van Leyen, Klaus] Massachusetts Gen Hosp, Charlestown, MA USA. [Antipenko, Alexander; Nikolov, Dimitar] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. RI van Leyen, Klaus/C-9126-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E180 EP E180 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400467 ER PT J AU Yigitkanli, K Pekcec, A Minamishima, S Ichinose, F Lo, EH van Leyen, K AF Yigitkanli, Kazim Pekcec, Anton Minamishima, Shizuka Ichinose, Fumito Lo, Eng H. van Leyen, Klaus TI 12/15-Lipoxygenase Contributes To Brain Damage In Transient Global Cerebral Ischemia SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Yigitkanli, Kazim; Pekcec, Anton; Lo, Eng H.; van Leyen, Klaus] Massachusetts Gen Hosp, Neuroprotect Rsch Lab, Dept Radiol, Charlestown, MA USA. [Minamishima, Shizuka; Ichinose, Fumito] Massachusetts Gen Hosp, Anesthesia Cntr Crit Care Rsch, Dept Anesthesia & Crit Care, Charlestown, MA USA. RI van Leyen, Klaus/C-9126-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E174 EP E174 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400443 ER PT J AU Burstein, H AF Burstein, H. TI Patients with anti-HER2 responsive disease: Definition and adjuvant therapies SO BREAST LA English DT Meeting Abstract ID BREAST-CANCER; HERA TRIAL; TRASTUZUMAB; CHEMOTHERAPY C1 [Burstein, H.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0960-9776 J9 BREAST JI Breast PD MAR PY 2011 VL 20 SU 1 BP S12 EP S13 PG 2 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 747MM UT WOS:000289324100031 ER PT J AU Harris, J Schoenfeld, J AF Harris, J. Schoenfeld, J. TI Abbreviated course of radiotherapy (RT) for breast cancer SO BREAST LA English DT Meeting Abstract C1 [Harris, J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Harris, J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Schoenfeld, J.] Harvard Univ, Sch Med, Harvard Radiat Oncol Program, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0960-9776 J9 BREAST JI Breast PD MAR PY 2011 VL 20 SU 1 BP S11 EP S12 PG 2 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 747MM UT WOS:000289324100028 ER PT J AU Mandelblatt, J Cronin, K Berry, D Feuer, E de Koning, H Lee, S Plevritis, S Schechter, C Stout, N van Ravesteyn, N Zelen, M AF Mandelblatt, J. Cronin, K. Berry, D. Feuer, E. de Koning, H. Lee, S. Plevritis, S. Schechter, C. Stout, N. van Ravesteyn, N. Zelen, M. TI Changing the guidelines for breast cancer screening: modeling mammography benefits and harms SO BREAST LA English DT Meeting Abstract C1 [Mandelblatt, J.] Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC USA. [Mandelblatt, J.] Lombardi Comprehens Canc Ctr, Dept Med, Washington, DC USA. [Cronin, K.; Feuer, E.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Berry, D.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA. [de Koning, H.; van Ravesteyn, N.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands. [Lee, S.; Zelen, M.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Lee, S.] Inst Canc Res, Boston, MA USA. [Plevritis, S.] Stanford Univ, Dept Radiol, Palo Alto, CA 94304 USA. [Schechter, C.] Albert Einstein Coll Med, Dept Family & Social Med, Bronx, NY 10467 USA. [Schechter, C.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Stout, N.] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA. [Stout, N.] Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care, Boston, MA USA. [Zelen, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0960-9776 J9 BREAST JI Breast PD MAR PY 2011 VL 20 SU 1 BP S7 EP S8 PG 2 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 747MM UT WOS:000289324100018 ER PT J AU Partridge, A AF Partridge, A. TI Adjuvant therapies for the very young SO BREAST LA English DT Meeting Abstract C1 [Partridge, A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0960-9776 J9 BREAST JI Breast PD MAR PY 2011 VL 20 SU 1 BP S14 EP S15 PG 2 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 747MM UT WOS:000289324100035 ER PT J AU Matulonis, UA AF Matulonis, Ursula A. TI Bevacizumab and its use in epithelial ovarian cancer SO FUTURE ONCOLOGY LA English DT Article DE antiangiogenesis; bevacizumab; fallopian tube cancer; ovarian cancer; peritoneal cancer ID ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; METASTATIC COLORECTAL-CANCER; GYNECOLOGIC-ONCOLOGY-GROUP; PEGYLATED LIPOSOMAL DOXORUBICIN; PLATINUM-BASED CHEMOTHERAPY; CELL LUNG-CANCER; RECURRENT OVARIAN; PRIMARY PERITONEAL; GASTROINTESTINAL PERFORATION AB Bevacizumab is a monoclonal antibody that binds to VEGF, a circulating protein involved in the promotion of angiogenesis and probably tumor growth and progression. Bevacizumab has demonstrated anticancer activity in several cancers, either combined with chemotherapy or when used as a single agent, and has been approved by the US FDA as a treatment for several cancers. As VEGF has been implicated in ovarian cancer progression and ascites formation, and high levels of VEGF have been found in plasma and ascites in women with ovarian cancer, bevacizumab has been tested as an anticancer therapy in ovarian cancer. Documented single-agent activity of bevacizumab in recurrent ovarian cancer has led to combination studies with both biologic agents as well as other chemotherapy agents in both recurrent and newly diagnosed cancer. One trial in patients with recurrent, heavily pretreated ovarian cancer demonstrated a higher than predicted risk of gastrointestinal perforation, and although a lower incidence of gastrointestinal perforation has been reported in less heavily pretreated patients, patients and their physicians must be aware of this risk. Upfront studies testing the impact of adding bevacizumab to carboplatin and paclitaxel chemotherapy for the treatment of newly diagnosed cancer are currently underway, and one Phase III randomized study (Gynecologic Oncology Group study 218) was recently presented and will be discussed in this article. C1 Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. RP Matulonis, UA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brooklyn Ave, Boston, MA 02215 USA. EM ursula_matulonis@dfci.harvard.edu NR 95 TC 6 Z9 7 U1 0 U2 0 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1479-6694 J9 FUTURE ONCOL JI Future Oncol. PD MAR PY 2011 VL 7 IS 3 BP 365 EP 379 DI 10.2217/FON.10.167 PG 15 WC Oncology SC Oncology GA 751CF UT WOS:000289594400010 PM 21323425 ER PT J AU Arar, N Knight, SJ Modell, SM Issa, AM AF Arar, Nedal Knight, Sara J. Modell, Stephen M. Issa, Amalia M. CA GAPPNetTM Inaugural Knowledge Synt TI The Genome-based Knowledge Management in Cycles model: a complex adaptive systems framework for implementation of genomic applications SO PERSONALIZED MEDICINE LA English DT Article DE breast cancer; complex-adaptive systems; GAPPNet (TM) initiative; genomic applications; genomics; knowledge translation; Lynch syndrome ID NONPOLYPOSIS COLORECTAL-CANCER; REVISED BETHESDA GUIDELINES; EGAPP WORKING GROUP; LYNCH-SYNDROME; BREAST-CANCER; CLINICAL-PRACTICE; HEALTH-POLICY; MICROSATELLITE INSTABILITY; TRANSLATIONAL RESEARCH; REDUCING MORBIDITY AB The main mission of the Genomic Applications in Practice and Prevention Network (TM) is to advance collaborative efforts involving partners from across the public health sector to realize the promise of genomics in healthcare and disease prevention. We introduce a new framework that supports the Genomic Applications in Practice and Prevention Network mission and leverages the characteristics of the complex adaptive systems approach. We call this framework the Genome-based Knowledge Management in Cycles model (G-KNOMIC). G-KNOMIC proposes that the collaborative work of multidisciplinary teams utilizing genome-based applications will enhance translating evidence-based genomic findings by creating ongoing knowledge management cycles. Each cycle consists of knowledge synthesis, knowledge evaluation, knowledge implementation and knowledge utilization. Our framework acknowledges that all the elements in the knowledge translation process are interconnected and continuously changing. It also recognizes the importance of feedback loops, and the ability of teams to self-organize within a dynamic system. We demonstrate how this framework can be used to improve the adoption of genomic technologies into practice using two case studies of genomic uptake. C1 [Knight, Sara J.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA USA. [Modell, Stephen M.] Univ Michigan, Sch Publ Hlth, Ctr Publ Hlth & Community Genom, Ann Arbor, MI 48109 USA. [Issa, Amalia M.] Univ Houston, Coll Pharm, Program Personalized Med & Targeted Therapeut, Houston, TX 77030 USA. RP Arar, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, S Texas Vet Hlth Care Syst, 7703 Floyd Curl, San Antonio, TX 78229 USA. EM ararn@uthscsa.edu FU InHealth; Institute of Health Technology Studies FX The authors acknowledge partial support by InHealth, the Institute of Health Technology Studies (principal investigator: Amalia M Issa).The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. NR 92 TC 2 Z9 2 U1 1 U2 5 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1741-0541 J9 PERS MED JI Pers. Med. PD MAR PY 2011 VL 8 IS 2 BP 191 EP 205 DI 10.2217/PME.11.5 PG 15 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 747SE UT WOS:000289338900014 ER PT J AU Rodriguez-Mari, A Wilson, C Titus, TA Canestro, C BreMiller, RA Yan, YL Nanda, I Johnston, A Kanki, JP Gray, EM He, XJ Spitsbergen, J Schindler, D Postlethwait, JH AF Rodriguez-Mari, Adriana Wilson, Catherine Titus, Tom A. Canestro, Cristian BreMiller, Ruth A. Yan, Yi-Lin Nanda, Indrajit Johnston, Adam Kanki, John P. Gray, Erin M. He, Xinjun Spitsbergen, Jan Schindler, Detlev Postlethwait, John H. TI Roles of brca2 (fancd1) in Oocyte Nuclear Architecture, Gametogenesis, Gonad Tumors, and Genome Stability in Zebrafish SO PLOS GENETICS LA English DT Article ID MULLERIAN HORMONE AMH; FANCONI-ANEMIA; BREAST-CANCER; GERM-CELLS; SEX-DIFFERENTIATION; EXPRESSION PATTERN; PROSTATE-CANCER; OVARIAN-CANCER; MESSENGER-RNA; DEAD-END AB Mild mutations in BRCA2 (FANCD1) cause Fanconi anemia (FA) when homozygous, while severe mutations cause common cancers including breast, ovarian, and prostate cancers when heterozygous. Here we report a zebrafish brca2 insertional mutant that shares phenotypes with human patients and identifies a novel brca2 function in oogenesis. Experiments showed that mutant embryos and mutant cells in culture experienced genome instability, as do cells in FA patients. In wildtype zebrafish, meiotic cells expressed brca2; and, unexpectedly, transcripts in oocytes localized asymmetrically to the animal pole. In juvenile brca2 mutants, oocytes failed to progress through meiosis, leading to female-to-male sex reversal. Adult mutants became sterile males due to the meiotic arrest of spermatocytes, which then died by apoptosis, followed by neoplastic proliferation of gonad somatic cells that was similar to neoplasia observed in ageing dead end (dnd)-knockdown males, which lack germ cells. The construction of animals doubly mutant for brca2 and the apoptotic gene tp53 (p53) rescued brca2-dependent sex reversal. Double mutants developed oocytes and became sterile females that produced only aberrant embryos and showed elevated risk for invasive ovarian tumors. Oocytes in double-mutant females showed normal localization of brca2 and pou5f1 transcripts to the animal pole and vasa transcripts to the vegetal pole, but had a polarized rather than symmetrical nucleus with the distribution of nucleoli and chromosomes to opposite nuclear poles; this result revealed a novel role for Brca2 in establishing or maintaining oocyte nuclear architecture. Mutating tp53 did not rescue the infertility phenotype in brca2 mutant males, suggesting that brca2 plays an essential role in zebrafish spermatogenesis. Overall, this work verified zebrafish as a model for the role of Brca2 in human disease and uncovered a novel function of Brca2 in vertebrate oocyte nuclear architecture. C1 [Rodriguez-Mari, Adriana; Wilson, Catherine; Titus, Tom A.; Canestro, Cristian; BreMiller, Ruth A.; Yan, Yi-Lin; Gray, Erin M.; He, Xinjun; Postlethwait, John H.] Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA. [Nanda, Indrajit; Schindler, Detlev] Univ Wurzburg, Bioctr, Inst Human Genet, Wurzburg, Germany. [Johnston, Adam; Kanki, John P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Spitsbergen, Jan] Oregon State Univ, Marine & Freshwater Biomed Sci Ctr, Corvallis, OR 97331 USA. RP Rodriguez-Mari, A (reprint author), Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA. EM jpostle@uoneuro.uoregon.edu RI He, Xinjun/F-9797-2011; Canestro, Cristian/L-9661-2014 OI Canestro, Cristian/0000-0003-4623-8105 FU NIH [1R01GM085318, 1P01HL048546, 2R01RR020833]; Schroeder-Kurth Fund; Ministerio de Ciencia e Innovacion (MICINN) [BFU2010-14875]; Fanconi Anemia Research Fund FX Work was supported by grants 1R01GM085318, 1P01HL048546, and 2R01RR020833 from NIH to JHP; by a grant from the Schroeder-Kurth Fund to JHP; by grant BFU2010-14875 from the Ministerio de Ciencia e Innovacion (MICINN) to CC; and by grants from the Fanconi Anemia Research Fund (http://www.fanconi.org/) to JPK and JHP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 92 TC 20 Z9 21 U1 1 U2 24 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD MAR PY 2011 VL 7 IS 3 AR e1001357 DI 10.1371/journal.pgen.1001357 PG 20 WC Genetics & Heredity SC Genetics & Heredity GA 743DD UT WOS:000288996600038 PM 21483806 ER PT J AU Mesidor, M Gidugu, V Rogers, ES Kash-MacDonald, VM Boardman, JB AF Mesidor, Marie Gidugu, Vasudha Rogers, E. Sally Kash-MacDonald, V. Megan Boardman, Judith B. TI A Qualitative Study: Barriers and Facilitators to Health Care Access for Individuals with Psychiatric Disabilities SO PSYCHIATRIC REHABILITATION JOURNAL LA English DT Article DE physical health; psychiatric disabilities; healthcare access; integrated care ID SERIOUS MENTAL-ILLNESS; PRIMARY MEDICAL-CARE; SERVICES; SCHIZOPHRENIA; DISORDERS; MORTALITY; COMORBIDITY; VETERANS; COHORT AB Objective: This qualitative study was conducted as part of a larger randomized trial to examine barriers and facilitators to accessing and providing comprehensive primary health care for individuals with serious mental illnesses. We examined the perspectives of administrators and providers in a behavioral health organization surrounding the use of a nurse practitioner model of delivering primary healthcare. Methods: Ten key informant interviews were conducted and analyzed using qualitative data analysis software. Concepts and themes regarding access to and delivery of primary healthcare were inductively derived from the data. Results: Results confirmed significant issues related to chronic physical health problems among individuals with psychiatric disabilities and detailed a host of barriers to receiving health care as well as the perceived benefit of the nurse practitioner intervention. Financial challenges played a significant role in the organization's ability to make primary and mental health care integration sustainable endeavor. In addition, staff faced increased burdens on their time due to adding a focus on physical health to their existing job duties. Conclusions and Implications for Practice: A nurse practitioner stationed in a behavioral healthcare setting is viewed by administrators and providers as extremely beneficial in addressing issues of access to comprehensive and integrated primary healthcare for individuals with severe psychiatric disabilities but sustaining such a model of care is not without organizational challenges. C1 [Gidugu, Vasudha; Rogers, E. Sally] Boston Univ, Ctr Psychiat Rehabil, Boston, MA 02215 USA. [Mesidor, Marie] Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA. [Kash-MacDonald, V. Megan] Kings Coll London, Inst Psychiat, London, England. [Boardman, Judith B.] Boston VA Healthcare Syst, Boston, MA USA. RP Rogers, ES (reprint author), Boston Univ, Ctr Psychiat Rehabil, 940 Commonwealth Ave W, Boston, MA 02215 USA. NR 35 TC 5 Z9 5 U1 4 U2 19 PU CENTER PSYCHIATRIC REHABILITATION PI BOSTON PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA SN 1095-158X J9 PSYCHIATR REHABIL J JI Psychiatr. Rehabil. J. PD SPR PY 2011 VL 34 IS 4 SI SI BP 285 EP 294 DI 10.2975/34.4.2011.285.294 PG 10 WC Psychiatry; Rehabilitation SC Psychiatry; Rehabilitation GA 749FL UT WOS:000289449100004 PM 21459744 ER PT J AU Sher, L AF Sher, Leo TI Brain-derived neurotrophic factor and suicidal behavior in patients with posttraumatic stress disorder SO REVISTA BRASILEIRA DE PSIQUIATRIA LA English DT Letter ID BDNF C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. [Sher, Leo] Mt Sinai Sch Med, New York, NY USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, New York, NY USA. NR 5 TC 1 Z9 1 U1 0 U2 0 PU ASSOC BRASILEIRA PSIQUIATRIA PI SAO PAULO PA SUBSCRIPTION DEPARTMENT, RUA PEDRO DE TOLEDO, 967 - CASA 01, SAO PAULO, SP 04039-032 A, BRAZIL SN 1516-4446 J9 REV BRAS PSIQUIATR JI Rev. Bras. Psiquiatr. PD MAR PY 2011 VL 33 IS 1 BP 105 EP 106 PG 2 WC Psychiatry SC Psychiatry GA 753CG UT WOS:000289741400025 PM 21537733 ER PT J AU Nguyen, BNH Azimzadeh, AM Schroeder, C Buddensick, T Zhang, T Laaris, A Cochrane, M Schuurman, HJ Sachs, DH Allan, JS Pierson, RN AF Nguyen, Bao-Ngoc H. Azimzadeh, Agnes M. Schroeder, Carsten Buddensick, Thomas Zhang, Tianshu Laaris, Amal Cochrane, Megan Schuurman, Henk-Jan Sachs, David H. Allan, James S. Pierson, Richard N., III TI Absence of Gal epitope prolongs survival of swine lungs in an ex vivo model of hyperacute rejection SO XENOTRANSPLANTATION LA English DT Article DE alphaGal; antibodies; ex vivo lung perfusion; genetically engineered; hyperacute rejection; lung; swine; Xenotransplantation ID DECAY-ACCELERATING FACTOR; TO-HUMAN MODEL; HUMAN PLATELETS; COMPLEMENT ACTIVATION; HEART-TRANSPLANTATION; NATURAL ANTIBODIES; TISSUE FACTOR; HUMAN BLOOD; ALPHA-GAL; IN-VITRO AB Background: Galactosyl transferase gene knock-out (GalTKO) swine offer a unique tool to evaluate the role of the Gal antigen in xenogenic lung hyperacute rejection. Methods: We perfused GalTKO miniature swine lungs with human blood. Results were compared with those from previous studies using wild-type and human decay-accelerating factor-transgenic (hDAF+/+) pig lungs. Results: GalTKO lungs survived 132 +/- 52 min compared to 10 +/- 9 min for wild-type lungs (P = 0.001) and 45 +/- 60 min for hDAF+/+ lungs (P = 0.18). GalTKO lungs displayed stable physiologic flow and pulmonary vascular resistance (PVR) until shortly before graft demise, similar to autologous perfusion, and unlike wild-type or hDAF+/+ lungs. Early (15 and 60 min) complement (C3a) and platelet activation and intrapulmonary platelet deposition were significantly diminished in GalTKO lungs relative to wild-type or hDAF+/+ lungs. However, GalTKO lungs adsorbed cytotoxic anti-non-Gal antibody and elaborated high levels of thrombin; their demise was associated with increased PVR, capillary congestion, intravascular thrombi and strong CD41 deposition not seen at earlier time points. Conclusions: In summary, GalTKO lungs are substantially protected from injury but, in addition to anti-non-Gal antibody and complement, platelet adhesion and non-physiologic intravascular coagulation contribute to Gal-independent lung injury mechanisms. C1 [Nguyen, Bao-Ngoc H.; Azimzadeh, Agnes M.; Schroeder, Carsten; Buddensick, Thomas; Zhang, Tianshu; Laaris, Amal; Pierson, Richard N., III] Univ Maryland, Dept Surg, Baltimore, MD 21201 USA. [Nguyen, Bao-Ngoc H.; Azimzadeh, Agnes M.; Schroeder, Carsten; Buddensick, Thomas; Zhang, Tianshu; Laaris, Amal; Pierson, Richard N., III] Baltimore VAMC, Baltimore, MD USA. [Schroeder, Carsten] Case Western Univ, Dept Surg, Cleveland, OH USA. [Cochrane, Megan; Sachs, David H.; Allan, James S.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA. [Schuurman, Henk-Jan] Immerge Biotherapeut Inc, Cambridge, MA USA. RP Azimzadeh, AM (reprint author), Univ Maryland, Dept Surg, 10 S Pine St,MSTF Bldg,Room 434C, Baltimore, MD 21201 USA. EM aazimzadeh@smail.umary-land.edu FU NIH [U01 AI 066335]; VA Merit Award (Pierson) [NIH R01 HL67110]; TSFRE resident research award (Nguyen); Deutsche Forschungsgemeinschaft (Schroeder); Maryland Cigarette Restitution Fund Program; General Clinical research Center (GCRC) of University of Maryland; [NIH F32 HL079818] FX This work was supported by: NIH U01 AI 066335 and a VA Merit Award (Pierson), NIH R01 HL67110 (Allan); NIH F32 HL079818 and a TSFRE resident research award (Nguyen); a Deutsche Forschungsgemeinschaft research award (Schroeder); and an Other Tobacco Related Diseases research grant from the Maryland Cigarette Restitution Fund Program. The work is also supported by the General Clinical research Center (GCRC) of University of Maryland for nursing staff and financial support in collecting blood from human donors for ex-vivo lung perfusion experiments. We thank Immerge Biotherapeutics for supplying GalTKO lungs and Dr. David Cooper for kindly providing the NeuGc antigen. We also thank Xiangfei Cheng, Qi Feng and Nitin Sangrampurkar for their valuable technical assistance. NR 49 TC 20 Z9 20 U1 1 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0908-665X J9 XENOTRANSPLANTATION JI Xenotransplantation PD MAR-APR PY 2011 VL 18 IS 2 BP 94 EP 107 DI 10.1111/j.1399-3089.2011.00633.x PG 14 WC Medicine, Research & Experimental; Transplantation SC Research & Experimental Medicine; Transplantation GA 751UA UT WOS:000289641900003 PM 21496117 ER PT J AU Zhernakova, A Stahl, EA Trynka, G Raychaudhuri, S Festen, E Franke, L Fehrmann, RSN Kurreeman, FAS Thomson, B Gupta, N Romanos, J McManus, R Ryan, AW Turner, G Remmers, EF Greco, L Toes, R Grandone, E Mazzilli, MC Rybak, A Cukrowska, B Li, YH de Bakker, PIW Gregersen, PK Worthington, J Siminovitch, KA Klareskog, L Huizinga, TWJ Wijmenga, C Plenge, RM AF Zhernakova, Alexandra Stahl, Eli A. Trynka, Gosia Raychaudhuri, Soumya Festen, Eleanora Franke, Lude Fehrmann, Rudolf S. N. Kurreeman, Fina A. S. Thomson, Brian Gupta, Namrata Romanos, Jihane McManus, Ross Ryan, Anthony W. Turner, Graham Remmers, Elaine F. Greco, Luigi Toes, Rene Grandone, Elvira Mazzilli, Maria Cristina Rybak, Anna Cukrowska, Bozena Li, Yonghong de Bakker, Paul I. W. Gregersen, Peter K. Worthington, Jane Siminovitch, Katherine A. Klareskog, Lars Huizinga, Tom W. J. Wijmenga, Cisca Plenge, Robert M. TI META-ANALYSIS OF GENOME-WIDE ASSOCIATION STUDIES IN CELIAC DISEASE AND RHEUMATOID ARTHRITIS IDENTIFIES FOURTEEN NON-HLA SHARED LOCI SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT 31st European Workshop for Rheumatology Research CY MAR 03-06, 2011 CL Amsterdam, NETHERLANDS C1 [Zhernakova, Alexandra; Kurreeman, Fina A. S.; Toes, Rene; Huizinga, Tom W. J.] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands. [Zhernakova, Alexandra] Univ Med Ctr Utrecht, Dept Med Genet, Utrecht, Netherlands. [Zhernakova, Alexandra; Stahl, Eli A.; Kurreeman, Fina A. S.; de Bakker, Paul I. W.; Plenge, Robert M.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA. [Stahl, Eli A.; Raychaudhuri, Soumya; Kurreeman, Fina A. S.; Thomson, Brian; Gupta, Namrata; de Bakker, Paul I. W.; Plenge, Robert M.] Broad Inst, Cambridge, MA USA. [Trynka, Gosia; Festen, Eleanora; Franke, Lude; Fehrmann, Rudolf S. N.; Romanos, Jihane; Wijmenga, Cisca] Univ Groningen, Groningen, Netherlands. [Trynka, Gosia; Festen, Eleanora; Franke, Lude; Fehrmann, Rudolf S. N.; Romanos, Jihane; Wijmenga, Cisca] Univ Med Ctr Groningen, Dept Genet, NL-9713 AV Groningen, Netherlands. [Raychaudhuri, Soumya] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA. [Franke, Lude] Univ London, Barts & London Sch Med & Dent, Blizard Inst Cell & Mol, London, England. [McManus, Ross; Ryan, Anthony W.; Turner, Graham] St James Hosp, Trinity Coll Dublin, Dept Clin Med, Trinity Ctr Hlth Sci, Dublin 8, Ireland. [Remmers, Elaine F.] NIAMSD, Genet & Genom Branch, US Natl Inst Hlth, Bethesda, MD 20892 USA. [Greco, Luigi] Univ Naples Federico 2, European Lab Food Induced Dis, Naples, Italy. [Grandone, Elvira] IRCCS Casa Sollievo Sofferenza, Unita Aterosclerosi & Trombosi, Foggia, Italy. [Mazzilli, Maria Cristina] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy. [Rybak, Anna] Childrens Mem Hlth Inst, Dept Gastroenterol Hepatol & Immunol, Warsaw, Poland. [Cukrowska, Bozena] Childrens Mem Hlth Inst, Dept Pathol, Warsaw, Poland. [Li, Yonghong] Celera, Alameda, CA USA. [de Bakker, Paul I. W.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Genet,Dept Med, Boston, MA 02115 USA. [de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands. [Gregersen, Peter K.] N Shore Long Isl Jewish Hlth Syst, Feinstein Inst Med Res, Manhasset, NY USA. [Worthington, Jane] Univ Manchester, Arthrit Res Campaign Epidemiol Unit, Manchester, Lancs, England. [Siminovitch, Katherine A.] Univ Toronto, Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada. [Siminovitch, Katherine A.] Univ Hlth Network, Toronto, ON, Canada. [Klareskog, Lars] Karolinska Inst, Dept Med, Rheumatol Unit, Stockholm, Sweden. [Klareskog, Lars] Karolinska Univ Hosp Solna, Stockholm, Sweden. RI Ryan, Anthony/A-1336-2010; Romanos, Jihane/F-7372-2012; Wijmenga, Cisca/D-2173-2009; de Bakker, Paul/B-8730-2009; Franke, Lude/P-7036-2016; Festen, Eleonora/S-3557-2016 OI de Bakker, Paul/0000-0001-7735-7858; Franke, Lude/0000-0002-5159-8802; NR 0 TC 0 Z9 0 U1 0 U2 3 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD MAR PY 2011 VL 70 SU 2 BP A21 EP A21 DI 10.1136/ard.2010.148965.20 PG 1 WC Rheumatology SC Rheumatology GA 724NE UT WOS:000287582400051 ER PT J AU Laghi, F Jubran, A AF Laghi, Franco Jubran, Amal TI Treating the septic muscle with electrical stimulations SO CRITICAL CARE MEDICINE LA English DT Editorial Material DE sepsis; intensive care unit; electrical stimulation; myopathy; ICU-acquired weakness; muscular atrophy; peripheral muscles ID CRITICALLY-ILL PATIENTS C1 [Laghi, Franco] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. Loyola Univ, Maywood, IL 60153 USA. RP Laghi, F (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 18 TC 2 Z9 2 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD MAR PY 2011 VL 39 IS 3 BP 585 EP 586 DI 10.1097/CCM.0b013e31820e2f6f PG 2 WC Critical Care Medicine SC General & Internal Medicine GA 723BB UT WOS:000287480000026 PM 21330856 ER PT J AU Albrecht, M Wiener-Kronish, JP AF Albrecht, Meredith Wiener-Kronish, Jeanine P. TI Newer technology is not always better SO CRITICAL CARE MEDICINE LA English DT Editorial Material DE emergency intubation; Airtraq; video laryngoscope; direct laryngoscope; randomized controlled trial ID PERFORMANCE; INTUBATION; LARYNGOSCOPES C1 [Albrecht, Meredith; Wiener-Kronish, Jeanine P.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. RP Albrecht, M (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. NR 10 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD MAR PY 2011 VL 39 IS 3 BP 591 EP 592 DI 10.1097/CCM.0b013e31820c6c01 PG 2 WC Critical Care Medicine SC General & Internal Medicine GA 723BB UT WOS:000287480000030 PM 21330860 ER PT J AU Pu, CL Pei, WJ AF Pu, Cun-Lai Pei, Wen-Jiang TI INTEGRATING LOCAL AND GLOBAL ROUTING ON SCALE-FREE NETWORKS SO INTERNATIONAL JOURNAL OF MODERN PHYSICS C LA English DT Article DE Routing; transport efficiency; network capacity; scale-free network ID SMALL-WORLD; NAVIGATION; DYNAMICS AB Network navigation is one of the main problems in large communication networks. We propose a new routing strategy in which some smart nodes in networks deliver messages to next hops on the paths towards destinations according to Yan's algorithm while the other nodes just deliver messages randomly. We test our routing strategy in a large scale-free network. Simulations show that the average delivery time decreases with increase of number of smart nodes, while the maximal network capacity increases with number of smart nodes in the network. Moreover our strategy is much more efficient when employed with target selection than with random selection of the smart nodes. C1 [Pu, Cun-Lai; Pei, Wen-Jiang] Southeast Univ, Sch Informat Sci & Engn, Nanjing 210096, Peoples R China. [Pu, Cun-Lai] Northeastern Univ, Dept Phys, Ctr Complex Network Res, Boston, MA 02115 USA. [Pu, Cun-Lai] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA. RP Pu, CL (reprint author), Southeast Univ, Sch Informat Sci & Engn, Nanjing 210096, Peoples R China. EM pucunlai@yahoo.cn FU National Natural Science Foundation of China [60672095, 60972165]; National High Technology Research and Development Program of China [2007AA11Z210]; Natural Science Foundation of Jiangsu Province [BK2008281] FX The authors thank Dr. Chao-Ming Song, Dr. Yang Liu, and Dr. Da-Shun Wang for their valuable comments and suggestions. This work was supported by the National Natural Science Foundation of China (Grant Nos. 60672095 and 60972165), the National High Technology Research and Development Program of China (Grant No. 2007AA11Z210), the Natural Science Foundation of Jiangsu Province (Grant No. BK2008281). NR 19 TC 0 Z9 0 U1 0 U2 5 PU WORLD SCIENTIFIC PUBL CO PTE LTD PI SINGAPORE PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE SN 0129-1831 J9 INT J MOD PHYS C JI Int. J. Mod. Phys. C PD MAR PY 2011 VL 22 IS 3 BP 297 EP 304 DI 10.1142/S0129183111016221 PG 8 WC Computer Science, Interdisciplinary Applications; Physics, Mathematical SC Computer Science; Physics GA 749LG UT WOS:000289467600007 ER PT J AU Biffi, A Greenberg, SM AF Biffi, Alessandro Greenberg, Steven M. TI Cerebral Amyloid Angiopathy: A Systematic Review SO JOURNAL OF CLINICAL NEUROLOGY LA English DT Review DE cerebral amyloid angiopathy; cerebral hemorrhage; dementia ID BLOOD-BRAIN-BARRIER; CENTRAL-NERVOUS-SYSTEM; RECURRENT INTRACEREBRAL HEMORRHAGE; RECEPTOR-MEDIATED TRANSPORT; APOLIPOPROTEIN-E GENOTYPE; BETA PRECURSOR PROTEIN; SMALL VESSEL DISEASE; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; TRANSGENIC MICE AB Cerebral amyloid angiopathy (CAA) is a disorder characterized by amyloid deposition in the walls of leptomeningeal and cortical arteries, arterioles, and less often capillaries and veins of the central nervous system. CAA occurs mostly as a sporadic condition in the elderly, its incidence associating with advancing age. All sporadic CAA cases are due to deposition of amyloid-P, originating from proteolytic cleavage of the Amyloid Precursor Protein. Hereditary forms of CAA are generally familial (and therefore rare in the general population), more severe and earlier in onset. CAA-related lobar intracerebral hemorrhage is the most well-studied clinical condition associated with brain amyloid deposition. Despite ever increasing understanding of CAA pathogenesis and availability of reliable clinical and diagnostic tools, preventive and therapeutic options remain very limited. Further research efforts are required in order to identify biological targets for novel CAA treatment strategies. We present a systematic review of existing evidence regarding the epidemiology, genetics, pathogenesis, diagnosis and clinical management of CAA. J Clin Neurol 2011;7:1-9 C1 [Biffi, Alessandro] Massachusetts Gen Hosp, Hemorrhag Stroke Res Grp, Ctr Human Genet Res, Boston, MA 02114 USA. [Biffi, Alessandro] Massachusetts Gen Hosp, Dept Neurol, Ctr Human Genet Res, Boston, MA 02114 USA. [Biffi, Alessandro; Greenberg, Steven M.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. RP Biffi, A (reprint author), Massachusetts Gen Hosp, Hemorrhag Stroke Res Grp, Ctr Human Genet Res, 185 Cambridge St,CPZN 6818, Boston, MA 02114 USA. EM abiffi@partners.org NR 89 TC 96 Z9 106 U1 3 U2 30 PU KOREAN NEUROLOGICAL ASSOC PI SEOUL PA 1111 DAEIL BLD, 43 INSA-DONG, JONGNO-GU, SEOUL, 110-741, SOUTH KOREA SN 1738-6586 J9 J CLIN NEUROL JI J. Clin. Neurol. PD MAR PY 2011 VL 7 IS 1 BP 1 EP 9 DI 10.3988/jcn.2011.7.1.1 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 751IQ UT WOS:000289611100001 PM 21519520 ER PT J AU Baldwin, ML Marcus, SC AF Baldwin, Marjorie L. Marcus, Steven C. TI The Effects of Mental and Substance Use Disorders on Employment Transitions SO JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS LA English DT Meeting Abstract C1 Arizona State Univ, WP Carey Sch Business, Dept Econ, Tempe, AZ 85287 USA. Univ Penn, Ctr Hlth Equ Res & Promot, Sch Social Policy & Practice, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INT CTR MENTAL HEALTH POLICY & ECONOMICS-ICMPE PI MILANO PA VIA DANIELE CRESPI 7, MILANO, 20123, ITALY SN 1091-4358 J9 J MENT HEALTH POLICY JI J. Ment. Health Policy Econ. PD MAR PY 2011 VL 14 SU 1 BP S3 EP S3 PG 1 WC Health Policy & Services; Psychiatry SC Health Care Sciences & Services; Psychiatry GA 749WR UT WOS:000289502600007 ER PT J AU Ingraham, AM Cohen, ME Raval, MV Ko, CY Nathens, AB AF Ingraham, Angela M. Cohen, Mark E. Raval, Mehul V. Ko, Clifford Y. Nathens, Avery B. TI Effect Of Trauma Center Status on 30-Day Outcomes After Emergency General Surgery SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID ACUTE-CARE SURGERY; INJURY-RELATED MORTALITY; NATIONAL EVALUATION; ACUTE APPENDICITIS; SURGICAL CARE; SYSTEMS; QUALITY; NSQIP; RISK AB BACKGROUND: Trauma surgeons increasingly care for emergency general surgery (EGS) patients. The extent to which trauma center (TC) performance improvement translates into improved quality for EGS is unknown. We hypothesized that EGS outcomes in TCs would be similar to outcomes in non-trauma centers (NTC); failure to support our hypothesis suggests that the effects of trauma performance improvement have extended beyond trauma patients. STUDY DESIGN: We retrospectively studied EGS procedures at TCs versus NTCs among American College of Surgeons National Surgical Quality Improvement Program participants (2005-2008). Thirty-day outcomes were overall morbidity, serious morbidity, and mortality. TC versus NTC outcomes were compared using regression modeling, observed-to-expected (O/E) ratios (among hospitals submitting >= 20 EGS procedures), and outlier status (hospitals whose O/E confidence interval excludes 1.0). RESULTS: Of 68,003 patients at 222 hospitals, 42,264 (62.2%) were treated at 121 TCs; 25,739 (37.8%) were treated at 101 NTCs. TCs had significantly higher overall morbidity (21.4% versus 17.2%; p < 0.0001), serious morbidity (15.8% versus 12.3%; p < 0.0001), and mortality (6.4% versus 4.8%; p < 0.0001) than NTCs. On adjusted analyses, TC status was a significant predictor of overall morbidity (odds ratio = 1.11; 95% CI, 1.01-1.21), but not serious morbidity (odds ratio = 1.08; 95% CI, 0.98-1.19) or mortality (odds ratio = 0.92; 95% CI, 0.82-1.04). Among 211 hospitals assigned O/E ratios, TCs were more likely, although not significantly so, to be high outliers for overall morbidity (7.6% versus 4.3%; p = 0.017), serious morbidity (5.1% versus 4.3%; p = 0.034), and mortality (3.4% versus 2.2%; p > 0.099). CONCLUSIONS: Although overall morbidity tended to favor NTCs, mortality was no different. This suggests that the trauma performance improvement processes have not been applied to EGS patients, despite being cared for by similar providers. Despite having processes for trauma, there remains the opportunity for quality improvement for EGS care. (J Am Coll Surg 2011;212:277-286. (c) 2011 by the American College of Surgeons) C1 [Ingraham, Angela M.; Cohen, Mark E.; Raval, Mehul V.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Ingraham, Angela M.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA. [Raval, Mehul V.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Nathens, Avery B.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Div Surg & Trauma, Toronto, ON M5B 1W8, Canada. RP Ingraham, AM (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,Floor 22NE, Chicago, IL 60611 USA. EM aingraham@facs.org OI Raval, Mehul/0000-0002-1527-2661 FU American College of Surgeons; John Gray Research Fellowship; Daniel F and Ada L Rice Foundation; Canada Research Chair FX Drs Ingraham and Raval are supported by the Clinical Scholar in Residence Program at the American College of Surgeons. Dr Raval is also supported by the John Gray Research Fellowship and the Daniel F and Ada L Rice Foundation. Dr Nathens is supported by a Canada Research Chair in Systems of Trauma Care. NR 22 TC 15 Z9 15 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD MAR PY 2011 VL 212 IS 3 BP 277 EP 286 DI 10.1016/j.jamcollsurg.2010.12.001 PG 10 WC Surgery SC Surgery GA 748XW UT WOS:000289427400002 PM 21356485 ER PT J AU Berra, L Alston, TA AF Berra, L. Alston, T. A. TI Hydrocortisone for stress of off-pump coronary surgery SO MINERVA ANESTESIOLOGICA LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; CARDIAC-SURGERY; CARDIOPULMONARY BYPASS; ATRIAL-FIBRILLATION; CORTICOSTEROIDS; INTERLEUKIN-6; PREVENTION; RATIO C1 [Berra, L.; Alston, T. A.] Harvard Univ, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Sch Med, Boston, MA 02114 USA. RP Alston, TA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Sch Med, 55 Fruit St, Boston, MA 02114 USA. EM talston@partners.org NR 23 TC 0 Z9 2 U1 0 U2 0 PU EDIZIONI MINERVA MEDICA PI TURIN PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY SN 0375-9393 EI 1827-1596 J9 MINERVA ANESTESIOL JI Minerva Anestesiol. PD MAR PY 2011 VL 77 IS 3 BP 259 EP 260 PG 2 WC Anesthesiology; Critical Care Medicine SC Anesthesiology; General & Internal Medicine GA 751CA UT WOS:000289593900001 PM 21441878 ER PT J AU Januzzi, JL AF Januzzi, J. L. TI What is the role of biomarker measurement after cardiac surgery? SO MINERVA ANESTESIOLOGICA LA English DT Review DE Cardiac surgical procedures; Troponin; Natriuretic peptides ID ARTERY-BYPASS SURGERY; BRAIN NATRIURETIC PEPTIDE; PERIOPERATIVE MYOCARDIAL-INFARCTION; TROPONIN-T ELEVATION; ACUTE CORONARY SYNDROMES; TERM PROGNOSTIC VALUE; CREATINE KINASE-MB; OPEN-HEART-SURGERY; OFF-PUMP; ON-PUMP AB Measurements of cardiac troponin (cTn) and natriuretic peptides can predict outcomes after cardiac surgery and may thus assist in decision making about diagnostic and therapeutic steps in this setting. Not every cardiac surgical procedure is associated with the same degree of cTn or natriuretic peptide elevation; the factors known to affect concentrations of these markers include the severity of preoperative coronary artery disease as well as presenting syndrome, while forms of cardioprotection and anesthesia may affect postoperative concentrations of biomarkers. Release of cTn appears to represent irreversibly damaged myocardium; however, clinicians are cautioned when measuring cTn in post-cardiac surgery venues not to assume an elevated concentration is equivalent to regional acute myocardial infarction; indeed, more often than not, excessive values of cTnT or cTnI more typically represent diffuse myocardial injury. Natriuretic peptide release may occur through both states of irreversible dysfunction as well as more reversible states, such as postoperative shock. Indeed, both cTn and natriuretic peptides are unequivocally prognostic for delayed recovery, intensive care unit utilization, as well as short- and longer-term mortalities following cardiac surgery. (Minerva Anestesiol 2011;77:334-41) C1 [Januzzi, J. L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Januzzi, J. L.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Januzzi, JL (reprint author), 32 Fruit St,Yawkey 5984, Boston, MA 02114 USA. EM JJanuzzi@partners.org FU Balson Scholar Fund; Roche Diagnostics; Siemens Diagnostics; Critical Diagnostics FX Dr. James Januzzi is supported in part by the Balson Scholar Fund. Dr. Januzzi has received grant funding from Roche Diagnostics, Siemens Diagnostics, and Critical Diagnostics. NR 59 TC 2 Z9 2 U1 2 U2 6 PU EDIZIONI MINERVA MEDICA PI TURIN PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY SN 0375-9393 EI 1827-1596 J9 MINERVA ANESTESIOL JI Minerva Anestesiol. PD MAR PY 2011 VL 77 IS 3 BP 334 EP 341 PG 8 WC Anesthesiology; Critical Care Medicine SC Anesthesiology; General & Internal Medicine GA 751CA UT WOS:000289593900013 PM 21441887 ER PT J AU Lehman, LA Woodbury, M Velozo, CA AF Lehman, Leigh A. Woodbury, Michelle Velozo, Craig A. TI Examination of the Factor Structure of the Disabilities of the Arm, Shoulder, and Hand Questionnaire SO AMERICAN JOURNAL OF OCCUPATIONAL THERAPY LA English DT Article DE data interpretation, statistical; disability evaluation; factor analysis, statistical; upper extremity ID CARPAL-TUNNEL-SYNDROME; ADMINISTERED BOSTON QUESTIONNAIRE; DASH OUTCOME QUESTIONNAIRE; CONSTRUCT-VALIDITY; ELECTROPHYSIOLOGICAL FINDINGS; RESPONSIVENESS; RELIABILITY; ARTHRITIS; SURGERY; VERSION AB OBJECTIVE. The Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire is a global scale evaluating the impact of upper-extremity disorders. We sought to validate or challenge the unidimensional factor structure of the DASH. METHOD. Secondary analysis was performed on data collected from outpatient clinics. Factor analysis was performed in two steps, exploratory factor analysis (EFA) followed by confirmatory factor analysis (CFA). To provide further support for unidimensionality, fit statistics were calculated using the Andrich Rasch rating-scale model. RESULTS. EFA revealed three potential factors (eigenvalues = 18.40, 1.56, and 1.54). CFA was performed fitting a three-factor model. Tucker-Lewis Index (.99) and standardized root mean square residual (.05) values indicated good fit. Comparative fit index (.89) and root mean square error of approximation (.13) did not. When divided into three constructs, only one item misfit. CONCLUSION. More research is needed to determine situations in which division of the DASH may enhance interpretability. C1 [Lehman, Leigh A.] Univ S Carolina Upstate, Dept Psychol, Spartanburg, SC 29303 USA. [Woodbury, Michelle] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Woodbury, Michelle] Med Univ S Carolina, Dept Hlth & Sci & Res, Div Occupat Therapy, Charleston, SC 29425 USA. [Velozo, Craig A.] N Florida S Georgia Vet Affairs Syst, Rehabil Outcomes Res Ctr, Gainesville, FL USA. [Velozo, Craig A.] Univ Florida, Dept Occupat Therapy, Gainesville, FL USA. RP Lehman, LA (reprint author), Univ S Carolina Upstate, Dept Psychol, 800 Univ Way, Spartanburg, SC 29303 USA. EM LALehman@aol.com NR 47 TC 13 Z9 13 U1 0 U2 1 PU AMER OCCUPATIONAL THERAPY ASSOC, INC PI BETHESDA PA 4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA SN 0272-9490 J9 AM J OCCUP THER JI Am. J. Occup. Ther. PD MAR-APR PY 2011 VL 65 IS 2 BP 169 EP 178 DI 10.5014/ajot.2011.000794 PG 10 WC Rehabilitation SC Rehabilitation GA 737MP UT WOS:000288573200007 PM 21476364 ER PT J AU Flaherty, AW AF Flaherty, Alice W. TI Brain Illness and Creativity: Mechanisms and Treatment Risks SO CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE LA English DT Review DE creativity; motivation; hypomania; writer's block; mood disorder; bipolar disorder; antidepressant; treatment; dopamine; hemispheric laterality; frontotemporal connections ID SEROTONIN REUPTAKE INHIBITORS; PARKINSONS-DISEASE; TEMPORAL-LOBE; HEMISPHERIC-SPECIALIZATION; FRONTOTEMPORAL DEMENTIA; ARTISTIC PRODUCTIVITY; POSITIVE AFFECT; HEDONIC TONE; MOOD; ACTIVATION AB Brain diseases and their treatment may help or hurt creativity in ways that shape quality of life. Increased creative drive is associated with bipolar disorder, depression, psychosis, temporal lobe epilepsy, frontotemporal dementia, Parkinson disease treatments, and autism. Creativity depends on goal-driven approach motivation from midbrain dopaminergic systems. Fear-driven avoidance motivation is of less aid to creativity. When serotonin and norepinephrine lower motivation and flexible behaviour, they can inhibit creativity. Hemispheric lateralization and frontotemporal connections must interact to create new ideas and conceptual schemes. The right brain and temporal lobe contribute skill in novelty detection, while the left brain and frontal lobe foster approach motivation and more easily generate new patterns of action from the novel perceptions. Genes and phenotypes that increase plasticity and creativity in tolerant environments with relaxed selection pressure may confer risk in rigorous environments. Few papers substantively address this important but fraught topic. Antidepressants (ADs) that inhibit fear-driven motivation, such as selective serotonin reuptake inhibitors, sometimes inhibit goal-oriented motivation as well. ADs that boost goal-directed motivation, such as bupropion, may remediate this effect. Benzodiazepines and alcohol may be counterproductive. Although dopaminergic agonists sometimes stimulate creativity, their doing so may inappropriately disinhibit behaviour. Dopamine antagonists may suppress creative motivation; lithium and anticonvulsant mood stabilizers may do so less. Physical exercise and REM sleep may help creativity. Art therapy and psychotherapy are not well studied. Preserving creative motivation can help creativity and other aspects of well-being in all patients, not just artists or researchers. C1 Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Flaherty, AW (reprint author), Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, WACC 729B,15 Parkman St, Boston, MA 02114 USA. EM aflaherty@partners.org NR 99 TC 24 Z9 25 U1 12 U2 68 PU CANADIAN PSYCHIATRIC ASSOC PI OTTAWA PA 141 LAURIER AVENUE WEST, STE 701, OTTAWA, ONTARIO K1P 5J3, CANADA SN 0706-7437 J9 CAN J PSYCHIAT JI Can. J. Psychiat.-Rev. Can. Psychiat. PD MAR PY 2011 VL 56 IS 3 BP 132 EP 143 PG 12 WC Psychiatry SC Psychiatry GA 741HY UT WOS:000288856000003 PM 21443820 ER PT J AU Ayoub, C Vallotton, CD Mastergeorge, AM AF Ayoub, Catherine Vallotton, Claire D. Mastergeorge, Ann M. TI Developmental Pathways to Integrated Social Skills: The Roles of Parenting and Early Intervention SO CHILD DEVELOPMENT LA English DT Article ID LOW-INCOME FAMILIES; SELF-REGULATION; INFANT ATTACHMENT; CHILD-DEVELOPMENT; BEHAVIOR PROBLEMS; STRESS; TODDLERS; BOYS AB Dynamic skill theory was utilized to explain the multiple mechanisms and mediating processes influencing development of self-regulatory and language skills in children at 14, 24, and 36 months of age. Relations were found between family risks, parenting-related stresses, and parent-child interactions that contribute either independently or through mediation to the child's acquisition of self-regulatory skills even when accounting for the influence of language development. Variation in impacts between control and Early Head Start (EHS) intervention samples was compared to explore the sequence of developmental mechanisms over time. Findings indicate that EHS protects parenting, child language, and self-regulatory development from the effects of demographic risks and parenting stress, and thus supports parents to raise healthy children. C1 [Ayoub, Catherine] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Vallotton, Claire D.] Michigan State Univ, E Lansing, MI 48824 USA. RP Ayoub, C (reprint author), Massachusetts Gen Hosp, 388 Commonwealth Ave, Boston, MA 02215 USA. EM cayoub@partners.org FU NICHD NIH HHS [1 F32 HD050040-01] NR 45 TC 18 Z9 18 U1 5 U2 28 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0009-3920 J9 CHILD DEV JI Child Dev. PD MAR-APR PY 2011 VL 82 IS 2 BP 583 EP 600 DI 10.1111/j.1467-8624.2010.01549.x PG 18 WC Psychology, Educational; Psychology, Developmental SC Psychology GA 739ZE UT WOS:000288760000009 PM 21410921 ER PT J AU Han, SH Reddy, KR Keeffe, EB Soldevila-Pico, C Gish, R Chung, RT Degertekin, B Lok, A AF Han, Steven-Huy Reddy, K. Rajender Keeffe, Emmet B. Soldevila-Pico, Consuelo Gish, Robert Chung, Raymond T. Degertekin, Bulent Lok, Anna CA NIH HBV OLT Study Grp TI Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study SO CLINICAL TRANSPLANTATION LA English DT Article DE hepatitis B virus; liver cancer; predictors; recurrence; risk factors ID CHRONIC HEPATITIS-B; SERUM ALPHA-FETOPROTEIN; ADEFOVIR DIPIVOXIL; RECURRENCE; LAMIVUDINE; SURVIVAL; CANDIDATES; CHEMOEMBOLIZATION; MANAGEMENT; ENTECAVIR AB Background: Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is an indication for orthotopic liver transplantation (OLT) in patients with tumor stage within the United Network for Organ Sharing criteria. The number of patients listed for HBV-related HCC is increasing, while the number of patients listed for HBV-related cirrhosis is declining presumptively because of the availability of more effective oral nucleos(t)ide analogues. This study presents the final, long-term outcome of patients transplanted for HBV-related HCC in the National Institutes of Health (NIH) HBV OLT Study Group. Results: Ninety-eight patients (52.4%) in the NIH HBV OLT cohort underwent OLT for HBV-related HCC. With a mean follow-up of 36.5 months post-OLT, 12 (12.2%) patients developed recurrence of HCC. Multivariate analysis did not find a statistically significant role of gender, tumor stage at OLT, pre-OLT HCC treatment, recurrence of HBV, or duration of HCC diagnosis pre-OLT in predicting HCC recurrence. Serum alpha-fetoprotein (AFP) level > 200 ng/mL at transplant was found to be statistically significant in predicting HCC recurrence (p = 0.003). HCC recurrence was significantly associated with decreased post-OLT survival. Conclusion: HCC is the most common indication for OLT in patients with chronic hepatitis B in the era of more effective oral antivirals. Serum AFP at the time of OLT is significantly associated with HCC recurrence. C1 [Han, Steven-Huy] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Reddy, K. Rajender] Univ Penn, Philadelphia, PA 19104 USA. [Keeffe, Emmet B.] Stanford Univ, Stanford, CA 94305 USA. [Soldevila-Pico, Consuelo] Univ Florida, Gainesville, FL USA. [Gish, Robert] Calif Pacific Med Ctr, San Francisco, CA USA. [Chung, Raymond T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Degertekin, Bulent; Lok, Anna] Univ Michigan, Ann Arbor, MI 48109 USA. RP Han, SH (reprint author), Pfleger Liver Inst, 200 UCLA Med Plaza,Suite 214, Los Angeles, CA 90095 USA. EM steven.han@ucla.edu OI Yang, Shuman/0000-0002-9638-0890 FU NIDDK [U01 DK57577]; Gilead; Genentech/Roche; BMS; Merck; Innogenetics; GSK; Roche Molecular Diagnostics FX This study was supported by a grant from the NIDDK (U01 DK57577).; K. Rajender Reddy: Research/grant support: Gilead, Genentech/Roche, BMS, Merck; Advisory board: Gilead, Genentech/Roche, Merck. Anna Lok: Research/grant support: Innogenetics, GSK, BMS, Gilead, Roche Molecular Diagnostics; Consulting: Gilead. All other authors: nothing to disclose. NR 31 TC 9 Z9 9 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0902-0063 EI 1399-0012 J9 CLIN TRANSPLANT JI Clin. Transplant. PD MAR-APR PY 2011 VL 25 IS 2 BP E152 EP E162 DI 10.1111/j.1399-0012.2010.01349.x PG 11 WC Surgery; Transplantation SC Surgery; Transplantation GA 745GH UT WOS:000289153400007 PM 21077950 ER PT J AU Ceppo, F Jager, J Gremeaux, T Ben Othman, N Bezy, O Vidal, H Tran, A Gual, P Le Marchand-Brustel, Y Cormont, M Tanti, JF AF Ceppo, F. Jager, J. Gremeaux, T. Ben Othman, N. Bezy, O. Vidal, H. Tran, A. Gual, P. Le Marchand-Brustel, Y. Cormont, M. Tanti, J. -F. TI Involvement of the kinasse inflammatory TPL2 in the deleterious effects of macrophages on the sensitivity to insulin of the adipocytes SO DIABETES & METABOLISM LA French DT Meeting Abstract C1 [Ceppo, F.; Jager, J.; Gremeaux, T.; Ben Othman, N.; Le Marchand-Brustel, Y.; Cormont, M.; Tanti, J. -F.] Univ Nice Sophia Antipolis, INSERM, U895 C3M, Team7, Nice, France. [Bezy, O.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Vidal, H.] INSERM, U870, F-69008 Lyon, France. [Tran, A.; Gual, P.] Univ Nice Sophia Antipolis, INSERM, U895 C3M, Team 8, Nice, France. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MASSON EDITEUR PI MOULINEAUX CEDEX 9 PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE SN 1262-3636 J9 DIABETES METAB JI Diabetes Metab. PD MAR PY 2011 VL 37 SI 1 BP A14 EP A14 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 743HT UT WOS:000289009800058 ER PT J AU Caro, JJ DeRenzo, EG Coleman, CN Weinstock, DM Knebel, AR AF Caro, J. Jaime DeRenzo, Evan G. Coleman, C. Norman Weinstock, David M. Knebel, Ann R. TI Resource Allocation After a Nuclear Detonation Incident: Unaltered Standards of Ethical Decision Making SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE ethics; resource allocation; nuclear detonation; priority setting; need; efficiency ID MASS CRITICAL-CARE; PANDEMIC INFLUENZA; SCARCE RESOURCES; SURGE CAPACITY; MEDICAL RESPONSE; RATIONING CARE; HEALTH; TRIAGE; EVENT; MODEL AB This article provides practical ethical guidance for clinicians making decisions after a nuclear detonation, in advance of the full establishment of a coordinated response. We argue that the utilitarian maxim of the greatest good for the greatest number, interpreted only as "the most lives saved," needs refinement. We take the philosophical position that utilitarian efficiency should be tempered by the principle of fairness in making decisions about providing lifesaving interventions and palliation. The most practical way to achieve these goals is to mirror the ethical precepts of routine clinical practice, in which 3 factors govern resource allocation: order of presentation, patient's medical need, and effectiveness of an intervention. Although these basic ethical standards do not change, priority is given in a crisis to those at highest need in whom interventions are expected to be effective. If available resources will not be effective in meeting the need, then it is unfair to expend them and they should be allocated to another patient with high need and greater expectation for survival if treated. As shortage becomes critical, thresholds for intervention become more stringent. Although the focus of providers will be on the victims of the event, the needs of patients already receiving care before the detonation also must be considered. Those not allocated intervention must still be provided as much appropriate comfort, assistance, relief of symptoms, and explanations as possible, given the available resources. Reassessment of patients' clinical status and priority for intervention also should be conducted with regularity. (Disaster Med Public Health Preparedness. 2011;5:S46-S53) C1 [Caro, J. Jaime] United Biosource Corp, Lexington, MA 02420 USA. [Caro, J. Jaime] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ H3A 2T5, Canada. [Caro, J. Jaime] McGill Univ, Div Gen Internal Med, Montreal, PQ H3A 2T5, Canada. [DeRenzo, Evan G.] Washington Hosp Ctr, Ctr Eth, Washington, DC USA. [Coleman, C. Norman; Knebel, Ann R.] US Dept HHS, Off Assistant Secretary Preparedness & Response, Washington, DC USA. [Weinstock, David M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA. RP Caro, JJ (reprint author), United Biosource Corp, 430 Bedford St,Suite 300, Lexington, MA 02420 USA. EM jaime.caro@mcgill.ca FU US Department of Health and Human Services (DHHS) FX The US Department of Health and Human Services (DHHS) provided funding to support this publication and convene the authors. The contents of the articles represent the personal views of the individual authors and do not necessarily express the opinion or policy of DHHS or its components. No statement in the articles should be construed as an official position of DHHS or its components. NR 54 TC 14 Z9 14 U1 3 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD MAR PY 2011 VL 5 SU 1 BP S46 EP S53 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 739VM UT WOS:000288748000006 PM 21402811 ER PT J AU Casagrande, R Wills, N Kramer, E Sumner, L Mussante, M Kurinsky, R McGhee, P Katz, L Weinstock, DM Coleman, N AF Casagrande, Rocco Wills, Nick Kramer, Elizabeth Sumner, Louise Mussante, Mark Kurinsky, Rachel McGhee, Patrick Katz, Luba Weinstock, David M. Coleman, Norman TI Using the Model of Resource and Time-Based Triage (MORTT) to Guide Scarce Resource Allocation in the Aftermath of a Nuclear Detonation SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE triage; modeling; nuclear detonation; improvised nuclear device; combined injury ID OPERATION-IRAQI-FREEDOM; LENGTH-OF-STAY; TRAUMA TEAM; MEDICAL REHABILITATION; CONSTRAINED TRIAGE; INJURY SCALE; MARINE-CORPS; MAJOR TRAUMA; RISK-FACTORS; EARTHQUAKE AB Conventional triage algorithms assume unlimited medical resource availability. After a nuclear detonation, medical resources are likely to be particularly limited, suggesting that conventional triage algorithms need to be rethought. To test various hypotheses related to the prioritization of victims in this setting, we developed the model of resource-and time-based triage (MORTT). This model uses information on time to death, probability of survival if treated and if untreated, and time to treat various types of traumatic injuries in an agent-based model in which the time of medical practitioners or materials can be limited. In this embodiment, MORTT focuses solely on triage for surgical procedures in the first 48 hours after a nuclear detonation. MORTT determines the impact on survival based on user-selected prioritization of victims by severity or type of injury. Using MORTT, we found that in poorly resourced settings, prioritizing victims with moderate life-threatening injuries over victims with severe life-threatening injuries saves more lives and reduces demand for intensive care, which is likely to outstrip local and national capacity. Furthermore, more lives would be saved if victims with combined injury (ie, trauma plus radiation >2 Gy) are prioritized after nonirradiated victims with similar trauma. (Disaster Med Public Health Preparedness. 2011;5:S98-S110) C1 [Casagrande, Rocco; Wills, Nick; Kramer, Elizabeth; Sumner, Louise; Mussante, Mark; Kurinsky, Rachel; McGhee, Patrick] Gryphon Sci, Takoma Pk, MD 20912 USA. [Weinstock, David M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA. [Katz, Luba] ABT Associates Inc, Cambridge, MA 02138 USA. [Coleman, Norman] US Dept HHS, Off Assistant Secretary Preparedness & Response, Washington, DC USA. RP Casagrande, R (reprint author), Gryphon Sci, 6930 Carroll Ave,Suite 810, Takoma Pk, MD 20912 USA. EM rocco@gryphonscientific.com FU US Department of Health and Human Services (DHHS) FX The US Department of Health and Human Services (DHHS) provided funding to support this publication and convene the authors. The contents of the articles represent the personal views of the individual authors and do not necessarily express the opinion or policy of DHHS or its components. No statement in the articles should be construed as an official position of DHHS or its components. This work was also supported by the Agency for Healthcare Research and Quality, Department of Health and Human Services, and Gryphon Scientific. NR 63 TC 13 Z9 13 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD MAR PY 2011 VL 5 SU 1 BP S98 EP S110 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 739VM UT WOS:000288748000011 PM 21402818 ER PT J AU Coleman, CN Knebel, AR Hick, JL Weinstock, DM Casagrande, R Caro, JJ DeRenzo, EG Dodgen, D Norwood, AE Sherman, SE Cliffer, KD McNally, R Bader, JL Murrain-Hill, P AF Coleman, C. Norman Knebel, Ann R. Hick, John L. Weinstock, David M. Casagrande, Rocco Caro, J. Jaime DeRenzo, Evan G. Dodgen, Daniel Norwood, Ann E. Sherman, Susan E. Cliffer, Kenneth D. McNally, Richard Bader, Judith L. Murrain-Hill, Paula TI Scarce Resources for Nuclear Detonation: Project Overview and Challenges SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Editorial Material ID CRITICAL-CARE SUMMIT; MASS CRITICAL-CARE; JANUARY 26-27; TASK-FORCE; DEFINITIVE CARE; SURGE CAPACITY; CRITICALLY-ILL; MEDICAL RESPONSE; ALLOCATION; HEALTH C1 [Coleman, C. Norman; Knebel, Ann R.; Dodgen, Daniel; Cliffer, Kenneth D.; Bader, Judith L.; Murrain-Hill, Paula] US Dept HHS, Off Assistant Secretary Preparedness & Response, Rockville, MD 20852 USA. [Hick, John L.] Univ Minnesota, Hennepin Cty Med Ctr, Minneapolis, MN 55455 USA. [Weinstock, David M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA. [Caro, J. Jaime] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Div Gen Internal Med, Montreal, PQ H3A 2T5, Canada. [DeRenzo, Evan G.] Washington Hosp Ctr, Ctr Eth, Washington, DC USA. [Norwood, Ann E.] Univ Pittsburgh, Med Ctr, Ctr Biosecur, Pittsburgh, PA 15260 USA. [Sherman, Susan E.] US Dept HHS, Off Gen Counsel, Rockville, MD 20852 USA. [McNally, Richard] Sci Applicat Int Corp, Mclean, VA 22102 USA. RP Coleman, CN (reprint author), US Dept HHS, Off Assistant Secretary Preparedness & Response, 6130 Execut Blvd, Rockville, MD 20852 USA. EM Norman.Coleman@nih.gov NR 27 TC 20 Z9 20 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD MAR PY 2011 VL 5 SU 1 BP S13 EP S19 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 739VM UT WOS:000288748000003 PM 21402805 ER PT J AU Coleman, CN Weinstock, DM Casagrande, R Hick, JL Bader, JL Chang, F Nemhauser, JB Knebel, AR AF Coleman, C. Norman Weinstock, David M. Casagrande, Rocco Hick, John L. Bader, Judith L. Chang, Florence Nemhauser, Jeffrey B. Knebel, Ann R. TI Triage and Treatment Tools for Use in a Scarce Resources-Crisis Standards of Care Setting After a Nuclear Detonation SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE nuclear detonation; triage; scarce resources; crisis standards of care ID BURN INJURIES; RADIATION; PROBABILITY; DEATH AB Based on background information in this special issue of the journal, possible triage recommendations for the first 4 days following a nuclear detonation, when response resources will be limited, are provided. The series includes: modeling for physical infrastructure damage; severity and number of injuries; expected outcome of triage to immediate, delayed, or expectant management; resources required for treating injuries of varying severity; and how resource scarcity (particularly medical personnel) worsens outcome. Four key underlying considerations are: 1.) resource adequacy will vary greatly across the response areas by time and location; 2.) to achieve fairness in resource allocation, a common triage approach is important; 3.) at some times and locations, it will be necessary to change from "conventional" to "contingency" or "crisis" standards of medical care (with a resulting change in triage approach from treating the "sickest first" to treating those "most likely to survive" first); and 4.) clinical reassessment and repeat triage are critical, as resource scarcity worsens or improves. Changing triage order and conserving and allocating resources for both lifesaving and palliative care can maintain fairness, support symptomatic care, and save more lives. Included in this article are printable triage cards that reflect our recommendations. These are not formal guidelines. With new research, data, and discussion, these recommendations will undoubtedly evolve. (Disaster Med Public Health Preparedness. 2011;5:S111-S121) C1 [Coleman, C. Norman; Bader, Judith L.; Knebel, Ann R.] US Dept HHS, Off Assistant Secretary Preparedness & Response, Rockville, MD 20852 USA. [Weinstock, David M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA. [Hick, John L.] Univ Minnesota, Hennepin Cty Med Ctr, Minneapolis, MN 55455 USA. [Chang, Florence] Natl Inst Hlth, Specialized Informat Serv, Natl Lib Med, Bethesda, MD 20892 USA. [Nemhauser, Jeffrey B.] Ctr Dis Control & Prevent, Radiat Studies Branch, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Coleman, CN (reprint author), US Dept HHS, Off Assistant Secretary Preparedness & Response, 6130 Execut Blvd, Rockville, MD 20852 USA. EM ccoleman@mail.nih.gov FU US Department of Health and Human Services (DHHS) FX The US Department of Health and Human Services (DHHS) provided funding to support this publication and convene the authors. The contents of the articles represent the personal views of the individual authors and do not necessarily express the opinion or policy of DHHS or its components. No statement in the articles should be construed as an official position of DHHS or its components. NR 22 TC 21 Z9 21 U1 0 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD MAR PY 2011 VL 5 SU 1 BP S111 EP S121 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 739VM UT WOS:000288748000012 PM 21402803 ER PT J AU DiCarlo, AL Maher, C Hick, JL Hanfling, D Dainiak, N Chao, N Bader, JL Coleman, CN Weinstock, DM AF DiCarlo, Andrea L. Maher, Carmen Hick, John L. Hanfling, Dan Dainiak, Nicholas Chao, Nelson Bader, Judith L. Coleman, C. Norman Weinstock, David M. TI Radiation Injury After a Nuclear Detonation: Medical Consequences and the Need for Scarce Resources Allocation SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Review DE nuclear detonation; radiation injury; acute radiation syndrome ID COLONY-STIMULATING FACTOR; BONE-MARROW TRANSPLANTATION; WHOLE-BODY IRRADIATION; IONIZING-RADIATION; RHESUS-MONKEYS; SUPPORTIVE CARE; GAMMA-RADIATION; X-IRRADIATION; G-CSF; EXPOSURE AB A 10- kiloton (kT) nuclear detonation within a US city could expose hundreds of thousands of people to radiation. The Scarce Resources for a Nuclear Detonation Project was undertaken to guide community planning and response in the aftermath of a nuclear detonation, when demand will greatly exceed available resources. This article reviews the pertinent literature on radiation injuries from human exposures and animal models to provide a foundation for the triage and management approaches outlined in this special issue. Whole-body doses >2 Gy can produce clinically significant acute radiation syndrome (ARS), which classically involves the hematologic, gastrointestinal, cutaneous, and cardiovascular/central nervous systems. The severity and presentation of ARS are affected by several factors, including radiation dose and dose rate, interindividual variability in radiation response, type of radiation (eg, gamma alone, gamma plus neutrons), partial-body shielding, and possibly age, sex, and certain preexisting medical conditions. The combination of radiation with trauma, burns, or both (ie, combined injury) confers a worse prognosis than the same dose of radiation alone. Supportive care measures, including fluid support, antibiotics, and possibly myeloid cytokines (eg, granulocyte colony-stimulating factor), can improve the prognosis for some irradiated casualties. Finally, expert guidance and surge capacity for casualties with ARS are available from the Radiation Emergency Medical Management Web site and the Radiation Injury Treatment Network. (Disaster Med Public Health Preparedness. 2011;5:S32-S44) C1 [DiCarlo, Andrea L.] NIAID, Radiat Nucl Countermeasures Program, NIH, Bethesda, MD 20892 USA. [Maher, Carmen] US FDA, Off Counterterrorism & Emerging Threats, Rockville, MD 20857 USA. [Hick, John L.] Univ Minnesota, Hennepin Cty Med Ctr, Minneapolis, MN 55455 USA. [Hanfling, Dan] George Washington Univ, Dept Emergency Med, Washington, DC 20052 USA. [Dainiak, Nicholas] Yale Univ, Sch Med, Bridgeport Hosp, New Haven, CT 06520 USA. [Chao, Nelson] Duke Univ, Bone Marrow & Stem Cell Transplant Program, Durham, NC 27706 USA. [Bader, Judith L.; Coleman, C. Norman] US Dept HHS, Off Assistant Secretary Preparedness & Response, Washington, DC USA. [Weinstock, David M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Weinstock, DM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 45 Brookline Ave,D510B, Boston, MA 02115 USA. EM DavidM_Weinstock@dfci.harvard.edu FU Genzyme; Novartis FX Dr Weinstock is a paid consultant by Genzyme and Novartis. NR 90 TC 68 Z9 69 U1 1 U2 21 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD MAR PY 2011 VL 5 SU 1 BP S32 EP S44 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 739VM UT WOS:000288748000005 PM 21402810 ER PT J AU Hick, JL Weinstock, DM Coleman, N Hanfling, D Cantrill, S Redlener, I Bader, JL Murrain-Hill, P Knebel, AR AF Hick, John L. Weinstock, David M. Coleman, Norman Hanfling, Dan Cantrill, Stephen Redlener, Irwin Bader, Judith L. Murrain-Hill, Paula Knebel, Ann R. TI Health Care System Planning for and Response to a Nuclear Detonation SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE nuclear detonation; disaster response; surge capacity ID MASS CRITICAL-CARE; MULTIPLE-CASUALTY INCIDENTS; SCARCE RESOURCES; SURGE CAPACITY; JANUARY 26-27; TASK-FORCE; DEFINITIVE CARE; CRITICALLY-ILL; HOSPITAL PREPAREDNESS; TERRORIST BOMBINGS AB The hallmark of a successful response to a nuclear detonation will be the resilience of the community, region, and nation. An incident of this magnitude will rapidly become a national incident; however, the initial critical steps to reduce lives lost, save the lives that can be saved with the resources available, and understand and apply resources available to a complex and dynamic situation will be the responsibility of the local and regional responders and planners. Expectations of the public health and health care systems will be met to the extent possible by coordination, cooperation, and an effort to produce as consistent a response as possible for the victims. Responders will face extraordinarily stressful situations, and their own physical and psychological health is of great importance to optimizing the response. This article illustrates through vignettes and supporting text how the incident may unfold for the various components of the health and medical systems and provides additional context for the discipline-related actions outlined in the state and local planners' playbook. (Disaster Med Public Health Preparedness. 2011;5:S73-S88) C1 [Hick, John L.] Univ Minnesota, Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Weinstock, David M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA. [Hanfling, Dan] George Washington Univ, Dept Emergency Med, Washington, DC 20052 USA. [Cantrill, Stephen] Denver Hlth Med Ctr, Dept Emergency Med, Denver, CO USA. [Redlener, Irwin] Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10027 USA. RP Hick, JL (reprint author), Univ Minnesota, Hennepin Cty Med Ctr, 701 Pk Ave S, Minneapolis, MN 55415 USA. EM john.hick@hcmed.org FU US Department of Health and Human Services (DHHS) FX The US Department of Health and Human Services (DHHS) provided funding to support this publication and convene the authors. The contents of the articles represent the personal views of the individual authors and do not necessarily express the opinion or policy of DHHS or its components. No statement in the articles should be construed as an official position of DHHS or its components. NR 75 TC 19 Z9 19 U1 1 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD MAR PY 2011 VL 5 SU 1 BP S73 EP S88 PG 16 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 739VM UT WOS:000288748000009 PM 21402815 ER PT J AU Knebel, AR Coleman, CN Cliffer, KD Murrain-Hill, P McNally, R Oancea, V Jacobs, J Buddemeier, B Hick, JL Weinstock, DM Hrdina, CM Taylor, T Matzo, M Bader, JL Livinski, AA Parker, G Yeskey, K AF Knebel, Ann R. Coleman, C. Norman Cliffer, Kenneth D. Murrain-Hill, Paula McNally, Richard Oancea, Victor Jacobs, Jimmie Buddemeier, Brooke Hick, John L. Weinstock, David M. Hrdina, Chad M. Taylor, Tammy Matzo, Marianne Bader, Judith L. Livinski, Alicia A. Parker, Gerald Yeskey, Kevin TI Allocation of Scarce Resources After a Nuclear Detonation: Setting the Context SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Editorial Material DE nuclear detonation; triage; scarce resources ID PALLIATIVE CARE; SURGE CAPACITY; CONTINGENCY; DISASTER; EVENTS AB The purpose of this article is to set the context for this special issue of Disaster Medicine and Public Health Preparedness on the allocation of scarce resources in an improvised nuclear device incident. A nuclear detonation occurs when a sufficient amount of fissile material is brought suddenly together to reach critical mass and cause an explosion. Although the chance of a nuclear detonation is thought to be small, the consequences are potentially catastrophic, so planning for an effective medical response is necessary, albeit complex. A substantial nuclear detonation will result in physical effects and a great number of casualties that will require an organized medical response to save lives. With this type of incident, the demand for resources to treat casualties will far exceed what is available. To meet the goal of providing medical care (including symptomatic/palliative care) with fairness as the underlying ethical principle, planning for allocation of scarce resources among all involved sectors needs to be integrated and practiced. With thoughtful and realistic planning, the medical response in the chaotic environment may be made more effective and efficient for both victims and medical responders. (Disaster Med Public Health Preparedness. 2011;5:S20-S31) C1 [McNally, Richard; Oancea, Victor; Jacobs, Jimmie] Sci Applicat Int Corp, Mclean, VA 22102 USA. [Buddemeier, Brooke] Lawrence Livermore Natl Lab, Dept Energy, Livermore, CA USA. [Hick, John L.] Univ Minnesota, Hennepin Cty Med Ctr, Minneapolis, MN 55455 USA. [Weinstock, David M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA. [Matzo, Marianne] Univ Oklahoma, Coll Nursing, Norman, OK 73019 USA. RP Knebel, AR (reprint author), 200 Independence Ave SW,Suite 638G, Washington, DC 20201 USA. EM ann.knebel@hhs.gov NR 30 TC 30 Z9 30 U1 1 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD MAR PY 2011 VL 5 SU 1 BP S20 EP S31 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 739VM UT WOS:000288748000004 PM 21402809 ER PT J AU Murrain-Hill, P Coleman, CN Hick, JL Redlener, I Weinstock, DM Koerner, JF Black, D Sanders, M Bader, JL Forsha, J Knebel, AR AF Murrain-Hill, Paula Coleman, C. Norman Hick, John L. Redlener, Irwin Weinstock, David M. Koerner, John F. Black, Delaine Sanders, Melissa Bader, Judith L. Forsha, Joseph Knebel, Ann R. TI Medical Response to a Nuclear Detonation: Creating a Playbook for State and Local Planners and Responders SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE nuclear detonation; disaster response; planning AB For efficient and effective medical responses to mass casualty events, detailed advanced planning is required. For federal responders, this is an ongoing responsibility. The US Department of Health and Human Services (DHHS) prepares playbooks with formal, written plans that are reviewed, updated, and exercised regularly. Recognizing that state and local responders with fewer resources may be helped in creating their own event-specific response plans, subject matter experts from the range of sectors comprising the Scarce Resources for a Nuclear Detonation Project, provided for this first time a state and local planner's playbook template for responding to a nuclear detonation. The playbook elements are adapted from DHHS playbooks with appropriate modification for state and local planners. Individualization by venue is expected, reflecting specific assets, populations, geography, preferences, and expertise. This playbook template is designed to be a practical tool with sufficient background information and options for step-by-step individualized planning and response. (Disaster Med Public Health Preparedness. 2011;5:S89-S97) C1 [Murrain-Hill, Paula; Coleman, C. Norman; Koerner, John F.; Black, Delaine; Sanders, Melissa; Bader, Judith L.; Forsha, Joseph; Knebel, Ann R.] US Dept HHS, Off Assistant Secretary Preparedness & Response, Washington, DC USA. [Hick, John L.] Univ Minnesota, Hennepin Cty Med Ctr, Minneapolis, MN 55455 USA. [Redlener, Irwin] Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10027 USA. [Weinstock, David M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA. RP Murrain-Hill, P (reprint author), Hubert H Humphrey Bldg,200 Independence Ave SW,Su, Washington, DC 20201 USA. EM Paula.Murrain-Hill@hhs.gov FU US Department of Health and Human Services (DHHS) FX The US Department of Health and Human Services (DHHS) provided funding to support this publication and convene the authors. The contents of the articles represent the personal views of the individual authors and do not necessarily express the opinion or policy of DHHS or its components. No statement in the articles should be construed as an official position of DHHS or its components. NR 19 TC 17 Z9 17 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD MAR PY 2011 VL 5 SU 1 BP S89 EP S97 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 739VM UT WOS:000288748000010 PM 21402817 ER PT J AU Tucker-Seeley, RD Subramanian, SV AF Tucker-Seeley, Reginald D. Subramanian, S. V. TI Childhood circumstances and height among older adults in the United States SO ECONOMICS & HUMAN BIOLOGY LA English DT Article DE Adult height; Childhood health; Childhood socioeconomic status; United States ID BODY-MASS INDEX; LEG LENGTH; SOCIOECONOMIC CIRCUMSTANCES; SECULAR TRENDS; LATER LIFE; HEALTH; WEIGHT; MORTALITY; GROWTH; CANCER AB We investigated the association between adult height and three indicators of childhood circumstances: mother's education, childhood financial hardship, and childhood health in the United States. Cross-sectional analysis of adults aged 50 and older in the 2004 Health and Retirement Study (N=14,079) was conducted. Gender and gender-race stratified regression models were used to model the association between adult height and childhood circumstances. The gender-stratified results showed a positive gradient association between mother's education and adult height; those reporting up to grade 8, high school graduate, and greater than high school education for their mother were 4.17 cm (p<0.001), 4.92 cm (p<0.001), and 5.83 cm (p<0.001) taller for men and 2.57 cm (p<0.001), 3.16 cm (p<0.001), and 3.85 cm (p<0.001) taller for women, respectively than those reporting no education for their mother. Childhood health was not statistically significantly associated with adult height, controlling for birth cohort, mother's education, and childhood financial hardship. Those who did not experience childhood financial hardship were slightly taller than those who did experience such hardship. Gender-race stratified results also showed a positive gradient association between mother's education and adult height; however, this association was only significant for white men and white women. The study reiterates the importance of childhood circumstances for adult height and for building health stock. (C) 2010 Elsevier B.V. All rights reserved. C1 [Tucker-Seeley, Reginald D.; Subramanian, S. V.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Ctr Community Based Res,Dana Farber Canc Inst, Boston, MA 02115 USA. RP Subramanian, SV (reprint author), Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Ctr Community Based Res,Dana Farber Canc Inst, 677 Huntington Ave, Boston, MA 02115 USA. EM retucker@hsph.harvard.edu; svsubram@hsph.harvard.edu FU Robert Wood Johnson Investigator Award in Health Policy Research; National Institutes of Health [NHLBI K25 HL081275] FX No direct funding was available for this study. SV Subramanian is supported by the Robert Wood Johnson Investigator Award in Health Policy Research, and the National Institutes of Health Career Development Award (NHLBI K25 HL081275). NR 33 TC 7 Z9 7 U1 1 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1570-677X J9 ECON HUM BIOL JI Econ. Hum. Biol. PD MAR PY 2011 VL 9 IS 2 BP 194 EP 202 DI 10.1016/j.ehb.2010.11.002 PG 9 WC Economics; Public, Environmental & Occupational Health SC Business & Economics; Public, Environmental & Occupational Health GA 744ZG UT WOS:000289133100008 PM 21159565 ER PT J AU Tinzl, MV Chen, B Fang, K Chen, SY Abrahamsson, PA Dizeyi, N AF Tinzl, M., V Chen, B. Fang, K. Chen, S. Y. Abrahamsson, P-A Dizeyi, N. TI C-JUN INTERVENES WITH DOCETAXEL THERAPY IN CASTRATION-RESISTANT PROSTATE CANCER: AR STILL MATTERS SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Meeting Abstract C1 [Tinzl, M., V; Chen, B.; Fang, K.; Abrahamsson, P-A; Dizeyi, N.] Lund Univ, Dept Clin Sci, Urol Res Unit, Malmo, Sweden. [Chen, S. Y.] Harvard Univ, Sch Med, Dept Haematol Oncol, BIDMC, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD MAR PY 2011 VL 10 IS 2 BP 294 EP 294 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 739KH UT WOS:000288715302172 ER PT J AU Brown, JE Cleeland, CS Fallowfield, LJ Patrick, DL Fizazi, K Smith, MR Maroto, JP Michel, MS Feng, A Goessl, C Chung, K AF Brown, J. E. Cleeland, C. S. Fallowfield, L. J. Patrick, D. L. Fizazi, K. Smith, M. R. Maroto, J. P. Michel, M. S. Feng, A. Goessl, C. Chung, K. TI PAIN OUTCOMES IN PATIENTS WITH BONE METASTASES FROM CASTRATE-RESISTANT PROSTATE CANCER: RESULTS FROM A PHASE 3 TRIAL OF DENOSUMAB VS. ZOLEDRONIC ACID SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Meeting Abstract C1 [Brown, J. E.] Canc Res UK Clin Ctr, Dept Clin & Med Oncol, Leeds, W Yorkshire, England. [Cleeland, C. S.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA. [Fallowfield, L. J.] Univ Sussex, Canc Res UK, Dept Psychosocial Oncol, Brighton, E Sussex, England. [Patrick, D. L.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Fizazi, K.] Univ Paris, Dept Med, Inst Gustave Roussy, Villejuif, France. [Smith, M. R.] Massachusetts Gen Hosp, Ctr Canc, Dept Genitourinary Med Oncol, Boston, MA USA. [Maroto, J. P.] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain. [Michel, M. S.] Univ Hosp Mannheim, Dept Urol, Mannheim, Germany. [Feng, A.] Amgen Inc, Dept Global Biostat Sci, Thousand Oaks, CA 91320 USA. [Goessl, C.] Amgen Inc, Dept Hematol Oncol, Thousand Oaks, CA 91320 USA. [Chung, K.] Amgen Inc, Dept Global Hlth Econ, Thousand Oaks, CA 91320 USA. NR 0 TC 8 Z9 8 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD MAR PY 2011 VL 10 IS 2 BP 336 EP 336 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 739KH UT WOS:000288715302319 ER PT J AU Higano, C Beer, T Yu, E Taplin, ME Efstathiou, E Anand, A Hirmand, M Fleisher, M Scher, H AF Higano, C. Beer, T. Yu, E. Taplin, M. E. Efstathiou, E. Anand, A. Hirmand, M. Fleisher, M. Scher, H. CA Prostate Canc Clin Trials Consorti TI LONG-TERM EFFICACY RESULTS FROM THE PHASE 1-2 STUDY OF MDV3100 IN PRE-AND POST-DOCETAXEL ADVANCED PROSTATE CANCER SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Meeting Abstract C1 [Higano, C.; Yu, E.] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Med Oncol, Sch Med, Seattle, WA 98195 USA. [Beer, T.] Oregon Hlth & Sci Univ, Dept Med Oncol, Portland, OR USA. [Taplin, M. E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Efstathiou, E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA. [Anand, A.; Scher, H.] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY 10021 USA. [Hirmand, M.] Medivation Inc, Clin Dev, San Francisco, CA USA. [Fleisher, M.] Mem Sloan Kettering Canc Ctr, Clin Labs, New York, NY 10021 USA. RI Anand, Aseem/P-1214-2014 OI Anand, Aseem/0000-0002-3606-540X NR 0 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD MAR PY 2011 VL 10 IS 2 BP 338 EP 338 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 739KH UT WOS:000288715302326 ER PT J AU Hamoda, HM Bauer, MS DeMaso, DR Sanders, KM Mezzacappa, E AF Hamoda, Hesham M. Bauer, Mark S. DeMaso, David R. Sanders, Katherine M. Mezzacappa, Enrico TI A Competency-Based Model for Research Training During Psychiatry Residency SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE core competencies; research careers; research training; residency training ID SCIENTISTS; MEDICINE; FUTURE AB The Institute of Medicine recently identified a critical shortage of psychiatrist-researchers and highlighted the need for competency-based curricula that promote research training during psychiatry residency as a way to address that shortage. In this article we review extant approaches to research training during psychiatry residency. We then identify five core elements necessary for promoting research training: (1) mentoring, (2) education, (3) experience, (4) time, and (5) support. We describe six interrelated domains of core research competencies that can be mastered gradually over the course of residency training: (1) research literacy, (2) content mastery of specific research topics, (3) principles of research design and methods, (4) principles of biostatistics, (5) presentation and writing skills, including grant writing, and (6) principles of responsible conduct of research. Finally, we propose a broadly applicable, developmental, competency-based framework for applying these core elements to research training during psychiatry residency.= 30 MIU/ml and non-pregnant at 1 year. The primary end-point was the percentage change in bone mineral density (BMD) in the lumbar spine (LS) from baseline to 12 months in the ZA and in control groups in women who developed CIOF; the secondary end-point was BMD in LS at 3 years in all randomised women. Findings: One hundred and fifty (56%) met the definition of CIOF at 1 year. Overall, grade 3 toxicities of ZA were fatigue (1%) arthralgias (21%) and pain (84%). The median percent change (interquartile range, IQR) at 1 year was +1.2% (-0.5% to +2.8%) and -6.7% (-9.7% to -2.9%) p < 0.001 and at 3 years was +1.0% (-1.6% to +5.2%) and -0.5% (-3.7% to +3.2%) p = 0.019 in arms A and B, respectively. Interpretation: ZA every 3 months is well tolerated and prevents rapid bone loss in premenopausal women that develop CIOF. Giving ZA with rather than 1 year after the start of adjuvant chemotherapy is the preferred sequence to prevent bone loss. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Shapiro, C. L.; Paskett, E.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Shapiro, C. L.; Paskett, E.] James Canc Hosp, Columbus, OH 43210 USA. [Halabi, S.; Hars, V.; Archer, L.] CALGB Stat Ctr, Durham, NC 27705 USA. [Weckstein, D.] New Hampshire Hematol & Oncol, Hooksett, NH 03106 USA. [Kirshner, J.] Hematol Oncol Associates Cent New York, E Syracuse, NY 13057 USA. [Sikov, W.] Rhode Isl Hosp, Providence, RI 02906 USA. [Winer, E.; Burstein, H. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hudis, C.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Isaacs, C.] Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA. [Schilsky, R.] Univ Chicago, Chicago, IL 60637 USA. RP Shapiro, CL (reprint author), B405 Starling Loving Hall,320 W 10th Ave, Columbus, OH 43210 USA. EM charles.shapiro@osumc.edu FU NCI NIH HHS [R29 CA060050-06] NR 37 TC 35 Z9 36 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0959-8049 J9 EUR J CANCER JI Eur. J. Cancer PD MAR PY 2011 VL 47 IS 5 BP 683 EP 689 DI 10.1016/j.ejca.2010.11.024 PG 7 WC Oncology SC Oncology GA 741RK UT WOS:000288881700005 PM 21324674 ER PT J AU Allen, ES Connelly, EN Morris, CD Elmer, PJ Zwickey, H AF Allen, Elizabeth S. Connelly, Erin N. Morris, Cynthia D. Elmer, Patricia J. Zwickey, Heather TI A TRAIN THE TRAINER MODEL FOR INTEGRATING EVIDENCE-BASED MEDICINE INTO A COMPLEMENTARY AND ALTERNATIVE MEDICINE TRAINING PROGRAM SO EXPLORE-THE JOURNAL OF SCIENCE AND HEALING LA English DT Article DE Complementary and alternative medicine; evidence-based medicine; teaching ID ORIENTAL-MEDICINE; RESEARCH LITERACY; OREGON-COLLEGE; EDUCATION; FACULTY; INITIATIVES AB Background: Public interest in complementary and alternative medicine (CAM) has grown over the past decade, accompanied by increased demand for evidence-based approaches to CAM practice. In order to define the role evidence-based decision making has in CAM practice, CAM professionals must have a full understanding of evidence-based medicine (EBM) concepts. Objective: This paper describes the design, implementation, and evaluation of a week-long intensive EBM short course for CAM faculty at a naturopathic and classical Chinese medicine institution. Intervention: This 20-hour course, entitled Principles of EBM for CAM Professionals, teaches participants how to access and appraise biomedical literature, apply it to their work, and teach these concepts to their students. Results: Results from precourse and postcourse evaluations suggest that, in a small group of participants, there were significant changes in EBM practice attitudes, self-appraised skills, and objectively assessed skills as a result of this course. Participants indicated they were committed to increasing their use of EBM in practice, enhancing EBM skills, using EBM in teaching, and working to change the culture at their institution to support use of EBM. At six months, 80% of participants had fully or partially followed through on their commitment to change plans. C1 [Allen, Elizabeth S.] Portland VA Med Ctr, Portland, OR 97207 USA. [Connelly, Erin N.; Elmer, Patricia J.; Zwickey, Heather] Natl Coll Nat Med, Helfgott Res Inst, Portland, OR USA. [Morris, Cynthia D.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Allen, ES (reprint author), Portland VA Med Ctr, P3 Med,POB 1034, Portland, OR 97207 USA. EM elizabeth.allen@va.gov FU National Institutes of Health, National Center for Complementary and Alternative Medicine [1R25 AT002878-01A1] FX This work is supported by education grant 1R25 AT002878-01A1 from the National Institutes of Health, National Center for Complementary and Alternative Medicine awarded to Heather Zwickey. NR 28 TC 9 Z9 10 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-8307 J9 EXPLORE-NY JI Explore-J Sci. Heal. PD MAR-APR PY 2011 VL 7 IS 2 BP 88 EP 93 DI 10.1016/j.explore.2010.12.001 PG 6 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 740VJ UT WOS:000288822200006 PM 21397869 ER PT J AU Nakazawa, T Kayama, M Ryu, M Kunikata, H Watanabe, R Yasuda, M Kinugawa, J Vavvas, D Miller, JW AF Nakazawa, Toru Kayama, Maki Ryu, Morin Kunikata, Hiroshi Watanabe, Ryou Yasuda, Masayuki Kinugawa, Jiro Vavvas, Demetrios Miller, Joan W. TI Tumor Necrosis Factor-alpha Mediates Photoreceptor Death in a Rodent Model of Retinal Detachment SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID TNF-ALPHA; INDUCED APOPTOSIS; CELL-DEATH; RECEPTORS; EXPRESSION; DEGENERATION; INFLIXIMAB; BRAIN; NEUROPROTECTION; INHIBITION AB PURPOSE. Photoreceptor degeneration is a major cause of visual loss in various retinal diseases, including retinal detachment (RD) and neovascular AMD, but the underlying mechanisms remain elusive. In this study, the role of TNF alpha in RD-induced photoreceptor degeneration was investigated. METHODS. RD was induced by subretinal injection of hyaluronic acid. Photoreceptor degeneration was assessed by counting the number of apoptotic cells with TdT-dUTP terminal nickend labeling (TUNEL) 3 days after RD and measurement of the outer nuclear layer (OM.) thickness 7 days after RD. As the target of anti-inflammatory treatment, the expression of TNF alpha, with or without dexamethasone (DEX) was examined in rats by real-time PCR. To understand the role of TNF alpha in photoreceptor degeneration, RD was induced in mice deficient in TNF alpha or its receptors (TNFR1, TNER2, and TNER1 and -2), or in wild-type (WT) mice by using a functionally blocking antibody to TNF alpha. CD11b(+) cells in the outer plexiform layer (OPL) and subretinal space were counted by immunohistochemistry (IIIC). RESULTS. Treatment with DEX (P = 0.001) significantly suppressed RD-induced photoreceptor degeneration and the expression of TNF alpha. RD-induced photoreceptor degeneration was significantly suppressed with specific blockade of TNF alpha (P = 0.032), in mice deficient for TNF alpha. (P < 0.001), TNER2 (P = 0.001), or TNER1 and -2 (P < 0.001). However, lack of TNER1 did not protect against RD-induced photoreceptor degeneration (P = 0.060). Muller cell activation was unchanged in WT and TNF alpha(-/-) mice. Recruitment of CD11b(+) monocytes was significantly lower in the TNF alpha(-/-) mice compared to WT mice (P = 0.002). CONCLUSION. TNF alpha plays a critical role in RD-induced photoreceptor degeneration. This pathway may become an important target in the prevention of RD-induced photoreceptor degeneration. (Invest Ophthalmol Sci. 2011;52:1384-1391) DOI:10.1167/iovs.10-6509 C1 [Nakazawa, Toru; Kayama, Maki; Vavvas, Demetrios; Miller, Joan W.] Harvard Univ, Sch Med, Angiogenesis Lab, Massachusetts Eye & Ear Infirm,Dept Ophthalmol, Boston, MA 02114 USA. [Nakazawa, Toru; Ryu, Morin; Kunikata, Hiroshi; Watanabe, Ryou; Yasuda, Masayuki; Kinugawa, Jiro] Tohoku Univ, Grad Sch Med, Dept Ophthalmol, Sendai, Miyagi 9808574, Japan. RP Miller, JW (reprint author), Harvard Univ, Sch Med, Angiogenesis Lab, Massachusetts Eye & Ear Infirm,Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. EM ntoru@oph.med.tohoku.ac.jp; joan_miller@meei.harvard.edu FU Alcon Research Award; Bausch Lomb; Ministry of Education, Science, and Technology of Japan [21659395, 22689045]; Uehara Memorial Research Foundation; Takeda Research Foundation; Imai Glaucoma Research Foundation; National Eye Institute [EY014104] FX Supported by an Alcon Research Award (JWM), a Bausch & Lomb Vitreoretinal Fellowship (TN), Grants-in-Aid 21659395 and 22689045 from the Ministry of Education, Science, and Technology of Japan (TN), the Uehara Memorial Research Foundation, the Takeda Research Foundation and Imai Glaucoma Research Foundation (TN), and National Eye Institute Grant EY014104 (MEEI Core Grant). NR 42 TC 25 Z9 28 U1 0 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR PY 2011 VL 52 IS 3 BP 1384 EP 1391 DI 10.1167/iovs.10-6509 PG 8 WC Ophthalmology SC Ophthalmology GA 742SR UT WOS:000288965300024 PM 21402953 ER PT J AU Gewirtz, H AF Gewirtz, Henry TI Cardiac PET: A Versatile, Quantitative Measurement Tool for Heart Failure Management SO JACC-CARDIOVASCULAR IMAGING LA English DT Article DE heart failure; myocardial blood flow; PET imaging ID POSITRON-EMISSION-TOMOGRAPHY; MYOCARDIAL BLOOD-FLOW; CORONARY-ARTERY-DISEASE; LEFT-VENTRICULAR DYSFUNCTION; TRANSPLANT RECIPIENTS; GLUCOSE-UPTAKE; HYPERTROPHIC CARDIOMYOPATHY; MICROVASCULAR DYSFUNCTION; DILATED CARDIOMYOPATHY; OXYGEN-CONSUMPTION AB Current American Heart Association/American College of Cardiology practice guidelines classify congestive heart failure (CHF) in 4 stages (A, B, C, and D). This review focuses on state-of-the-art and future applications of quantitative positron emission tomography (PET) myocardial perfusion and metabolic imaging in the clinical evaluation and treatment of patients in all CHF stages. Basic physiological and metabolic principles related to the regulation of myocardial blood flow and metabolism at various stages of CHF are briefly reviewed. The advantages of quantitative PET image analysis in contrast to simple qualitative visual analysis of the scans also will be addressed. Finally, potential future clinical applications of quantitative PET for CHF evaluation and treatment will be discussed. (J Am Coll Cardiol Img 2011;4:292-302) (C) 2011 by the American College of Cardiology Foundation C1 Harvard Univ, Cardiac Unit Yawkey 5E, Massachusetts Gen Hosp, Dept Med,Cardiol Div,Med Sch, Boston, MA 02114 USA. RP Gewirtz, H (reprint author), Harvard Univ, Cardiac Unit Yawkey 5E, Massachusetts Gen Hosp, Dept Med,Cardiol Div,Med Sch, Boston, MA 02114 USA. EM hgewirtz@partners.org NR 83 TC 8 Z9 8 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD MAR PY 2011 VL 4 IS 3 BP 292 EP 302 DI 10.1016/j.jcmg.2010.12.006 PG 11 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 744GN UT WOS:000289083000013 PM 21414579 ER PT J AU Singh, JA Fitzgerald, PM AF Singh, Jasvinder A. Fitzgerald, Patrick M. TI Botulinum Toxin for Shoulder Pain: A Cochrane Systematic Review SO JOURNAL OF RHEUMATOLOGY LA English DT Review DE BOTULINUM TOXIN; SHOULDER PAIN; BENEFIT SAFETY; COCHRANE SYSTEMATIC REVIEW ID MODIFIED RANKIN SCALE; DOUBLE-BLIND; PRIMARY-CARE; SPASTIC HEMIPLEGIA; SUBSCAPULAR MUSCLE; BARTHEL INDEX; TENNIS ELBOW; INJECTION; STROKE; DISABILITY AB Objective. To perform a Cochrane Systematic Review of benefits and harms of botulinum toxin for shoulder pain. Methods. We included clinical trials of adults with shoulder pain (population), comparing botulinum toxin (intervention) to placebo or other therapies (comparison), and reporting benefits or harms (outcomes). We calculated relative risk (RR) for categorical outcomes and mean differences (MD) for continuous outcomes. Results. Six randomized controlled trials (RCT) with 164 patients all comparing single botulinum toxin type A injections to placebo were included. Five RCT in patients with post-stroke shoulder pain found that an intramuscular injection of botulinum toxin type A significantly reduced pain at 3-6 months (MD -1.2 points on 0-10 scale, 95% CI -2.4 to -0.07) and improved shoulder external rotation at 1 month (MD 9.8 degrees, 95% CI 0.2 degrees to 19.4 degrees). Number of adverse events did not differ between groups (RR 1.46, 95% CI 0.6 to 24.3). One RCT in arthritis-related shoulder pain showed that single intraarticular botulinum toxin type A injection reduced pain (MD -2.0 on 0-10 scale, 95% Cl -3.7 to -0.3) and shoulder disability (MD -13.4 on 0-100 scale, 95% Cl -24.9 to 1.9) and improved shoulder abduction (MD 13.8 degrees, 95% Cl 3.2 degrees to 44.0 degrees) at 1 month, compared with placebo. Serious adverse events did not differ between groups (RR 0.35, 95% CI 0.11, 1.12). Conclusion. With evidence from few studies with small sample sizes and medium to high risk of bias, botulinum toxin type A injections decreased pain and improved shoulder function in patients with chronic shoulder pain clue to spastic hemiplegia or arthritis. (First Release Feb 1 2011; J Rheumatol 2011;38:409-18; doi:10.3899/jrheum.101081) C1 [Singh, Jasvinder A.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama, Sch Publ Hlth, Div Epidemiol, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Hlth Sci Res, Rochester, MN USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA. [Fitzgerald, Patrick M.] Minneapolis VA Med Ctr, Med Serv, Minneapolis, MN USA. RP Singh, JA (reprint author), Univ Alabama, Dept Med, Fac Off Tower,Room 805B,510 20th St S, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU National Institutes of Health (NW) [1 KL2 RR024151-01]; Birmingham VA Medical Center, Alabama, USA; Allergan; Allergan, Takeda; Savient; Wyeth; Amgen; URL pharmaceuticals; Novartis FX Supported by National Institutes of Health (NW) Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research) and the Birmingham VA Medical Center, Alabama, USA. Dr. Singh has received speaker honoraria from Abbott; research and travel grants from Allergan, Takeda, Savient, Wyeth, and Amgen; rind consultant fees from Savient, URL pharmaceuticals, and Novartis. NR 50 TC 11 Z9 13 U1 0 U2 3 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD MAR PY 2011 VL 38 IS 3 BP 409 EP 418 DI 10.3899/jrheum.101081 PG 10 WC Rheumatology SC Rheumatology GA 740DB UT WOS:000288770700004 PM 21285169 ER PT J AU Tepper, P Crawford, S McConnell, D Joffe, H El Khoudary, SR Gold, E Bromberger, J Randolph, J Sutton-Tyrrell, K AF Tepper, Ping Crawford, Sybil McConnell, Daniel Joffe, Hadine El Khoudary, Samar R. Gold, Ellen Bromberger, Joyce Randolph, John Sutton-Tyrrell, Kim TI Distinct Estradiol and Follicle Stimulating Hormone Trajectory Patterns During Menopausal Transition Among Women in the Study of Women's Health Across the Nation (SWAN) SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Tepper, Ping; El Khoudary, Samar R.; Sutton-Tyrrell, Kim] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Crawford, Sybil] Univ Massachusetts, Grad Sch Biomed Sci, Sch Med, Amherst, MA 01003 USA. [McConnell, Daniel] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Joffe, Hadine] Harvard Univ, Massachusetts Gen Hosp, Ctr Womens Mental Hlth, Sch Med, Cambridge, MA 02138 USA. [Gold, Ellen] Univ Calif Davis, Dept Epidemiol & Prevent Med, Davis, CA USA. [Bromberger, Joyce] Univ Pittsburgh, Dept Psychiat, Sch Med, Pittsburgh, PA 15260 USA. [Randolph, John] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2011 VL 20 IS 3 BP 481 EP 481 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 735RS UT WOS:000288435400092 ER PT J AU Tyksienski, C AF Tyksienski, Carol TI Patient Safety and Hemodialysis Catheters SO NEPHROLOGY NURSING JOURNAL LA English DT Meeting Abstract C1 [Tyksienski, Carol] Massachusetts Gen Hosp, Hemodialysis Unit, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JANNETTI PUBLICATIONS, INC PI PITMAN PA EAST HOLLY AVENUE, BOX 56, PITMAN, NJ 08071-0056 USA SN 1526-744X J9 NEPHROL NURS J JI Nephrol. Nurs. J. PD MAR-APR PY 2011 VL 38 IS 2 BP 202 EP 202 PG 1 WC Nursing; Urology & Nephrology SC Nursing; Urology & Nephrology GA 738DD UT WOS:000288618600049 ER PT J AU Tumani, H Cadavid, D AF Tumani, Hayrettin Cadavid, Diego TI Are high CSF levels of CXCL13 helpful for diagnosis of Lyme neuroborreliosis? SO NEUROLOGY LA English DT Editorial Material ID LYMPHOCYTE CHEMOATTRACTANT; BORRELIA-BURGDORFERI; CHEMOKINE CXCL13; DISEASE; RELEVANCE; MUSCLE C1 [Tumani, Hayrettin] Univ Ulm, Dept Neurol, CSF Lab, D-89081 Ulm, Germany. [Tumani, Hayrettin] Univ Ulm, Dept Neurol, Multiple Sclerosis Outpatient Unit, D-89081 Ulm, Germany. [Cadavid, Diego] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cadavid, Diego] Biogen Idec Inc, Expt Neurol, Weston, MA USA. RP Tumani, H (reprint author), Univ Ulm, Dept Neurol, CSF Lab, Oberer Eselsberg 45, D-89081 Ulm, Germany. EM hayrettin.tumani@uni-ulm.de NR 14 TC 3 Z9 4 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAR PY 2011 VL 76 IS 12 BP 1034 EP 1035 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 741GW UT WOS:000288853200005 PM 21422454 ER PT J AU Freeman, WD Nolte, CM Matthews, BR Coleman, M Corboy, JR AF Freeman, W. D. Nolte, C. M. Matthews, B. R. Coleman, M. Corboy, J. R. TI Results of the American Academy of Neurology Resident Survey SO NEUROLOGY LA English DT Article ID MILLENNIUM; EDUCATION AB Background: To assess the effect of neurology residency education as trainees advance into independent practice, the American Academy of Neurology (AAN) elected to survey all graduating neurology residents at time of graduation and in 3-year cycles thereafter. Methods: A 22-question survey was sent to all neurology residents completing residency training in the United States in 2007. Results: Of 523 eligible residents, 285 (54.5%) responded. Of these, 92% reported good to excellent quality teaching of basic neurology from their faculty; however, 47% noted less than ideal training in basic neuroscience. Two-thirds indicated that the Residency In-service Training Examination was used only as a self-assessment tool, but reports of misuse were made by some residents. After residency, 78% entered fellowships (with 61% choosing a fellowship based on interactions with a mentor at their institution), whereas 20% entered practice directly. After adjustment for the proportion of residents who worked before the duty hour rules were implemented and after their implementation, more than half reported improvement in quality of life (87%), education (60%), and patient care (62%). The majority of international medical graduates reported wanting to stay in the United States to practice rather than return to their country of residence. Conclusions: Neurology residents are generally satisfied with training, and most entered a fellowship. Duty hour implementation may have improved resident quality of life, but reciprocal concerns were raised about impact on patient care and education. Despite the majority of international trainees wishing to stay in the United States, stricter immigration laws may limit their entry into the future neurology workforce. Neurology (R) 2011;76:e61-e67 C1 [Freeman, W. D.] Mayo Clin, Coll Med, Dept Neurol, Jacksonville, FL 32224 USA. [Nolte, C. M.] Vanderbilt Univ, Dept Sleep Med, Nashville, TN USA. [Matthews, B. R.] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA. [Coleman, M.] Amer Acad Neurol, St Paul, MN USA. [Corboy, J. R.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA. [Corboy, J. R.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Corboy, JR (reprint author), 12631 E 17th St,POB 6511,Mailstop B-185, Aurora, CO 80045 USA. EM john.corboy@ucdenver.edu FU NIH; Novartis; BioMS Medical; Orasi Medical Inc.; NIH/NINDS; National MS Society FX Dr. Freeman has served as officer of the American Academy of Neurology, Resident & Fellow section. Dr. Nolte has served as officer of the American Academy of Neurology, Resident & Fellow section. Dr. Matthews has served as officer of the American Academy of Neurology, Resident & Fellow section, and receives research support from the NIH. M. Coleman is an employee of the American Academy of Neurology. Dr. Corboy has served as Chair of the Graduate Education Subcommittee (GES); serves as Editor for Neurology: Clinical Practice and as Section Editor for Neurology Today; serves as a consultant for Bayer Schering Pharma, EMD Serono, Inc., Advanced Studies in Medicine (ASiM), and Novartis; has received research support from Novartis, BioMS Medical, Orasi Medical Inc., the NIH/NINDS, and the National MS Society; and has reviewed files and give expert testimony in medicolegal cases. NR 10 TC 12 Z9 12 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAR PY 2011 VL 76 IS 13 BP E61 EP E67 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 741VD UT WOS:000288892600001 PM 21444895 ER PT J AU Erickson, JI Ditomassi, M AF Erickson, Jeanette Ives Ditomassi, Marianne TI Professional Practice Model: Strategies for Translating Models into Practice SO NURSING CLINICS OF NORTH AMERICA LA English DT Article DE Professional practice model; Magnet recognition; Staff satisfaction; Professional practice environment ID INTENSIVE-CARE UNITS; PSYCHOMETRIC EVALUATION; SERVICES; SCALE AB In the current health care climate, economic and cultural conditions have created an optimal opportunity to envision a new direction for nursing as a profession. Nurses find themselves at the formative stages of charting this new direction. The articulation of a professional practice model provides a framework for setting this new direction and thus the achievement of exemplary clinical outcomes. In this article, the authors describe the evolution of the professional practice model at the Massachusetts General Hospital and how the model continues to be evaluated and modified over time by the nurses within the system. C1 [Ditomassi, Marianne] Massachusetts Gen Hosp, Nursing & Patient Care Serv, Boston, MA 02114 USA. [Erickson, Jeanette Ives] Massachusetts Gen Hosp, Patient Care Serv Operat, Boston, MA 02114 USA. RP Ditomassi, M (reprint author), Massachusetts Gen Hosp, Nursing & Patient Care Serv, 55 Fruit St,Bulfinch 230, Boston, MA 02114 USA. EM mditomassi@partners.org NR 13 TC 4 Z9 6 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0029-6465 J9 NURS CLIN N AM JI Nurs. Clin. North Am. PD MAR PY 2011 VL 46 IS 1 BP 35 EP + DI 10.1016/j.cnur.2010.10.011 PG 12 WC Nursing SC Nursing GA 727YL UT WOS:000287839200005 PM 21320659 ER PT J AU Sones, HM Thorp, SR Raskind, M AF Sones, Heather M. Thorp, Steven R. Raskind, Murray TI Prevention of Posttraumatic Stress Disorder SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE Posttraumatic stress disorder; Prevention; Mental health; Psychological distress ID RANDOMIZED CONTROLLED-TRIAL; NATIONAL COMORBIDITY SURVEY; COMBAT VETERANS; SEPTIC SHOCK; FUTURE-DIRECTIONS; EMOTIONAL EVENTS; PTSD PREVENTION; DOUBLE-BLIND; TRAUMA; SLEEP AB Traumatic events are common, but the psychological distress that may follow usually subsides naturally. For some individuals, distress develops into posttraumatic stress disorder (PTSD). PTSD lends itself to the application of prevention strategies for at-risk individuals. The identification of a causal event may make prevention efforts for PTSD more feasible and effective than for other psychological disorders. For PTSD, these efforts target those traumatized persons who are beginning to exhibit symptoms of PTSD. These interventions could also target individuals meeting criteria for acute stress disorder with the goal of preventing chronic PTSD. C1 [Thorp, Steven R.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92108 USA. [Sones, Heather M.] Univ Calif San Diego, San Diego State Univ, San Diego Joint Doctoral Program Clin Psychol, San Diego, CA 92120 USA. [Thorp, Steven R.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Raskind, Murray] VA Puget Sound Hlth Care Syst, Educ & Clin Ctr, Seattle Div, Seattle, WA 98108 USA. [Raskind, Murray] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Thorp, SR (reprint author), VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, 8810 Rio San Diego Dr,Mail Code 116A4Z, San Diego, CA 92108 USA. EM sthorp@ucsd.edu NR 81 TC 9 Z9 9 U1 4 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD MAR PY 2011 VL 34 IS 1 BP 79 EP + DI 10.1016/j.psc.2010.11.001 PG 17 WC Psychiatry SC Psychiatry GA 734OM UT WOS:000288344200006 PM 21333841 ER PT J AU Maust, DT Mavandadi, S Klaus, J Oslin, DW AF Maust, Donovan T. Mavandadi, Shahrzad Klaus, Johanna Oslin, David W. TI Missed Opportunities: Fewer Service Referrals After Positive Alcohol Misuse Screens in VA Primary Care SO PSYCHIATRIC SERVICES LA English DT Article ID DEPRESSION AB Objective: The primary purpose of this study was to compare referral to additional clinical services after primary care clinicians screened for and found a positive screen for alcohol misuse, depression, or posttraumatic stress disorder (PTSD). Methods: Results from the Alcohol Use Disorders Identification Test, Patient Health Questionnaire 2, and Primary Care PTSD screens performed over two years at the Philadelphia Veterans Affairs (VA) Medical Center and affiliated VA community sites were analyzed by mixed-effects logistic regression. A total of 9,052 veterans with positive screens were eligible for additional clinical services. Results: Odds of referral to additional clinical services for positive depression or PTSD screens were significantly higher than for positive screens for alcohol misuse (odds ratio=10.60 and 19.49, respectively). Conclusion: Primary care-based screening for alcohol misuse is managed differently than for depression or PTSD. (Psychiatric Services 62:310-312, 2011) C1 [Maust, Donovan T.; Oslin, David W.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Mavandadi, Shahrzad; Klaus, Johanna; Oslin, David W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Maust, DT (reprint author), Univ Penn, Dept Psychiat, 3535 Market St,2nd floor, Philadelphia, PA 19104 USA. EM donovan.maust@uphs.upenn.edu FU National Institute of Mental Health; Department of Psychiatry, University of Pennsylvania FX Dr. Maust is supported by the National Institute of Mental Health-Clinical Research Scholars Program of the Department of Psychiatry, University of Pennsylvania. The authors thank Kevin Lynch, Ph.D., and Caroline McKay, Ph.D., for their assistance with the statistical analysis. NR 9 TC 8 Z9 8 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAR PY 2011 VL 62 IS 3 BP 310 EP 312 DI 10.1176/appi.ps.62.3.310 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 728AL UT WOS:000287845800013 PM 21363905 ER PT J AU Bergmann, LL Zimmerman, P Kaunitz, JD AF Bergmann, Liisa L. Zimmerman, Peter Kaunitz, Jonathan D. TI Unusual complication: superior mesenteric artery syndrome and closed loop gastroduodenal obstruction after adjustable gastric banding SO SURGERY FOR OBESITY AND RELATED DISEASES LA English DT Editorial Material ID BYPASS C1 [Kaunitz, Jonathan D.] W Los Angeles Vet Affairs Med Ctr, Med Serv, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA. [Zimmerman, Peter] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA. [Zimmerman, Peter] W Los Angeles Vet Affairs Med Ctr, Serv Radiol, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90024 USA. RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, Med Serv, Greater Los Angeles Vet Affairs Healthcare Syst, Bldg 114,Suite 217E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU NIDDK NIH HHS [R01 DK054221] NR 9 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-7289 J9 SURG OBES RELAT DIS JI Surg. Obes. Relat. Dis. PD MAR-APR PY 2011 VL 7 IS 2 BP 237 EP 239 DI 10.1016/j.soard.2010.03.283 PG 3 WC Surgery SC Surgery GA 743PT UT WOS:000289031700022 PM 21130049 ER PT J AU Mattocks, KM Nikolajski, C Haskell, S Brandt, C McCall-Hosenfeld, J Yano, E Tan, P Borrero, S AF Mattocks, Kristin M. Nikolajski, Cara Haskell, Sally Brandt, Cynthia McCall-Hosenfeld, Jennifer Yano, Elizabeth Tan Pham Borrero, Sonya TI Women Veterans' Reproductive Health Preferences and Experiences: A Focus Group Analysis SO WOMENS HEALTH ISSUES LA English DT Article ID GENDER DISCRIMINATION; QUALITATIVE RESEARCH; CARE; AFFAIRS; DELIVERY; IMPACT; RACE AB Objective: Although women veterans are seeking care at the Veterans Administration (VA) in record numbers, there is little information regarding women veterans' experiences and preferences for reproductive health care services. We sought to characterize women veterans' experiences with, and preferences for, reproductive health services in the VA. Methods: We conducted five focus groups with a total of 25 participants using a semistructured interview guide to elicit women veterans' experiences and preferences with reproductive health care. Women Veterans' utilizing VA health care at two VA facilities who responded to advertisements were selected on a first-come basis to participate in the study. We analyzed transcripts of these audiorecorded sessions using the constant comparative method of grounded theory. Results: Five main themes emerged from the focus group discussions: 1) Women veterans prefer VA women's clinics for comprehensive medical care; 2) Women veterans have had both positive and negative reproductive health experiences in the VA; 3) Women veterans experience knowledge gaps regarding VA coverage for reproductive health services; 4) Women veterans believe the VA should provide additional coverage for advanced infertility care and for newborns; and 5) Perceived gender discrimination shapes how women veterans view the VA. Conclusion: As the VA continues to tailor its services to women veterans, attention should be given to women's reproductive health care needs. Copyright (c) 2011 by the Jacobs Institute of Women's Health. Published by Elsevier Inc. C1 [Mattocks, Kristin M.; Haskell, Sally; Tan Pham] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. [Mattocks, Kristin M.; Haskell, Sally; Brandt, Cynthia; Tan Pham] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Nikolajski, Cara; Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Nikolajski, Cara; Borrero, Sonya] Univ Pittsburgh, Ctr Res Hlth Care, Dept Med, Pittsburgh, PA 15260 USA. [Brandt, Cynthia] Yale Univ, Sch Med, Yale Ctr Med Informat, New Haven, CT USA. [McCall-Hosenfeld, Jennifer] PennState Milton S Hershey Med Ctr, Hershey, PA USA. [Yano, Elizabeth] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Excellence Study Healthcare Provider, Sepulveda, CA USA. [Yano, Elizabeth] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. [Borrero, Sonya] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Mattocks, KM (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave,11-ACSLG, West Haven, CT 06516 USA. EM Kristin.mattocks@va.gov FU HSRD VA [I01 HX000915] NR 23 TC 10 Z9 10 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD MAR-APR PY 2011 VL 21 IS 2 BP 124 EP 129 DI 10.1016/j.whi.2010.11.002 PG 6 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA 735NH UT WOS:000288422100005 PM 21353978 ER PT J AU Bradford, A Upchurch, C Bass, D Judge, K Snow, AL Wilson, N Kunik, ME AF Bradford, Andrea Upchurch, Christina Bass, David Judge, Katherine Snow, A. Lynn Wilson, Nancy Kunik, Mark E. TI Knowledge of Documented Dementia Diagnosis and Treatment in Veterans and Their Caregivers SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS LA English DT Article DE dementia; diagnosis; self-report; veterans ID PRIMARY-CARE PHYSICIANS; GENERAL-PRACTITIONERS; ALZHEIMERS-DISEASE; FAMILY CAREGIVERS; DISCLOSURE; PERSPECTIVES; ATTITUDES; PATIENT; TRUTH AB We studied perceptions of dementia diagnosis and treatment in patient-caregiver dyads enrolled in a care coordination intervention trial for veterans with dementia. We compared patient and caregiver perceptions of diagnosis and treatment to information in the medical record and assessed concordance between patient and caregiver perceptions. Data were derived from medical record abstraction and structured interviews with 132 patients and 183 caregivers. Most caregivers, but only about one fourth of patients, reported having received information about a diagnosis related to memory loss. Caregivers were more accurate than patients in recalling the patient's use of memory-enhancing medications. Within dyads there was poor agreement regarding a diagnosis of dementia. Our findings suggest that there is substantial room for improvement in disclosure and education of dementia diagnosis, especially at the level of the patient-caregiver dyad. C1 [Bradford, Andrea; Upchurch, Christina; Wilson, Nancy; Kunik, Mark E.] Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Bradford, Andrea; Wilson, Nancy; Kunik, Mark E.] Baylor Coll Med, Houston, TX 77030 USA. [Kunik, Mark E.] VA S Cent Mental Illness Res Educ & Clin Ctr, Houston, TX USA. [Judge, Katherine] Cleveland State Univ, Cleveland, OH 44115 USA. [Bass, David; Judge, Katherine] Margaret Blenkner Res Inst, Cleveland, OH USA. [Snow, A. Lynn] Univ Alabama, Tuscaloosa, AL USA. [Snow, A. Lynn] Tuscaloosa Vet Affairs Med Ctr, Tuscaloosa, AL USA. RP Kunik, ME (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mkunik@bcm.edu OI Bradford, Andrea/0000-0002-8390-8844 FU Robert Wood Johnson Foundation [57816]; Alzheimer's Association [IIRG-08-89058]; Houston VA HSR&D Center of Excellence [HFP90-020] FX The authors disclosed receipt of the following financial support for the research and/or authorship of this article: Grant No. 57816 from the Robert Wood Johnson Foundation and Grant No. IIRG-08-89058 from the Alzheimer's Association and was supported in part by the Houston VA HSR&D Center of Excellence (HFP90-020). NR 31 TC 5 Z9 5 U1 3 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1533-3175 J9 AM J ALZHEIMERS DIS JI Am. J. Alzheimers Dis. Other Dement. PD MAR PY 2011 VL 26 IS 2 BP 127 EP 133 DI 10.1177/1533317510394648 PG 7 WC Geriatrics & Gerontology; Clinical Neurology SC Geriatrics & Gerontology; Neurosciences & Neurology GA 740QG UT WOS:000288808900007 PM 21273206 ER PT J AU Filippi, M Rocca, MA Barkhof, F Bakshi, R Fazekas, F Khan, O Pelletier, D Rovira, A Simon, J AF Filippi, M. Rocca, M. A. Barkhof, F. Bakshi, R. Fazekas, F. Khan, O. Pelletier, D. Rovira, A. Simon, J. TI Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency: The Neuroimaging Perspective SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Editorial Material ID DEEP GRAY-MATTER; WHITE-MATTER; QUANTITATIVE ASSESSMENT; IRON DEPOSITION; MS LESIONS; IN-VIVO; MR; PERFUSION; NEURODEGENERATION; FLOW C1 [Filippi, M.; Rocca, M. A.] Inst Sci, Neuroimaging Res Unit, Inst Expt Neurol, Div Neurosci, Milan, Italy. [Filippi, M.; Rocca, M. A.] Univ Hosp San Raffaele, Milan, Italy. [Barkhof, F.] Vrije Univ Amsterdam Med Ctr, Dept Radiol, Amsterdam, Netherlands. [Bakshi, R.] Harvard Univ, Brigham & Womens Hosp, Partners Multiple Sclerosis Ctr, Sch Med,Dept Neurol,Lab Neuroimaging Res, Boston, MA 02115 USA. [Fazekas, F.] Med Univ Graz, Dept Neurol, Graz, Austria. [Pelletier, D.] Wayne State Univ, Sch Med, Dept Neurol, Multiple Sclerosis Ctr, Detroit, MI 48201 USA. [Pelletier, D.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Pelletier, D.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. [Rovira, A.] Hosp Valle dHebron, Dept Radiol, Barcelona, Spain. [Simon, J.] Oregon Hlth & Sci Univ, Dept Radiol, Portland, OR 97201 USA. [Simon, J.] Portland VA Med Ctr, Portland, OR USA. RP Filippi, M (reprint author), Inst Sci, Neuroimaging Res Unit, Inst Expt Neurol, Div Neurosci, Milan, Italy. NR 49 TC 12 Z9 14 U1 0 U2 6 PU AMER SOC NEURORADIOLOGY PI OAK BROOK PA 2210 MIDWEST RD, OAK BROOK, IL 60521 USA SN 0195-6108 J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD MAR PY 2011 VL 32 IS 3 BP 424 EP 427 DI 10.3174/ajnr.A2348 PG 4 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 738KX UT WOS:000288639800002 PM 21292801 ER PT J AU Mike, A Glanz, BI Hildenbrand, P Meier, D Bolden, K Liguori, M Dell'Oglio, E Healy, BC Bakshi, R Guttmann, CRG AF Mike, A. Glanz, B. I. Hildenbrand, P. Meier, D. Bolden, K. Liguori, M. Dell'Oglio, E. Healy, B. C. Bakshi, R. Guttmann, C. R. G. TI Identification and Clinical Impact of Multiple Sclerosis Cortical Lesions as Assessed by Routine 3T MR Imaging SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID COGNITIVE IMPAIRMENT; INVERSION-RECOVERY; BRAIN ATROPHY; NEUROPSYCHOLOGICAL IMPAIRMENT; INTRACORTICAL LESIONS; MINIMAL ASSESSMENT; MATTER PATHOLOGY; MS PATIENTS; GRAY; DEMYELINATION AB BACKGROUND AND PURPOSE: Histopathologic studies have reported widespread cortical lesions in MS; however, in vivo detection by using routinely available pulse sequences is challenging. We investigated the relative frequency and subtypes of cortical lesions and their relationships to white matter lesions and cognitive and physical disability. MATERIALS AND METHODS: Cortical lesions were identified and classified on the basis of concurrent review of 3D FLAIR and 3D T1-weighted IR-SPGR 3T MR images in 26 patients with MS. Twenty-five patients completed the MACFIMS battery. White matter lesion volume, cortical lesion number, and cortical lesion volume were assessed. RESULTS: Overall, 249 cortical lesions were detected. Cortical lesions were present in 24/26 patients (92.3%) (range per patient, 0-30; mean, 9.6 +/- 8.8). Most (94.4%, n = 235) cortical lesions were classified as mixed cortical-subcortical (type I); the remaining 5.6% (n = 14) were classified as purely intracortical (type II). Subpial cortical lesions (type III) were not detected. White matter lesion volume correlated with cortical lesion number and cortical lesion volume Vs = 0.652, r(S) = 0.705, respectively; both P < .0011. After controlling for age, depression, and premorbid intelligence, we found that all MR imaging variables (cortical lesion number, cortical lesion volume, white matter lesion volume) correlated with the SDMT score (R(2) = 0.513, R(2) = 0.449, R(2) = 0.418, respectively; P < .014); cortical lesion number also correlated with the CVLT-II scores (R(2) = 0.542-0.461, P < .043). The EDSS scores correlated with cortical lesion number and cortical lesion volume (r(S) = 0.472, r(S) = 0.404, respectively; P < .05), but not with white matter lesion volume. CONCLUSIONS: Our routinely available imaging method detected many cortical lesions in patients with MS and was useful in their precise topographic characterization in the context of the gray matter white matter junction. Routinely detectable cortical lesions were related to physical disability and cognitive impairment. C1 [Mike, A.; Hildenbrand, P.; Meier, D.; Bolden, K.; Liguori, M.; Dell'Oglio, E.; Guttmann, C. R. G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Imaging, Boston, MA 02115 USA. [Glanz, B. I.; Healy, B. C.; Bakshi, R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Partners Multiple Sclerosis Ctr, Brookline, MA USA. [Hildenbrand, P.] Lahey Clin Fdn, Dept Radiol, Burlington, MA USA. [Liguori, M.] CNR, Inst Neurol Sci, Cosenza, Italy. [Healy, B. C.] Massachusetts Gen Hosp, Dept Neurol, Ctr Biostat, Boston, MA 02114 USA. RP Guttmann, CRG (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Imaging, 221 Longwood Ave,RF 394, Boston, MA 02115 USA. EM guttmann@bwh.harvard.edu RI Liguori, Maria/D-4390-2016 OI Liguori, Maria/0000-0003-4338-0392 FU National Multiple Sclerosis Society [RG3574A1]; Multiple Sclerosis International Federation; McDonald Fellowship FX This work was supported by the National Multiple Sclerosis Society (grant RG3574A1). A. Mike, MD, receives support for her research activities from the Multiple Sclerosis International Federation with the McDonald Fellowship 2008. NR 45 TC 30 Z9 30 U1 0 U2 4 PU AMER SOC NEURORADIOLOGY PI OAK BROOK PA 2210 MIDWEST RD, OAK BROOK, IL 60521 USA SN 0195-6108 J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD MAR PY 2011 VL 32 IS 3 BP 515 EP 521 DI 10.3174/ajnr.A2340 PG 7 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 738KX UT WOS:000288639800018 PM 21310857 ER PT J AU Karajanagi, SS Lopez-Guerra, G Park, H Kobler, JB Galindo, M Aanestad, J Mehta, DD Kumai, Y Giordano, N d'Almeida, A Heaton, JT Langer, R Herrera, VLM Faquin, W Hillman, RE Zeitels, SM AF Karajanagi, Sandeep S. Lopez-Guerra, Gerardo Park, Hyoungshin Kobler, James B. Galindo, Marilyn Aanestad, Jon Mehta, Daryush D. Kumai, Yoshihiko Giordano, Nicholas d'Almeida, Anthony Heaton, James T. Langer, Robert Herrera, Victoria L. M. Faquin, William Hillman, Robert E. Zeitels, Steven M. TI Assessment of Canine Vocal Fold Function After Injection of a New Biomaterial Designed to Treat Phonatory Mucosal Scarring SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Article DE hoarseness; hydrogel; polyethylene glycol; scar ID EXTRACELLULAR-MATRIX; HYALURONIC-ACID; TISSUE-REPAIR; GROWTH-FACTOR; PHONOSURGERY; CORD AB Objectives: Most cases of irresolvable hoarseness are due to deficiencies in the pliability and volume of the superficial lamina propria of the phonatory mucosa. By using a US Food and Drug Administration approved polymer, polyethylene glycol (PEG), we created a novel hydrogel (PEG30) and investigated its effects on multiple vocal fold structural and functional parameters. Methods: We injected PEG30 unilaterally into 16 normal canine vocal folds with survival times of I to 4 months. Highspeed videos of vocal fold vibration, induced by intratracheal airflow, and phonation threshold pressures were recorded at 4 time points per subject. Three-dimensional reconstruction analysis of 11.7 T magnetic resonance images and histologic analysis identified 3 cases wherein PEG30 injections were the most superficial, so as to maximally impact vibratory function. These cases were subjected to in-depth analyses. Results: High-speed video analysis of the 3 selected cases showed minimal to no reduction in the maximum vibratory amplitudes of vocal folds injected with PEG30 compared to the non-injected, contralateral vocal fold. All PEG30-injected vocal folds displayed mucosal wave activity with low average phonation threshold pressures. No significant inflammation was observed on microlaryngoscopic examination. Magnetic resonance imaging and histologic analyses revealed time-dependent resorption of the PEG30 hydrogel by phagocytosis with minimal tissue reaction or fibrosis. Conclusions: The PEG30 hydrogel is a promising biocompatible candidate biomaterial to restore form and function to deficient phonatory mucosa, while not mechanically impeding residual endogenous superficial lamina propria. C1 [Kobler, James B.; Heaton, James T.; Langer, Robert; Hillman, Robert E.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Karajanagi, Sandeep S.; Park, Hyoungshin; Langer, Robert] MIT, Dept Chem Engn, Cambridge, MA 02139 USA. [Herrera, Victoria L. M.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Karajanagi, Sandeep S.; Lopez-Guerra, Gerardo; Park, Hyoungshin; Kobler, James B.; Kumai, Yoshihiko; Heaton, James T.; Hillman, Robert E.; Zeitels, Steven M.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. [Giordano, Nicholas] Boston Univ, Sch Engn, Boston, MA 02118 USA. [Mehta, Daryush D.] Harvard Univ, Sch Engn & Appl Sci, Boston, MA 02115 USA. [Faquin, William] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Karajanagi, Sandeep S.; Lopez-Guerra, Gerardo; Park, Hyoungshin; Kobler, James B.; Galindo, Marilyn; Aanestad, Jon; Mehta, Daryush D.; Kumai, Yoshihiko; d'Almeida, Anthony; Heaton, James T.; Hillman, Robert E.; Zeitels, Steven M.] Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, Boston, MA 02114 USA. [Faquin, William] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Karajanagi, SS (reprint author), Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, Bartlett Hall Extens 413, Boston, MA 02114 USA. FU Eugene B. Casey Foundation; Institute of Laryngology and Voice Restoration FX From the Center for Laryngeal Surgery and Voice Rehabilitation (Karajanagi, Lopez-Guerra, Park, Kobler, Galindo, Aanestad, Mehta, Kumai, d'Almeida, Heaton, Hillman, Zeitels) and the Department of Pathology (Faquin), Massachusetts General Hospital, the Departments of Surgery (Karajanagi, Lopez-Guerra, Park, Kobler, Kumai, Heaton, Hillman, Zeitels) and Pathology (Faquin), Harvard Medical School, the Department of Medicine, Boston University School of Medicine (Herrera), the School of Engineering and Applied Sciences, Harvard University (Mehta), and the School of Engineering, Boston University (Giordano), Boston, and the Department of Chemical Engineering (Karajanagi, Park, Langer) and the Harvard-MIT Division of Health Sciences and Technology (Kobler, Heaton, Langer, Hillman), Massachusetts Institute of Technology, Cambridge, Massachusetts. This work was supported in part by the Eugene B. Casey Foundation and the Institute of Laryngology and Voice Restoration. Dr Zeitels has an equity interest in Endocraft LLC. This study was performed in accordance with the PHS Policy on Humane Care and Use of Laboratory Animals, the NIH Guide for the care and Use of Laboratory Animals, and the Animal Welfare Act (7 U.S.C. et seq.); the animal use protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of the Massachusetts General Hospital. NR 28 TC 10 Z9 10 U1 1 U2 16 PU ANNALS PUBL CO PI ST LOUIS PA 4507 LACLEDE AVE, ST LOUIS, MO 63108 USA SN 0003-4894 J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD MAR PY 2011 VL 120 IS 3 BP 175 EP 184 PG 10 WC Otorhinolaryngology SC Otorhinolaryngology GA 741BE UT WOS:000288837300006 PM 21510143 ER PT J AU Henstrom, DK Lindsay, RW Cheney, ML Hadlock, TA AF Henstrom, Douglas K. Lindsay, Robin W. Cheney, Mack L. Hadlock, Tessa A. TI Surgical Treatment of the Periocular Complex and Improvement of Quality of Life in Patients With Facial Paralysis SO ARCHIVES OF FACIAL PLASTIC SURGERY LA English DT Article ID FOLLOW-UP; VALIDATION; INSTRUMENT; SINUSITIS; SURGERY; ADULTS AB Objective: A devastating sequela of facial paralysis is the inability to close the eye. The resulting loss of corneal protection can potentially lead to severe consequences. Eyelid weight placement, lower eyelid suspension, and brow ptosis correction are frequently performed to protect the eye. We sought to measure and report the change in quality of life (QOL) after surgical treatment of the periocular complex, using the validated Facial Clinimetric Evaluation (FaCE) QOL instrument. Methods: From March 2009 to May 2010, 49 patients presenting to the Facial Nerve Center with paralytic lagophthalmos requiring intervention were treated with static periocular reanimation. Thirty-seven of the patients completed preoperative and postoperative FaCE surveys. Results: Overall QOL, measured by the FaCE instrument, significantly improved following static periocular treatment. Mean FaCE scores increased from 44.1 to 52.7 (P<.001). Patients also reported a significant decrease in the amount of time their eye felt dry, irritated, or scratchy (P<.001). The amount of artificial tears and/or ointment also significantly decreased (P=.03). There were 2 cases of localized cellulitis with 1 eyelid weight extrusion. Conclusions: We report the first series of postoperative QOL changes following static periocular treatment for paralytic lagophthalmos. Patients report a notable improvement in periocular comfort and overall QOL. C1 [Henstrom, Douglas K.; Cheney, Mack L.; Hadlock, Tessa A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA USA. [Lindsay, Robin W.] Bethesda Naval Med Ctr, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA. RP Hadlock, TA (reprint author), Massachusetts Eye & Ear Infirm, Facial Nerve Ctr, Dept Otolaryngol Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA. EM tessa_hadlock@meei.harvard.edu NR 17 TC 27 Z9 27 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1521-2491 J9 ARCH FACIAL PLAST S JI Arch. Facial Plast. Surg. PD MAR-APR PY 2011 VL 13 IS 2 BP 125 EP 128 PG 4 WC Surgery SC Surgery GA 738AB UT WOS:000288610600009 PM 21422446 ER PT J AU Blanchard, HT AF Blanchard, Howard T. TI GRADE-ing the Evidence: Education to Advance Innovations in Practice SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Blanchard, Howard T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2011 VL 25 IS 2 BP 85 EP 85 PG 1 WC Nursing SC Nursing GA 719XS UT WOS:000287245400038 ER PT J AU Milbury, CA Li, J Liu, PF Makrigiorgos, GM AF Milbury, Coren A. Li, Jin Liu, Pingfang Makrigiorgos, G. Mike TI COLD-PCR: improving the sensitivity of molecular diagnostics assays SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS LA English DT Review DE cancer; coamplification at lower denaturation temperature; COLD-PCR; denaturation temperature; low-abundance mutations; variant and mutation enrichment ID RESOLUTION MELTING ANALYSIS; KRAS MUTATION DETECTION; CELL LUNG-CANCER; NUCLEIC-ACIDS; DNA; DENATURATION; ENRICHMENT; RESISTANCE; PHENOTYPE; SAMPLES AB The detection of low-abundance DNA variants or mutations is of particular interest to medical diagnostics, individualized patient treatment and cancer prognosis; however, detection sensitivity for low-abundance variants is a pronounced limitation of most currently available molecular assays. We have recently developed coamplification at lower denaturation temperature-PCR (COLD-PCR) to resolve this limitation. This novel form of PCR selectively amplifies low-abundance DNA variants from mixtures of wild-type and mutant-containing (or variant-containing) sequences, irrespective of the mutation type or position on the amplicon, by using a critical denaturation temperature. The use of a lower denaturation temperature in COLD-PCR results in selective denaturation of amplicons with mutation-containing molecules within wild-type mutant heteroduplexes or with a lower melting temperature. COLD-PCR can be used in lieu of conventional PCR in several molecular applications, thus enriching the mutant fraction and improving the sensitivity of downstream mutation detection by up to 100-fold. C1 [Milbury, Coren A.; Li, Jin; Liu, Pingfang; Makrigiorgos, G. Mike] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Div DNA Repair & Genome Stabil,Dept Radiat Oncol, Boston, MA 02115 USA. [Makrigiorgos, G. Mike] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Div Med Phys & Biophys,Dept Radiat Oncol, Boston, MA USA. RP Makrigiorgos, GM (reprint author), Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Div DNA Repair & Genome Stabil,Dept Radiat Oncol, Boston, MA 02115 USA. EM mmakrigiorgos@partners.org FU National Cancer Institute and National Institutes of Health [T32-CA009078, CA-138280, CA-111994] FX This work was supported by T32-CA009078 from the National Cancer Institute and National Institutes of Health grants CA-138280 and CA-111994. COLD-PCR technology is patent-pending, and assigned to the Dana Farber Cancer Institute (MA, USA). Certain portions of the COLD-PCR technology have been licensed to Transgenomic Inc. (NE, USA). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 43 TC 16 Z9 19 U1 1 U2 13 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7159 J9 EXPERT REV MOL DIAGN JI Expert Rev. Mol. Diagn. PD MAR PY 2011 VL 11 IS 2 BP 159 EP 169 DI 10.1586/ERM.10.115 PG 11 WC Pathology SC Pathology GA 737TW UT WOS:000288592100007 PM 21405967 ER PT J AU Barry, M Levin, C MacCuaig, M Mulley, A Sepucha, K AF Barry, Michael Levin, Carrie MacCuaig, Morgan Mulley, Al Sepucha, Karen CA Boston ISDM Planning Comm TI Shared Decision Making: Vision to Reality SO HEALTH EXPECTATIONS LA English DT Editorial Material C1 [Barry, Michael; Levin, Carrie; MacCuaig, Morgan; Sepucha, Karen] Harvard Univ, Sch Med, Fdn Informed Med Decis Making, Cambridge, MA 02138 USA. [Barry, Michael; Mulley, Al] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. RP Barry, M (reprint author), Harvard Univ, Sch Med, Fdn Informed Med Decis Making, Cambridge, MA 02138 USA. NR 8 TC 8 Z9 8 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1369-6513 J9 HEALTH EXPECT JI Health Expect. PD MAR PY 2011 VL 14 SU 1 BP 1 EP 5 DI 10.1111/j.1369-7625.2010.00641.x PG 5 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 722DU UT WOS:000287412200001 PM 21323818 ER PT J AU Feibelmann, S Yang, TS Uzogara, EE Sepucha, K AF Feibelmann, Sandra Yang, Theresa S. Uzogara, Ekeoma E. Sepucha, Karen TI What does it take to have sustained use of decision aids? A programme evaluation for the Breast Cancer Initiative SO HEALTH EXPECTATIONS LA English DT Article DE clinical care; community; decision aids; early stage breast cancer; feasibility; implementation AB Background The Breast Cancer Initiative (BCI) was started in 2002 to disseminate breast cancer decision aids (PtDAs) to providers. Methods We analysed BCI programme data for 195 sites and determined the proportion of sites involved in each of five stages of dissemination and implementation of PtDAs. We conducted cross-sectional mail and telephone surveys of 79 sites with the most interest in implementation. We examined barriers associated with sustained use of the PtDAs. Results Since 2002 we attempted contact with 195 sites to join the BCI. The majority indicated interest in using PtDAs 172 of 195 (88%), 93 of 195 signed up for the BCI (48%), 57 of 195 reported distributing PtDAs to at least one patient (57%), and 46 of 195 reported sustained use (24%). We analysed data from interviews with 59 of 79 active sites (75% response rate). The majority of providers 49 of 59 (83%) had watched the PtDAs, and 46 of 59 (78%) distributed them to patients. The most common barriers were lack of a reliable way to identify patients before decisions are made (37%), a lack of time to distribute the PtDAs (22%) and having too many educational materials (15%). Sites that indicated a lack of clinician support as a barrier were significantly less likely to have sustained use compared to sites that didn't (33% vs. 74%, P = 0.02). Conclusions Community breast cancer providers, both physicians and non-physicians, express a high interest in using PtDAs with their patients. About a quarter of sites report sustained use of the PtDAs in routine care. C1 [Sepucha, Karen] Harvard Univ, Sch Med, Hlth Decis Res Unit, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Yang, Theresa S.] Albany Med Coll, Grad Sch Med, Albany, NY 12208 USA. [Uzogara, Ekeoma E.] Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA. RP Sepucha, K (reprint author), Harvard Univ, Sch Med, Hlth Decis Res Unit, Massachusetts Gen Hosp, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM ksepucha@partners.org FU Foundation for Informed Medical Decision Making (FIMDM); Foundation for Informed Medical Decision Making, Boston, USA FX Dr Sepucha receives research and salary support from the Foundation for Informed Medical Decision Making (FIMDM). FIMDM produces the decision aids used in this project. The other authors declare that they have no competing interests.; Foundation for Informed Medical Decision Making, 40 Court Street, Suite 300, Boston, MA 02108, USA. NR 13 TC 12 Z9 12 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1369-6513 J9 HEALTH EXPECT JI Health Expect. PD MAR PY 2011 VL 14 SU 1 BP 85 EP 95 DI 10.1111/j.1369-7625.2010.00640.x PG 11 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 722DU UT WOS:000287412200008 PM 21323821 ER PT J AU Braw, Y Aviram, S Bloch, Y Levkovitz, Y AF Braw, Yoram Aviram, Shai Bloch, Yuval Levkovitz, Yechiel TI The effect of age on frontal lobe related cognitive functions of unmedicated depressed patients SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Depression; Age; Cognition; Executive functions; Higher-order cognition ID WORKING-MEMORY; EXECUTIVE DYSFUNCTION; UNIPOLAR DEPRESSION; MAJOR DEPRESSION; NORMATIVE DATA; HYPOTHESIS; ATTENTION; ADULTS; IMPAIRMENTS; EDUCATION AB Background: Aging is associated with a decline in frontal lobe related cognitive functioning of healthy subjects (i.e., executive functioning and higher-order cognition). Unipolar depression is associated with dysfunctions in similar cognitive domains deficits that impact the functioning and quality of life of these patients. The effect of age on frontal lobe related cognitive functions of depressed patients, however, has not been adequately studied. The current study therefore assessed a wide age range of depressed patients and compared their frontal lobe related cognitive functions to that of matched healthy controls. Recruitment of unmedicated patients minimized the confounding effect of psychiatric medications. Method: Depressed patients and healthy controls were divided into three age groups (< 25, 25-45, and 46-65 years of age) and matched in gender, age and education level (N total = 170). Cognition was assessed using the Cambridge Neuropsychological Test Automated Battery (CANTAB). Results: The depressed patients had deficits in cognitive planning/organization, working memory, and sustained attention compared to the healthy controls. Aging was associated with a decrease in frontal lobe related functioning. Except for working memory, no significant interactions were found between the age groups and the study group (depressed/healthy). Conclusions: Depressed patients are impaired in most domains of frontal lobe related cognitive functions. These deficits are already evident at an early age and persist in older age cohorts (despite an overall age related decline). These findings may help clarify the profile and course of cognitive deficits among depressed patients while providing tentative support for a developmental model of cognitive impairment in depression. (C) 2010 Elsevier B.V. All rights reserved. C1 [Levkovitz, Yechiel] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA. [Braw, Yoram; Aviram, Shai; Bloch, Yuval; Levkovitz, Yechiel] Tel Aviv Univ, Sackler Fac Med, Emot Cognit Res Ctr, Shalvata Mental Hlth Care Ctr, Hod Hasharon, Israel. [Braw, Yoram] Ariel Univ Ctr Samaria, Dept Behav Sci, Ariel, Israel. [Bloch, Yuval; Levkovitz, Yechiel] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel. RP Levkovitz, Y (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, 50 Staniford St,Suite 401, Boston, MA 02114 USA. EM ylevk@clalit.org.il NR 33 TC 10 Z9 10 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD MAR PY 2011 VL 129 IS 1-3 BP 342 EP 347 DI 10.1016/j.jad.2010.07.032 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 733VW UT WOS:000288293400048 PM 20817307 ER PT J AU Takada, Y Ono, Y Saegusa, J Mitsiades, C Mitsiades, N Tsai, J He, Y Maningding, E Coleman, A Ramirez-Maverakis, D Rodriguez, R Takada, Y Maverakis, E AF Takada, Yoshikazu Ono, Yoko Saegusa, Jun Mitsiades, Constantine Mitsiades, Nicholas Tsai, Jean He, Yong Maningding, Ernest Coleman, Annie Ramirez-Maverakis, Dalila Rodriguez, Raphael Takada, Yoko Maverakis, Emanual TI A T cell-binding fragment of fibrinogen can prevent autoimmunity (vol 34, pg 453, 2010) SO JOURNAL OF AUTOIMMUNITY LA English DT Correction C1 [Takada, Yoshikazu; Ono, Yoko; Saegusa, Jun; Tsai, Jean; He, Yong; Maningding, Ernest; Coleman, Annie; Ramirez-Maverakis, Dalila; Takada, Yoko; Maverakis, Emanual] Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95816 USA. [Mitsiades, Constantine; Mitsiades, Nicholas] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Maverakis, Emanual] Univ Calif Davis, Dept Med Microbiol & Immunol, Davis, CA 95616 USA. [Rodriguez, Raphael] Univ Calif Davis, Dept Pathol, Sacramento, CA 95817 USA. [Maverakis, Emanual] Dept Vet Affairs No Calif Hlth Care Syst, Sacramento, CA 95655 USA. RP Takada, Y (reprint author), Univ Calif Davis, Sch Med, Dept Dermatol, 3301 C St,Suite 1400, Sacramento, CA 95816 USA. EM ytakada@ucdavis.edu; ytakada@ucdavis.edu RI Maverakis, Emanual/E-1185-2013; OI takada, yoshikazu/0000-0001-5481-9589 NR 1 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0896-8411 J9 J AUTOIMMUN JI J. Autoimmun. PD MAR PY 2011 VL 36 IS 2 BP 170 EP 170 DI 10.1016/j.jaut.2010.11.002 PG 1 WC Immunology SC Immunology GA 739OC UT WOS:000288726500010 ER PT J AU Ghali, JK Massie, BM Mann, DL Rich, MW AF Ghali, Jalal K. Massie, Barry M. Mann, Douglas L. Rich, Michael W. TI Guidelines are Merely Guidelines SO JOURNAL OF CARDIAC FAILURE LA English DT Editorial Material ID PERFORMANCE-MEASURES; CLINICAL GUIDELINES C1 [Ghali, Jalal K.] DMC Cardiovasc Inst, Detroit, MI 48201 USA. [Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Massie, Barry M.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. [Mann, Douglas L.; Rich, Michael W.] Washington Univ, Sch Med, St Louis, MO USA. RP Ghali, JK (reprint author), DMC Cardiovasc Inst, 3990 John R,Suite 9370, Detroit, MI 48201 USA. EM jghali@dmc.org OI Mann, Douglas /0000-0002-2516-0145 NR 7 TC 1 Z9 1 U1 0 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD MAR PY 2011 VL 17 IS 3 BP 208 EP 209 DI 10.1016/j.cardfail.2011.01.004 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 736WN UT WOS:000288525800005 PM 21362528 ER PT J AU Shinagare, AB Fennessy, FM Ramaiya, NH Jagannathan, JP Taplin, ME Van den Abbeele, AD AF Shinagare, Atul B. Fennessy, Fiona M. Ramaiya, Nikhil H. Jagannathan, Jyothi P. Taplin, Mary Ellen Van den Abbeele, Annick D. TI Urothelial Cancers of the Upper Urinary Tract: Metastatic Pattern and Its Correlation With Tumor Histopathology and Location SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LA English DT Article DE upper tract urothelial cancer; renal pelvis; ureter; pattern of metastasis; transitional cell carcinoma ID TRANSITIONAL-CELL-CARCINOMA; RENAL PELVIS; BLADDER AB Objective: To study the metastatic pattern of upper urinary tract urothelial cancer and to correlate it with tumor histopathology and location. Methods: After approval by the institutional review board, we studied patients with pathologically proven metastatic urothelial cancers of renal pelvis or ureter, who presented between January 2003 and December 2009. The metastasis- free interval and metastatic pattern were compared for T stage, histopathological subtype (transitional cell carcinoma versus atypical histology), and location (renal pelvis versus ureter). Results: The study group consisted of 52 patients (33 men and 19 women: transitional cell carcinoma, 69% [36/52]; atypical histology, 31% [16/52]; renal pelvis, 73% [38/52]; ureter, 27% [14/52]). Lymph nodes (75% [39/52]), lung (65% [34/52]), liver (54% [28/52]), bone (39% [20/52]), and peritoneum (19% [10/52]) were the most common metastatic sites. There was no difference in the metastatic pattern for different T stages, histologic groups, or locations. Conclusion: Lymph nodes, lung, liver, bone, and peritoneum are the most common metastatic sites of upper urinary tract urothelial cancers. Tumor histology and location within the upper urinary tract have no effect on metastatic pattern. C1 [Shinagare, Atul B.; Fennessy, Fiona M.; Ramaiya, Nikhil H.; Jagannathan, Jyothi P.; Van den Abbeele, Annick D.] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA. [Shinagare, Atul B.; Fennessy, Fiona M.; Ramaiya, Nikhil H.; Jagannathan, Jyothi P.; Van den Abbeele, Annick D.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. [Taplin, Mary Ellen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Shinagare, AB (reprint author), Dana Farber Canc Inst, Dept Imaging, 44 Binney St, Boston, MA 02115 USA. EM ashinagare@partners.org NR 19 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0363-8715 J9 J COMPUT ASSIST TOMO JI J. Comput. Assist. Tomogr. PD MAR-APR PY 2011 VL 35 IS 2 BP 217 EP 222 DI 10.1097/RCT.0b013e31820d7a37 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 736MM UT WOS:000288498800010 PM 21412093 ER PT J AU Hadley, D Anderson, BS Borckardt, JJ Arana, A Li, XB Nahas, Z George, MS AF Hadley, Dakota Anderson, Berry S. Borckardt, Jeffrey J. Arana, Ashley Li, Xingbao Nahas, Ziad George, Mark S. TI Safety, Tolerability, and Effectiveness of High Doses of Adjunctive Daily Left Prefrontal Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression in a Clinical Setting SO JOURNAL OF ECT LA English DT Article DE rTMS; TMS; transcranial magnetic stimulation; high-dose TMS; safety; effectiveness; concomitant medication; panic disorder; suicidal ideation; suicidality; unipolar; bipolar; depression; VNS; VNS implant ID MAJOR DEPRESSION; FUNCTIONAL CONNECTIVITY; CONTROLLED-TRIAL; MOTOR THRESHOLD; CORTEX; MOOD; TMS; EXCITABILITY; METAANALYSIS; EFFICACY AB Objective: Daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) recently received Food and Drug Administration (FDA) approval for the treatment of depression and offers an alternative to traditional approaches. This approval was based on a study using 3000 stimuli per day (15,000 stimuli per week) in adults with unipolar depression not taking antidepressant medications. Several meta-analyses suggest a dose-response relationship with TMS. This study was carried out before US FDA approval to test the safety, tolerability, and effectiveness of adjunctive high-dose left prefrontal rTMS in a clinical setting with particular attention to safety of higher doses and potential interactions with antidepressant medications, speed of response, and effects on suicidality. Method: We enrolled 19 patients who were in a current major depressive episode with treatment-resistant unipolar or bipolar depression and treated them in their acute episode and in a maintenance fashion for 18 months. The patients received daily left prefrontal rTMS at 120% resting motor threshold, 10 Hz, 5 seconds on, and 10 seconds off and for a mean of 6800 stimuli per session (34,000 stimuli per week), more than twice the dose delivered in the pivotal FDA trial. All patients continued antidepressant medication throughout the rTMS treatment; thus rTMS was an adjunctive treatment. We measured adverse effects, depression, quality of life, suicidal ideation, and social and physical functioning. Results: These higher rTMS doses were well tolerated without significant adverse effects or adverse events. All measured dimensions showed improvement, with many showing improvement in 1 to 2 weeks. Of perhaps most importance, suicidal ideation diminished in 67% of the patients after just 1 week. Conclusions: These uncontrolled data suggest that higher doses of daily left prefrontal rTMS may safely be used in outpatients with major depressive episode even as an adjunctive treatment. C1 [Hadley, Dakota; Anderson, Berry S.; Borckardt, Jeffrey J.; Arana, Ashley; Li, Xingbao; Nahas, Ziad; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Hadley, D (reprint author), 105 Cottonwood Dr, Summerville, SC 29483 USA. EM DakotaHadley88@gmail.com NR 34 TC 43 Z9 47 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1095-0680 J9 J ECT JI J. ECT PD MAR PY 2011 VL 27 IS 1 BP 18 EP 25 DI 10.1097/YCT.0b013e3181ce1a8c PG 8 WC Behavioral Sciences; Psychiatry SC Behavioral Sciences; Psychiatry GA 726CU UT WOS:000287697100023 PM 21343710 ER PT J AU Lynch, M Dahlin, C Hultman, T Coakley, EE AF Lynch, Maureen Dahlin, Constance Hultman, Todd Coakley, Edward E. TI Palliative Care Nursing Defining the Discipline? SO JOURNAL OF HOSPICE & PALLIATIVE NURSING LA English DT Article DE nurse-patient relationship; palliative nursing ID OF-LIFE CARE; NURSES; PERCEPTIONS; QUALITY; PATIENT AB Nursing and palliative care share common roots, goals, and values. To advance palliative nursing practice, it is essential to discern the unique contribution of palliative nursing to the field of palliative care. The goal of palliative care is to prevent and relieve suffering and to support the best possible quality of life for patients and their families, regardless of the stage of the disease or the need for other therapies. The alleviation of suffering through the diagnosis and treatment of human responses to health issues is an essential function of nursing as defined by the American Nurses Association. For nurses, human response is a complex phenomenon that encompasses the physical, social, emotional, and spiritual aspects of being. Through the art of being present and the science of evidence-based interventions, palliative nurses assess, diagnose, and intervene to support or modify these responses in patients with acute or chronic, potentially life-limiting illnesses and their families to achieve positive patient outcomes that maximize quality of life and alleviate suffering. As the palliative nurse comes to know the patient and family in the nurse-patient relationship, the values, beliefs, past experiences, and goals of all parties emerge and shape future care from symptom management, to advanced directives, treatment choices, and care at the time of death. C1 [Lynch, Maureen] Dana Farber Canc Inst, Adult Palliat Care Program, Boston, MA 02115 USA. [Dahlin, Constance; Hultman, Todd; Coakley, Edward E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Lynch, M (reprint author), Dana Farber Canc Inst, Adult Palliat Care Program, 44 Binney St, Boston, MA 02115 USA. EM mtlynch@partners.org NR 44 TC 8 Z9 8 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1522-2179 J9 J HOSP PALLIAT NURS JI J. Hosp. Palliat. Nurs. PD MAR-APR PY 2011 VL 13 IS 2 BP 106 EP 111 DI 10.1097/NJH.0b013e3182075b6e PG 6 WC Nursing SC Nursing GA 723AM UT WOS:000287478200006 ER PT J AU Blake, V Joffe, S Kodish, E AF Blake, Valarie Joffe, Steve Kodish, Eric TI Harmonization of Ethics Policies in Pediatric Research SO JOURNAL OF LAW MEDICINE & ETHICS LA English DT Article C1 [Blake, Valarie; Kodish, Eric] Cleveland Clin, Ctr Eth Humanities & Spiritual Care, Cleveland, OH USA. [Joffe, Steve] Dana Farber Canc Inst, Boston, MA 02115 USA. [Joffe, Steve] Childrens Hosp, Boston, MA 02115 USA. [Joffe, Steve] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Kodish, Eric] Case Western Reserve Univ, Lerner Coll Med, Cleveland, OH 44106 USA. RP Blake, V (reprint author), Cleveland Clin, Ctr Eth Humanities & Spiritual Care, Cleveland, OH USA. OI Joffe, Steven/0000-0002-0667-7384 NR 13 TC 6 Z9 6 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1073-1105 J9 J LAW MED ETHICS JI J. Law Med. Ethics PD SPR PY 2011 VL 39 IS 1 BP 70 EP + DI 10.1111/j.1748-720X.2011.00551.x PG 10 WC Ethics; Law; Medical Ethics; Medicine, Legal SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine GA 719WE UT WOS:000287241400010 PM 21314796 ER PT J AU Rogers, JT Mikkilineni, S Cantuti-Castelvetri, I Smith, DH Huang, XD Bandyopadhyay, S Cahill, CM Maccecchini, ML Lahiri, DK Greig, NH AF Rogers, Jack T. Mikkilineni, Sohan Cantuti-Castelvetri, Ippolita Smith, Deborah H. Huang, Xudong Bandyopadhyay, Sanghamitra Cahill, Catherine M. Maccecchini, Maria L. Lahiri, Debomoy K. Greig, Nigel H. TI The alpha-synuclein 5 ' untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen SO JOURNAL OF NEURAL TRANSMISSION LA English DT Article DE Parkinson's disease; Alpha-synuclein; 5 ' untranslated region; Transfection-based screen; Natural product; Translation blockers; Amyloid precursor protein; Posiphen; Phenserine ID AMYLOID PRECURSOR PROTEIN; IRON-RESPONSIVE ELEMENT; APP-MESSENGER-RNA; MULTIPLE SYSTEM ATROPHY; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; 5'-UNTRANSLATED REGION; LEWY BODIES; NEURODEGENERATIVE DISEASES; MYCOPHENOLATE-MOFETIL AB Increased brain alpha-synuclein (SNCA) protein expression resulting from gene duplication and triplication can cause a familial form of Parkinson's disease (PD). Dopaminergic neurons exhibit elevated iron levels that can accelerate toxic SNCA fibril formation. Examinations of human post mortem brain have shown that while mRNA levels for SNCA in PD have been shown to be either unchanged or decreased with respect to healthy controls, higher levels of insoluble protein occurs during PD progression. We show evidence that SNCA can be regulated via the 5'untranslated region (5'UTR) of its transcript, which we modeled to fold into a unique RNA stem loop with a CAGUGN apical loop similar to that encoded in the canonical iron-responsive element (IRE) of L- and H-ferritin mRNAs. The SNCA IRE-like stem loop spans the two exons that encode its 5'UTR, whereas, by contrast, the H-ferritin 5'UTR is encoded by a single first exon. We screened a library of 720 natural products (NPs) for their capacity to inhibit SNCA 5'UTR driven luciferase expression. This screen identified several classes of NPs, including the plant cardiac glycosides, mycophenolic acid (an immunosuppressant and Fe chelator), and, additionally, posiphen was identified to repress SNCA 5'UTR conferred translation. Western blotting confirmed that Posiphen and the cardiac glycoside, strophanthidine, selectively blocked SNCA expression (similar to 1 mu M IC(50)) in neural cells. For Posiphen this inhibition was accelerated in the presence of iron, thus providing a known APP-directed lead with potential for use as a SNCA blocker for PD therapy. These are candidate drugs with the potential to limit toxic SNCA expression in the brains of PD patients and animal models in vivo. C1 [Rogers, Jack T.; Mikkilineni, Sohan; Cantuti-Castelvetri, Ippolita; Huang, Xudong; Cahill, Catherine M.] Massachusetts Gen Hosp, Neurochem Lab, Charlestown, MA 02129 USA. [Cantuti-Castelvetri, Ippolita] Massachusetts Gen Hosp, MIND, Charlestown, MA 02129 USA. [Smith, Deborah H.] Yale Univ, New Haven, CT USA. [Bandyopadhyay, Sanghamitra] Indian Inst Toxicol Res CSIR, Lucknow, Uttar Pradesh, India. [Maccecchini, Maria L.] QR Pharma Inc, Radnor, PA 19087 USA. [Lahiri, Debomoy K.] Indiana Univ Sch Med, Inst Psychiat Res, Dept Psychiat, Mol Neurogenet Lab, Indianapolis, IN USA. [Greig, Nigel H.] NIA, Drug Design & Dev Sect, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA. RP Rogers, JT (reprint author), Massachusetts Gen Hosp, Neurochem Lab, Charlestown, MA 02129 USA. EM Jrogers@partners.org OI Bandyopadhyay, Sanghamitra /0000-0002-1490-3599 FU Michael J. Fox Foundation; National Institute of Aging [R01 AG20181]; Alzheimer's Association [09-131352]; ISOA; QR Pharma Inc.; National Institutes of Health [AG18379, AG18884]; National Institute on Aging, National Institutes of Health (NHG); MGH/MIT Morris Udall Center of Excellence in PD Research [NIH NS38372]; APDA Advanced Center for Parkinson Research at MGH FX This research was supported by the Michael J. Fox Foundation Novel Drug Discoveries Award, National Institute of Aging R01 AG20181 (JTR), Alzheimer's Association Zenith Award 09-131352 (JTR), ISOA (JTR), QR Pharma Inc. (MLM), the National Institutes of Health Grants [AG18379 and AG18884 (DKL)] and the Intramural Research Program, National Institute on Aging, National Institutes of Health (NHG). ICC was supported by the MGH/MIT Morris Udall Center of Excellence in PD Research (NIH NS38372), and the APDA Advanced Center for Parkinson Research at MGH. We are indebted for the input and support of Professor Moussa Youdim, a pioneer in the fields of Parkinson's disease research, and an innovative drug discoverer and developer. NR 85 TC 18 Z9 19 U1 0 U2 6 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0300-9564 J9 J NEURAL TRANSM JI J. Neural Transm. PD MAR PY 2011 VL 118 IS 3 BP 493 EP 507 DI 10.1007/s00702-010-0513-5 PG 15 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 737HB UT WOS:000288558600020 PM 21221670 ER PT J AU Nelson, CA Spector, JM AF Nelson, Christina A. Spector, Jonathan M. TI Neonatal resuscitation capacity in Nepal SO JOURNAL OF PAEDIATRICS AND CHILD HEALTH LA English DT Article DE developing countries; neonatal mortality; resuscitation ID BIRTH ASPHYXIA; DEATHS; HEALTH AB Aim: Perinatal asphyxia is a major contributor to the nearly 4 million neonatal deaths worldwide each year in resource-limited settings. Neonatal resuscitation, a proven method for preventing newborn deaths, is effective only when local caregivers have proper training and access to essential supplies. There are few published data describing neonatal resuscitation capacity in Nepal, where neonatal mortality rates are high. The goal of this study was to quantify neonatal resuscitation capacity at birthing sites in urban and rural Nepal. Methods: Seventeen birth centres ranging from tertiary care hospitals to rural health posts were evaluated. Assessments included standardised interviews of health-care workers and evaluation of newborn resuscitation areas. The availability of essential resuscitation tools was recorded. Results: Eleven of the 17 health centres conducted deliveries on-site. Of those, 45% had posted and visible resuscitation algorithms; 72% had infant warmers; 91% had mechanical suction machines; 36% had bulb suctions and 82% had bag-mask ventilation devices available. Tertiary hospitals were much better equipped compared with smaller health centres. None of the health-care workers who attended home deliveries had access to algorithms, warming devices, suction or bag-mask ventilation devices. Conclusions: Availability of appropriate resuscitation supplies was variable in health centres providing delivery services on-site and was severely deficient among health staff attending to home deliveries. Limited availability of resuscitation equipment may contribute to the high neonatal mortality rates seen in Nepal. Sustainable training programmes and distribution of neonatal resuscitation equipment are critical priorities in this region. C1 [Nelson, Christina A.] Univ Colorado, Colorado Sch Publ Hlth, Denver, CO 80202 USA. [Spector, Jonathan M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Neonatol, Boston, MA USA. RP Nelson, CA (reprint author), Care of Fayette Augillard, Colorado Sch Publ Hlth, Campus Box B-119,13001 E 17th Ave, Aurora, CO 80045 USA. EM cnelson.medicine@gmail.com NR 14 TC 2 Z9 2 U1 2 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1034-4810 J9 J PAEDIATR CHILD H JI J. Paediatr. Child Health PD MAR PY 2011 VL 47 IS 3 BP 83 EP 86 DI 10.1111/j.1440-1754.2010.01893.x PG 4 WC Pediatrics SC Pediatrics GA 735WD UT WOS:000288450400004 PM 21091578 ER PT J AU Emingil, G Gurkan, A Atilla, G Kantarci, A AF Emingil, Gulnur Gurkan, Ali Atilla, Gul Kantarci, Alpdogan TI Subantimicrobial-Dose Doxycycline and Cytokine-Chemokine Levels in Gingival Crevicular Fluid SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE Chemokines; cytokines; doxycycline; gingival crevicular fluid ID PERIODONTAL-DISEASE PROGRESSION; TUMOR-NECROSIS-FACTOR; ADULT PERIODONTITIS; CLINICAL-PARAMETERS; TISSUE DESTRUCTION; POTENTIAL ROLE; EXPRESSION; THERAPY; INTERLEUKIN-17; RANTES AB Background: The present randomized, double-masked, placebo-controlled, parallel-arm study examines the impact of adjunctive subantimicrobial-dose doxycycline (SDD) on the local inflammatory response through cytokine and chemokine levels in gingival crevicular fluid (GCF) samples from patients with chronic periodontitis. Methods: Forty-six patients with chronic periodontitis received scaling and root planing with or without adjunctive SDD. GCF samples were collected and clinical parameters including probing depth, clinical attachment level, gingival index, and plaque index were recorded every 3 months for 12 months. GCF tumor necrosis factor-a, interleukin (IL)-6, IL-4, IL-10, IL-13, IL-17, macrophage inhibitory protein 1 alpha, macrophage inhibitory protein 1 beta, monocyte chemoattractant protein 1, and regulated on activated normal T-cell expressed and secreted protein levels were determined by xMAP multiplex immunoassay. Results: Significant improvements were observed in all clinical parameters in both groups over 12 months (P<0.0125), whereas the SDD group showed significantly better reduction in gingival index, probing depth, and gain in clinical attachment compared to the placebo group (P<0.05). Decrease in IL-6 in the SDD group was significantly higher compared to the placebo group at 6 and 9 months in deep pockets (P<0.05), whereas tumor necrosis factor-a was significantly reduced in moderately deep pockets (P<0.05). SDD resulted in a stable IL-4 and IL-10 response while reducing the monocyte chemoattractant protein 1 levels at 3 months (P<0.05). Conclusions: These results show that SDD, as an adjunct to non-surgical periodontal therapy, stabilizes the inflammatory response by promoting the suppression of proinflammatory cytokines and increasing the anti-inflammatory cytokines. The chemokine activity would account for the regulation of the inflammatory response to SDD therapy. J Periodontol 2011;82:452-461. C1 [Kantarci, Alpdogan] Forsyth Inst, Dept Periodontol, Cambridge, MA 02142 USA. [Emingil, Gulnur; Gurkan, Ali; Atilla, Gul] Ege Univ, Sch Dent, Dept Periodontol, Izmir, Turkey. [Kantarci, Alpdogan] Boston Univ, Dept Periodontol & Oral Biol, Henry M Goldman Sch Dent Med, Boston, MA 02215 USA. RP Kantarci, A (reprint author), Forsyth Inst, Dept Periodontol, 245 1st St,Suite 6103, Cambridge, MA 02142 USA. EM AKantarci@forsyth.org RI Gurkan, Ali/S-8840-2016 NR 50 TC 16 Z9 16 U1 1 U2 4 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 J9 J PERIODONTOL JI J. Periodont. PD MAR PY 2011 VL 82 IS 3 BP 452 EP 461 DI 10.1902/jop.2010.100036 PG 10 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 737RZ UT WOS:000288587200014 PM 20932155 ER PT J AU Hostetter, TH Kochis, DJ Shaffer, RN Chertow, G Harmon, WE Klotman, PE Powe, NR Sedor, JR Smedberg, PC Watnick, S Winkelmayer, WC AF Hostetter, Thomas H. Kochis, Daniel J. Shaffer, Rachel N. Chertow, Glenn Harmon, William E. Klotman, Paul E. Powe, Neil R. Sedor, John R. Smedberg, Paul C. Watnick, Suzanne Winkelmayer, Wolfgang C. CA ASN Public Policy Board TI World Kidney Day 2011 SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material C1 [Kochis, Daniel J.; Shaffer, Rachel N.; Smedberg, Paul C.] Amer Soc Nephrol, Washington, DC 20006 USA. [Hostetter, Thomas H.] Albert Einstein Coll Med, New York, NY USA. [Chertow, Glenn] Stanford Univ, Sch Med, Dept Med, Div Nephrol, Palo Alto, CA 94304 USA. [Harmon, William E.] Harvard Univ, Sch Med, Boston, MA USA. [Harmon, William E.] Childrens Hosp, Boston, MA 02115 USA. [Klotman, Paul E.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Powe, Neil R.] San Francisco Gen Hosp, Med Serv, San Francisco, CA 94110 USA. [Powe, Neil R.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Sedor, John R.] Case Western Reserve Univ, Dept Med, Ctr Study Kidney Dis & Biol, Sch Med, Cleveland, OH 44106 USA. [Watnick, Suzanne] Portland VA Med Ctr, Portland, OR USA. [Watnick, Suzanne] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Kochis, DJ (reprint author), Amer Soc Nephrol, 1725 1 St NW,Suite 510, Washington, DC 20006 USA. EM dkochis@asn-online.org NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD MAR PY 2011 VL 22 IS 3 BP 397 EP 398 DI 10.1681/ASN.2011020115 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 740GE UT WOS:000288778800001 PM 21355055 ER PT J AU Alexander, MP Lafleche, G Schnyer, D Lim, C Verfaellie, M AF Alexander, Michael P. Lafleche, Ginette Schnyer, David Lim, Chun Verfaellie, Mieke TI Cognitive and Functional Outcome After Out of Hospital Cardiac Arrest SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE Hypoxia-ischemia; Brain; Amnesia; Executive functions; Psychomotor; Ventricular fibrillation; Recovery of function ID COMATOSE SURVIVORS; UTSTEIN STYLE; RESUSCITATION; PROGNOSIS; CARDIOPULMONARY; SEQUELAE AB The nature of residual cognitive deficits after out of hospital cardiac arrest (OHCA) is incompletely described and has never been defined against a cardiac control (CC) group. The objective of this study is to examine neuropsychological outcomes 3 months after OHCA in patients in a. "middle range" of acute severity. Thirty prospective OHCA admissions, with coma > 1 day and responsive but confused at 1 week, and 30 non-OHCA coronary care admissions were administered standard tests in five cognitive domains. OHCA subjects fell into two deficit profiles. One group (N = 20) had mild memory deficits and borderline psychomotor deficits compared to the CC group; 40% had returned to work. The other group (N = 10) had severe impairments in all domains. Coma duration was associated with group. Neither group had a high prevalence of depression. For most patients within the "middle range" of acute severity of OHCA, cognitive and functional outcomes at 3 months were encouraging. (JINS, 2011, 17, 364-368) C1 [Alexander, Michael P.; Lim, Chun] Harvard Univ, Cognit Neurol Unit, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Alexander, Michael P.] Baycrest Hosp, Rotman Res Inst, Toronto, ON, Canada. [Lafleche, Ginette; Verfaellie, Mieke] VA Boston Healthcare Syst, Memory Disorders Res Ctr, Boston, MA USA. [Lafleche, Ginette; Verfaellie, Mieke] Boston Univ, Sch Med, Boston, MA 02118 USA. [Schnyer, David] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA. RP Alexander, MP (reprint author), Harvard Univ, Cognit Neurol Unit, Beth Israel Deaconess Med Ctr, Sch Med, KS 253,330 Brookline Ave, Boston, MA 02215 USA. EM malexand@bidmc.harvard.edu OI Verfaellie, Mieke/0000-0001-5535-4584 FU NIH [R01 HD046442]; Office of Research and Development, Medical Research Service, Department of Veterans Affairs FX This research was supported by NIH R01 HD046442 (to MPA) and the Office of Research and Development, Medical Research Service, Department of Veterans Affairs (to MV). We are grateful to Kate McNamara, Lily Wong, and Elana Anastasia for research assistance. The authors have no conflicts of interest to disclose. NR 20 TC 20 Z9 20 U1 0 U2 7 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD MAR PY 2011 VL 17 IS 2 BP 364 EP 368 DI 10.1017/S1355617710001633 PG 5 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 738DY UT WOS:000288620900017 PM 21208480 ER PT J AU Hintermann, E Bayer, M Luster, A Christen, U AF Hintermann, E. Bayer, M. Luster, A. Christen, U. TI CXCL10 plays a key role in the development of hepatic fibrosis SO NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY LA English DT Meeting Abstract CT 77th Annual Meeting on German-Society-for-Experimental-and-Clinical-Pharmacology-and-Toxicology CY MAR 30-APR 01, 2011 CL Frankfurt, GERMANY SP German Soc Expt & Clin Pharmacol & Toxicol C1 [Hintermann, E.; Bayer, M.; Christen, U.] Klinikum Goethe Univ, Pharmazentrum Frankfurt ZAFES, Frankfurt, Germany. [Luster, A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA USA. RI Christen, Urs/A-7338-2009 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0028-1298 J9 N-S ARCH PHARMACOL JI Naunyn-Schmiedebergs Arch. Pharmacol. PD MAR PY 2011 VL 383 SU 1 BP 48 EP 48 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 737MO UT WOS:000288573100233 ER PT J AU Richter, C San Juan, MH Weigmann, B Giegold, O Schroder, M Pfeilschifter, J Daniel, C Radeke, HH AF Richter, C. San Juan, Herrero M. Weigmann, B. Giegold, O. Schroeder, M. Pfeilschifter, J. Daniel, C. Radeke, H. H. TI A highly sensitive bioassay proved basic survival function and TCR co-stimulatory role of interleukin-23 exclusively for Th17 memory lymphocytes SO NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY LA English DT Meeting Abstract CT 77th Annual Meeting on German-Society-for-Experimental-and-Clinical-Pharmacology-and-Toxicology CY MAR 30-APR 01, 2011 CL Frankfurt, GERMANY SP German Soc Expt & Clin Pharmacol & Toxicol C1 [Richter, C.] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Klin Kinder & Jugendmed, Dresden, Germany. [San Juan, Herrero M.; Giegold, O.; Schroeder, M.; Pfeilschifter, J.; Radeke, H. H.] Klin JWG Univ, Pharmazentrum Frankfurt, Frankfurt, Germany. [Weigmann, B.] Univ Erlangen Nurnberg, Med Klin 1, Erlangen, Germany. [Daniel, C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. RI Radeke, Heinfried/E-3772-2013 OI Radeke, Heinfried/0000-0002-4499-2510 NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0028-1298 J9 N-S ARCH PHARMACOL JI Naunyn-Schmiedebergs Arch. Pharmacol. PD MAR PY 2011 VL 383 SU 1 BP 70 EP 70 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 737MO UT WOS:000288573100352 ER PT J AU Jones, D Duffy, ME Flanagan, J AF Jones, Dorothy Duffy, Mary E. Flanagan, Jane TI Randomized Clinical Trial Testing Efficacy of a Nurse-Coached Intervention in Arthroscopy Patients SO NURSING RESEARCH LA English DT Article DE functional health; symptom distress; telephone-mediated nurse coaching intervention ID HEALTH SURVEY SF-36; DAY SURGERY; PATIENTS EXPERIENCES; DISTRESS; QUALITY; PAIN AB Background: Emerging data suggest limited patient preparation for ambulatory surgery, decreased access to healthcare providers postoperatively, increased patient and family anxiety, and increased patient suffering. Thus, there is a need for nursing interventions to improve the postoperative experience for patients and families. Objective: The purpose of this study was to test the hypothesis that ambulatory arthroscopic surgery patients who receive a nurse-coached telephone intervention will have significantly less symptom distress and better functional health status than a comparable group who receive usual practice. Methods: The study sample in this randomized clinical trial with repeated measures was 102 participants (52 in the intervention group and 50 in the usual practice group) drawn from a large academic medical center in the Northeast United States. Symptom distress was measured using the Symptom Distress Scale, and functional health was measured using the Medical Outcomes Study 36-Item Short-Form Health Survey General Health Perceptions and Mental Health subscales. Results: Multivariate analysis of covariance, with three repeated measures of the Symptom Distress Scale (baseline, 72 hours postsurgery, and 1 week postsurgery) and five covariates, was used to test the hypothesis. After removal of the covariate influence, intervention participants had significantly less symptom distress at 72 hours and 1 week postsurgery and significantly better overall physical and mental health at 1 week postsurgery than those who received usual practice. Discussion: The findings suggest that telephone calls from nurses during the immediate postoperative period resulted in improved patient outcomes, namely, less symptom distress and better physical and mental health states. In future research, the study sample should be expanded to older and more diverse patients. C1 [Jones, Dorothy; Duffy, Mary E.; Flanagan, Jane] Boston Coll, Connell Sch Nursing, Chestnut Hill, MA 02467 USA. [Jones, Dorothy; Duffy, Mary E.] Massachusetts Gen Hosp, Yvonne Munn Ctr Nursing Res, Boston, MA 02114 USA. RP Jones, D (reprint author), Boston Coll, Connell Sch Nursing, 140 Commonwealth Ave, Chestnut Hill, MA 02467 USA. EM jones@bc.edu FU National Institutes of Health; National Institute of Nursing Research [1RN15 NR05174-01A1] FX Funding was received from the National Institutes of Health, the National Institute of Nursing Research (grant no. 1RN15 NR05174-01A1). NR 41 TC 5 Z9 5 U1 3 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-6562 J9 NURS RES JI Nurs. Res. PD MAR-APR PY 2011 VL 60 IS 2 BP 92 EP 99 DI 10.1097/NNR.0b013e3182002e46 PG 8 WC Nursing SC Nursing GA 726OZ UT WOS:000287736000003 PM 21358373 ER PT J AU Berry, NC Sosnovik, DE AF Berry, Natalia C. Sosnovik, David E. TI Cardiomyocyte Death: Insights from Molecular and Microstructural Magnetic Resonance Imaging SO PEDIATRIC CARDIOLOGY LA English DT Article DE Apoptosis; Diffusion; Molecular imaging; MRI; Myocardium; Necrosis ID IN-VIVO; INFARCTED MYOCARDIUM; CONTRAST AGENT; ATHEROSCLEROSIS; NANOPARTICLES; APOPTOSIS; MICE; MRI AB Cardiomyocytes can die via necrosis, apoptosis, and autophagy. Although the molecular signals and pathways underlying these processes have been well elucidated, the pathophysiology of cardiomyocyte death remains incompletely understood. This review describes the development and application of novel imaging techniques to detect and characterize cardiomyocyte death noninvasively in vivo. It focuses on molecular and microstructural magnetic resonance images (MRIs) and their respective abilities to image cellular events such as apoptosis, inflammation, and myofiber architecture. These in vivo imaging techniques have the potential to provide novel insights into the mechanisms of cardiomyocyte death and to help guide the development of novel cardioprotective therapies. C1 [Berry, Natalia C.; Sosnovik, David E.] Harvard Univ, Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA. [Berry, Natalia C.; Sosnovik, David E.] Harvard Univ, Ctr Mol Imaging Res, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA. RP Sosnovik, DE (reprint author), Harvard Univ, Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp, Sch Med, 5404,149 13th St, Charlestown, MA 02129 USA. EM sosnovik@nmr.mgh.harvard.edu FU [R01 HL093038] FX This study was funded in part by R01 HL093038 (DES). NR 25 TC 1 Z9 1 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0172-0643 EI 1432-1971 J9 PEDIATR CARDIOL JI Pediatr. Cardiol. PD MAR PY 2011 VL 32 IS 3 SI SI BP 290 EP 296 DI 10.1007/s00246-011-9894-y PG 7 WC Cardiac & Cardiovascular Systems; Pediatrics SC Cardiovascular System & Cardiology; Pediatrics GA 737IU UT WOS:000288563300007 PM 21298427 ER PT J AU Rassovsky, Y Horan, WP Lee, J Sergi, MJ Green, MF AF Rassovsky, Y. Horan, W. P. Lee, J. Sergi, M. J. Green, M. F. TI Pathways between early visual processing and functional outcome in schizophrenia SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Functional outcome; neurocognition; schizophrenia; social cognition; visual masking ID BACKWARD-MASKING PERFORMANCE; NEGATIVE SYMPTOMS; SOCIAL COGNITION; UNAFFECTED SIBLINGS; FIT INDEXES; PERCEPTION; DEFICITS; SCALE; MEDIATOR; SYMPTOMATOLOGY AB Background. Early visual processing deficits are reliably detected in schizophrenia and show relationships to poor real-world functioning. However, the nature of this relationship is complex. Theoretical models and recent studies using statistical modeling approaches suggest that multiple intervening factors are involved. We previously reported that a direct and significant association between visual processing and functional status was mediated by a measure of social perception. The present study examined the contribution of negative symptoms to this model. Method. We employed structural equation modeling (SEM) to test several models of outcome, using data from 174 schizophrenia out-patients. Specifically, we examined the direct and indirect relative contributions of early visual processing, social perception and negative symptoms to functional outcome. Results. First, we found that, similar to social perception, a measure of negative symptoms mediated the association between visual information processing and functional status. Second, we found that the inclusion of negative symptoms substantially enhanced the explanatory power of the model. Notably, it was the experiential aspect of negative symptoms (avolition and anhedonia) more than the expressive aspect (affective flattening and alogia) that accounted for significant variance in functional outcome, especially in the social component of the construct of functional outcome. Conclusions. Social perception and negative symptoms play relevant roles in functional impairment in schizophrenia. Both social perception and negative symptoms statistically mediate the connection between visual processing and functional outcome. However, given the lack of association between social perception and negative symptoms, these constructs appear to have an impact on functioning through separate pathways. C1 [Rassovsky, Y.; Horan, W. P.; Lee, J.; Green, M. F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Horan, W. P.; Green, M. F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Sergi, M. J.] Calif State Univ Northridge, Northridge, CA 91330 USA. RP Rassovsky, Y (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza,C8-746, Los Angeles, CA 90095 USA. EM yurir@ucla.edu RI Lee, Junghee/C-5226-2014 OI Lee, Junghee/0000-0001-9567-8700 FU National Institute of Mental Health (NIMH) [MH-43292, MH-65707]; Department of Veterans Affairs, VISN 22 Mental Illness Research, Education, and Clinical Center FX This research was supported by National Institute of Mental Health (NIMH) grants MH-43292 and MH-65707 to M.F.G., and by the Department of Veterans Affairs, VISN 22 Mental Illness Research, Education, and Clinical Center. Additional statistical support was provided by Gerhard Hellemann, Ph.D. NR 68 TC 38 Z9 39 U1 2 U2 11 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 J9 PSYCHOL MED JI Psychol. Med. PD MAR PY 2011 VL 41 IS 3 BP 487 EP 497 DI 10.1017/S0033291710001054 PG 11 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 725CF UT WOS:000287622100005 PM 20482936 ER PT J AU Weatherill, RP Vogt, DS Taft, CT King, LA King, DW Shipherd, JC AF Weatherill, Robin P. Vogt, Dawne S. Taft, Casey T. King, Lynda A. King, Daniel W. Shipherd, Jillian C. TI Training Experiences as Mediators of the Association Between Gender-Role Egalitarianism and Women's Adjustment to Marine Recruit Training SO SEX ROLES LA English DT Article DE Gender-role attitudes; Sex-role egalitarianism scale; Women in the military; US Marine recruit training; Sexual harassment ID SEX-ROLE EGALITARIANISM; POSTTRAUMATIC-STRESS-DISORDER; US ARMY SOLDIERS; ROLE ATTITUDES; PSYCHOMETRIC PROPERTIES; MENTAL-HEALTH; SCALE; HARASSMENT; MILITARY; PERCEPTIONS AB Women may face particular challenges adjusting to the military environment, in part due to their numerical minority status in a traditionally male culture. In addition, women are more likely than men to experience the added stressor of sexual harassment. We examined several potential mediators of the relationship between gender-role egalitarianism and adjustment to boot camp training in a sample of 658 female U.S. Marine recruits. Results indicated that sexual harassment, performance stress, and unit cohesion mediated the relationship between egalitarianism and mental health symptomatology. These findings suggest that beliefs about gender roles are important to consider in efforts to improve women's adjustment in the military. C1 [Weatherill, Robin P.; Vogt, Dawne S.; Taft, Casey T.; King, Lynda A.; King, Daniel W.; Shipherd, Jillian C.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA. RP Weatherill, RP (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, 150 S Huntington Ave 116B-4, Boston, MA 02130 USA. EM robin.weatherill@va.gov NR 60 TC 2 Z9 2 U1 4 U2 6 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0360-0025 J9 SEX ROLES JI Sex Roles PD MAR PY 2011 VL 64 IS 5-6 BP 348 EP 359 DI 10.1007/s11199-010-9921-0 PG 12 WC Psychology, Developmental; Psychology, Social; Women's Studies SC Psychology; Women's Studies GA 723HT UT WOS:000287498100005 ER PT J AU Strote, J Schroeder, E Lemos, J Paganelli, R Solberg, J Hutson, HR AF Strote, Jared Schroeder, Erika Lemos, John Paganelli, Ryan Solberg, Jonathan Hutson, H. Range TI Academic Emergency Physicians' Experiences With Patient Death SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID OF-LIFE CARE; MEDICAL-EDUCATION; HOSPITAL DOCTORS; GRIEF; ONCOLOGY; STRESS; HEALTH; NEEDS; ILL AB P>Objectives: There is a growing awareness of the effects of patient death on physician well-being, and the importance of cultural and educational changes to improve coping mechanisms. The objective of this study was to explore both the effects of patient death on academic emergency physicians (EPs) and the coping mechanisms they use to deal with these events. Methods: Faculty at a convenience sample of four emergency medicine (EM) residency programs were questioned about their responses to patient death in a 15-question on-line survey. Descriptive analysis of the data was performed. Independent variables were analyzed for differences in complaints of physical symptoms or consideration of important life changes after patient death. Results: Of 207 EPs surveyed, 145 (70%) responded. Patient death was experienced frequently, with 95 (66%) witnessing a death at least every month. No training on coping with patient death had occurred for 35 (24%); 93 (64%) had less than 6 hours of training. The most common coping mechanisms included talking with colleagues (113; 78%) or friends and family (100; 69%), as well as simply continuing to work (89; 61%). Postdeath debriefing occurred rarely or never for 93 (64%) of respondents. Most EPs had experienced physical responses to patient death, the most common being insomnia (54; 37%) and fatigue (21; 14%). Common emotional responses included sadness (112; 70%) and disappointment (55; 38%). No significant differences in response rates for physical symptoms or consideration of life changes were found for any of the variables. Conclusions: Patient death was reported to lead to both physical and emotional symptoms in academic EPs. Postdeath debriefing appears to happen infrequently in teaching settings, and most respondents reported that they themselves received limited training in coping with patient death. Further study is needed to both identify coping mechanisms that are feasible and effective in emergency department settings and develop teaching strategies to incorporate this information into EM residency training. C1 [Strote, Jared] Univ Washington, Div Emergency Med, Seattle, WA 98195 USA. [Schroeder, Erika] Univ Utah, Dept Emergency Med, Salt Lake City, UT USA. [Lemos, John] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA. [Paganelli, Ryan] Stanford Univ, Div Emergency Med, Palo Alto, CA 94304 USA. [Solberg, Jonathan] Madigan Army Med Ctr, Dept Emergency Med, Ft Lewis, WA USA. [Hutson, H. Range] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. RP Strote, J (reprint author), Univ Washington, Div Emergency Med, Seattle, WA 98195 USA. EM strote@u.washington.edu NR 33 TC 5 Z9 5 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD MAR PY 2011 VL 18 IS 3 BP 255 EP 260 DI 10.1111/j.1553-2712.2011.01004.x PG 6 WC Emergency Medicine SC Emergency Medicine GA 734YM UT WOS:000288379600008 PM 21401787 ER PT J AU Talley, BE Moore, SA Camargo, CA Rogers, J Ginde, AA AF Talley, Brad E. Moore, S. Ann Camargo, Carlos A., Jr. Rogers, John Ginde, Adit A. TI Availability and Potential Effect of Rural Rotations in Emergency Medicine Residency Programs SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID PHYSICIANS; WORKFORCE AB P>Objectives: Increased exposure of emergency medicine (EM) residents to rural rotations may enhance recruitment to rural areas. This study sought to characterize the availability and types of rural rotations in EM residency programs and to correlate rotation type with rural practice after graduation. Methods: Program directors from all 126 Accreditation Council for Graduate Medical Education (ACGME)-accredited EM residency programs with at least 2 years of graduates were surveyed. Directors were asked about availability of rural rotations, categorized as: 1) required, 2) elective (with or without predesignated sites), or 3) not available. Completion of rotations and initial practice location after graduation by rotation type were compared. Results: The 111 (88%) directors reported 2,380 graduates over the past 2 years. Rural rotations were required by six (5%) programs, elective at 92 (83%), and not available at 13 (12%). Overall, 197 (8%) residents completed a rural rotation during residency, and 160 (7%) selected their initial job in a rural area. More residents completed an elective rural rotation in programs with versus without a predesignated site (7% vs. 4%, respectively). EM residency graduates were more likely to select a rural job when rural rotations were required (22%), compared to other options: predesignated (7%) or no predesignated (6%) elective or not available (7%; p < 0.001). Conclusions: Elective rural rotations at predesignated sites increase resident exposure to rural areas compared to programs without predesignated sites, but neither approach was associated with rural practice after graduation. EM residency programs that required a rural rotation had increased resident selection of rural jobs, but only 5% of programs had this requirement. C1 [Ginde, Adit A.] Univ Colorado Denver, Sch Med, Aurora, CO USA. [Talley, Brad E.] Denver Hlth Med Ctr, Dept Emergency Med, Denver, CO USA. [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Rogers, John] Monroe Cty Hosp, Forsyth, GA USA. RP Ginde, AA (reprint author), Univ Colorado Denver, Sch Med, Aurora, CO USA. EM adit.ginde@ucdenver.edu RI Siry, Bonnie/D-7189-2017 NR 10 TC 7 Z9 7 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD MAR PY 2011 VL 18 IS 3 BP 297 EP 300 DI 10.1111/j.1553-2712.2010.00987.x PG 4 WC Emergency Medicine SC Emergency Medicine GA 734YM UT WOS:000288379600015 PM 21401792 ER PT J AU Menchine, MD Arora, S Camargo, CA Ginde, AA AF Menchine, Michael D. Arora, Sanjay Camargo, Carlos A., Jr. Ginde, Adit A. TI Prevalence of Undiagnosed and Suboptimally Controlled Diabetes by Point-of-care HbA1C in Unselected Emergency Department Patients SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID BRIEF INTERVENTION; HEALTH AB Objectives: The objective was to estimate the glycemic control of patients with known diabetes and to assess the prevalence of undiagnosed diabetes in an unselected emergency department (ED) population. Secondary objectives include evaluating the prevalence of undiagnosed diabetes in high-risk groups of ED patients such as Hispanic patients, African Americans, and patients with body mass index (BMI) >= 30 kg/m2. Methods: A convenience sample of adult ED patients was screened for diabetes using a National Glycohemoglobin Standardization Program-certified point-of-care (POC) glycated hemoglobin (HbA1C) meter at a single academic medical center during eight 24-hour periods. Diabetes was defined as HbA1C >= 6.5%, consistent with new American Diabetes Association (ADA) guidelines. Results: Of the 1,611 patients evaluated in the ED during the study period, 313 were included in the study sample. Of these, 15% reported a history of diabetes, 42% of whom were suboptimally controlled. An additional 14% of the study sample was found to have previously undiagnosed diabetes. In our limited sample, the prevalence of previously undiagnosed diabetes in Hispanics, African Americans, and patients with BMI >= 30 kg/m2 was 14, 27, and 22%, respectively. Conclusions: Patients in our sample had a high prevalence of suboptimally controlled and undiagnosed diabetes. New POC HbA1C devices and simplified diagnostic criteria for diabetes significantly enhance the possibility of ED-based screening programs. Future research should validate our findings in a broader array of EDs and study the acceptance of such ED-based diabetes screening programs. ACADEMIC EMERGENCY MEDICINE 2011; 18:1-4 (C) 2011 by the Society for Academic Emergency Medicine. C1 [Menchine, Michael D.; Arora, Sanjay] Univ So Calif, Keck Sch Med, Dept Emergency Med, Los Angeles, CA 90033 USA. [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. [Ginde, Adit A.] Univ Colorado, Denver Sch Med, Dept Emergency Med, Denver, CO USA. RP Menchine, MD (reprint author), Univ So Calif, Keck Sch Med, Dept Emergency Med, Los Angeles, CA 90033 USA. EM menchine@usc.edu RI Siry, Bonnie/D-7189-2017 FU Bayer Healthcare Diabetes Care (Tarrytown, NY); Mallinck-rodt General Clinical Research Center at Massachusetts General Hospital [M01-RR-01066]; Emergency Medicine Foundation; National Institutes of Health, National Center for Research Resources FX This study was funded by an investigator-initiated grant from Bayer Healthcare Diabetes Care (Tarrytown, NY) and by the Mallinck-rodt General Clinical Research Center at Massachusetts General Hospital (Grant M01-RR-01066, National Institutes of Health, National Center for Research Resources, General Clinical Research Centers Program). AAG was supported by the Emergency Medicine Foundation Research Fellowship Grant (Dallas, TX). NR 11 TC 14 Z9 14 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD MAR PY 2011 VL 18 IS 3 BP 326 EP 329 DI 10.1111/j.1553-2712.2011.01014.x PG 4 WC Emergency Medicine SC Emergency Medicine GA 734YM UT WOS:000288379600023 PM 21362098 ER PT J AU Szilagyi, PG Kuhlthau, KA AF Szilagyi, Peter G. Kuhlthau, Karen A. TI Children With Special Health Care Needs: A Celebration of Success! SO ACADEMIC PEDIATRICS LA English DT Editorial Material C1 [Szilagyi, Peter G.] Univ Rochester, Sch Med & Dent, Dept Pediat, Div Gen Pediat, Rochester, NY 14642 USA. [Kuhlthau, Karen A.] MassGen Hosp Children, Ctr Child & Adolescent Hlth Policy, Boston, MA USA. [Kuhlthau, Karen A.] Harvard Univ, Sch Med, Boston, MA USA. RP Szilagyi, PG (reprint author), Univ Rochester, Sch Med & Dent, Div Gen Pediat, Dept Pediat,Strong Mem Hosp, 601 Elmwood Ave,Box 777, Rochester, NY 14642 USA. EM peter_szilagyi@urmc.rochester.edu NR 7 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 J9 ACAD PEDIATR JI Acad. Pediatr. PD MAR-APR PY 2011 VL 11 IS 2 BP 94 EP 95 PG 2 WC Pediatrics SC Pediatrics GA 736WO UT WOS:000288525900001 PM 21396613 ER PT J AU Perrin, JM AF Perrin, James M. TI Children With Special Health Care Needs and Changing Policy SO ACADEMIC PEDIATRICS LA English DT Editorial Material C1 [Perrin, James M.] MassGen Hosp Children, Ctr Child & Adolescent Hlth Policy, Boston, MA 02114 USA. [Perrin, James M.] Harvard Univ, Sch Med, Boston, MA USA. RP Perrin, JM (reprint author), MassGen Hosp Children, Ctr Child & Adolescent Hlth Policy, 50 Staniford St,901, Boston, MA 02114 USA. EM jperrin@partners.org FU PHS HHS [UA3 MC 11054] NR 7 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 J9 ACAD PEDIATR JI Acad. Pediatr. PD MAR-APR PY 2011 VL 11 IS 2 BP 103 EP 104 DI 10.1016/j.acap.2010.08.010 PG 2 WC Pediatrics SC Pediatrics GA 736WO UT WOS:000288525900005 PM 21296045 ER PT J AU Kuhlthau, KA Bloom, S Van Cleave, J Knapp, AA Romm, D Klatka, K Homer, CJ Newacheck, PW Perrin, JM AF Kuhlthau, Karen A. Bloom, Sheila Van Cleave, Jeanne Knapp, Alixandra A. Romm, Diane Klatka, Kirsten Homer, Charles J. Newacheck, Paul W. Perrin, James M. TI Evidence for Family-Centered Care for Children With Special Health Care Needs: A Systematic Review SO ACADEMIC PEDIATRICS LA English DT Review DE children with special health care needs; family-centered care ID MEDICAL HOME; NATIONAL-SURVEY; MENTAL-HEALTH; ASTHMA; SERVICES; OUTCOMES; SATISFACTION; PHYSICIANS; INSURANCE; EDUCATION AB OBJECTIVE: Family-centered care (FCC) has received widespread endorsement for use in care in the United States. In this study, we conducted a systematic review of evidence for FCC focusing specifically on family-provider partnership as the activity that constitutes FCC. METHODS: We found and reviewed articles from the medical, nursing, psychology, and sociology literature spanning 1986 to 2010. We also reviewed articles obtained through related references and through recommendations from key informants. Four sets of terms were used to search, including FCC, child/adolescent, children with special health care needs (CSHCN, defined broadly or by condition), and a relevant outcome. RESULTS: Twenty-four studies met the review criteria. Eight were cross-sectional studies from the National Survey of Children With Special Health Care Needs, and 7 were reports of randomized, controlled trials. Of the 24 articles reviewed, 13 examined populations of CSHCN or similar populations, 6 examined children with asthma, and the remaining studied children with other specific conditions. We found positive associations of FCC with improvements in efficient use of services, health status, satisfaction, access to care, communication, systems of care, family functioning, and family impact/cost. There was little available evidence, however, for some outcomes, including cost and transition. CONCLUSIONS: The available evidence suggests that FCC is associated with improved outcomes for CSHCN. With positive findings for most of the studies reviewed here and the compelling arguments for FCC, we recommend the use of this approach by individuals and organizations. C1 [Kuhlthau, Karen A.; Bloom, Sheila; Van Cleave, Jeanne; Knapp, Alixandra A.; Romm, Diane; Klatka, Kirsten; Perrin, James M.] MassGen Hosp Children, Ctr Child & Adolescent Hlth Policy, Boston, MA 02114 USA. [Kuhlthau, Karen A.; Van Cleave, Jeanne; Perrin, James M.] Harvard Univ, Sch Med, Boston, MA USA. [Homer, Charles J.] Natl Initiat Child Healthcare Qual, Boston, MA USA. [Newacheck, Paul W.] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA. [Newacheck, Paul W.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. RP Kuhlthau, KA (reprint author), MassGen Hosp Children, Ctr Child & Adolescent Hlth Policy, 50 Staniford St,Ste 901, Boston, MA 02114 USA. EM kkuhlthau@partners.org FU Maternal and Child Health Bureau [5 U53MC04473-03-00] FX We thank our funders at the Maternal and Child Health Bureau, cooperative agreement 5 U53MC04473-03-00, members of our advisory group, and Jill Hurson. NR 39 TC 70 Z9 70 U1 4 U2 29 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 J9 ACAD PEDIATR JI Acad. Pediatr. PD MAR-APR PY 2011 VL 11 IS 2 BP 136 EP 143 PG 8 WC Pediatrics SC Pediatrics GA 736WO UT WOS:000288525900012 PM 21396616 ER PT J AU Kumbhani, DJ Bavry, AA Harvey, JE de Souza, R Scarpioni, R Bhatt, DL Kapadia, SR AF Kumbhani, Dharam J. Bavry, Anthony A. Harvey, James E. de Souza, Russell Scarpioni, Roberto Bhatt, Deepak L. Kapadia, Samir R. TI Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: A meta-analysis of randomized controlled trials SO AMERICAN HEART JOURNAL LA English DT Article ID ATHEROSCLEROTIC RENOVASCULAR DISEASE; HYPERTENSIVE PATIENTS; BALLOON ANGIOPLASTY; OXIDATIVE STRESS; FOLLOW-UP; THERAPY; CORONARY; INTERVENTIONS; ANGIOGRAPHY AB Background We sought to systematically evaluate whether percutaneous revascularization is associated with additional clinical benefit in patients with renal artery stenosis (RAS) as compared with medical management alone. Methods We included randomized controlled trials that compared percutaneous revascularization in addition to medical therapy versus medical management alone in patients with RAS. Six trials with 1,208 patients were included. Results At a mean follow-up of 29 months, there was no change in systolic blood pressure (weighted mean difference [WMD] = 1.20 mm Hg, 95% CI -1.18 to 3.58 mm Hg) or diastolic blood pressure (WMD = -1.60 mm Hg, 95% CI -4.22 to 1.02 mm Hg) from baseline in the percutaneous revascularization arm compared with the medical management arm. There was a reduction in the mean number of antihypertensive medications (WMD = -0.26, 95% CI -0.39 to -0.13, P b.001), but not serum creatinine (WMD = -0.14 mg/ dL, 95% CI -0.29 to 0.007 mg/ dL), in the percutaneous revascularization arm at the end of follow-up. Percutaneous revascularization was not associated with a significant difference in all-cause mortality (relative risk [RR] = 0.96, 95% CI 0.74-1.25), congestive heart failure (RR = 0.79, 95% CI 0.56-1.13), stroke (RR = 0.86, 95% CI 0.50-1.47), or worsening renal function (RR = 0.91, 95% CI 0.67-1.23) as compared with medical management. Conclusions In patients with RAS, percutaneous renal revascularization in addition to medical therapy may result in a lower requirement for antihypertensive medications, but not with improvements in serum creatinine or clinical outcomes, as compared with medical management over an intermediate period of follow-up. Further studies are needed to identify the appropriate patient population most likely to benefit from its use. (Am Heart J 2011; 161: 622-630. e1.) C1 [Kumbhani, Dharam J.; Harvey, James E.; Kapadia, Samir R.] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44195 USA. [Bavry, Anthony A.] Univ Florida, Div Cardiovasc Med, Gainesville, FL USA. [de Souza, Russell] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Scarpioni, Roberto] Guglielmo da Saliceto Hosp, Unit Nephrol & Dialysis, Piacenza, Italy. [Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA. [Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA. RP Kapadia, SR (reprint author), Cleveland Clin, Dept Cardiovasc Med, 9500 Euclid Ave Desk J2-3, Cleveland, OH 44195 USA. EM kapadis@ccf.org OI de Souza, Russell/0000-0001-8945-513X NR 37 TC 56 Z9 59 U1 0 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD MAR PY 2011 VL 161 IS 3 BP 622 EP + DI 10.1016/j.ahj.2010.12.006 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 732BH UT WOS:000288156400030 PM 21392620 ER PT J AU Naunheim, MR Walcott, BP Nahed, BV MacRae, CA Levinson, JR Ogilvy, CS AF Naunheim, Matthew R. Walcott, Brian P. Nahed, Brian V. MacRae, Calum A. Levinson, John R. Ogilvy, Christopher S. TI Arterial Tortuosity Syndrome With Multiple Intracranial Aneurysms A Case Report SO ARCHIVES OF NEUROLOGY LA English DT Article ID CHROMOSOME 20Q13; HOMOZYGOSITY; MUTATIONS AB Objective: To report a new manifestation of the rare connective tissue disorder arterial tortuosity syndrome in the absence of skin and soft-tissue abnormalities and with bilateral, giant fusiform intracranial aneurysms. Design: Case report. Settling: University teaching hospital. Patient: A 67-year-old man with a history of hypertension presented to medical attention after a syncopal episode. Imaging revealed incidental, bilateral, giant fusiform intracranial aneurysms of the internal carotid artery at their junction of the circle of Willis. There was also aneurysmal dilatation of the left main coronary artery ectasia and aneurysmal dilation of the aorta and bilateral iliac arteries, suggestive of arterial tortuosity syndrome. Results: The patient's syncope was attributed to transient complete heart block for which a permanent pacemaker was placed. The patient started taking aspirin for stroke prevention and losartan potassium for blood pressure control. Conclusions: To our knowledge, we present the first case of arterial tortuosity syndrome with marked bilateral intracranial artery dilation in the absence of concurrent skin and soft tissue abnormalities. Workup may include systemic vascular imaging to characterize the extent of disease. Antiplatelet therapy can be used for stroke prevention by reducing the risk of clot formation in ectatic vessels with altered hemodynamics and subsequent embolism. Losartan is known to inhibit transforming growth factor 13 signaling and may be a specific modulator of disease expression in this syndrome. C1 [Naunheim, Matthew R.; Walcott, Brian P.; Nahed, Brian V.; Ogilvy, Christopher S.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Levinson, John R.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [MacRae, Calum A.] Harvard Univ, Sch Med, Boston, MA USA. [MacRae, Calum A.] Brigham & Womens Hosp, Div Cardiol, Boston, MA 02115 USA. RP Ogilvy, CS (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St, Boston, MA 02114 USA. EM cogilvy@partners.org NR 18 TC 7 Z9 8 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD MAR PY 2011 VL 68 IS 3 BP 369 EP 371 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 735JE UT WOS:000288409400015 PM 21403023 ER PT J AU Goldstein, JN Marrero, M Masrur, S Pervez, M Barrocas, AM Abdullah, A Oleinik, A Rosand, J Smith, EE Dzik, WH Schwamm, LH AF Goldstein, Joshua N. Marrero, Marisela Masrur, Shihab Pervez, Muhammad Barrocas, Alex M. Abdullah, Abdul Oleinik, Alexandra Rosand, Jonathan Smith, Eric E. Dzik, Walter H. Schwamm, Lee H. TI Thrombolysis-Associated Symptomatic Intracerebral Hemorrhage reply SO ARCHIVES OF NEUROLOGY LA English DT Letter ID STROKE C1 [Goldstein, Joshua N.; Marrero, Marisela] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Masrur, Shihab; Pervez, Muhammad; Abdullah, Abdul; Oleinik, Alexandra; Rosand, Jonathan; Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Dzik, Walter H.] Massachusetts Gen Hosp, Dept Hematol, Boston, MA 02114 USA. [Barrocas, Alex M.] Mt Sinai Med Ctr, Dept Radiol, Miami Beach, FL USA. [Smith, Eric E.] Univ Calgary, Calgary Stroke Program, Calgary, AB, Canada. RP Goldstein, JN (reprint author), Massachusetts Gen Hosp, Emergency Med, Zero Emerson Pl,Ste 3B, Boston, MA 02114 USA. EM jgoldstein@partners.org RI Smith, Eric/C-5443-2012; Goldstein, Joshua/H-8953-2016; OI Smith, Eric/0000-0003-3956-1668; Schwamm, Lee/0000-0003-0592-9145 NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD MAR PY 2011 VL 68 IS 3 BP 396 EP 397 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 735JE UT WOS:000288409400025 ER PT J AU Growdon, JH Herskovits, AZ AF Growdon, John H. Herskovits, A. Zara TI Primum non nocere Reply SO ARCHIVES OF NEUROLOGY LA English DT Letter ID ALZHEIMERS-DISEASE; DIAGNOSIS C1 [Growdon, John H.] Massachusetts Gen Hosp, Dept Neurol, Wang Ambulatory Ctr, Boston, MA 02114 USA. [Herskovits, A. Zara] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Growdon, JH (reprint author), Massachusetts Gen Hosp, Dept Neurol, Wang Ambulatory Ctr, Ste 715, Boston, MA 02114 USA. EM growdon@helix.mgh.harvard.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD MAR PY 2011 VL 68 IS 3 BP 398 EP 398 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 735JE UT WOS:000288409400027 ER PT J AU Stacy, RC Jakobiec, FA Michaud, NA Dohlman, CH Colby, KA AF Stacy, Rebecca C. Jakobiec, Frederick A. Michaud, Norman A. Dohlman, Claes H. Colby, Kathryn A. TI Characterization of Retrokeratoprosthetic Membranes in the Boston Type 1 Keratoprosthesis SO ARCHIVES OF OPHTHALMOLOGY LA English DT Article ID RETROCORNEAL MEMBRANE; ENDOTHELIAL KERATOPLASTY; HISTOPATHOLOGY; COMPLICATIONS AB Objective: To evaluate retroprosthetic membranes that can occur in 25% to 65% of patients with the Boston type 1 keratoprosthesis (KPro). Methods: Two patients with Peter anomaly and 2 with neurotrophic scarred corneas underwent revisions of their type 1 KPros because of visually compromising retroprosthetic membranes. The excised membranes were studied by light microscopy with hematoxylin-eosin, periodic acid-Schiff, and toluidine blue stains. Immunohistochemical and transmission electron microscopic examination were also used. Results: Light microscopic examination revealed that the retro-KPro fibrous membranes originated from the host's corneal stroma. These mildly to moderately vascularized membranes grew through gaps in the Descemet membrane to reach behind the KPro back plate and adhere to the anterior iris surface, which had undergone partial lysis. In 2 cases, the fibrous membranes merged at the pupil with matrical portions of metaplastic lens epithelium, forming a bilayered structure that crossed the optical axis. Retro-KPro membranes stained positively for alpha-smooth muscle actin but negatively for pancytokeratin. Electron microscopy confirmed the presence of actin filaments within myofibroblasts and small surviving clusters of metaplastic lens epithelial cells. Conclusions: Stromal downgrowth, rather than epithelial downgrowth, was the major element of the retro-KPro membranes in this series. Metaplastic lens epithelium also contributed to opacification of the visual axis. Florid membranous inflammation was not a prominent finding and thus probably not a requisite stimulus for membrane development. Further advances in prosthetic design and newer antifibroproliferative agents may reduce membrane formation. C1 [Stacy, Rebecca C.; Jakobiec, Frederick A.] Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, Boston, MA 02114 USA. [Michaud, Norman A.] Massachusetts Eye & Ear Infirm, Howe Lab, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Stacy, RC (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, Boston, MA 02114 USA. NR 25 TC 22 Z9 24 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9950 J9 ARCH OPHTHALMOL-CHIC JI Arch. Ophthalmol. PD MAR PY 2011 VL 129 IS 3 BP 310 EP 316 PG 7 WC Ophthalmology SC Ophthalmology GA 734ID UT WOS:000288326900011 PM 21402987 ER PT J AU Ho, YY Parmigiani, G Louis, TA Cope, LM AF Ho, Yen-Yi Parmigiani, Giovanni Louis, Thomas A. Cope, Leslie M. TI Modeling Liquid Association SO BIOMETRICS LA English DT Article DE Gene expression; Generalized estimating equations; Higher-order interaction; Liquid association; Non-Gaussian multivariate distribution ID EXPRESSED GENE COMBINATIONS; WIDE COEXPRESSION DYNAMICS; ESTIMATING EQUATIONS AB In 2002, Ker-Chau Li introduced the liquid association measure to characterize three-way interactions between genes, and developed a computationally efficient estimator that can be used to screen gene expression microarray data for such interactions. That study, and others published since then, have established the biological validity of the method, and clearly demonstrated it to be a useful tool for the analysis of genomic data sets. To build on this work, we have sought a parametric family of multivariate distributions with the flexibility to model the full range of trivariate dependencies encompassed by liquid association. Such a model could situate liquid association within a formal inferential theory. In this article, we describe such a family of distributions, a trivariate, conditional normal model having Gaussian univariate marginal distributions, and in fact including the trivariate Gaussian family as a special case. Perhaps the most interesting feature of the distribution is that the parameterization naturally parses the three-way dependence structure into a number of distinct, interpretable components. One of these components is very closely aligned to liquid association, and is developed as a measure we call modified liquid association. We develop two methods for estimating this quantity, and propose statistical tests for the existence of this type of dependence. We evaluate these inferential methods in a set of simulations and illustrate their use in the analysis of publicly available experimental data. C1 [Ho, Yen-Yi] Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA. [Parmigiani, Giovanni] Dana Farber Canc Inst, Boston, MA 02115 USA. [Parmigiani, Giovanni] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Louis, Thomas A.] Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21205 USA. [Cope, Leslie M.] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD 21205 USA. RP Ho, YY (reprint author), Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA. EM yho@jhsph.edu; lcope1@jhmi.edu NR 21 TC 3 Z9 3 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0006-341X J9 BIOMETRICS JI Biometrics PD MAR PY 2011 VL 67 IS 1 BP 133 EP 141 DI 10.1111/j.1541-0420.2010.01440.x PG 9 WC Biology; Mathematical & Computational Biology; Statistics & Probability SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology; Mathematics GA 735AW UT WOS:000288386800015 PM 20528865 ER PT J AU Holalkere, NS Matthes, K Kalva, SP Brugge, WR Sahani, DV AF Holalkere, N-S Matthes, K. Kalva, S. P. Brugge, W. R. Sahani, D. V. TI 64-Slice multidetector row CT angiography of the abdomen: comparison of low versus high concentration iodinated contrast media in a porcine model SO BRITISH JOURNAL OF RADIOLOGY LA English DT Article ID COMPUTED-TOMOGRAPHY; VASCULAR ENHANCEMENT; LIVER; PROTOCOL AB Objective: In this study we aimed to assess the image quality and degree of vascular enhancement using low-concentration contrast media (LCCM) (300 mg l ml(-1)) and high-concentration contrast media (HCCM) (370 mg l ml(-1)) on 64-slice multidetector row CT (MDCT) abdominal CT angiography (CIA). In addition, we aimed to study the feasibility of using HCCM with a reduced total iodine dose. Methods: CTA of the abdomen on a 64-slice MDCT was performed on 15 anaesthetised pigs. Study pigs were divided into three groups of five each based on the iodine concentration and dose received: Group A (LCCM; 300 mg l ml(-1)), Group B (HCCM; 370 mg l ml(-1)) and Group C HCCM with 20% less iodine dose. The total iodine injected was kept constant (600 mg kg(-1)) in Groups A and B. Qualitative and quantitative analyses were performed to study and compare each group for image quality, visibility of the branch order of the superior mesenteric artery (SMA), artefacts, degree of enhancement in the aorta and main stem arteries and uniformity of enhancement in the aorta. Groups were compared using the analysis of variance test. Results: The image quality of 64-slice MDCT angiography was excellent with a mean score of 4.63 and confident visualisation of the third to fifth order branches of the SMA in all groups. Group B demonstrated superior vascular enhancement, as compared with Groups A and C (p <= 0.05). Uniform aortic enhancement was achieved with the use of LCCM and HCCM with 20% less iodine dose. Conclusion: 64-slice MDCT angiography of the abdomen was of excellent quality. HCCM improves contrast enhancement and overall CIA image quality and allows the iodine dose to be reduced. C1 [Holalkere, N-S] Boston Med Ctr, Dept Radiol, Boston, MA 02118 USA. [Matthes, K.; Brugge, W. R.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Kalva, S. P.; Sahani, D. V.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Holalkere, NS (reprint author), Boston Med Ctr, Dept Radiol, 820 Harrison Ave,FGH Bldg,3rd Floor, Boston, MA 02118 USA. EM Nagaraj.Holalkere@bmc.org OI Holalkere, Nagaraj/0000-0001-6324-7682 NR 23 TC 9 Z9 11 U1 0 U2 1 PU BRITISH INST RADIOLOGY PI LONDON PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND SN 0007-1285 J9 BRIT J RADIOL JI Br. J. Radiol. PD MAR PY 2011 VL 84 IS 999 BP 221 EP 228 DI 10.1259/bjr/14535110 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 735JU UT WOS:000288411100005 PM 21081582 ER PT J AU Beffa, DC Fischman, AJ Fagan, SP Hamrahi, VF Paul, KW Kaneki, M Yu, YM Tompkins, RG Carter, EA AF Beffa, David C. Fischman, Alan J. Fagan, Shawn P. Hamrahi, Victoria F. Paul, Kasie W. Kaneki, Masao Yu, Yong-Ming Tompkins, Ronald G. Carter, Edward A. TI Simvastatin treatment improves survival in a murine model of burn sepsis: Role of interleukin 6 SO BURNS LA English DT Article DE Sepsis; Cecal ligation; Simvastatin; Burn; Sepsis; Survival; Interleukin-6 (IL-6) ID STATIN THERAPY; THERMAL-INJURY; MORTALITY; INFECTION AB Infection is the most common and most serious complication of a major burn related to burn size. Recent studies have demonstrated that statin treatment can decrease mortality in murine or human sepsis. In the current study mice were anesthetized and subjected to a dorsal 30% TBSA scald burn. Simvastatin or placebo were administered by intraperitoneal injection once daily or every 12 h. On post burn day 7 cecal ligation and puncture with a 21-gauge needle (CLP) was performed under ketamine/xylazine anesthesia, the two different dosing schedules were continued and survival was monitored. In other groups of mice, interleukin-6 (IL-6) levels in blood were measured in mice at 7 days after injury. A simvastatin dependent improvement in survival was observed in the burn sepsis model. This protection was found to be dose and time dependent. In addition, statin treatment reduced the elevation in IL-6 levels of mice burned 7 days previously. However, IL-6 levels in burned mice with or without statin treatment were elevated by CLP to the same degree. The results of these studies suggest that statin treatment reduces mortality in mice with burns and CLP and that this effect may not be mediated via IL-6 levels. (C) 2010 Elsevier Ltd and ISBI. All rights reserved. C1 [Carter, Edward A.] Shriners Hosp Children, Massachusetts Gen Hosp, Surg Serv, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Carter, EA (reprint author), Shriners Hosp Children, Massachusetts Gen Hosp, Surg Serv, 51 Blossom St, Boston, MA 02114 USA. EM eacarter@partners.org FU National Institutes of Health [NIGMS P50 GM21000]; Shriners Hospitals for Children FX This work was supported in part by grants from the National Institutes of Health (NIGMS P50 GM21000) and Shriners Hospitals for Children. NR 22 TC 19 Z9 20 U1 1 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0305-4179 J9 BURNS JI Burns PD MAR PY 2011 VL 37 IS 2 BP 222 EP 226 DI 10.1016/j.burns.2010.10.010 PG 5 WC Critical Care Medicine; Dermatology; Surgery SC General & Internal Medicine; Dermatology; Surgery GA 735JS UT WOS:000288410900006 PM 21145172 ER PT J AU Hage, FG Iskandrian, AE AF Hage, Fadi G. Iskandrian, Ami E. TI Cardiac Autonomic Denervation in Diabetes Mellitus SO CIRCULATION-CARDIOVASCULAR IMAGING LA English DT Editorial Material DE Editorials; meta-iodobenzylguanidine; heart failure; diabetes mellitus ID HEART-RATE RESPONSE; VENTRICULAR SYSTOLIC DYSFUNCTION; CORONARY BLOOD-FLOW; SYMPATHETIC INNERVATION; EJECTION FRACTION; FAILURE; ARTERIES; REGADENOSON; NEUROPATHY; ADENOSINE C1 [Hage, Fadi G.; Iskandrian, Ami E.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA. RP Hage, FG (reprint author), Zeigler Res Bldg 1024,1530 3rd Ave S, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 22 TC 9 Z9 10 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-9651 J9 CIRC-CARDIOVASC IMAG JI Circ.-Cardiovasc. Imaging PD MAR PY 2011 VL 4 IS 2 BP 79 EP 81 DI 10.1161/CIRCIMAGING.111.963967 PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 734WC UT WOS:000288370500004 PM 21406659 ER PT J AU Huffman, JC Mastromauro, CA Sowden, G Fricchione, GL Healy, BC Januzzi, JL AF Huffman, Jeff C. Mastromauro, Carol A. Sowden, Gillian Fricchione, Gregory L. Healy, Brian C. Januzzi, James L. TI Impact of a Depression Care Management Program for Hospitalized Cardiac Patients SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE myocardial infarction; arrhythmia; heart failure; depression ID ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED-CONTROLLED-TRIAL; CORONARY-ARTERY-DISEASE; COLLABORATIVE CARE; MAJOR DEPRESSION; UNSTABLE ANGINA; SYMPTOMS; VALIDITY; ANTIDEPRESSANT; METAANALYSIS AB Background-Depression is independently associated with poor outcomes among patients with acute cardiac disease. Collaborative care depression management programs have been used in outpatients to improve depression outcomes, but such a program had never been initiated in the hospital or used for patients with a wide range of cardiac illnesses. Methods and Results-This was a prospective, randomized trial of a low-intensity, 12-week collaborative care program versus usual care for 175 depressed patients hospitalized for acute coronary syndrome, arrhythmia, or heart failure. Study outcomes, assessed using mixed regression models to compare groups at 6 weeks, 12 weeks, and 6 months, included mental health (depression, cognitive symptoms of depression, anxiety, and mental health-related quality of life) and medical (physical health-related quality of life, adherence to medical recommendations, and cardiac symptoms) outcomes. Collaborative care subjects (n = 90) had significantly greater improvements on all mental health outcomes at 6 and 12 weeks, including rates of depression response (collaborative care, 59.7% versus usual care 33.7%; odds ratio, 2.91; P = 0.003 at 6 weeks; 51.5% versus 34.4%; odds ratio, 2.02; P = 0.04 at 12 weeks), though these effects decreased after intervention. At 6 months, intervention subjects had significantly greater self-reported adherence and significantly reduced number and intensity of cardiac symptoms. Conclusions-Among patients with a broad range of cardiac diagnoses, a collaborative care depression management program initiated during hospitalization led to significant improvements in multiple clinically important mental health outcomes and had promising effects on relevant medical outcomes after intervention. C1 [Huffman, Jeff C.; Mastromauro, Carol A.; Sowden, Gillian; Fricchione, Gregory L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Healy, Brian C.] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA. [Januzzi, James L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Huffman, Jeff C.; Sowden, Gillian; Fricchione, Gregory L.; Healy, Brian C.; Januzzi, James L.] Harvard Univ, Sch Med, Boston, MA USA. RP Huffman, JC (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 55 Fruit St,Blake 11, Boston, MA 02114 USA. EM jhuffman@partners.org FU American Heart Association [0735530T] FX This work was supported by an American Heart Association Scientist Development Grant 0735530T (Dr Huffman). NR 33 TC 36 Z9 38 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD MAR PY 2011 VL 4 IS 2 BP 198 EP 205 DI 10.1161/CIRCOUTCOMES.110.959379 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 734WN UT WOS:000288372200011 PM 21386067 ER PT J AU Seeff, LB Everson, GT Morgan, TR Curto, TM Lee, WM Ghany, MG Shiffman, ML Fontana, RJ Di Bisceglie, AM Bonkovsky, HL Dienstag, JL AF Seeff, Leonard B. Everson, Gregory T. Morgan, Timothy R. Curto, Teresa M. Lee, William M. Ghany, Marc G. Shiffman, Mitchell L. Fontana, Robert J. Di Bisceglie, Adrian M. Bonkovsky, Herbert L. Dienstag, Jules L. TI Percutaneous Liver Biopsy Reply SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Letter C1 [Seeff, Leonard B.] NIDDKD, Div Digest Dis & Nutr, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Everson, Gregory T.] Univ Colorado, Sch Med, Div Gastroenterol & Hepatol, Sect Hepatol, Aurora, CO USA. [Morgan, Timothy R.] Univ Calif Irvine, Div Gastroenterol, Irvine, CA USA. [Morgan, Timothy R.] VA Long Beach Healthcare Syst, Gastroenterol Serv, Long Beach, CA USA. [Curto, Teresa M.] New England Res Inst, Watertown, MA 02172 USA. [Lee, William M.] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA. [Ghany, Marc G.] NIDDKD, Liver Dis Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Shiffman, Mitchell L.] Bon Secours Hlth Syst, Liver Inst Virginia, Newport News, VA USA. [Shiffman, Mitchell L.] Bon Secours Hlth Syst, Liver Inst Virginia, Richmond, VA USA. [Fontana, Robert J.] Univ Michigan, Sch Med, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI USA. [Di Bisceglie, Adrian M.] St Louis Univ, Sch Med, Div Gastroenterol & Hepatol, St Louis, MO USA. [Bonkovsky, Herbert L.] Univ Connecticut, Ctr Hlth, Dept Med, Liver Biliary Pancreat Ctr, Farmington, CT USA. [Bonkovsky, Herbert L.] Univ Connecticut, Ctr Hlth, Liver Biliary Pancreat Ctr, Dept Mol & Struct Biol, Farmington, CT USA. [Dienstag, Jules L.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Gastrointestinal Unit,Med, Boston, MA USA. RP Seeff, LB (reprint author), NIDDKD, Div Digest Dis & Nutr, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAR PY 2011 VL 9 IS 3 BP 278 EP 279 DI 10.1016/j.cgh.2010.12.006 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 737FY UT WOS:000288555700026 ER PT J AU Bailey, E Kroshinsky, D AF Bailey, Elizabeth Kroshinsky, Daniela TI Cellulitis: diagnosis and management SO DERMATOLOGIC THERAPY LA English DT Article DE cellulitis; diagnosis; erysipelas; hospitalized patient; treatment ID DEEP-VEIN THROMBOSIS; SOFT-TISSUE INFECTIONS; RESISTANT STAPHYLOCOCCUS-AUREUS; OCCUPATIONAL CONTACT-DERMATITIS; ERYTHEMA-NODOSUM; LYME-DISEASE; RISK-FACTOR; SKIN; EPIDEMIOLOGY; PREVALENCE AB Cellulitis is an acute infection of the dermal and subcutaneous layers of the skin, often occurring after a local skin trauma. It is a common diagnosis in both inpatient and outpatient dermatology, as well as in the primary care setting. Cellulitis classically presents with erythema, swelling, warmth, and tenderness over the affected area. There are many other dermatologic diseases, which can present with similar findings, highlighting the need to consider a broad differential diagnosis. Some of the most common mimics of cellulitis include venous stasis dermatitis, contact dermatitis, deep vein thrombosis, and panniculitis. History, local characteristics of the affected area, systemic signs, laboratory tests, and, in some cases, skin biopsy can be helpful in confirming the correct diagnosis. Most patients can be treated as an outpatient with oral antibiotics, with dicloxacillin or cephalexin being the oral therapy of choice when methicillin-resistant Staphylococcus aureus is not a concern. C1 [Kroshinsky, Daniela] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA USA. [Bailey, Elizabeth] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. RP Kroshinsky, D (reprint author), Massachusetts Gen Hosp, Dept Dermatol, 1653 W Congress Pkwy, Boston, MA USA. EM dkroshinsky@gmail.com NR 42 TC 12 Z9 12 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1396-0296 EI 1529-8019 J9 DERMATOL THER JI Dermatol. Ther. PD MAR-APR PY 2011 VL 24 IS 2 BP 229 EP 239 DI 10.1111/j.1529-8019.2011.01398.x PG 11 WC Dermatology SC Dermatology GA 735YD UT WOS:000288455800008 PM 21410612 ER PT J AU Strom, JL Lynch, CP Egede, LE AF Strom, Joni L. Lynch, Cheryl P. Egede, Leonard E. TI Rural/Urban Variations in Diabetes Self-Care and Quality of Care in a National Sample of US Adults With Diabetes SO DIABETES EDUCATOR LA English DT Article ID RURAL AMERICA; EDUCATION; ACCESS; STATE AB Purpose The purpose of this study was to examine differences in diabetes self-care and provider-based quality-of-care indicators between rural and urban dwellers in a nationally representative sample of adults with diabetes. Methods Data were analyzed on 52 817 individuals with type 2 diabetes from the 2007 Behavioral Risk Factor Surveillance Survey. Rural and urban residence was based on metropolitan statistical area. Self-care behaviors (nutrition, physical activity, self-monitoring) and quality-of-care indicators (clinical visits, glycemic control, preventive measures) were self-reported. Logistic regression analyses were done using STATA 10 to assess the independent effect of rural/urban residence on self-care and each quality measure and to account for the complex survey design. Results Rural residents comprised 21% of the sample and were less likely to receive diabetes education (57% vs 51%, P < .001). The final adjusted model showed that foot self-checks (odds ratio, 1.42; 95% confidence interval, 1.27-1.59) and blood glucose testing at least once daily (odds ratio, 1.14; 95% confidence interval, 1.02-1.26) were significantly higher among rural individuals. Provider-based quality of care was not significantly different by rural/urban residence. Conclusion Contrary to what has been reported, there were no significant differences in diabetes quality of care between rural and urban dwellers. In addition, rural dwellers appeared to have better self-care behaviors than urban dwellers. Further research is needed to clarify the reasons for these findings. C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Vet Affairs Hlth Serv Res & Dev, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. EM Egedel@musc.edu NR 20 TC 6 Z9 7 U1 0 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0145-7217 J9 DIABETES EDUCATOR JI Diabetes Educ. PD MAR-APR PY 2011 VL 37 IS 2 BP 254 EP 262 DI 10.1177/0145721710394875 PG 9 WC Endocrinology & Metabolism; Public, Environmental & Occupational Health SC Endocrinology & Metabolism; Public, Environmental & Occupational Health GA 737KS UT WOS:000288568300009 PM 21289298 ER PT J AU Scirica, BM Sabatine, MS Jarolim, P Murphy, SA de Lemos, JL Braunwald, E Morrow, DA AF Scirica, Benjamin M. Sabatine, Marc S. Jarolim, Petr Murphy, Sabina A. de Lemos, James L. Braunwald, Eugene Morrow, David A. TI Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 Trial SO EUROPEAN HEART JOURNAL LA English DT Article DE Acute coronary syndrome; Biomarkers; Risk-stratification; Troponin; Natriuretic peptides; Myeloperoxidase ID C-REACTIVE PROTEIN; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; NATRIURETIC PEPTIDE; PROGNOSTIC VALUE; ARTERY-DISEASE; TROPONIN-I; ROC CURVE; MYELOPEROXIDASE; MORTALITY AB Aims The aim of this study is to simultaneously evaluate the incremental prognostic value of multiple cardiac biomarkers reflecting different underlying pathophysiological processes in a well-characterized population of patients with non-ST-segment acute coronary syndrome (NSTE-ACS). Methods and results We measured cardiac troponin I (cTnI), N-terminal pro B-type natriuretic peptide (NT-proBNP), C-reactive protein, and myeloperodixase (MPO) among 4352 patients with NSTE-ACS in the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischaemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial and followed them for a mean of 343 days. When added individually to a multivariable model adjusted for clinical characteristics, the risk of cardiovascular (CV) death rose in a stepwise fashion with increasing quartiles of each biomarker, and when using their pre-defined cut-points [HR(adj) 2.71 (P < 0.001) for cTnI >= 0.03 ng/mL; HR(adj) 3.01 (P < 0.001) for NT-proBNP >= 400 pg/mL; HR(adj) 1.45 (P = 0.019) for high-sensitivity (hs) C-reactive protein >= 15 mg/L; and HR(adj) 1.49 (P = 0.006) for MPO >= 670 pmol/L]. After including all biomarkers, only NT-proBNP and cTnI were independently associated with CV death, and only cTnI with myocardial infarction (MI). The addition of NT-proBNP to a model adjusted for TIMI risk score incorporating cTnI significantly improved both the discrimination and re-classification of the model for CV death and heart failure (HF) while there was no such improvement after the addition of either MPO or hs-C-reactive protein. Conclusion In this study of over 4300 patients presenting with NSTEACS, we found that both cTnI and NT-proBNP offer prognostic information beyond that achieved with clinical risk variables for CV death, MI, and HF. Myeloperoxidase and hs-C-reactive protein, while independently associated with some adverse CV outcomes, did not provide substantial incremental prognostic information when evaluated together with cTnI and NT-proBNP. C1 [Scirica, Benjamin M.; Sabatine, Marc S.; Murphy, Sabina A.; Braunwald, Eugene; Morrow, David A.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA. [Jarolim, Petr] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [de Lemos, James L.] Univ Texas SW Med Ctr Dallas, Div Cardiol, Dallas, TX 75390 USA. [de Lemos, James L.] Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA. [Scirica, Benjamin M.; Sabatine, Marc S.; Jarolim, Petr; Murphy, Sabina A.; Braunwald, Eugene; Morrow, David A.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Scirica, BM (reprint author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA. EM bscirica@partners.org FU CV Therapeutics (now Gilead Sciences); CV Therapeutics; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals LP; Daiichi-Sankyo, Inc.; Merck Co., Inc.; Johnson and Johnson Pharmaceutical Research & Development, L.L.C.; Bayer HealthCare Pharmaceuticals; Bristol-Myers-Squibb Company; BRAHMS; dia-Dexus; Ortho-Clinical Diagnostics; Amgen; Beckman-Coulter; Roche Diagnostics; Siemens Healthcare Diagnostics; Biosite; Roche; Accumetrics; Bayer Healthcare; Bristol-Myers Squibb; Daiichi Sankyo; Eli Lilly and Co.; Genentech; Johnson Johnson; Merck and Company; Nanosphere; Sanofi-Aventis; Siemens; Singulex; Schering-Plough FX MERLIN-TIMI 36 was sponsored by CV Therapeutics (now Gilead Sciences).; B.M.S. has received grants for clinical research via the TIMI Study Group and Brigham and Women's Hospital from CV Therapeutics; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals LP; Daiichi-Sankyo, Inc.; Merck & Co., Inc.; Johnson and Johnson Pharmaceutical Research & Development, L.L.C.; Bayer HealthCare Pharmaceuticals; Bristol-Myers-Squibb Company; and served as a consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; CV Therapeutics; Cogentus; Shionogi & Co., Ltd; Gilead Sciences, Inc.; Merck & Co., Inc.; Schering-Plough Corporation. Dr M.S.S. has received research grants from BRAHMS, dia-Dexus, and Ortho-Clinical Diagnostics, and is a consultant for Singulex. Dr P.J. has received research support from Amgen, Beckman-Coulter, Ortho Clinical Diagnostics, Roche Diagnostics, and Siemens Healthcare Diagnostics, and honoraria for educational presentations from Ortho Clinical Diagnostics. J.L.de L. reports grant support from Biosite and Roche, and consulting income from Johnson and Johnson and Tethys. E.B. is the chairman of the TIMI Study Group, who receives grant support from Beckman-Coulter, CV Therapeutics (now Gilead Sciences), and Roche Diagnostics. Dr D.A.M. has received research/educational grant support through the TIMI Study Group from Accumetrics, AstraZeneca, Bayer Healthcare, Beckman Coulter, Bristol-Myers Squibb, CV Therapeutics, Daiichi Sankyo, Eli Lilly and Co., Genentech, Johnson & Johnson, Merck and Company, Nanosphere, Novartis Pharmaceuticals, Ortho-Clinical Diagnostics, Pfizer, Roche Diagnostics, Sanofi-Aventis, Siemens, Singulex, and Schering-Plough; has received honoraria for educational presentations from CV Therapeutics and Eli Lilly and Co.; and is a consultant/on the advisory board of AstraZeneca, Beckman-Coulter, Cardiokinetix, Gilead, Ikaria, Menarini, Molecular Insight, OrthoClinical Diagnostics, Sanofi-Aventis, Schering-Plough Research Institute, Siemens, and Roche Diagnostics. NR 34 TC 39 Z9 46 U1 0 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X J9 EUR HEART J JI Eur. Heart J. PD MAR PY 2011 VL 32 IS 6 BP 697 EP 705 DI 10.1093/eurheartj/ehq468 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 737DO UT WOS:000288549100013 PM 21183500 ER PT J AU Moroz, V Machin, D Faldum, A Hero, B Iehara, T Mosseri, V Ladenstein, R De Bernardi, B Rubie, H Berthold, F Matthay, KK Monclair, T Ambros, PF Pearson, ADJ Cohn, SL London, WB AF Moroz, Veronica Machin, David Faldum, Andreas Hero, Barbara Iehara, Tomoko Mosseri, Veronique Ladenstein, Ruth De Bernardi, Bruno Rubie, Herve Berthold, Frank Matthay, Katherine K. Monclair, Tom Ambros, Peter F. Pearson, Andrew D. J. Cohn, Susan L. London, Wendy B. TI Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project SO EUROPEAN JOURNAL OF CANCER LA English DT Article DE Neuroblastoma; Outcome; Prognosis; Age-at-diagnosis; INRG ID CHROMOSOME 1P AB Purpose: Increasing age has been an adverse risk factor in children with neuroblastoma (NB) since the 1970's, with a 12-month age-at-diagnosis cut-off for treatment stratification. Over the last 30 years, treatment intensity for children > 12 months with advanced-stage disease has increased; to investigate if this strategy has improved outcome and/or reduced the prognostic influence of age, we analysed the International Neuroblastoma Risk Group (INRG) database. Patients and methods: Data from 11,037 children with NB (1974-2002) from Australia, Europe, Japan, North America. Cox modelling of event-free survival (EFS) tested if the era and prognostic significance of age-of-diagnosis, adjusted for bone marrow (BM) metastases and MYCN status, effects on outcome had changed. Results: Outcome improved over time: 3-year EFS 46% (1974-1989) and 71% (1997-2002). The risk for those > 18 months against <= 12 decreased: hazard ratio (HR); 4.61 and 3.94. For age 13-18 months, EFS increased from 42% to 77%. Outcome was worse if: > 18 months (HR 4.47); BM metastases (HR 4.00); and MYCN amplified (HR 3.97). For 1997-2002, the EFS for > 18 months with BM involvement and MYCN amplification was 18%, but 89% for 0-12 months with neither BM involvement nor MYCN amplification. Conclusions: There is clear evidence for improving outcomes for children with NB over calendar time. The adverse influence of increasing age-at-diagnosis has declined but it remains a powerful indicator of unfavourable prognosis. These results support the age-of-diagnosis cut-off of greater than 18 months as a risk criterion in the INRG classification system. (c) 2010 Elsevier Ltd. All rights reserved. C1 [Moroz, Veronica; Machin, David] Univ Leicester, Childrens Canc & Leukaemia Grp Data Ctr, Leicester, Leics, England. [Faldum, Andreas] Johannes Gutenberg Univ Mainz, Inst Med Biostat Epidemiol & Informat, D-6500 Mainz, Germany. [Hero, Barbara; Berthold, Frank] Univ Cologne, Childrens Hosp, Dept Pediat Oncol & Hematol, D-5000 Cologne 41, Germany. [Iehara, Tomoko] Kyoto Prefectural Univ Med, Dept Pediat, Kyoto 602, Japan. [Mosseri, Veronique] Inst Curie, Serv Biostat, Paris, France. [Ambros, Peter F.] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria. [De Bernardi, Bruno] Giannina Gaslini Childrens Hosp, Dept Hematol Oncol, Genoa, Italy. [Rubie, Herve] Hop Enfants, Dept Hematol Oncol, Toulouse, France. [Matthay, Katherine K.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [Matthay, Katherine K.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Monclair, Tom] Rikshosp Univ Hosp, Div Surg, Sect Paediat Surg, Oslo, Norway. [Pearson, Andrew D. J.] Inst Canc Res, Paediat Sect, Surrey, England. [Pearson, Andrew D. J.] Royal Marsden Hosp, Surrey, England. [Cohn, Susan L.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA. [London, Wendy B.] Harvard Univ, Sch Med, Dana Faber Childrens Hosp Canc Ctr, Childrens Oncol Grp Stat & Data Ctr, Boston, MA USA. RP London, WB (reprint author), Dana Farber Canc Inst, Childrens Oncol Grp COG Stat & Data Ctr, 1 Autumn St,AU 022, Boston, MA 02215 USA. EM wendy@cog.ufl.edu RI Faldum, Andreas/A-7894-2013; OI Ambros, Peter F./0000-0002-5507-7211; Cohn, Susan/0000-0001-5749-7650 FU William Guy Forbeck Research Foundation; Little Heroes Pediatric Cancer Research Foundation; Italian Neuroblastoma Foundation; Italian Ministry of Health "Ricerca Finalizzata - Bando Oncologia"; COG Group [NIH/NCI U10-CA98543]; COG member institution [NIH/NCI U10-CA98413]; COG Statistics and Data Center [NIH/NCI U10-CA29139, U10 CA98413] FX Supported in part by the William Guy Forbeck Research Foundation, Little Heroes Pediatric Cancer Research Foundation, the Italian Neuroblastoma Foundation, the Italian Ministry of Health "Ricerca Finalizzata - Bando Oncologia 2006", NIH/NCI U10-CA98543 COG Group Chair's Grant, NIH/NCI U10-CA98413 COG member institution's grant and NIH/NCI U10-CA29139 and U10 CA98413 COG Statistics and Data Center grants. We thank all the collaborators and patients from centres in the following countries who have participated in the INRG project: Australia, Austria, Belgium, Canada, Denmark, France, Germany, Italy, Ireland, Japan, New Zealand, Norway, Spain, Sweden, Switzerland, UK and the USA. NR 16 TC 35 Z9 42 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0959-8049 J9 EUR J CANCER JI Eur. J. Cancer PD MAR PY 2011 VL 47 IS 4 BP 561 EP 571 DI 10.1016/j.ejca.2010.10.022 PG 11 WC Oncology SC Oncology GA 736CW UT WOS:000288468700010 PM 21112770 ER PT J AU Agarwal, N Spiegel, BMR AF Agarwal, Nikhil Spiegel, Brennan M. R. TI The Effect of Irritable Bowel Syndrome on Health-Related Quality of Life and Health Care Expenditures SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Irritable bowel syndrome; Health-related quality of life; Health care expenditures ID GASTROINTESTINAL SYMPTOMS; RESOURCE UTILIZATION; WORK PRODUCTIVITY; CONTROLLED-TRIAL; UNITED-STATES; IBS-QOL; PREVALENCE; COLONOSCOPY; IMPACT; VALIDATION AB Irritable bowel syndrome (IBS) is a highly prevalent condition with a large health economic burden of illness marked by impaired health-related quality of life (HRQOL), diminished work productivity, and high expenditures. Clinicians should routinely screen for diminished HRQOL by performing a balanced biopsychosocial history rather than focusing just on bowel symptoms. HRQOL decrements should be acknowledged and addressed when making treatment decisions. C1 [Agarwal, Nikhil; Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA 90073 USA. RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Gastroenterol, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu NR 42 TC 52 Z9 56 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8553 J9 GASTROENTEROL CLIN N JI Gastroenterol. Clin. North Am. PD MAR PY 2011 VL 40 IS 1 BP 11 EP + DI 10.1016/j.gtc.2010.12.013 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 734ON UT WOS:000288344300003 PM 21333898 ER PT J AU Refaat, M Mansour, M Singh, JP Ruskin, J Heist, EK AF Refaat, Marwan Mansour, Moussa Singh, Jagmeet P. Ruskin, Jeremy Heist, E. Kevin TI Electrocardiographic characteristics in right ventricular vs biventricular pacing in patients with paced right bundle-branch block QRS pattern SO JOURNAL OF ELECTROCARDIOLOGY LA English DT Article; Proceedings Paper CT 37th International Congress on Electrocardiology CY JUN, 2010 CL Lund, SWEDEN DE Electrocardiography; Cardiac resynchronization therapy; Pacemaker ID CHRONIC HEART-FAILURE; FOLLOW-UP; RESYNCHRONIZATION AB Background: A paced right bundle-branch block (RBBB) QRS morphology is present in most patients with biventricular pacing (BiVP) but is also present in some patients with right ventricular pacing (RVP). The aim of this study was to determine if there are electrocardiographic characteristics that distinguish BiVP from RVP in patients with a paced RBBB QRS pattern. Methods: Twelve-lead paced electrocardiograms (ECGs) were analyzed from 356 consecutive patients (302 RVP and 54 BiVP). Further analyses were performed on those ECGs with a paced RBBB morphology, which included QRS pattern, axis, amplitude, and precordial transition. Chest radiography and coronary sinus venography were used to determine the location of the pacing leads. Results: Fifty (16.6%) of 302 RVP ECGs and 50 (92.6%) of 54 BiVP ECGs had RBBB-paced morphology, respectively. Electrocardiographic characteristics identified in this study with a paced RBBB QRS morphology that are associated with RVP but not with BiVP (P < .05) include positive concordance in the precordial leads, qR configuration in lead V(1), and a late QRS transition beyond lead V(3). Biventricular pacing had shorter mean paced QRS duration than did RVP and was associated with right superior quadrant mean frontal QRS axis (P < .05). Right ventricular pacing was associated with a mean frontal QRS axis in the left superior quadrant (P < .05). Regarding left ventricular (LV) pacing site, a late precordial transition (especially beyond lead V(2)) was significantly associated with a more posterior LV lead location (P <.05). Conclusions: Even among patients with a paced RBBB QRS pattern, the 12-lead ECG can help distinguish RVP from BiVP and determine LV lead location during BiVP. This information may be useful in evaluating nonresponse to BiVP resulting either from LV noncapture (with consequent RVP) or from suboptimal LV lead location during BiVP. (C) 2011 Elsevier Inc. All rights reserved. C1 [Mansour, Moussa; Singh, Jagmeet P.; Ruskin, Jeremy; Heist, E. Kevin] Harvard Univ, Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Sch Med, Boston, MA 02114 USA. [Refaat, Marwan] Univ Calif San Francisco, Med Ctr, Cardiac Electrophysiol Serv, San Francisco, CA 94143 USA. RP Heist, EK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Sch Med, 55 Fruit St,Gray 109, Boston, MA 02114 USA. EM kheist@partners.org NR 14 TC 13 Z9 13 U1 0 U2 3 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0022-0736 J9 J ELECTROCARDIOL JI J. Electrocardiol. PD MAR-APR PY 2011 VL 44 IS 2 BP 289 EP 295 DI 10.1016/j.jelectrocard.2010.08.003 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 733SK UT WOS:000288282900037 PM 20888007 ER PT J AU Baudendistel, TE Lindenauer, PK Normand, SLT Drye, EE Lin, ZQ Goodrich, K Desai, MM Bratzler, DW O'Donnell, WJ Metersky, ML Krumholz, HM AF Baudendistel, Thomas E. Lindenauer, Peter K. Normand, Sharon-Lise T. Drye, Elizabeth E. Lin, Zhenqiu Goodrich, Katherine Desai, Mayur M. Bratzler, Dale W. O'Donnell, Walter J. Metersky, Mark L. Krumholz, Harlan M. TI Continuing Medical Education Program in the Journal of Hospital Medicine SO JOURNAL OF HOSPITAL MEDICINE LA English DT Editorial Material C1 [Lindenauer, Peter K.] Baystate Med Ctr, Ctr Qual Care Res, Springfield, MA USA. [Lindenauer, Peter K.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Normand, Sharon-Lise T.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Drye, Elizabeth E.; Lin, Zhenqiu; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. [Goodrich, Katherine] Dept Hlth & Human Serv, Off Assistant Secretary Planning & Evaluat, Washington, DC USA. [Desai, Mayur M.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Bratzler, Dale W.] Oklahoma Fdn Med Qual, Oklahoma City, OK USA. [O'Donnell, Walter J.] Massachusetts Gen Hosp, Dept Pulm Crit Care Med, Boston, MA 02114 USA. [Metersky, Mark L.] Univ Connecticut, Sch Med, Ctr Bronchiectasis Care, Div Pulm & Crit Care Med, Farmington, CT USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06510 USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD MAR PY 2011 VL 6 IS 3 BP 141 EP 141 DI 10.1002/jhm.912 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 736AP UT WOS:000288462200006 PM 21387550 ER PT J AU Lindenauer, PK Normand, SLT Drye, EE Lin, ZQ Goodrich, K Desai, MM Bratzler, DW O'Donnell, WJ Metersky, ML Krumholz, HM AF Lindenauer, Peter K. Normand, Sharon-Lise T. Drye, Elizabeth E. Lin, Zhenqiu Goodrich, Katherine Desai, Mayur M. Bratzler, Dale W. O'Donnell, Walter J. Metersky, Mark L. Krumholz, Harlan M. TI Development, Validation, and Results of a Measure of 30-Day Readmission Following Hospitalization for Pneumonia SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article DE cost analysis; cost per day; end of life; hospice; length of stay; palliative care; triggers ID COMMUNITY-ACQUIRED PNEUMONIA; HEART-FAILURE; HEALTH-CARE; OUTCOMES; PERFORMANCE; QUALITY; REFORM; TRIAL AB BACKGROUND: Readmission following hospital discharge has become an important target of quality improvement. OBJECTIVE: To describe the development, validation, and results of a risk-standardized measure of hospital readmission rates among elderly patients with pneumonia employed in federal quality measurement and efficiency initiatives. DESIGN: A retrospective cohort study using hospital and outpatient Medicare claims from 2005 and 2006. SETTING: A total of 4675 hospitals in the United States. PATIENTS: Medicare beneficiaries aged >65 years with a principal discharge diagnosis of pneumonia. INTERVENTION: None. MEASUREMENTS: Hospital-specific, risk-standardized 30-day readmission rates calculated as the ratio of predicted-to-expected readmissions, multiplied by the national unadjusted rate. Comparison of the areas under the receiver operating curve (AUC) and measurement of correlation coefficient in development and validation samples. RESULTS: The development sample consisted of 226,545 hospitalizations at 4675 hospitals, with an overall unadjusted 30-day readmission rate of 17.4%. The median risk-standardized hospital readmission rate was 17.3%, and the odds of readmission for a hospital one standard deviation above average was 1.4 times that of a hospital one standard deviation below average. Performance of the medical record and administrative models was similar (areas under the AUC curve 0.59 and 0.63, respectively) and the correlation coefficient of estimated state-specific standardized readmission rates from the administrative and medical record models was 0.96. CONCLUSIONS: Rehospitalization within 30 days of treatment for pneumonia is common, and rates vary across hospitals. A risk-standardized measure of hospital readmission rates derived from administrative claims has similar performance characteristics to one based on medical record review. Journal of Hospital Medicine 2011;6:142-150. (C) 2011 Society of Hospital Medicine 2011 Society of Hospital Medicine DOI 10.1002/jhm.890 C1 [Lindenauer, Peter K.] Baystate Med Ctr, Ctr Qual Care Res, Springfield, MA 01199 USA. [Lindenauer, Peter K.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Normand, Sharon-Lise T.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Drye, Elizabeth E.; Lin, Zhenqiu; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. [Goodrich, Katherine] Dept Hlth & Human Serv, Off Assistant Secretary Planning & Evaluat, Washington, DC USA. [Desai, Mayur M.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Bratzler, Dale W.] Oklahoma Fdn Med Qual, Oklahoma City, OK USA. [O'Donnell, Walter J.] Massachusetts Gen Hosp, Dept Pulm Crit Care Med, Boston, MA 02114 USA. [Metersky, Mark L.] Univ Connecticut, Sch Med, Ctr Bronchiectasis Care, Div Pulm & Crit Care Med, Farmington, CT USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06510 USA. RP Lindenauer, PK (reprint author), Baystate Med Ctr, Ctr Qual Care Res, 280 Chestnut St, Springfield, MA 01199 USA. EM peter.lindenauer@baystatehealth.org NR 24 TC 65 Z9 65 U1 2 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD MAR PY 2011 VL 6 IS 3 BP 142 EP 150 DI 10.1002/jhm.890 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 736AP UT WOS:000288462200007 PM 21387551 ER PT J AU Hadano, Y Dhaliwal, G Saint, S Tierney, LM Sakemi, H AF Hadano, Yoshiro Dhaliwal, Gurpreet Saint, Sanjay Tierney, Lawrence M., Jr. Sakemi, Hideta TI Mapping Out the Diagnosis SO JOURNAL OF HOSPITAL MEDICINE LA English DT Editorial Material ID KIKUCHI-FUJIMOTO-DISEASE C1 [Hadano, Yoshiro] Rakuwakai Otowa Hosp, Dept Gen Internal Med, Yamashina Ku, Kyoto 6078062, Japan. [Dhaliwal, Gurpreet; Tierney, Lawrence M., Jr.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Dhaliwal, Gurpreet; Tierney, Lawrence M., Jr.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Saint, Sanjay] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Saint, Sanjay] Univ Michigan, Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI 48109 USA. RP Sakemi, H (reprint author), Rakuwakai Otowa Hosp, Dept Gen Internal Med, Yamashina Ku, Otowachinji Cho, Kyoto 6078062, Japan. EM rakuwadr073@rakuwadr.com NR 6 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD MAR PY 2011 VL 6 IS 3 BP 167 EP 170 DI 10.1002/jhm.875 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 736AP UT WOS:000288462200011 PM 21387553 ER PT J AU Ruchelsman, DE Christoforou, D Wasserman, B Lee, SK Rettig, ME AF Ruchelsman, David E. Christoforou, Dimitrios Wasserman, Bradley Lee, Steve K. Rettig, Michael E. TI Avulsion Injuries of the Flexor Digitorum Profundus Tendon SO JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS LA English DT Review ID VIVO BIOMECHANICAL ANALYSIS; RHEUMATOID-ARTHRITIS; SUTURE TECHNIQUES; DISTAL FIXATION; PULLOUT BUTTON; SURFACE REPAIR; TUNNEL REPAIR; GROWTH-FACTOR; GAP FORMATION; RING FINGER AB Avulsions of the flexor digitorum profundus tendon may involve tendon retraction into the palm and fractures of the distal phalanx. Although various repair techniques have been described, none has emerged as superior to others. Review of the literature does provide evidence-based premises for treatment: multi-strand repairs perform better, gapping may be seen with pullout suture dorsal button repairs, and failure because of bone pullout remains a concern with suture anchor methods. Clinical prognostic factors include the extent of proximal tendon retraction, chronicity of the avulsion, and the presence and size of associated osseous fragments. Patients must be counseled appropriately regarding anticipated outcomes, the importance of postoperative rehabilitation, and potential complications. Treatment alternatives for the chronic avulsion injury remain patient-specific and include nonsurgical management, distal interphalangeal joint arthrodesis, and staged reconstruction. C1 [Ruchelsman, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Hand & Upper Extrem Serv,Dept Orthopaed Surg, Boston, MA 02115 USA. [Ruchelsman, David E.] Tufts Univ, Dept Orthopaed Surg, PC, Newton Wellesley Hosp,Sch Med, Newton, MA USA. [Christoforou, Dimitrios; Wasserman, Bradley; Lee, Steve K.; Rettig, Michael E.] NYU, Hosp Joint Dis, Dept Orthopaed Surg, New York, NY USA. RP Ruchelsman, DE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Hand & Upper Extrem Serv,Dept Orthopaed Surg, Boston, MA 02115 USA. NR 49 TC 14 Z9 14 U1 0 U2 2 PU AMER ACAD ORTHOPAEDIC SURGEONS PI ROSEMENT PA 6300 N RIVER ROAD, ROSEMENT, IL 60018-4262 USA SN 1067-151X J9 J AM ACAD ORTHOP SUR JI J. Am. Acad. Orthop. Surg. PD MAR PY 2011 VL 19 IS 3 BP 152 EP 162 PG 11 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 734UH UT WOS:000288364500004 PM 21368096 ER PT J AU Zeliadt, SB Hoffman, RM Etzioni, R Gore, JL Kessler, LG Lin, DW AF Zeliadt, Steven B. Hoffman, Richard M. Etzioni, Ruth Gore, John L. Kessler, Larry G. Lin, Daniel W. TI Influence of Publication of US and European Prostate Cancer Screening Trials on PSA Testing Practices SO JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID SERVICES-TASK-FORCE; MORTALITY; PATTERNS; UPDATE; MEN AB In 2009, results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial indicated no difference in mortality between the screening and the control groups (rate ratio = 1.13, 95% confidence interval = 0.75 to 1.70), whereas those from the European Randomized study of Screening for Prostate Cancer trial indicated a 20% reduction in mortality among the screening group (rate ratio = 0.80, 95% confidence interval = 0.65 to 0.98). In this study, we examined whether prostate-specific antigen (PSA) testing has changed following these publications. The primary outcome measure was the proportion of men seen at least once in a primary care or urology clinic between August 1, 2004, and March 31, 2010, who received a PSA test. Following the publications, PSA use declined slightly-by 3.0 percentage points and 2.7 percentage points among men aged 40-54 and 55-74 years, respectively. PSA testing among men older than 75 years initially declined slightly following the recommendations by the US Preventive Services Task Force in 2008 and continued to decline after the trial publications. C1 [Zeliadt, Steven B.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98101 USA. [Lin, Daniel W.] VA Puget Sound Hlth Care Syst, Dept Urol, Seattle, WA 98101 USA. [Zeliadt, Steven B.; Etzioni, Ruth; Kessler, Larry G.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Gore, John L.; Lin, Daniel W.] Univ Washington, Dept Urol, Seattle, WA 98195 USA. [Hoffman, Richard M.] Univ New Mexico, Med Serv, Dept Vet Affairs Med Ctr, Albuquerque, NM 87131 USA. [Hoffman, Richard M.] Univ New Mexico, Dept Med, Albuquerque, NM 87131 USA. [Zeliadt, Steven B.; Etzioni, Ruth; Gore, John L.; Lin, Daniel W.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RP Zeliadt, SB (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, 1100 Olive Way,Ste 1400, Seattle, WA 98101 USA. EM steven.zeliadt@va.gov OI Gore, John/0000-0002-2847-5062 FU Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs [HSRD SHP 08-165]; Cancer Prevention and Control Research Network, Centers for Disease Control and Prevention [U48 DP001911] FX Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs (HSR&D SHP 08-165 to S.B.Z.); Cancer Prevention and Control Research Network, Centers for Disease Control and Prevention (U48 DP001911 to Vicky Taylor who was the principal investigator of the center but had no direct involvement with the study). NR 11 TC 31 Z9 31 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 J NATL CANCER I JI J. Natl. Cancer Inst. PD MAR PY 2011 VL 103 IS 6 BP 520 EP 523 DI 10.1093/jnci/djr007 PG 4 WC Oncology SC Oncology GA 737FQ UT WOS:000288554900012 PM 21357307 ER PT J AU Vigneault, F Woods, M Buzon, MJ Li, C Pereyra, F Crosby, SD Rychert, J Church, G Martinez-Picado, J Rosenberg, ES Telenti, A Yu, XG Lichterfeld, M AF Vigneault, Francois Woods, Matthew Buzon, Maria J. Li, Chun Pereyra, Florencia Crosby, Seth D. Rychert, Jennifer Church, George Martinez-Picado, Javier Rosenberg, Eric S. Telenti, Amalio Yu, Xu G. Lichterfeld, Mathias TI Transcriptional Profiling of CD4 T Cells Identifies Distinct Subgroups of HIV-1 Elite Controllers SO JOURNAL OF VIROLOGY LA English DT Article ID LOW-LEVEL VIREMIA; ANTIRETROVIRAL THERAPY; INFECTION; IMMUNODEFICIENCY; VIRUS; REPLICATION; ACTIVATION; PROLIFERATION; INDIVIDUALS; ASSOCIATION AB Human immunodeficiency virus type 1 (HIV-1) elite controllers maintain undetectable levels of viral replication in the absence of antiretroviral therapy (ART), but their underlying immunological and virological characteristics may vary. Here, we used a whole-genome transcriptional profiling approach to characterize gene expression signatures of CD4 T cells from an unselected cohort of elite controllers. The transcriptional profiles for the majority of elite controllers were similar to those of ART-treated patients but different from those of HIV-1-negative persons. Yet, a smaller proportion of elite controllers showed an alternative gene expression pattern that was indistinguishable from that of HIV-1-negative persons but different from that of highly active antiretroviral therapy (HAART)-treated individuals. Elite controllers with the latter gene expression signature had significantly higher CD4 T cell counts and lower levels of HIV-1-specific CD8(+) T cell responses but did not significantly differ from other elite controllers in terms of HLA class I alleles, HIV-1 viral loads determined by ultrasensitive single-copy PCR assays, or chemokine receptor polymorphisms. Thus, these data identify a specific subgroup of elite controllers whose immunological and gene expression characteristics approximate those of HIV-1-negative persons. C1 [Rychert, Jennifer; Rosenberg, Eric S.; Lichterfeld, Mathias] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Vigneault, Francois; Church, George] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Vigneault, Francois; Woods, Matthew; Li, Chun; Pereyra, Florencia; Yu, Xu G.] Ragon Inst MGH MIT & Harvard, Boston, MA USA. [Buzon, Maria J.; Martinez-Picado, Javier] Hosp Badalona Germans Trias & Pujol, IrsiCaixa Fdn, Badalona, Spain. [Crosby, Seth D.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA. [Martinez-Picado, Javier] ICREA, Barcelona, Spain. [Telenti, Amalio] CHU Vaudois, Inst Microbiol, CH-1011 Lausanne, Switzerland. RP Lichterfeld, M (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St, Boston, MA 02114 USA. EM mlichterfeld@partners.org RI Martinez-Picado, Javier/G-5507-2012; Buzon, Maria J/G-8286-2015 OI Martinez-Picado, Javier/0000-0002-4916-2129; Buzon, Maria J/0000-0003-4427-9413 FU U.S. National Institutes of Health [AI078799]; Harvard University Center for AIDS Research; Doris Duke Clinical Scientist Development Award; Canadian Institutes of Health Research; Ragon Institute; Spanish AIDS network [RD06/0006]; Catalan HIV Vaccine Development Program (HIVACAT); Swiss National Science Foundation; Bill and Melinda Gates Foundation; Mark and Lisa Schwartz Foundation FX This study was supported by the U.S. National Institutes of Health (grant AI078799 to X.G.Y.) and by a Feasibility Grant (to M. L.) of the Harvard University Center for AIDS Research. X.G.Y. and M. L. are both recipients of the Doris Duke Clinical Scientist Development Award. F. V. is supported by a Canadian Institutes of Health Research and a Ragon Institute Fellowship. Work in the laboratory of J.M.-P. was supported by the Spanish AIDS network (RD06/0006) and the Catalan HIV Vaccine Development Program (HIVACAT). A. T. is supported by the Swiss National Science Foundation. Recruitment of study patients was supported by the Bill and Melinda Gates Foundation and the Mark and Lisa Schwartz Foundation. NR 33 TC 37 Z9 37 U1 1 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAR PY 2011 VL 85 IS 6 BP 3015 EP 3019 DI 10.1128/JVI.01846-10 PG 5 WC Virology SC Virology GA 735AT UT WOS:000288386500052 PM 21177805 ER PT J AU Galsky, MD Hahn, NM Rosenberg, J Sonpavde, G Hutson, T Oh, WK Dreicer, R Vogelzang, N Sternberg, C Bajorin, DF Bellmunt, J AF Galsky, Matthew D. Hahn, Noah M. Rosenberg, Jonathan Sonpavde, Guru Hutson, Thomas Oh, William K. Dreicer, Robert Vogelzang, Nicholas Sternberg, Cora Bajorin, Dean F. Bellmunt, Joaquim TI A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy SO LANCET ONCOLOGY LA English DT Editorial Material ID BLADDER-CANCER C1 [Galsky, Matthew D.; Oh, William K.] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA. [Hahn, Noah M.] Indiana Univ, Indianapolis, IN 46204 USA. [Rosenberg, Jonathan] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sonpavde, Guru] Texas Oncol & Vet Affairs Med Ctr, Houston, TX USA. [Sonpavde, Guru] Baylor Coll Med, Houston, TX 77030 USA. [Hutson, Thomas] Baylor Sammons Canc Ctr, Dallas, TX USA. [Dreicer, Robert] Cleveland Clin, Cleveland, OH 44106 USA. [Vogelzang, Nicholas] Comprehens Canc Ctr Nevada, Las Vegas, NV USA. [Sternberg, Cora] San Camillo Forlanini Hosp, Rome, Italy. [Bajorin, Dean F.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Bellmunt, Joaquim] Univ Hosp Del Mar, Barcelona, Spain. RP Galsky, MD (reprint author), Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA. EM matthew.galsky@mssm.edu RI Oh, William/B-9163-2012 OI Oh, William/0000-0001-5113-8147 NR 10 TC 51 Z9 51 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 J9 LANCET ONCOL JI Lancet Oncol. PD MAR PY 2011 VL 12 IS 3 BP 211 EP 214 DI 10.1016/S1470-2045(10)70275-8 PG 4 WC Oncology SC Oncology GA 736HY UT WOS:000288483500009 PM 21376284 ER PT J AU Purschke, M Anderson, RR Zurakowski, D Manstein, D AF Purschke, Martin Anderson, R. Rox Zurakowski, David Manstein, Dieter TI Cell-Cycle-Dependent Active Thermal Bystander Effect (ATBE) SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE hyperthermia; heat stress; cell cycle; cell viability; cell damage; bystander ID PRIMARY HUMAN FIBROBLASTS; DOUBLE-STRAND BREAKS; ALPHA-PARTICLES; LOW FLUENCES; X-RAYS; RADIATION; INDUCTION; DNA; RESPONSES AB Objective: To determine whether the active thermal bystander effect (ATBE) is cell-cycle dependent. Materials and Methods: Dividing cells were directly heated for 10 minutes and co-cultured for 24 hours with different bystander cells. We compared the ATBE for dividing and non-dividing human fibroblasts, as well as for dividing human white preadipocytes (HWP) and non-dividing, mature differentiated human white adipocytes. ATBE was assessed as loss of cell viability of the bystander cells by using the MTT assay. Cell-cycle analysis was performed by using flow cytometry. Results: Dividing fibroblasts and preadipocytes showed a significant ATBE (P < 0.008 and P < 0.05) with loss of cell viability of about 10% in the temperature range of 40-488 degrees C. There was no significant difference between the extent of the bystander effect for these two cell populations (P = 0.30). In contrast, non-dividing fibroblasts and mature adipocytes did not generate any ATBE within this temperature range. There was a statistically significant difference in ATBE between dividing and non-dividing cell subpopulations for both fibroblasts (P = 0.003) and preadipocytes (P < 0.001) compared to their non-dividing counterparts. Conclusion: These results suggest that the ATBE is a cell-cycle-dependent process which requires actively dividing cells as receiving bystander cells. The cell-cycle dependency of the ATBE could have useful clinical applications in selectively targeting fast growing cells such as tumor cells. Whether the yield of the ATBE can be amplified by synchronizing the exposure to the ATBE with specific phases of the cell cycle remains subject to further investigation. Lasers Surg. Med. 43:230-235, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Purschke, Martin; Anderson, R. Rox; Manstein, Dieter] Harvard Univ, Wellman Ctr Photomed, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Zurakowski, David] Childrens Hosp, Dept Anesthesia & Surg, Boston, MA 02115 USA. RP Purschke, M (reprint author), Harvard Univ, Wellman Ctr Photomed, Massachusetts Gen Hosp, Sch Med, 55 Fruit St,BHX 631, Boston, MA 02114 USA. EM mpurschke@partners.org FU Department of Defense through the Air Force Office of Scientific Research [FA 4990-04-1-0079]; ASLMS [NS 310] FX Contract grant sponsor: Department of Defense through the Air Force Office of Scientific Research; Contract grant number: FA 4990-04-1-0079; Contract grant sponsor: ASLMS Research Grant 2010; Contract grant number: NS 310. NR 30 TC 3 Z9 3 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD MAR PY 2011 VL 43 IS 3 BP 230 EP 235 DI 10.1002/lsm.21021 PG 6 WC Dermatology; Surgery SC Dermatology; Surgery GA 735EC UT WOS:000288395200007 PM 21308697 ER PT J AU Papay, K Mamikonyan, E Siderowf, AD Duda, JE Lyons, KE Pahwa, R Driver-Dunckley, ED Adler, CH Weintraub, D AF Papay, Kimberly Mamikonyan, Eugenia Siderowf, Andrew D. Duda, John E. Lyons, Kelly E. Pahwa, Rajesh Driver-Dunckley, Erika D. Adler, Charles H. Weintraub, Daniel TI Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: Validity and variability SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Impulse control disorders; Parkinson's disease; QUIP ID IMPULSE CONTROL DISORDERS; BEHAVIORS AB Questions exist regarding the validity of patient-reporting of psychiatric symptoms in Parkinson's disease (PD). We assessed observer variability and validity in reporting of impulse control disorder (ICD) symptoms in PD by using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP). PD patients and their informants (71 pairs) completed the QUIP to assess four ICDs (compulsive gambling, buying, sexual behavior, and eating) in patients. Trained raters then administered a diagnostic interview. Sensitivity of the QUIP for a diagnosed ICD was 100% for both patient- and informant-completed instruments, and specificity was 75% for both raters. Approximately 40% of patients without an ICD diagnosis had a positive QUIP, suggesting that many PD patients experience subsyndromal ICD symptoms that require ongoing monitoring. Agreement between patient- and informant-reporting of any ICD behaviors on the QUIP was moderate (kappa = 0.408), and for individual ICDs was highest for gambling (kappa = 0.550). Overall, a negative QUIP from either the patient or informant rules out the possibility of an ICD, while a positive QUIP requires a follow-up diagnostic interview and ongoing monitoring to determine if symptoms currently are, or in the future become, clinically significant. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Papay, Kimberly; Mamikonyan, Eugenia; Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Siderowf, Andrew D.; Duda, John E.; Weintraub, Daniel] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Duda, John E.; Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA. [Lyons, Kelly E.; Pahwa, Rajesh] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA. [Driver-Dunckley, Erika D.; Adler, Charles H.] Mayo Clin Scottsdale, Dept Neurol, Scottsdale, AZ USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC, Philadelphia, PA USA. RP Weintraub, D (reprint author), Univ Penn, Dept Psychiat, 3615 Chestnut St,Room 330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu FU NINDS NIH HHS [P50 NS053488-02, P50 NS053488] NR 17 TC 29 Z9 29 U1 1 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD MAR PY 2011 VL 17 IS 3 BP 153 EP 155 DI 10.1016/j.parkreldis.2010.11.015 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 736FC UT WOS:000288475100004 PM 21186135 ER PT J AU Hough, S AF Hough, Sigmund TI Sexuality and Disability: A New Year With Continuing Challenges and Established Accomplishments SO SEXUALITY AND DISABILITY LA English DT Editorial Material C1 VA Boston Healthcare Syst, Spinal Cord Injury Serv SCI 128, W Roxbury, MA 02132 USA. RP Hough, S (reprint author), VA Boston Healthcare Syst, Spinal Cord Injury Serv SCI 128, 1400 VFW Pkwy, W Roxbury, MA 02132 USA. EM Sigmund_Hough@hms.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0146-1044 J9 SEX DISABIL JI Sex. Disabil. PD MAR PY 2011 VL 29 IS 1 BP 1 EP 1 DI 10.1007/s11195-011-9194-8 PG 1 WC Rehabilitation SC Rehabilitation GA 718DD UT WOS:000287099400001 ER PT J AU Bates-Jensen, BM MCCreath, HE Mehrnia, A Sun, L Wang, F Lam, L Patlan, A Walker, M Sarrafzadeh, M Kaiser, WJ AF Bates-Jensen, B. M. MCCreath, H. E. Mehrnia, A. Sun, L. Wang, F. Lam, L. Patlan, A. Walker, M. Sarrafzadeh, M. Kaiser, W. J. TI DEVELOPMENT AND SAFETY TESTING OF THE SEM SCANNER FOR DETECTING EARLY PRESSURE ULCERS SO WOUND REPAIR AND REGENERATION LA English DT Meeting Abstract C1 [Bates-Jensen, B. M.; Sun, L.; Patlan, A.; Walker, M.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Bates-Jensen, B. M.; MCCreath, H. E.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA. [Bates-Jensen, B. M.] Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. [Mehrnia, A.; Wang, F.; Lam, L.; Sarrafzadeh, M.; Kaiser, W. J.] Univ Calif Los Angeles, Wireless Hlth Inst, Los Angeles, CA USA. [Lam, L.; Sarrafzadeh, M.] Univ Calif Los Angeles, Sch Comp Sci, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1067-1927 J9 WOUND REPAIR REGEN JI Wound Repair Regen. PD MAR-APR PY 2011 VL 19 IS 2 BP A12 EP A12 PG 1 WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery GA 728ML UT WOS:000287878100018 ER PT J AU Kafanas, A Zabolotny, J Tellechea, A Tecilazich, F Pradhan, L Veves, A AF Kafanas, A. Zabolotny, J. Tellechea, A. Tecilazich, F. Pradhan, L. Veves, A. TI INFLAMMATION AND PTP1B EXPRESSION IS INCREASED IN DIABETIC PATIENTS AND IS ASSOCIATED WITH IMPAIRED WOUND HEALING SO WOUND REPAIR AND REGENERATION LA English DT Meeting Abstract C1 [Kafanas, A.; Zabolotny, J.; Tellechea, A.; Tecilazich, F.; Pradhan, L.; Veves, A.] Harvard Univ, Sch Med, Microcirculat Lab, Boston, MA USA. [Kafanas, A.; Zabolotny, J.; Tellechea, A.; Tecilazich, F.; Pradhan, L.; Veves, A.] Harvard Univ, Sch Med, Joslin Beth Israel Deaconess Foot Ctr, Boston, MA USA. RI Tellechea, Ana/C-4900-2013 NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1067-1927 J9 WOUND REPAIR REGEN JI Wound Repair Regen. PD MAR-APR PY 2011 VL 19 IS 2 BP A30 EP A30 PG 1 WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery GA 728ML UT WOS:000287878100091 ER PT J AU Harman, SM Vittinghoff, E Brinton, EA Budoff, MJ Cedars, MI Lobo, RA Merriam, GR Miller, VM Naftolin, F Pal, L Santoro, N Taylor, HS Black, DM AF Harman, S. Mitchell Vittinghoff, Eric Brinton, Eliot A. Budoff, Matthew J. Cedars, Marcelle I. Lobo, Rogerio A. Merriam, George R. Miller, Virginia M. Naftolin, Frederick Pal, Lubna Santoro, Nanette Taylor, Hugh S. Black, Dennis M. TI Timing and Duration of Menopausal Hormone Treatment May Affect Cardiovascular Outcomes SO AMERICAN JOURNAL OF MEDICINE LA English DT Review DE Cardiovascular disease; Estrogen; Hormones; Menopause; Women's health ID CORONARY-HEART-DISEASE; ESTROGEN PLUS PROGESTIN; CONJUGATED EQUINE ESTROGENS; RANDOMIZED CONTROLLED-TRIAL; ACUTE MYOCARDIAL-INFARCTION; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; VENOUS THROMBOEMBOLISM; ARTERY ATHEROSCLEROSIS; CLINICAL-TRIAL AB Largely on the basis of the first publication of findings of net harm with menopausal hormone treatment in the Women's Health Initiative (WHI) hormone trials, current Food and Drug Administration recommendations limit menopausal hormone treatment to the "... shortest duration consistent with treatment goals ...," with goals generally taken to mean relief of menopausal symptoms and maximal duration as approximately 5 years. The WHI finding of net harm was due largely to the absence of beneficial effects on coronary heart disease incidence rates. Published analyses of WHI data by age or time since menopause find that excess coronary heart disease risk with menopausal hormone treatment is confined to more remotely menopausal or older women, with younger women showing nonsignificant trends toward benefit (the "timing hypothesis"). Moreover, a recently published reexamination of data from the WHI Estrogen plus Progestin trial suggests that reduced coronary heart disease risk may appear only after 5 to 6 years of treatment. Consistent with this finding, risk ratios for coronary heart disease were calculated as 1.08 (95% confidence interval, 0.86-1.36) in years 1 to 6 and as 0.46 (confidence interval, 0.28-0.78) in years 7 to 8+ in the WHI Estrogen Alone trial. Previous studies also support the beneficial effects of menopausal hormone treatment after prolonged exposure. Thus, current analyses do not support a generalized recommendation for short duration of menopausal hormone treatment. Rather, they suggest that current Food and Drug Administration practice guidelines should be reconsidered to allow individualized care based on risk: benefit considerations. New research is urgently needed evaluating influences of timing, duration, dose, route of administration, and agents on menopausal hormone treatment-related risks and benefits to better understand how to optimize recommendations for individual patients. (C) 2011 Elsevier Inc. All rights reserved. . The American Journal of Medicine (2011) 124, 199-205 C1 [Harman, S. Mitchell] Kronos Longev Res Inst, Phoenix, AZ 85016 USA. [Vittinghoff, Eric; Cedars, Marcelle I.; Black, Dennis M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Brinton, Eliot A.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Budoff, Matthew J.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. [Lobo, Rogerio A.] Columbia Univ, Coll Med, New York, NY USA. [Merriam, George R.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Merriam, George R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Miller, Virginia M.] Mayo Clin, Rochester, MN USA. [Naftolin, Frederick] NYU, Sch Med, New York, NY USA. [Pal, Lubna; Taylor, Hugh S.] Yale Univ, Sch Med, New Haven, CT USA. [Santoro, Nanette] Univ Colorado, Denver Sch Med, Aurora, CO USA. RP Harman, SM (reprint author), Kronos Longev Res Inst, 2222 E Camelback,Suite 220, Phoenix, AZ 85016 USA. EM mitch.harman@kronosinstitute.org FU Aurora Foundation, Phoenix, Arizona FX Funding: The Aurora Foundation, a private charitable foundation based in Phoenix, Arizona, via a grant to the Kronos Longevity Research Institute. NR 81 TC 50 Z9 51 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD MAR PY 2011 VL 124 IS 3 BP 199 EP 205 DI 10.1016/j.amjmed.2010.09.021 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 732QM UT WOS:000288203700011 PM 21396500 ER PT J AU Perlis, RH AF Perlis, Roy H. TI Betting on Biomarkers SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Editorial Material C1 Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. RP Perlis, RH (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, 15 Parkman St,WACC 812, Boston, MA 02114 USA. EM rperlis@partners.org FU NIMH NIH HHS [R01 MH086026] NR 7 TC 5 Z9 5 U1 0 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD MAR PY 2011 VL 168 IS 3 BP 234 EP 236 DI 10.1176/appi.ajp.2010.10121738 PG 3 WC Psychiatry SC Psychiatry GA 729AG UT WOS:000287916900002 PM 21368302 ER PT J AU Subotnik, KL Nuechterlein, KH Ventura, J Gitlin, MJ Marder, S Mintz, J Hellemann, GS Thornton, LA Singh, IR AF Subotnik, Kenneth L. Nuechterlein, Keith H. Ventura, Joseph Gitlin, Michael J. Marder, Stephen Mintz, Jim Hellemann, Gerhard S. Thornton, Leslie A. Singh, Indira R. TI Risperidone Nonadherence and Return of Positive Symptoms in the Early Course of Schizophrenia SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID SUPPORTED EMPLOYMENT; 1ST EPISODE; RELAPSE; MEDICATION; ADHERENCE; PREDICTORS; DISORDER; CRITERIA AB Objective: This study examined the effect of medication nonadherence on the return of positive symptoms among recent-onset schizophrenia patients. Method: Three sets of operational criteria for medication nonadherence with differing levels of severity were compared for their ability to predict relapse. Explicit operational criteria are provided with the hope that they will be adopted by others. Psychotic symptoms were prospectively rated on a frequent basis, and systematic criteria were applied using a computer scoring program to identify periods of psychotic symptom return. In addition, a specialized statistical survival analysis method, optimal for examining risk periods and outcomes that can recur during the follow-up assessment, was used. Results: As hypothesized, medication nonadherence robustly predicted a return of psychotic symptoms during the early phase of schizophrenia (hazard ratios=3.7-28.5, depending on the severity of nonadherence). Conclusions: Even brief periods of partial nonadherence lead to greater risk of relapse than what is commonly assumed. Patients in the early phase of schizophrenia should be cautioned about the possible consequences of partial or relatively brief periods of antipsychotic medication nonadherence. (Am J Psychiatry 2011; 168:286-292) C1 [Subotnik, Kenneth L.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Subotnik, KL (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, 300 UCLA Med Plaza,Rm 2240, Los Angeles, CA 90095 USA. EM ksubotnik@mednet.ucla.edu FU Ortho-McNeil Janssen Scientific Affairs; Pfizer; GlaxoSmithKline; Novartis; National Institute of Mental Health [MH-037705, MH-066286] FX Dr. Subotnik has received support from Ortho-McNeil Janssen Scientific Affairs for an investigator-initiated study. Dr. Nuechterlein has received support from Ortho-McNeil Janssen Scientific Affairs for an investigator-initiated study; he has also served as a consultant for Merck. Dr. Ventura has received support from Pfizer for an investigator-initiated study. Dr. Gitlin has received honoraria from AstraZeneca, Bristol-Myers Squibb, Lilly, and Servier. Dr. Marder has served on the advisory boards of Abbott, Otsuka, Pfizer, Sanofi Aventis, Schering Plough, and Wyeth; he has also received research support from GlaxoSmithKline and Novartis; and he is a shareholder with MedAvante. All other authors report no financial relationships with commercial interests.; Supported by National Institute of Mental Health research grants MH-037705 and MH-066286 (Dr. Nuechterlein) and a supplementary grant from Ortho-McNeil Janssen Scientific Affairs. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health, the National Institutes of Health, or Ortho-McNeil Janssen Scientific Affairs. NR 30 TC 43 Z9 45 U1 1 U2 5 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD MAR PY 2011 VL 168 IS 3 BP 286 EP 292 DI 10.1176/appi.ajp.2010.09010087 PG 7 WC Psychiatry SC Psychiatry GA 729AG UT WOS:000287916900012 PM 21205805 ER PT J AU Forman, SA AF Forman, Stuart A. TI Clinical and Molecular Pharmacology of Etomidate SO ANESTHESIOLOGY LA English DT Review ID GENERAL ANESTHETIC ETOMIDATE; GATED ION-CHANNEL; EXTRASYNAPTIC GABA(A) RECEPTORS; RAPID-SEQUENCE INTUBATION; MULTIPLE TRAUMA PATIENTS; CRITICALLY-ILL PATIENTS; PLASMA-PROTEIN BINDING; X-RAY-STRUCTURE; A RECEPTOR; INDUCTION AGENT AB This review focuses on the unique clinical and molecular pharmacologic features of etomidate. Among general anesthesia induction drugs, etomidate is the only imidazole, and it has the most favorable therapeutic index for single-bolus administration. It also produces a unique toxicity among anesthetic drugs: inhibition of adrenal steroid synthesis that far outlasts its hypnotic action and that may reduce survival of critically ill patients. The major molecular targets mediating anesthetic effects of etomidate in the central nervous system are specific gamma-aminobutyric acid type A receptor subtypes. Amino acids forming etomidate binding sites have been identified in transmembrane domains of these proteins. Etomidate binding site structure models for the main enzyme mediating etomidate adrenotoxicity have also been developed. Based on this deepening understanding of molecular targets and actions, new etomidate derivatives are being investigated as potentially improved sedative-hypnotics or for use as highly selective inhibitors of adrenal steroid synthesis. C1 Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. RP Forman, SA (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Jackson 444,55 Fruit St, Boston, MA 02114 USA. EM saforman@partners.org FU National Institutes of Health (Bethesda, Maryland) [P01GM58448]; Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts FX Received from Massachusetts General Hospital, Boston, Massachusetts. Submitted for publication July 6, 2010. Accepted for publication September 17, 2010. Supported by grant P01GM58448 from the National Institutes of Health (Bethesda, Maryland); and the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts. Massachusetts General Hospital has submitted patent applications for MOC etomidate, carboetomidate, and related analogs. The author and his laboratory, department, and institution could receive royalties relating to the development or sale of these drugs. NR 160 TC 82 Z9 90 U1 0 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-3022 J9 ANESTHESIOLOGY JI Anesthesiology PD MAR PY 2011 VL 114 IS 3 BP 695 EP 707 DI 10.1097/ALN.0b013e3181ff72b5 PG 13 WC Anesthesiology SC Anesthesiology GA 725QH UT WOS:000287660300030 PM 21263301 ER PT J AU Clayton, AC Wasserman, PG Souers, RJ Chmara, BA Renshaw, A Wilbur, DC Moriarty, AT AF Clayton, Amy C. Wasserman, Patricia G. Souers, Rhona J. Chmara, Beth Anne Renshaw, Andrew Wilbur, David C. Moriarty, Ann T. CA Coll Amer Pathologists TI The Multiple Faces of Carcinoid Tumor Performance Characteristics of Low-Grade Neuroendocrine Carcinoma Metastatic to the Liver in an Educational Interlaboratory Slide Comparison Program SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID NEEDLE ASPIRATION CYTOLOGY; DIAGNOSIS AB Context.-Cytologic features of low-grade neuroendocrine carcinoma are well described in primary sites. There are fewer reports of the cytologic features specific to metastatic liver lesions or the frequency of misdiagnosis. Objective.-To identify discriminating cytologic features and characterize the rate of misdiagnosis of low-grade neuroendocrine tumors metastatic to the liver in an educational interlaboratory slide comparison program. Design.-Glass slides with the specific reference diagnosis of metastatic low-grade neuroendocrine tumor involving liver were circulated to 175 laboratories, with 575 participant responses in the College of American Pathologists Interlaboratory Comparison Program in Non-gynecologic Cytology. Eight specific cytologic features were assessed to identify predictors of poor performance (> 10% misdiagnosis). Results- There was an exact match diagnosis in 496 of 575 responses (86%); 555 of 575 responses (96.5%) were correctly identified as malignant. Incorrect responses included adenocarcinoma (27), hepatocellular neoplasm (21), small cell carcinoma (11), benign neoplasm not otherwise specified (6), benign liver (3) and inflammation (3). Three features were significantly associated with the misdiagnosis of adenocarcinoma: presence of large clusters (P=.02), lack of single-cell pattern (P=.02), and lack of stripped nuclei (P=.01). Conclusion.-Participants often recognize metastatic low-grade neuroendocrine carcinoma in an educational glass-slide program. Adenocarcinoma was the most common incorrect diagnosis, especially in the presence of large cellular clusters or absence of a single-cell pattern or stripped nuclei. (Arch Pathol Lab Med. 2011;135:354-360) C1 [Clayton, Amy C.] Mayo Clin, Dept Pathol, Rochester, MN 55905 USA. [Wasserman, Patricia G.] N Shore Long Isl Jewish Hlth Syst, Dept Pathol, New Hyde Pk, NY USA. [Souers, Rhona J.; Chmara, Beth Anne] Coll Amer Pathologists, Northfield, IL USA. [Renshaw, Andrew] Baptist Hosp Miami, Dept Pathol, Miami, FL USA. [Wilbur, David C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Moriarty, Ann T.] AmeriPath Indiana, Pathol, Indianapolis, IN USA. RP Clayton, AC (reprint author), Mayo Clin, Dept Pathol, 200 1st St SW,Hilton 11, Rochester, MN 55905 USA. EM clayton.amy@mayo.edu NR 11 TC 1 Z9 1 U1 0 U2 2 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD MAR PY 2011 VL 135 IS 3 BP 354 EP 360 PG 7 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 732AQ UT WOS:000288153600017 PM 21366460 ER PT J AU Marino, RJ Burns, S Graves, DE Leiby, BE Kirshblum, S Lammertse, DP AF Marino, Ralph J. Burns, Stephen Graves, Daniel E. Leiby, Benjamin E. Kirshblum, Steven Lammertse, Daniel P. TI Upper- and Lower-Extremity Motor Recovery After Traumatic Cervical Spinal Cord Injury: An Update From the National Spinal Cord Injury Database SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Outcomes; Recovery; Rehabilitation; Spinal cord injuries; Tetraplegia ID NEUROLOGICAL CLASSIFICATION; INTERNATIONAL STANDARDS; COMPLETE QUADRIPLEGIA; CLINICAL-TRIALS; RELIABILITY; PROGNOSIS; TETRAPLEGIA; MULTICENTER; SCALE AB Objective: To present upper- (UEMS) and lower-extremity motor score (LEMS) recovery, American Spinal Injury Association Impairment Scale (AIS) change, and motor level change in persons with traumatic tetraplegia from the Spinal Cord Injury Model Systems (SCIMS). Design: Longitudinal cohort; follow-up to 1 year. Setting: U.S. SCIMS. Participants: Subjects (N = 1436; age > 15y) with tetraplegia with at least 2 examinations, the first within 7 days of injury. Subjects were 80% men injured by vehicular collisions (44%), falls (30%), sports (12%), and violence (11%). Interventions: Not applicable. Main Outcome Measures: Change in AIS, UEMS, LEMS, and motor levels. Results: From a baseline of 7 days or less, 22% of subjects with AIS grade A converted to AIS grade B or better by rehabilitation discharge; and 30%, by 1 year, with 8% to AIS grade C and 7.1% to grade D. Conversion from complete to motor incomplete was not related to timing of the initial examination (P=.54) or initial neurologic level (P=.96). For AIS grade B, 34% remained motor complete, 30% became AIS grade C, and 37% became grade D by 1 year. Although 82.5% of those with AIS grade C improved to AIS grades D and E, mean 1-year UEMS score was only 35 points. UEMS scores in patients with AIS grade A increased a mean of 9 to 11 points, except for C1 to C3 and C8 to T1 motor levels (gain, 2-3 points). Motor level was unchanged or ascended in 35% and improved 1 level in 42%, 2 levels in 14%, and more than 2 levels in 9%. Motor zone of partial preservation of 2 segments or more was associated with gain of 2 or more motor levels, with a relative risk of 5.0 (95% confidence interval, 3.2-7.8; P <.001). Conclusions: More patients with cervical complete spinal cord injury may be converting to AIS grade D compared with earlier reports. Motor level recovery in those with AIS grade A and UEMS recovery in those with AIS grade C injuries are potential outcomes for acute clinical trials. C1 [Marino, Ralph J.] Thomas Jefferson Univ, Dept Rehabil Med, Philadelphia, PA 19107 USA. [Leiby, Benjamin E.] Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA. [Burns, Stephen] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Burns, Stephen] Vet Affairs Puget Sound Hlth Care Syst, Spinal Cord Injury Serv, Seattle, WA USA. [Graves, Daniel E.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Kirshblum, Steven] Kessler Inst Rehabil, W Orange, NJ USA. [Kirshblum, Steven] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. [Lammertse, Daniel P.] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO 80202 USA. [Lammertse, Daniel P.] Craig Hosp, Englewood, CO USA. RP Marino, RJ (reprint author), Thomas Jefferson Univ, Dept Rehabil Med, 132 S 10th St,Ste 375,Main Bldg, Philadelphia, PA 19107 USA. EM ralph.marino@jefferson.edu OI Marino, Ralph/0000-0003-2670-4113; Lammertse, Daniel/0000-0003-4590-2481 FU National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, Department of Education [H133N060011] FX Supported by the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, Department of Education (grant no. H133N060011). NR 27 TC 27 Z9 28 U1 3 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2011 VL 92 IS 3 BP 369 EP 375 DI 10.1016/j.apmr.2010.09.027 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 732NF UT WOS:000288191400007 PM 21353821 ER PT J AU Myaskovsky, L Burkitt, KH Lichy, AM Ljungberg, IH Fyffe, DC Ozawa, H Switzer, GE Fine, MJ Boninger, ML AF Myaskovsky, Larissa Burkitt, Kelly H. Lichy, Alison M. Ljungberg, Inger H. Fyffe, Denise C. Ozawa, Haishin Switzer, Galen E. Fine, Michael J. Boninger, Michael L. TI The Association of Race, Cultural Factors, and Health-Related Quality of Life in Persons With Spinal Cord Injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Health status disparities; Minority health; Quality of life; Rehabilitation; Spinal cord injuries ID PRESSURE ULCER PREVALENCE; ASSISTIVE TECHNOLOGY; PERCEIVED DISCRIMINATION; PSYCHOSOCIAL FACTORS; RACIAL DISPARITIES; ETHNIC-DIFFERENCES; CARE; SATISFACTION; OUTCOMES; MODEL AB Objective: To examine the association of race and cultural factors with quality-of-life factors (participation, life satisfaction, perceived health status) in people with spinal cord injury (SCI). Design: Cross-sectional multisite study using structured questionnaires. Setting: Six National SO Model Systems centers. Participants: People with SCI (N=275; age >= 16y; SCI with discernable neurologic impairments; used power or manual wheelchair for > 1y as primary means of mobility; nonambulatory except for exercise purposes). Interventions: None. Main Outcome Measures: Participation (Craig Handicap Assessment and Reporting Technique Short Form); satisfaction (Satisfaction With Life Scale); and perceived health status (2 items from 36-Item Short Form Health Survey). Results: African American (n=96) with SCI reported more experiences of discrimination in health care, greater perceived racism, more health care system distrust, and lower health literacy than whites (n=156; P range, <.001-<.05). Participants who reported experiencing more discrimination in health care reported better occupational functioning (odds ratio [OR], 1.5; 95% confidence interval [CI], 1.07-2.09; P <.05). Those who perceived more racism in health care settings reported better occupational functioning (OR, 1.65; 95% CI, 1.12-2.43; P <.05) and greater perceived health (beta=.36; 95% CI,.05.68; P <.05). Those who reported more distrust in the health care system reported better current health compared with 1 year ago (beta=.38; 95% CI,.06.69; P <.05). Those who reported better communication with their health care provider reported higher levels of mobility (OR, 1.5; 95% Cl, 1.05-2.13; P <.05) and better general health (beta=.27; 95% CI, .01.53; P <.05). Conclusions: In this cross-sectional study of people with SCI, higher levels of perceived discrimination and racism and better communication with health care providers were associated with an increase in participation and functioning and improvements in perceptions of well-being. These associations are different from those reported in other study populations and warrant confirmation in future prospective studies. C1 [Myaskovsky, Larissa; Burkitt, Kelly H.; Switzer, Galen E.; Fine, Michael J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Boninger, Michael L.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Excellence Wheelchairs & Associated Rehabil E, Pittsburgh, PA USA. [Myaskovsky, Larissa; Switzer, Galen E.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Ozawa, Haishin; Boninger, Michael L.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Lichy, Alison M.; Ljungberg, Inger H.] Natl Rehabil Hosp, Spinal Cord Injury Res Ctr, Washington, DC USA. [Fyffe, Denise C.] Kessler Fdn Res Ctr, Spinal Cord Injury Lab, W Orange, NJ USA. RP Myaskovsky, L (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7160 Highland Dr 151C-H, Pittsburgh, PA 15206 USA. EM larissa.myaskovsky@va.gov OI Boninger, Michael/0000-0001-6966-919X FU Department of Education, National Institute on Disability and Rehabilitation Research [H133N060019, H113N060022, H133N060028]; Veterans Administration [B3142C, MRP04-409, HFP01-063, IIR06-220-3] FX Supported by the Department of Education, National Institute on Disability and Rehabilitation Research (grant nos. H133N060019, H113N060022, H133N060028) and the Veterans Administration (grant nos. B3142C, MRP04-409, HFP01-063, IIR06-220-3). NR 47 TC 11 Z9 11 U1 3 U2 16 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2011 VL 92 IS 3 BP 441 EP 448 DI 10.1016/j.apmr.2010.10.007 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 732NF UT WOS:000288191400016 PM 21353826 ER PT J AU McClure, LA Boninger, ML Oyster, ML Roach, MJ Nagy, J Nemunaitis, G AF McClure, Laura A. Boninger, Michael L. Oyster, Michelle L. Roach, Mary Joan Nagy, Jennifer Nemunaitis, Gregory TI Emergency Evacuation Readiness of Full-Time Wheelchair Users With Spinal Cord Injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Disabled persons; Emergency preparedness; Rehabilitation; Self-help devices; Spinal cord injuries ID PREPAREDNESS; TERRORISM AB Objectives: To determine the percentage of full-time wheelchair users with spinal cord injuries who felt they could evacuate from various locations, and the percentage who have a plan for evacuation. Study results will help clinicians and emergency officials understand needs related to evacuation preparedness. Design: Convenience sample survey. Setting: Six Spinal Cord Injury Model System centers, part of the national database funded through the Department of Education, National Institute on Disability and Rehabilitation Research. Participants: People (N=487) with spinal cord injuries who use a wheelchair more than 40 hours a week. Interventions: Not applicable. Main Outcome Measures: The percentage of wheelchair users who felt they would be able to safely evacuate, had a plan for safe evacuation, or reported a need for assistive technology and human assistance to evacuate from various locations in the event of an emergency. Results: The highest percentage of participants felt they would be able to safely evacuate and had a plan for work evacuation. The lowest percentage of participants reported they could evacuate from their city/town in the event of an emergency and had a plan to evacuate their city/town in the event of a natural disaster. A large difference exists between the percentage of participants who felt they could evacuate and those who have a plan for evacuation. Conclusions: A large discrepancy exists between the perception that one can evacuate and actually having a plan. The perception that one can evacuate without a plan or the use of assistive technology is an area of concern that must be further addressed by educators. Education must emphasize the need to have a defined evacuation plan and effective utilization of assistive technology. C1 [McClure, Laura A.; Boninger, Michael L.; Oyster, Michelle L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, Pittsburgh, PA 15206 USA. [McClure, Laura A.; Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Boninger, Michael L.; Oyster, Michelle L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Roach, Mary Joan; Nagy, Jennifer; Nemunaitis, Gregory] MetroHlth Rehabil Inst Ohio, Cleveland, OH USA. [Roach, Mary Joan; Nemunaitis, Gregory] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. RP Boninger, ML (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, 7180 Highland Dr 151R1-H,Bldg 4,2nd Fl, Pittsburgh, PA 15206 USA. EM boninger@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitation Services, U.S. Department of Education [H133N060019]; National Science Foundation Interdisciplinary Research Training in Assistive Technology [DGE0333420] FX Supported by the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitation Services, U.S. Department of Education (grant no. H133N060019) and the National Science Foundation Interdisciplinary Research Training in Assistive Technology (grant no. DGE0333420). The material presented here is solely the responsibility of the authors and does not necessarily reflect the opinions of the funding agency or the United States Department of Education. NR 31 TC 7 Z9 7 U1 2 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2011 VL 92 IS 3 BP 491 EP 498 DI 10.1016/j.apmr.2010.08.030 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 732NF UT WOS:000288191400023 PM 21353832 ER PT J AU McClure, LA Boninger, ML Ozawa, H Koontz, A AF McClure, Laura A. Boninger, Michael L. Ozawa, Haishin Koontz, Alicia TI Reliability and Validity Analysis of the Transfer Assessment Instrument SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Outcome Assessment (health care); Rehabilitation ID WHEELCHAIR-RELATED ACCIDENTS; SPINAL-CORD-INJURY; SKILLS TEST; SEVERITY; USERS; PAIN AB Objectives: To describe the development and evaluate the reliability and validity of a newly created outcome measure, the Transfer Assessment Instrument (TAI), to assess the quality of transfers performed by full-time wheelchair users. Design: Repeated measures. Setting: 2009 National Veterans Wheelchair Games in Spokane, WA. Participants: A convenience sample of full-time wheelchair users (N=40) who perform sitting pivot or standing pivot transfers. Interventions: Not applicable. Main Outcome Measures: Intraclass correlation coefficients (ICCs) for reliability and Spearman correlation coefficients for concurrent validity between the TAI and a global assessment scale (0-100 visual analog scale [VAS]). Results: No adverse events occurred during testing. Intrarater ICCs for 3 raters ranged between .35 and .89, and the interrater ICC was .642. Correlations between the TAI and a global assessment VAS ranged between .19 (P=.285) and .69 (P >.000). Item analyses of the tool found a wide range of results, from weak to good reliability. Evaluators found the TAI to be safe and able to be completed in a short time. Conclusions: The TAI is a safe, quick outcome measure that uses equipment typically found in a clinical setting and does not ask participants to perform new skills. Reliability and validity testing found the TAI to have acceptable interrater and a wide range of intrarater reliability. Future work indicates the need for continued refinement including removal or modification of items found to have low reliability, improved education for clinicians, and further reliability and validity analysis with a more diverse subject population. The TAI has the potential to fill a void in assessment of transfers. C1 [McClure, Laura A.; Boninger, Michael L.; Ozawa, Haishin; Koontz, Alicia] Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [McClure, Laura A.; Boninger, Michael L.; Koontz, Alicia] Univ Pittsburgh, Dept Rehabil Sci, Pittsburgh, PA USA. [McClure, Laura A.; Boninger, Michael L.; Koontz, Alicia] Univ Pittsburgh, Dept Technol, Pittsburgh, PA USA. [Boninger, Michael L.; Ozawa, Haishin] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP Boninger, ML (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 7180 Highland Dr 15IR1-H,Bldg 4,2nd Fl, Pittsburgh, PA 15206 USA. EM boninger@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU Veterans Affairs Center for Excellence for Wheelchairs; Associated Rehabilitation Engineering Award [B3142C] FX Supported by the Veterans Affairs Center for Excellence for Wheelchairs and Associated Rehabilitation Engineering Award (award no. B3142C). NR 15 TC 10 Z9 10 U1 3 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2011 VL 92 IS 3 BP 499 EP 508 DI 10.1016/j.apmr.2010.07.231 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 732NF UT WOS:000288191400024 PM 21276957 ER PT J AU Ojha, RP Felini, MJ Singh, KP Faramawi, MF Thertulien, R AF Ojha, Rohit P. Felini, Martha J. Singh, Karan P. Faramawi, Mohammed F. Thertulien, Raymond TI RADIATION THERAPY FOR LOCALIZED OR LOCALLY ADVANCED PROSTATE ADENOCARCINOMA AND MYELOMA INCIDENCE IN A POPULATION-BASED COHORT SO BJU INTERNATIONAL LA English DT Editorial Material ID UNDETERMINED SIGNIFICANCE; MONOCLONAL GAMMOPATHY; IONIZING-RADIATION; MULTIPLE-MYELOMA; CANCER PATIENTS; MALIGNANCIES; RADIOTHERAPY; MANAGEMENT; EXPOSURE C1 [Ojha, Rohit P.; Felini, Martha J.; Faramawi, Mohammed F.] Univ N Texas, Hlth Sci Ctr, Dept Epidemiol, Sch Publ Hlth, Ft Worth, TX USA. [Singh, Karan P.] Univ N Texas, Hlth Sci Ctr, Dept Biostat, Sch Publ Hlth, Ft Worth, TX USA. [Thertulien, Raymond] US Oncol, Canc Ctr N Carolina, Asheville, NC USA. [Ojha, Rohit P.] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA. RP Ojha, RP (reprint author), 44 Binney St,SM 271, Boston, MA 02115 USA. EM rohit_ojha@dfci.harvard.edu OI Ojha, Rohit/0000-0003-0595-8990 NR 34 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1464-4096 J9 BJU INT JI BJU Int. PD MAR PY 2011 VL 107 IS 5 BP 693 EP 697 DI 10.1111/j.1464-410X.2010.09976.x PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 727ON UT WOS:000287810800003 PM 21210963 ER PT J AU Kim, HS Moreira, DM Smith, MR Presti, JC Aronson, WJ Terris, MK Kane, CJ Amling, CL Freedland, SJ AF Kim, Howard S. Moreira, Daniel M. Smith, Matthew R. Presti, Joseph C., Jr. Aronson, William J. Terris, Martha K. Kane, Christopher J. Amling, Christopher L. Freedland, Stephen J. TI A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database SO BJU INTERNATIONAL LA English DT Article DE prostate cancer; androgen deprivation; side-effects; weight ID CARDIOVASCULAR-DISEASE; BODY-COMPOSITION; METABOLIC SYNDROME; CARCINOMA; MORTALITY; BLOCKADE; MASS; FAT AB What's known on the subject? and What does the study add? Prior studies have shown that men undergoing ADT tend to gain weight, with a net increase in fat mass and decrease in bone density and lean body mass. We sought to characterize the natural history of weight gain on ADT by studying patients over a three-year interval, finding that most weight gain occurs within the first year of initiating therapy. Furthermore, we confirm these prior findings in a more racially heterogeneous population of men, an important finding given the different outcomes of prostate cancer in black and white men. OBJECTIVES To better understand the natural history of weight change with androgen-deprivation therapy (ADT), we investigated the effect of ADT on body weight among men from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Men undergoing ADT lose lean muscle but gain fat mass, contributing to an overall gain in weight. PATIENTS AND METHODS We identified 132 men in SEARCH who received ADT after radical prostatectomy. 'Weight change' was defined as the difference in weight before starting ADT (6 months before ADT) and the on-ADT weight (between 6 and 18 months after starting ADT). In a subanalysis, baseline characteristics of weight-gainers and -losers were analysed using univariate and multivariate analysis to test association with weight change. RESULTS In all, 92 men (70%) gained weight, and 40 (30%) either lost or maintained a stable weight. On average, weight on ADT was 2.2 kg higher than the weight before ADT, with the mean change for weight-gainers and -losers being +4.2 kg and -2.4 kg, respectively. This compared with no significant weight change in the year before starting ADT (paired t-test, change -0.7 kg, P = 0.19) or in the second year on ADT (paired t-test, change -0.5 kg, P = 0.46) for 84 men in whom these additional weight values were recorded. There was no significant association between any of the features examined and weight change on univariate and multivariate analysis. CONCLUSION In this longitudinal study, ADT was accompanied by significant weight gain (+2.2 kg). This change occurred primarily in the first year of therapy, with men neither losing nor gaining additional weight thereafter. C1 [Freedland, Stephen J.] Duke Univ, Sch Med, Div Urol, Dept Pathol, Durham, NC 27710 USA. [Kim, Howard S.; Moreira, Daniel M.; Freedland, Stephen J.] Duke Univ, Sch Med, Div Urol Surg, Dept Surg, Durham, NC 27710 USA. [Kim, Howard S.; Moreira, Daniel M.; Freedland, Stephen J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA. [Kim, Howard S.; Moreira, Daniel M.] Duke Univ, Sch Med, Duke Prostate Ctr, Durham, NC 27710 USA. [Smith, Matthew R.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. [Presti, Joseph C., Jr.] Stanford Univ, Med Ctr, Dept Urol, Palo Alto, CA 94304 USA. [Presti, Joseph C., Jr.] Vet Affairs Med Ctr, Dept Surg, Urol Sect, Palo Alto, CA 94304 USA. [Aronson, William J.] Vet Affairs Med Ctr, Dept Surg, Urol Sect, Los Angeles, CA USA. [Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Div Surg, Augusta, GA USA. [Terris, Martha K.] Med Coll Georgia, Dept Surg, Div Urol Surg, Augusta, GA 30912 USA. [Kane, Christopher J.] Univ Calif San Diego, Dept Surg, Div Urol, San Diego Med Ctr, San Diego, CA 92103 USA. [Amling, Christopher L.] Oregon Hlth & Sci Univ, Dept Surg, Div Urol, Portland, OR 97201 USA. RP Freedland, SJ (reprint author), Duke Univ, Sch Med, Div Urol, Dept Pathol, Box 2626 DUMC, Durham, NC 27710 USA. EM steve.freedland@duke.edu OI Terris, Martha/0000-0002-3843-7270 FU Department of Veterans Affairs, National Institute of Health [R01CA100938]; NIH [P50 CA92131-01A1]; Georgia Cancer Coalition; Department of Defense; American Urological Association Foundation; Howard Hughes Medical Institute FX Supported by the Department of Veterans Affairs, National Institute of Health R01CA100938 (W.J.A.), NIH Specialized Programs of Research Excellence Grant P50 CA92131-01A1 (W.J.A.), the Georgia Cancer Coalition (M.K.T.), the Department of Defense, Prostate Cancer Research Program (L.L.B./S.J.F.), the American Urological Association Foundation/Astellas Rising Star in Urology Award (S.J.F.) and the Howard Hughes Medical Institute Medical Fellows Program (H.S.K.). Views and opinions of, and endorsements by the author(s) do not reflect those of the US Army or the Department of Defense. NR 21 TC 16 Z9 17 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-4096 J9 BJU INT JI BJU Int. PD MAR PY 2011 VL 107 IS 6 BP 924 EP 928 DI 10.1111/j.1464-410X.2010.09679.x PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 732TN UT WOS:000288212700012 PM 20860651 ER PT J AU Ballen, KK Spitzer, TR AF Ballen, K. K. Spitzer, T. R. TI The great debate: haploidentical or cord blood transplant SO BONE MARROW TRANSPLANTATION LA English DT Review DE haploidentical transplant; cord blood transplant; alternative donors; GVHD ID STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; MISMATCHED FAMILY DONORS; ACUTE-LEUKEMIA; HEMATOLOGIC MALIGNANCIES; HIGH-RISK; IMMUNE RECONSTITUTION; CONDITIONING REGIMEN; UNRELATED DONORS; ADULT PATIENTS AB One of the truly revolutionary advances in hematopoietic cell transplantation (HCT) is the increasingly successful use of alternative donors, thereby allowing the delivery of a potentially curative transplant to similar to 75% of patients who do not have an HLA-matched sibling donor. A substantial proportion of the need has been met by HLA-matched volunteer unrelated donors, but an unmet need still exists, particularly among minority populations and for people who need a more immediate source of hematopoietic cells. Two such sources, umbilical cord blood (UCB) and haploidentical related donors, have filled most of this need, and outcomes following transplants from these donor sources are very promising. UCB has the advantages of ready availability and is less capable of causing GVHD but hematological recovery and immune reconstitution are slow. Haploidentical HCT is characterized by the nearly uniform and immediate availability of a donor and the availability of the donor for post transplant cellular immunotherapy, but is complicated by a high risk of GVHD and poor immune reconstitution when GVHD is prevented by vigorous ex vivo or in vivo T-cell depletion. This review will discuss the pertinent issues that affect the choice of one donor source over another and offer recommendations regarding the optimal utilization of these donor sources. Bone Marrow Transplantation (2011) 46, 323-329; doi:10.1038/bmt.2010.260; published online 1 November 2010 C1 [Ballen, K. K.] Massachusetts Gen Hosp, Div Hematol Oncol, Dept Med, Boston, MA 02114 USA. RP Ballen, KK (reprint author), Massachusetts Gen Hosp, Div Hematol Oncol, Dept Med, 0 Emerson Suite 118, Boston, MA 02114 USA. EM kballen@partners.org NR 42 TC 29 Z9 31 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD MAR PY 2011 VL 46 IS 3 BP 323 EP 329 DI 10.1038/bmt.2010.260 PG 7 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 732DI UT WOS:000288164000001 PM 21042314 ER PT J AU DeLisi, LE Fleischhacker, WW AF DeLisi, Lynn E. Fleischhacker, W. Wolfgang TI Technology-driven science: will it advance treatment of schizophrenia going into the second decade of the 21st century? SO CURRENT OPINION IN PSYCHIATRY LA English DT Editorial Material ID ANTIPSYCHOTIC-DRUGS C1 [DeLisi, Lynn E.] VA Boston Healthcare Syst, Brockton, MA 02301 USA. Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. [Fleischhacker, W. Wolfgang] Med Univ Innsbruck, A-6020 Innsbruck, Austria. RP DeLisi, LE (reprint author), VA Boston Healthcare Syst, 900 Belmont Ave, Brockton, MA 02301 USA. EM DeLisi76@aol.com NR 8 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7367 J9 CURR OPIN PSYCHIATR JI Curr. Opin. Psychiatr. PD MAR PY 2011 VL 24 IS 2 BP 89 EP 90 DI 10.1097/YCO.0b013e3283446bde PG 2 WC Psychiatry SC Psychiatry GA 715IH UT WOS:000286876300001 PM 21285700 ER PT J AU Rosenquist, JN AF Rosenquist, James N. TI Lessons from social network analyses for behavioral medicine SO CURRENT OPINION IN PSYCHIATRY LA English DT Article DE health behaviors; relationships; Social network analysis ID COMPLEX NETWORKS; HEALTH; SPREAD AB Purpose of review This study presents an overview of the rapidly expanding field of social network analysis, with an emphasis placed on work relevant to behavioral health clinicians and researchers. I outline how social network analysis is a distinct empirical methodology within the social sciences that has the potential to deepen our understanding of how mental health and addiction are influenced by social environmental factors. Recent findings Whereas there have been a number of recent studies in the mental health literature that discuss social influences on mental illness and addiction, and a number of studies looking at how social networks influence health and behaviors, there are still relatively few studies that combine the two. Those that have suggest that mood symptoms as well as alcohol consumption are clustered within, and may travel along, social networks. Summary Social networks appear to have an important influence on a variety of mental health conditions. This avenue of research has the potential to influence both clinical practice and public policy. C1 [Rosenquist, James N.] Harvard Univ, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA. [Rosenquist, James N.] Harvard Univ, Inst Quantitat Social Sci, Cambridge, MA 02138 USA. RP Rosenquist, JN (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA. EM jrosenquist@partners.org FU N.I.H. [P01AG031093-01] FX The author reports funding from N.I.H., NIA P-01 Grant P01AG031093-01. NR 19 TC 3 Z9 3 U1 3 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7367 J9 CURR OPIN PSYCHIATR JI Curr. Opin. Psychiatr. PD MAR PY 2011 VL 24 IS 2 BP 139 EP 143 DI 10.1097/YCO.0b013e3283438061 PG 5 WC Psychiatry SC Psychiatry GA 715IH UT WOS:000286876300009 PM 21285704 ER PT J AU Wilson, DM Xing, DY Beck, RW Block, J Bode, B Fox, LA Hirsch, I Kollman, C Laffel, L Ruedy, KJ Steffes, M Tamborlane, WV AF Wilson, Darrell M. Xing, Dongyuan Beck, Roy W. Block, Jennifer Bode, Bruce Fox, Larry A. Hirsch, Irl Kollman, Craig Laffel, Lori Ruedy, Katrina J. Steffes, Michael Tamborlane, William V. CA JDRF Continuous Glucose Monitoring TI Hemoglobin A(1c) and Mean Glucose in Patients With Type 1 Diabetes Analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial SO DIABETES CARE LA English DT Article ID GLYCEMIC CONTROL; BLOOD-GLUCOSE; GLYCATED HEMOGLOBIN; INTENSIVE TREATMENT; CHILDREN; A1C; COMPLICATIONS; ACCURACY; SYSTEM; ASSAY AB OBJECTIVE To determine the relationship between mean sensor glucose concentrations and hemoglobin A(1c) (HbA(1c)) values measured in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications laboratory at the University of Minnesota in a cohort of subjects with type 1 diabetes from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. RESEARCH DESIGN AND METHODS Near-continuous glucose sensor data (>= 4 days/week) were collected for 3 months before a central laboratory measured HbA(1c) was performed for 252 subjects aged 8-74 years, the majority of whom had stable HbA(1c) values (77% within +/- 0.4% of the patient mean). RESULTS The slope (95% Cl) for mean sensor glucose concentration (area under the curve) versus a centrally measured HbA(1c) was 24.4 mg/dL (22.0-26.7) for each 1% change in HbA(1c), with an intercept of -16.2 mg/dL (-32.9 to 0.6). Although the slope did not vary with age or sex, there was substantial individual variability, with mean sensor glucose concentrations ranging from 128 to 187 mg/dL for an HbA(1c) of 6.9-7.1%. The root mean square of the errors between the actual mean sensor glucose concentration versus the value calculated using the regression equation was 14.3 mg/dL, whereas the median absolute difference was 10.1 mg/dL. CONCLUSIONS There is substantial individual variability between the measured versus calculated mean glucose concentrations. Consequently, estimated average glucose concentrations calculated from measured HbA(1c) values should be used with caution. Diabetes Care 34:540-544, 2011 C1 [Xing, Dongyuan; Beck, Roy W.; Kollman, Craig; Ruedy, Katrina J.] Jaeb Ctr Hlth Res, Tampa, FL USA. [Wilson, Darrell M.; Block, Jennifer] Stanford Univ, Stanford, CA 94305 USA. [Bode, Bruce] Atlanta Diabet Associates, Atlanta, GA USA. [Fox, Larry A.] Nemours Childrens Clin, Jacksonville, FL USA. [Hirsch, Irl] Univ Washington, Seattle, WA 98195 USA. [Laffel, Lori] Joslin Diabet Ctr, Boston, MA 02215 USA. [Steffes, Michael] Univ Minnesota, Minneapolis, MN USA. [Tamborlane, William V.] Yale Univ, New Haven, CT USA. RP Beck, RW (reprint author), Jaeb Ctr Hlth Res, Tampa, FL USA. EM jdrfapp@jaeb.org FU JDRF [22-2006-1107, 22-2006-1117, 22-2006-1112, 22-2006-1123, 01-2006-8031]; Abbott Medtronic MiniMed; Medtronic MiniMed; DexCom; Abbott Diabetes Care FX This study was supported by JDRF (Grants 22-2006-1107, 22-2006-1117, 22-2006-1112, 22-2006-1123, and 01-2006-8031).; J.B. has received consulting fees from Abbott Medtronic MiniMed. B.B. has received consulting fees, honoraria, travel reimbursement, and research funds from Medtronic MiniMed and grant support from DexCom. I.H. has received consulting fees and travel reimbursement from Abbott Diabetes Care. C.K. has received consulting fees from Medtronic MiniMed. L.L. has received consulting fees and a speaker honorarium from Abbott Diabetes Care and consulting fees and research funding from Medtronic MiniMed. W.V.T. has received consulting fees from Medtronic MiniMed. No other potential conflicts of interest relevant to this article were reported. NR 22 TC 17 Z9 17 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAR PY 2011 VL 34 IS 3 BP 540 EP 544 DI 10.2337/dc10-1054 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 731YA UT WOS:000288145400002 ER PT J AU Stetson, B Schlundt, D Rothschild, C Floyd, JE Rogers, W Mokshagundam, SP AF Stetson, Barbara Schlundt, David Rothschild, Chelsea Floyd, Jennifer E. Rogers, Whitney Mokshagundam, Sri Prakash TI Development and validation of The Personal Diabetes Questionnaire (PDQ): A measure of diabetes self-care behaviors, perceptions and barriers SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Self-care; Diabetes; Reliability; Validity; Questionnaire ID ASSESSMENT REPORT TOOL; SITUATIONAL OBSTACLES; MANAGEMENT; PATIENT; EDUCATION; INFORMATION; ADHERENCE; OUTCOMES AB Aim: To develop and evaluate the validity and reliability of The Personal Diabetes Questionnaire (PDQ), a brief, yet comprehensive measure of diabetes self-care behaviors, perceptions and barriers. To examine individual items to provide descriptive and normative information and provide data on scale reliability and associations between PDQ scales and concurrently assessed HBA(1c) and BMI. Method: Items were written to address nutritional management, medication utilization, blood glucose monitoring, and physical activity. The initial instrument was reviewed by multidisciplinary diabetes care providers and items subsequently revised until the measure provided complete coverage of the diabetes care domains using as few items as possible. The scoring scheme was generated rationally. Subjects were 790 adults (205 with type 1 and 585 with type 2 diabetes) who completed the PDQ while waiting for clinic appointments. Results: Item completion rates were high, with few items skipped by participants. Subscales demonstrated good internal consistency (Cronbach alpha = .650-.834) and demonstrated significant associations with BMI (p <= .001) and HbA(1c) (p <= .001). Conclusions: The PDQ is a useful measure of diabetes self-care behaviors and related perceptions and barriers that is reliable and valid and feasible to administer in a clinic setting. This measure may be used to obtain data for assessing diabetes self-management and barriers and to guide patient care. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Stetson, Barbara; Rothschild, Chelsea; Floyd, Jennifer E.; Rogers, Whitney] Univ Louisville, Dept Psychol & Brain Sci, Louisville, KY 40292 USA. [Schlundt, David] Vanderbilt Univ, Ctr Diabet Res & Training, Dept Psychol, Nashville, TN 37203 USA. [Mokshagundam, Sri Prakash] Univ Louisville, Dept Med, Louisville, KY 40292 USA. [Mokshagundam, Sri Prakash] Floyd Mem Hosp, Joslin Diabet Ctr, New Albany, IN USA. RP Stetson, B (reprint author), Univ Louisville, Dept Psychol & Brain Sci, 317 Life Sci Bldg, Louisville, KY 40292 USA. EM barbara.stetson@louisville.edu NR 40 TC 11 Z9 12 U1 0 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD MAR PY 2011 VL 91 IS 3 BP 321 EP 332 DI 10.1016/j.diabres.2010.12.002 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 732EW UT WOS:000288168800015 PM 21215487 ER PT J AU Harris, DP Ortiz, F Adler, FM Yu, K Maines, ML Barba, D Viggiani, SI Wolf, SM Fitten, LJ Chodosh, J Vickrey, BG AF Harris, Dorothy P. Ortiz, Freddy Adler, Fredric M. Yu, Katherine Maines, Michele L. Barba, Dora Viggiani, Sandra I. Wolf, Sheldon M. Fitten, L. Jaime Chodosh, Joshua Vickrey, Barbara G. TI Challenges to screening and evaluation of memory impairment among Hispanic elders in a primary care safety net facility SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE memory screening; Hispanic elders; quality improvement ID ALZHEIMERS-DISEASE; HEALTH-CARE; INFORMANT QUESTIONNAIRE; COGNITIVE IMPAIRMENT; MEXICAN-AMERICANS; OLDER-ADULTS; DEMENTIA; PREVALENCE; DEPRESSION; ACCESS AB Objective: Implement a memory impairment screening procedure for elderly Hispanic primary care patients, and analyze its yield and challenges to further triage and diagnostic evaluation. Methods: Three hundred twenty nine Hispanic patients aged >= 60 years or proxy informants were enrolled from outpatient primary care clinics at an urban safety-net medical center. Patients were screened for memory impairment using the WHO-UCLA AVLT; for those without consent capacity, proxies were given the IQCODE. Bilingual research assistants conducted in-person or telephone screening. Age, gender, education, comorbidities, acculturation, overall health, access to care, and memory concerns were assessed as potential predictors of memory impairment. Based on identified implementation challenges, a multi-disciplinary stakeholder committee proposed revised approaches to increase diagnostic evaluation and sustainability. Results: Of 677 eligible patients approached, 329 (49%) were screened, and 77 (23%) met criteria for memory impairment using the WHO-UCLA AVLT (N = 60) or the IQCODE (N = 17). Only male gender and higher comorbidity uniquely predicted memory impairment (ps < 0.05). Few screen-positive patients declined further triage and evaluation, but a substantial proportion could not be subsequently contacted. Challenges to implementing a memory screening program included staff time and adequate clinic space for in-person screening; challenges to follow-up of positive screening results included inability to contact patients and lack of primary care continuity to facilitate further triage and referral. Conclusions: Nearly one-fourth of primary care Hispanic elders screened as memory-impaired, but few factors predicted positive screening. Stakeholder-guided adaptations are needed-particularly in resource-constrained settings-to overcome challenges to further diagnostic evaluation and referral. Copyright (C) 2010 John Wiley & Sons, Ltd. C1 [Harris, Dorothy P.; Ortiz, Freddy; Maines, Michele L.; Wolf, Sheldon M.; Vickrey, Barbara G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Ortiz, Freddy; Fitten, L. Jaime; Chodosh, Joshua; Vickrey, Barbara G.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Ortiz, Freddy; Adler, Fredric M.; Yu, Katherine; Barba, Dora; Viggiani, Sandra I.; Wolf, Sheldon M.] Olive View UCLA Med Ctr, Sylmar, CA 91342 USA. [Chodosh, Joshua] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. [Fitten, L. Jaime] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Vickrey, BG (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. EM bvickrey@ucla.edu OI Chodosh, Joshua/0000-0001-7784-4306 FU California Department of Health Services [06-55314] FX The authors would like to thank Stefanie Vassar, MS for programming assistance and Sandy Cerda for administrative assistance. Karina Martinez and Farida Kazvinova provided important service in conducting the screening of study subjects. This work was supported by the California Department of Health Services (grant number 06-55314) for the Alzheimer's Disease Research Center of California. NR 31 TC 2 Z9 3 U1 1 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD MAR PY 2011 VL 26 IS 3 BP 268 EP 276 DI 10.1002/gps.2524 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 731GE UT WOS:000288093500007 PM 20629169 ER PT J AU Clark, S Espinola, J Rudders, SA Banerji, A Camargo, CA AF Clark, Sunday Espinola, Janice Rudders, Susan A. Banerji, Aleena Camargo, Carlos A., Jr. TI Frequency of US emergency department visits for food-related acute allergic reactions SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Letter ID ANAPHYLAXIS; MULTICENTER C1 [Clark, Sunday] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. [Espinola, Janice; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Banerji, Aleena; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. [Rudders, Susan A.] Hasbro Childrens Hosp, Ctr Asthma & Allergy, Providence, RI USA. RP Clark, S (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. EM sunday.clark@gmail.com NR 9 TC 34 Z9 34 U1 3 U2 11 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD MAR PY 2011 VL 127 IS 3 BP 682 EP 683 DI 10.1016/j.jaci.2010.10.040 PG 3 WC Allergy; Immunology SC Allergy; Immunology GA 730FG UT WOS:000288018400021 PM 21167574 ER PT J AU Breton, S AF Breton, Sylvie TI ACQUISITION OF MALE FERTILITY: NOVEL ROLES OF THE EPIDIDYMAL EPITHELIUM SO JOURNAL OF ANDROLOGY LA English DT Meeting Abstract CT 36th Annual Meeting of Genes and Harmones - State-of-the-Art Reproductive and Sexual Development CY APR 02-05, 2011 CL Hyatt Regency Montreal, Montreal, CANADA HO Hyatt Regency Montreal C1 [Breton, Sylvie] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Membrane Biol,Ctr Syst Biol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC ANDROLOGY, INC PI LAWRENCE PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 USA SN 0196-3635 J9 J ANDROL JI J. Androl. PD MAR-APR PY 2011 SU S BP 25 EP 25 PG 1 WC Andrology SC Endocrinology & Metabolism GA 724AZ UT WOS:000287549800009 ER PT J AU Dussel, V Bona, K Heath, JA Hilden, JM Weeks, JC Wolfe, J AF Dussel, Veronica Bona, Kira Heath, John A. Hilden, Joanne M. Weeks, Jane C. Wolfe, Joanne TI Unmeasured Costs of a Child's Death: Perceived Financial Burden, Work Disruptions, and Economic Coping Strategies Used by American and Australian Families Who Lost Children to Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID LOW-INCOME FAMILIES; ILLNESS; IMPACT; SYMPTOMS; LIFE; END AB Purpose Financial concerns represent a major stressor for families of children with cancer but remain poorly understood among those with terminally ill children. We describe the financial hardship, work disruptions, income loss, and coping strategies of families who lost children to cancer. Methods Retrospective cross-sectional survey of 141 American and 89 Australian bereaved parents whose children died between 1990 and 1999 and 1996 to 2004, respectively, at three tertiary-care pediatric hospitals (two American, one Australian). Response rate: 63%. Results Thirty-four (24%) of 141 families from US centers and 34 (39%) of 88 families from the Australian center reported a great deal of financial hardship resulting from their children's illness. Work disruptions were substantial (84% in the United States, 88% in Australia). Australian families were more likely to report quitting a job (49% in Australia v 35% in the United States; P = .037). Sixty percent of families lost more than 10% of their annual income as a result of work disruptions. Australians were more likely to lose more than 40% of their income (34% in Australia v 19% in the United States; P = .035). Poor families experienced the greatest income loss. After accounting for income loss, 16% of American and 22% of Australian families dropped below the poverty line. Financial hardship was associated with poverty and income loss in all centers. Fundraising was the most common financial coping strategy (52% in the United States v 33% in Australia), followed by reduced spending. Conclusion In these US and Australian centers, significant household-level financial effects of a child's death as a result of cancer were observed, especially for poor families. Interventions aimed at reducing the effects of income loss may ease financial distress. C1 [Wolfe, Joanne] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA. Childrens Hosp Boston, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Inst Clin Effectiveness & Hlth Policy Res, Buenos Aires, DF, Argentina. Royal Childrens Hosp, Childrens Canc Ctr, Parkville, Vic, Australia. Peyton Manning Childrens Hosp St Vincent, Indianapolis, IN USA. RP Wolfe, J (reprint author), Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, 44 Binney St,SM 206, Boston, MA 02115 USA. EM veronica_dussel@dfci.harvard.edu FU National Health and Medical Research Council (NHMRC); Gloria Spivak Merit Award FX J.A.H. was supported by a National Health and Medical Research Council (NHMRC) Health Professional Fellowship and is the recipient of an NHMRC Palliative Care Grant. J.W. was the recipient of a Gloria Spivak Merit Award. Authors' work was independent of funders. NR 26 TC 24 Z9 24 U1 1 U2 15 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR PY 2011 VL 29 IS 8 BP 1007 EP 1013 DI 10.1200/JCO.2009.27.8960 PG 7 WC Oncology SC Oncology GA 732CN UT WOS:000288161000024 PM 21205758 ER PT J AU Kornblith, AB Lan, L Archer, L Partridge, A Kimmick, G Hudis, C Winer, E Casey, R Bennett, S Cohen, HJ Muss, HB AF Kornblith, Alice B. Lan, Lan Archer, Laura Partridge, Ann Kimmick, Gretchen Hudis, Clifford Winer, Eric Casey, Rebecca Bennett, Samantha Cohen, Harvey Jay Muss, Hyman B. TI Quality of Life of Older Patients With Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy: A Companion Study to Cancer and Leukemia Group B 49907 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID EUROPEAN-ORGANIZATION; PHASE-II; CAPECITABINE; DEPRESSION; ANXIETY; DISEASE AB Purpose A phase III trial (Cancer and Leukemia Group B CALGB-49907) was conducted to test whether older patients with early-stage breast cancer would have equivalent relapse-free and overall survival with capecitabine compared with standard chemotherapy. The quality of life (QoL) substudy tested whether capecitabine treatment would be associated with a better QoL than standard chemotherapy. Patients and Methods QoL was assessed in 350 patients randomly assigned to either standard chemotherapy (cyclophosphamide, methotrexate, and fluorouracil [CMF] or doxorubicin and cyclophosphamide [AC]; n = 182) or capecitabine (n = 168). Patients were interviewed by telephone before treatment (baseline), midtreatment, within 1 month post-treatment, and at 12, 18, and 24 months postbaseline by using questionnaires from the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30), a breast systemic adverse effects scale (EORTC BR23), and the Hospital Anxiety and Depression Scale (HADS). Results Compared with patients who were treated with standard chemotherapy, patients who were treated with capecitabine had significantly better QoL, role function, and social function, fewer systemic adverse effects, less psychological distress, and less fatigue during and at the completion of treatment (P <= .005). Capecitabine treatment was associated with less nausea, vomiting, and constipation and with better appetite than standard treatment (P <= .004), but worse hand-foot syndrome and diarrhea (P < .005). These differences all resolved by 12 months. Conclusion Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survival for older women with early-stage breast cancer. Although capecitabine was associated with better QoL during treatment, QoL was similar for both groups at 1 year. The brief period of poorer QoL with standard treatment is a modest price to pay for a chance at improved survival. J Clin Oncol 29:1022-1028. (c) 2011 by American Society of Clinical Oncology C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Duke Univ, Med Ctr, Canc & Leukemia Grp B Stat Ctr, Durham, NC USA. Cornell Univ, Med Ctr, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Vermont, Burlington, VT USA. RP Kornblith, AB (reprint author), 140 8th Ave,Apt 4-O, Brooklyn, NY 11215 USA. EM akornblith@gmail.com FU National Cancer Institute [CA31946, CA33601, CA32291, CA47577, CA77651, CA77406]; National Institute on Aging [P30-AG-028716, U10CA85850] FX Supported in part by Grants No. CA31946 from the National Cancer Institute to Cancer and Leukemia Group B, No. CA33601 to the CALGB Statistical Center, No. P30-AG-028716 from the National Institute on Aging to the Duke Claude Pepper Older Americans Independence Center, and No. U10CA85850 from the National Institute on Aging, along with Grants No. CA32291, CA33601, CA47577, CA77651, and CA77406 from the National Cancer Institute. NR 15 TC 29 Z9 29 U1 1 U2 7 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR PY 2011 VL 29 IS 8 BP 1022 EP 1028 DI 10.1200/JCO.2010.29.9859 PG 7 WC Oncology SC Oncology GA 732CN UT WOS:000288161000026 PM 21300923 ER PT J AU Berry, DL Blumenstein, BA Halpenny, B Wolpin, S Fann, JR Austin-Seymour, M Bush, N Karras, BT Lober, WB McCorkle, R AF Berry, Donna L. Blumenstein, Brent A. Halpenny, Barbara Wolpin, Seth Fann, Jesse R. Austin-Seymour, Mary Bush, Nigel Karras, Bryant T. Lober, William B. McCorkle, Ruth TI Enhancing Patient-Provider Communication With the Electronic Self-Report Assessment for Cancer: A Randomized Trial SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID QUALITY-OF-LIFE; PHYSICIAN COMMUNICATION; SYMPTOM ASSESSMENT; ONCOLOGY; OUTCOMES; SCREEN; SYSTEM AB Purpose Although patient-reported cancer symptoms and quality-of-life issues (SQLIs) have been promoted as essential to a comprehensive assessment, efficient and efficacious methods have not been widely tested in clinical settings. The purpose of this trial was to determine the effect of the Electronic Self-Report Assessment-Cancer (ESRA-C) on the likelihood of SQLIs discussed between clinicians and patients with cancer in ambulatory clinic visits. Secondary objectives included comparison of visit duration between groups and usefulness of the ESRA-C as reported by clinicians. Patients and Methods This randomized controlled trial was conducted in 660 patients with various cancer diagnoses and stages at two institutions of a comprehensive cancer center. Patient-reported SQLIs were automatically displayed on a graphical summary and provided to the clinical team before an on-treatment visit (n = 327); in the control group, no summary was provided (n = 333). SQLIs were scored for level of severity or distress. One on-treatment clinic visit was audio recorded for each participant and then scored for discussion of each SQLI. We hypothesized that problematic SQLIs would be discussed more often when the intervention was delivered to the clinicians. Results The likelihood of SQLIs being discussed differed by randomized group and depended on whether an SQLI was first reported as problematic (P = .032). Clinic visits were similar with regard to duration between groups, and clinicians reported the summary as useful. Conclusion The ESRA-C is the first electronic self-report application to increase discussion of SQLIs in a US randomized clinical trial. J Clin Oncol 29:1029-1035. (c) 2011 by American Society of Clinical Oncology C1 Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Trial Architecture Consulting, Washington, DC USA. Univ Washington, Seattle, WA 98195 USA. Samaritan Healthcare, Moses Lake, WA USA. Joint Base Lewis McChord, Natl Ctr Telehealth & Technol, Tacoma, WA USA. Yale Univ, New Haven, CT USA. RP Berry, DL (reprint author), Dana Farber Canc Inst, Phyllis F Cantor Ctr, FAAN, 44 Binney St,CP 305, Boston, MA 02115 USA. EM donna_berry@dfci.harvard.edu FU National Institute of Nursing Research, National Institutes of Health [R01 NR008726] FX Supported by National Institute of Nursing Research, National Institutes of Health, Grant No. R01 NR008726; 2004-2007. NR 19 TC 91 Z9 91 U1 1 U2 10 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR PY 2011 VL 29 IS 8 BP 1029 EP 1035 DI 10.1200/JCO.2010.30.3909 PG 7 WC Oncology SC Oncology GA 732CN UT WOS:000288161000027 PM 21282548 ER PT J AU Johanson, ME Murray, WM Hentz, VR AF Johanson, M. Elise Murray, Wendy M. Hentz, Vincent R. TI Comparison of Wrist and Elbow Stabilization Following Pinch Reconstruction in Tetraplegia SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE Electromyography; lateral pinch; spinal cord injury; tendon transfer; tetraplegia ID UPPER EXTREMITY; KEY PINCH; BRACHIORADIALIS; MUSCLES AB Purpose Individuals with spinal cord injuries resulting in tetraplegia may receive tendon transfer surgery to restore grasp and pinch function. These procedures often involve rerouting the brachioradialis (Br) and the extensor carpi radialis longus tendons volar to the flexion-extension axis of the wrist, leaving the extensor carpi radialis brevis (ECRB) muscle to provide wrist extension strength. The purpose of this study was to determine whether externally stabilizing the wrist after transfer procedures would improve the ability to activate the transferred Br and resulting pinch force, similar to the effect observed when the elbow is externally stabilized. Methods We used a one-way repeated-measures study design to determine the effect of 3 support conditions on muscle activation and lateral pinch force magnitude in 8 individuals with tetraplegia and previous tendon transfer surgeries. Muscle activation was recorded from Br and ECRB with intramuscular electrodes and from biceps and triceps muscles with surface electrodes. We quantified pinch strength with a 6-axis force sensor and custom grip. We recorded measurements in 3 support conditions: with the arm self-stabilized, with elbow stabilization, and with elbow and wrist stabilization. Pairwise differences were tested using Wilcoxon signed-rank tests. Results Maximum effort pinch force magnitude and Br activation were significantly increased in both supported conditions compared with the self-supported trials. The addition of wrist stabilization had no significant effect compared with elbow stabilization alone. Conclusions A strong ECRB has adequate strength to extend the wrist, even after multiple transfers that contribute an additional flexion moment from strong activation of donor muscles. Anatomical and functional differences between the wrist and elbow musculature are important determinants for self-stabilizing joints proximal to the tendon transfer. The ability to increase Br activation and resulting pinch force may be determined, in part, by the individual's ability to develop new coordination strategies. (J Hand Surg 2011;36A:480-485. Copyright (C) 2011 by the American Society for Surgery of the Hand. All rights reserved.) C1 [Johanson, M. Elise] VA Palo Alto Hlth Care Syst, Rehabil Res & Dev Ctr, Palo Alto, CA 94304 USA. Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA. Northwestern Univ, Dept Phys Med & Rehabil, Evanston, IL 60208 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Johanson, ME (reprint author), VA Palo Alto Hlth Care Syst, Rehabil Res & Dev Ctr, 3801 Miranda Ave-153, Palo Alto, CA 94304 USA. EM johanson@va51.stanford.edu RI Murray, Wendy/B-7629-2009; Murray, Wendy/D-1520-2009 OI Murray, Wendy/0000-0002-7547-621X FU Department of Veterans Affairs, Rehabilitation Research and Development Service [A3741R] FX Supported by the Department of Veterans Affairs, Rehabilitation Research and Development Service, Project A3741R. NR 18 TC 4 Z9 4 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD MAR PY 2011 VL 36A IS 3 BP 480 EP 485 DI 10.1016/j.jhsa.2010.11.006 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 733AG UT WOS:000288232200017 PM 21277699 ER PT J AU Abramson, Z Susarla, SM Lawler, M Bouchard, C Troulis, M Kaban, LB AF Abramson, Zachary Susarla, Srinivas M. Lawler, Matthew Bouchard, Carl Troulis, Maria Kaban, Leonard B. TI Three-Dimensional Computed Tomographic Airway Analysis of Patients with Obstructive Sleep Apnea Treated by Maxillomandibular Advancement SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID MANDIBULAR ADVANCEMENT; SURGERY; ANATOMY; MORPHOLOGY; SNORERS; SIZE AB Purpose: To evaluate changes in airway size and shape in patients with obstructive sleep apnea (OSA) after maxillomandibular advancement (MMA) and genial tubercle advancement (GTA). Materials and Methods: This was a retrospective cohort study, enrolling a sample of adults with polysomnography-confirmed OSA who underwent MMA + GTA. All subjects who had preoperative and postoperative 3-dimensional computed tomography (CT) scans to evaluate changes in airway size and shape after MMA + GTA were included. Preoperative and postoperative sleep- and breathing-related symptoms were recorded. Descriptive and bivariate statistics were computed. For all analyses, P < .05 was considered statistically significant. Results: During the study period, 13 patients underwent MMA + GTA, of whom 11(84.6%) met the inclusion criteria. There were 9 men and 2 women with a mean age of 39 years. The mean body mass index was 26.3; mean respiratory disturbance index (RIM), 48.8; and mean lowest oxygen saturation, 80.5%. After MMA + GTA, there were significant increases in lateral and anteroposterior airway diameters (P < .01), volume (P = .02), surface area (P < .01), and cross-sectional areas at multiple sites (P < .04). Airway length decreased (P < .01) and airway shape (P = .04) became more uniform. The mean change in RDI was -60%. Conclusions: Results of this preliminary study indicate that MMA + GTA appears to produce significant changes in airway size and shape that correlate with a decrease in RDI. (C) 2011 American Association of Oral and Maxillofacial Surgeons Oral Maxillofac Surg 69:677-686, 2011 C1 [Kaban, Leonard B.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. RP Kaban, LB (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, 55 Fruit St,WRN 1201, Boston, MA 02114 USA. EM lkaban@partners.org OI Susarla, Srinivas/0000-0003-0155-8260 FU Hanson Foundation; AO/Synthes Research Fellowship in Pediatric Oral and Maxillofacial Surgery; Oral and Maxillofacial Surgery Foundation; Massachusetts General Hospital Department of Oral and Maxillofacial Surgery; Center for Applied Clinical Investigation FX This study was supported by the Hanson Foundation, the AO/Synthes Research Fellowship in Pediatric Oral and Maxillofacial Surgery (Z.A., M.L.), the Oral and Maxillofacial Surgery Foundation Fellowship in Clinical Investigation (S.M.S.), and the Massachusetts General Hospital Department of Oral and Maxillofacial Surgery Education and Research Fund (Z.R.A., S.M.S., M.L.) and Center for Applied Clinical Investigation (S.M.S.). NR 31 TC 47 Z9 50 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD MAR PY 2011 VL 69 IS 3 BP 677 EP 686 DI 10.1016/j.joms.2010.11.037 PG 10 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 731LW UT WOS:000288109400011 PM 21353929 ER PT J AU Leyro, TM Bernstein, A Vujanovic, AA McLeish, AC Zvolensky, MJ AF Leyro, Teresa M. Bernstein, Amit Vujanovic, Anka A. McLeish, Alison C. Zvolensky, Michael J. TI Distress Tolerance Scale: A Confirmatory Factor Analysis Among Daily Cigarette Smokers SO JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT LA English DT Article DE Distress tolerance; Distress intolerance; Emotion regulation; Cigarette smokers; Nicotine; Substance use; Confirmatory factor analysis ID OF-FIT INDEXES; NICOTINE DEPENDENCE; SMOKING-CESSATION; FAGERSTROM TEST; SAMPLE-SIZE; QUESTIONNAIRE; GOODNESS; VALIDATION; PREDICTOR; ADULT AB The present investigation evaluated the factor structure of the Distress Tolerance Scale (DTS; Simons and Gaher 2005) among a sample of 173 (54.9% males) daily cigarette smokers (M = 16.64 cigarettes per day, SD = 7.83). Comparison of a single higher-order model and a hierarchical multidimensional model was conducted using confirmatory factor analyses (CFA). In addition, evaluation of the internal consistency and convergent and discriminant validity of the better-fitting model was completed. CFA of the DTS indicated a single second-order factor of distress tolerance, and four lower-order factors including Tolerance, Appraisal, Absorption, and Regulation; each factor demonstrated acceptable levels of internal consistency. In addition, the DTS displayed good convergent and discriminant validity with theoretically relevant smoking and affect variables. Results are discussed in terms of explicating the latent structure of distress tolerance, as measured by the DTS, within the context of smoking research. C1 [Zvolensky, Michael J.] Univ Vermont, Anxiety & Hlth Res Lab, Dept Psychol, Burlington, VT 05405 USA. [Bernstein, Amit] Univ Haifa, Dept Psychol, IL-31905 Haifa, Israel. [Vujanovic, Anka A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Behav Sci Div, Boston, MA USA. [Vujanovic, Anka A.] Boston Univ, Sch Med, Div Psychiat, Boston, MA 02130 USA. [McLeish, Alison C.] Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA. RP Zvolensky, MJ (reprint author), Univ Vermont, Anxiety & Hlth Res Lab, Dept Psychol, John Dewey Hall,2 Colchester Ave, Burlington, VT 05405 USA. EM teresa.leyro@uvm.edu; abernstein@psy.haifa.ac.il; anka.vujanovic@gmail.com; alison.mcleish@uc.edu; michael.zvolensky@uvm.edu FU NIDA NIH HHS [F31 DA024919, R01 DA018734, R03 DA016307]; NIMH NIH HHS [R01 MH076629] NR 54 TC 23 Z9 24 U1 3 U2 9 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0882-2689 J9 J PSYCHOPATHOL BEHAV JI J. Psychopathol. Behav. Assess. PD MAR PY 2011 VL 33 IS 1 BP 47 EP 57 DI 10.1007/s10862-010-9197-2 PG 11 WC Psychology, Clinical SC Psychology GA 726WL UT WOS:000287757300007 PM 23935238 ER PT J AU Vujanovic, AA Bonn-Miller, MO Potter, CM Marshall, EC Zvolensky, MJ AF Vujanovic, Anka A. Bonn-Miller, Marcel O. Potter, Carrie M. Marshall, Erin C. Zvolensky, Michael J. TI An Evaluation of the Relation Between Distress Tolerance and Posttraumatic Stress within a Trauma-Exposed Sample SO JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT LA English DT Article DE Distress tolerance; Posttraumatic stress; PTSD; Emotion regulation; Trauma ID SELF-REPORT MEASURE; ANXIETY SENSITIVITY; PANIC DISORDER; DISCOMFORT INTOLERANCE; SYMPTOM SEVERITY; NEGATIVE AFFECT; VALIDATION; HYPERVENTILATION; RELEVANT; ADULTS AB The present investigation examined the incremental associations between distress tolerance, or the perceived capacity to tolerate emotional distress, and global posttraumatic stress symptom severity as well as symptom cluster severity, beyond the variance accounted for by number of trauma exposure types and negative affectivity. The sample consisted of 140 adults (72 women; M (age) = 25.9, SD = 11.1) who endorsed exposure to traumatic life events, as defined by posttraumatic stress disorder diagnostic criterion A (American Psychiatric Association 2000). Participants did not meet diagnostic criteria for current axis I psychopathology. Distress tolerance demonstrated significant incremental associations with global posttraumatic stress symptom severity (p < .01) as well as re-experiencing (p < .05), avoidance (p = .05), and hyperarousal (p < .001) symptom cluster severity. Given the cross-sectional study design, causation cannot be inferred. Theoretical implications and future directions for better understanding associations between distress tolerance and posttraumatic stress are discussed. C1 [Vujanovic, Anka A.; Potter, Carrie M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Behav Sci Div, Boston, MA 02130 USA. [Vujanovic, Anka A.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Bonn-Miller, Marcel O.] VA Palo Alto Healthcare Syst, Natl Ctr PTSD, Disseminat & Training Div, Palo Alto, CA USA. [Bonn-Miller, Marcel O.] VA Palo Alto Healthcare Syst, Ctr Hlth Care Evaluat, Palo Alto, CA USA. [Marshall, Erin C.; Zvolensky, Michael J.] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA. RP Vujanovic, AA (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, Behav Sci Div, 150 S Huntington Ave,116B-2, Boston, MA 02130 USA. EM anka.vujanovic@va.gov FU NIDA NIH HHS [R01 DA027533]; NIMH NIH HHS [F31 MH080453, F31 MH080453-01A1, R01 MH076629, R01 MH076629-01A2] NR 34 TC 38 Z9 38 U1 4 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0882-2689 J9 J PSYCHOPATHOL BEHAV JI J. Psychopathol. Behav. Assess. PD MAR PY 2011 VL 33 IS 1 BP 129 EP 135 DI 10.1007/s10862-010-9209-2 PG 7 WC Psychology, Clinical SC Psychology GA 726WL UT WOS:000287757300015 PM 22039316 ER PT J AU Marques, L Weingarden, HM LeBlanc, NJ Wilhelm, S AF Marques, Luana Weingarden, Hilary M. LeBlanc, Nicole J. Wilhelm, Sabine TI Treatment utilization and barriers to treatment engagement among people with body dysmorphic symptoms SO JOURNAL OF PSYCHOSOMATIC RESEARCH LA English DT Article DE Body dysmorphic disorder (BDD); Barriers to treatment; Treatment utilization ID OBSESSIVE-COMPULSIVE DISORDER; MENTAL-HEALTH-CARE; QUALITY-OF-LIFE; UNITED-STATES; HELP-SEEKING; POPULATION; PREVALENCE; SATISFACTION; INDIVIDUALS; RELIABILITY AB Objectives: Body dysmorphic disorder (BDD) is characterized by an excessive preoccupation with an imagined or minor appearance flaw. Many aspects of BDD remain unknown, such as rates of treatment utilization, types of treatment sought, and barriers to treatment. The present study sought to examine rates and patterns of treatment utilization as well as barriers to treatment among individuals with body dysmorphic symptoms. Methods: The present study consists of 401 individuals with symptoms consistent with a diagnosis of BDD who completed self-reported measures of treatment utilization and barriers to treatment in an internet survey. Results: Consistent with past research, results showed that individuals with probable BDD reported seeking non-mental health treatments for BDD (e.g., plastic surgery). Additionally, an examination of treatment barriers demonstrated significant barriers for the sample for the three domains examined: logistic and financial; stigma, shame, and discrimination; and treatment skepticism. Secondary analyses revealed a differential endorsement of treatment barriers across ethnic groups for all three barrier domains. Conclusion: These data suggest that BDD is still an underrecognized disorder with marked barriers to treatment. Increased education and dissemination efforts are warranted. (C) 2011 Elsevier Inc. All rights reserved. C1 [Marques, Luana; Weingarden, Hilary M.; LeBlanc, Nicole J.; Wilhelm, Sabine] Harvard Univ, Dept Psychiat, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Weingarden, Hilary M.; LeBlanc, Nicole J.] Tufts Univ, Medford, MA 02155 USA. RP Marques, L (reprint author), Harvard Univ, Dept Psychiat, Massachusetts Gen Hosp, Sch Med, 1 Bowdoin St, Boston, MA 02114 USA. EM lmarques@partners.org FU NIMH; Tourette Syndrome Association; Obsessive Compulsive Foundation; FDA; Forest Laboratories FX Disclosures: Luana Marques, Ph.D.: past 3 years: NIMH (salary and research funding). Hilary Weingarden: no disclosures. Nicole LeBlanc: no disclosures. Sabine Wilhelm, Ph.D.: past 3 years: NIMH (salary and research funding), Tourette Syndrome Association (salary and research funding), Obsessive Compulsive Foundation (salary and research funding), FDA (salary and research funding), Forest Laboratories (medication for NIMH-funded study), New Harbinger Publications (book royalties), Oxford University Press (book royalties), Guilford Press (potential future book royalties), speaking honoraria from various academic institutions. NR 41 TC 15 Z9 15 U1 0 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3999 J9 J PSYCHOSOM RES JI J. Psychosomat. Res. PD MAR PY 2011 VL 70 IS 3 BP 286 EP 293 DI 10.1016/j.jpsychores.2010.10.002 PG 8 WC Psychiatry SC Psychiatry GA 730PS UT WOS:000288047100011 PM 21334500 ER PT J AU Chong, PY Srikumaran, U Kuye, IO Warner, JJP AF Chong, Paul Y. Srikumaran, Umasuthan Kuye, Ifedayo O. Warner, Jon J. P. TI Glenohumeral arthritis in the young patient SO JOURNAL OF SHOULDER AND ELBOW SURGERY LA English DT Article ID TOTAL SHOULDER ARTHROPLASTY; ARTHROSCOPIC CAPSULAR RELEASE; LOCKED POSTERIOR DISLOCATION; ARTICULAR-CARTILAGE DEFECTS; PUTTI-PLATT REPAIR; TERM-FOLLOW-UP; HUMERAL HEAD; RECURRENT DISLOCATION; ANTERIOR INSTABILITY; LATARJET PROCEDURE C1 [Warner, Jon J. P.] Massachusetts Gen Hosp, Harvard Shoulder Serv, Yawkey Ctr Outpatient Care, Boston, MA 02114 USA. RP Warner, JJP (reprint author), Massachusetts Gen Hosp, Harvard Shoulder Serv, Yawkey Ctr Outpatient Care, 55 Fruit St,Ste 3200,3G,Rm 3-046, Boston, MA 02114 USA. EM jwarner@partners.org NR 97 TC 4 Z9 5 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1058-2746 J9 J SHOULDER ELB SURG JI J. Shoulder Elbow Surg. PD MAR PY 2011 VL 20 IS 2 SU S SI SI BP S30 EP S40 DI 10.1016/j.jse.2010.11.014 PG 11 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA 730VA UT WOS:000288061700006 PM 21281920 ER PT J AU Ring, D AF Ring, David TI Radial head fracture: open reduction-internal fixation or prosthetic replacement SO JOURNAL OF SHOULDER AND ELBOW SURGERY LA English DT Article ID SILICONE-RUBBER REPLACEMENT; ELBOW FOLLOWING EXCISION; MASON TYPE-II; COMMINUTED FRACTURES; DISLOCATION; ARTHROPLASTY; INSTABILITY; STABILITY; ADULTS; EXPERIENCE C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Yawkey 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org NR 67 TC 14 Z9 14 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1058-2746 J9 J SHOULDER ELB SURG JI J. Shoulder Elbow Surg. PD MAR PY 2011 VL 20 IS 2 SU S SI SI BP S107 EP S112 DI 10.1016/j.jse.2010.11.011 PG 6 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA 730VA UT WOS:000288061700014 PM 21281915 ER PT J AU Raval, MV Bentrem, DJ Eskandari, MK Ingraham, AM Hall, BL Randolph, B Ko, CY Morton, JM AF Raval, Mehul V. Bentrem, David J. Eskandari, Mark K. Ingraham, Angela M. Hall, Bruce L. Randolph, Barbara Ko, Clifford Y. Morton, John M. TI The Role of Surgical Champions in the American College of Surgeons National Surgical Quality Improvement Program - A National Survey SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE ACS NSQIP; surgeon champion; survey; quality improvement; surgery ID OF-VETERANS-AFFAIRS; RISK ADJUSTMENT; PRIVATE-SECTOR; NSQIP; CARE; HOSPITALS AB Background. The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) empowers surgeons and medical centers to reliably collect, analyze, and act on clinically collected outcomes data. How individual ACS NSQIP leaders designated as Surgeon Champions (SC) utilize the ACS NSQIP at the hospital level and the obstacles they encounter are not well studied. Materials and Methods. All SC representing the 236 hospitals participating in the ACS NSIQP were invited to complete a survey designed to assess the role of the SC, data use, continuous quality improvement (CQI) efforts, CQI culture, and financial implications. Results. We received responses from 109 (46.2%) SC. The majority (72.5%) of SC were not compensated for their CQI efforts. Factors associated with demonstrable CQI efforts included longer duration of participation in the program, frequent meetings with clinical reviewers, frequent presentation of data to administration, compensation for Surgical Champion efforts and providing individual surgeons with feedback (all P < 0.05). Almost all SC stated ACS NSQIP data improved the quality of care that patients received at the hospital level (92.4%) and that the ACS NSQIP provided data that could not be obtained by other sources (95.2%). All SCs considered future funding for participation in the ACS NSQIP secure. Conclusions. Active use of ACS NSQIP data provide SC with demonstrable CQI by regularly reviewing data, having frequent interaction with clinical reviewers, and frequently sharing data with hospital administration and colleagues. SC thus play a key role in successful quality improvement at the hospital level. (C) 2011 Elsevier Inc. All rights reserved. C1 [Raval, Mehul V.; Ingraham, Angela M.; Randolph, Barbara; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, Chicago, IL 60611 USA. [Raval, Mehul V.; Bentrem, David J.; Eskandari, Mark K.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. [Bentrem, David J.] Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA. [Ingraham, Angela M.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA. [Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Barnes Jewish Hosp, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Morton, John M.] Stanford Univ, Dept Surg, Stanford, CA 94305 USA. RP Raval, MV (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM m-raval@md.northwestern.edu OI Raval, Mehul/0000-0002-1527-2661 FU John Gray Research Fellowship; Daniel F. and Ada L. Rice Foundation; Department of Veterans Affairs, Veterans Health Administration, Health Services Research, and Development Service FX MVR participates in the American College of Surgeons Clinical Scholars in Residence Program. MVR is supported by the John Gray Research Fellowship and the Daniel F. and Ada L. Rice Foundation. DJB is supported by a career development award from the Department of Veterans Affairs, Veterans Health Administration, Health Services Research, and Development Service. The authors thank all SC for participation in the survey. The authors offer recognition of all ACS NSQIP staff in conducting this study, especially Matt Fordham and Molly Clear for their leadership and coordination. MVR thanks Professors Elizabeth Hahn and Susan Yount for providing feedback on survey design and methodology. NR 21 TC 6 Z9 6 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD MAR PY 2011 VL 166 IS 1 BP E15 EP E25 DI 10.1016/j.jss.2010.10.036 PG 11 WC Surgery SC Surgery GA 732EI UT WOS:000288167300002 PM 21176914 ER PT J AU Alam, HB Hamwi, KB Duggan, M Fikry, K Lu, J Fukudome, EY Chong, W Bramos, A Kim, K Velmahos, G AF Alam, Hasan B. Hamwi, Kristopher B. Duggan, Michael Fikry, Karim Lu, Jennifer Fukudome, Eugene Y. Chong, Wei Bramos, Athanasios Kim, Kyuseok Velmahos, George TI Hemostatic and Pharmacologic Resuscitation: Results of a Long-Term Survival Study in a Swine PolyTrauma Model SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article; Proceedings Paper CT 69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma CY SEP 22-25, 2010 CL Boston, MA SP Amer Assoc Surg Trauma DE Plasma; Spray dried; Blood; Coagulopathy; Acidosis; Hypothermia; Polytrauma; Resuscitation; Hemodilution; Liver; Spleen; Injury; Valproic acid; Histones ID FLUID RESUSCITATION; HISTONE DEACETYLASE; HEMORRHAGIC-SHOCK; CARDIAC HISTONES; BLOOD-PRODUCTS; DAMAGE CONTROL; VALPROIC ACID; TRAUMA; INJURY; STRATEGIES AB Background: We have previously demonstrated that valproic acid (VPA), a histone deacetylase inhibitor, and spray-dried plasma (SDP) improve early survival after lethal hemorrhage and polytrauma, but their effect on long-term survival and organ function remains untested. Methods: Yorkshire swine (n = 27; 6-8/group) underwent a protocol simulating different phases of trauma care: (1) prehospital-rib fracture, soft-tissue injury, hemorrhage (50% blood volume), 30 minutes of shock, and infusion of 0.9% saline (3x shed blood); (2) early hospital/treatment-grade IV liver (partial amputation of the median lobe) and grade V splenic (transection of spleen into three pieces) injuries to simulate rupture of contained hematomas, followed by 30 minutes of uncontrolled hemorrhage. Animals were treated with (a) Hextend (6% hetastarch), (b) fresh whole blood (FWB), (c) SDP, and (d) VPA (300 mg/kg) plus Hextend. VPA was given during the prehospital phase, and the volumes of Hextend, FWB and SDP (reconstituted in water) matched shed blood; (3) repair/resuscitation-liver injury was controlled by suture control of the transected edge, and splenic injury was treated by partial splenectomy; 1 hour after repair of injuries, surviving animals were fully resuscitated with packed red blood cells; and (4) monitoring-survival was monitored for 7 days (primary endpoint), and blood samples were drawn serially to measure organ function. Results: Only 25% of the Hextend-treated animals survived. Addition of VPA improved survival to only 50% (p = 0.28), whereas treatment with SDP and FWB increased survival significantly to 83% and 100%, respectively (p < 0.05). Surviving animals showed no long-term organ dysfunction, postoperative hemorrhage, and delayed complications. Conclusions: In a clinically relevant lethal polytrauma model, administration of SDP significantly improves survival without any long-term organ dysfunction or complications. C1 [Alam, Hasan B.; Hamwi, Kristopher B.; Duggan, Michael; Fikry, Karim; Lu, Jennifer; Fukudome, Eugene Y.; Chong, Wei; Bramos, Athanasios; Kim, Kyuseok; Velmahos, George] Harvard Univ, Div Trauma Emergency Surg & Surg Crit Care, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Hamwi, Kristopher B.] Washington Hosp Ctr, Dept Surg, Washington, DC 20010 USA. [Kim, Kyuseok] Seoul Natl Univ, Dept Emergency Med, Bundang Hosp, Seoul, South Korea. RP Alam, HB (reprint author), Harvard Univ, Div Trauma Emergency Surg & Surg Crit Care, Massachusetts Gen Hosp, Sch Med, 165 Cambridge St,Suite 810, Boston, MA 02114 USA. EM hbalam@partners.org OI Kim, Kyuseok/0000-0002-7991-9428 NR 35 TC 29 Z9 29 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD MAR PY 2011 VL 70 IS 3 BP 636 EP 644 DI 10.1097/TA.0b013e31820d0dcc PG 9 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 732PU UT WOS:000288201200035 PM 21610354 ER PT J AU Shuja, F Finkelstein, RA Fukudome, E Duggan, M Kheirbek, T Hamwi, K Fischer, TH Fikry, K deMoya, M Velmahos, GC Alam, HB AF Shuja, Fahad Finkelstein, Robert A. Fukudome, Eugene Duggan, Michael Kheirbek, Tareq Hamwi, Kristopher Fischer, Thomas H. Fikry, Karim deMoya, Marc Velmahos, George C. Alam, Hasan B. TI Development and Testing of Low-Volume Hyperoncotic, Hyperosmotic Spray-Dried Plasma for the Treatment of Trauma-Associated Coagulopathy SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article; Proceedings Paper CT 40th Annual Meeting of the Western-Trauma-Association CY FEB 28-MAR 07, 2010 CL Telluride, CO SP Western Trauma Assoc, Novo Nordisk A/S DE Lyophilized; Freeze dried; Plasma; Spray dried; Hyperoncotic; Hyperosmotic; blood; Coagulopathy; Acidosis; Hypothermia; Multiple injuries; Resuscitation; Hemodilution; Liver injury; Femur fracture ID BLOOD-PRODUCTS; THROMBIN GENERATION; COAGULATION; MODEL; HYPOTHERMIA; ACIDOSIS; INJURY; SWINE; HYPERCOAGULABILITY; RESUSCITATION AB Background: Trauma-associated coagulopathy carries an extremely high mortality. Fresh-frozen plasma (FFP) is the mainstay of treatment; however, its availability in the battlefield is limited. We have already shown that lyophilized, freeze-dried plasma (FDP) reconstituted in its original volume can reverse trauma-associated coagulopathy. To enhance the logistical advantage (lower volume and weight), we developed and tested a hyperoncotic, hyperosmotic spray-dried plasma (SDP) product in a multiple injuries/hemorrhagic shock swine model. Methods: Plasma separated from fresh porcine blood was stored as FFP or preserved as FDP and SDP. In in vitro testing, SDP was reconstituted in distilled water that was either equal (1 x SDP) or one-third (3 x SDP) the original volume of FFP. Analysis included measurements of prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen levels, and activity of selected clotting factors. In in vivo testing, swine were subjected to multiple injuries (femur fracture and grade V liver injury) and hemorrhagic shock (60% arterial hemorrhage, with the "lethal triad" of acidosis, coagulopathy, and hypothermia) and were treated with FFP, FDP, or 3 x SDP (n = 4-5/group). Coagulation profiles (PT, PTT, and thromboelastography) were measured at baseline, post-shock, post-crystalloid, treatment (M 0), and during 4 hours of monitoring (M(1-4)). Results: In vitro testing revealed that clotting factors were preserved after spray drying. The coagulation profiles of FFP and 1 x SDP were similar, with 3 x SDP showing a prolonged PT/PTT. Multiple injuries/hemorrhagic shock produced significant coagulopathy, and 3 x SDP infusion was as effective as FFP and FDP in reversing it. Conclusion: Plasma can be spray dried and reconstituted to one-third of its original volume without compromising the coagulation properties in vivo. This shelf-stable, low-volume, hyperoncotic, hyperosmotic plasma is a logistically attractive option for the treatment of trauma-associated coagulopathy in austere environments, such as a battlefield. C1 [Alam, Hasan B.] Harvard Univ, Div Trauma Emergency Surg & Surg Crit Care, Massachusetts Gen Hosp, Med Sch,Dept Surg, Boston, MA 02114 USA. [Kheirbek, Tareq; Hamwi, Kristopher] Washington Hosp Ctr, Dept Surg, Washington, DC 20010 USA. [Fischer, Thomas H.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA. RP Alam, HB (reprint author), Harvard Univ, Div Trauma Emergency Surg & Surg Crit Care, Massachusetts Gen Hosp, Med Sch,Dept Surg, 165 Cambridge St,Suite 810, Boston, MA 02114 USA. EM hbalam@partners.org NR 40 TC 18 Z9 18 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD MAR PY 2011 VL 70 IS 3 BP 664 EP 671 DI 10.1097/TA.0b013e31820e83be PG 8 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 732PU UT WOS:000288201200039 PM 21610357 ER PT J AU Ryu, H Jeon, GS Cashman, NR Kowall, NW Lee, J AF Ryu, Hoon Jeon, Gye Sun Cashman, Neil R. Kowall, Neil W. Lee, Junghee TI Differential expression of c-Ret in motor neurons versus non-neuronal cells is linked to the pathogenesis of ALS SO LABORATORY INVESTIGATION LA English DT Article DE amyotrophic lateral sclerosis; astrocyte; c-Ret; glial cell line-derived neurotrophic factor; microglia; motor neuron ID AMYOTROPHIC-LATERAL-SCLEROSIS; CU,ZN SUPEROXIDE-DISMUTASE; SPINAL-CORD; GDNFR-ALPHA; PROLONGS SURVIVAL; EXTEND SURVIVAL; MESSENGER-RNAS; FAMILIAL ALS; RAT MODEL; MICE AB Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder characterized by selective degeneration of motor neurons throughout the central nervous systems. Non-cell autonomous damage induced by glial cells is linked to the selective susceptibility of motor neurons in ALS, but the mechanisms underlying this phenomenon are not known. We found that the expression of non-phosphorylated and phosphorylated forms (tyrosine (Tyr) residue 905, 1016, and 1062) of c-Ret, a member of the glial cell line-derived neurotrophic factor (GDNF) receptor, are altered in motor neurons of the lumbar spinal cord in ALS transgenic (G93A) mice and ALS (G93A) cell line models. Phosphorylated forms of c-Ret were colocalized with neurofilament aggregates in motor neurons of ALS mice. Consistent with the in vivo data, levels of non-phosphorylated and phosphorylated c-Ret (Tyr 905, 1016, and 1062) were decreased by oxidative stress in motor neuronal cells (NSC-34). Non-phosphorylated and phosphorylated forms of c-Ret immunoreactivity were markedly elevated in active microglia of ALS mice. Our findings suggest that constitutive oxidative stress modulates c-Ret function, thereby reducing GDNF signaling in motor neurons. Furthermore, the induction of c-Ret expression in microglia may contribute to non-cell autonomous cell death of motor neurons by available GDNF in ALS. Laboratory Investigation (2011) 91, 342-352; doi: 10.1038/labinvest.2010.203; published online 31 January 2011 C1 [Ryu, Hoon; Kowall, Neil W.; Lee, Junghee] Boston Univ, Sch Med, VA Boston Healthcare Syst, Dept Neurol & Pathol, Boston, MA 02130 USA. [Cashman, Neil R.] Univ British Columbia, Dept Med Neurol, Vancouver, BC V5Z 1M9, Canada. [Cashman, Neil R.] Univ British Columbia, Brain Res Ctr, Univ British Columbia Hosp, Vancouver, BC V5Z 1M9, Canada. [Ryu, Hoon; Jeon, Gye Sun] Seoul Natl Univ, Coll Med, Dept Biomed Sci, WCU Neurocyt Grp, Seoul, South Korea. RP Ryu, H (reprint author), Boston Univ, Sch Med, VA Boston Healthcare Syst, Dept Neurol & Pathol, Bldg 1A,Room 105, Boston, MA 02130 USA. EM hoonryu@bu.edu; junghee@bu.edu RI Kowall, Neil/G-6364-2012 OI Kowall, Neil/0000-0002-6624-0213 FU Korea Ministry of Health and Welfare; KOSEF [800-20080848]; VA; NIH FX This study was supported by Rare Disease Research Center Grant from Korea Ministry of Health and Welfare (HR) and WCU Neurocytomics Program Grant (800-20080848) (HR) through SNU from KOSEF. This study was also supported in part by a VA Merit Award and NIH Grants (JL and NK). NR 45 TC 13 Z9 13 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD MAR PY 2011 VL 91 IS 3 BP 342 EP 352 DI 10.1038/labinvest.2010.203 PG 11 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 726PC UT WOS:000287736500002 PM 21283077 ER PT J AU Ling, YB Pong, T Vassiliou, CC Huang, PL Cima, MJ AF Ling, Yibo Pong, Terrence Vassiliou, Christophoros C. Huang, Paul L. Cima, Michael J. TI Implantable magnetic relaxation sensors measure cumulative exposure to cardiac biomarkers SO NATURE BIOTECHNOLOGY LA English DT Article ID UNRECOGNIZED MYOCARDIAL-INFARCTION; MOLECULAR-INTERACTIONS; CONTRAST AGENTS; MODELS; DEVICE; ASSAYS AB Molecular biomarkers can be used as objective indicators of pathologic processes. Although their levels often change over time, their measurement is often constrained to a single time point. Cumulative biomarker exposure would provide a fundamentally different kind of measurement to what is available in the clinic. Magnetic resonance relaxometry can be used to noninvasively monitor changes in the relaxation properties of antibody-coated magnetic particles when they aggregate upon exposure to a biomarker of interest. We used implantable devices containing such sensors to continuously profile changes in three clinically relevant cardiac biomarkers at physiological levels for up to 72 h. Sensor response differed between experimental and control groups in a mouse model of myocardial infarction and correlated with infarct size. Our prototype for a biomarker monitoring device also detected doxorubicin-induced cardiotoxicity and can be adapted to detect other molecular biomarkers with a sensitivity as low as the pg/ml range. C1 [Ling, Yibo; Pong, Terrence] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Ling, Yibo; Vassiliou, Christophoros C.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA. [Ling, Yibo; Vassiliou, Christophoros C.; Cima, Michael J.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Pong, Terrence; Huang, Paul L.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Pong, Terrence] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. [Huang, Paul L.] Harvard Univ, Sch Med, Div Cardiol, Boston, MA USA. [Cima, Michael J.] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA. RP Cima, MJ (reprint author), MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. EM mjcima@mit.edu FU National Cancer Institute Centers of Cancer Nanotechnology Excellence [5 U54 CA119349-12, CA151844]; National Science Foundation Division of Materials Research [0746264]; National Defense Science and Engineering; American Heart Association FX This work was supported by National Cancer Institute Centers of Cancer Nanotechnology Excellence no. 5 U54 CA119349-12 and CA151844 grants and National Science Foundation Division of Materials Research Award no. 0746264. Y.L. was supported by a National Defense Science and Engineering Graduate fellowship. T. P. was supported by an American Heart Association fellowship. NR 25 TC 32 Z9 32 U1 1 U2 28 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1087-0156 J9 NAT BIOTECHNOL JI Nat. Biotechnol. PD MAR PY 2011 VL 29 IS 3 BP 273 EP U137 DI 10.1038/nbt.1780 PG 6 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA 732RL UT WOS:000288206700023 PM 21317907 ER PT J AU Polyak, K Garber, J AF Polyak, Kornelia Garber, Judy TI Targeting the missing links for cancer therapy SO NATURE MEDICINE LA English DT Editorial Material ID POLY(ADP-RIBOSE) POLYMERASE; RESISTANCE; MUTATION; PARP-1; TUMORS C1 [Polyak, Kornelia; Garber, Judy] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Polyak, Kornelia; Garber, Judy] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Polyak, Kornelia; Garber, Judy] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Polyak, K (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. EM kornelia_polyak@dfci.harvard.edu NR 13 TC 22 Z9 22 U1 1 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD MAR PY 2011 VL 17 IS 3 BP 283 EP 284 DI 10.1038/nm0311-283 PG 2 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 730XF UT WOS:000288070000033 PM 21383736 ER PT J AU Wu, H Pomeroy, SL Ferreira, M Teider, N Mariani, J Nakayama, KI Hatakeyama, S Tron, VA Saltibus, LF Spyracopoulos, L Leng, RP AF Wu, Hong Pomeroy, Scott L. Ferreira, Manuel Teider, Natalia Mariani, Juliana Nakayama, Keiichi I. Hatakeyama, Shigetsugu Tron, Victor A. Saltibus, Linda F. Spyracopoulos, Leo Leng, Roger P. TI UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53 SO NATURE MEDICINE LA English DT Article ID EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; NEGATIVE REGULATOR; CELL-CYCLE; UBIQUITIN; LIGASE; MDM2; MEDULLOBLASTOMA; MUTATIONS; GENE AB The TP53 gene (encoding the p53 tumor suppressor) is rarely mutated, although frequently inactivated, in medulloblastoma and ependymoma. Recent work in mouse models showed that the loss of p53 accelerated the development of medulloblastoma. The mechanism underlying p53 inactivation in human brain tumors is not completely understood. We show that ubiquitination factor E4B (UBE4B), an E3 and E4 ubiquitin ligase, physically interacts with p53 and Hdm2 (also known as Mdm2 in mice). UBE4B promotes p53 polyubiquitination and degradation and inhibits p53-dependent transactivation and apoptosis. Notably, silencing UBE4B expression impairs xenotransplanted tumor growth in a p53-dependent manner and overexpression of UBE4B correlates with decreased expression of p53 in these tumors. We also show that UBE4B overexpression is often associated with amplification of its gene in human brain tumors. Our data indicate that amplification and overexpression of UBE4B represent previously undescribed molecular mechanisms of inactivation of p53 in brain tumors. C1 [Wu, Hong; Leng, Roger P.] Univ Alberta, Heritage Med Res Ctr, Dept Lab Med & Pathol, Edmonton, AB, Canada. [Pomeroy, Scott L.; Teider, Natalia; Mariani, Juliana] Harvard Univ, Sch Med, Dept Neurol, Childrens Hosp Boston, Boston, MA 02115 USA. [Ferreira, Manuel] Harvard Univ, Dept Neurosurg, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Nakayama, Keiichi I.] Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 812, Japan. [Hatakeyama, Shigetsugu] Hokkaido Univ, Dept Mol Biochem, Grad Sch Med, Kita Ku, Sapporo, Hokkaido, Japan. [Tron, Victor A.] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada. [Saltibus, Linda F.; Spyracopoulos, Leo] Univ Alberta, Dept Biochem, Edmonton, AB, Canada. RP Leng, RP (reprint author), Univ Alberta, Heritage Med Res Ctr, Dept Lab Med & Pathol, Edmonton, AB, Canada. EM rleng@ualberta.ca RI Hatakeyama, Shigetsugu/C-8333-2012 OI Hatakeyama, Shigetsugu/0000-0002-2150-9979 FU Alberta Heritage Foundation for Medical Research; Canadian Institutes of Health Research; US National Institutes of Health FX We gratefully acknowledge W. Gu (Columbia University) for the His-ubiquitin (wild-type) and His-Ub-ko plasmids, A.G. Jochemsen (Erasmus University Medical Center) for the Myc-Mdm2 plasmid, C. Blattner (Universitat Heidelberg) for pSuper.neo.gpf-Mdm2 siRNA plasmid, J.A. Mahoney (Johns Hopkins University) for pEF-DEST51-Flag-UBE4B plasmid, B. Vogelstein (Johns Hopkins University) for HCT116 TP53-/- cells, S. Benchimol (York University) for BJT and BJT/DD cell lines and G. Lozano (University of Texas, M. D. Anderson Cancer Center) for Mdm2-/- Trp53-/- MEFs as described in the text. We thank T. Turner for technical help in making the figures. This work was supported by grants from the Alberta Heritage Foundation for Medical Research and Canadian Institutes of Health Research (to R.P.L.) and from the US National Institutes of Health (to S.L.P.). R.P.L. is an Alberta Heritage Foundation for Medical Research scholar. NR 42 TC 38 Z9 41 U1 2 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD MAR PY 2011 VL 17 IS 3 BP 347 EP U150 DI 10.1038/nm.2283 PG 10 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 730XF UT WOS:000288070000046 PM 21317885 ER PT J AU Kurtz, MP Eisner, BH AF Kurtz, Michael P. Eisner, Brian H. TI Dietary therapy for patients with hypocitraturic nephrolithiasis SO NATURE REVIEWS UROLOGY LA English DT Review ID KIDNEY-STONE FORMATION; POTASSIUM CITRATE; CALCIUM-OXALATE; RISK-FACTORS; JUICE CONSUMPTION; URINARY LITHOGENICITY; MEDICAL-MANAGEMENT; CRANBERRY JUICE; ANIMAL PROTEIN; ORANGE JUICE AB Citrate is an inhibitor of urinary stone formation. Clinical and in vitro data suggest that increasing urine citrate levels will decrease the precipitation of calcium stones. Historically, low urinary citrate has been treated with oral potassium citrate or sodium citrate supplementation, but recent studies have shown the potential of dietary interventions to raise urine citrate levels. Dietary therapy with commercial or homemade beverages is attractive to patients who would prefer nonpharmacological intervention. To date, several drinks have shown promise but no single beverage has been found to consistently raise urine citrate levels in a reproducible fashion. Further research is necessary to develop the ideal dietary therapy for hypocitraturic calcium nephrolithiasis. C1 [Kurtz, Michael P.; Eisner, Brian H.] Harvard Univ, Dept Urol, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Eisner, BH (reprint author), Harvard Univ, Dept Urol, Massachusetts Gen Hosp, Sch Med, GRB 1102,55 Fruit St, Boston, MA 02114 USA. EM beisner@partners.org NR 42 TC 8 Z9 8 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4812 J9 NAT REV UROL JI Nat. Rev. Urol. PD MAR PY 2011 VL 8 IS 3 BP 146 EP 152 DI 10.1038/nrurol.2011.9 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 733CQ UT WOS:000288238400007 PM 21321574 ER PT J AU Ostrem, JL Racine, CA Glass, GA Grace, JK Volz, MM Heath, SL Starr, PA AF Ostrem, J. L. Racine, C. A. Glass, G. A. Grace, J. K. Volz, M. M. Heath, S. L. Starr, P. A. TI Subthalamic nucleus deep brain stimulation in primary cervical dystonia SO NEUROLOGY LA English DT Article ID PRIMARY GENERALIZED DYSTONIA; GLOBUS-PALLIDUS INTERNUS; PARKINSONS-DISEASE; NEURONAL-ACTIVITY; BASAL GANGLIA; PATTERNS AB Objectives: The globus pallidus internus (GPi) has been the primary target for deep brain stimulation (DBS) to treat severe medication-refractory dystonia. Some patients with primary cervical or segmental dystonia develop subtle bradykinesia occurring in previously nondystonic body regions during GPi DBS. Subthalamic nucleus (STN) DBS may provide an alternative target choice for treating dystonia, but has only been described in a few short reports, without blinded rating scales, statistical analysis, or detailed neuropsychological studies. Methods: In this prospective pilot study, we analyzed the effect of bilateral STN DBS on safety, efficacy, quality of life, and neuropsychological functioning in 9 patients with medically refractory primary cervical dystonia. Severity of dystonia was scored by a blinded rater (unaware of the patient's preoperative or postoperative status) using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) preoperatively and 3, 6, and 12 months postsurgery. Lead location, medications, and adverse events were also measured. Results: STN DBS was well-tolerated with no serious adverse effects. The TWSTRS total score improved (p < 0.001) from a mean (+/- SEM) of 53.1 (+/- 2.57), to 19.6 (+/- 5.48) at 12 months. Quality of life measures were also improved. STN DBS induced no consistent neuropsychological deficits. Several patients reported depression in the study and 3 had marked weight gain. No patients developed bradykinetic side effects from stimulation, but all patients developed transient dyskinetic movements during stimulation. Conclusions: This prospective study showed that bilateral STN DBS resulted in improvement in dystonia and suggests that STN DBS may be an alternative to GPi DBS for treating primary cervical dystonia. Classification of evidence: This study provides Class III evidence that bilateral subthalamic nucleus deep brain stimulation results in significant improvement in cervical dystonia without bradykinetic side effects. Neurology (R) 2011;76:870-878 C1 [Ostrem, J. L.; Glass, G. A.; Grace, J. K.; Volz, M. M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94115 USA. [Racine, C. A.; Starr, P. A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94115 USA. [Ostrem, J. L.; Glass, G. A.; Heath, S. L.; Starr, P. A.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA. RP Ostrem, JL (reprint author), Univ Calif San Francisco, Dept Neurol, 1635 Divisadero St,5th Floor,Suites 520-530, San Francisco, CA 94115 USA. EM jill.ostrem@ucsf.edu FU Benign Essential Blepharospasm Research Foundation; Ceregene, St. Jude Medical, Inc.; SurgiVision, Inc.; Allergan, Inc.; NIH; Novartis; UC Discovery Grant Award; UCSF; Anonymous Foundation; Medtronic, Inc.; Dystonia Medical Research Foundation FX Supported by the Benign Essential Blepharospasm Research Foundation and by private donors Larry and Kana Miao.Dr. Ostrem serves on the speakers' bureau for and has received funding for travel and speaker honoraria from Allergan, Inc.; serves as a consultant for Boston Scientific; performs clinical examinations (80% effort) for the UCSF Surgical Movement Disorders Center; and receives research support from Ceregene, St. Jude Medical, Inc., SurgiVision, Inc., Allergan, Inc., the NIH, UC Discovery Grant, and the Benign Essential Blepharospasm Research Foundation. Dr. Racine has served as a consultant for Novartis and has received/receives research support from Novartis, UC Discovery Grant Award, UCSF Brain Tumor SPORE Developmental Award, private donors, and the Anonymous Foundation. Dr. Glass serves on the speakers' bureau for and has received funding for travel and speaker honoraria from Allergan, Inc. J.K. Grace reports no disclosures. M.M. Volz serves as a consultant and on the speakers' bureau for and has received funding for travel and speaker honoraria from Medtronic, Inc.; employs SurgiVision imaging technology (25% effort) in the UCSF Surgical Movement Disorders Practice; and receives research support from SurgiVision, Inc. and the Benign Essential Blepharospasm Research Foundation. S.L. Heath serves as a consultant and on the speakers' bureau for and has received funding for travel and speaker honoraria from Medtronic, Inc. Dr. Starr serves on a scientific advisory board for Protein Therapeutics, Inc.; serves on the editorial board of Stereotactic and Functional Neurosurgery; serves as a consultant for Boston Scientific; and receives research support from SurgiVision, Inc. the NIH, and the Dystonia Medical Research Foundation. NR 30 TC 75 Z9 77 U1 2 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAR PY 2011 VL 76 IS 10 BP 870 EP 878 DI 10.1212/WNL.0b013e31820f2e4f PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 731NZ UT WOS:000288117500008 PM 21383323 ER PT J AU Batchelor, TT Grossman, SA Mikkelsen, T Ye, X Desideri, S Lesser, GJ AF Batchelor, T. T. Grossman, S. A. Mikkelsen, T. Ye, X. Desideri, S. Lesser, G. J. TI RITUXIMAB MONOTHERAPY FOR PATIENTS WITH RECURRENT PRIMARY CNS LYMPHOMA SO NEUROLOGY LA English DT Editorial Material C1 [Batchelor, T. T.] Massachusetts Gen Hosp, Ctr Canc, Stephen E & Catherine Pappas Ctr Neurooncol, Dept Neurol, Boston, MA 02114 USA. [Batchelor, T. T.] Massachusetts Gen Hosp, Dept Radiat Oncol, Div Hematol & Oncol, Boston, MA 02114 USA. [Grossman, S. A.; Ye, X.; Desideri, S.] Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD 21287 USA. [Mikkelsen, T.] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA. [Lesser, G. J.] Wake Forest Univ, Med Ctr, Dept Med, Winston Salem, NC 27103 USA. RP Batchelor, TT (reprint author), Massachusetts Gen Hosp, Ctr Canc, Stephen E & Catherine Pappas Ctr Neurooncol, Dept Neurol, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA. EM tbatchelor@partners.org FU NCI NIH HHS [U01 CA62475] NR 6 TC 55 Z9 55 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAR PY 2011 VL 76 IS 10 BP 929 EP 930 DI 10.1212/WNL.0b013e31820f2d94 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 731NZ UT WOS:000288117500017 PM 21383331 ER PT J AU Murphy, S Cserti-Gazdewich, C Dhabangi, A Musoke, C Nabukeera-Barungi, N Price, D King, ME Romero, J Noviski, N Dzik, W AF Murphy, Sarah Cserti-Gazdewich, Christine Dhabangi, Aggrey Musoke, Charles Nabukeera-Barungi, Nicolette Price, Daniel King, Mary Etta Romero, Javier Noviski, Natan Dzik, Walter TI Ultrasound findings in Plasmodium falciparum malaria: A pilot study SO PEDIATRIC CRITICAL CARE MEDICINE LA English DT Article DE malaria; pediatrics; ultrasound; optic nerve sheath diameter ID SICKLE-CELL-DISEASE; HUMAN CEREBRAL MALARIA; NERVE SHEATH DIAMETER; INTRACRANIAL-PRESSURE; PULMONARY-HYPERTENSION; TRANSCRANIAL DOPPLER; AFRICAN CHILDREN; BLOOD-FLOW; HEMODYNAMICS; TRANSFUSION AB Objective: To investigate whether hand-carried ultrasound technology may be valuable in the assessment of children with acute malaria. Every year, approximately 800,000 children under the age of 5 yrs die of complications of Plasmodium falciparum malaria infection. The advent of hand-carried ultrasound technology has made diagnostic ultrasonography possible in underresourced settings. Design: We performed a pilot observational study collecting clinical data and performing ultrasound examinations on children diagnosed with P. falciparum malaria infection. The targeted ultrasound examination included measurement of optic nerve sheath diameter, color transcranial Doppler insonation of the cerebral vasculature, cardiac ultrasound, and abdominal ultrasound. Setting: Pediatric acute care unit of Mulago Hospital in Kampala, Uganda. Patients: Thirty-three hospitalized children between the ages of 6 months and 12 yrs with documented acute P. falciparum infection. Intervention: Targeted bedside ultrasound examination. Measurements and Main Results: Increased optic nerve sheath diameter was observed in one third of all patients with malaria and in 100% of the patients diagnosed with cerebral malaria. Although higher-than-normal cerebral blood flow velocities were demonstrated in three (25%) of 12 patients with severe anemia, most patients demonstrated a normal cerebral blood flow velocity, suggesting a blunted response to anemia. We did not find evidence of pulmonary hypertension by cardiac ultrasound, and cardiac function did not seem depressed, even among patients with severe anemia and lactic acidosis. Finally, spleen size as determined by palpation significantly overestimated the true incidence of splenomegaly as measured by ultrasound (48% and 24%, respectively). Conclusions: A targeted ultrasound examination focusing on optic nerve sheath diameter, color transcranial Doppler, cardiac ultrasound, and spleen size may prove useful for patient classification, risk stratification, research studies, and treatment monitoring in pediatric malaria. More studies should be done. (Pediatr Crit Care Med 2011; 12:e58-e63) C1 [Murphy, Sarah; King, Mary Etta; Noviski, Natan] Harvard Univ, Sch Med, Dept Pediat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Cserti-Gazdewich, Christine] Univ Toronto, Toronto Gen Hosp, Dept Lab Hematol & Clin Hematol, Univ Hlth Network, Toronto, ON M5G 1L7, Canada. [Dhabangi, Aggrey; Musoke, Charles; Nabukeera-Barungi, Nicolette] Makerere Univ, Dept Pediat, Mulago Hosp, Kampala, Uganda. [Price, Daniel] Highland Hosp, Dept Emergency Med, Alameda Cty Med Ctr, Oakland, CA USA. [Romero, Javier] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Dzik, Walter] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Murphy, S (reprint author), Harvard Univ, Sch Med, Dept Pediat, Massachusetts Gen Hosp, Boston, MA 02115 USA. EM samurphy@partners.org FU Department of Pediatrics, Massachusetts General Hospital for Children; SonoSite, Inc.; International Society of Blood Transfusions Foundation; National Blood Foundation FX Dr. Murphy received funding for travel from the Department of Pediatrics, Massachusetts General Hospital for Children. Dr. Price previously received airfare for travel to a conference to present research and an honorarium from SonoSite, Inc. Dr. Cserti-Gazdewich received grant support from the International Society of Blood Transfusions Foundation and National Blood Foundation. The remaining authors have not disclosed any potential conflicts of interest. NR 32 TC 12 Z9 12 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1529-7535 J9 PEDIATR CRIT CARE ME JI Pediatr. Crit. Care Med. PD MAR PY 2011 VL 12 IS 2 BP E58 EP E63 DI 10.1097/PCC.0b013e3181e89992 PG 6 WC Critical Care Medicine; Pediatrics SC General & Internal Medicine; Pediatrics GA 730BY UT WOS:000288006100036 PM 20581730 ER PT J AU Goldstein, G Haas, GL AF Goldstein, Gerald Haas, Gretchen L. TI SUICIDAL BEHAVIOR IN HOMELESS VETERANS SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA. [Goldstein, Gerald; Haas, Gretchen L.] VA Pittsburgh HCS, MIRECC, Pittsburgh, PA USA. [Haas, Gretchen L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 4 EP 4 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000011 ER PT J AU Freudenreich, O Tranulis, C Goff, DC Henderson, DC AF Freudenreich, Oliver Tranulis, C. Goff, D. C. Henderson, D. C. TI HOW DOES ONE BECOME ADHERENT TO ANTIPSYCHOTIC MEDICATION? A QUALITATIVE STUDY OF THE PERSPECTIVES OF TREATMENT-EXPERIENCED SCHIZOPHRENIA PATIENTS SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Freudenreich, Oliver; Goff, D. C.; Henderson, D. C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Tranulis, C.] Univ Montreal, Montreal, PQ, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 15 EP 15 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000043 ER PT J AU Tarbox, SI Brown, LH Haas, GL AF Tarbox, Sarah I. Brown, Leslie Horton Haas, Gretchen L. TI PREMORBID ADJUSTMENT IN AFFECTIVE AND NON-AFFECTIVE PSYCHOSIS: A FIRST EPISODE STUDY SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Tarbox, Sarah I.; Brown, Leslie Horton; Haas, Gretchen L.] Univ Pittsburgh, Pittsburgh, PA USA. [Haas, Gretchen L.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 21 EP 22 PG 2 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000063 ER PT J AU Copeland, LA Zeber, JE Sako, EY Flynn, J MacCarthy, AA MacCarthy, DJ Lawrence, VA AF Copeland, Laurel A. Zeber, John E. Sako, E. Y. Flynn, J. MacCarthy, A. A. MacCarthy, D. J. Lawrence, V. A. TI EPIDEMIOLOGY OF THREE COMMON SURGERIES IN VETERANS WITH SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Copeland, Laurel A.; Zeber, John E.] Vet Affairs Scott & White, Ctr Appl Hlth Res, Temple, TX USA. [Sako, E. Y.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Sako, E. Y.; Flynn, J.] Vet Affairs, S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Flynn, J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [MacCarthy, A. A.; MacCarthy, D. J.; Lawrence, V. A.] Vet Affairs, VERDICT, San Antonio, TX USA. [Lawrence, V. A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Epidemiol, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 24 EP 24 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000068 ER PT J AU Mathis, KI Wynn, J Green, MF AF Mathis, Kristopher Ian Wynn, Jonathan Green, Michael F. TI ATTENTIONAL BLINK IN SCHIZOPHRENIA: PERFORMANCE AND ERP EVIDENCE FOR ABNORMALITY SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Mathis, Kristopher Ian; Wynn, Jonathan; Green, Michael F.] W Los Angeles VA Healthcare Ctr, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA. [Wynn, Jonathan; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 37 EP 37 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000106 ER PT J AU Perez, VB Woods, S Roach, BJ Ford, JM McGlashan, TH Srihari, VH Mathalon, DH AF Perez, Veronica B. Woods, Scott Roach, Brian J. Ford, Judith M. McGlashan, Thomas H. Srihari, Vinod H. Mathalon, Daniel H. TI GAMMA-BAND ASYNCHRONY ACROSS THE ILLNESS COURSE OF SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Perez, Veronica B.; Roach, Brian J.; Ford, Judith M.; Mathalon, Daniel H.] UCSF, San Francisco, CA USA. [Perez, Veronica B.; Roach, Brian J.; Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Woods, Scott; McGlashan, Thomas H.; Srihari, Vinod H.] Yale Univ, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 40 EP 40 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000114 ER PT J AU Wynn, J Mathis, KI Gibson, C Altshuler, L Green, MF AF Wynn, Jonathan Mathis, Kristopher Ian Gibson, C. Altshuler, L. Green, Michael F. TI EVENT-RELATED POTENTIAL FACIAL PROCESSING DEFICITS IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Wynn, Jonathan; Mathis, Kristopher Ian; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, MIRECC, Los Angeles, CA USA. [Wynn, Jonathan; Gibson, C.; Altshuler, L.; Green, Michael F.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 43 EP 43 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000122 ER PT J AU Bergen, SE Wilkins, JM Ferreira, MA Moran, J Chambert, K Ruderfer, DM Lee, PH Purcell, SM Sklar, P AF Bergen, Sarah E. Wilkins, James M. Ferreira, Manuel A. Moran, Jennifer Chambert, Kimberley Ruderfer, Douglas M. Lee, Phil H. Purcell, Shaun M. Sklar, Pamela CA Int Schizophrenia Consortium TI LARGE-SCALE SEQUENCING OF DISC1 IN SCHIZOPHRENIA AND BIPOLAR DISEASE YIELDS NOVEL VARIANTS SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Bergen, Sarah E.; Ruderfer, Douglas M.; Lee, Phil H.; Purcell, Shaun M.; Sklar, Pamela] Mass Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA USA. [Bergen, Sarah E.; Moran, Jennifer; Chambert, Kimberley; Ruderfer, Douglas M.; Lee, Phil H.; Purcell, Shaun M.; Sklar, Pamela] Broad Inst, Stanley Ctr Psychiat Res, Cambridge, MA USA. [Ferreira, Manuel A.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia. RI Bergen, Sarah/I-8313-2012; Ruderfer, Douglas/M-5795-2016 OI Ruderfer, Douglas/0000-0002-2365-386X NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 69 EP 69 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000198 ER PT J AU Roussos, P Katsel, P Siever, LJ Haroutunian, V AF Roussos, Panos Katsel, Pavel Siever, Larry J. Haroutunian, Vahram TI THE NF-KAPPA B PATHWAY IN SCHIZOPHRENIA POSTMORTEM BRAIN TISSUE SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Roussos, Panos; Katsel, Pavel; Siever, Larry J.; Haroutunian, Vahram] Mt Sinai Sch Med, New York, NY USA. [Roussos, Panos; Siever, Larry J.; Haroutunian, Vahram] James J Peters VA Med Ctr, Bronx, NY USA. RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 75 EP 76 PG 2 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000219 ER PT J AU Roussos, P Katsel, P Siever, LJ Davis, KL Haroutunian, V AF Roussos, Panos Katsel, P. Siever, Larry J. Davis, K. L. Haroutunian, Vahram TI THE NODE OF RANVIER IN SCHIZOPHRENIA POSTMORTEM BRAIN TISSUE SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Roussos, Panos; Katsel, P.; Siever, Larry J.; Davis, K. L.; Haroutunian, Vahram] Mt Sinai Sch Med, New York, NY USA. [Roussos, Panos; Siever, Larry J.; Haroutunian, Vahram] James J Peters VA Med Ctr, Bronx, NY USA. RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 76 EP 76 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000220 ER PT J AU Siever, LJ Roussos, P Buxbaum, J Greenwood, T Giakoumaki, S Bitsios, P Braff, DL Hardiman, G AF Siever, Larry J. Roussos, Panos Buxbaum, J. Greenwood, T. Giakoumaki, S. Bitsios, P. Braff, David L. Hardiman, G. TI CANDIDATE GENE AND CNV GENOTYPE/PHENOTYPE ASSOCIATIONS IN THE SCHIZOPHRENIA SPECTRUM SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Siever, Larry J.; Roussos, Panos; Buxbaum, J.] Mt Sinai Sch Med, New York, NY USA. [Siever, Larry J.] James J Peters VA Med Ctr, VISN MIRECC 3, Bronx, NY USA. [Roussos, Panos; Giakoumaki, S.; Bitsios, P.] Univ Crete, Iraklion, Greece. [Greenwood, T.; Braff, David L.; Hardiman, G.] Univ Calif San Diego, San Diego, CA 92103 USA. RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 90 EP 91 PG 2 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000263 ER PT J AU Siever, LJ Roussos, P Greenwood, T Braff, DL Weinstein, S Hardiman, G AF Siever, Larry J. Roussos, Panos Greenwood, T. Braff, David L. Weinstein, S. Hardiman, G. TI GENETIC ASSOCIATION AND PATHWAY ANALYSIS OF 94 CANDIDATE GENES IN SCHIZOTYPAL PERSONALITY DISORDER SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Siever, Larry J.; Roussos, Panos] Mt Sinai Sch Med, New York, NY USA. [Siever, Larry J.; Weinstein, S.] James J Peters VA Med Ctr, VISN MIRECC 3, Bronx, NY USA. [Roussos, Panos] James J Peters VA Med Ctr, Psychiat Serv, Bronx, NY USA. [Greenwood, T.; Braff, David L.; Hardiman, G.] Univ Calif San Diego, San Diego, CA 92103 USA. RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 90 EP 90 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000262 ER PT J AU Woo, TUW Petryshen, T AF Woo, Tsung-Ung Wilson Petryshen, Tracey TI CIDAR RESEARCH CORES: GENETIC AND NEUROBIOLOGICAL INVESTIGATION OF SCHIZOPHRENIA PROGRESSION BIOMARKERS SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Woo, Tsung-Ung Wilson] McLean Hosp, Lab Cellular Neuropathol, Belmont, MA 02178 USA. [Woo, Tsung-Ung Wilson; Petryshen, Tracey] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Petryshen, Tracey] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 95 EP 95 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000275 ER PT J AU Castillo, DA Lopez, LA Manaugh, B Milam, AC Boone, H Dassori, AM Velligan, DI Li, X Scott, L Miller, AL AF Castillo, Desiree A. Lopez, L. A. Manaugh, B. Milam, A. C. Boone, H. Dassori, A. M. Velligan, D. I. Li, X. Scott, L. Miller, A. L. TI CONCORDANCE BETWEEN PHYSICIANS' AND PATIENTS' RATINGS OF COGNITIVE IMPAIRMENTS AND FUNCTIONING ASSOCIATED WITH SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Castillo, Desiree A.; Dassori, A. M.; Velligan, D. I.; Li, X.; Miller, A. L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lopez, L. A.; Manaugh, B.; Milam, A. C.; Boone, H.; Scott, L.] Ctr Hlth Care Serv, San Antonio, TX USA. [Dassori, A. M.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 96 EP 97 PG 2 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000279 ER PT J AU Yao, JK Reddy, R Dougherty, G Magan, S Gurklis, J Sonel, A Sonel, E Kisslinger, B Keshavan, M Chengappa, K AF Yao, Jeffrey K. Reddy, R. Dougherty, G. Magan, S. Gurklis, J. Sonel, A. Sonel, E. Kisslinger, B. Keshavan, Matcheri Chengappa, K. TI ASSOCIATION OF HSCRP WITH HIGH-RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Yao, Jeffrey K.; Reddy, R.; Dougherty, G.; Magan, S.; Gurklis, J.; Sonel, A.; Sonel, E.; Kisslinger, B.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. [Yao, Jeffrey K.; Reddy, R.; Dougherty, G.; Gurklis, J.; Keshavan, Matcheri; Chengappa, K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Keshavan, Matcheri] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA. [Keshavan, Matcheri] Harvard Univ, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 120 EP 120 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000344 ER PT J AU Lim, KO Bustillo, JR Goff, D Schulz, SC AF Lim, Kelvin O. Bustillo, Juan Ricardo Goff, Donald Schulz, S. Charles TI RELATIONSHIP OF BRAIN METABOLITE ABNORMALITIES WITH WHITE MATTER INTEGRITY IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Lim, Kelvin O.; Schulz, S. Charles] Univ Minnesota, Minneapolis, MN 02114 USA. [Bustillo, Juan Ricardo] Univ New Mexico, Albuquerque, NM USA. [Goff, Donald] Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 126 EP 126 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000360 ER PT J AU Brent, BK Coombs, G Moran, JM Holt, DJ AF Brent, Benjamin K. Coombs, Garth Moran, Joseph M. Holt, Daphne Jane TI NEURAL CORRELATES OF DELUSION-PRONENESS DURING REFLECTION ON SELF AND OTHERS SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Brent, Benjamin K.; Holt, Daphne Jane] Harvard Univ, Sch Med, Boston, MA USA. [Brent, Benjamin K.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Coombs, Garth; Holt, Daphne Jane] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Moran, Joseph M.] Harvard Univ, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 132 EP 132 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000375 ER PT J AU Fryer, SL Woods, S Kiehl, K Calhoun, V Pearlson, GD McGlashan, TH Mathalon, DH AF Fryer, Susanna L. Woods, Scott Kiehl, K. Calhoun, Vince Pearlson, Godfrey D. McGlashan, Thomas H. Mathalon, Daniel H. TI FMRI REVEALS DECREASED PREFRONTAL CORTICAL ENGAGEMENT DURING RESPONSE INHIBITION IN YOUTH AT CLINICAL RISK FOR DEVELOPING SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Fryer, Susanna L.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Fryer, Susanna L.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Woods, Scott; Pearlson, Godfrey D.; McGlashan, Thomas H.] Yale Univ, New Haven, CT USA. [Kiehl, K.; Calhoun, Vince] Univ New Mexico, Albuquerque, NM 87131 USA. [Kiehl, K.] Mind Res Network, Albuquerque, NM USA. [Pearlson, Godfrey D.] Inst Living, Olin Neuropsychiat Res Ctr, Hartford, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 136 EP 136 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000386 ER PT J AU Goldstein, JM Abbs, B Seidman, LJ Buka, S Klibanski, A AF Goldstein, Jill M. Abbs, Brandon Seidman, Larry J. Buka, S. Klibanski, A. TI STRESS RESPONSE CIRCUITRY DEFICITS IN SCHIZOPHRENIA: IMPACT OF NEUROENDOCRINE AND SEX EFFECTS SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Goldstein, Jill M.; Abbs, Brandon; Seidman, Larry J.] Brigham & Womens Hosp, Psychiat & Div Womens Hlth, Boston, MA 02115 USA. [Goldstein, Jill M.; Abbs, Brandon; Seidman, Larry J.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Seidman, Larry J.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA. [Buka, S.] Brown Univ, Dept Community Hlth, Providence, RI 02912 USA. [Klibanski, A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Klibanski, A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RI Buka, Stephen/H-7335-2014 OI Buka, Stephen/0000-0002-8578-9308 NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 136 EP 137 PG 2 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000388 ER PT J AU Holt, DJ Liu, H Coombs, G Goff, DC Buckner, RL AF Holt, Daphne Jane Liu, H. Coombs, Garth Goff, D. C. Buckner, R. L. TI RESTING-STATE FUNCTIONAL CONNECTIVITY OF THE MEDIAL PREFRONTAL CORTEX IN SCHIZOPHRENIA AND THE DELUSION-PRONE SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Holt, Daphne Jane; Liu, H.; Coombs, Garth; Goff, D. C.; Buckner, R. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Buckner, R. L.] Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA. [Holt, Daphne Jane; Goff, D. C.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 140 EP 140 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000396 ER PT J AU Hooker, CI Bruce, L Fisher, M Verosky, SC Miyakawa, A D'Esposito, M Vinogradov, S AF Hooker, Christine I'Lee Bruce, L. Fisher, Melissa Verosky, S. C. Miyakawa, A. D'Esposito, M. Vinogradov, Sophia TI THE INFLUENCE OF COMBINED COGNITIVE AND SOCIAL-COGNITIVE TRAINING ON AMYGDALA RESPONSE DURING FACE EMOTION PROCESSING IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Hooker, Christine I'Lee; Bruce, L.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA. [Fisher, Melissa; Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Fisher, Melissa; Vinogradov, Sophia] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. [Verosky, S. C.; Miyakawa, A.; D'Esposito, M.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 140 EP 140 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000397 ER PT J AU Lahti, A Avsar, KB White, D Reid, M Bolding, M Stoeckel, L Weller, R Cox, J AF Lahti, Adrienne Avsar, K. B. White, D. Reid, M. Bolding, M. Stoeckel, L. Weller, R. Cox, J. TI AN FMRI INVESTIGATION OF PREDICTION ERROR AND TEMPORAL DISCOUNTING IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Lahti, Adrienne; Avsar, K. B.; White, D.; Reid, M.; Bolding, M.; Weller, R.; Cox, J.] Univ Alabama, Birmingham, AL USA. [Stoeckel, L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 143 EP 143 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000406 ER PT J AU Mathalon, DH Loewy, RL Ford, JM Miller, RM Shanbhag, H Vinogradov, S AF Mathalon, Daniel H. Loewy, Rachel L. Ford, Judith M. Miller, R. M. Shanbhag, H. Vinogradov, Sophia TI ABERRANT DEFAULT MODE NETWORK CONNECTIVITY DURING REST IN EARLY SCHIZOPHRENIA AND IN PATIENTS AT HIGH CLINICAL RISK FOR PSYCHOSIS SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Mathalon, Daniel H.; Loewy, Rachel L.; Ford, Judith M.; Miller, R. M.; Shanbhag, H.; Vinogradov, Sophia] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Mathalon, Daniel H.; Ford, Judith M.; Miller, R. M.; Shanbhag, H.; Vinogradov, Sophia] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 145 EP 146 PG 2 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000412 ER PT J AU Roffman, JL Nitenson, A Brohawn, DG Isom, M Friedman, JS Agam, Y Goff, DC Manoach, DS AF Roffman, Joshua L. Nitenson, A. Brohawn, D. G. Isom, M. Friedman, J. S. Agam, Y. Goff, D. C. Manoach, D. S. TI EFFECTS OF MTHFR 677C > T GENOTYPE ON DORSAL ANTERIOR CINGULATE ACTIVATION DURING RESPONSE MONITORING: A CASE-CONTROL FMRI STUDY SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Roffman, Joshua L.; Nitenson, A.; Brohawn, D. G.; Isom, M.; Friedman, J. S.; Agam, Y.; Goff, D. C.; Manoach, D. S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 151 EP 151 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000427 ER PT J AU Seidman, LJ Abbs, B Thermenos, HW Juelich, R Goldstein, JM AF Seidman, Larry J. Abbs, Brandon Thermenos, Heidi Wencel Juelich, R. Goldstein, Jill M. TI EVOLUTION OF NEURAL CIRCUITRY ALTERATIONS IN MEMORY PROCESSING IN SCHIZOPHRENIA: IMPACT OF SEX SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Seidman, Larry J.; Thermenos, Heidi Wencel] Harvard Univ, Sch Med, Dept Psychiat,Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr,Div Publ Psychiat, Boston, MA 02115 USA. [Seidman, Larry J.; Abbs, Brandon; Thermenos, Heidi Wencel; Juelich, R.; Goldstein, Jill M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02115 USA. [Abbs, Brandon; Goldstein, Jill M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Womens Hlth,Connors Ctr Womens Hlth, Boston, MA 02115 USA. [Abbs, Brandon; Goldstein, Jill M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 152 EP 152 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000430 ER PT J AU Thermenos, HW Seidman, LJ Whitfield-Gabrieli, S Juelich, R Jabbar, G Salwen, KK Shenton, M Kubicki, M Kuperberg, G Gabrieli, JD Keshavan, M Delisi, L AF Thermenos, Heidi Wencel Seidman, Larry J. Whitfield-Gabrieli, S. Juelich, R. Jabbar, G. Salwen, K. K. Shenton, Martha Kubicki, Marek Kuperberg, G. Gabrieli, J. D. Keshavan, Matcheri Delisi, L. TI ALTERED LANGUAGE NETWORK ACTIVITY AND VERBAL MEMORY DEFICITS IN YOUNG ADULT FIRST-DEGREE RELATIVES OF PERSONS WITH SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Thermenos, Heidi Wencel; Seidman, Larry J.; Keshavan, Matcheri] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Thermenos, Heidi Wencel; Seidman, Larry J.; Juelich, R.; Salwen, K. K.; Kuperberg, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Whitfield-Gabrieli, S.; Gabrieli, J. D.] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA. [Whitfield-Gabrieli, S.; Gabrieli, J. D.] MIT, Poitras Ctr Affect Disorders Res, Cambridge, MA 02139 USA. [Jabbar, G.; Shenton, Martha; Delisi, L.] Vet Affairs Boston Hlth Care Syst, Brockton, MA USA. [Shenton, Martha; Kubicki, Marek] Brigham & Womens Hosp, Boston, MA 02115 USA. [Kuperberg, G.] Tufts Univ, Medford, MA 02155 USA. [Keshavan, Matcheri] Univ Pittsburgh, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 153 EP 154 PG 2 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000434 ER PT J AU Tregellas, J Wongngamnit, N Tanabe, J Eichman, L Martin, L AF Tregellas, Jason Wongngamnit, N. Tanabe, J. Eichman, L. Martin, L. TI NICOTINE ENHANCES CEREBELLAR RESPONSE DURING FINGER TAPPING SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Tregellas, Jason; Martin, L.] Denver VA Med Ctr, Res Serv, Denver, CO USA. [Tregellas, Jason; Wongngamnit, N.; Eichman, L.; Martin, L.] Univ Colorado Denver, Dept Psychiat, Aurora, CO USA. [Tanabe, J.] Univ Colorado Denver, Dept Radiol, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 154 EP 154 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000435 ER PT J AU Abbs, B Lang, LC Makris, N Tsuang, M Seidman, L Goldstein, J AF Abbs, Brandon Lang, Lichen Makris, Nikos Tsuang, Ming Seidman, Larry Goldstein, Jill TI COVARIANCE MODELING OF MRI BRAIN VOLUMES IN MEMORY CIRCUITRY IN SCHIZOPHRENIA: IMPACT OF GENDER SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Abbs, Brandon; Tsuang, Ming; Seidman, Larry; Goldstein, Jill] Harvard Univ, Sch Med, Boston, MA USA. [Abbs, Brandon; Goldstein, Jill] Brigham & Womens Hosp, Boston, MA 02115 USA. [Lang, Lichen; Makris, Nikos] Massachusetts Gen Hosp, Athinoula Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Lang, Lichen; Makris, Nikos] MIT, Boston, MA USA. [Tsuang, Ming] Univ Calif San Diego, La Jolla, CA 92093 USA. [Seidman, Larry] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 158 EP 158 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000445 ER PT J AU Seidman, LJ Rosso, IM Whitfield-Gabrieli, S Thermenos, HW Gabrieli, J Makris, N Faraone, SV Tsuang, MT AF Seidman, Larry J. Rosso, I. M. Whitfield-Gabrieli, S. Thermenos, Heidi Wencel Gabrieli, J. Makris, N. Faraone, S. V. Tsuang, M. T. TI MEDIAL PREFRONTAL CORTEX STRUCTURE AND FUNCTION IN YOUTH AT FAMILIAL RISK FOR SCHIZOPHRENIA FROM THE HARVARD ADOLESCENT HIGH RISK STUDY SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Seidman, Larry J.; Rosso, I. M.; Thermenos, Heidi Wencel; Makris, N.; Tsuang, M. T.] Harvard Univ, Sch Med, Boston, MA USA. [Rosso, I. M.] McLean Hosp, Neuroimaging Ctr, Belmont, MA 02178 USA. [Makris, N.] Massachusetts Gen Hosp, Ctr Morphometr Anal, Charlestown, MA USA. [Seidman, Larry J.] Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Div Publ Psychiat, Boston, MA 02215 USA. [Thermenos, Heidi Wencel] Harvard Univ, Sch Med, MIT, Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Faraone, S. V.] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA. [Faraone, S. V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY USA. [Faraone, S. V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY USA. [Tsuang, M. T.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Whitfield-Gabrieli, S.; Gabrieli, J.] Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Dept Brain & Cognit Sci, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 175 EP 176 PG 2 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000497 ER PT J AU Shenton, M Schneiderman, J Pelavin, P Kubicki, M AF Shenton, Martha Schneiderman, Jason Pelavin, P. Kubicki, Marek TI CHANGES IN WHITE MATTER IN THE EARLY STAGES OF SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Shenton, Martha; Schneiderman, Jason; Pelavin, P.; Kubicki, Marek] Harvard Univ, Brigham & Womens Hosp, Sch Med, Psychiat Neuroimaging Lab, Boston, MA 02115 USA. [Shenton, Martha; Kubicki, Marek] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Neurosci Lab, Brockton, MA 02401 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 176 EP 176 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000498 ER PT J AU Siever, LJ Hazlett, E McClure, MM Koenigsberg, H Thompson, J Abi-Dargham, A AF Siever, Larry J. Hazlett, E. McClure, M. McNamara Koenigsberg, H. Thompson, J. Abi-Dargham, Anissa TI PREFRONTAL PROTECTIVE FACTORS IN SCHIZOTYPAL PERSONALITY DISORDER SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Siever, Larry J.; Hazlett, E.; McClure, M. McNamara; Koenigsberg, H.] Mt Sinai Sch Med, New York, NY USA. [Siever, Larry J.; Hazlett, E.; McClure, M. McNamara] James J Peters Med Ctr, VISN MIRECC 3, Bronx, NY USA. [Koenigsberg, H.] James J Peters Med Ctr, Psychiat Serv, Bronx, NY USA. [Thompson, J.; Abi-Dargham, Anissa] Columbia Sch Med, New York State Psychiat Inst, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 177 EP 177 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000501 ER PT J AU Turner, J King, M Belger, A Calhoun, V Ehrlich, S Csernansky, JG Potkin, SG Gollub, R Mathalon, DH Ford, JM Segall, JM Kikinis, R Macciardi, F Morgan, M Lim, KO O'Leary, DS Toga, AW van Erp, TG Wang, L Wible, CG AF Turner, Jessica King, M. Belger, A. Calhoun, Vince Ehrlich, Stefan Csernansky, J. G. Potkin, S. G. Gollub, R. Mathalon, Daniel H. Ford, Judith M. Segall, J. M. Kikinis, R. Macciardi, F. Morgan, M. Lim, Kelvin O. O'Leary, D. S. Toga, A. W. van Erp, T. G. Wang, Lei Wible, C. G. TI HERITABILITY AND GENETICS OF SOURCE BASED MORPHOMETRY IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Turner, Jessica; King, M.; Calhoun, Vince; Segall, J. M.; Morgan, M.] Mind Res Network, Albuquerque, NM USA. [Potkin, S. G.; Macciardi, F.; van Erp, T. G.] Univ Calif Irvine, Irvine, CA USA. [Ehrlich, Stefan; Gollub, R.] Harvard, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Cambridge, MA USA. [Mathalon, Daniel H.; Ford, Judith M.] Univ San Francisco, San Francisco, CA 94117 USA. [Mathalon, Daniel H.; Ford, Judith M.] Vet Affairs Healthcare Syst, San Francisco, CA USA. [Lim, Kelvin O.] Univ Minnesota, Minneapolis, MN USA. [Kikinis, R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Wible, C. G.] Brockton VAMC, Boston, MA USA. [Turner, Jessica; Calhoun, Vince] Univ New Mexico, Albuquerque, NM 87131 USA. [Toga, A. W.] Univ Calif Los Angeles, Los Angeles, CA USA. [Belger, A.] Univ N Carolina, Chapel Hill, NC USA. [O'Leary, D. S.] Univ Iowa, Iowa City, IA USA. [Csernansky, J. G.; Wang, Lei] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. RI Potkin, Steven/A-2021-2013; Macciardi, Fabio/N-3768-2014 OI Macciardi, Fabio/0000-0003-0537-4266 NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 180 EP 180 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000508 ER PT J AU Green, MF Lee, J AF Green, Michael F. Lee, Junghee TI EARLY VISUAL PERCEPTION AND SOCIAL COGNITION IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Green, Michael F.; Lee, Junghee] UCLA NPI, Los Angeles, CA USA. [Green, Michael F.; Lee, Junghee] VA Greater Angeles, MIRECC, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 208 EP 208 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000589 ER PT J AU Hall, MH Smoller, JW Lee, PH Taylor, G Coleman, MJ Salisbury, DF Levy, DL AF Hall, Mei-Hua Smoller, J. W. Lee, P. H. Taylor, G. Coleman, M. J. Salisbury, D. F. Levy, D. L. TI PATTERNS OF DEFICITS IN BRAIN FUNCTION IN BIPOLAR DISORDER AND SCHIZOPHRENIA: A CLUSTER ANALYTIC STUDY SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Hall, Mei-Hua; Coleman, M. J.; Levy, D. L.] Harvard Univ, McLean Hosp, Sch Med, Psychol Res Lab, Belmont, MA 02178 USA. [Hall, Mei-Hua; Taylor, G.; Salisbury, D. F.] Harvard Univ, McLean Hosp, Sch Med, Cognit Neurosci Lab, Belmont, MA 02178 USA. [Smoller, J. W.; Lee, P. H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Psychiat Genet Program Mood & Anxiety Disorders, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 210 EP 210 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000593 ER PT J AU Hoffman, RE Grasemann, U Gueorguieva, R Lane, DW Miikkulainen, R AF Hoffman, Ralph Edward Grasemann, U. Gueorguieva, R. Lane, D. W. Miikkulainen, R. TI USING COMPUTATIONAL PATIENTS TO EVALUATE ILLNESS MECHANISMS IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Hoffman, Ralph Edward; Gueorguieva, R.] Yale Univ, Sch Med, New Haven, CT USA. [Grasemann, U.; Miikkulainen, R.] Univ Texas Austin, Austin, TX 78712 USA. [Lane, D. W.] VA Puget Sound Healthcare Syst, Integrated Gerontol Program, Tacoma, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 211 EP 211 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000596 ER PT J AU Lee, J Harvey, PO Kern, RS Kee, K Green, MF AF Lee, Junghee Harvey, Philippe-Olivier Kern, Robert S. Kee, K. Green, Michael F. TI CONTEXTUAL MODULATION OF FACIAL AFFECT RECOGNITION IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Lee, Junghee; Harvey, Philippe-Olivier; Kern, Robert S.; Kee, K.; Green, Michael F.] Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90024 USA. [Lee, Junghee; Harvey, Philippe-Olivier; Kern, Robert S.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, MIRECC, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 215 EP 216 PG 2 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000610 ER PT J AU Bell, MD Weinstein, A AF Bell, Morris David Weinstein, A. TI COMPUTER-BASED SIMULATED JOB INTERVIEW TRAINING FOR VOCATIONAL REHABILITATION: FEASIBILITY AND TOLERABILITY SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Bell, Morris David; Weinstein, A.] Yale Univ, Sch Med, West Haven, CT 06516 USA. [Bell, Morris David] US Dept Vet Affairs, West Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 259 EP 259 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000734 ER PT J AU Caponigro, J Valenti, L Luther, J Haas, GL AF Caponigro, Janelle Valenti, L. Luther, J. Haas, Gretchen L. TI SOCIAL COGNITION IN SCHIZOPHRENIA AND BIPOLAR DISORDER: PRELIMINARY FINDINGS FROM A CROSS-DIAGNOSTIC COMPARISON STUDY SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Caponigro, Janelle] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Valenti, L.] Arcadia Univ, Glenside, PA USA. [Luther, J.; Haas, Gretchen L.] VA Pittsburgh Healthcare Syst, VISN MIRECC 4, Pittsburgh, PA USA. [Luther, J.; Haas, Gretchen L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 261 EP 261 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000740 ER PT J AU Haas, GL Brown, LH Luther, JF AF Haas, Gretchen L. Brown, Leslie Horton Luther, J. F. TI COGNITIVE FLEXIBILITY AS A PREDICTOR OF PERSPECTIVE-TAKING IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Haas, Gretchen L.; Brown, Leslie Horton; Luther, J. F.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Haas, Gretchen L.; Luther, J. F.] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 266 EP 266 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000755 ER PT J AU Byun, N Lawson, K Gore, JC Conn, PJ Jones, CK AF Byun, Nellie Lawson, K. Gore, J. C. Conn, P. J. Jones, C. K. TI ANTIPSYCHOTIC-LIKE PROFILE AND REVERSAL OF COGNITIVE IMPAIRMENT WITH THE POSITIVE ALLOSTERIC MODULATOR OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR VU0152100 SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Byun, Nellie; Gore, J. C.] Vanderbilt Univ, Inst Imaging Sci, Nashville, TN USA. [Lawson, K.; Conn, P. J.] Vanderbilt Univ, Program Drug Discovery, Nashville, TN USA. [Jones, C. K.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN USA. RI Conn, Peter/D-7848-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 286 EP 286 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000814 ER PT J AU Martin, L Guese, M Kisley, M Davalos, D AF Martin, Laura Guese, M. Kisley, M. Davalos, D. TI NICOTINE ENHANCES AUTOMATIC TEMPORAL PROCESSING AS MEASURED BY THE MISMATCH NEGATIVITY WAVEFORM IN INDIVIDUALS WITH SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Martin, Laura; Davalos, D.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Martin, Laura; Guese, M.] Univ Colorado, Denver Sch Med, Aurora, CO USA. [Kisley, M.] Univ Colorado, Colorado Springs, CO 80907 USA. [Davalos, D.] Colorado State Univ, Ft Collins, CO 80523 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 290 EP 290 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000825 ER PT J AU Buller, R Mittoux, A Green, MF Keefe, R Forray, C Schooler, N Marder, S AF Buller, Raimund Mittoux, A. Green, Michael F. Keefe, Richard Forray, C. Schooler, N. Marder, S. TI A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, FLEXIBLE-DOSE STUDY EXPLORING THE NEUROCOGNITIVE EFFECT OF SERTINDOLE VS. QUETIAPINE IN PATIENTS WITH SCHIZOPHRENIA USING THE MATRICS CONSENSUS COGNITIVE BATTERY (MCCB) SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Buller, Raimund; Mittoux, A.] Lundbeck, Issy Les Moulineaux, France. [Green, Michael F.; Marder, S.] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA. [Green, Michael F.; Marder, S.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Keefe, Richard] Duke Univ, Med Ctr, Durham, NC USA. [Forray, C.] Synapt Pharmaceut Corp, Paramus, NJ USA. [Schooler, N.] Bar Ilan Univ, Ramat Gan, Israel. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 298 EP 298 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000845 ER PT J AU Garrett, C Alexander, P Lee, A Fisher, M Loewy, RL Vinogradov, S AF Garrett, Coleman Alexander, P. Lee, A. Fisher, Melissa Loewy, Rachel L. Vinogradov, Sophia TI PREDICTORS OF ATTRITION IN NEUROPLASTICITY-BASED AUDITORY TRAINING IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Garrett, Coleman; Alexander, P.; Lee, A.; Fisher, Melissa; Loewy, Rachel L.; Vinogradov, Sophia] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Garrett, Coleman; Alexander, P.; Fisher, Melissa; Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 303 EP 303 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000860 ER PT J AU Green, MF AF Green, Michael F. TI FUNCTIONAL CAPACITY MEASURES IN CLINICAL TRIALS AND MODELS OF FUNCTIONAL OUTCOME SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Green, Michael F.] UCLA NPI, Los Angeles, CA USA. [Green, Michael F.] VA Greater Los Angeles, MIRECC, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 304 EP 304 PG 1 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000863 ER PT J AU Kasckow, J Gurklis, J Haas, G AF Kasckow, John Gurklis, J. Haas, G. TI A TELEHEALTH INTERVENTION FOR SUICIDAL PATIENTS WITH SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 13th International Congress on Schizophrenia Research (ICSR) CY APR 02-06, 2011 CL Colorado Springs, CO C1 [Kasckow, John; Gurklis, J.; Haas, G.] VA Pittsburgh Hlth Care Syst, MIRECC, Pittsburgh, PA USA. [Kasckow, John; Haas, G.] Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Pittsburgh, PA 15213 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2011 VL 37 SU 1 BP 308 EP 309 PG 2 WC Psychiatry SC Psychiatry GA 726SI UT WOS:000287746000875 ER PT J AU Kingston, RE AF Kingston, Robert E. TI THOUGHT EXPERIMENT The Mark of Faith SO SCIENTIST LA English DT Editorial Material C1 [Kingston, Robert E.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Kingston, Robert E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Kingston, RE (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SCIENTIST INC PI PHILADELPHIA PA 400 MARKET ST, STE 1250, PHILADELPHIA, PA 19106 USA SN 0890-3670 J9 SCIENTIST JI Scientist PD MAR PY 2011 VL 25 IS 3 BP 28 EP 29 PG 2 WC Information Science & Library Science; Multidisciplinary Sciences SC Information Science & Library Science; Science & Technology - Other Topics GA 727UH UT WOS:000287827700013 ER PT J AU Pandalai, PK Lauwers, GY Chung, DC Patel, D Yoon, SS AF Pandalai, Prakash K. Lauwers, Greg Y. Chung, Daniel C. Patel, Devanshi Yoon, Sam S. TI Prophylactic total gastrectomy for individuals with germline CDH1 mutation SO SURGERY LA English DT Article; Proceedings Paper CT 63rd Annual Meeting of the Society-of-Surgical-Oncology CY MAR 03-07, 2010 CL St Louis, MO SP Soc Surg Oncol ID DIFFUSE GASTRIC-CANCER; E-CADHERIN GENE; LYMPH-NODE DISSECTION; RING-CELL-CARCINOMA; BREAST-CANCER; RECONSTRUCTION; SURVEILLANCE; POPULATION; MANAGEMENT; FAMILIES AB Background. Germ line mutation of the CDH1 gene, which encodes for the E-cadherin adhesion protein, is rare but confers an estimated lifetime risk of hereditary diffuse gastric cancer of 87%. Fewer than 100 prophylactic total gastrectomies have been reported for this condition. Methods. Patients with germline CDH1 mutation who underwent multidisciplinary counseling followed by prophylactic total gastrectomy were reviewed. Results. Ten patients (6 male, 4 female) with a median age of 42 years (range, 26-51) underwent prophylactic total gastrectomy between 2006 and 2009. Of the 6 families represented, there were 4 missense, 1 frameshift, and 1 splice site mutation. Median time from genetic testing to surgery was 3 months (range, 1-7). All patients had an upper endoscopy before surgery, identifying only 1 patient with a focus of diffuse gastric cancer After prophylactic total gastrectomy, extensive pathologic analysis demonstrated that 9 patients had up to 77 foci of noninvasive cancel; anal, 2 of these patients had 4-12 foci of T1 invasive cancer Median operative time was 213 minutes; there were no. anastomotic leaks, and the length of stay was 7-8 days. One patient had a complication within 30 days (pulmonary embolism), and 3 patients had late complications (2 small bowel obstructions and 1 anastomotic stricture). Median weight loss at 6 months was 19%. Conclusion. The majority of patients with germline CDH1 mutation have foci of noninvasive or invasive gastric cancer by middle age. Serial upper endoscopies provide inadequate screening. Prophylactic total gastrectomy is the procedure of choice for definitive treatment. (Surgery 2011;149:347-55.) C1 [Pandalai, Prakash K.; Yoon, Sam S.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Lauwers, Greg Y.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Chung, Daniel C.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Patel, Devanshi] Massachusetts Gen Hosp, Ctr Canc Risk Anal, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. [Yoon, Sam S.] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA. RP Yoon, SS (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St, Boston, MA 02114 USA. EM syoon@partners.org NR 40 TC 19 Z9 20 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD MAR PY 2011 VL 149 IS 3 BP 347 EP 355 DI 10.1016/j.surg.2010.07.005 PG 9 WC Surgery SC Surgery GA 731MQ UT WOS:000288111500007 PM 20719348 ER PT J AU Klupa, T Skupien, J Cyganek, K Katra, B Sieradzki, J Malecki, MT AF Klupa, Tomasz Skupien, Jan Cyganek, Katarzyna Katra, Barbara Sieradzki, Jacek Malecki, Maciej T. TI The dual-wave bolus feature in type 1 diabetes adult users of insulin pumps SO ACTA DIABETOLOGICA LA English DT Article DE Diabetes; Insulin pump; CSII; Dual bolus; Square bolus ID INFUSION; MELLITUS; IMPACT AB One of the attributes of CSII (continuous subcutaneous insulin infusion) is its ability to tailor prandial insulin delivery to the composition of a meal and anticipated glycemic effects. The dual-wave bolus (DWB) is a tool implemented in contemporary insulin pumps that delivers a combination of an instant insulin bolus followed by a square bolus (SB) infused over several hours. We assessed the effectiveness of DWB in 56 adult patients with type 1 diabetes (T1DM) who were on continuous subcutaneous insulin infusion via insulin pump for at least 2 years. We divided patients into frequent (DWB+, n = 32) and infrequent (DWB-, n = 24) DWB users (> 20% vs. < 20% of daily bolus dose delivered as SB). CSII implementation resulted in a decrease of adjusted HbA1c level by 0.80% (95% CI 0.67-0.93, P < 0.0001) and adjusted mean glycemia by 18.4 mg/dl (95% CI 15.3-21.4, P < 0.0001) in the whole cohort within the first year of observation. It was sustained in the second year, but without further improvement. Frequent DWB use was associated with male sex (59% vs. 17%, p = 0.001) and shorter duration of T1DM (3.4 vs. 11.3 yrs, p < 0.0001), but not with patients' age (25.7 vs. 27.0 years, P = 0.6). DWB+ patients improved their HbA1c by 0.45% more (95% CI 0.20-0.71, P = 0.0009) than DWB- individuals. In conclusion, DWB might be a tool potentially helping to improve glycemic control in T1DM adult users of insulin pumps. Male patients and those with a shorter duration of diabetes seem to use it more willingly. C1 [Klupa, Tomasz; Cyganek, Katarzyna; Katra, Barbara; Sieradzki, Jacek; Malecki, Maciej T.] Jagiellonian Univ, Coll Med, Dept Metab Dis, PL-31501 Krakow, Poland. [Klupa, Tomasz; Cyganek, Katarzyna; Katra, Barbara; Sieradzki, Jacek; Malecki, Maciej T.] Univ Hosp, Krakow, Poland. [Skupien, Jan] Joslin Diabet Ctr, Sect Genet & Epidemiol, Boston, MA 02215 USA. RP Malecki, MT (reprint author), Jagiellonian Univ, Coll Med, Dept Metab Dis, 15 Kopernika St, PL-31501 Krakow, Poland. EM malecki_malecki@yahoo.com NR 8 TC 5 Z9 5 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0940-5429 J9 ACTA DIABETOL JI Acta Diabetol. PD MAR PY 2011 VL 48 IS 1 BP 11 EP 14 DI 10.1007/s00592-009-0173-9 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 730ET UT WOS:000288016800002 PM 20063022 ER PT J AU Lugli, A Clemenza, M Corso, PE di Costanzo, J Dirnhofer, R Fiorini, E Herborg, C Hindmarsh, JT Orvini, E Piazzoli, A Previtali, E Santagostino, A Sonnenberg, A Genta, RM AF Lugli, Alessandro Clemenza, Massimiliano Corso, Philip E. di Costanzo, Jacques Dirnhofer, Richard Fiorini, Ettore Herborg, Costanza Hindmarsh, John Thomas Orvini, Edoardo Piazzoli, Adalberto Previtali, Ezio Santagostino, Angela Sonnenberg, Amnon Genta, Robert M. TI The Medical Mystery of Napoleon Bonaparte An Interdisciplinary Expose SO ADVANCES IN ANATOMIC PATHOLOGY LA English DT Review DE Napoleon Bonaparte gastric cancer; arsenic poisoning; interdisciplinary taskforce ID GASTRIC-CANCER; PEPTIC-ULCER; 2 SPECIMENS; HAIR; DEATH; CARCINOMA; STOMACH; DIE AB Napoleon Bonaparte (1769 to 1821) is one of the most studied historical figures in European history. Not surprisingly, amongst the many mysteries still surrounding his person is the cause of his death, and particularly the suspicion that he was poisoned, continue to intrigue medical historians. After the defeat of the Napoleonic Army at the battle of Waterloo in 1815, Napoleon was exiled to the small island of Saint Helena in the South Atlantic, where he died 6 years later. Although his personal physician, Dr Francois Carlo Antommarchi, stated in his autopsy report that stomach cancer was the cause of death, this diagnosis was challenged in 1961 by the finding of an elevated arsenic concentration in one of Napoleon's hair samples. At that time it was suggested that Napoleon had been poisoned by one of his companions in exile who was allegedly supported by the British Government. Since then Napoleon's cause of death continues to be a topic of debate. The aim of this review is to use a multi-disciplinary approach to provide a systematic and critical assessment of Napoleon's cause of death. C1 [Dirnhofer, Richard] Univ Bern, Inst Forens Med, CH-3012 Bern, Switzerland. [Lugli, Alessandro] Univ Basel Hosp, Inst Pathol, Basel, Switzerland. [Clemenza, Massimiliano; Fiorini, Ettore; Previtali, Ezio] Univ Milano Bicocca, Dept Phys, GPS Occhialini, Milan, Italy. [Santagostino, Angela] Univ Milano Bicocca, Dept Environm Sci, Milan, Italy. [Herborg, Costanza; Orvini, Edoardo] Univ Pavia, Dept Gen Chem, I-27100 Pavia, Italy. [Piazzoli, Adalberto] Univ INFN, Dept Nucl & Theoret Phys, Pavia, Italy. [Corso, Philip E.] Yale Univ, Sch Med, Dept Plast Surg, New Haven, CT 06520 USA. [di Costanzo, Jacques] Hop Conception, Dept Digest Intens Care, Marseilles, France. [di Costanzo, Jacques] Hop Conception, Nutr Support Unit, Marseilles, France. [Hindmarsh, John Thomas] Ottawa Hosp, Div Biochem, Ottawa, ON, Canada. [Hindmarsh, John Thomas] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON K1N 6N5, Canada. [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Genta, Robert M.] Caris Life Sci, Irving, TX USA. [Genta, Robert M.] VAMC, Dept Pathol, Dallas, TX USA. [Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. RP Genta, RM (reprint author), Caris Res Inst, 6655 N MacArthur Blvd, Irving, TX 75039 USA. EM robert.genta@utsouthwestern.edu OI Clemenza, Massimiliano/0000-0002-8064-8936 NR 51 TC 4 Z9 4 U1 4 U2 34 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-4109 J9 ADV ANAT PATHOL JI Adv. Anat. Pathol. PD MAR PY 2011 VL 18 IS 2 BP 152 EP 158 DI 10.1097/PAP.0b013e31820ca329 PG 7 WC Pathology SC Pathology GA 728RD UT WOS:000287891300004 PM 21326012 ER PT J AU Rogers, IS Banerji, D Siegel, EL Truong, QA Ghoshhajra, BB Irlbeck, T Abbara, S Gupta, R Benenstein, RJ Choy, G Avery, LL Novelline, RA Bamberg, F Brady, TJ Nagurney, JT Hoffmann, U AF Rogers, Ian S. Banerji, Dahlia Siegel, Emily L. Truong, Quynh A. Ghoshhajra, Brian B. Irlbeck, Thomas Abbara, Suhny Gupta, Rajiv Benenstein, Ricardo J. Choy, Garry Avery, Laura L. Novelline, Robert A. Bamberg, Fabian Brady, Thomas J. Nagurney, John T. Hoffmann, Udo TI Usefulness of Comprehensive Cardiothoracic Computed Tomography in the Evaluation of Acute Undifferentiated Chest Discomfort in the Emergency Department (CAPTURE) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID CORONARY-ANGIOGRAPHY; PAIN; TRIAL; ACCURACY; CT AB Newer cardiac computed tomographic (CT) technology has permitted comprehensive cardiothoracic evaluations for coronary artery disease, pulmonary embolism, and aortic dissection within a single breath hold, independent of the heart rate. We conducted a randomized diagnostic trial to compare the efficiency of a comprehensive cardiothoracic CT examination in the evaluation of patients p resenting to the emergency department with undifferentiated acute chest discomfort or dyspnea. We randomized the emergency departrnent patients clinically scheduled to undergo a dedicated CT protocol to assess coronary artery disease, pulmonary embolism, or aortic dissection to either the planned dedicated CT protocol or a comprehensive cardiothoracic CT protocol. All CT examinations were performed using a 64-slice dual source CT scanner. The CT results were immediately communicated to the emergency department providers, who directed further management at their discretion. The subjects were then followed for the remainder of their hospitalization and for 30 days after hospitalization. Overall, 59 patients (mean age 51.2 +/- 11.4 years, 72.9% men) were randomized to either dedicated (n = 30) or comprehensive (n = 29) CT scanning. No significant difference was found in the median length of stay (7.6 vs 8.2 hours, p = 0.79), rate of hospital discharge without additional imaging (70% vs 69%, p = 0.99), median interval to exclusion of an acute event (5.2 vs 6.5 hours, p = 0.64), costs of care (p = 0.16), or the number of revisits (p = 0.13) between the dedicated and comprehensive arms, respectively. In addition, radiation exposure (11.3 mSv vs 12.8 mSv, p = 0.16) and the frequency of incidental findings requiring follow-up (24.1% vs 33.3%, p = 0.57) were similar between the 2 arms. Comprehensive cardiothoracic CT scanning was feasible, with a similar diagnostic yield to dedicated protocols. However, it did not reduce the length of stay, rate of subsequent testing, or costs. In conclusion, although this "triple rule out" protocol might be helpful in the evaluation of select patients, these findings suggest that it should not be used routinely with the expectation that it will improve efficiency or reduce resource use. (c) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:643-650) C1 [Rogers, Ian S.; Banerji, Dahlia; Siegel, Emily L.; Truong, Quynh A.; Ghoshhajra, Brian B.; Irlbeck, Thomas; Abbara, Suhny; Gupta, Rajiv; Benenstein, Ricardo J.; Choy, Garry; Bamberg, Fabian; Brady, Thomas J.; Hoffmann, Udo] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Div Cardiol, Boston, MA 02114 USA. [Rogers, Ian S.; Banerji, Dahlia; Siegel, Emily L.; Truong, Quynh A.; Ghoshhajra, Brian B.; Irlbeck, Thomas; Abbara, Suhny; Gupta, Rajiv; Benenstein, Ricardo J.; Choy, Garry; Bamberg, Fabian; Brady, Thomas J.; Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Avery, Laura L.; Novelline, Robert A.] Massachusetts Gen Hosp, Div Emergency Imaging, Boston, MA 02114 USA. [Nagurney, John T.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. [Rogers, Ian S.] Stanford Univ, Div Cardiovasc Med, Falk Cardiovasc Res Ctr, Stanford, CA 94305 USA. RP Hoffmann, U (reprint author), Massachusetts Gen Hosp, Cardiac MR PET CT Program, Div Cardiol, Boston, MA 02114 USA. EM uhoffmann@partners.org OI Benenstein, Ricardo/0000-0002-7599-2118 FU Bracco Diagnostics, Inc, Princeton, New Jersey; National Institutes of Health, Bethesda, Maryland [T32HL076136] FX This trial was investigator initiated and supported by an unrestricted grant from Bracco Diagnostics, Inc, Princeton, New Jersey. Drs. Rogers, Truong, and Ghoshhajra received salary support from grant T32HL076136 from the, National Institutes of Health, Bethesda, Maryland. NR 16 TC 16 Z9 16 U1 0 U2 4 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD MAR 1 PY 2011 VL 107 IS 5 BP 643 EP 650 DI 10.1016/j.amjcard.2010.10.039 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 727XS UT WOS:000287837200001 PM 21247533 ER PT J AU Spiegel, BMR Khanna, D Bolus, R Agarwal, N Khanna, P Chang, L AF Spiegel, Brennan M. R. Khanna, Dinesh Bolus, Roger Agarwal, Nikhil Khanna, Puja Chang, Lin TI Understanding Gastrointestinal Distress: A Framework for Clinical Practice SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID IRRITABLE-BOWEL-SYNDROME; QUALITY-OF-LIFE; VISCERAL SENSITIVITY INDEX; COPING STRATEGIES; ILLNESS SEVERITY; PERCEIVED STIGMA; BRAIN RESPONSES; ABDOMINAL-PAIN; VALIDATION; DISEASE AB We describe a framework to help clinicians think about health-related quality of life in their gastrointestinal (GI) patients. We introduce "GI distress" as a clinically relevant concept and explain how it may result from physical symptoms, cognitions, and emotions. The GI distress framework suggests that providers should divide GI physical symptoms into four categories: pain, gas/bloat, altered defecation, and foregut symptoms. We describe how these physical symptoms can be amplified by maladaptive cognitions, including external locus of control, catastrophizing, and anticipation anxiety. We suggest determining the level of embarrassment from GI symptoms and asking about stigmatization. GI patients may also harbor emotional distress from their illness and may exhibit visceral anxiety marked by hypervigilance, fear, and avoidance of GI sensations. Look for signs of devitalization, indicated by inappropriate fatigue. When appropriate, screen for suicidal ideations. Finally, we provide a list of high-yield questions to screen for these maladaptive cognitions and emotions, and explain how the GI distress framework can be used in clinical practice. C1 [Spiegel, Brennan M. R.; Bolus, Roger; Chang, Lin] VA Greater Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA 90073 USA. [Spiegel, Brennan M. R.; Chang, Lin] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Spiegel, Brennan M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Sci, Los Angeles, CA 90024 USA. [Spiegel, Brennan M. R.] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA USA. [Spiegel, Brennan M. R.; Chang, Lin] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Los Angeles, CA 90095 USA. [Spiegel, Brennan M. R.; Bolus, Roger; Agarwal, Nikhil; Chang, Lin] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA. [Khanna, Dinesh; Khanna, Puja] Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA. RP Spiegel, BMR (reprint author), VA Greater Angeles Healthcare Syst, Dept Gastroenterol, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ulca.edu FU National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases [U01 AR057936A]; NIH through NIH Roadmap for Medical Research [AR052177]; Takeda North America; Rose Pharmaceuticals; Prometheus Laboratories; Scleroderma Clinical Trial Consortium FX Financial support: National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases grant U01 AR057936A and the NIH through NIH Roadmap for Medical Research grant AR052177.; Potential competing interests: Drs Spiegel and Chang have served as advisors to Prometheus Laboratories and Ironwood Pharmaceuticals and have received grant support from Takeda North America, Rose Pharmaceuticals, and Prometheus Laboratories. Dr Chang has also served as a consultant to Salix, Movetis, GlaxoSmithKline, and Ocera. Dr D. Khanna has received grants from the Scleroderma Clinical Trial Consortium to develop a GI-specific instrument in scleroderma. NR 47 TC 9 Z9 9 U1 3 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAR PY 2011 VL 106 IS 3 BP 380 EP 385 DI 10.1038/ajg.2010.383 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 730VT UT WOS:000288064200001 PM 21378758 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Starting a Career in Gastroenterology and Breaking All Records SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAR PY 2011 VL 106 IS 3 BP 393 EP 394 DI 10.1038/ajg.2010.356 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 730VT UT WOS:000288064200003 PM 21378760 ER PT J AU Ioannou, GN AF Ioannou, George N. TI Hepatitis B Virus in the United States: Infection, Exposure, and Immunity Rates in a Nationally Representative Survey SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID AREA VACCINATION COVERAGE; LONG-TERM IMMUNOGENICITY; AGED 19-35 MONTHS; ADOLESCENTS; PREVENTION; DISEASES; BOOSTER; ADULTS; HEALTH; POLICY AB Background: Up-to-date estimates of the prevalence of hepatitis B virus (HBV) infection, exposure, and immunity are necessary to assess the effectiveness of ongoing programs aimed at preventing HBV transmission. Objective: To determine the prevalence and associations of chronic HBV infection, past exposure, and immunity in the United States from 1999 to 2008. Design: Nationally representative, cross-sectional household survey. Setting: U.S. civilian, noninstitutionalized population. Participants: 39 787 participants in the National Health and Nutrition Examination Survey (1999 to 2008) aged 2 years or older. Measurements: Chronic HBV infection was defined by presence of serum HBV surface antigen and past exposure by serum antibody to hepatitis B core antigen among persons aged 6 years or older. Infant immunity was defined by presence of serum antibody to hepatitis B surface antigen among children aged 2 years. Results: Among persons aged 6 years or older, 0.27% (95% CI, 0.20% to 0.34%) had chronic HBV infection (corresponding to approximately 704 000 persons nationwide), and 4.6% (CI, 4.1% to 5.0%) had been exposed to HBV (approximately 11 993 000 persons). These estimates are lower (P < 0.001) than estimates of HBV infection (0.42%) and exposure (5.1%) in the United States reported from 1988 to 1994. Infection and past exposure were very uncommon among persons aged 6 to 19 years. Children aged 2 years have high rates of immunity (68.6% [CI, 64.1% to 73.2%]). Adults, including those at high risk for infection, have much lower rates of immunity. Limitations: Incarcerated and homeless persons were not sampled. Categorization of race or ethnicity did not identify high-risk groups, such as persons of Asian and Pacific Islander descent. Conclusion: A cohort of children and adolescents is growing up in the United States with high rates of immunity against HBV and very low rates of infection. Vaccination of high-risk adults should continue to be emphasized. C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU Veterans Affairs Research Enhancement Award Program FX Grant Support: By the Veterans Affairs Research Enhancement Award Program. NR 32 TC 68 Z9 70 U1 0 U2 3 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 1 PY 2011 VL 154 IS 5 BP 319 EP 328 DI 10.7326/0003-4819-154-5-201103010-00006 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 727LA UT WOS:000287799900004 PM 21357909 ER PT J AU Tan, G Dao, TK Farmer, L Sutherland, RJ Gevirtz, R AF Tan, Gabriel Dao, Tam K. Farmer, Lorie Sutherland, Roy John Gevirtz, Richard TI Heart Rate Variability (HRV) and Posttraumatic Stress Disorder (PTSD): A Pilot Study SO APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK LA English DT Article DE Heart rate variability; Posttraumatic stress disorder ID COGNITIVE-PROCESSING THERAPY; POWER SPECTRAL-ANALYSIS; MENTAL-HEALTH PROBLEMS; PSYCHOPHYSIOLOGICAL ASSESSMENT; PROLONGED EXPOSURE; ASSAULT VICTIMS; VETERANS; METAANALYSIS; BIOFEEDBACK; WAR AB Exposure to combat experiences is associated with increased risk of developing Post Traumatic Stress Disorder. Prolonged exposure therapy and cognitive processing therapy have garnered a significant amount of empirical support for PTSD treatment; however, they are not universally effective with some patients continuing to struggle with residual PTSD symptoms. Heart rate variability (HRV) is a measure of the autonomic nervous system functioning and reflects an individual's ability to adaptively cope with stress. A pilot study was undertaken to determine if veterans with PTSD (as measured by the Clinician-Administered PTSD Scale and the PTSD Checklist) would show significantly different HRV prior to an intervention at baseline compared to controls; specifically, to determine whether the HRV among veterans with PTSD is more depressed than that among veterans without PTSD. The study also aimed at assessing the feasibility, acceptability, and potential efficacy of providing HRV biofeedback as a treatment for PTSD. The findings suggest that implementing an HRV biofeedback as a treatment for PTSD is effective, feasible, and acceptable for veterans. Veterans with combat-related PTSD displayed significantly depressed HRV as compared to subjects without PTSD. When the veterans with PTSD were randomly assigned to receive either HRV biofeedback plus treatment as usual (TAU) or just TAU, the results indicated that HRV biofeedback significantly increased the HRV while reducing symptoms of PTSD. However, the TAU had no significant effect on either HRV or symptom reduction. A larger randomized control trial to validate these findings appears warranted. C1 [Dao, Tam K.; Sutherland, Roy John] Univ Houston, Houston, TX 77004 USA. [Tan, Gabriel; Farmer, Lorie; Sutherland, Roy John] Michael E DeBakey Vet Affair Med Ctr, Houston, TX USA. [Tan, Gabriel; Dao, Tam K.; Sutherland, Roy John] Baylor Coll Med, Houston, TX 77030 USA. [Gevirtz, Richard] Alliant Int Univ, San Diego, CA USA. RP Dao, TK (reprint author), Univ Houston, 491 Farish Hall, Houston, TX 77004 USA. EM tkdao@uh.edu RI Schueter, nicos/A-3625-2014 NR 41 TC 56 Z9 58 U1 3 U2 29 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-0586 J9 APPL PSYCHOPHYS BIOF JI Appl. Psychophysiol. Biofeedback PD MAR PY 2011 VL 36 IS 1 BP 27 EP 35 DI 10.1007/s10484-010-9141-y PG 9 WC Psychology, Clinical SC Psychology GA 728BW UT WOS:000287850000003 PM 20680439 ER PT J AU Tadros, NN Garzotto, M AF Tadros, Nicholas N. Garzotto, Mark TI Androgen deprivation therapy for prostate cancer: not so simple SO ASIAN JOURNAL OF ANDROLOGY LA English DT Editorial Material ID MEN; IMPACT C1 [Tadros, Nicholas N.; Garzotto, Mark] Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97239 USA. [Garzotto, Mark] Portland VA Med Ctr, Portland, OR 97239 USA. RP Garzotto, M (reprint author), Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97239 USA. EM garzotto@ohsu.edu NR 7 TC 3 Z9 3 U1 0 U2 3 PU SHANGHAI INST MATERIA MEDICA PI SHANGHAI PA 555 ZU CHONG ZHI RD, ZHANG JIANG HI-TECH PARK, SHANGHAI, PUDONG 201203, PEOPLES R CHINA SN 1008-682X J9 ASIAN J ANDROL JI Asian J. Androl. PD MAR PY 2011 VL 13 IS 2 BP 187 EP 188 DI 10.1038/aja.2010.174 PG 2 WC Andrology; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 730YV UT WOS:000288074400006 PM 21278759 ER PT J AU Feuchtner, GM Cury, RC Jodocy, D Friedrich, GJ Blumenthal, RS Budoff, MJ Nasir, K AF Feuchtner, Gudrun M. Cury, Ricardo C. Jodocy, Daniel Friedrich, Guy J. Blumenthal, Roger S. Budoff, Matthew J. Nasir, Khurram TI Differences in coronary plaque composition by noninvasive computed tomography angiography in individuals with and without obstructive coronary artery disease SO ATHEROSCLEROSIS LA English DT Article DE Plaque composition; CTA; Significant CAD ID INTRAVASCULAR ULTRASOUND; MAGNETIC-RESONANCE; PROGNOSTIC VALUE; LESIONS; ATHEROSCLEROSIS; SIMVASTATIN; REGRESSION; ACCURACY; STENOSES; CULPRIT AB Background: Coronary CT angiography (CCTA) has emerged as a promising non-invasive tool to detect coronary artery disease (CAD) which provides additional information about atherosclerotic plaque composition. We aimed to assess whether differences in plaque composition and plaque burden exist across patients with more and < 50% coronary stenosis. Methods: 1060 patients (58 +/- 11 years, 43% females) with an intermediate risk of CAD referred for 64-slice CCTA were studied. Plaque characteristics and burden was analyzed on CCTA images on a per-segment basis (modified 16-segment AHA classification). Plaques types were classified as: calcified (type 1), mixed (predominantly calcified) (type 2), mixed (predominantly non-calcified) (type 3), and non-calcified (type 4). Plaque types in patients with more and < 50% stenosis were compared. Results: Overall 373 (35.2%) patients had normal coronaries without evidence of plaque. In the remaining 687 patients, 353 (33%) and 334 (31%) were found to have luminal narrowing of < 50% and >= 50% in atleast one coronary artery segment, respectively. Those with >= 50% stenotic CAD demonstrated were more likely to have segments with mixed plaque subtype and less likely to be exclusively non-calcified (relative distribution of 58%, 22%, 10%, 11% for type 1-4 respectively) compared to those with < 50% stenosis with (59%, 11%, 6% and 24%, respectively (p = 0.006). In multivariable adjustment models, individuals with significant CAD were 5-fold more likely to have increased burden type 1 plaque (>= 3 coronary segments) as compared to those with non-obstructive CAD (OR: 5.00, 95% CI: 1.05-23.78). The respective odds ratio (95% CI) for > 3 coronary segments of type 2, 3 and 4 were 8.73 (3.01-25.23), 4.62 (2.99-0.22-1.55), respectively. Conclusions: Plaque composition is different according to severity of CAD with a higher mixed plaque and lesser non-calcified plaque burden among those patients with >= 50% stenotic CAD. These findings should stimulate further investigations to assess the prognostic value of coronary plaque subtypes according to their underlying composition. (C) 2011 Published by Elsevier Ireland Ltd. C1 [Nasir, Khurram] Yale Univ, Sect Cardiovasc Med, New Haven, CT 06520 USA. [Feuchtner, Gudrun M.; Jodocy, Daniel; Friedrich, Guy J.] Innsbruck Med Univ, Innsbruck, Austria. [Feuchtner, Gudrun M.; Cury, Ricardo C.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Feuchtner, Gudrun M.] Univ Hosp Zuerich, Inst Diagnost Radiol, Zurich, Switzerland. [Cury, Ricardo C.] Baptist Cardiac & Vasc Inst, Miami, FL USA. [Blumenthal, Roger S.; Nasir, Khurram] Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Baltimore, MD USA. [Budoff, Matthew J.] Harbor UCLA, Div Cardiol, Torrance, CA USA. RP Nasir, K (reprint author), Yale Univ, Sect Cardiovasc Med, 333 Cedar St,POB 208017, New Haven, CT 06520 USA. EM khurram.nasir@yale.edu NR 23 TC 10 Z9 10 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD MAR PY 2011 VL 215 IS 1 BP 90 EP 95 DI 10.1016/j.atherosclerosis.2010.07.058 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 730CN UT WOS:000288008700013 PM 21227421 ER PT J AU Nabavi, V Ahmadi, N Bhatia, HS Flores, F Ebrahimi, R Karlsberg, RP Budoff, MJ AF Nabavi, Vahid Ahmadi, Naser Bhatia, Harpreet S. Flores, Ferdinand Ebrahimi, Ramin Karlsberg, Ronald P. Budoff, Matthew J. TI Increased carotid wall thickness measured by computed tomography is associated with the presence and severity of coronary artery calcium SO ATHEROSCLEROSIS LA English DT Article DE Coronary artery calcium (CAC); Carotid wall thickness (CWT); Coronary artery disease (CAD); Cerebrovascular disease (CVD); Carotid computed tomography; Metabolic syndrome (MetS); Diabetes mellitus (DM) ID INTIMA-MEDIA THICKNESS; CARDIOVASCULAR RISK-FACTORS; CT-ANGIOGRAPHY; VASCULAR FUNCTION; ATHEROSCLEROTIC DISEASE; METABOLIC SYNDROME; DIABETES-MELLITUS; HEART-DISEASE; ADVENTITIA; STENOSIS AB Background: Previous studies have shown that increase in carotid wall thickness (CWT) is associated with cardiovascular risk factors. However, simultaneous systemic and local involvement of atherosclerosis in subjects with high risk of coronary atherosclerosis is not well studied. This study investigates the relation of carotid subclinical atherosclerosis assessed by CWT with the presence and severity of coronary artery calcium(CAC). Methods: One hundred and twenty nine subjects (age of 69 +/- 10 years, 72% male) underwent CAC, carotid CT angiography, and their metabolic status was evaluated. CAC was defined as 0, 1-100, 101-400, 401-1000 and 1000+. CWT (mm) was calculated as: [mean of both right and left CT measured CWT 10-mm below the common carotid bifurcation]. Results: Modest correlation between CWT and CAC was noted (r = 0.48, p = 0.0001). CWT increased substantially with the severity of CAC from CAC 0 to CAC 1000+ (p < 0.05). Increased CWT(1.0mm+) was more prevalent in subjects with significant CAC (100+) as compared to CAC 0 (44.7% vs. 3.3%, p < 0.05). Increase in CWT was associated with increased rates of metabolic syndrome and diabetes mellitus. After adjustment for cardiovascular risk factors, the risk of metabolic syndrome and DM was 1.7 and 2.3 respectively for each standard deviation (SD) increase in CWT. Similarly, the risk for each SD increase in CWT increased with severity of CAC as compared to CAC 0 (RR: CAC 1-100: 1.2, CAC 101-400: 1.5, CAC 400-1000: 2.1, and CAC 1000+: 3.4, respectively). Conclusion: Increased CWT is associated with the presence and severity of CAC, metabolic syndrome and DM independent of conventional cardiovascular risk factors; highlighting the important role of comprehensive carotid and coronary atherosclerotic assessment to identify at-risk individuals. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Nabavi, Vahid; Ahmadi, Naser; Flores, Ferdinand; Budoff, Matthew J.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA. [Ebrahimi, Ramin] Univ Calif Los Angeles, Sch Med, Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. [Bhatia, Harpreet S.; Karlsberg, Ronald P.] Cardiovasc Res Inst So Calif, Beverly Hills, CA USA. RP Budoff, MJ (reprint author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, 1124 W Carson St,RB2, Torrance, CA 90502 USA. EM mbudoff@labiomed.org NR 49 TC 4 Z9 4 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD MAR PY 2011 VL 215 IS 1 BP 103 EP 109 DI 10.1016/j.atherosclerosis.2010.11.034 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 730CN UT WOS:000288008700015 PM 21196006 ER PT J AU Holt, DJ Cassidy, BS Andrews-Hanna, JR Lee, SM Coombs, G Goff, DC Gabrieli, JD Moran, JM AF Holt, Daphne J. Cassidy, Brittany S. Andrews-Hanna, Jessica R. Lee, Su Mel Coombs, Garth Goff, Donald C. Gabrieli, John D. Moran, Joseph M. TI An Anterior-to-Posterior Shift in Mid line Cortical Activity in Schizophrenia During Self-Reflection SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Cingulate gyrus; connectivity; fMRI; medial prefrontal cortex; schizophrenia; self ID STATE FUNCTIONAL CONNECTIVITY; MEDIAL PREFRONTAL CORTEX; DEFAULT MODE NETWORK; SOCIAL COGNITION; BRAIN; FMRI; PERSPECTIVE; REGIONS; MIND; NEUROCOGNITION AB Background: Deficits in social cognition, including impairments in self-awareness, contribute to the overall functional disability associated with schizophrenia. Studies in healthy subjects have shown that social cognitive functions, including self-reflection, rely on the medial prefrontal cortex (mPFC) and posterior cingulate gyrus, and these regions exhibit highly correlated activity during "resting" states. In this study, we tested the hypothesis that patients with schizophrenia show dysfunction of this network during self-reflection and that this abnormal activity is associated with changes in the strength of resting-state correlations between these regions. Methods: Activation during self-reflection and control tasks was measured with functional magnetic resonance imaging in 19 patients with schizophrenia and 20 demographically matched control subjects. In addition, the resting-state functional connectivity of midline cortical areas showing abnormal self-reflection-related activation in schizophrenia was measured. Results: Compared with control subjects, the schizophrenia patients demonstrated lower activation of the right ventral mPFC and greater activation of the mid/posterior cingulate gyri bilaterally during self-reflection, relative to a control task. A similar pattern was seen during overall social reflection. In addition, functional connectivity between the portion of the left mid/posterior cingulate gyrus showing abnormally elevated activity during self-reflection in schizophrenia, and the dorsal anterior cingulate gyrus was lower in the schizophrenia patients compared with control subjects. Conclusions: Schizophrenia is associated with an anterior-to-posterior shift in introspection-related activation, as well as changes in functional connectivity, of the midline cortex. These findings provide support for the hypothesis that aberrant midline cortical function contributes to social cognitive impairment in schizophrenia. C1 [Holt, Daphne J.; Cassidy, Brittany S.; Coombs, Garth; Goff, Donald C.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Holt, Daphne J.; Cassidy, Brittany S.; Coombs, Garth] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Andrews-Hanna, Jessica R.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA. [Lee, Su Mel; Gabrieli, John D.; Moran, Joseph M.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. RP Holt, DJ (reprint author), 149 13th St, Charlestown, MA 02129 USA. EM dholt@partners.org FU National Institute of Mental Health [K23MH076054]; National Alliance for Research on Depression and Schizophrenia; Sidney R. Baer, Jr. Foundation; Poitras Center for Affective Disorders Research FX This study was supported by the National Institute of Mental Health Grant No. K23MH076054 (DH), the National Alliance for Research on Depression and Schizophrenia with the Sidney R. Baer, Jr. Foundation (OH) and the Poitras Center for Affective Disorders Research (JG, JM, and SL). We thank Dr. Randy Buckner for valuable advice throughout the study. NR 58 TC 61 Z9 63 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 1 PY 2011 VL 69 IS 5 BP 415 EP 423 DI 10.1016/j.biopsych.2010.10.003 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 727SO UT WOS:000287822000005 PM 21144498 ER PT J AU Cutler, C Kesselheim, A Gabardi, S Andersson, BS Carpenter, P Khoury, HJ Litzow, M Rowley, SD Lanum, S Leather, H Shih, YCT Gale, RP Wingard, JR Appelbaum, FR Anasetti, C AF Cutler, Corey Kesselheim, Aaron Gabardi, Steven Andersson, Borje S. Carpenter, Paul Khoury, Hanna J. Litzow, Mark Rowley, Scott D. Lanum, Scott Leather, Helen Shih, Ya-Chen Tina Gale, Robert Peter Wingard, John R. Appelbaum, Frederick R. Anasetti, Claudio TI Generic Immunosuppressants in Hematopoietic Cell Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article ID RENAL-TRANSPLANTATION; 1ST-FILL ADHERENCE; TACROLIMUS; DRUGS; RECIPIENTS; SUBSTITUTION; METAANALYSIS; PREDICTORS; INNOVATOR; PROGRAF C1 [Cutler, Corey] Dana Farber Canc Inst, Boston, MA 02115 USA. [Gabardi, Steven] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA. [Andersson, Borje S.; Shih, Ya-Chen Tina] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Carpenter, Paul; Lanum, Scott; Appelbaum, Frederick R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Khoury, Hanna J.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Litzow, Mark] Mayo Clin, Rochester, MN USA. [Rowley, Scott D.] Hackensack Univ, Med Ctr, Blood & Marrow Transplantat Program, Hackensack, NJ USA. [Leather, Helen] NucleusX, New York, NY USA. [Gale, Robert Peter] Celgene Corp, Summit, NJ USA. [Wingard, John R.] Univ Florida, Coll Med, Gainesville, FL USA. [Anasetti, Claudio] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant, Tampa, FL USA. [Gabardi, Steven] Brigham & Womens Hosp, Serv Pharm, Boston, MA 02115 USA. RP Cutler, C (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM corey_cutler@dfci.harvard.edu OI Gabardi, Steven/0000-0001-8022-2751 FU Otsuka; Astellas; Pfizer FX Financial disclosures: Corey Cutler has received research support from Otsuka, Astellas, and Pfizer and serves on the Advisory Board or as a consultant to Otsuka, Astellas, Celgene, and Spectrum. Aaron Kesselheim serves as a consultant to the Alosa Foundation/Independent Drug Information Service. Scott D. Rowley serves on the Eusa speaker's bureau and has equity in Pfizer and Johnson & Johnson. John R. Wingard has received honoraria from Pfizer, Astellas, Vical, and Merck. None of the other authors has any conflicts of interest to disclose. NR 27 TC 8 Z9 9 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD MAR PY 2011 VL 17 IS 3 BP 285 EP 290 DI 10.1016/j.bbmt.2010.11.006 PG 6 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 725GM UT WOS:000287633200001 PM 21087678 ER PT J AU Koreth, J Biernacki, M Aldridge, J Kim, HT Alyea, EP Armand, P Cutler, C Ho, VT Wu, CJ Antin, JH Soiffer, RJ AF Koreth, John Biernacki, Melinda Aldridge, Julie Kim, Haesook T. Alyea, Edwin P., III Armand, Philippe Cutler, Corey Ho, Vincent T. Wu, Catherine J. Antin, Joseph H. Soiffer, Robert J. TI Syngeneic Donor Hematopoietic Stem Cell Transplantation Is Associated with High Rates of Engraftment Syndrome SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Syngeneic; Transplantation; Engraftment syndrome; Capillary leak syndrome ID AUTOLOGOUS BONE-MARROW; ACUTE MYELOID-LEUKEMIA; DIAGNOSTIC-CRITERIA; COMPETING RISK; METAANALYSIS; CHEMOTHERAPY AB Engraftment syndrome (ES), typically characterized by noninfectious fever, rash, and/or noncardiogenic pulmonary edema, is a complication of autologous and allogeneic hematopoietic stem cell transplantation (HSCT). There are no data on ES after syngeneic HSCT. We retrospectively analyzed syngeneic HSCT outcomes and determined ES incidence, risk factors, and prognostic impact. Thirty-two adult patients with a median age of 46 years (range: 22-60) underwent syngeneic HSCT at our institution between July 1986 and April 2009, primarily for hematologic malignancies (65% lymphoid-including 15% plasma cell; 31% myeloid). The median duration of follow-up was 6.1 years (range: 3.7 months to 18.1 years). Five-year progression-free and overall survival (PFS, OS) was 52% and 67%, respectively. Five-year overall cumulative incidence of relapse and nonrelapse mortality (NRM) was 37.6% and 10.2%, respectively; with increased relapse incidence of 76.3% in myeloid disease (P=.002). Fifteen patients (47%) met diagnostic criteria for ES, 10 (67%) of whom received systemic steroids. Five-year PFS was 47% in patients with ES versus 56% in those without (P=.37). Five-year OS was 63% with ES versus 71% without (P=.80). Five-year cumulative incidence of NRM was 21% with ES versus 0% without (P=.06). Five-year cumulative incidence of relapse was 32% with ES and 44% without (P=.68). Older age (P=.05) and possibly total body irradiation based conditioning (P=.09) were risk factors for developing ES. In multivariable Cox models only diagnosis (myeloid disease) impaired OS and PFS. In summary, we document a high incidence of ES after syngeneic HSCT. The trend of increased NRM after ES requires reevaluation in a larger syngeneic HSCT cohort. Biol Blood Marrow Transplant 17: 421-428 (2011) (C) 2011 American Society for Blood and Marrow Transplantation C1 [Koreth, John; Alyea, Edwin P., III; Armand, Philippe; Cutler, Corey; Ho, Vincent T.; Wu, Catherine J.; Antin, Joseph H.; Soiffer, Robert J.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Biernacki, Melinda] Brown Univ, Dept Med, Providence, RI 02912 USA. [Aldridge, Julie; Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. RP Koreth, J (reprint author), Dana Farber Canc Inst, Div Hematol Malignancies, 44 Binney St, Boston, MA 02115 USA. EM john_koreth@dfci.harvard.edu FU Jock and Bunny Adams Education and Research Endowment FX Financial disclosure: None; no conflicts of interest. Supported by the Jock and Bunny Adams Education and Research Endowment. NR 19 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD MAR PY 2011 VL 17 IS 3 BP 421 EP 428 DI 10.1016/j.bbmt.2010.09.013 PG 8 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 725GM UT WOS:000287633200016 PM 20870027 ER PT J AU Parast, L Cheng, SC Cai, TX AF Parast, Layla Cheng, Su-Chun Cai, Tianxi TI Incorporating short-term outcome information to predict long-term survival with discrete markers SO BIOMETRICAL JOURNAL LA English DT Article DE Biomarkers; Disease prognosis; Risk prediction; Survival analysis ID STAGE RENAL-DISEASE; BREAST-CANCER; COMPETING RISKS; MODEL; ERYTHROPOIETIN; LANDMARKING; REGRESSION; CURVE; ERROR AB In disease screening and prognosis studies, an important task is to determine useful markers for identifying high-risk subgroups. Once such markers are established, they can be incorporated into public health practice to provide appropriate strategies for treatment or disease monitoring based on each individual's predicted risk. In the recent years, genetic and biological markers have been examined extensively for their potential to signal progression or risk of disease. In addition to these markers, it has often been argued that short-term outcomes may be helpful in making a better prediction of disease outcomes in clinical practice. In this paper we propose model-free non-parametric procedures to incorporate short-term event information to improve the prediction of a long-term terminal event. We include the optional availability of a single discrete marker measurement and assess the additional information gained by including the short-term outcome. We focus on the semi-competing risk setting where the short-term event is an intermediate event that may be censored by the terminal event while the terminal event is only subject to administrative censoring. Simulation studies suggest that the proposed procedures perform well in finite samples. Our procedures are illustrated using a data set of post-dialysis patients with end-stage renal disease. C1 [Parast, Layla; Cai, Tianxi] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Cheng, Su-Chun] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Parast, L (reprint author), Harvard Univ, Sch Publ Hlth, Dept Biostat, 677 Huntington Ave, Boston, MA 02115 USA. EM lparast@hsph.harvard.edu FU National Institutes of Health [T32GM074897, R01-GM079330] FX The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government. The authors are grateful to the Editor and the reviewers for their insightful comments on the article. Support for this research was provided by National Institutes of Health grants T32GM074897 (Parast) and is R01-GM079330 (Cai). NR 44 TC 9 Z9 9 U1 1 U2 8 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0323-3847 J9 BIOMETRICAL J JI Biom. J. PD MAR PY 2011 VL 53 IS 2 BP 294 EP 307 DI 10.1002/bimj.201000150 PG 14 WC Mathematical & Computational Biology; Statistics & Probability SC Mathematical & Computational Biology; Mathematics GA 730KO UT WOS:000288032400009 PM 21337601 ER PT J AU Trippa, L Muller, P Johnson, W AF Trippa, Lorenzo Mueller, Peter Johnson, Wesley TI The multivariate beta process and an extension of the Polya tree model SO BIOMETRIKA LA English DT Article DE Dependent random probability measures; Multivariate beta process; Polya tree distribution ID DISTRIBUTIONS; REGRESSION AB We introduce a novel stochastic process that we term the multivariate beta process. The process is defined for modelling-dependent random probabilities and has beta marginal distributions. We use this process to define a probability model for a family of unknown distributions indexed by covariates. The marginal model for each distribution is a Polya tree prior. An important feature of the proposed prior is the easy centring of the nonparametric model around any parametric regression model. We use the model to implement nonparametric inference for survival distributions. The nonparametric model that we introduce can be adopted to extend the support of prior distributions for parametric regression models. C1 [Trippa, Lorenzo] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Mueller, Peter] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA. [Johnson, Wesley] Univ Calif Irvine, Dept Stat, Irvine, CA 92697 USA. RP Trippa, L (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. EM ltrippa@jimmy.harvard.edu; pmueller@mdanderson.org; wjohnson@uci.edu FU National Institutes of Health, U.S.A.; National Cancer Institute FX The authors thank the editor, the associate editor and two referees for helpful comments. This article was written while the first author was a visiting student at the Department of Biostatistics, University of Texas M. D. Anderson Cancer Center. The second author was partially supported by the National Institutes of Health, U.S.A., and the National Cancer Institute. NR 25 TC 14 Z9 14 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-3444 J9 BIOMETRIKA JI Biometrika PD MAR PY 2011 VL 98 IS 1 BP 17 EP 34 DI 10.1093/biomet/asq072 PG 18 WC Biology; Mathematical & Computational Biology; Statistics & Probability SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology; Mathematics GA 726XA UT WOS:000287759000002 PM 23956460 ER PT J AU Shirai, K Kaneshiro, T Wada, M Furuya, H Bielawski, J Hannun, YA Obeid, LM Ogretmen, B Kawamori, T AF Shirai, Keisuke Kaneshiro, Tatsuya Wada, Masayuki Furuya, Hideki Bielawski, Jacek Hannun, Yusuf A. Obeid, Lina M. Ogretmen, Besim Kawamori, Toshihiko TI A Role of Sphingosine Kinase 1 in Head and Neck Carcinogenesis SO CANCER PREVENTION RESEARCH LA English DT Article ID SQUAMOUS-CELL CARCINOMA; 4-NITROQUINOLINE 1-OXIDE; ORAL-CAVITY; CANCER; PROLIFERATION; EXPRESSION; CYCLOOXYGENASE-2; PATHOGENESIS; NIMESULIDE; INHIBITOR AB It is important to identify novel and effective targets for cancer prevention and therapy against head and neck squamous cell carcinoma (HNSCC), one of the most lethal cancers. Accumulating evidence suggests that the bioactive sphingolipids, such as sphingosine-1-phosphate (S1P) and its generating enzyme, sphingosine kinase 1 (SphK1) play pivotal roles in several important biological functions including promoting tumor growth and carcinogenesis. However, roles of SphK1/S1P in HNSCC development and/or progression have not been defined previously. Therefore, in this study, we first analyzed the expression of SphK1 in human HNSCC tumor samples and normal head & neck tissues (n = 78 and 17, respectively) using immunohistochemistry. The data showed that SphK1 is overexpressed in all of the HNSCC tumors tested (stages I-IV). We next investigated whether SphK1 is necessary for HNSCC development. To define the role of SphK1/S1P in HNSCC development, we utilized 4-nitroquinoline-1-oxide (4-NQO)-induced HNSCC model in wild-type mice compared with SphK1(-/-) knockout (KO) mice. Remarkably, we found that the genetic loss of SphK1, which reduced S1P generation, significantly prevented 4-NQO-induced HNSCC carcinogenesis, with decreased tumor incidence, multiplicity, and volume when compared with controls. Moreover, our data indicated that prevention of 4-NQO-induced HNSCC development in SphK1(-/-) KO mice might be associated with decreased cell proliferation, increased levels of cleaved (active) caspase 3, and downregulation of phospho (active) AKT expression. Thus, these novel data suggest that SphK1/S1P signaling may play important roles in HNSCC carcinogenesis, and that targeting SphK1/S1P might provide a novel strategy for chemoprevention and treatment against HNSCC. Cancer Prev Res; 4(3); 454-62. (C)2011 AACR. C1 [Furuya, Hideki; Kawamori, Toshihiko] Univ Hawaii, Ctr Canc, Honolulu, HI 96813 USA. [Shirai, Keisuke] Med Univ S Carolina, Dept Med Hematol Oncol, Charleston, SC 29425 USA. [Kaneshiro, Tatsuya; Wada, Masayuki; Furuya, Hideki; Kawamori, Toshihiko] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Bielawski, Jacek; Hannun, Yusuf A.; Ogretmen, Besim] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Obeid, Lina M.] Med Univ S Carolina, Dept Internal Med, Charleston, SC 29425 USA. [Shirai, Keisuke; Bielawski, Jacek; Hannun, Yusuf A.; Obeid, Lina M.; Ogretmen, Besim; Kawamori, Toshihiko] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Obeid, Lina M.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. RP Kawamori, T (reprint author), Univ Hawaii, Ctr Canc, 651 Ilalo St,BSB 222H, Honolulu, HI 96813 USA. EM kawamori@crch.hawaii.edu RI Kawamori, Toshihiko/G-7636-2012 OI obeid, lina/0000-0002-0734-0847; FU NIH [P01CA097132, R01CA124687, C06RR015455]; Office of Research and Development, Department of Veterans Affairs, Ralph H. Johnson VA Medical Center, Charleston, South Carolina FX NIH grants P01CA097132 (J. Bielawski, Y. A. Hannun, L. M. Obeid, B. Ogretmen, and T. Kawamori), R01CA124687 (T. Kawamori), R01DE016572 (B. Ogretmen), and C06RR015455 (Research Facilities Support grant). A MERIT Award by the Office of Research and Development, Department of Veterans Affairs, Ralph H. Johnson VA Medical Center, Charleston, South Carolina (L. M. Obeid). NR 33 TC 36 Z9 39 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 J9 CANCER PREV RES JI Cancer Prev. Res. PD MAR PY 2011 VL 4 IS 3 BP 454 EP 462 DI 10.1158/1940-6207.CAPR-10-0299 PG 9 WC Oncology SC Oncology GA 729PV UT WOS:000287963800022 PM 21209394 ER PT J AU Dejam, A Hokinson, M Laham, R AF Dejam, Andre Hokinson, Michelle Laham, Roger TI Repeated Successful Balloon Valvuloplasty of a Bioprosthetic Aortic Valve in A Nonagenerian SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE intracardiac echo; valvular heart disease; diagnostic cardiac catheterization ID TRANSCATHETER VALVE; FOLLOW-UP; IMPLANTATION; REPLACEMENT; POSITION AB Calcific aortic stenosis remains a major cause of mortality and morbidity in the aging population. Surgical replacement remains the treatment of choice for this disease. Balloon aortic valvuloplasty was introduced as a palliative procedure for these patients, but was tempered by a high rate of recurrence, which has limited its usefulness. However, the introduction of smaller-profile balloons, rapid pacing, and closure devices have brought it back as an alternative treatment strategy in selected patients who are at too high risk for surgery with repeat valvuloplasty as needed for recurrences. We report a case of prosthetic aortic valve stenosis treated with valvuloplasty with intracardiac and fluoroscopic guidance with recurrence treated with repeat valvuloplasty with promising intermediate-term outcome and describe the growing valve in valve procedures. (C) 2011 Wiley-Liss, Inc. C1 [Laham, Roger] Harvard Univ, Sch Med, BIDMC, Angiogenesis Res Ctr,Div Cardiol, Boston, MA 02215 USA. Harvard Univ, Sch Med, BIDMC, Intervent Cardiol Sect, Boston, MA 02215 USA. RP Laham, R (reprint author), Harvard Univ, Sch Med, BIDMC, Angiogenesis Res Ctr,Div Cardiol, 330 Brookline Ave, Boston, MA 02215 USA. EM rlaham@bidmc.harvard.edu FU AHA [10CRP2660009]; MTTC Award; DeBakey Foundation at Balamand University FX This work was funded in part by AHA grant 10CRP2660009 (AD), MTTC Award and DeBakey Foundation at Balamand University (RL). NR 16 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1522-1946 J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD MAR 1 PY 2011 VL 77 IS 4 BP 589 EP 592 DI 10.1002/ccd.22816 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 727IV UT WOS:000287792800024 PM 21351233 ER PT J AU Crothers, K Daly, KR Rimland, D Goetz, MB Gibert, CL Butt, AA Justice, AC Djawe, K Levin, L Walzer, PD AF Crothers, Kristina Daly, Kieran R. Rimland, David Goetz, Matthew Bidwell Gibert, Cynthia L. Butt, Adeel A. Justice, Amy C. Djawe, Kpandja Levin, Linda Walzer, Peter D. TI Decreased Serum Antibody Responses to Recombinant Pneumocystis Antigens in HIV-Infected and Uninfected Current Smokers SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID MAJOR SURFACE GLYCOPROTEIN; OBSTRUCTIVE PULMONARY-DISEASE; RESPIRATORY VIRUS-ANTIBODIES; SEROLOGIC RESPONSES; CIGARETTE-SMOKING; IMMUNE-SYSTEM; UNITED-STATES; ALCOHOL-USE; TOBACCO USE; JIROVECI AB Serologic studies can provide important insights into the epidemiology and transmission of Pneumocystis jirovecii. Exposure to P. jirovecii can be assessed by serum antibody responses to recombinant antigens from the major surface glycoprotein (MsgC), although factors that influence the magnitude of the antibody response are incompletely understood. We determined the magnitudes of antibody responses to P. jirovecii in comparison to adenovirus and respiratory syncytial virus (RSV) in HIV-infected and uninfected patients and identified predictors associated with the magnitude of the response. We performed a cross-sectional analysis using serum samples and data from 153 HIV-positive and 92 HIV-negative subjects enrolled in a feasibility study of the Veterans Aging Cohort 5 Site Study (VACS 5). Antibodies were measured using an enzyme-linked immunosorbent assay (ELISA). Independent predictors of antibody responses were determined using multivariate Tobit regression models. The results showed that serum antibody responses to P. jirovecii MsgC fragments were significantly and independently decreased in current smokers. Antibodies to P. jirovecii also tended to be lower with chronic obstructive pulmonary disease (COPD), hazardous alcohol use, injection drug use, and HIV infection, although these results were not statistically significant. These results were specific to P. jirovecii and did not correlate with adenovirus. Antibody responses to RSV were in the inverse direction. Thus, current smoking was independently associated with decreased P. jirovecii antibody responses. Whether smoking exerts an immunosuppressive effect that affects the P. jirovecii antibody response, colonization, or subsequent risk for disease is unclear; prospective, longitudinal studies are needed to evaluate these findings further. C1 [Crothers, Kristina] Univ Washington, Harborview Med Ctr, Sch Med, Dept Med,Div Pulm & Crit Care Med, Seattle, WA 98104 USA. [Daly, Kieran R.; Djawe, Kpandja; Levin, Linda; Walzer, Peter D.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Infect Dis, Cincinnati, OH USA. [Rimland, David] Emory Univ, Sch Med, Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA. [Goetz, Matthew Bidwell] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Infect Dis Sect, Dept Med, Los Angeles, CA 90095 USA. [Gibert, Cynthia L.] George Washington Univ, Infect Dis Sect, Vet Affairs Med Ctr, Washington, DC USA. [Gibert, Cynthia L.] George Washington Univ, Dept Med, Washington, DC USA. [Butt, Adeel A.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Dept Internal Med, Pittsburgh, PA USA. [Justice, Amy C.] Vet Affairs Connecticut Healthcare Syst, New Haven, CT USA. [Justice, Amy C.] Yale Univ, Sch Med, Dept Internal Med, Sect Pulm & Crit Care Med, New Haven, CT 06510 USA. [Justice, Amy C.] Yale Univ, Sch Publ Hlth, Dept Internal Med, Sect Pulm & Crit Care Med, New Haven, CT USA. [Djawe, Kpandja; Levin, Linda; Walzer, Peter D.] Univ Cincinnati, Coll Med, Dept Environm Hlth, Div Epidemiol, Cincinnati, OH 45267 USA. [Walzer, Peter D.] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA. RP Crothers, K (reprint author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Med,Div Pulm & Crit Care Med, 325 9th Ave,Box 359762, Seattle, WA 98104 USA. EM crothk@uw.edu OI Goetz, Matthew/0000-0003-4542-992X FU National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) [R01 HL090342]; NIH/National Center for Research Resources (NCRR) [KL2 RR024138]; National Institute on Alcohol and Alcohol Abuse [U01 AA 13566, U10 AA 13566]; National Institute of Aging (NIA) [K23 AG00826]; Robert Wood Johnson Generalist Faculty Scholar Award; NIH Roadmap for Medical Research FX Funding for this work was from National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) grant R01 HL090342 (K. C.), NIH/National Center for Research Resources (NCRR) grant KL2 RR024138 (K. C.), National Institute on Alcohol and Alcohol Abuse grants U01 AA 13566 and U10 AA 13566 (A.C.J.), National Institute of Aging (NIA) grant K23 AG00826 (A.C.J.), a Robert Wood Johnson Generalist Faculty Scholar Award (A.C.J.), and an interagency agreement between the NIA and the National Institute of Mental Health. Funding for this publication was made possible in part by CTSA grant KL2 RR024138 from the NCRR, a component of the NIH, and NIH Roadmap for Medical Research. The authors have no commercial or other associations that pose a conflict of interest. NR 40 TC 5 Z9 6 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD MAR PY 2011 VL 18 IS 3 BP 380 EP 386 DI 10.1128/CVI.00421-10 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 729CH UT WOS:000287925100005 PM 21191078 ER PT J AU Uddin, T Harris, JB Bhuiyan, TR Shirin, T Uddin, MI Khan, AI Chowdhury, F LaRocque, RC Alam, NH Ryan, ET Calderwood, SB Qadri, F AF Uddin, Taher Harris, Jason B. Bhuiyan, Taufiqur Rahman Shirin, Tahmina Uddin, Muhammad Ikhtear Khan, Ashraful Islam Chowdhury, Fahima LaRocque, Regina C. Alam, Nur Haque Ryan, Edward T. Calderwood, Stephen B. Qadri, Firdausi TI Mucosal Immunologic Responses in Cholera Patients in Bangladesh SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID B-CELL RESPONSES; IMMUNE-RESPONSES; SECRETING CELLS; VACCINE; MEMORY; IMMUNIZATION; INFECTION; O1; PATHOGEN; BAFF AB Vibrio cholerae O1 causes dehydrating diarrhea with a high mortality rate if untreated. The infection also elicits long-term protective immunity. Since V. cholerae is noninvasive, mucosal immunity is likely important for protection. In this study, we compared humoral immune responses in the duodenal mucosa and blood of cholera patients at different time points after the onset of disease and compared them with those of healthy controls (HCs). Immune responses to lipopolysaccharide (LPS) and the recombinant cholera toxin B subunit (rCTB) were assessed by enzyme-linked immunosorbent assay (ELISA) and enzyme-linked immunospot (ELISPOT) assay. Significant increases in V. cholerae LPS-specific IgA and IgG antibody levels were seen in duodenal extracts on day 30, but the levels decreased to baseline by day 180; plasma V. cholerae LPS-specific IgA levels remained elevated longer. Levels of mucosal CTB antibodies also peaked on day 30, but the increase reached statistical significance only for IgG. A significant correlation was found between the CTB antibody-secreting cell (ASC) response in the circulatory system on day 7 and subsequent CTB-specific IgA levels in duodenal extracts on day 30 and the numbers of CTB-specific IgA ASCs in duodenal tissues on day 180. The proportion (0.07%) of mucosal V. cholerae LPS IgA ASCs peaked on day 30 and remained elevated through day 180 compared to that of HCs (P = 0.03). These results suggest that protective immunity against V. cholerae is not likely mediated by the constitutive secretion of antibodies at the mucosal surface; our results are consistent with those of other studies that suggest instead that anamnestic immune responses of mucosal lymphocytes may play a major role in protection against cholera. C1 [Qadri, Firdausi] Int Ctr Diarrhoeal Dis Res, Immunol Lab, Div Sci Lab, Ctr Hlth & Populat Res,Bangladesh ICDDR B, Dhaka 1000, Bangladesh. [Harris, Jason B.; LaRocque, Regina C.; Ryan, Edward T.; Calderwood, Stephen B.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Harris, Jason B.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [LaRocque, Regina C.; Ryan, Edward T.; Calderwood, Stephen B.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Ryan, Edward T.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. [Calderwood, Stephen B.] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA. RP Qadri, F (reprint author), Int Ctr Diarrhoeal Dis Res, Immunol Lab, Div Sci Lab, Ctr Hlth & Populat Res,Bangladesh ICDDR B, GPO Box 128, Dhaka 1000, Bangladesh. EM fqadri@icddrb.org FU ICDDR,B Centre for Health and Population Research [U01 AI058935, RO3 AI063079, U01 AI077883]; International Research Scientist Development Award [KO1 TW07409]; Fogarty International Center of the National Institutes of Health [D43 TW005572, R24TW007988] FX This research was supported by the ICDDR,B Centre for Health and Population Research and by the following grants: U01 AI058935 (S. B. C.), RO3 AI063079 (F. Q.), U01 AI077883 (E. T. R.), and International Research Scientist Development Award KO1 TW07409 (J.B.H.). F. C., A. I. K., and T. R. B. are recipients of Fogarty International Clinical Research Scholars awards from the Fogarty International Center of the National Institutes of Health (D43 TW005572 and R24TW007988). NR 24 TC 16 Z9 16 U1 2 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD MAR PY 2011 VL 18 IS 3 BP 506 EP 512 DI 10.1128/CVI.00481-10 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 729CH UT WOS:000287925100024 PM 21248157 ER PT J AU Gupta, K Hooton, TM Naber, KG Wullt, B Colgan, R Miller, LG Moran, GJ Nicolle, LE Raz, R Schaeffer, AJ Soper, DE AF Gupta, Kalpana Hooton, Thomas M. Naber, Kurt G. Wullt, Bjorn Colgan, Richard Miller, Loren G. Moran, Gregory J. Nicolle, Lindsay E. Raz, Raul Schaeffer, Anthony J. Soper, David E. TI Executive Summary: International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID URINARY-TRACT-INFECTIONS; ANTIMICROBIAL SUSCEPTIBILITY; RESISTANCE; PATHOGENS; ECO.SENS; THERAPY; CARE AB A Panel of International Experts was convened by the Infectious Diseases Society of America (IDSA) in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) to update the 1999 Uncomplicated Urinary Tract Infection Guidelines by the IDSA. Co-sponsoring organizations include the American Congress of Obstetricians and Gynecologists, American Urological Association, Association of Medical Microbiology and Infectious Diseases-Canada, and the Society for Academic Emergency Medicine. The focus of this work is treatment of women with acute uncomplicated cystitis and pyelonephritis, diagnoses limited in these guidelines to premenopausal, non-pregnant women with no known urological abnormalities or co-morbidities. The issues of in vitro resistance prevalence and the ecological adverse effects of antimicrobial therapy (collateral damage) were considered as important factors in making optimal treatment choices and thus are reflected in the rankings of recommendations. C1 [Gupta, Kalpana] Vet Affairs Boston Hlth Care Syst, Dept Med, Boston, MA USA. [Gupta, Kalpana] Boston Univ, Sch Med, Boston, MA 02118 USA. [Hooton, Thomas M.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA. [Colgan, Richard] Univ Maryland, Dept Family & Community Med, Baltimore, MD 21201 USA. [Miller, Loren G.] Harbor UCLA Med Ctr, Div Infect Dis, Torrance, CA 90509 USA. [Moran, Gregory J.] Olive View UCLA Med Ctr, Dept Emergency Med, Slymar, CA USA. [Moran, Gregory J.] Olive View UCLA Med Ctr, Div Infect Dis, Slymar, CA USA. [Schaeffer, Anthony J.] Northwestern Univ, Dept Urol, Chicago, IL 60611 USA. [Soper, David E.] Med Univ S Carolina, Dept Obstet & Gynecol, Charleston, SC 29425 USA. [Soper, David E.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Nicolle, Lindsay E.] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada. [Nicolle, Lindsay E.] Univ Manitoba, Dept Med Mirobiol, Winnipeg, MB, Canada. [Naber, Kurt G.] Tech Univ Munich, Munich, Germany. [Wullt, Bjorn] Univ Lund Hosp, S-22185 Lund, Sweden. [Raz, Raul] HaEmek Med Ctr, Infect Dis Unit, Afula, Israel. [Raz, Raul] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel. RP Gupta, K (reprint author), VA Boston HCS, 1400 VFW Pkwy,111 Med, W Roxbury, MA 02132 USA. EM kalpana.gupta@va.gov FU The Infectious Diseases Society of America; UpToDate; American Urological Association; Bionorica; Daiichi Sankyo; Janssen Cilag; Johnson Johnson; OM Pharma; Pierre Fabre; Sanofi Aventis; Zambon; MerLion Pharmaceuticals; Rosen Pharma; Cubist; Pfizer Pharmaceuticals FX Financial support. The Infectious Diseases Society of America.; K.G. (Chair) has served as a consultant to Pfizer and Pinnacle Pharmaceutical. A.J.S. has served as a consultant to Novabay Pharmaceuticals, Pfizer, Propagate Pharmaceuticals, Hagen/Sinclair Research Recruiting, Swiss Precision Diagnostics Development Company, and FlashPointMedica; has received honoraria from BMJ Group (British Medical Journal) and Advanstar Communications; received a royalty payment from UpToDate; and received remuneration from the American Urological Association. G.J.M. has served as a consultant to Cerexa, Cubist, Eisai, Forest, Merck, Ortho-McNeil, Pfizer, and Schering-Plough and has received honoraria from Cubist and Merck. K.G.N. has received remuneration as consultant or speaker from Bionorica, Daiichi Sankyo, Janssen Cilag, Johnson & Johnson, OM Pharma, Pierre Fabre, Sanofi Aventis, and Zambon and has received research grants from MerLion Pharmaceuticals, Rosen Pharma, and OM Pharma. L.E.N. has served as a consultant to Pfizer, Leo pharmaceuticals, Cerexa, and Johnson & Johnson and served on the advisory board for Leo Pharmaceuticals and Cerexa. L.G.M. has served as a consultant to Forest and Theravance Laboratories and received research grants from Cubist and Pfizer Pharmaceuticals. T.M.H. has served as a consultant to Pfizer, Alita Pharmaceuticals, and Pinnacle Pharmaceuticals All other authors: no conflicts. NR 11 TC 6 Z9 6 U1 2 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 1 PY 2011 VL 52 IS 5 BP 561 EP 564 DI 10.1093/cid/cir102 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 716RR UT WOS:000286991700005 ER PT J AU Wagner, TH Holman, W Lee, K Sethi, G Ananth, L Hoang, T Goldman, S AF Wagner, Todd H. Holman, William Lee, Kelvin Sethi, Gulshan Ananth, Lakshmi Hoang Thai Goldman, Steven TI The generalizability of participants in Veterans Affairs Cooperative Studies Program 474, a multi-site randomized cardiac bypass surgery trial SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Coronary artery bypass surgery; Study design; Generalizability ID RADIAL-ARTERY; SAPHENOUS-VEIN; PATENCY; GRAFTS AB Objective: The Department of Veterans Affairs (VA) Cooperative Studies Program (CSP) initiated a multi-site randomized trial (CSP 474) to determine graph patency between radial artery or saphenous vein grafts in coronary artery bypass surgery (CABG). In this paper, we describe the study and compare participants' baseline characteristics to non-participants who received CABG surgery in the VA. Method: We identified our participants in the VA administrative databases along with all other CABG patients who did not have a concomitant valve procedure between FY2003 and FY2008. We extracted demographic, clinical information and organizational information at the time of the surgery from the databases. We conducted multiple logistic regression to determine characteristics associated with participation at three levels: between participants and non-participants within participating sites, between participating sites and non-participating sites. between participants and all non-participants. Results: Enrollment ended in early 2008. Participants were similar to non-participants across many parameters. Likewise, participating sites were also quite similar to non-participating sites, although participating sites had a higher volume of CABG surgery, a lower percentage of CABG patients with a prior inpatient mental health admission than non-participating sites. After controlling for site differences, CSP 474 participants were younger and had fewer co-morbid conditions than non-participants. Conclusions: Participants were significantly younger than non-participants. Participants also had lower rates of some cardiac-related illness including, congestive heart failure, peripheral vascular disease, and cerebrovascular disease than non-participants. Published by Elsevier Inc. C1 [Wagner, Todd H.; Ananth, Lakshmi] Stanford Univ, VA Palo Alto Hlth Econ Resource Ctr, Menlo Pk, CA 94025 USA. [Wagner, Todd H.] Stanford Univ, Dept Hlth Res & Policy, Menlo Pk, CA 94025 USA. [Holman, William] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Holman, William] Univ Alabama, VA Med Ctr, Birmingham, AL 35233 USA. [Lee, Kelvin] VA Palo Alto Cooperat Studies Coordinating Ctr, Menlo Pk, CA 94025 USA. [Hoang Thai; Goldman, Steven] Univ Arizona, Sarver Heart Ctr, Tucson, AZ 85723 USA. So Arizona VA Hlth Care Syst, Tucson, AZ 85723 USA. RP Wagner, TH (reprint author), Stanford Univ, VA Palo Alto Hlth Econ Resource Ctr, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM Todd.Wagner@va.gov; William.Holman@va.gov; Kelvin.Lee@va.gov; sethi@u.arizona.edu; Lakshmi.Ananth@va.gov FU VA Cooperative Studies Program FX The study was funded by the VA Cooperative Studies Program. NR 16 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAR PY 2011 VL 32 IS 2 BP 260 EP 266 DI 10.1016/j.cct.2010.11.008 PG 7 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 730TG UT WOS:000288056700016 PM 21078416 ER PT J AU Wang, M Medeiros, BC Erba, HP DeAngelo, DJ Giles, FJ Swords, RT AF Wang, Meng Medeiros, Bruno C. Erba, Harry P. DeAngelo, Daniel J. Giles, Francis J. Swords, Ronan T. TI Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer SO EXPERT OPINION ON THERAPEUTIC TARGETS LA English DT Review DE acute myeloid leukemia; MLN4924; neddylation; therapy ID CHRONIC MYELOID-LEUKEMIA; NEDD8 CONJUGATION PATHWAY; SCF UBIQUITIN-LIGASE; CULLIN-RING LIGASES; TRANSCRIPTIONAL ACTIVITY; NEDD8-ACTIVATING ENZYME; MULTIPLE-MYELOMA; P53 RESTORATION; MODIFIER NEDD8; INHIBITOR AB Introduction: The NEDD8 (neural precursor cell-expressed developmentally downregulated 8) conjugation pathway regulates the post-translational modification of oncogenic proteins. This pathway has important potential for cancer therapeutics. Several proteins vital in cancer biology are regulated by protein neddylation. These observations led to the development of a small molecule inhibitor that disrupts protein neddylation and leads to cancer cell death and important activity in early phase clinical trials. Areas covered: This review provides an extensive coverage of cellular protein homeostasis with particular emphasis on the NEDD8 conjugation pathway. Insights into a new investigational drug that specifically disrupts the NEDD8 pathway are discussed. The clinical data for this agent are also updated. Expert opinion: Neddylation controls key cellular pathways found to be dysregulated in many cancers. Protein neddylation is a relatively under-explored pathway for pharmacologic inhibition in cancer. Selective disruption of this pathway has demonstrated clinical activity in patients with myeloid neoplasms and is worth exploring further in combination with other anti-leukemia agents. C1 [Swords, Ronan T.] Canc Therapy & Res Ctr S Texas, Sa, TX 78230 USA. [Wang, Meng] Univ Cambridge, Cambridge, England. [Erba, Harry P.] Univ Michigan, Ann Arbor, MI 48109 USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Giles, Francis J.] Natl Univ Ireland Galway, Dept Canc Therapeut, Galway, Ireland. [Medeiros, Bruno C.] Stanford, Hematol Oncol, Palo Alto, CA USA. RP Swords, RT (reprint author), Canc Therapy & Res Ctr S Texas, 7979 Wurzbach Rd, Sa, TX 78230 USA. EM swordsr@uthscsa.edu FU Millennium Pharmaceuticals FX HP Erba and FJ Giles have received research funding from Millennium Pharmaceuticals. NR 68 TC 35 Z9 35 U1 0 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1472-8222 J9 EXPERT OPIN THER TAR JI Expert Opin. Ther. Targets PD MAR PY 2011 VL 15 IS 3 BP 253 EP 264 DI 10.1517/14728222.2011.550877 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 719KL UT WOS:000287203500003 PM 21219242 ER PT J AU Lee, HJ Quaas, AM Wright, DL Toth, TL Teixeira, JM AF Lee, Ho-Joon Quaas, Alexander M. Wright, Diane L. Toth, Thomas L. Teixeira, Jose M. TI In vitro maturation (IVM) of murine and human germinal vesicle (GV)-stage oocytes by coculture with immortalized human fallopian tube epithelial cells SO FERTILITY AND STERILITY LA English DT Article DE Oocytes; in vitro maturation; tubal feeder cells ID EMBRYONIC STEM-CELLS; AUTOLOGOUS ENDOMETRIAL COCULTURE; FERTILITY PRESERVATION; FREE CULTURE; SERUM-FREE; UNDIFFERENTIATED GROWTH; ASSISTED REPRODUCTION; MATURED OOCYTES; CANCER-PATIENTS; SUPPORT AB Objective: To improve the maturation rate of murine and human germinal vesicle (GV) oocytes using human tubal epithelial cells (hTECs). Design: Murine and human GV oocytes were randomized to human tubal fluid (HTF) media alone or cocultured with mouse embryonic fibroblasts (MEFs) or primary hTECs or immortalized hTECS (ihTECs) for various times. Rates of maturation to meiosis II (MII) were compared between groups. Intervention(s): TECs were isolated from discarded salpingectomy specimens. One batch was immortalized with TERT and SV40 large T-antigen. GV oocytes (n = 710) were isolated from 8-week-old-mice at 40 hours after pregnant mare's serum gonadotropin stimulation. Discarded human GV oocytes (n 62) were obtained from intracytoplasmic sperm injection cycle IVF center patients. Oocytes were cultured in HTF media alone or with MEFs, hTECs, or ihTECs. Main Outcome Measure(s): Maturation rates were assessed by standard morphological criteria and compared. Result(s): The maturation rate of murine GV oocytes to MII at 12 and 24 hours increased significantly in coculture with hTECS and ihTECS compared with MEF and HTF media alone. In addition, the development rate after IVF was significantly higher with hTECS and ihTECS than in MEF and HTF media alone. Maturation of human GV oocytes to MII at 24 and 48 hours was significantly higher in hTECS and ihTECS compared with HTF media alone. Conclusion(s): Coculture with either primary or immortalized TECs might improve oocyte quality and significantly raise in vitro maturation rates for GV oocytes. (Fertil Steril (R) 2011;95:1344-8. (C) 2011 by American Society for Reproductive Medicine.) C1 [Lee, Ho-Joon; Quaas, Alexander M.; Teixeira, Jose M.] Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Boston, MA 02114 USA. [Teixeira, Jose M.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Wright, Diane L.; Toth, Thomas L.] Massachusetts Gen Hosp, Div Reprod Med, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Wright, Diane L.; Toth, Thomas L.] Massachusetts Gen Hosp, IVF, Dept Obstet & Gynecol, Boston, MA 02114 USA. RP Teixeira, JM (reprint author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol Thier 931, 55 Fruit St, Boston, MA 02114 USA. EM teixeira@helix.mgh.harvard.edu OI Teixeira, Jose/0000-0002-6438-5064 FU Harvard Stem Cell Institute; Vincent Memorial Research Fund FX Supported by a grant from the Harvard Stem Cell Institute and by the Vincent Memorial Research Fund (to JMT). NR 34 TC 3 Z9 3 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD MAR PY 2011 VL 95 IS 4 BP 1344 EP 1348 DI 10.1016/j.fertnstert.2010.08.034 PG 5 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 730DA UT WOS:000288010900025 PM 20864100 ER PT J AU Skaznik-Wikiel, ME Sharma, RK Selesniemi, K Lee, HJ Tilly, JL Falcone, T AF Skaznik-Wikiel, Malgorzata E. Sharma, Rakesh K. Selesniemi, Kaisa Lee, Ho-Joon Tilly, Jonathan L. Falcone, Tommaso TI Granulocyte colony-stimulating factor in conjunction with vascular endothelial growth factor maintains primordial follicle numbers in transplanted mouse ovaries SO FERTILITY AND STERILITY LA English DT Article DE Atresia; follicle; granulocyte colony-stimulating factor; oocyte; stem cell factor; vascular endothelial growth factor ID STEM-CELL FACTOR; C-KIT RECEPTOR; HYPERSTIMULATION SYNDROME; LAPAROSCOPIC OOPHOROPEXY; OOCYTE GROWTH; EXPRESSION; TISSUE; ANGIOGENESIS; LIGAND; PRESERVATION AB Objective: To determine whether granulocyte colony-stimulating factor (G-CSF), stem cell factor (SCF), or vascular endothelial growth factor (VEGF) improve the outcome of ovarian grafting. Design: Experimental animal study. Setting: Tertiary care hospital, animal facilities. Animal(s): Young adult (6- to 8-week-old) C57BL/6 female mice. Intervention(s): Orthotopic transplantation of the frozen-thawed ovary. Group 1 (n = 6) received VEGF (8 g/kg/day); group 2 (n = 6) received VEGF and G-CSF (50 g/kg/day), group 3 (n = 6) received G-CSF and SCF (100 g/kg/day), and group 4 (n = 5) received saline (vehicle controls). All injections were given once daily for 5 days starting the day after surgery. Ovaries were collected 2 weeks after transplantation. Main Outcome Measure(s): Number of nonatretic immature (primordial, primary, and small preantral) follicles. Result(s): Transplanted ovaries in mice injected with VEGF concurrently with G-CSF maintained a statistically significantly larger pool of primordial follicles compared with transplanted ovaries in saline-injected controls. Follicle numbers (total immature and primordial) in transplanted ovaries showed no statistically significant difference in mice injected with VEGF alone or G-CSF plus SCF compared with saline-injected controls. Conclusion(s): After ovarian transplantation, mice treated with VEGF and G-CSF maintain a significantly greater number of primordial follicles compared with the transplanted ovaries in control animals, suggesting that the combination of G-CSF and VEGF minimizes ischemic damage and thus improves the viability and function of the ovarian graft. (Fertil Steril (R) 2011;95:1405-9. (C)2011 by American Society for Reproductive Medicine.) C1 [Skaznik-Wikiel, Malgorzata E.; Sharma, Rakesh K.; Falcone, Tommaso] Cleveland Clin, Obstet Gynecol & Womens Hlth Inst, Cleveland, OH 44195 USA. [Selesniemi, Kaisa; Lee, Ho-Joon; Tilly, Jonathan L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Dept Obstet & Gynecol,Vincent Ctr Reprod, Boston, MA USA. RP Sharma, RK (reprint author), Cleveland Clin, Obstet Gynecol & Womens Hlth Inst, Desk A19-1,9500 Euclid Ave, Cleveland, OH 44195 USA. EM sharmar@ccf.org NR 43 TC 15 Z9 15 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD MAR PY 2011 VL 95 IS 4 BP 1405 EP 1409 DI 10.1016/j.fertnstert.2010.12.036 PG 5 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 730DA UT WOS:000288010900035 PM 21269609 ER PT J AU Zelinski, MB Murphy, MK Lawson, MS Jurisicova, A Pau, KYF Toscano, NP Jacob, DS Fanton, JK Casper, RF Dertinger, SD Tilly, JL AF Zelinski, Mary B. Murphy, Mark K. Lawson, Maralee S. Jurisicova, Andrea Pau, K. Y. Francis Toscano, Natalia P. Jacob, Darla S. Fanton, John K. Casper, Robert F. Dertinger, Stephen D. Tilly, Jonathan L. TI In vivo delivery of FTY720 prevents radiation-induced ovarian failure and infertility in adult female nonhuman primates SO FERTILITY AND STERILITY LA English DT Article DE Fertility preservation; cancer; ovary; oocyte; monkey; human; sphingosine-1-phosphate; FTY720 ID CANCER-PATIENTS; MACACA-MULATTA; RHESUS-MONKEYS; TISSUE CRYOPRESERVATION; FOLLICLE NUMBER; CHEMOTHERAPY; DAMAGE; APOPTOSIS; SPHINGOSINE-1-PHOSPHATE; RADIOSENSITIVITY AB Objective: To determine whether sphingosine-1-phosphate (S1P), or the S1P mimetic FTY720 shields ovaries of adult female rhesus monkeys from damage caused by 15 Gy of targeted radiotherapy, allowing for the retention of long-term fertility, and to evaluate whether S1P protects human ovarian tissue (xenografted into mice) from radiation-induced damage. Design: Research animal study. Setting: Research laboratory and teaching hospital. Patient(s): Adult female rhesus macaques (8-14 years of age; n = 21) and two women (24 and 27 years of age) undergoing gynecologic surgery for benign reasons, after informed consent and approval. Intervention(s): None. Main Outcome Measure(s): Ovarian histologic analysis, ovarian reserve measurements, and fertility in mating trials. Result(s): Rapid ovarian failure was induced in female macaques by ovarian application of 15 Gy of radiation. Females given S1P or FTY720 by direct intraovarian cannulation for 1 week before ovarian irradiation rapidly resumed menstrual cycles because of maintenance of follicles, with greater beneficial effects achieved using FTY720. Monkeys given the S1P mimetic before ovarian irradiation also became pregnant in mating trials. Offspring conceived and delivered by radioprotected females developed normally and showed no evidence of genomic instability, as measured by micronucleus frequency in reticulocytes. Adult human ovarian cortical tissue xenografted into mice also exhibited a reduction in radiation-induced primordial oocyte depletion when preexposed to S1P. Conclusion(s): S1P and its analogs hold clinical promise as therapeutic agents to preserve ovarian function and fertility in female cancer patients exposed to cytotoxic treatments. (Fertil Steril (R) 2011;95:1440-5. (C)2011 by American Society for Reproductive Medicine.) C1 [Tilly, Jonathan L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Dept Obstet & Gynecol,Vincent Ctr Reprod, Boston, MA 02114 USA. [Zelinski, Mary B.; Lawson, Maralee S.; Pau, K. Y. Francis; Toscano, Natalia P.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Reprod Sci, Beaverton, OR USA. [Murphy, Mark K.] Battelle Pacific NW Div, Richland, WA USA. [Jurisicova, Andrea; Casper, Robert F.] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Obstet & Gynecol, Toronto, ON M5G 1X5, Canada. [Jurisicova, Andrea; Casper, Robert F.] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Physiol, Toronto, ON M5G 1X5, Canada. [Jacob, Darla S.; Fanton, John K.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Anim Sci, Beaverton, OR USA. [Dertinger, Stephen D.] Litron Labs, Rochester, NY USA. RP Tilly, JL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Dept Obstet & Gynecol,Vincent Ctr Reprod, THR-901B,55 Fruit St, Boston, MA 02114 USA. EM jtilly@partners.org RI Jurisicova, Andrea/E-4580-2013; Casper, Robert/E-3775-2013 OI Casper, Robert/0000-0002-6249-462X FU United States National Institutes of Health [R01-HD45787, U54-HD18185, NCRR-RR00163]; Canada Research Chair Program; Canadian Institutes of Health Research [MOP 14058, MOP 84328]; Vincent Memorial Research Funds FX Supported by the United States National Institutes of Health (R01-HD45787, U54-HD18185, NCRR-RR00163), Canada Research Chair Program, Canadian Institutes of Health Research (operating grants MOP 14058 and MOP 84328), and Vincent Memorial Research Funds. NR 42 TC 30 Z9 32 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD MAR PY 2011 VL 95 IS 4 BP 1440 EP U289 DI 10.1016/j.fertnstert.2011.01.012 PG 13 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 730DA UT WOS:000288010900041 PM 21316047 ER PT J AU Chen, JY Chung, RT AF Chen, Jennifer Y. Chung, Raymond T. TI Can We Use the "C" Word With Confidence? Cure for Chronic Hepatitis C SO GASTROENTEROLOGY LA English DT Editorial Material ID SUSTAINED VIROLOGICAL RESPONSE; INTERFERON-ALPHA THERAPY; PLUS RIBAVIRIN; PEGINTERFERON ALPHA-2A; HCV RNA; VIRUS; MORTALITY; LIVER C1 [Chen, Jennifer Y.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Chung, Raymond T.] Massachusetts Gen Hosp, GI Unit, Boston, MA 02114 USA. RP Chen, JY (reprint author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. FU NIDDK NIH HHS [K24 DK078772, T32 DK007191] NR 14 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD MAR PY 2011 VL 140 IS 3 BP 766 EP 768 DI 10.1053/j.gastro.2011.01.018 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 730EC UT WOS:000288014700012 PM 21256845 ER PT J AU Stock, C Knudsen, AB Lansdorp-Vogelaar, I Haug, U Brenner, H AF Stock, Christian Knudsen, Amy B. Lansdorp-Vogelaar, Iris Haug, Ulrike Brenner, Hermann TI Colorectal cancer mortality prevented by use and attributable to nonuse of colonoscopy SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID SERVICES TASK-FORCE; COST-EFFECTIVENESS; SCREENING SIGMOIDOSCOPY; DECISION-ANALYSIS; AMERICAN-COLLEGE; RISK-FACTORS; SURVEILLANCE; POPULATION; ENDOSCOPY; REDUCTION AB Background: Use of colonoscopy is thought to reduce colorectal cancer (CRC) mortality, but its impact at the population level is unclear. Objective: To estimate the effect of current colonoscopy use on CRC mortality and its further potential in reducing CRC mortality. Design: Population-level analysis was performed by using the concepts of prevented and attributable fractions, by using data from the National Health Interview Survey, the Surveillance, Epidemiology and End Results Program, and estimates of the effectiveness of colonoscopy at reducing CRC mortality. Setting: The 2005 U.S. population aged 50 years and older. Exposure: Colonoscopy within 10 years or less. Main Outcome Measurements: Percentages and absolute numbers of CRC deaths prevented and potentially preventable by colonoscopy. Limitations: Uncertainty in effectiveness estimates. Results: Overall, the proportions of CRC deaths in 2005 prevented by colonoscopy (ie, the prevented fractions) range from 13% (95% CI, 11%-15%) to 19% (95% CI, 12%-24%) across the estimates of colonoscopy effectiveness. Corresponding numbers of CRC deaths prevented range from 7314 (95% Cl, 6010-8467) to 11,711(95% CI, 7077-14,898). The proportions of CRC deaths attributable to nonuse of colonoscopy (ie, the attributable fractions) range from 28% (95% CI, 22%-33%) to 44% (95% CI, 24%-60%), depending on the assumed effectiveness. Corresponding numbers of CRC deaths attributed to nonuse of colonoscopy range from 13,796 (95% CI, 11,076-16,255) to 22,088 (95% CI, 12,189-29,947). Conclusions: Although we estimate that colonoscopy has prevented substantial numbers of CRC deaths, many more deaths could have been prevented with more widespread use. These findings highlight the potential benefits from public health interventions to increase the use of screening colonoscopy. (Gastrointest Enclose 2011;73:435-43.) C1 [Stock, Christian; Haug, Ulrike; Brenner, Hermann] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, D-69120 Heidelberg, Germany. [Knudsen, Amy B.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Lansdorp-Vogelaar, Iris] Erasmus MC, Rotterdam, Netherlands. RP Brenner, H (reprint author), German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Neuenheimer Feld 280, D-69120 Heidelberg, Germany. RI Stock, Christian/F-6180-2015; Brenner, Hermann/B-4627-2017; OI Brenner, Hermann/0000-0002-6129-1572; Haug, Ulrike/0000-0002-1886-2923 FU German Research Association, Bonn, Germany; Klaus Tschira Foundation, Heidelbeig, Germany FX This work was supported in part by grants from the German Research Association (Graduate Program 793), Bonn, Germany, and from the Klaus Tschira Foundation, Heidelbeig, Germany. All authors disclosed no financial relationships relevant to this publication. NR 55 TC 19 Z9 21 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2011 VL 73 IS 3 BP 435 EP 443 DI 10.1016/j.gie.2010.12.005 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 728VU UT WOS:000287903400005 PM 21353840 ER PT J AU Ko, CW Dominitz, JA Green, P Kreuter, W Baldwin, LM AF Ko, Cynthia W. Dominitz, Jason A. Green, Pam Kreuter, William Baldwin, Laura-Mae TI Accuracy of Medicare claims for identifying findings and procedures performed during colonoscopy SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID POSITIVE PREDICTIVE-VALUE; COLORECTAL-CANCER; ADENOMA DETECTION; SCREENING COLONOSCOPY; ADMINISTRATIVE DATA; FAMILY PHYSICIAN; POLYP DETECTION; DETECTION RATES; UNITED-STATES; SURVEILLANCE AB Background: Administrative claims data are frequently used for quality measurement. Objective: To examine the accuracy of administrative claims for potential colonoscopy quality measures, including findings (polyp or tumor detection), procedures (biopsy or polypectomy), and incomplete colonoscopy. Design: Cross-sectional study. Patients: Patients age 65 and older undergoing colonoscopy in the Clinical Outcomes Research Initiative National Endoscopic Database in 2006. We linked colonoscopy records for these patients to Medicare colonoscopy claims by using patient age, sex, date of procedure, and performing provider's Unique Physician Identification Number. Main Outcome Measurements: Sensitivity, specificity, positive and negative predictive values of the Medicare claims for potential quality measures, including colonoscopy findings and procedures. Results: We linked Medicare colonoscopy claims to 15,168 of the 30,011 Clinical Outcomes Research Initiative colonoscopy records. Sensitivity of the claims for colon polyps was 93.4%, with a specificity of 97.8%. Sensitivity of claims for other diagnoses, including colorectal tumors was suboptimal, although specificity was high. In contrast, sensitivity of claims for procedures biopsy (with or without cautery) or polypectomy was high (87.2%-97.6%), with specificity > 97%. Claims had poor sensitivity for identification of incomplete colonoscopy. Limitations: Potential for inaccurate matching of colonoscopy records and Medicare claims. Conclusions: Medicare claims have high sensitivity and specificity for polyp detection, biopsy, and polypectomy at colonoscopy, but sensitivity is low for other diagnoses such as tumor detection and for incomplete colonoscopy. Caution is needed when using Medicare claims data for certain important quality measures, in particular tumor detection and incomplete colonoscopy. (Gastrointest Enclose 2011;73:447-53.) C1 [Ko, Cynthia W.] Univ Washington, Div Gastroenterol, Dept Med, Seattle, WA 98195 USA. [Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Ko, CW (reprint author), Univ Washington, Div Gastroenterol, Dept Med, Box 356424, Seattle, WA 98195 USA. EM cwko@u.washington.edu OI Dominitz, Jason/0000-0002-8070-7086 FU NIH [1R01CA127659]; American Society of Gastrointestinal Endoscopy; VA Puget Sound Health Care System, Seattle, Washington FX This work was supported by NM grant 1R01CA127659. Dr. Dominitz is supported in part by a career development award from the American Society of Gastrointestinal Endoscopy. This material is the result of work supported in part by resources from the VA Puget Sound Health Care System, Seattle, Washington. The views and opinions of authors expressed herein do not necessarily slate or reflect those of the United States Government or the Department of Veterans Affairs. All other authors disclosed no financial relationships relevant to this publication. NR 29 TC 19 Z9 19 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2011 VL 73 IS 3 BP 447 EP 453 DI 10.1016/j.gie.2010.07.044 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 728VU UT WOS:000287903400007 PM 20950800 ER PT J AU Spiegel, BMR AF Spiegel, Brennan M. R. TI Does time of day affect polyp detection rates from colonoscopy? SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material ID COLORECTAL-CANCER; TECHNICAL PERFORMANCE; SLEEP-DEPRIVATION; QUALITY; POLYPECTOMY; ENDOSCOPY; PATIENT; FATIGUE; SAFETY; IMPACT C1 [Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Spiegel, Brennan M. R.] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Vet Affairs Ctr Outcomes Res & Educ, Los Angeles, CA 90095 USA. RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. NR 23 TC 3 Z9 3 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2011 VL 73 IS 3 BP 476 EP 479 DI 10.1016/j.gie.2010.09.026 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 728VU UT WOS:000287903400012 PM 21353844 ER PT J AU Stoffel, EM Saltzman, JR AF Stoffel, Elena M. Saltzman, John R. TI Preventing missed colorectal cancers: is "rear view" the answer? SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material ID COLONOSCOPY; NEOPLASMS C1 [Stoffel, Elena M.] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Sch Med,Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA. RP Stoffel, EM (reprint author), Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Sch Med,Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2011 VL 73 IS 3 BP 490 EP 492 DI 10.1016/j.gie.2010.11.004 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 728VU UT WOS:000287903400014 PM 21353845 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Arguments against costly quality assurance SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID COLONOSCOPY; INDICATORS; GASTROENTEROLOGY; MANAGEMENT; CANCER C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. NR 11 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2011 VL 73 IS 3 BP 567 EP 569 DI 10.1016/j.gie.2010.12.020 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 728VU UT WOS:000287903400028 PM 21353854 ER PT J AU Karaca, C Cizginer, S Konuk, Y Kambadakone, A Turner, BG Mino-Kenudson, M Sahani, DV Macfarlane, C Brugge, W AF Karaca, Cetin Cizginer, Sevdenur Konuk, Yusuf Kambadakone, Avinash Turner, Brian G. Mino-Kenudson, Mari Sahani, Dushyant V. Macfarlane, Chelsea Brugge, William TI Feasibility of EUS-guided injection of irinotecan-loaded microspheres into the swine pancreas SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID TRANSARTERIAL CHEMOEMBOLIZATION; CANCER AB Background: LC beads (Biocompatibles International plc) are designed for the time-released delivery of the chemotherapeutic agent irinotecan into focal, hypervascularized, hepatic tumors. Objective: To determine the feasibility of EUS-guided injection of LC beads (with/without irinotecan) into the swine pancreas. Design: Survival animal study. Setting: Academic center. Subjects: This study involved 12 Yorkshire swine. Intervention: LC beads without irinotecan and loaded with up to 300 mg of irinotecan were injected under EUS guidance with a 19-gauge needle into the tail of the pancreas. CT scanning and necropsy with histology were performed at day 7. Main Outcome Measurements: Feasibility of the injections, gross and microscopic evidence of pancreatic inflammation, and clinical tolerance by the animals. Results: After injection of LC beads with/without irinotecan, in 10 of 12 animals an intrapancreatic, hyperechoic focus with an average diameter of 2.2 cm was visible by EIS, and a hypodense area in the tail of the pancreas was visible by contrast CT. In 2 animals (1 with irinotecan and 1 without) no beads were seen on CT. In 10 of 12 animals, a depot of beads was located in the tail of the pancreas on gross inspection and histology. Drug depot with only localized pancreatic tissue reactions was seen on histopathologic review. Limitations: Animal study. Conclusion: The EUS-guided injection of LC beads (with/without irinotecan) into the pancreas of the pig is feasible and safe. This technique is a potential minimally invasive local treatment option for locally advanced pancreatic cancer. C1 [Karaca, Cetin; Cizginer, Sevdenur; Turner, Brian G.; Brugge, William] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Konuk, Yusuf] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Kambadakone, Avinash; Sahani, Dushyant V.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Macfarlane, Chelsea] Biocompatibles Int Plc, Surrey, England. RP Brugge, W (reprint author), 55 Fruit St,Blake 4, Boston, MA 02114 USA. FU Biocompatibles UK Ltd. FX W. Brugge was funded by a grant from Biocompatibles UK Ltd. C. Macfarlane is an employee of Biocompatibles, and W. Brugge is a consultant for Boston Scientific and Xlumena. No other financial relationships relevant to this publication were disclosed. NR 13 TC 7 Z9 7 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2011 VL 73 IS 3 BP 603 EP 606 DI 10.1016/j.gie.2010.11.003 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 728VU UT WOS:000287903400034 PM 21238959 ER PT J AU Cai, WL Lee, JG Zalis, ME Yoshida, H AF Cai, Wenli Lee, June-Goo Zalis, Michael E. Yoshida, Hiroyuki TI Mosaic Decomposition: An Electronic Cleansing Method for Inhomogeneously Tagged Regions in Noncathartic CT Colonography SO IEEE TRANSACTIONS ON MEDICAL IMAGING LA English DT Article DE Abdominal; computer-aided diagnosis; CT colonography; electronic cleansing; X-ray and CT ID ORAL SODIUM-PHOSPHATE; VIRTUAL COLONOSCOPY; COLORECTAL-CANCER; PERFORMANCE; SUBTRACTION; CLASSIFICATION; SEGMENTATION; PREFERENCES; INTENSITY; POLYPS AB Electronic cleansing (EC) is a method that segments fecal material tagged by an X-ray-opaque oral contrast agent in computed tomographic colonography (CTC) images, and effectively removes the material for digitally cleansing the colon. In this study, we developed a novel EC method, called mosaic decomposition (MD), for reduction of the artifacts due to incomplete cleansing of inhomogeneously tagged fecal material in CTC images, especially in noncathartic CTC images. In our approach, the entire colonic region, including the residual fecal regions, was first decomposed into a set of local homogeneous regions, called tiles, after application of a 3-D watershed transform to the CTC images. Each tile was then subjected to a single-class support vector machine (SVM) classifier for soft-tissue discrimination. The feature set of the soft-tissue SVM classifier was selected by a genetic algorithm (GA). A scalar index, called a soft-tissue likelihood, is formulated for differentiation of the soft-tissue tiles from those of other materials. Then, EC based on MD, called MD-cleansing, is performed by first initializing of the level-set front with the classified tagged regions; the front is then evolved by use of a speed function that was designed, based on the soft-tissue index, to reserve the submerged soft-tissue structures while suppressing the residual fecal regions. The performance of the MD-cleansing method was evaluated by use of a phantom and of clinical cases. In the phantom evaluation, our MD-cleansing was trained with the supine (prone) scan and tested on the prone (supine) scan, respectively. In both cases, the sensitivity and specificity of classification were 100%. The average cleansing ratio was 90.6%, and the soft-tissue preservation ratio was 97.6%. In the clinical evaluation, 10 noncathartic CTC cases (20 scans) were collected, and the ground truth of a total of 2095 tiles was established by manual assignment of a material class to each tile. Five cases were randomly selected for training GA/SVM, and the remaining five cases were used for testing. The overall sensitivity and specificity of the proposed classification scheme were 97.1% and 85.3%, respectively, and the accuracy was 94.6%. The area under the ROC curve (Az) was 0.96. Our results indicated that the use of MD-cleansing substantially improved the effectiveness of our EC method in the reduction of incomplete cleansing artifacts. C1 [Cai, Wenli; Lee, June-Goo; Zalis, Michael E.; Yoshida, Hiroyuki] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Cai, Wenli; Lee, June-Goo; Zalis, Michael E.; Yoshida, Hiroyuki] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Cai, WL (reprint author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. EM cai.wenli@mgh.harvard.edu; lee.june@mgh.harvard.edu; mzalis@mgh.harvard.edu; yoshida.hiro@mgh.harvard.edu FU Cancer Prevent Foundation [CA095279, CA131718]; U.S. Public Health Service; American Cancer Society [RSG-05-088-01-CCE] FX Manuscript received June 14, 2010; revised September 19, 2010; accepted September 27, 2010. Date of publication October 14, 2010; date of current version March 02, 2011. This work was supported in part by Cancer Prevent Foundation Research Grant CA095279 and Grant CA131718, in part by the U.S. Public Health Service, and in part by the American Cancer Society under Research Scholar Grant RSG-05-088-01-CCE. Asterisk indicates corresponding author. NR 58 TC 12 Z9 16 U1 0 U2 5 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 0278-0062 J9 IEEE T MED IMAGING JI IEEE Trans. Med. Imaging PD MAR PY 2011 VL 30 IS 3 BP 559 EP 574 DI 10.1109/TMI.2010.2087389 PG 16 WC Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Engineering, Electrical & Electronic; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Engineering; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA 728GJ UT WOS:000287862300003 PM 20952332 ER PT J AU Guerin, B El Fakhri, G AF Guerin, Bastien El Fakhri, Georges TI Novel Scatter Compensation of List-Mode PET Data Using Spatial and Energy Dependent Corrections SO IEEE TRANSACTIONS ON MEDICAL IMAGING LA English DT Article DE Absolute quantification; energy information; fully three-dimensional (3-D) reconstruction; list-mode positron emission tomography (PET) data; scatter correction ID MONTE-CARLO-SIMULATION; EMISSION-TOMOGRAPHY; 3D PET; IMAGE-RECONSTRUCTION; ALGORITHM; IMPLEMENTATION; COINCIDENCES; PERFORMANCE AB With the widespread use of positron emission tomography (PET) crystals with greatly improved energy resolution (e. g., 11.5% with LYSO as compared to 20% with BGO) and of list-mode acquisitions, the use of the energy of individual events in scatter correction schemes becomes feasible. We propose a novel scatter approach that incorporates the energy of individual photons in the scatter correction and reconstruction of list-mode PET data in addition to the spatial information presently used in clinical scanners. First, we rewrite the Poisson likelihood function of list-mode PET data including the energy distributions of primary and scatter coincidences and show that this expression yields an MLEM reconstruction algorithm containing both energy and spatial dependent corrections. To estimate the spatial distribution of scatter coincidences we use the single scatter simulation (SSS). Next, we derive two new formulae which allow estimation of the 2-D (coincidences) energy probability density functions (E-PDF) of primary and scatter coincidences from the 1-D (photons) E-PDFs associated with each photon. We also describe an accurate and robust object-specific method for estimating these 1-D E-PDFs based on a decomposition of the total energy spectra detected across the scanner into primary and scattered components. Finally, we show that the energy information can be used to accurately normalize the scatter sinogram to the data. We compared the performance of this novel scatter correction incorporating both the position and energy of detected coincidences to that of the traditional approach modeling only the spatial distribution of scatter coincidences in 3-D Monte Carlo simulations of a medium cylindrical phantom and a large, nonuniform NCAT phantom. Incorporating the energy information in the scatter correction decreased bias in the activity distribution estimation by similar to 20% and similar to 40% in the cold regions of the large NCAT phantom at energy resolutions 11.5% and 20% at 511 keV, respectively, compared to when using the spatial information alone. C1 [El Fakhri, Georges] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Guerin, Bastien; El Fakhri, Georges] Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA. RP El Fakhri, G (reprint author), Harvard Univ, Sch Med, Boston, MA 02114 USA. EM guerin@pet.mgh.harvard.edu; elfakhri@pet.mgh.harvard.edu RI Guerin, Bastien/P-1412-2014 FU American Heart Association [AHA-0655909T]; U.S. National Institutes of Health [NIH-R01-HL95076] FX Manuscript received August 31, 2010; revised November 09, 2010; accepted November 15, 2010. Date of publication November 29, 2010; date of current version March 02, 2011. This work was supported in part by the American Heart Association under Grant AHA-0655909T and in part by the U.S. National Institutes of Health under Grant NIH-R01-HL95076. Asterisk indicates corresponding author. NR 26 TC 11 Z9 11 U1 2 U2 10 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 0278-0062 J9 IEEE T MED IMAGING JI IEEE Trans. Med. Imaging PD MAR PY 2011 VL 30 IS 3 BP 759 EP 773 DI 10.1109/TMI.2010.2095025 PG 15 WC Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Engineering, Electrical & Electronic; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Engineering; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA 728GJ UT WOS:000287862300019 PM 21118770 ER PT J AU Lewinsohn, DA Gold, MC Lewinsohn, DM AF Lewinsohn, Deborah A. Gold, Marielle C. Lewinsohn, David M. TI Views of immunology: effector T cells SO IMMUNOLOGICAL REVIEWS LA English DT Review DE infectious diseases; T cells; natural killer T cells; antigen presentation; processing; cytotoxicity ID TUMOR-NECROSIS-FACTOR; MYCOBACTERIUM-TUBERCULOSIS INFECTION; LISTERIA-MONOCYTOGENES INFECTION; INTERFERON-GAMMA PRODUCTION; ANTIGEN-PROCESSING PATHWAY; NITRIC-OXIDE SYNTHASE; IFN-GAMMA; DENDRITIC CELLS; FACTOR-ALPHA; PROTECTIVE IMMUNITY AB For many intracellular bacteria, both adaptively acquired and innately encoded effector T cells play a central role in the control, and in some cases, clearance of these pathogens. Through the rapid identification of those cells harboring intracellular bacteria, effector T cells have the capacity to both directly control the infection and shape the immune response to the pathogen. Here, we review the mechanisms by which effector T cells control intracellular infection and emphasize the means by which they recognize their targets. As will become evident, the diversity of both redundant and non-redundant effector mechanisms in conjunction with broad recognition of both protein and non-protein antigens allows for the identification of a broad array of bacterial pathogens and lessens the likelihood of immune evasion. C1 [Lewinsohn, Deborah A.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97201 USA. [Gold, Marielle C.; Lewinsohn, David M.] Portland VA Med Ctr, Portland, OR USA. RP Lewinsohn, DM (reprint author), PVAMC OHSU, R&D 11,3710 SW US Vet Rd, Portland, OR 97239 USA. EM lewinsod@ohsu.edu RI Lewinsohn, David/I-4936-2013; OI Lewinsohn, David/0000-0001-9906-9494; Gold, Marielle/0000-0003-2505-3291 NR 160 TC 16 Z9 17 U1 0 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0105-2896 J9 IMMUNOL REV JI Immunol. Rev. PD MAR PY 2011 VL 240 BP 25 EP 39 DI 10.1111/j.1600-065X.2010.00997.x PG 15 WC Immunology SC Immunology GA 726FO UT WOS:000287705100003 PM 21349084 ER PT J AU Singh, T Katiyar, SK AF Singh, Tripti Katiyar, Santosh K. TI Honokiol, a phytochemical from Magnolia spp., inhibits breast cancer cell migration by targeting nitric oxide and cyclooxygenase-2 SO INTERNATIONAL JOURNAL OF ONCOLOGY LA English DT Article DE cancer cell migration; cyclooxygenase-2; guanylate cyclase; nitric oxide; prostaglandin E(2); breast cancer cells; honokiol ID GRAPE SEED PROANTHOCYANIDINS; PROSTAGLANDIN-H SYNTHASE; TUMOR PROGRESSION; LUNG-CANCER; MULTIFACETED ROLES; IN-VITRO; KAPPA-B; GROWTH; EXPRESSION; ANGIOGENESIS AB In the present study, we report the effects of honokiol, a phytochemical from Magnolia spp., on cancer cell migration capacity and the molecular mechanisms underlying these effects using breast cancer cell lines as an in vitro model. Using cell migration assays, we found that the treatment of human breast cancer cells (MCF-7) and murine mammary cancer cells (4T1) with honokiol resulted in a dose-dependent inhibition of migration of these cells, which was associated with a reduction in nitric oxide (NO) levels. The cell migration capacity was decreased in the presence of N(G)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NO synthase. Honokiol reduced the elevated levels of cyclic guanosine monophosphate (cGMP) in the cells, while the treatment of 4T1 cells with guanylate cyclase (GC) inhibitor 1-H-[1,2,4]oxadiaxolo[4,3-a]quinolalin-1-one (ODQ) reduced the migration of cells and the levels of cGMP. The presence of 8-bromoguanosine 3'5'-cyclic monophosphate, an analogue of cGMP, enhanced the migration of these cells, suggesting a role for GC in the migration of 4T1 cells. Honokiol also inhibited the levels of cyclooxygenase-2 (COX-2) and prostaglandin (PG) E(2) in 4T1 cells. The transfection of 4T1 cells with COX-2 siRNA resulted in a reduction in cell migration. ODQ and L-NAME also decreased the levels of PGE(2) in 4T1 cells suggesting a role for COX-2/PGE(2) in cell migration. Moreover, honokiol inhibited the activation of nuclear factor kappa B (NF-kappa B), an upstream regulator of COX-2 and iNOS, in 4T1 cells. These results indicate that NO and COX-2 are the key targets of honokiol in the inhibition of breast cancer cell migration, an essential step in invasion and metastasis. C1 [Singh, Tripti; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama, Nutr Obes Res Ctr, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration FX This study was supported by funds from the Veterans Administration Merit Review Award (S.K.K.). NR 42 TC 17 Z9 20 U1 1 U2 5 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1019-6439 J9 INT J ONCOL JI Int. J. Oncol. PD MAR PY 2011 VL 38 IS 3 BP 769 EP 776 DI 10.3892/ijo.2011.899 PG 8 WC Oncology SC Oncology GA 727UV UT WOS:000287829200019 PM 21225228 ER PT J AU Cerda, R Munoz, M Zeladita, J Wong, M Sebastian, JL Bonilla, C Bayona, J Sanchez, E Arevalo, J Caldas, A Shin, S AF Cerda, R. Munoz, M. Zeladita, J. Wong, M. Sebastian, J. L. Bonilla, C. Bayona, J. Sanchez, E. Arevalo, J. Caldas, A. Shin, S. TI Health care utilization and costs of a support program for patients living with the human immunodeficiency virus and tuberculosis in Peru SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE adherence interventions; TB-HIV co-infection; cost analysis; health care utilization ID ANTIRETROVIRAL THERAPY ADHERENCE; HIV-ASSOCIATED TUBERCULOSIS; SELF-ADMINISTERED THERAPY; TRIAL; SURVIVAL; USERS AB OBJECTIVE : To evaluate a support program for patients co-infected with the human immunodeficiency virus and tuberculosis in terms of its impact on clinical outcomes and resource utilization. METHODS: We compared co-infected patients receiving Community-Based Accompaniment with Supervised Antiretrovirals (CASA) with matched patients receiving standard of care (control group) in two health districts of Lima, Peru. We recorded clinical outcomes, costs of the intervention, and health care utilization by each patient during 24 months of follow-up. RESULTS: There were 33 patients in each group, representing 58.0 person-years (py) in the CASA group and 45.6 py in the control group. At 24 months of follow-up, the CASA group had a lower hazard of dying or defaulting from treatment (HR adj 0.34, 95%CI 0.12-0.98), experienced fewer hospital days (IRR adj 0.37, 95%CI 0.14-0.99) and had fewer out-patient visits (IRR adj 0.75, 95%CI 0.63-0.89). Assigning costs to significantly different measures of health care utilization using WHO-CHOICE (World Health Organization Choosing interventions that are cost effective) data, CASA was associated with savings of US$551/py. Considering intervention costs of US$2097/py, the net costs of CASA were US$1546/py. CONCLUSIONS: Our intervention was associated with clinical improvements and reduced health care utilization, which significantly offset the cost of the intervention over 2 years of follow-up. C1 [Cerda, R.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Cerda, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Munoz, M.; Zeladita, J.; Wong, M.; Bayona, J.] Socios Salud, Carabayllo, Peru. [Sebastian, J. L.; Bonilla, C.] Minist Salud, Peruvian HIV Program, Lima, Peru. [Bayona, J.; Caldas, A.; Shin, S.] Partners Hlth, Boston, MA USA. [Sanchez, E.] Hosp Nacl Hipolito Unanue, Lima, Peru. [Arevalo, J.] Hosp Dos de Mayo, Lima, Peru. [Shin, S.] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA. RP Cerda, R (reprint author), Harvard Univ, Sch Publ Hlth, 7th Floor,651 Huntington Ave, Boston, MA 02115 USA. EM rcerda@partners.org FU Office for AIDS Research at the National Institutes for Health; Harvard Medical School, David Rockefeller Center for Latin American Studies at 20 Harvard University, Socios En Salud, and Partners In Health FX The authors thank C Rojas, M Callacna, the accounting team of Socios En Salud, as well as the patients and community health workers who participated in the study. This project was supported by the Office for AIDS Research at the National Institutes for Health, the Eleanor and Miles Shore Fellowship at Harvard Medical School, David Rockefeller Center for Latin American Studies at 20 Harvard University, Socios En Salud, and Partners In Health. NR 25 TC 2 Z9 2 U1 1 U2 4 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD MAR PY 2011 VL 15 IS 3 BP 363 EP 368 PG 6 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 729WH UT WOS:000287984200012 PM 21333104 ER PT J AU Korthuis, PT Fiellin, DA Fu, RW Lum, PJ Altice, FL Sohler, N Tozzi, MJ Asch, SM Botsko, M Fishl, M Flanigan, TP Boverman, J McCarty, D AF Korthuis, P. Todd Fiellin, David A. Fu, Rongwei Lum, Paula J. Altice, Frederick L. Sohler, Nancy Tozzi, Mary J. Asch, Steven M. Botsko, Michael Fishl, Margaret Flanigan, Timothy P. Boverman, Joshua McCarty, Dennis CA BHIVES Collaborative TI Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE quality of health care; HIV; quality indicators; health care; buprertorphine; opioid-related disorders; heroin dependence ID HUMAN-IMMUNODEFICIENCY-VIRUS; SUBSTANCE-ABUSE TREATMENT; RESEARCH INITIATIVE QUERI; ADDICTION SEVERITY INDEX; HEALTH-CARE; UNITED-STATES; DRUG-USERS; INTEGRATED BUPRENORPHINE/NALOXONE; ANTIRETROVIRAL ADHERENCE; SERVICES UTILIZATION AB Background: Opioid-dependent HIV-infected patients are less likely to receive HIV quality of care indicators (QIs) compared with nondependent patients. Buprenorphine/naloxone maintenance therapy (bup/nx) could affect the quality of HIV care for opioid-dependent patients. Methods: We abstracted 16 QIs from medical records at nine HIV clinics 12 months before and after initiation of bup/nx versus other treatment for opioid dependence. Summary quality scores (number of QIs received/number eligible X 100) were calculated. We compared change in QIs and summary quality scores in patients receiving bup/nx versus other participants. Results: One hundred ninety-four of 268 participants summary quality scores increased over 12 months for participants receiving bup/nx (45.6% to 51.6%, P < 0.001) but not other treatment (48.6% to 47.8%, P = 0.788). Bup/nx participants experienced improvements in six of 16 HIV QIs versus three of 16 QIs in other participants. Improvements were mostly in preventive and monitoring care domains. In multivariable analysis, bup/nx was associated with improved summary quality score (beta 8.55; 95% confidence interval, 2.06-15.0). Conclusions: In this observational cohort study, HIV-infected patients with opioid dependence received approximately half of HIV QIs at baseline. Buprenorphine treatment was associated with improvement in HIV QIs at 12 months. Integration of bup/nx into HIV clinics may increase receipt of high-quality HIV care. Further research is required to assess the effect of improved quality of HIV care on clinical outcomes. C1 [Korthuis, P. Todd; Boverman, Joshua] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. [Korthuis, P. Todd; Fu, Rongwei; McCarty, Dennis] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. [Fu, Rongwei] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97239 USA. [Fiellin, David A.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA. [Fiellin, David A.] Yale Univ, Sch Med, Dept Invest Med, New Haven, CT 06510 USA. [Altice, Frederick L.] AIDS Program, Infect Dis Sect, New Haven, CT USA. [Lum, Paula J.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Posit Hlth Program, San Francisco, CA USA. [Sohler, Nancy] CUNY City Coll, Sophie Davis Sch Biomed Educ, New York, NY 10031 USA. [Tozzi, Mary J.] CORE Ctr, Chicago, IL USA. [Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Botsko, Michael] Ctr HIV Educ Studies & Training, New York, NY USA. [Fishl, Margaret] Univ Miami, Sch Med, Miami, FL USA. [Flanigan, Timothy P.] Miriam Hosp, Providence, RI 02906 USA. [Flanigan, Timothy P.] Brown Med Sch, Providence, RI USA. RP Korthuis, PT (reprint author), Oregon Hlth & Sci Univ, Dept Med, 3181 SW Sam Jackson Pk Rd,Mail Code L-475, Portland, OR 97239 USA. EM korthuis@ohsu.edu FU US Department of Health and Human Services, Health Resources and Services Administration; HIV/AIDS Bureau's Special Project of National Significance [H97HA03799]; National Institutes of Health, National Institute on Drug Abuse [K23 DA019809, K24 DA 0170720] FX This publication was funded by grants from the US Department of Health and Human Services, Health Resources and Services Administration, HIV/AIDS Bureau's Special Project of National Significance (H97HA03799), and the National Institutes of Health, National Institute on Drug Abuse (K23 DA019809 for P.T.K. and K24 DA 0170720 for F.L.A.). The contents of the publication are solely the responsibility of the authors and do not necessarily represent the views of the funding agencies or the US government. NR 41 TC 22 Z9 22 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAR 1 PY 2011 VL 56 SU 1 BP S83 EP S90 DI 10.1097/QAI.0b013e31820bc9a5 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 729YL UT WOS:000287990500013 PM 21317600 ER PT J AU Attardi, BJ Marck, BT Matsumoto, AM Koduri, S Hild, SA AF Attardi, Barbara J. Marck, Brett T. Matsumoto, Alvin M. Koduri, Sailaja Hild, Sheri A. TI Long-Term Effects of Dimethandrolone 17 beta-Undecanoate and 11 beta-Methyl-19-Nortestosterone 17 beta-Dodecylcarbonate on Body Composition, Bone Mineral Density, Serum Gonadotropins, and Androgenic/Anabolic Activity in Castrated Male Rats SO JOURNAL OF ANDROLOGY LA English DT Article DE Synthetic androgens; DEXA; lean body mass; fat body mass ID TESTOSTERONE THERAPY; ANDROGENS; MEN AB The potent androgens dimethandrolone 17 beta-undecanoate (DMAU) and 11 beta-methyl-19-nortestosterone 17 beta-dodecylcarbonate (11 beta-MNTDC) are in development for androgen replacement therapy and hormonal contraception in men. They can be delivered either orally or as long-acting injectables. In the current study, their long-term effects on body composition (percentage lean and fat mass); bone mineral density (BMD); serum gonadotropin levels; and weights of the prostate, seminal vesicles, and levator ani muscle were assessed. Four-week-old male rats were sham-operated (intact) or castrated (Cx) and treated subcutaneously for 16 weeks postsurgery with vehicle (Cx, intact), DMAU, or 11 beta-MNTDC every 4 weeks; testosterone enanthate (TE) every 2 weeks; or a testosterone (T) implant. There were significant differences in body weights over time with a general trend of intact = Cx + T = Cx + TE > Cx + 11 beta-MNTDC > Cx > Cx + DMAU. At week 18, rats were evaluated by dual-energy x-ray absorptiometry using the whole-body function of the Hologic software. The percentage lean body mass and BMD were lower (P<.05) in Cx rats than intact rats but equivalent in all groups of androgen-treated Cx rats and intact rats (P>.05). The highest percentage body fat was observed in Cx rats. Only DMAU- and 11 beta-MNTDC treated rats had lower percentage body fat compared with Cx rats (P<.05). Prostate, seminal vesicles, and levator ani muscle weights, corrected for final body weight, were decreased (P<.05) in Cx compared with intact rats and increased to varying extents in androgen-treated Cx rats compared with Cx rats (P<.05). The most marked increases were observed in the DMAU-treated rats in which prostate and seminal vesicle weights/kg body weight were 2.4 to 2.7 times those of intact rats, and levator ani muscle weights were increased approximately 1.5-fold. Blood was collected from the tail vein at weeks 4, 8, 12, and 16 for measurement of serum levels of androgens and at necropsy at week 18 for measurement of serum gonadotropins. Serum levels of luteinizing hormone and follicle-stimulating hormone were greatly elevated in Cx rats at week 18 and suppressed to levels comparable to those in intact rats by DMAU, 11 beta-MNTDC, and T implants (P>.05). Collectively, our data indicate that androgen replacement with DMAU or 11 beta-MNTDC in Cx rats resulted in favorable changes in body composition and maintenance of BMD comparable to those of T. C1 [Attardi, Barbara J.] BIOQUAL Inc, Mol Endocrinol Lab, Div Reprod Endocrinol & Toxicol, Rockville, MD 20850 USA. [Marck, Brett T.; Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Marck, Brett T.; Matsumoto, Alvin M.] Univ Washington, Sch Med, Seattle, WA USA. RP Attardi, BJ (reprint author), BIOQUAL Inc, Mol Endocrinol Lab, Div Reprod Endocrinol & Toxicol, 9600 Med Ctr Dr, Rockville, MD 20850 USA. EM bjattardi@bioqual.com FU NICHD [NO1-HD-2-3338] FX This work was supported by NICHD contract NO1-HD-2-3338 awarded to BIOQUAL Inc. NR 16 TC 9 Z9 10 U1 0 U2 2 PU AMER SOC ANDROLOGY, INC PI LAWRENCE PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 USA SN 0196-3635 J9 J ANDROL JI J. Androl. PD MAR-APR PY 2011 VL 32 IS 2 BP 183 EP 192 DI 10.2164/jandrol.110.010371 PG 10 WC Andrology SC Endocrinology & Metabolism GA 724BA UT WOS:000287549900011 PM 20798389 ER PT J AU Stathatos, N Gaz, R Ross, DS Daniels, GH AF Stathatos, N. Gaz, R. Ross, D. S. Daniels, G. H. TI High Radioactive Iodine Uptake Despite a Fully Suppressed TSH in a Patient with Thyroid Cancer SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Editorial Material ID GRAVES-DISEASE C1 [Gaz, R.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Stathatos, N.; Ross, D. S.; Daniels, G. H.] Massachusetts Gen Hosp, Thyroid Unit, Boston, MA 02114 USA. [Stathatos, N.; Ross, D. S.; Daniels, G. H.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Stathatos, N (reprint author), Massachusetts Gen Hosp, Dept Med, 15 Parkman St,WACC 730S, Boston, MA 02114 USA. EM nstathatos@partners.org NR 2 TC 0 Z9 0 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAR PY 2011 VL 96 IS 3 BP 589 EP 589 DI 10.1210/jc.2010-2053 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 730GA UT WOS:000288020600022 PM 21378221 ER PT J AU Okike, K Kocher, MS Torpey, JL Nwachukwu, BU Mehlman, CT Bhandari, M AF Okike, Kanu Kocher, Mininder S. Torpey, Jennifer L. Nwachukwu, Benedict U. Mehlman, Charles T. Bhandari, Mohit TI Level of evidence and conflict of interest disclosure associated with higher citation rates in orthopedics SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE Citation rates; Impact factor; Conflict of interest; Level of evidence; Orthopedic surgery; Bibliometrics ID JOURNAL IMPACT FACTOR; ARTICLES AB Objective: To identify the scientific and nonscientific factors associated with rates of citation in the orthopedic literature. Study Design and Setting: All original clinical articles published in three general orthopedics journals between July 2002 and December 2003 were reviewed. Information was collected on variables plausibly related to rates of citation, including scientific and nonscientific factors. The number of citations at 5 years was ascertained and linear regression was used to identify factors associated with rates of citation. Results: In the multivariate analysis, factors associated with increased rates of citation at 5 years were high level of evidence (22.2 citations for level I or II vs. 10.8 citations for level III or IV; P = 0.0001), large sample size (18.8 citations for sample size of 100 or more vs. 7.9 citations for sample size of 25 or fewer; P < 0.0001), multiple institutions (15.2 citations for two or more centers vs. 11.1 citations for single center; P = 0.023), self-reported conflict of interest disclosure involving a nonprofit organization (17.4 citations for nonprofit disclosure vs. 10.6 citations for no disclosure; P = 0.027), and self-reported conflict of interest disclosure involving a for-profit company (26.1 citations for for-profit disclosure vs. 10.6 citations for no disclosure; P = 0.011). Conclusion: High level of evidence, large sample size, representation from multiple institutions, and conflict of interest disclosure are associated with higher rates of citation in orthopedics. (C) 2011 Elsevier Inc. All rights reserved. C1 [Okike, Kanu] Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA 02114 USA. [Okike, Kanu] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA. [Kocher, Mininder S.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Orthoped Surg, Boston, MA USA. [Torpey, Jennifer L.; Nwachukwu, Benedict U.] Harvard Univ, Sch Med, Boston, MA USA. [Mehlman, Charles T.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Pediat Orthoped Surg, Cincinnati, OH USA. [Bhandari, Mohit] McMaster Univ, Hamilton Gen Hosp, Div Orthopaed Surg, Hamilton, ON L8S 4L8, Canada. RP Okike, K (reprint author), Massachusetts Gen Hosp, Dept Orthoped Surg, 55 Fruit St, Boston, MA 02114 USA. EM okike@post.harvard.edu OI Okike, Kanu/0000-0001-9310-9969 FU ConMed Linvatec; National Institutes of Health; Scoliosis Research Society; University of Cincinnati; Abbott Spine; Depuy Spine; Globus Medical; Medtronic; Synthes; AO Foundation; Canadian Institutes of Health Research; Orthopaedic Research and Education Foundation; Orthopaedic Trauma Association; Osteosynthesis and Trauma Care Foundation; Physicians Services Incorporated Foundation; U.S Department of Defense; Depuy; Stryker; Smith & Nephew and Zimmer; Amgen; Osteogenix; Pfizer; Zelos FX The authors gratefully acknowledge the invaluable assistance of Dr. David Zurakowski. Dr. M.S.K. reports receiving grant support from ConMed Linvatec and serving as a consultant for ConMed Linvatec, Covidien, EBI/Biomet, and Smith & Nephew. Dr. C.T.M. reports receiving grant support from the National Institutes of Health, the Scoliosis Research Society, the University of Cincinnati, Abbott Spine, Depuy Spine, Globus Medical, Medtronic, and Synthes. Dr. M.B. reports receiving grant support from the AO Foundation, the Canadian Institutes of Health Research, the National Institutes of Health, the Orthopaedic Research and Education Foundation, the Orthopaedic Trauma Association, the Osteosynthesis and Trauma Care Foundation, the Physicians Services Incorporated Foundation, the U.S Department of Defense, Depuy, Stryker, Smith & Nephew and Zimmer and serving as a consultant for Amgen, Osteogenix, Pfizer, and Zelos. NR 17 TC 19 Z9 19 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD MAR PY 2011 VL 64 IS 3 BP 331 EP 338 DI 10.1016/j.jclinepi.2010.03.019 PG 8 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 712ZD UT WOS:000286703900016 PM 20947295 ER PT J AU Gradman, AH Basile, JN Carter, BL Bakris, GL AF Gradman, Alan H. Basile, Jan N. Carter, Barry L. Bakris, George L. CA Amer Soc Hypertension Writing Grp TI Combination Therapy in Hypertension SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID BLOOD-PRESSURE CONTROL; LOW-DOSE HYDROCHLOROTHIAZIDE; FELODIPINE EXTENDED-RELEASE; CONVERTING-ENZYME-INHIBITOR; HIGH CARDIOVASCULAR RISK; CALCIUM-CHANNEL BLOCKER; DOUBLE-BLIND; RANDOMIZED-TRIAL; ANTIHYPERTENSIVE TREATMENT; SYSTEMIC HYPERTENSION AB The goal of antihypertensive therapy is to abolish the risks associated with blood pressure (BP) elevation without adversely affecting quality of life. Drug selection is based on efficacy in lowering BP and in reducing cardiovascular (CV) end points, including stroke, myocardial infarction, and heart failure. Although the choice of initial drug therapy exerts some effect on long-term outcomes, it is evident that BP reduction per se is the primary determinant of CV risk reduction. Available data suggest that at least 75% of patients will require combination therapy to achieve contemporary BP targets, and increasing emphasis is being placed on the practical tasks involved in consistently achieving and maintaining goal BP in clinical practice. It is within this context that the American Society of Hypertension presents this Position Paper on Combination Therapy for Hypertension. It will address the scientific basis of combination therapy, present the pharmacologic rationale for choosing specific drug combinations, and review patient selection criteria for initial and secondary use. The advantages and disadvantages of single-pill (fixed) drug combinations and the implications of recent clinical trials involving specific combination strategies will also be discussed. J Clin Hypertens (Greenwich). 2011;13:146-154. (C) 2010 Wiley Periodicals, Inc. C1 [Gradman, Alan H.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA. [Basile, Jan N.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Carter, Barry L.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Iowa City, IA USA. [Bakris, George L.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA. [Gradman, Alan H.] Western Penn Hosp, Pittsburgh, PA 15224 USA. RP Gradman, AH (reprint author), 4800 Friendship Ave,Suite 3411N, Pittsburgh, PA 15224 USA. EM gradmanmd@aol.com NR 64 TC 41 Z9 43 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD MAR PY 2011 VL 13 IS 3 BP 146 EP 154 DI 10.1111/j.1751-7176.2010.00397.x PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 729FD UT WOS:000287933100004 PM 21366845 ER PT J AU Basile, J Babazadeh, S Lillestol, M Botha, J Yurkovic, C Weitzman, R AF Basile, Jan Babazadeh, Simon Lillestol, Michael Botha, Jaco Yurkovic, Carol Weitzman, Richard TI Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy With Hydrochlorothiazide Monotherapy in Older Patients With Stage 2 Systolic Hypertension: Results of the ACTION Study SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID BLOOD-PRESSURE; DOUBLE-BLIND; NATIONAL-HEALTH; ALISKIREN; TRIAL; AGE; PREVALENCE; PREVENTION; GUIDELINES; MANAGEMENT AB Patients with stage 2 systolic hypertension require sizable blood pressure (BP) reductions to achieve recommended targets. This randomized double-blind study compared a single-pill combination of the direct renin inhibitor aliskiren and hydrochlorothiazide (aliskiren/HCTZ) with HCTZ monotherapy in older patients (older than 55 years) with systolic BP >= 160 mm Hg and < 200 mm Hg. After a 1- to 4-week washout, 451 patients were randomized to once-daily aliskiren/HCTZ 150/12.5 mg or HCTZ 12.5 mg for 1 week, and then double the doses for 7 weeks. Overall baseline BP was 168.8/91.4 mm Hg. At week 4 (primary) end point, aliskiren/HCTZ provided significantly greater BP reductions from baseline than HCTZ monotherapy (29.6/9.3 mm Hg vs 22.3/6.8 mm Hg) and resulted in a greater proportion of patients achieving BP goal of < 140/90 mm Hg (51.1% vs 33.3%). Aliskiren/HCTZ therapy provides substantial BP reductions and may thus be a useful treatment option for older patients with stage 2 hypertension. J Clin Hypertens (Greenwich). 2011;13:162-169. (C) 2011 Wiley Periodicals, Inc. C1 [Basile, Jan] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Div Gen Internal Med, Seinsheimer Cardiovasc Hlth Program, Charleston, SC 29401 USA. [Lillestol, Michael] Lillestol Res LLC, Fargo, ND USA. [Botha, Jaco] Novartis Pharma AG, Basel, Switzerland. [Yurkovic, Carol; Weitzman, Richard] Novartis Pharmaceut, E Hanover, NJ USA. [Babazadeh, Simon] Crest Clin Trials Inc, Santa Ana, CA USA. RP Basile, J (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Div Gen Internal Med, Seinsheimer Cardiovasc Hlth Program, Charleston, SC 29401 USA. EM basilejn@musc.edu FU Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis; National Heart, Lung and Blood Institute; Boehringer-Ingelheim FX This work was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Jan Basile has received research support from Novartis, The National Heart, Lung and Blood Institute and Boehringer-Ingelheim; has acted as a consultant for Novartis, Abbott Laboratories, Boehringer-Ingelheim, Forest Laboratories, Daiichi-Sankyo and Takeda Pharmaceuticals; and has been a member of the speakers' bureau for Novartis, Abbott Laboratories, AstraZeneca, Boehringer-Ingelheim, Forest Laboratories, GSK, Merck, Pfizer and Daiichi-Sankyo. Michael Lillestol has received research support from Novartis. Jaco Botha, Carol Yurkovic, and Richard Weitzman are employees of Novartis and are therefore eligible for Novartis stock and stock options. NR 21 TC 7 Z9 8 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD MAR PY 2011 VL 13 IS 3 BP 162 EP 169 DI 10.1111/j.1751-7176.2010.00418.x PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 729FD UT WOS:000287933100006 PM 21366847 ER PT J AU Jin, WZ Goldfine, AB Boes, T Henry, RR Ciaraldi, TP Kim, EY Emecan, M Fitzpatrick, C Sen, A Shah, A Mun, E Vokes, M Schroeder, J Tatro, E Jimenez-Chillaron, J Patti, ME AF Jin, Wanzhu Goldfine, Allison B. Boes, Tanner Henry, Robert R. Ciaraldi, Theodore P. Kim, Eun-Young Emecan, Merve Fitzpatrick, Connor Sen, Anish Shah, Ankit Mun, Edward Vokes, Martha Schroeder, Joshua Tatro, Elizabeth Jimenez-Chillaron, Jose Patti, Mary-Elizabeth TI Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID SERUM RESPONSE FACTOR; DEPENDENT DIABETES-MELLITUS; GLUCOSE-TRANSPORT; GENE-EXPRESSION; ACTIN DYNAMICS; OXIDATIVE-PHOSPHORYLATION; MUTANT ACTINS; ACTIVATION; PATHOGENESIS; SENSITIVITY AB Insulin resistance in skeletal muscle is a key phenotype associated with type 2 diabetes (T2D) for which the molecular mediators remain unclear. We therefore conducted an expression analysis of human muscle biopsies from patients with T2D; normoglycemic but insulin-resistant subjects with a parental family history (FH+) of T2D; and family history-negative control individuals (FH-). Actin cytoskeleton genes regulated by serum response factor (SRF) and its coactivator megakaryoblastic leukemia 1 (MKL1) had increased expression in T2D and FH+ groups. Furthermore, striated muscle activator of Rho signaling (STARS), an activator of SRF, was upregulated in T2D and FH+ and was inversely correlated with insulin sensitivity. Skeletal muscle from insulin-resistant mice recapitulated this gene expression pattern and showed reduced G-actin and increased nuclear localization of MKL1, each of which regulates SRF activity. Overexpression of MKL1 or reduction in G-actin decreased insulin-stimulated Akt phosphorylation, whereas reduction of STARS expression increased insulin signaling and glucose uptake. Pharmacological SRF inhibition by CCG-1423 reduced nuclear MKL1 and improved glucose uptake and tolerance in insulin-resistant mice in vivo. Thus, SRF pathway alterations are linked to insulin resistance, may contribute to T2D pathogenesis, and could represent therapeutic targets. C1 [Jin, Wanzhu; Goldfine, Allison B.; Boes, Tanner; Kim, Eun-Young; Emecan, Merve; Fitzpatrick, Connor; Sen, Anish; Shah, Ankit; Vokes, Martha; Schroeder, Joshua; Tatro, Elizabeth; Jimenez-Chillaron, Jose; Patti, Mary-Elizabeth] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA. [Jin, Wanzhu; Goldfine, Allison B.; Boes, Tanner; Kim, Eun-Young; Emecan, Merve; Fitzpatrick, Connor; Sen, Anish; Shah, Ankit; Mun, Edward; Vokes, Martha; Schroeder, Joshua; Tatro, Elizabeth; Jimenez-Chillaron, Jose; Patti, Mary-Elizabeth] Harvard Univ, Sch Med, Boston, MA USA. [Henry, Robert R.; Ciaraldi, Theodore P.] VA San Diego Healthcare Syst, La Jolla, CA USA. [Henry, Robert R.; Ciaraldi, Theodore P.] UCSD, La Jolla, CA USA. [Mun, Edward] Partners HealthCare, Faulkner Brigham & Womens Hosp, Dept Surg, Boston, MA USA. RP Patti, ME (reprint author), 1 Joslin Pl, Boston, MA 02215 USA. EM mary.elizabeth.patti@joslin.harvard.edu FU NIH [DK062948, DK02795, DK070648, DK060837, LM008748, 5P30 DK 36836, ADA-06-CD-07]; Graetz Fund FX We gratefully acknowledge research support from NIH DK062948 (to M.E. Patti), DK02795 (to A.B. Goldfine), DK070648 (to A.B. Goldfine), DK060837 (Diabetes Genome Anatomy Project to M.E. Patti), LM008748 (i2b2), 5P30 DK 36836 (DERC Animal Core and Specialized Assay Core), ADA-06-CD-07 (to A.B. Goldfine), and the Graetz Fund. We thank Amira Klip (University of Toronto) for the gift of L6 myoblasts expressing GLUT4 and thank Amira Klip, Shunsuke Ishii (Riken Institute, Japan), and C. Ronald Kahn (Joslin Diabetes Center) for valuable suggestions. We thank Guido Posern (Max-Planck-Institute, Germany), Paul Herring (Indiana University, USA), Techung Lee (University of Buffalo, USA), and Ron Prywes (Columbia University, USA) for DNA plasmids and adenovirus materials. NR 58 TC 37 Z9 40 U1 0 U2 3 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD MAR PY 2011 VL 121 IS 3 BP 918 EP 929 DI 10.1172/JCI41940 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 729YQ UT WOS:000287991000013 PM 21393865 ER PT J AU Gandhi, L Camidge, DR de Oliveira, MR Bonomi, P Gandara, D Khaira, D Hann, CL McKeegan, EM Litvinovich, E Hemken, PM Dive, C Enschede, SH Nolan, C Chiu, YL Busman, T Xiong, H Krivoshik, AP Humerickhouse, R Shapiro, GI Rudin, CM AF Gandhi, Leena Camidge, D. Ross de Oliveira, Moacyr Ribeiro Bonomi, Philip Gandara, David Khaira, Divis Hann, Christine L. McKeegan, Evelyn M. Litvinovich, Elizabeth Hemken, Philip M. Dive, Caroline Enschede, Sari H. Nolan, Cathy Chiu, Yi-Lin Busman, Todd Xiong, Hao Krivoshik, Andrew P. Humerickhouse, Rod Shapiro, Geoffrey I. Rudin, Charles M. TI Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID CONTINUAL REASSESSMENT METHOD; APOPTOSIS PROTEIN XIAP; BH3 MIMETIC ABT-737; X-LINKED INHIBITOR; CLINICAL-EFFICACY; DEATH; RESISTANCE; EXPRESSION; ETOPOSIDE; MEMBERS AB Purpose Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conducted to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with solid tumors. Patients and Methods Patients enrolled to intermittent dosing cohorts received navitoclax on day -3, followed by dosing on days 1 to 14 of a 21-day cycle. Patients on continuous dosing received a 1-week lead-in dose of 150 mg followed by continuous daily administration. Blood samples were collected for pharmacokinetic analyses, biomarker analyses, and platelet monitoring. Results Forty-seven patients, including 29 with small-cell lung cancer (SCLC) or pulmonary carcinoid, were enrolled between 2007 and 2008, 35 on intermittent and 12 on continuous dosing cohorts. Primary toxicities included diarrhea (40%), nausea (34%), vomiting (36%), and fatigue (34%); most were grade 1 or 2. Dose-and schedule-dependent thrombocytopenia was seen in all patients. One patient with SCLC had a confirmed partial response lasting longer than 2 years, and eight patients with SCLC or carcinoid had stable disease (one remained on study for 13 months). Pro-gastrin releasing peptide (pro-GRP) was identified as a surrogate marker of Bcl-2 amplification and changes correlated with changes in tumor volume. Conclusion Navitoclax is safe and well tolerated, with dose-dependent thrombocytopenia as the major adverse effect. Preliminary efficacy data are encouraging in SCLC. Efficacy in SCLC and the utility of pro-GRP as a marker of treatment response will be further evaluated in phase II studies. J Clin Oncol 29: 909-916. (C) 2011 by American Society of Clinical Oncology C1 [Gandhi, Leena] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02215 USA. Univ Colorado, Ctr Canc, Aurora, CO USA. NW Med Specialties, Tacoma, WA USA. Rush Univ, Med Ctr, Chicago, IL 60612 USA. Abbott Labs, Abbott Pk, IL 60064 USA. Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA. Sunterra Oncol Associates, Phoenix, AZ USA. Johns Hopkins Univ, Baltimore, MD USA. Univ Manchester, Paterson Inst Canc Res, Manchester M13 9PL, Lancs, England. RP Gandhi, L (reprint author), Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, 450 Brookline Ave, Boston, MA 02215 USA. OI Dive, Caroline/0000-0002-1726-8850; Gandhi, Leena/0000-0002-2398-9179 FU Abbott Laboratories; Genentech; Dana-Farber Cancer Institute; Bristol-Myers Squibb/ImClone; Genetech; Eli Lilly; Merck; Novartis; Pfizer; Schering-Plough FX Supported by Abbott Laboratories and Genentech; and in part by the Alice and Steve Cutler Fund for Young Investigators at the Dana-Farber Cancer Institute (L.G.).; Research Funding: Philip Bonomi, Abbott Laboratories; David Gandara, Abbott Laboratories, Bristol-Myers Squibb/ImClone, Genetech, Eli Lilly, Merck, Novartis, Pfizer; Divis Khaira, Abbott Laboratories, Schering-Plough; Caroline Dive, Abbott Laboratories NR 35 TC 221 Z9 225 U1 6 U2 21 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 1 PY 2011 VL 29 IS 7 BP 909 EP 916 DI 10.1200/JCO.2010.31.6208 PG 8 WC Oncology SC Oncology GA 726NO UT WOS:000287729900034 PM 21282543 ER PT J AU Goel, S Beith, JM AF Goel, Shom Beith, Jane M. TI Troponin I As a Predictor for Trastuzumab-Related Cardiotoxicity: Current Data Do Not Provide Mechanistic Insights or Allow for Incorporation Into Clinical Practice SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Letter ID CARDIAC TROPONIN; HEART-FAILURE; MORTALITY C1 [Goel, Shom] Massachussetts Gen Hosp, Boston, MA 02114 USA. [Goel, Shom; Beith, Jane M.] Royal Prince Alfred Hosp, Sydney Canc Ctr, Camperdown, NSW 2050, Australia. RP Goel, S (reprint author), Massachussetts Gen Hosp, Boston, MA 02114 USA. OI Beith, Jane/0000-0002-4946-2789 NR 10 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 1 PY 2011 VL 29 IS 7 BP E175 EP E176 DI 10.1200/JCO.2010.32.7353 PG 2 WC Oncology SC Oncology GA 726NO UT WOS:000287729900008 PM 21189375 ER PT J AU Jeyaretna, DS Curry, WT Batchelor, TT Stemmer-Rachamimov, A Plotkin, SR AF Jeyaretna, Deva Sanjeeva Curry, William T., Jr. Batchelor, Tracy T. Stemmer-Rachamimov, Anat Plotkin, Scott R. TI Exacerbation of Cerebral Radiation Necrosis by Bevacizumab SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; MALIGNANT GLIOMAS; THERAPY; NORMALIZATION; CHEMOTHERAPY; VASCULATURE; MECHANISMS; CANCER; INJURY C1 [Jeyaretna, Deva Sanjeeva; Curry, William T., Jr.; Batchelor, Tracy T.; Stemmer-Rachamimov, Anat; Plotkin, Scott R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Jeyaretna, DS (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. FU Genentech FX Research Funding: Scott R. Plotkin, Genentech NR 12 TC 27 Z9 29 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 1 PY 2011 VL 29 IS 7 BP E159 EP E162 DI 10.1200/JCO.2010.31.4815 PG 4 WC Oncology SC Oncology GA 726NO UT WOS:000287729900003 PM 21149667 ER PT J AU Gros, DF Simms, LJ Antony, MM AF Gros, Daniel F. Simms, Leonard J. Antony, Martin M. TI A Hybrid Model of Social Phobia: An Analysis of Social Anxiety and Related Symptoms of Anxiety SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE social anxiety; social phobia; component analysis; hybrid model ID DSM-IV ANXIETY; MOOD DISORDERS; SCALE DEVELOPMENT; SPECIAL SECTION; RISK-FACTORS; VALIDITY; CLASSIFICATION; COMORBIDITY; DIMENSIONS; SPECTRUM AB The categorical underpinnings of the current diagnostic nomenclature have been the subject of repeated criticism. Recently, researchers have proposed several alternatives to the current system, including hybrid models of combined diagnostic categories and symptom dimensions. In the present study, we investigated the symptoms associated with a hybrid model of social phobia. The study included (a) the development of the initial set of symptom dimensions, generation of an item pool, and review by an expert panel, and (b) data collection and component analysis of the item pool to determine the structure of the symptoms. Six separate theoretically relevant symptom dimensions were identified. Implications of these findings on the development of a new hybrid model of social phobia were discussed. (C) 2010 Wiley Periodicals, Inc. J Clin Psychol 67:293-307, 2011. C1 [Gros, Daniel F.] Ralph H Johnson VAMC, Mental Hlth Serv 116, Charleston, SC 29401 USA. [Gros, Daniel F.] Med Univ S Carolina, Charleston, SC USA. [Simms, Leonard J.] SUNY Buffalo, Buffalo, NY 14260 USA. [Antony, Martin M.] Ryerson Univ, Toronto, ON, Canada. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu RI Antony, Martin/K-1991-2012 OI Antony, Martin/0000-0002-3508-377X NR 43 TC 13 Z9 13 U1 5 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0021-9762 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD MAR PY 2011 VL 67 IS 3 BP 293 EP 307 DI 10.1002/jclp.20763 PG 15 WC Psychology, Clinical SC Psychology GA 712VG UT WOS:000286693800008 PM 21254057 ER PT J AU Krieger, N Kaddour, A Koenen, K Kosheleva, A Chen, JT Waterman, PD Barbeau, EM AF Krieger, Nancy Kaddour, Afamia Koenen, Karestan Kosheleva, Anna Chen, Jarvis T. Waterman, Pamela D. Barbeau, Elizabeth M. TI Occupational, social, and relationship hazards and psychological distress among low-income workers: implications of the 'inverse hazard law' SO JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH LA English DT Article ID INTIMATE PARTNER VIOLENCE; CONFLICT-TACTICS-SCALES; SEXUAL-HARASSMENT; WORKPLACE ABUSE; RACIAL-DISCRIMINATION; PSYCHOMETRIC DATA; PHYSICAL HEALTH; WOMENS HEALTH; MENTAL-HEALTH; UNITED-STATES AB Background Few studies have simultaneously included exposure information on occupational hazards, relationship hazards (eg, intimate partner violence) and social hazards (eg, poverty and racial discrimination), especially among low-income multiracial/ethnic populations. Methods A cross-sectional study (2003-2004) of 1202 workers employed at 14 worksites in the greater Boston area of Massachusetts investigated the independent and joint association of occupational, social and relationship hazards with psychological distress (K6 scale). Results Among this low-income cohort (45% were below the US poverty line), exposure to occupational, social and relationship hazards, per the 'inverse hazard law,' was high: 82% exposed to at least one occupational hazard, 79% to at least one social hazard, and 32% of men and 34% of women, respectively, stated they had been the perpetrator or target of intimate partner violence (IPV). Fully 15.4% had clinically significant psychological distress scores (K6 score >= 13). All three types of hazards, and also poverty, were independently associated with increased risk of psychological distress. In models including all three hazards, however, significant associations with psychological distress occurred among men and women for workplace abuse and high exposure to racial discrimination only; among men, for IPV; and among women, for high exposure to occupational hazards, poverty and smoking. Conclusions Reckoning with the joint and embodied reality of diverse types of hazards involving how people live and work is necessary for understanding determinants of health status. C1 [Krieger, Nancy; Koenen, Karestan; Kosheleva, Anna; Chen, Jarvis T.; Waterman, Pamela D.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Kaddour, Afamia] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA. [Barbeau, Elizabeth M.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. [Barbeau, Elizabeth M.] Hlth Dialog, Boston, MA USA. RP Krieger, N (reprint author), Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, 677 Huntington Ave,Kresge 717, Boston, MA 02115 USA. EM nkrieger@hsph.harvard.edu RI Koenen, Karestan/K-5402-2014 OI Koenen, Karestan/0000-0003-3293-4281 FU Dana-Farber Cancer Institute, Boston, Massachusetts, USA; New England Research Institutes, Watertown, Massachusetts, USA; University of Massachusetts, Lowell, Massachusetts, USA; NIOSH; Centers for Disease Control and Prevention, Atlanta, GA, USA [OHO7366-01, OHO7366-018] FX The following persons, all funded coinvestigators on the United for Health study contributed to the design, implementation and database construction and coding for the original study and all have provided written consent to be included as contributing non-authors on this manuscript: Cathy Hartman (Dana-Farber Cancer Institute, Boston, Massachusetts, USA), Anne M. Stoddard (New England Research Institutes, Watertown, Massachusetts, USA), Margaret M. Quinn (University of Massachusetts, Lowell, Massachusetts, USA), Glorian Sorensen (Dana-Farber Cancer Institute, Boston, Massachusetts, USA).; NIOSH, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, USA, grants OHO7366-01 and OHO7366-018. NR 49 TC 11 Z9 11 U1 1 U2 5 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0143-005X J9 J EPIDEMIOL COMMUN H JI J. Epidemiol. Community Health PD MAR PY 2011 VL 65 IS 3 BP 260 EP 272 DI 10.1136/jech.2009.087387 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 716MC UT WOS:000286972000011 PM 20713372 ER PT J AU Panda, B Stiller, R Panda, A AF Panda, Britta Stiller, Robert Panda, Alexander TI Influenza vaccination during pregnancy and factors for lacking compliance with current CDC guidelines SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE LA English DT Article DE Influenza; vaccination rates; pregnancy; physician and patients attitudes; compliance ID HEALTH-CARE WORKERS; IMMUNIZATION; PHYSICIANS; ATTITUDES; KNOWLEDGE; WOMEN; US AB Methods. aEuro integral This prospective study initially analyzed patient and physician knowledge regarding the influenza vaccine in pregnancy and then examined the impact of several interventions aimed to increase immunization rates implemented over the following year. Influenza vaccination rates were assessed before and after the interventions. Results. aEuro integral Five hundred twenty patients were enrolled in the study during the influenza season 2007/2008. Only 19%% of those patients reported receiving the influenza vaccination and only 28%% recalled that the vaccine was offered. Following this, in the summer and fall of 2008, we performed a physician education program and distributed posters advertising the influenza vaccine to all offices offering prenatal care in our area in order to increase patient awareness of the need for the vaccine. In the following influenza season, we again reassessed the vaccination rate and patient's knowledge and awareness of the vaccine in 480 postpartum women. Influenza vaccination rates increased from 19%% to 31%%. After the intervention, 51%% of patients recalled that the vaccine was offered to them during the pregnancy as opposed to only 28%% the year prior. Conclusion. aEuro integral Understanding the specific barriers to vaccination that our population faced was helpful in designing the interventions to improve knowledge and acceptance of influenza vaccination in pregnancy, which led to an increased vaccination rates in women. C1 [Panda, Alexander] Yale Univ, Sch Med, Sect Pulm Crit Care Med, New Haven, CT 06520 USA. [Panda, Britta] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Stiller, Robert] Yale New Haven Hlth Syst, Bridgeport Hosp, Dept Obstet & Gynecol, Bridgeport, CT 06610 USA. RP Panda, A (reprint author), Yale Univ, Sch Med, Sect Pulm Crit Care Med, 300 Cedar St,TAC 441,POB 208057, New Haven, CT 06520 USA. EM alexander.panda@yale.edu NR 20 TC 47 Z9 48 U1 1 U2 5 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1476-7058 J9 J MATERN-FETAL NEO M JI J. Matern.-Fetal Neonatal Med. PD MAR PY 2011 VL 24 IS 3 BP 402 EP 406 DI 10.3109/14767058.2010.497882 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 716SE UT WOS:000286993000003 PM 20593974 ER PT J AU Elstner, A Stockhammer, F Nguyen-Dobinsky, TN Quang, LN Pilgermann, I Gill, A Guhr, A Zhang, TG von Eckardstein, K Picht, T Veelken, J Martuza, RL von Deimling, A Kurtz, A AF Elstner, Anja Stockhammer, Florian Nguyen-Dobinsky, Trong-Nghia Quang Long Nguyen Pilgermann, Ingo Gill, Amanjit Guhr, Anke Zhang, Tingguo von Eckardstein, Kajetan Picht, Thomas Veelken, Julian Martuza, Robert L. von Deimling, Andreas Kurtz, Andreas TI Identification of diagnostic serum protein profiles of glioblastoma patients SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Data mining; Glioblastoma; Serum marker proteins ID GENE-EXPRESSION PROFILES; ACID-BINDING PROTEIN; CELL LUNG-CANCER; MICROARRAY ANALYSIS; GROWTH-FACTOR; HUMAN GLIOMAS; MOLECULAR CLASSIFICATION; MALIGNANT GLIOMAS; BRAIN-TUMORS; IN-VIVO AB Diagnosis of a glioblastoma (GBM) is triggered by the onset of symptoms and is based on cerebral imaging and histological examination. Serum-based biomarkers may support detection of GBM. Here, we explored serum protein concentrations of GBM patients and used data mining to explore profiles of biomarkers and determine whether these are associated with the clinical status of the patients. Gene and protein expression data for astrocytoma and GBM were used to identify secreted proteins differently expressed in tumors and in normal brain tissues. Tumor expression and serum concentrations of 14 candidate proteins were analyzed for 23 GBM patients and nine healthy subjects. Data-mining methods involving all 14 proteins were used as an initial evaluation step to find clinically informative profiles. Data mining identified a serum protein profile formed by BMP2, HSP70, and CXCL10 that enabled correct assignment to the GBM group with specificity and sensitivity of 89 and 96%, respectively (p < 0.0001, Fischer's exact test). Survival for more than 15 months after tumor resection was associated with a profile formed by TSP1, HSP70, and IGFBP3, enabling correct assignment in all cases (p < 0.0001, Fischer's exact test). No correlation was found with tumor size or age of the patient. This study shows that robust serum profiles for GBM may be identified by data mining on the basis of a relatively small study cohort. Profiles of more than one biomarker enable more specific assignment to the GBM and survival group than those based on single proteins, confirming earlier attempts to correlate single markers with cancer. These conceptual findings will be a basis for validation in a larger sample size. C1 [Elstner, Anja; Kurtz, Andreas] Charite, Berlin Brandenburg Ctr Regenerat Therapies, D-13353 Berlin, Germany. [Stockhammer, Florian; Picht, Thomas] Charite, Dept Neurosurg, D-13353 Berlin, Germany. [Nguyen-Dobinsky, Trong-Nghia; Quang Long Nguyen; Gill, Amanjit] Charite, D-10098 Berlin, Germany. [Pilgermann, Ingo] Cent Res Inst Ambulatory Hlth Care, D-10623 Berlin, Germany. [Guhr, Anke] Robert Koch Inst, Licensing Off hESC Res, D-13353 Berlin, Germany. [Zhang, Tingguo; Martuza, Robert L.] Massachusetts Gen Hosp, Dept Neurosurg, Charlestown, MA 02129 USA. [von Eckardstein, Kajetan] Univ Med Gottingen, Dept Neurosurg, D-37099 Gottingen, Germany. [Veelken, Julian] Vivantes Klinikum, Dept Neurosurg, D-12351 Berlin, Germany. [von Deimling, Andreas] Univ Heidelberg, Dept Neuropathol, D-69120 Heidelberg, Germany. [von Deimling, Andreas] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, D-69120 Heidelberg, Germany. [Kurtz, Andreas] Seoul Natl Univ, Coll Vet Med, Seoul, South Korea. RP Kurtz, A (reprint author), Charite, Berlin Brandenburg Ctr Regenerat Therapies, Augustenburger Pl 1, D-13353 Berlin, Germany. EM anja.elstner@charite.de; florian.stockhammer@charite.de; trong-nghia.nguyen-dobinsky@charite.de; nqlong@informatik.hu-berlin.de; pille.p@freenet.de; amanjit.gill@gmx.de; guhra@rki.de; ztguo@sdu.edu.cn; kajetan.voneckardstein@med.uni-goettingen.de; thomas.picht@charite.de; julian.veelken@vivantes.de; rmartuza@partners.org; andreas.vondeimling@med.uni-heidelberg.de; andreas.kurtz@charite.de RI von Deimling, Andreas/F-7774-2013 OI von Deimling, Andreas/0000-0002-5863-540X FU Berliner Krebsgesellschaft e.V; Goldhirsh Foundation, Boston, USA FX We wish to thank Dr Lydia Naumann (Charite, Berlin, Germany) for providing serum samples, Dr Sadatoshi Sakuma (CellSignals, Japan) for kindly providing MK antibodies and ELISA kit, and Dr Thomas Muller (MDC Berlin-Buch, Germany) for providing FABP7 antibodies. We are grateful to Drs David Louis, Cathrin Nutt, and Samuel Rabkin (MGH, Boston, USA) for their continuous support of this study and their valuable suggestions. A. E. and F. S. were supported by the Berliner Krebsgesellschaft e.V. The study was funded by the Goldhirsh Foundation, Boston, USA. NR 56 TC 14 Z9 15 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD MAR PY 2011 VL 102 IS 1 BP 71 EP 80 DI 10.1007/s11060-010-0284-8 PG 10 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 723KC UT WOS:000287504400009 PM 20617365 ER PT J AU Wu, S Harber, P Yun, D Bansal, S Li, YA Santiago, S AF Wu, Samantha Harber, Philip Yun, David Bansal, Siddharth Li, Yuan Santiago, Silverio TI Anxiety During Respirator Use: Comparison of Two Respirator Types SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE anxiety; personal protective equipment; respirator ID HEALTH-CARE WORKERS; PHYSIOLOGICAL IMPACT; INDUSTRIAL RESPIRATORS; SUBJECTIVE RESPONSE; SIMULATED WORK; MENTAL STRESS; PERFORMANCE; VENTILATION; PREDICTION; EXERCISE AB Anxiety may interfere with proper respirator use. This study directly compares the effect of two types of respirators-elastomeric half-face mask with dual-cartridges (HFM) and N95 filtering facepiece-on anxiety levels. Twelve volunteers with normal or mildly impaired respiratory conditions performed a series of simulated work tasks using the HFM and N95 on different days. The State-Trait Anxiety Inventory (STAI) measured state anxiety (SA) before and during respirator use. STAI also measured trait anxiety (TA), a stable personal characteristic. The effect of the respirator was measured as the difference between SA pre-use and during use. Work with HFM was associated with an increase in SA (2.92 units, p < .01), whereas work with the N95 had no observed effect. Anxiety should be considered in the selection of the best respirator for a user. Impact on anxiety should be considered for respirator design and certification purposes, particularly if the device is to be widely used in workplace and community settings. C1 [Wu, Samantha; Harber, Philip; Yun, David; Bansal, Siddharth; Li, Yuan] Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, Occupat & Environm Med Div, Los Angeles, CA 90095 USA. [Harber, Philip; Santiago, Silverio] Vet Adm Greater Los Angeles Healthcare Syst, Dept Med, Div Pulm Med, Los Angeles, CA USA. RP Harber, P (reprint author), UCLA Occupat & Environm Med, 10880 Wilshire,1800, Los Angeles, CA 90024 USA. EM pharber@ucla.edu FU CDC/NIOSH [R01 OH-8119] FX The authors acknowledge and thank David Liu for data collection, Yihang Liu, M.D., for statistical assistance, and Johnny Bontemps for assistance in manuscript preparation. This work was supported by Grant # R01 OH-8119 from CDC/NIOSH. NR 27 TC 5 Z9 5 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD MAR PY 2011 VL 8 IS 3 BP 123 EP 128 DI 10.1080/15459624.2011.549780 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 731KX UT WOS:000288106600001 PM 21318920 ER PT J AU Smith, D Caragian, N Kazlo, E Bernstein, J Richardson, D Casarett, D AF Smith, Dawn Caragian, Nicole Kazlo, Elena Bernstein, Jennie Richardson, Diane Casarett, David TI Can We Make Reports of End-of-Life Care Quality More Consumer-Focused? Results of a Nationwide Quality Measurement Program SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID BEREAVED FAMILY-MEMBERS; SERIOUSLY ILL PATIENTS; HOSPICE CARE; SATISFACTION; PERCEPTIONS; VALIDATION; SERVICES; DEATH AB Objectives: The goal of this study was to define families' priorities for various aspects of end-of-life care, and to determine whether scores that reflect these priorities alter facilities' quality rankings. Design: Nationwide telephone survey. Setting: 62 VA medical centers, including acute and long term care. Participants: For each patient who died in a participating facility, one family member was invited to participate. Measurements: A survey included 14 items describing key aspects of the patient's care in his or her last month of life, and one global rating. A weighted score was calculated based on the association between each item and the global rating. Results: Interviews were completed with family members for 3,897 of 7,110 patients (55%). Items showed an approximately 5-fold range of weights, indicating a wide variation in the importance that families placed on aspects of palliative care (low: pain management, weight 0.54, 95% CI 0.38-0.70; /P/< 0.001; high: providers were "kind, caring, and respectful: weight 2.46, 95% CI 2.24-2.68; /P/< 0.001). Weights were homogeneous across patient subgroups, and there were no significant changes in facilities' quality rankings when weights were used. Both weighted and unweighted scores showed similar evidence of the impact of process measures. Conclusion: There appears to be wide variation in the importance that families place on several aspects of end-of-life care. However, the impact of weighting was generally even across patient subgroups and facilities. Therefore, the use of weights to account for families' priorities is not likely to alter a facility's quality score. C1 [Casarett, David] Univ Penn, Sch Med, Div Geriatr Med, Philadelphia, PA 19104 USA. [Smith, Dawn; Caragian, Nicole; Kazlo, Elena; Bernstein, Jennie; Richardson, Diane; Casarett, David] Dept Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. RP Casarett, D (reprint author), Univ Penn, Penn Wissahickon Hosp, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM Casarett@mail.med.upenn.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, HSRD FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, HSR&D. NR 29 TC 6 Z9 7 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD MAR PY 2011 VL 14 IS 3 BP 301 EP 307 DI 10.1089/jpm.2010.0321 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 728ZZ UT WOS:000287915700013 PM 21288125 ER PT J AU Jacobsen, J Robinson, E Jackson, VA Meigs, JB Billings, JA AF Jacobsen, Juliet Robinson, Ellen Jackson, Vicki A. Meigs, James B. Billings, J. Andrew TI Development of a Cognitive Model for Advance Care Planning Discussions: Results from a Quality Improvement Initiative SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OF-LIFE DISCUSSIONS; FAMILY-MEMBERS; DECISION-MAKING; UNIT PATIENTS; CARDIOPULMONARY-RESUSCITATION; TREATMENT PREFERENCES; END; COMMUNICATION; PHYSICIANS; SYMPTOMS AB Background: Residents struggle with advance care planning (ACP) discussions in the inpatient setting, and may not be aware of newer models for ACP that stress the importance of giving prognostic information and making a recommendation about cardiopulmonary resuscitation to patients and families. Methods: A controlled study of a cognitive model for ACP embedded in a quality improvement (QI) project. Results: In the setting of a QI project for medical residents and interdisciplinary staff, we developed and implemented a cognitive model of ACP discussions that involved two types of meetings for patients: (1) information-sharing meetings for seriously ill but clinically stable patients and (2) decision-making meetings for clinically unstable patients. Patients on the intervention floor were significantly more likely to have a discussion about goals of care (33.8%) than patients on the control floor (21.2%, p = < 0.001) and significantly more likely to have a limitation of life-sustaining treatment upon discharge (19.1% vs. 13.9%, p = 0.04). Conclusions: For both residents and interdisciplinary staff, application of a cognitive model that clearly defines goals and expectations for ACP discussions prior to meeting with patients and families improves rates of ACP discussions. C1 [Jacobsen, Juliet; Jackson, Vicki A.; Billings, J. Andrew] Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA. [Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Robinson, Ellen] Massachusetts Gen Hosp, Optimum Care Comm, Boston, MA 02114 USA. [Robinson, Ellen] Massachusetts Gen Hosp, Patient Care Serv, Boston, MA 02114 USA. [Jacobsen, Juliet; Jackson, Vicki A.; Meigs, James B.; Billings, J. Andrew] Harvard Univ, Sch Med, Boston, MA USA. RP Jacobsen, J (reprint author), Massachusetts Gen Hosp, Palliat Care Serv, Founders 600,55 Fruit St, Boston, MA 02114 USA. EM jjacobsen@partners.org NR 29 TC 7 Z9 7 U1 0 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD MAR PY 2011 VL 14 IS 3 BP 331 EP 336 DI 10.1089/jpm.2010.0383 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 728ZZ UT WOS:000287915700017 PM 21247300 ER PT J AU Jackson, V AF Jackson, Vicki TI Poster and Abstract Presentations at National Meetings: A Right of Passage SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Editorial Material C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Jackson, V (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM VJackson@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD MAR PY 2011 VL 14 IS 3 BP 351 EP 351 DI 10.1089/jpm.2011.9721 PG 1 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 728ZZ UT WOS:000287915700020 ER PT J AU Masrur, S Abdullah, AR Smith, EE Hidalgo, R El-Ghandour, A Rordorf, G Schwamm, LH AF Masrur, Shihab Abdullah, Abdul R. Smith, Eric E. Hidalgo, Renzo El-Ghandour, Ahmed Rordorf, Guy Schwamm, Lee H. TI Risk of Thrombolytic Therapy for Acute Ischemic Stroke in Patients With Current Malignancy SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES LA English DT Article DE tPA; thrombolysis; ICH; in-hospital mortality ID RT-PA STROKE; BREAST-CANCER; METAANALYSIS; ASSOCIATION; MORTALITY; CARCINOMA; DISEASE AB Little is known about the risk of thrombolysis in patients with malignancy, because these patients have been excluded from most clinical trials. We reviewed our acute ischemic stroke (AIS) database for clinical outcomes and complications in patients with current malignancy (CM) who received thrombolytic therapy. Consecutive AIS patients receiving thrombolysis between January 2003 and December 2006 were retrospectively abstracted in accordance with the American Stroke Association's Get With the Guidelines-Stroke definitions and charts were reviewed for history of malignancy. Patients with brain metastases did not receive tissue plasminogen activator (tPA). Stepwise logistic regression was used to identify independent predictors of in-hospital mortality. Of 308 AIS patients treated with thrombolytic therapy, 210 (68%) received intravenous (IV) tPA only, 41(13%) received IV tPA plus intra-arterial therapy (TAT), and 57 (18%) received TAT only. Eighteen patients (5.8%) had a CM, and 26 patients (8.4%) had a remote history of malignancy. Patients with CM had a higher in-hospital mortality (38.9% vs 19.7%; P = .05) and were more likely to have died due to worsening medical comorbidity (71.4% vs 9.6%; P < .001). The rate of symptomatic intracranial hemorrhage (ICH) was similar in the 2 groups (5.6% vs 2.7%; P = .47). In multivariate analysis, the only independent predictors of mortality were National Institutes of Health Stroke Scale score, history of hypertension, and smoking. CM was not independently associated with increased in-hospital mortality following thrombolysis. Mortality was attributable largely to medical comorbidities, not to symptomatic ICH. Our data suggest that thrombolysis may be a reasonable option for patients with malignancy who have acceptable medical comorbidities and performance status. Further research is warranted. C1 [Masrur, Shihab; Abdullah, Abdul R.; Smith, Eric E.; Hidalgo, Renzo; El-Ghandour, Ahmed; Rordorf, Guy; Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Stroke Serv, Boston, MA 02114 USA. RP Masrur, S (reprint author), Massachusetts Gen Hosp, Dept Neurol, Stroke Serv, WAC 729-L,15 Parkman St, Boston, MA 02114 USA. EM shihabmasrur@hotmail.com OI Schwamm, Lee/0000-0003-0592-9145; Smith, Eric/0000-0003-3956-1668 NR 20 TC 15 Z9 16 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1052-3057 J9 J STROKE CEREBROVASC JI J. Stroke Cerebrovasc. Dis. PD MAR-APR PY 2011 VL 20 IS 2 BP 124 EP 130 DI 10.1016/j.jstrokecerebrovasdis.2009.10.010 PG 7 WC Neurosciences; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 730PV UT WOS:000288047400006 PM 20598579 ER PT J AU Hussaini, BE Thatte, HS Rhodes, BA Treanor, PR Birjiniuk, V AF Hussaini, Bader E. Thatte, Hemant S. Rhodes, Barbara A. Treanor, Patrick R. Birjiniuk, Vladimir TI Thromboresistant surfaces with low-dose anticoagulation alleviate clopidogrel-related complications in patients undergoing coronary artery bypass grafting SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID ST-SEGMENT ELEVATION; MYOCARDIAL-INFARCTION; BLOOD-LOSS; SURGERY; ASPIRIN; TRANSFUSION; INCREASES; IMPACT; TRIAL; RISK AB Objective: Numerous studies have shown that, when using conventional perfusion methodology, patients undergoing coronary artery bypass grafting within 7 days of receiving clopidogrel are at increased risk of bleeding, re-exploration, and blood transfusion. The purpose of this study was to evaluate the effect of clopidogrel administration before coronary artery bypass grafting on patients using thromboresistant surfaces with low-dose heparin during surgical intervention. Methods: Patients who underwent isolated coronary artery bypass grafting between 2005 and 2009 were incorporated in this retrospective study. Of these, 52 (22.2%) received clopidogrel within 5 days before the operation, and 182 (77.8%) did not. Regression models determined the effect of clopidogrel on the rate of chest re-exploration because of bleeding, 24-hour chest tube output, perioperative blood product transfusion, length of stay, morbidity, and perioperative mortality. Hemorrhage-related preoperative risk factors, as well as those found to be significant in univariate models, were included in the multivariate model. Results: Chest tube drainage was significantly increased during the first 24 hours after the operation in the clopidogrel group (679.7 +/- 305.8 vs 516.6 +/- 209.8 mL, P = .0007). The need for intraoperative blood product transfusion was similar; nevertheless, more patients receiving clopidogrel required fresh frozen plasma postoperatively (7.7% vs 1.1%, P = .0232). However, risk-adjusted logistic regression showed that exposure to clopidogrel was not a predictor of intraoperative or postoperative blood product transfusion. Lengths of stay in the intensive care unit and hospital were shorter in patients receiving clopidogrel. Conclusions: Hemostatic complications related to clopidogrel exposure within 5 days before an isolated coronary artery bypass grafting operation can be alleviated by the application of a biocompatible perfusion strategy using low-dose heparin in conjunction with a closed thromboresistant circuit. (J Thorac Cardiovasc Surg 2011;141:782-8) C1 [Hussaini, Bader E.; Thatte, Hemant S.; Birjiniuk, Vladimir] Brigham & Womens Hosp, Dept Cardiothorac Surg, Boston, MA 02115 USA. [Hussaini, Bader E.; Thatte, Hemant S.; Treanor, Patrick R.] VA Boston Healthcare Syst, Dept Cardiothorac Surg, Boston, MA USA. [Hussaini, Bader E.; Thatte, Hemant S.; Birjiniuk, Vladimir] Harvard Univ, Sch Med, Dept Cardiothorac Surg, Boston, MA USA. [Rhodes, Barbara A.; Treanor, Patrick R.; Birjiniuk, Vladimir] Mt Auburn Hosp, Dept Cardiothorac Surg, Cambridge, MA 02132 USA. RP Birjiniuk, V (reprint author), Mt Auburn Hosp, Dept Surg, Div Cardiothorac Surg, 300 Mt Auburn St, Cambridge, MA 02132 USA. EM vbirjini@mah.harvard.edu NR 20 TC 3 Z9 3 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD MAR PY 2011 VL 141 IS 3 BP 782 EP 788 DI 10.1016/j.jtcvs.2010.09.002 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 722OK UT WOS:000287443000029 PM 21146837 ER PT J AU Creaney, J Segal, A Musk, AW Skates, SJ Robinson, BWS AF Creaney, J. Segal, A. Musk, A. W. Skates, S. J. Robinson, B. W. S. TI MESOTHELIOMA BIOMARKERS - NOW AND THE FUTURE SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article; Proceedings Paper CT 3rd Australian Lung Cancer Conference (ALCC) CY OCT 07-09, 2010 CL Melbourne, AUSTRALIA C1 [Creaney, J.; Musk, A. W.; Robinson, B. W. S.] Natl Res Ctr Asbestos Related Dis, Perth, WA, Australia. [Creaney, J.; Robinson, B. W. S.] Sir Charles Gairdner Hosp, Australian Mesothelioma Tissue Bank, Nedlands, WA 6009, Australia. [Musk, A. W.; Robinson, B. W. S.] Sir Charles Gairdner Hosp, Dept Resp Med, Nedlands, WA 6009, Australia. [Skates, S. J.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. RI Robinson, Bruce/N-1900-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD MAR PY 2011 VL 6 IS 3 SU S BP S4 EP S4 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 729YM UT WOS:000287990600014 ER PT J AU Conrad, MF Chung, TK Cambria, MR Paruchuri, V Brady, TJ Cambria, RP AF Conrad, Mark F. Chung, Thomas K. Cambria, Matthew R. Paruchuri, Vikram Brady, Thomas J. Cambria, Richard P. TI Effect of chronic dissection on early and late outcomes after descending thoracic and thoracoabdominal aneurysm repair SO JOURNAL OF VASCULAR SURGERY LA English DT Article; Proceedings Paper CT Annual Meeting of the Society-for-Vascular-Surgery CY MAR, 2008 CL Las Vegas, NV SP Soc Vasc Surg ID MOTOR-EVOKED-POTENTIALS; SPINAL-CORD PROTECTION; B AORTIC DISSECTION; RISK-FACTOR; NEUROLOGIC DEFICIT; POSTOPERATIVE PARAPLEGIA; CLINICAL-EXPERIENCE; SEGMENTAL ARTERIES; OPERATIONS; MORTALITY AB Objective: Although chronic aortic dissection (CD) has traditionally been considered a predictor of perioperative morbidity and mortality after descending thoracic/thoracoabdominal aneurysm repair (thoracoabdominal aortic aneurysm [TAA]), recent reports have rejected this assertion. Still, few contemporary studies document late outcomes after TAA for CD, which is the goal of this study. Methods: From August 1987 to December 2005, 480 patients underwent TAA; 73 (15%) CD and 407(85%) degenerative aneurysms (DA). Operative management consisted of a clamp-and-sew technique with adjuncts in 53 (78%) CD and 355 (93%) DA patients (P < .001). Epidural cooling was used to prevent spinal cord injury (SCI) in 51 (70%) CD and 214 (53%) DA patients (P = .007). Study end points included perioperative SCl/mortality, freedom from reintervention, and long-term survival. Results: CD patients were younger (mean age 64.5 years CD vs 72.5 years DA, P < .001) and more frequently had a family history of aneurysmal disease (23% CD vs 6% DA, P < .001). Forty-three (59%) CD patients had elective TAA (vs 322 (79%) DA, P = .001). Eleven (15%) CD patients had Marfan's syndrome (vs 0% DA, P < .001), and 17 (23%) CD patients had a prior arch or ascending aortic repair (vs 16 [4%] DA, P < .001). CD patients were more likely to have Crawford type I & II thoracoabdominal aneurysms (44 [60%] vs 120 [29%] DA, P < .001), while only two (3%) CD patients had type IV aneurysms (vs 99 [24%] DA). There was no difference in perioperativc mortality between the two groups (11% CD vs 8.6% DA, P = .52), nor was there a difference in flaccid paralysis, which occurred in five (7%) CD and 22 (5%) DA patients (P = .92). At 5 years, 70% of CD patients were free from reintervention versus 74% of DA (P = .36). The actuarial survival was 53% and 32% at 5 and 10 years for CD versus 47% and 17% for DA (P = .07). Conclusions: Despite increased operative complexity, CD does not appear to increase perioperative SCI or mortality after TAA when compared with DA. Long-term freedom from aneurysm-related reintervention is similar for both groups as is survival, despite patients with CD being of younger age at presentation. (J Vasc Surg 2011;53:600-7.) C1 [Conrad, Mark F.; Chung, Thomas K.; Cambria, Matthew R.; Paruchuri, Vikram; Cambria, Richard P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Div Vasc & Endovasc Surg, Boston, MA 02114 USA. [Brady, Thomas J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Cardiovasc Imaging & Intervent Ra, Boston, MA 02114 USA. RP Conrad, MF (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Div Vasc & Endovasc Surg, 15 Parkman St,WAC 440, Boston, MA 02114 USA. EM mconrad@partners.org OI Chung, Thomas/0000-0001-6148-1184 FU NCATS NIH HHS [KL2 TR000168]; NCRR NIH HHS [1 KL2 RR025757-0 1,, KL2 RR025757] NR 54 TC 6 Z9 6 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD MAR PY 2011 VL 53 IS 3 BP 600 EP 607 DI 10.1016/j.jvs.2010.09.053 PG 8 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 727HF UT WOS:000287788200005 PM 21112177 ER PT J AU Conrad, MF AF Conrad, Mark F. TI Regarding "Infrapopliteal balloon angioplasty for the treatment of chronic occlusive disease" Reply SO JOURNAL OF VASCULAR SURGERY LA English DT Letter C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Vasc & Endovasc Surg, Boston, MA 02163 USA. RP Conrad, MF (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Vasc & Endovasc Surg, Boston, MA 02163 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD MAR PY 2011 VL 53 IS 3 BP 884 EP 884 DI 10.1016/j.jvs.2010.10.063 PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 727HF UT WOS:000287788200060 ER PT J AU Lee, SR Kardos, KW Schiff, E Berne, CA Mounzer, K Banks, AT Tatum, HA Friel, TJ DeMicco, MP Lee, WM Eder, SE Monto, A Yearwood, GD Guillon, GB Kurtz, LA Fischl, M Unangst, JL Kriebel, L Feiss, G Roehler, M AF Lee, Stephen R. Kardos, Keith W. Schiff, Eugene Berne, Cheryl A. Mounzer, Karam Banks, Alpha T. Tatum, Harvey A. Friel, Timothy J. DeMicco, Michael P. Lee, William M. Eder, Scott E. Monto, Alexander Yearwood, Graham D. Guillon, Geraldine B. Kurtz, Lisa A. Fischl, Mark Unangst, Jay Lynn Kriebel, Laura Feiss, Gary Roehler, Michele TI Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE HCV; Rapid test; Oral fluid ID HEPATITIS-C VIRUS; UNITED-STATES; DRUG-USERS; ENZYME-IMMUNOASSAY; VIRAL-HEPATITIS; ASSAY; POPULATION; ANTIBODIES; RISK; PERFORMANCE AB The availability of a highly accurate, rapid, point-of-care test for hepatitis C virus (HCV) may be useful in addressing the problem of under-diagnosis of HCV, by increasing opportunities for testing outside of traditional clinical settings. A new HCV rapid test device (OraQuick (R) HCV Rapid Antibody Test), approved recently in Europe for use with venous blood, fingerstick blood, serum, plasma, or oral fluid was evaluated in a multi-center study and performance compared to established laboratory-based tests for detection of HCV. The HCV rapid test was evaluated in prospective testing of subjects with signs and/or symptoms of hepatitis, or who were at risk for hepatitis C using all 5 specimen types. Performance was assessed relative to HCV serostatus established by laboratory methods (EIA. RIBA and PCR) approved in Europe for diagnosis of hepatitis C infection. Sensitivity to antibody in early infection was also compared to EA in 27 seroconversion panels. In addition, the reliability of the oral fluid sample for accurate detection of anti-HCV was assessed by studying the impact of various potentially interfering conditions of oral health, use of oral care products and consumption of food and drink. In this large study of at-risk and symptomatic persons, the overall specificities of the OraQuick (R) HCV Rapid Antibody Test were equivalent (99.6-99.9%) for all 5 specimen types and the 95% CIs substantially overlapped. Overall sensitivities were virtually identical for venous blood, fingerstick blood, serum and plasma (99.7-99.9%). Observed sensitivity was slightly lower for oral fluid at 98.1% though the upper Cl (99.0%) was equal to the lower CI for venous blood and fingerstick blood. Most of the HCV positive subjects which gave nonreactive results in oral fluid had serological and virological results consistent with resolved infection. Sensitivity for anti-HCV in early seroconversion was virtually identical between the HCV rapid test and EIA. Detection of anti-HCV in oral fluid appeared generally robust to conditions of oral health, consumption of food and drink and use of oral care products. The OraQuick (R) HCV Rapid Antibody Test demonstrated clinical performance that was equivalent to current laboratory-based EIA. This new, HCV rapid test appears suitable as an aid in the diagnosis of HCV infection and may increase testing opportunities due to its simplicity and flexibility to use multiple specimen types, including fingerstick blood and oral fluid. (C) 2010 Elsevier BM. All rights reserved. C1 [Lee, Stephen R.; Kardos, Keith W.; Yearwood, Graham D.; Guillon, Geraldine B.; Kurtz, Lisa A.; Fischl, Mark; Unangst, Jay Lynn; Kriebel, Laura; Feiss, Gary; Roehler, Michele] OraSure Technol Inc, Bethlehem, PA 18015 USA. [Schiff, Eugene] Univ Miami, Miller Sch Med, Hepatol Diagnost Lab, Miami, FL 33136 USA. [Berne, Cheryl A.] Biol Specialty Corp, Reading, PA 19602 USA. [Mounzer, Karam] Philadelphia FIGHT, Philadelphia, PA 19107 USA. [Banks, Alpha T.] Banks Hepatol Inst, College Pk, MD 20740 USA. [Tatum, Harvey A.] Opt Hlth Res LLC, Tulsa, OK 74104 USA. [Friel, Timothy J.] Lehigh Valley Hosp, Allentown, PA 18102 USA. [DeMicco, Michael P.] Associated Gastroenterol Med Grp, Anaheim, CA 92801 USA. [Lee, William M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Eder, Scott E.] Womens Hlth Res Ctr, Plainsboro, NJ 08536 USA. [Monto, Alexander] San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA. RP Lee, SR (reprint author), OraSure Technol Inc, 220 E 1st St, Bethlehem, PA 18015 USA. EM slee@orasure.com NR 30 TC 39 Z9 39 U1 0 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 J9 J VIROL METHODS JI J. Virol. Methods PD MAR PY 2011 VL 172 IS 1-2 BP 27 EP 31 DI 10.1016/j.jviromet.2010.12.009 PG 5 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 728YB UT WOS:000287909300005 PM 21182871 ER PT J AU Nagarkatti, SS Mekel, M Sofferman, RA Parangi, S AF Nagarkatti, Sushruta S. Mekel, Michal Sofferman, Robert A. Parangi, Sareh TI Overcoming Obstacles to Setting Up Office-Based Ultrasound for Evaluation of Thyroid and Parathyroid Diseases SO LARYNGOSCOPE LA English DT Review DE Head and neck ultrasound; surgeon-performed ultrasound; thyroid and parathyroid imaging; thyroid nodules ID SURGEON-PERFORMED ULTRASOUND; NEEDLE-ASPIRATION BIOPSY; SUFFICIENT SURGICAL-TREATMENT; UNILATERAL TOTAL LOBECTOMY; VALUABLE CLINICAL TOOL; LOW-RISK; PREOPERATIVE ULTRASONOGRAPHY; IMPROVES LOCALIZATION; THERAPEUTIC OUTCOMES; ENDOCRINE SURGEON AB Ultrasound is an integral part of the preoperative workup for patients who are being evaluated for thyroid and parathyroid surgery. It helps improve the accuracy of a fine-needle aspiration biopsy and complements other imaging modalities used for planning the extent of surgery. It also allows imaging of vital structures in relation to the thyroid and parathyroid. The compact nature and portability of ultrasound machines in recent years has made it easier for motivated surgeons (head and neck, general, and endocrine surgeons) to incorporate them into their practice. However, successfully setting up such a service needs adequate planning and an understanding of the obstacles that are involved. We aim to discuss these obstacles in detail, with practical suggestions on how to overcome them. This review may serve as a resource when dealing with issues such as purchasing equipment, training, credentialing, billing, documentation, and collaboration. Although these are discussed with respect to surgeons with an interest in endocrine disease, with some modifications they may also apply to any surgeon who uses ultrasound frequently. C1 [Parangi, Sareh] Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Endocrine Surg Unit,Sch Med, Boston, MA 02114 USA. [Mekel, Michal] Rambam Hlth Care Campus, Dept Gen Surg A, Haifa, Israel. [Sofferman, Robert A.] Univ Vermont, Coll Med, Dept Surg, Div Otolaryngol, Burlington, VT USA. RP Parangi, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Endocrine Surg Unit,Sch Med, 15 Parkman St,Wang 460, Boston, MA 02114 USA. EM sparangi@partners.org NR 21 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD MAR PY 2011 VL 121 IS 3 BP 548 EP 554 DI 10.1002/lary.21391 PG 7 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 727HR UT WOS:000287789400020 PM 21305549 ER PT J AU Soler, ZM Platt, MP Leung, MK Mong, S Metson, R AF Soler, Zachary M. Platt, Michael P. Leung, Man-kit Mong, Sandy Metson, Ralph TI Sinonasal Abnormalities in Patients with Graves' Orbitopathy SO LARYNGOSCOPE LA English DT Article DE Graves' disease; orbitopathy; ophthalmopathy; sinus; sinusitis; computed tomography; imaging; thyrotropin receptor; IGF-1R ID ORBITAL FIBROBLASTS; IGF-1 RECEPTOR; OPHTHALMOPATHY; DISEASE; RHINOSINUSITIS; PATHOGENESIS; DERMOPATHY; EXPRESSION AB Objectives: To compare radiographic sinus mucosal thickening in patients with Graves' orbitopathy versus controls and determine whether target autoantigens thought to underlie systemic manifestations of Graves' disease are present within paranasal sinus mucosa. Study Design: Case-control study. Methods: Sinus computed tomography (CT) scans from patients with Graves' orbitopathy scheduled for orbital decompression surgery (n = 50) were compared with maxillofacial CT scans from control patients (n = 50). Scans were rated for sinus mucosal disease by two independent reviewers using the Lund-MacKay and Harvard staging systems. Gene expression for thyrotropin receptor and type 1 insulin-like growth factor receptor (IGF-1R) was assessed in ethmoid mucosal samples using real-time quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry (IHC). Results: Increased sinus mucosal thickening was found in patients with Graves' orbitopathy compared with controls for both the Lund-MacKay (6.2 vs. 2.7; P < .01) and Harvard (2.1 vs. 1.3; P < .01) systems. Compared with control scans, the Graves' orbitopathy group exhibited greater mucosal thickening in the ethmoid, frontal, and sphenoid sinuses (P < .05 for all). RT-qPCR and IHC demonstrated gene expression for both the thyrotropin receptor and the IGF-1R in ethmoid mucosa. Conclusions: Patients with Graves' orbitopathy who present for orbital decompression exhibit a higher prevalence of sinus mucosal thickening on CT scan. These findings may be explained by circulating autoantibodies to target antigens, thyrotropin receptor and IGF-1R, associated with Graves' disease and found to be expressed in sinus mucosa. C1 [Soler, Zachary M.; Leung, Man-kit; Mong, Sandy; Metson, Ralph] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Soler, Zachary M.; Leung, Man-kit; Mong, Sandy; Metson, Ralph] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Platt, Michael P.] Boston Univ, Dept Otolaryngol Head & Neck Surg, Boston, MA 02215 USA. RP Metson, R (reprint author), 0 Emerson Pl, Boston, MA 02114 USA. EM ralph_metson@meei.harvard.edu NR 19 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD MAR PY 2011 VL 121 IS 3 BP 656 EP 660 DI 10.1002/lary.21392 PG 5 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 727HR UT WOS:000287789400044 PM 21344449 ER PT J AU Wang, SA Abruzzo, LV Hasserjian, RP Zhang, LP Hu, Y Zhang, YP Zhao, M Galili, N Raza, A Medeiros, LJ Garcia-Manero, G Miranda, RN AF Wang, Sa A. Abruzzo, Lynne V. Hasserjian, Robert P. Zhang, Liping Hu, Ying Zhang, Yanpeng Zhao, Ming Galili, Naomi Raza, Azar Medeiros, L. Jeffrey Garcia-Manero, Guillermo Miranda, Roberto N. TI Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features SO LEUKEMIA RESEARCH LA English DT Article DE Myelodysplastic syndromes; Deletion 11q; Acute myeloid leukemia; Overall survival; Ring sideroblasts; Tumor suppressor genes ID IN-SITU HYBRIDIZATION; HEMATOLOGICAL MALIGNANCIES; PROGNOSTIC-SIGNIFICANCE; SCORING SYSTEM; SYNDROMES MDS; LEUKEMIA; ABNORMALITIES; KARYOTYPE; PROGRESSION; MORPHOLOGY AB Deletions of chromosome 11q[del(11q)] as part of a non-complex karyotype are infrequent in myelodysplastic syndromes (MDS), leaving the clinicopathologic and genetic features largely undefined. From three large medical centers over a 10-year period, we identified 32 MDS cases where del(11q) was present either as a sole (n = 23) or associated with another abnormality (n = 9), showing an overall 0.6% frequency in MDS. These patients included 15 men and 17 women, with a median age of 68 years. Three were therapy-related, and 29 were primary MDS. These cases were characterized by transfusion-dependent anemia (65%); frequent ring sideroblasts (RS) (59%); bone marrow hypocellularity (22%), and less severe thrombocytopenia. With a median follow-up of 32 months, 9/24 (38%) cases progressed to acute myeloid leukemia (AML), and the overall survival (OS) was 35 months (3-105). Fluorescence in situ hybridization (FISH) showed MLL deletion in 6/10 cases, but no cryptic MLL translocations in all 15 MDS cases tested. In contrast, FISH performed in AML with del(11q) showed MLL rearrangement in 3/17 (18%) cases. In summary, del(11)q occurring in a non-complex karyotype is predominantly associated with primary MDS, lack of cryptic MLL rearrangements, and shows characteristic clinicopathological features. These clinicopathological features are likely attributed to commonly deleted regions of 11q and their involved genes. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Wang, Sa A.; Abruzzo, Lynne V.; Hu, Ying; Medeiros, L. Jeffrey; Miranda, Roberto N.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA. [Hasserjian, Robert P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Zhang, Liping] Univ Massachusetts, Med Ctr, Dept Pathol, Worcester, MA USA. [Zhang, Yanpeng; Zhao, Ming] Univ Texas MD Anderson Canc Ctr, Sch Hlth Profess, Houston, TX 77030 USA. [Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Galili, Naomi; Raza, Azar] St Vincents Comprehens Canc Ctr, Dept Internal Med, New York, NY USA. RP Wang, SA (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, 1515 Holcombe Blvd, Houston, TX 77030 USA. EM swang5@mdanderson.org OI Miranda, Roberto/0000-0002-8467-5464 FU NCI NIH HHS [P30 CA016672] NR 31 TC 7 Z9 7 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0145-2126 J9 LEUKEMIA RES JI Leuk. Res. PD MAR PY 2011 VL 35 IS 3 BP 351 EP 357 DI 10.1016/j.leukres.2010.07.018 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA 729QH UT WOS:000287965100021 PM 20691474 ER PT J AU Ippolito, A Wallace, DJ Gladman, D Fortin, PR Urowitz, M Werth, V Costner, M Gordon, C Alarcon, GS Ramsey-Goldman, R Maddison, P Clarke, A Bernatsky, S Manzi, S Bae, SC Merrill, JT Ginzler, E Hanly, JG Nived, O Sturfelt, G Sanchez-Guerrero, J Bruce, I Aranow, C Isenberg, D Zoma, A Magder, LS Buyon, J Kalunian, K Dooley, MA Steinsson, K van Vollenhoven, RF Stoll, T Weisman, M Petri, M AF Ippolito, A. Wallace, D. J. Gladman, D. Fortin, P. R. Urowitz, M. Werth, V. Costner, M. Gordon, C. Alarcon, G. S. Ramsey-Goldman, R. Maddison, P. Clarke, A. Bernatsky, S. Manzi, S. Bae, S-C Merrill, J. T. Ginzler, E. Hanly, J. G. Nived, O. Sturfelt, G. Sanchez-Guerrero, J. Bruce, I. Aranow, C. Isenberg, D. Zoma, A. Magder, L. S. Buyon, J. Kalunian, K. Dooley, M. A. Steinsson, K. van Vollenhoven, R. F. Stoll, T. Weisman, M. Petri, M. TI Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity SO LUPUS LA English DT Article DE ANA; autoantibodies; systemic lupus erythematosus ID B-CELL DEPLETION; REVISED CRITERIA; ANTIBODY-TITERS; NEPHRITIS; CLASSIFICATION; FLUCTUATION; PROFILES; EFFICACY; THERAPY; SM AB Systemic lupus erythematosus (SLE) is characterized by multiple autoantibodies and complement activation. Recent studies have suggested that anti-nuclear antibody (ANA) positivity may disappear over time in some SLE patients. Anti-double-stranded DNA (dsDNA) antibody titers and complement levels may vary with time and immunosuppressive treatment, while the behavior of anti-extractable nuclear antigen (ENA) over time is less well understood. This study sought to determine the correlation between historical autoantibody tests and current testing in patients with SLE. Three hundred and two SLE patients from the ACR Reclassification of SLE (AROSE) database with both historical and current laboratory data were selected for analysis. The historical laboratory data were compared with the current autoantibody tests done at the reference laboratory and tested for agreement using percent agreement and Kappa statistic. Serologic tests included ANA, anti-dsDNA, anti-Smith, anti-ribonucleoprotein (RNP), anti-Ro, anti-La, rheumatoid factor (RF), C3 and C4. Among those historically negative for immunologic markers, a current assessment of the markers by the reference laboratory generally yielded a low percentage of additional positives (3-13%). However, 6/11 (55%) of those historically negative for ANA were positive by the reference laboratory, and the reference laboratory test also identified 20% more patients with anti-RNP and 18% more with RF. Among those historically positive for immunologic markers, the reference laboratory results were generally positive on the same laboratory test (range 57% to 97%). However, among those with a history of low C3 or C4, the current reference laboratory results indicated low C3 or C4 a low percentage of the time (18% and 39%, respectively). ANA positivity remained positive over time, in contrast to previous studies. Anti-Ro, La, RNP, Smith and anti-dsDNA antibodies had substantial agreement over time, while complement had less agreement. This variation could partially be explained by variability of the historical assays, which were done by local laboratories over varying periods of time. Variation in the results for complement, however, is more likely to be explained by response to treatment. These findings deserve consideration in the context of diagnosis and enrolment in clinical trials. Lupus (2011) 20, 250-255. C1 [Ippolito, A.; Isenberg, D.] Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD 21205 USA. [Wallace, D. J.; Weisman, M.] Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Los Angeles, CA 90095 USA. [Gladman, D.; Fortin, P. R.; Urowitz, M.] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada. [Werth, V.] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Dept Dermatol, Philadelphia, PA 19104 USA. [Costner, M.] N Dallas Dermatol Associates, Dallas, TX USA. [Gordon, C.] Univ Birmingham, Sch Med, Dept Rheumatol, Birmingham, W Midlands, England. [Alarcon, G. S.] Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Ramsey-Goldman, R.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Maddison, P.] Ysbyty Gwynedd, Dept Rheumatol, Bangor, Gwynedd, Wales. [Clarke, A.; Bernatsky, S.] McGill Univ, Div Clin Epidemiol, Montreal, PQ, Canada. [Manzi, S.] Univ Pittsburgh, Sch Med, Dept Med, Div Rheumatol, Pittsburgh, PA USA. [Bae, S-C] Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, Seoul 133791, South Korea. [Merrill, J. T.] Oklahoma Med Res Fdn, Dept Clin Pharmacol, Oklahoma City, OK 73104 USA. [Ginzler, E.] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA. [Hanly, J. G.] Capital Hlth & Dalhousie Univ, Div Rheumatol, Dept Med, Halifax, NS, Canada. [Hanly, J. G.] Capital Hlth & Dalhousie Univ, Div Rheumatol, Dept Pathol, Halifax, NS, Canada. [Nived, O.; Sturfelt, G.] Univ Hosp, Dept Rheumatol, Lund, Sweden. [Bruce, I.] Univ Manchester, ARC Epidemiol Unit, Manchester, Lancs, England. [Aranow, C.] Feinstein Inst Med Res, Manhasset, NY USA. [Isenberg, D.] Ctr Rheumatol Res, Div Med, London, England. [Zoma, A.] Hairmyres Hosp, Lanarkshire Ctr Rheumatol, E Kilbride, Lanark, Scotland. [Magder, L. S.] Univ Maryland, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA. [Buyon, J.] NYU Med Ctr, New York, NY 10016 USA. [Kalunian, K.] UCSD Sch Med, Div Rheumatol Allergy & Immunol, La Jolla, CA USA. [Dooley, M. A.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC USA. [Steinsson, K.] Univ Hosp, Landspitali, Dept Rheumatol, Reykjavik, Iceland. [Steinsson, K.] Ctr Rheumatol Res, Reykjavik, Iceland. [van Vollenhoven, R. F.] Karolinska Univ Hosp, Dept Rheumatol, Stockholm, Sweden. [Stoll, T.] Kantonsspital Schaffhausen, Schaffhausen, Switzerland. RP Ippolito, A (reprint author), Johns Hopkins Univ, Sch Med, Div Rheumatol, 1830 E Monument St,Suite 7500, Baltimore, MD 21205 USA. EM ippolitoa@mail.nih.gov OI Isenberg, David/0000-0001-9514-2455; Bruce, Ian/0000-0003-3047-500X FU Institute for Clinical and Translational Research [UL1RR025005]; NIH [AR43727] FX This study was supported by the Institute for Clinical and Translational Research (UL1RR025005) and NIH AR43727. NR 30 TC 31 Z9 32 U1 3 U2 10 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 J9 LUPUS JI Lupus PD MAR PY 2011 VL 20 IS 3 BP 250 EP 255 DI 10.1177/0961203310385738 PG 6 WC Rheumatology SC Rheumatology GA 728BN UT WOS:000287849000004 PM 21362750 ER PT J AU Sun, HY Singh, N AF Sun, Hsin-Yun Singh, Nina TI Potential role of statins for the management of immune reconstitution syndrome SO MEDICAL HYPOTHESES LA English DT Article ID REGULATORY T-CELLS; VERSUS-HOST-DISEASE; HMG-COA REDUCTASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INFLAMMATORY SYNDROME; ANTIRETROVIRAL THERAPY; PARADOXICAL RESPONSE; RESTORATION SYNDROME; INFECTED PATIENTS; DOUBLE-BLIND AB It has become evident that while a robust inflammatory response plays a critical role in eradicating invading microbes, dysregulated immunity can be detrimental to the host if an optimal balance between the inflammatory and anti-inflammatory reactions is disrupted. Opportunistic infection-associated immune reconstitution syndrome is characterized by an aggressive inflammatory immune response and its management remains challenging and largely unknown. Statins, in addition to their lipid lower effects have anti-inflammatory attributes and there is precedence for the use of these agents as a therapeutic modality for autoimmune inflammatory disorders which have similar underlying pathogenesis as immune reconstitution syndrome. We hypothesize that statins may have a potential role for the management of immune reconstitution syndrome. Our proposal has biologic and translational implications for optimizing outcomes in patients with immune reconstitution syndrome. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Sun, Hsin-Yun] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15240 USA. [Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan. [Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan. [Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA. RP Singh, N (reprint author), VA Pittsburgh Healthcare Syst, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu OI SUN, HSIN-YUN/0000-0003-0074-7721 NR 55 TC 4 Z9 4 U1 0 U2 2 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0306-9877 J9 MED HYPOTHESES JI Med. Hypotheses PD MAR PY 2011 VL 76 IS 3 BP 307 EP 310 DI 10.1016/j.mehy.2010.09.019 PG 4 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 728QK UT WOS:000287888600001 PM 20965666 ER PT J AU Zhang, D Li, XH Liu, B AF Zhang, Da Li, Xinhua Liu, Bob TI Objective characterization of GE Discovery CT750 HD scanner: Gemstone spectral imaging mode SO MEDICAL PHYSICS LA English DT Article ID DUAL-ENERGY CT; NOISE POWER SPECTRUM; COMPUTED-TOMOGRAPHY; ACCURACY; PHANTOM; IMAGES; SYSTEM AB Purpose: To objectively characterize the performance of the gemstone spectral imaging (GSI) mode of GE CT750 HD scanner from a user's perspective. Methods: A regular scan protocol that approximates the adult abdomen scan protocol frequently used in the authors' institute was selected as the baseline, and a GSI protocol (preset 11) that is similar to the regular protocol and has a moderate dose level (CTDI(vol)=26.27 mGy) was compared to the baseline protocol. The resolving power of both protocols was characterized in terms of modulation transfer functions and high contrast resolution bar readings. Their noise characteristics were studied through noise power spectra, and their low contrast detectability was compared via contrast-to-noise ratio. Material decomposition capability of GSI was evaluated by scanning iodine solutions of 9-24 mg/ml iodine concentration in a Gammex CT phantom and by examining the estimated iodine concentration. In addition, a formula describing the dependency of HU in iodine enhanced area on GSI monochromatic energies and iodine concentrations was provided and the theoretical values were compared with the measured results. Results: The resolutions levels of 50%, 10%, and 5% MTF of GSI monochromatic images at 65 keV agree with those of the regular protocol within 0.1 lp/cm. GSI monochromatic images at 65 keV demonstrated the lowest noise level among GSI images of different monochromatic energies and showed very similar noise magnitude and noise power distribution as compared to the regular protocol images. The CNR of 60 and 65 keV GSI monoimages are approximately 100% of those of the regular protocol images. Estimated iodine concentration levels agreed with the actual values within 2% when the iodine solutions were placed at 3, 9, 12 o'clock positions of the phantom; when iodine solutions were placed at the phantom center and at 6 o'clock position, higher discrepancies of 2%-10% were observed. The observed dependency of HU on keV and iodine concentration levels agreed with the expectation from x-ray attenuations. Conclusions: Equivalent performances were observed in the comparison between GSI 65 keV monochromatic images and images from a regular abdomen scan protocol. This suggests the possibility of GSI to be employed in routine abdominal scans, which would potentially offer more information through its capabilities of material decomposition. (C) 2011 American Association of Physicists in Medicine. [DOI: 10.1118/1.3551999] C1 [Zhang, Da; Li, Xinhua; Liu, Bob] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Zhang, D (reprint author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. EM bliu7@bics.bwh.harvard.edu NR 31 TC 71 Z9 102 U1 3 U2 30 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD MAR PY 2011 VL 38 IS 3 BP 1178 EP 1188 DI 10.1118/1.3551999 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 728MY UT WOS:000287879400007 PM 21520830 ER PT J AU Goma, C Ruiz, A Jornet, N Latorre, A Pallerol, RM Carrasco, P Eudaldo, T Ribas, M AF Goma, Carles Ruiz, Agustin Jornet, Nuria Latorre, Artur Pallerol, Rosa M. Carrasco, Pablo Eudaldo, Teresa Ribas, Montserrat TI Radiation dose assessment in a 320-detector-row CT scanner used in cardiac imaging SO MEDICAL PHYSICS LA English DT Article DE computed tomography; radiation dose; cone-beam CT ID CONE-BEAM CT; COMPUTED-TOMOGRAPHY; DOSIMETRY; PROFILES; QUALITY; ROW; OPTIMIZATION; ANGIOGRAPHY; CHAMBER; CTDI100 AB Purpose: In the present era of cone-beam CT scanners, the use of the standardized CTDI(100) as a surrogate of the idealized CTDI is strongly discouraged and, consequently, so should be the use of the dose-length product (DLP) as an estimate of the total energy imparted to the patient. However, the DLP is still widely used as a reference quantity to normalize the effective dose for a given scan protocol mainly because the CTDI(100) is an easy-to-measure quantity. The aim of this article is therefore to describe a method for radiation dose assessment in large cone-beam single axial scans, which leads to a straightforward estimation of the total energy imparted to the patient. The authors developed a method accessible to all medical physicists and easy to implement in clinical practice in an attempt to update the bridge between CT dosimetry and the estimation of the effective dose. Methods: The authors used commercially available material and a simple mathematical model. The method described herein is based on the dosimetry paradigm introduced by the AAPM Task Group 111. It consists of measuring the dose profiles at the center and the periphery of a long body phantom with a commercial solid-state detector. A weighted dose profile is then calculated from these measurements. To calculate the CT dosimetric quantities analytically, a Gaussian function was fitted to the dose profile data. Furthermore, the Gaussian model has the power to condense the z-axis information of the dose profile in two parameters: The single-scan central dose, f(0), and the width of the profile, sigma. To check the energy dependence of the solid-state detector, the authors compared the dose profiles to measurements made with a small volume ion chamber. To validate the overall method, the authors compared the CTDI(100) calculated analytically to the measurement made with a 100 mm pencil ion chamber. Results: For the central and weighted dose profiles, the authors found a good agreement between the measured dose profile data and the fitted Gaussian functions. The solid-state detector had no energy dependence-within the energy range of interest-and the analytical model succeeded in reproducing the absolute dose values obtained with the pencil ion chamber. For the case of large cone-beam single axial scans, the quantity that better characterizes the total energy imparted to the patient is the weighted dose profile integral (DPI(w)). The DPI(w) can be easily determined from the two parameters that define the Gaussian functions: f(0) and sigma. The authors found that the DLP underestimated the total energy imparted to the patient by more than 20%. The authors also found that the calculated CT dosimetric quantities were higher than those displayed on the scanner console. Conclusions: The authors described and validated a method to assess radiation dose in large cone-beam single axial scans. This method offers a simple and more accurate estimation of the total energy imparted to the patient, thus offering the possibility to update the bridge between CT dosimetry and the estimation of the effective dose for cone-beam CT examinations in radiology, nuclear medicine, and radiation therapy. (C) 2011 American Association of Physicists in Medicine. [DOI: 10.1118/1.3558020] C1 [Goma, Carles; Ruiz, Agustin; Jornet, Nuria; Latorre, Artur; Pallerol, Rosa M.; Carrasco, Pablo; Eudaldo, Teresa; Ribas, Montserrat] Hosp Santa Creu & Sant Pau, Serv Radiofis & Radioproteccio, Barcelona 08025, Spain. RP Goma, C (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Francis H Burr Proton Therapy Ctr, Boston, MA 02114 USA. EM carles.goma@gmail.com OI Goma, Carles/0000-0003-0336-390X NR 36 TC 4 Z9 4 U1 0 U2 3 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD MAR PY 2011 VL 38 IS 3 BP 1473 EP 1480 DI 10.1118/1.3558020 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 728MY UT WOS:000287879400036 PM 21520859 ER PT J AU Waisbren, SE Potter, NL Gordon, CM Green, RC Greenstein, P Gubbels, CS Rubio-Gozalbo, E Schomer, D Welt, C Anastasoaie, V D'Anna, K Gentile, J Guo, CY Hecht, L Jackson, R Jansma, BM Li, Y Lip, V Murray, M Power, L Quinn, N Rohr, F Skinder-Meredith, A Timmers, I Tunick, R Wessel, A Levy, H Elsas, L Berry, G AF Waisbren, S. E. Potter, N. L. Gordon, C. M. Green, R. C. Greenstein, P. Gubbels, C. S. Rubio-Gozalbo, E. Schomer, D. Welt, C. Anastasoaie, V D'Anna, K. Gentile, J. Guo, C-Y Hecht, L. Jackson, R. Jansma, B. M. Li, Y. Lip, V Murray, M. Power, L. Quinn, N. Rohr, F. Skinder-Meredith, A. Timmers, I Tunick, R. Wessel, A. Levy, H. Elsas, L. Berry, G. TI The adult galactosemic phenotype SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 34th Annual Meeting of the Society-for-Inherited-Metabolic-Disorders (SIMD 2011) CY FEB 27-MAR 02, 2011 CL Pacific Groove, CA SP Soc Inherited Metabol Disorders, Genzyme, Abbott Metabol, Shire, ARUP Labs, Cytonet LLC, GeneDx, Hyperion Therapeut, Nautricia N Amer, Vitaflo, Ucyclyd Pharma, RDT, BIOMARIN, Applied Nutr Corp, CamBrooke Foods, Hitachi, Mead Johnson, PreventionGenetics, Canadian PKU & Allied Disorders Inc, Transgenomic, Emory Genet Lab, FOD, Kakkis EveryLife Fdn, Natl PKU Alliance, Organ Acidemia Assoc C1 [Waisbren, S. E.; Gordon, C. M.; Anastasoaie, V; D'Anna, K.; Gentile, J.; Guo, C-Y; Hecht, L.; Li, Y.; Lip, V; Quinn, N.; Rohr, F.; Tunick, R.; Wessel, A.; Levy, H.; Berry, G.] Childrens Hosp Boston, Boston, MA USA. [Potter, N. L.; Power, L.; Skinder-Meredith, A.] Washington State Univ, Pullman, WA 99164 USA. [Green, R. C.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Greenstein, P.; Schomer, D.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Gubbels, C. S.; Rubio-Gozalbo, E.; Timmers, I] Maastricht Univ, Med Ctr, Maastricht, Netherlands. [Welt, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Jackson, R.] Eastern Washington Univ, Seattle, WA USA. [Murray, M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Elsas, L.] Univ Miami, Coral Gables, FL 33124 USA. RI Timmers, Inge/H-1887-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD MAR PY 2011 VL 102 IS 3 BP 319 EP 320 PG 2 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 727CA UT WOS:000287773800144 ER PT J AU Xu, HS Yi, BA Chien, KR AF Xu, Huansheng Yi, B. Alexander Chien, Kenneth R. TI Shortcuts to making cardiomyocytes SO NATURE CELL BIOLOGY LA English DT Editorial Material ID PROGENITOR CELLS; HEART; REGENERATION; LINEAGES; MUSCLE AB The adult human heart lacks sufficient regenerative capacity to recover after a myocardial infarction. Cell-based therapy has emerged as a potential treatment for the failing heart; however, a key issue for the success of future cell-based therapies is the ability to obtain patient-specific high-quality cardiomyocytes in a fast and efficient manner. Recent progress has been made towards this goal using reprogramming-based approaches. C1 [Xu, Huansheng; Yi, B. Alexander; Chien, Kenneth R.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Xu, Huansheng; Yi, B. Alexander; Chien, Kenneth R.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. RP Xu, HS (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charles River Plaza CPZN 3208,185 Cambridge St, Boston, MA 02114 USA. EM krchien@partners.org FU NHLBI NIH HHS [U01 HL100408] NR 16 TC 9 Z9 9 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1465-7392 J9 NAT CELL BIOL JI Nat. Cell Biol. PD MAR PY 2011 VL 13 IS 3 BP 191 EP 193 DI 10.1038/ncb0311-191 PG 3 WC Cell Biology SC Cell Biology GA 728BB UT WOS:000287847600003 PM 21364566 ER PT J AU Di Micco, R Sulli, G Dobreva, M Liontos, M Botrugno, OA Gargiulo, G dal Zuffo, R Matti, V d'Ario, G Montani, E Mercurio, C Hahn, WC Gorgoulis, V Minucci, S di Fagagna, FD AF Di Micco, Raffaella Sulli, Gabriele Dobreva, Miryana Liontos, Michalis Botrugno, Oronza A. Gargiulo, Gaetano dal Zuffo, Roberto Matti, Valentina d'Ario, Giovanni Montani, Erica Mercurio, Ciro Hahn, William C. Gorgoulis, Vassilis Minucci, Saverio di Fagagna, Fabrizio d'Adda TI Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer SO NATURE CELL BIOLOGY LA English DT Article ID DOUBLE-STRAND BREAKS; CELLULAR SENESCENCE; CHROMATIN-STRUCTURE; HISTONE METHYLTRANSFERASE; HUMAN FIBROBLASTS; CELLS; ARREST; REPAIR; REPLICATION; CHECKPOINT AB Two major mechanisms have been causally implicated in the establishment of cellular senescence: the activation of the DNA damage response (DDR) pathway and the formation of senescence-associated heterochromatic foci (SAHF). Here we show that in human fibroblasts resistant to premature p16(INK4a) induction, SAHF are preferentially formed following oncogene activation but are not detected during replicative cellular senescence or on exposure to a variety of senescence-inducing stimuli. Oncogene-induced SAHF formation depends on DNA replication and ATR (ataxia telangiectasia and Rad3-related). Inactivation of ATM (ataxia telangiectasia mutated) or p53 allows the proliferation of oncogene-expressing cells that retain increased heterochromatin induction. In human cancers, levels of heterochromatin markers are higher than in normal tissues, and are independent of the proliferative index or stage of the tumours. Pharmacological and genetic perturbation of heterochromatin in oncogene-expressing cells increase DDR signalling and lead to apoptosis. In vivo, a histone deacetylase inhibitor (HDACi) causes heterochromatin relaxation, increased DDR, apoptosis and tumour regression. These results indicate that heterochromatin induced by oncogenic stress restrains DDR and suggest that the use of chromatin-modifying drugs in cancer therapies may benefit from the study of chromatin and DDR status of tumours. C1 [Di Micco, Raffaella; Sulli, Gabriele; Dobreva, Miryana; Matti, Valentina; d'Ario, Giovanni; di Fagagna, Fabrizio d'Adda] IFOM Fdn, FIRC Inst Mol Oncol Fdn, Milan, Italy. [Liontos, Michalis; Gorgoulis, Vassilis] Univ Athens, Sch Med, Dept Histol & Embryol, Mol Carcinogenesis Grp, GR-11527 Athens, Greece. [Botrugno, Oronza A.; Gargiulo, Gaetano; Minucci, Saverio] European Inst Oncol, Dept Expt Oncol, Milan, Italy. [dal Zuffo, Roberto; Mercurio, Ciro] DAC Genextra Grp, Milan, Italy. [Montani, Erica] Consortium Genom Technol, Milan, Italy. [Hahn, William C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hahn, William C.] Univ Milan, Dept Biomol Sci & Biotechnol, Milan, Italy. RP di Fagagna, FD (reprint author), IFOM Fdn, FIRC Inst Mol Oncol Fdn, Milan, Italy. EM fabrizio.dadda@ifom-ieo-campus.it RI qiao, zhixin/I-3408-2012; Minucci, Saverio/J-9669-2012; OI DADDADIFAGAGNA, FABRIZIO/0000-0002-1976-3185 FU European Commission; U.S. NIH/NIA [ROI AG023145]; European Community [202230]; Associazione Italiana per la Ricerca sul Cancro; Fondazione Telethon FX We thank M. Fumagalli for providing fibroblasts undergoing senescence following telomere shortening and for editing the manuscript; A. Oldani and D. Parazzoli from IFOM Imaging Unit for help with imaging; qRT-PCR and Cell Biology Units for support; S. Vultaggio for help with tumour xenograft generation and M. Romanenghi for technical assistance with ChIP. We thank O. Fernandez-Capetillo for pLKO.1 shATR; G. Smith for KU55933 (KuDOS Pharmaceuticals Ltd.). G. Manfioletti for sharing HMGA antibodies; P.P. Di Fiore for support; U. Herbig, B. Amati and M. Foiani for critical reading of the manuscript and all F.d'A.d.F. lab members for discussion and feedback throughout this work. M.L. and V.G. are funded by the European Commission (FP7-GENICA project). W.C.H. is supported in part by an U.S. NIH/NIA grant (ROI AG023145). The S.M. laboratory is supported in part by the European Union (Epitron). The F.d'A.d.F laboratory is supported by AIRC (Associazione Italiana per la Ricerca sul Cancro), the European Community's 7th Framework Programme (FP7/2007-2013) under grant agreement number 202230 (Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer; GENINCA), HFSP (Human Frontier Science Program), AICR (Association for International Cancer Research), EMBO Young Investigator Program and Telethon. NR 64 TC 131 Z9 132 U1 0 U2 22 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1465-7392 J9 NAT CELL BIOL JI Nat. Cell Biol. PD MAR PY 2011 VL 13 IS 3 BP 292 EP U244 DI 10.1038/ncb2170 PG 23 WC Cell Biology SC Cell Biology GA 728BB UT WOS:000287847600017 PM 21336312 ER PT J AU Bocking, T Aguet, F Harrison, SC Kirchhausen, T AF Boecking, Till Aguet, Francois Harrison, Stephen C. Kirchhausen, Tomas TI Single-molecule analysis of a molecular disassemblase reveals the mechanism of Hsc70-driven clathrin uncoating SO NATURE STRUCTURAL & MOLECULAR BIOLOGY LA English DT Article ID COATED VESICLES; LIGHT-CHAINS; AUXILIN; CHAPERONES; HSC70; ENDOCYTOSIS; INITIATION; COMPLEXES; DYNAMICS; ATPASE AB Heat shock cognate protein-70 (Hsc70) supports remodeling of protein complexes, such as disassembly of clathrin coats on endocytic coated vesicles. To understand how a simple ATP-driven molecular clamp catalyzes a large-scale disassembly reaction, we have used single-particle fluorescence imaging to track the dynamics of Hsc70 and its clathrin substrate in real time. Hsc70 accumulates to a critical level, determined by kinetic modeling to be one Hsc70 for every two functional attachment sites; rapid, all-or-none uncoating then ensues. We propose that Hsc70 traps conformational distortions, seen previously by cryo-EM, in the vicinity of each occupied site and that accumulation of local strains destabilizes the clathrin lattice. Capture of conformational fluctuations may be a general mechanism for chaperone-driven disassembly of protein complexes. C1 [Boecking, Till; Kirchhausen, Tomas] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. [Boecking, Till; Aguet, Francois; Kirchhausen, Tomas] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA. [Harrison, Stephen C.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Harrison, Stephen C.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA. [Boecking, Till] Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia. RP Kirchhausen, T (reprint author), Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. EM kirchhausen@crystal.harvard.edu OI Bocking, Till/0000-0003-1165-3122 FU Human Frontier Science Program Organization; Swiss National Science Foundation; US National Institutes of Health (NIH) [GM-073165]; NIH (New England Regional Center of Excellence in Biodefense and Emerging Infectious Disease, Core Imaging Facility) [GM-075252, U54 AI057159] FX We thank W. Boll and I. Rapoport for help with protein preparations; E. Marino for maintaining the Imaging Resource used in this study; G. Danuser, A. van Oijen and D. Floyd for advice; and members of our laboratories for discussions. T.B. acknowledges a Cross-Disciplinary Fellowship of the Human Frontier Science Program Organization, and F.A. a Swiss National Science Foundation fellowship and partial support from US National Institutes of Health (NIH) grant GM-073165 (to G. Danuser, Harvard Medical School). This work was supported by NIH grants GM-075252 and U54 AI057159 (New England Regional Center of Excellence in Biodefense and Emerging Infectious Disease, Core Imaging Facility) to T.K. S.C.H. is an investigator in the Howard Hughes Medical Institute. NR 28 TC 38 Z9 39 U1 1 U2 14 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1545-9985 J9 NAT STRUCT MOL BIOL JI Nat. Struct. Mol. Biol. PD MAR PY 2011 VL 18 IS 3 BP 295 EP U78 DI 10.1038/nsmb.1985 PG 8 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 730XZ UT WOS:000288072200009 PM 21278753 ER PT J AU Nigwekar, SU Bhan, I Thadhani, R AF Nigwekar, Sagar U. Bhan, Ishir Thadhani, Ravi TI Nutritional vitamin D in dialysis patients: what to D-iscern? SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article ID HEMODIALYSIS-PATIENTS; D DEFICIENCY; RISK-FACTOR; POPULATION; MORTALITY; SURVIVAL; OUTCOMES; COHORT; TRENDS C1 [Nigwekar, Sagar U.; Bhan, Ishir; Thadhani, Ravi] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. RP Thadhani, R (reprint author), Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. EM rthadhani@partners.org FU Abbott Laboratories FX R.T. has received a research grant from Abbott Laboratories. NR 20 TC 8 Z9 8 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD MAR PY 2011 VL 26 IS 3 BP 764 EP 766 DI 10.1093/ndt/gfq799 PG 4 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 726SN UT WOS:000287746500003 PM 21239385 ER PT J AU Rosenbloom, MH Atri, A AF Rosenbloom, Michael Henry Atri, Alireza TI The Evaluation of Rapidly Progressive Dementia SO NEUROLOGIST LA English DT Review DE rapidly progressive dementia; Jakob-Creutzfeldt disease; immune-mediated dementia; paraneoplastic syndrome; Hashimoto encephalopathy ID CREUTZFELDT-JAKOB-DISEASE; ANTIBODY-ASSOCIATED ENCEPHALOPATHY; PARANEOPLASTIC LIMBIC ENCEPHALITIS; ANTI-MA2-ASSOCIATED ENCEPHALITIS; OLDER-ADULTS; DIAGNOSIS; AUTOANTIBODIES; NEUROMYOTONIA; THYROIDITIS; CHANNELS AB Background: Rapidly progressive dementia (RPD) is a unique set of disorders resulting in cognitive, behavioral, and motor decline within 2 years. A variety of etiologies may contribute to RPD including neurodegenerative, inflammatory, infectious, and toxic-metabolic conditions. Jakob-Creutzfeldt disease (CJD) is frequently the most concerning diagnosis on the differential. The challenge for the neurologist is distinguishing prion disease from reversible processes that result in dementia. Review Summary: This review discusses the clinical aspects and the diagnostic workup of RPD. Particular focus is given to both CJD and the potentially treatable inflammatory conditions that may cause a similar presentation. Furthermore, a standardized stepwise approach is outlined for patients presenting with RPD. Conclusions: Neurologists should adopt a standardized approach to the rapidly presenting disease processes that may mimic CJD in their clinical and radiologic features. C1 [Rosenbloom, Michael Henry; Atri, Alireza] Bedford VA Hosp, GRECC, Bedford, MA USA. [Atri, Alireza] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Rosenbloom, MH (reprint author), HealthPartners Specialty Clin, Ctr Dementia & Alzheimers Dis, 401 Phalen Blvd, St Paul, MN 55130 USA. EM Michael.H.Rosenbloom@HealthPartners.com OI Atri, Alireza/0000-0003-4405-6973 FU Geriatric Research Education and Clinical Center [PI ATRI: NIA K23 AG0217] FX Supported by Geriatric Research Education and Clinical Center Fellowship PI ATRI: NIA K23 AG0217. NR 45 TC 17 Z9 19 U1 3 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1074-7931 J9 NEUROLOGIST JI Neurologist PD MAR PY 2011 VL 17 IS 2 BP 67 EP 74 DI 10.1097/NRL.0b013e31820ba5e3 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 728AA UT WOS:000287844000001 PM 21364356 ER PT J AU Loggia, ML Juneau, M Bushnell, MC AF Loggia, Marco L. Juneau, Mylene Bushnell, M. Catherine TI Autonomic responses to heat pain: Heart rate, skin conductance, and their relation to verbal ratings and stimulus intensity SO PAIN LA English DT Article DE Psychophysics; Human; Measurement; Autonomic nervous system; Variability; Nonverbal ID EMOTIONAL MODULATION; POSTOPERATIVE PAIN; HEALTHY-SUBJECTS; SEX-DIFFERENCES; STIMULATION; VALIDATION; SYSTEM; RELIABILITY; NOCICEPTION; PERCEPTION AB In human pain experiments, as well as in clinical settings, subjects are often asked to assess pain using scales (eg, numeric rating scales). Although most subjects have little difficulty in using these tools, some lack the necessary basic cognitive or motor skills (eg, paralyzed patients). Thus, the identification of appropriate nonverbal measures of pain has significant clinical relevance. In this study, we assessed heart rate (HR), skin conductance (SC), and verbal ratings in 39 healthy male subjects during the application of twelve 6-s heat stimuli of different intensities on the subjects' left forearm. Both HR and SC increased with more intense painful stimulation. However, HR but not SC, significantly correlated with pain ratings at the group level, suggesting that HR may be a better predictor of between-subject differences in pain than is SC. Conversely, changes in SC better predicted variations in ratings within a given individual, suggesting that it is more sensitive to relative changes in perception. The differences in findings derived from between-and within-subject analyses may result from greater within-subject variability in HR. We conclude that at least for male subjects, HR provides a better predictor of pain perception than SC, but that data should be averaged over several stimulus presentations to achieve consistent results. Nevertheless, variability among studies, and the indication that gender of both the subject and experimenter could influence autonomic results, lead us to advise caution in using autonomic or any other surrogate measures to infer pain in individuals who cannot adequately report their perception. (C) 2010 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved. C1 [Loggia, Marco L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02129 USA. [Loggia, Marco L.; Bushnell, M. Catherine] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada. [Loggia, Marco L.; Juneau, Mylene; Bushnell, M. Catherine] McGill Univ, Alan Edwards Ctr Res Pain, Montreal, PQ, Canada. [Loggia, Marco L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02129 USA. [Loggia, Marco L.] MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA USA. [Juneau, Mylene] Concordia Univ, Coll Sci, Montreal, PQ, Canada. [Juneau, Mylene] Concordia Univ, Dept Biol, Montreal, PQ H3G 1M8, Canada. [Bushnell, M. Catherine] McGill Univ, Fac Dent, Montreal, PQ, Canada. [Bushnell, M. Catherine] McGill Univ, Dept Anesthesiol, Montreal, PQ, Canada. RP Loggia, ML (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Bldg 120,2nd Ave,Suite 101E, Boston, MA 02129 USA. EM marco@nmr.mgh.harvard.edu FU Canadian Institutes of Health Research (CIHR) FX We thank Dr. Robert Edwards, Dr. Vitaly Napadow, and Dr. Riccardo Barbieri for helpful comments on the manuscript. This work was supported by a grant from the Canadian Institutes of Health Research (CIHR). NR 46 TC 35 Z9 38 U1 4 U2 23 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD MAR PY 2011 VL 152 IS 3 BP 592 EP 598 DI 10.1016/j.pain.2010.11.032 PG 7 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 719GZ UT WOS:000287192200021 PM 21215519 ER PT J AU Woythaler, MA McCormick, MC Smith, VC AF Woythaler, Melissa A. McCormick, Marie C. Smith, Vincent C. TI Late Preterm Infants Have Worse 24-Month Neurodevelopmental Outcomes Than Term Infants SO PEDIATRICS LA English DT Article DE infant; premature; infant; very low birth weight; developmental disabilities; postnatal development; cognition; follow-up studies ID LOW-BIRTH-WEIGHT; CARE UTILIZATION INDEX; SCHOOL-AGE OUTCOMES; PREMATURE-INFANTS; UNITED-STATES; DEVELOPMENT PROGRAM; GESTATIONAL-AGE; RISK; CHILDREN; HEALTH AB BACKGROUND: Late preterm infants (34-37 weeks' gestation) are often perceived at similar risks for morbidity and mortality as term infants. OBJECTIVE: To compare the neurodevelopmental outcomes of late preterm to term infants. METHODS: Our study sample of 6300 term and 1200 late preterm infants came from the Early Childhood Longitudinal Study-Birth Cohort. We used general estimating equations to get weighted odds of having developmental delay, mental index scores (MDI) or psychomotor index scores (PDI) < 70, at 24 months of age. RESULTS: Late preterm infants compared with term infants had lower MDI (85 vs 89) and PDI (88 vs 92), both P < .0001, respectively. A higher proportion of late preterm infants compared with term infants had an MDI < 70 (21% vs 16%; P < .0001). An equal number had PDIs < 70 (6.1% vs 6.5%). After controlling for statistically significant and clinically relevant descriptive characteristics, late preterm infants still had higher odds of mental (odds ratio: 1.52 [95% confidence interval: 1.26-1.82] P < .0001) or physical (odds ratio: 1.56 [95% confidence interval: 1.30-1.89] P < .0001) developmental delay. CONCLUSIONS: Late preterm infants have poorer neurodevelopmental outcomes than term infants and have increased odds to have a mental and/or physical developmental delay. Pediatrics 2011;127:e622-e629 C1 [Woythaler, Melissa A.] Massachusetts Gen Hosp, Dept Neonatol, Boston, MA 02114 USA. [McCormick, Marie C.; Smith, Vincent C.] Beth Israel Deaconess Med Ctr, Dept Neonatol, Boston, MA 02215 USA. [McCormick, Marie C.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. RP Woythaler, MA (reprint author), 55 Fruit St,Founders 528, Boston, MA 02114 USA. EM mwoythaler@partners.org OI McCormmick, Marie/0000-0002-3938-1707 NR 44 TC 99 Z9 102 U1 3 U2 16 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD MAR PY 2011 VL 127 IS 3 BP E622 EP E629 DI 10.1542/peds.2009-3598 PG 8 WC Pediatrics SC Pediatrics GA 728AI UT WOS:000287845400011 PM 21321024 ER PT J AU Winthrop, KL Baxter, R Liu, LY McFarland, B Austin, D Varley, C Radcliffe, L Suhler, E Choi, D Herrinton, LJ AF Winthrop, Kevin L. Baxter, Roger Liu, Liyan McFarland, Bentson Austin, Donald Varley, Cara Radcliffe, Leann Suhler, Eric Choi, Dongsoek Herrinton, Lisa J. TI The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE tuberculosis; nontuberculous mycobacteria; biologic therapy; tumor necrosis factor-alpha; electronic medical records; case-finding ID GRANULOMATOUS INFECTIONS; MANAGEMENT; BLOCKADE; RISK AB Purpose Anti-tumor necrosis factor-alpha (anti-TNF) therapies are associated with severe mycobacterial infections in rheumatoid arthritis patients. We developed and validated electronic record search algorithms for these serious infections. Methods The study used electronic clinical, microbiologic, and pharmacy records from Kaiser Permanente Northern California (KPNC) and the Portland Veterans Affairs Medical Center (PVAMC). We identified suspect tuberculosis and nontuberculous mycobacteria (NTM) cases using inpatient and outpatient diagnostic codes, culture results, and anti-tuberculous medication dispensing. We manually reviewed records to validate our case-finding algorithms. Results We identified 64 tuberculosis and 367 NTM potential cases, respectively. For tuberculosis, diagnostic code positive predictive value (PPV) was 54% at KPNC and 9% at PVAMC. Adding medication dispensings improved these to 87% and 46%, respectively. Positive tuberculosis cultures had a PPV of 100% with sensitivities of 79% (KPNC) and 55% (PVAMC). For NTM, the PPV of diagnostic codes was 91% (KPNC) and 76% (PVAMC). At KPNC, >= 1 positive NTM culture was sensitive (100%) and specific (PPV, 74%) if non-pathogenic species were excluded; at PVAMC, >= 1 positive NTM culture identified 76% of cases with PPV of 41%. Application of the American Thoracic Society NTM microbiology criteria yielded the highest PPV (100% KPNC, 78% PVAMC). Conclusions The sensitivity and predictive value of electronic microbiologic data for tuberculosis and NTM infections is generally high, but varies with different facilities or models of care. Unlike NTM, tuberculosis diagnostic codes have poor PPV, and in the absence of laboratory data, should be combined with anti-tuberculous therapy dispensings for pharmacoepidemiologic research. Copyright (C) 2010 John Wiley & Sons, Ltd. C1 [Winthrop, Kevin L.; McFarland, Bentson; Austin, Donald; Varley, Cara; Suhler, Eric; Choi, Dongsoek] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Winthrop, Kevin L.; Austin, Donald; Radcliffe, Leann; Suhler, Eric] Portland VA Med Ctr, Portland, OR USA. [Baxter, Roger; Liu, Liyan; Herrinton, Lisa J.] Kaiser Permanente No Calif, Oakland, CA USA. RP Winthrop, KL (reprint author), CEI OHSU, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA. EM winthrop@ohsu.edu OI McFarland, Bentson/0000-0001-9149-5616 FU UCB pharmaceuticals; Agency for Healthcare Research and Quality (AHRQ) [1K08HS017552-01] FX This work was funded by a grant from UCB pharmaceuticals. KL Winthrop's work on this manuscript was funded by an Agency for Healthcare Research and Quality (AHRQ) grant (1K08HS017552-01). NR 19 TC 20 Z9 20 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD MAR PY 2011 VL 20 IS 3 BP 229 EP 235 DI 10.1002/pds.2049 PG 7 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 731BZ UT WOS:000288082600002 PM 21351303 ER PT J AU Zampighi, GA Schietroma, C Zampighi, LM Woodruff, M Wright, EM Brecha, NC AF Zampighi, Guido A. Schietroma, Cataldo Zampighi, Lorenzo M. Woodruff, Michael Wright, Ernest M. Brecha, Nicholas C. TI Conical Tomography of a Ribbon Synapse: Structural Evidence for Vesicle Fusion SO PLOS ONE LA English DT Article ID RETINAL BIPOLAR CELLS; FROG NEUROMUSCULAR-JUNCTION; SENSITIVE CALCIUM-CHANNEL; SALAMANDER ROD SYNAPSE; OUTER PLEXIFORM LAYER; ACTIVE ZONE PROTEINS; SACCULAR HAIR-CELLS; TRANSMITTER RELEASE; ELECTRON TOMOGRAPHY; PHOTORECEPTOR TERMINALS AB To characterize the sites of synaptic vesicle fusion in photoreceptors, we evaluated the three-dimensional structure of rod spherules from mice exposed to steady bright light or dark-adapted for periods ranging from 3 to 180 minutes using conical electron tomography. Conical tilt series from mice retinas were reconstructed using the weighted back projection algorithm, refined by projection matching and analyzed using semiautomatic density segmentation. In the light, rod spherules contained similar to 470 vesicles that were hemi-fused and similar to 187 vesicles that were fully fused (omega figures) with the plasma membrane. Active zones, defined by the presence of fully fused vesicles, extended along the entire area of contact between the rod spherule and the horizontal cell ending, and included the base of the ribbon, the slope of the synaptic ridge and ribbon-free regions apposed to horizontal cell axonal endings. There were transient changes of the rod spherules during dark adaptation. At early periods in the dark (3-15 minutes), there was a) an increase in the number of fully fused synaptic vesicles, b) a decrease in rod spherule volume, and c) an increase in the surface area of the contact between the rod spherule and horizontal cell endings. These changes partially compensate for the increase in the rod spherule plasma membrane following vesicle fusion. After 30 minutes of dark-adaptation, the rod spherules returned to dimensions similar to those measured in the light. These findings show that vesicle fusion occurs at both ribbon-associated and ribbon-free regions, and that transient changes in rod spherules and horizontal cell endings occur shortly after dark onset. C1 [Zampighi, Guido A.; Schietroma, Cataldo; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Zampighi, Guido A.; Zampighi, Lorenzo M.; Wright, Ernest M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. [Woodruff, Michael] Univ Calif Los Angeles, Coll Letters & Sci, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Zampighi, GA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. EM nbrecha@ucla.edu FU National Institutes of Health [EY04410, DK44602, EY15573]; Jules Stein Eye Institute FX This work was supported by National Institutes of Health EY04410 (GZ), DK44602 (EMW), EY15573 (NCB) and the Jules Stein Eye Institute. NCB is a VA Career Scientist. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 119 TC 22 Z9 22 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 1 PY 2011 VL 6 IS 3 AR e16944 DI 10.1371/journal.pone.0016944 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 729ET UT WOS:000287932100008 PM 21390245 ER PT J AU Xu, WH Seok, J Mindrinos, MN Schweitzer, AC Jiang, H Wilhelmy, J Clark, TA Kapur, K Xing, Y Faham, M Storey, JD Moldawer, LL Maier, RV Tompkins, RG Wong, WH Davis, RW Xiao, WZ AF Xu, Weihong Seok, Junhee Mindrinos, Michael N. Schweitzer, Anthony C. Jiang, Hui Wilhelmy, Julie Clark, Tyson A. Kapur, Karen Xing, Yi Faham, Malek Storey, John D. Moldawer, Lyle L. Maier, Ronald V. Tompkins, Ronald G. Wong, Wing Hung Davis, Ronald W. Xiao, Wenzhong CA Inflammation Host Response Injury TI Human transcriptome array for high-throughput clinical studies SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE gene isoform; next-generation sequencing; exon junction; blood leukocyte ID MOLECULAR CLASSIFICATION; RNA-SEQ; EXPRESSION; GENOME; MICROARRAYS; DISEASE; CELL; DISCOVERY; INSIGHTS; REVEAL AB A 6.9 million-feature oligonucleotide array of the human transcriptome [Glue Grant human transcriptome (GG-H array)] has been developed for high-throughput and cost-effective analyses in clinical studies. This array allows comprehensive examination of gene expression and genome-wide identification of alternative splicing as well as detection of coding SNPs and noncoding transcripts. The performance of the array was examined and compared with mRNA sequencing (RNA-Seq) results over multiple independent replicates of liver and muscle samples. Compared with RNA-Seq of 46 million uniquely mappable reads per replicate, the GG-H array is highly reproducible in estimating gene and exon abundance. Although both platforms detect similar expression changes at the gene level, the GG-H array is more sensitive at the exon level. Deeper sequencing is required to adequately cover low-abundance transcripts. The array has been implemented in a multicenter clinical program and has generated high-quality, reproducible data. Considering the clinical trial requirements of cost, sample availability, and throughput, the GG-H array has a wide range of applications. An emerging approach for large-scale clinical genomic studies is to first use RNA-Seq to the sufficient depth for the discovery of transcriptome elements relevant to the disease process followed by high-throughput and reliable screening of these elements on thousands of patient samples using custom-designed arrays. C1 [Xu, Weihong; Seok, Junhee; Mindrinos, Michael N.; Wilhelmy, Julie; Davis, Ronald W.] Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA. [Xu, Weihong; Seok, Junhee; Mindrinos, Michael N.; Wilhelmy, Julie; Davis, Ronald W.] Stanford Univ, Dept Biochem, Palo Alto, CA 94304 USA. [Schweitzer, Anthony C.; Clark, Tyson A.; Faham, Malek] Affymetrix Inc, Assay & Applicat Prod Dev, Santa Clara, CA 95051 USA. [Jiang, Hui; Kapur, Karen; Xing, Yi; Wong, Wing Hung] Stanford Univ, Dept Stat, Stanford, CA 94305 USA. [Jiang, Hui; Kapur, Karen; Xing, Yi; Wong, Wing Hung] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA. [Xing, Yi] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA. [Xing, Yi] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA. [Storey, John D.] Princeton Univ, Lewis Sigler Inst, Princeton, NJ 08544 USA. [Storey, John D.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA. [Moldawer, Lyle L.] Univ Florida, Dept Surg, Coll Med, Gainesville, FL 32610 USA. [Maier, Ronald V.] Univ Washington, Dept Surg, Seattle, WA 98104 USA. [Tompkins, Ronald G.; Xiao, Wenzhong] Harvard Univ, Massachusetts Gen Hosp, Shriners Hosp Children, Sch Med, Boston, MA 02114 USA. RP Davis, RW (reprint author), Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA. EM dbowe@stanford.edu; wxiao1@partners.org RI Storey, John/B-5282-2011; Xing, yi/E-2884-2010; Jiang, Hui/N-7083-2013; Xu, Weihong/C-4175-2012; OI xiao, wenzhong/0000-0003-4944-6380 FU National Institutes of Health [U54GM062119, P01HG000205, R01HG004634] FX We thank Dr. Weng-Onn Lui for assistance and comments during the development of the GG-H array and the groups of Drs. Michael Snyder, Steven Kunkel, and Ulysses Balis for assistance with the sequencing experiments. This work was supported in part by National Institutes of Health Grants U54GM062119, P01HG000205, and R01HG004634. NR 34 TC 51 Z9 52 U1 2 U2 22 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAR 1 PY 2011 VL 108 IS 9 BP 3707 EP 3712 DI 10.1073/pnas.1019753108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 728AD UT WOS:000287844400051 PM 21317363 ER PT J AU Scaltriti, M Eichhorn, PJ Cortes, J Prudkin, L Aura, C Jimenez, J Chandarlapaty, S Serra, V Prat, A Ibrahim, YH Guzman, M Gili, M Rodriguez, O Rodriguez, S Perez, J Green, SR Mai, S Rosen, N Hudis, C Baselga, J AF Scaltriti, Maurizio Eichhorn, Pieter J. Cortes, Javier Prudkin, Ludmila Aura, Claudia Jimenez, Jose Chandarlapaty, Sarat Serra, Violeta Prat, Aleix Ibrahim, Yasir H. Guzman, Marta Gili, Magui Rodriguez, Olga Rodriguez, Sonia Perez, Jose Green, Simon R. Mai, Sabine Rosen, Neal Hudis, Clifford Baselga, Jose TI Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2(+) breast cancer patients SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID FACTOR-I RECEPTOR; GROWTH-FACTOR; E EXPRESSION; ADJUVANT CHEMOTHERAPY; E OVEREXPRESSION; PI3K PATHWAY; P27(KIP1); CELLS; SURVIVAL; AMPLIFICATION AB Clinical benefits from trastuzumab and other anti-HER2 therapies in patients with HER2 amplified breast cancer remain limited by primary or acquired resistance. To identify potential mechanisms of resistance, we established trastuzumab-resistant HER2 amplified breast cancer cells by chronic exposure to trastuzumab treatment. Genomewide copy-number variation analyses of the resistant cells compared with parental cells revealed a focal amplification of genomic DNA containing the cyclin E gene. In a cohort of 34 HER2(+) patients treated with trastuzumab-based therapy, we found that cyclin E amplification/overexpression was associated with a worse clinical benefit (33.3% compared with 87.5%, P < 0.02) and a lower progression-free survival (6 mo vs. 14 mo, P < 0.002) compared with nonoverexpressing cyclin E tumors. To dissect the potential role of cyclin E in trastuzumab resistance, we studied the effects of cyclin E overexpression and cyclin E suppression. Cyclin E overexpression resulted in resistance to trastuzumab both in vitro and in vivo. Inhibition of cyclin E activity in cyclin E-amplified trastuzumab resistant clones, either by knockdown of cyclin E expression or treatment with cyclin-dependent kinase 2 (CDK2) inhibitors, led to a dramatic decrease in proliferation and enhanced apoptosis. In vivo, CDK2 inhibition significantly reduced tumor growth of trastuzumab-resistant xenografts. Our findings point to a causative role for cyclin E overexpression and the consequent increase in CDK2 activity in trastuzumab resistance and suggest that treatment with CDK2 inhibitors may be a valid strategy in patients with breast tumors with HER2 and cyclin E coamplification/overexpression. C1 [Scaltriti, Maurizio; Eichhorn, Pieter J.; Cortes, Javier; Serra, Violeta; Prat, Aleix; Ibrahim, Yasir H.; Guzman, Marta; Gili, Magui; Rodriguez, Olga; Perez, Jose; Baselga, Jose] Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona 08035, Spain. [Prudkin, Ludmila; Aura, Claudia; Jimenez, Jose; Rodriguez, Sonia] Vall dHebron Inst Oncol, Dept Mol Pathol, Barcelona 08035, Spain. [Scaltriti, Maurizio; Eichhorn, Pieter J.; Baselga, Jose] Harvard Univ, Massachusetts Gen Hosp, Div Hematol & Oncol, Canc Ctr,Med Sch, Boston, MA 02114 USA. [Chandarlapaty, Sarat; Rosen, Neal] Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Chem, New York, NY 10065 USA. [Chandarlapaty, Sarat; Rosen, Neal; Hudis, Clifford] Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, New York, NY 10065 USA. [Green, Simon R.] Cyclacel Ltd, Dundee DD1 5JJ, Scotland. [Mai, Sabine] Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada. [Baselga, Jose] Univ Autonoma Barcelona, Fac Med, E-08193 Barcelona, Spain. RP Baselga, J (reprint author), Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona 08035, Spain. EM jbaselga@partners.org RI Prat, Aleix/P-8561-2014; Mai, Sabine/E-5667-2017; OI Prat, Aleix/0000-0003-2377-540X; Mai, Sabine/0000-0002-5797-2201; Cortes, Javier/0000-0001-7623-1583 FU Breast Cancer Research Foundation; European Research Council [AdG09 250244]; Instituto de Salud Carlos III [PSO9/00623] FX This work was supported by the Breast Cancer Research Foundation, European Research Council Grant AdG09 250244, and Instituto de Salud Carlos III Intrasalud Grant PSO9/00623. NR 47 TC 115 Z9 122 U1 1 U2 21 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAR 1 PY 2011 VL 108 IS 9 BP 3761 EP 3766 DI 10.1073/pnas.1014835108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 728AD UT WOS:000287844400059 PM 21321214 ER PT J AU Preis, O Blake, MA Scott, JA AF Preis, Ori Blake, Michael A. Scott, James A. TI Neural Network Evaluation of PET Scans of the Liver: A Potentially Useful Adjunct in Clinical Interpretation SO RADIOLOGY LA English DT Article ID INTERSTITIAL LUNG-DISEASE; POSITRON-EMISSION-TOMOGRAPHY; SOLITARY PULMONARY NODULES; HIGH-RESOLUTION CT; DIFFERENTIAL-DIAGNOSIS; CHEST RADIOGRAPHS; METASTASES; MALIGNANCY; LIKELIHOOD; LESIONS AB Purpose: To assess the performance of an artificial neural network in the evaluation of fluorine 18 fluorodeoxyglucose (FDG) uptake in the liver, compared with the results of expert interpretation of abdominal liver magnetic resonance (MR) images. Materials and Methods: The study was approved by the institutional human research committee and was HIPAA compliant, with waiver of informed consent. Digital data from positron emission tomographic (PET)/computed tomographic (CT) examinations, along with patient demographics, were obtained from 98 consecutive patients who underwent both whole-body PET/CT examinations and liver MR imaging examinations within 2 months. Interpretations of the scans from PET/CT examinations by trained neural networks were cross-classified with expert interpretations of the findings on images from MR examinations for intrahepatic benignity or malignancy. Receiver operating characteristic (ROC) curves were obtained for the designed networks. The significance of the difference between neural network ROC curves and the ROC curves detailing the performance of two expert blinded observers in the interpretation of liver FDG uptake was determined. Results: A neural network incorporating lesion data demonstrated an ROC curve with an area under the curve (AUC) of 0.905 (standard error, 0.0370). A network independent of lesion data demonstrated an ROC curve with an AUC of 0.896 (standard error, 0.0386). These results compare favorably with results of expert blinded observers 1 and 2 who demonstrated ROCs with AUCs of 0.786 (standard error, 0.0522) and 0.796 (standard error, 0.0514), respectively. Following unblinding to network data, the AUCs for readers 1 and 2 improved to 0.924 (standard error, 0.0335) and 0.881 (standard error, 0.0409), respectively. Conclusion: Computers running artificial neural networks employing PET/CT scan data are sensitive and specific in the designation of the presence of intrahepatic malignancy, with comparison with interpretation by expert observers. When used in conjunction with human expertise, network data improve accuracy of the human interpreter. (C)RSNA, 2011 C1 [Preis, Ori] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Preis, O (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA. EM opreis@gmail.com NR 21 TC 3 Z9 3 U1 0 U2 1 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD MAR PY 2011 VL 258 IS 3 BP 714 EP 721 DI 10.1148/radiol.10100547 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 724JX UT WOS:000287573100007 PM 21339347 ER PT J AU Demehri, S Kalra, MK Rybicki, FJ Steigner, ML Lang, MJ Houseman, EA Curhan, GC Silverman, SG AF Demehri, Shadpour Kalra, Mannudeep K. Rybicki, Frank J. Steigner, Michael L. Lang, Matthew J. Houseman, E. Andres Curhan, Gary C. Silverman, Stuart G. TI Quantification of Urinary Stone Volume: Attenuation Threshold-based CT Method-A Technical Note SO RADIOLOGY LA English DT Article ID SHOCK-WAVE LITHOTRIPSY; CORONARY-ARTERY CALCIUM; MULTIDETECTOR ROW CT; HELICAL COMPUTED-TOMOGRAPHY; PERCUTANEOUS NEPHROLITHOTOMY; RENAL STONE; IN-VITRO; RECURRENCE; PREDICTOR; DIAGNOSIS AB Purpose: To compare two threshold-based computed tomographic (CT) methods for the quantification of urinary stone volume; to assess their accuracy and precision at varying tube voltages, tube currents, and section thicknesses in a phantom; and to determine interobserver agreement with each of these methods in a pilot clinical study. Materials and Methods: After institutional review board approval, written informed consent was waived. The study was HIPAA compliant. Thirty-six calcium oxalate stones were scanned in an anthropomorphic phantom. For the fixed threshold method, stones were segmented with 0.6-mm-thick sections by using attenuation thresholds of 130 and 575 HU (equal to half of mean attenuation of all stones). For the variable threshold method, stones were segmented at an attenuation threshold equal to half of the attenuation of each stone and at variable section thicknesses (0.6, 1, and 3 mm), tube currents (150, 100, and 50 mAs [reference]), and tube voltages (100 and 80 kVp). Normalized Bland-Altman analysis was used to assess the bias and precision of the two CT methods compared with that of the fluid displacement method (reference standard). Two independent readers retrospectively measured stone volumes in 17 patients (male-to-female ratio, 1.4; mean age, 55 years), and interobserver agreement was assessed by using Bland-Altman limits of agreement. Results: The variable threshold method was more accurate and precise than the fixed threshold method with an attenuation threshold of 130 HU (P < .0001). Thinner sections (0.6 and 1 mm) resulted in more accurate (P < .05) and precise (P < .0001) stone volume measurements than 3-mm-thick sections. With the variable threshold method, no significant difference was seen in the accuracy and precision of stone volume measurements at various tube currents and tube potentials. Interobserver agreement was high with the fixed and variable threshold methods (r > 0.97). Conclusion: An attenuation threshold-based CT method can be used to quantify urinary stone volume even at low radiation doses. The most accurate and precise method utilizes variable attenuation derived from the attenuation of each stone and thin sections. C1 [Demehri, Shadpour; Rybicki, Frank J.; Steigner, Michael L.; Silverman, Stuart G.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. [Kalra, Mannudeep K.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Lang, Matthew J.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA. [Houseman, E. Andres] Harvard Univ, Sch Publ Hlth, Dept Biostat, Sch Med, Boston, MA 02115 USA. [Curhan, Gary C.] Harvard Univ, Sch Med, Channing Lab, Brigham & Womens Hosp,Dept Med, Boston, MA 02115 USA. RP Demehri, S (reprint author), Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. EM sdemehri@partners.org OI Houseman, Eugene Andres/0000-0003-0703-1830 FU National Institutes of Health/National Center for Research Resources; Astellas; Vanderbilt; National Institutes of Health; Massachusetts Eye and Ear Infirmary FX Financial activities related to the present article: author and institution received a Clinical and Translational Science Awards grant from National Institutes of Health/National Center for Research Resources.; Financial activities not related to the present article: is a consultant for Takeda, Cellectar, and NiCox (no money paid to this point from NiCox); received grant support from Astellas, Vanderbilt, National Institutes of Health, and Massachusetts Eye and Ear Infirmary; received payment for lectures from Takeda; received royalties from Up to Date, is on the editorial board of Clinical Journal of the American Society of Nephrology; is on the advisory council for National Center for Complementary and Alternative Medicine; is a grant reviewer and workshop organizer and participant for National Institutes of Health. NR 32 TC 15 Z9 16 U1 0 U2 5 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD MAR PY 2011 VL 258 IS 3 BP 915 EP 922 DI 10.1148/radiol.10100333 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 724JX UT WOS:000287573100028 PM 21339353 ER PT J AU Bankier, AA Levine, D Halpern, EF Kressel, HY AF Bankier, Alexander A. Levine, Deborah Halpern, Elkan F. Kressel, Herbert Y. TI Considerations of Prevalence and Reporting Environment for Achieving Realistic Test Conditions Response SO RADIOLOGY LA English DT Letter C1 [Bankier, Alexander A.; Levine, Deborah; Kressel, Herbert Y.] Radiol Editorial Off, Boston, MA 02199 USA. [Halpern, Elkan F.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. RP Bankier, AA (reprint author), Radiol Editorial Off, 800 Boylston St,15th Floor, Boston, MA 02199 USA. EM abankier@bidmc.harvard.edu NR 2 TC 0 Z9 0 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD MAR PY 2011 VL 258 IS 3 BP 960 EP 960 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 724JX UT WOS:000287573100037 ER PT J AU Kovacs, KD Quirk, MT Kinoshita, T Gautam, S Ceron, OM Murtha, TJ Arroyo, JG AF Kovacs, Kyle D. Quirk, Matthew T. Kinoshita, Taiga Gautam, Shiva Ceron, Olga M. Murtha, Timothy J. Arroyo, Jorge G. TI A RETROSPECTIVE ANALYSIS OF TRIPLE COMBINATION THERAPY WITH INTRAVITREAL BEVACIZUMAB, POSTERIOR SUB-TENON'S TRIAMCINOLONE ACETONIDE, AND LOW-FLUENCE VERTEPORFIN PHOTODYNAMIC THERAPY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article DE age-related macular degeneration; bevacizumab; combination therapy; triamcinolone acetonide; verteporfin; low-fluence ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIAL; SUBTENON INJECTION; PHARMACOKINETICS; RANIBIZUMAB; MACULOPATHY; PREVALENCE; AVASTIN; EYES AB Purpose: To assess the efficacy of triple combination therapy (TCT) including bevacizumab (BEV), low-fluence photodynamic therapy, and posterior sub-Tenon's triamcinolone acetonide in patients with wet age-related macular degeneration. Methods: This institutional review board-approved retrospective consecutive case series included 31 eyes treated for wet age-related macular degeneration with TCT at the Beth Israel Deaconess Medical Center between June 2004 and November 2008. Outcome measures included visual acuity, retinal thickness as measured by optical coherence tomography, time to retreatment, and complications. Results: Triple combination therapy eyes showed significant 3-month and 6-month improvement in visual acuity of 0.140 +/- 0.273 logarithm of the minimum angle of resolution and 0.182 +/- 0.383 logarithm of the minimum angle of resolution after treatment, respectively (P = 0.0219 and 0.0470, respectively). Central retinal thickness significantly improved at 3 months (-123.8 +/- 102.7 mu m), 6 months (-87.7 +/- 99.8 mu m), and 12 months (-101.6 +/- 103.3 mu m) on optical coherence tomography. Half of eyes that underwent TCT required retreatment by the conclusion of their follow-up, and eyes that underwent TCT had a 1-year Kaplan-Meier survival rate of 62.1 +/- 10.8%. Conclusion: Triple combination therapy (TCT) appears to effectively improve visual acuity and decrease retinal thickness often without need for subsequent retreatment within the first year of follow-up. Further investigation of TCT in prospective trials is warranted. RETINA 31: 446-452, 2011 C1 [Arroyo, Jorge G.] Beth Israel Deaconess Med Ctr, Div Ophthalmol, Retina Serv, Boston, MA 02215 USA. [Murtha, Timothy J.] Joslin Diabet Ctr, Beetham Eye Inst, Retina Serv, Boston, MA 02215 USA. RP Arroyo, JG (reprint author), Beth Israel Deaconess Med Ctr, Div Ophthalmol, Retina Serv, 330 Brookline Ave, Boston, MA 02215 USA. EM jarroyo@bidmc.harvard.edu FU Beth Israel Deaconess Medical Center Retina Service; Grimshaw-Gudewicz Charitable Foundation; Novartis Pharmaceuticals FX Supported in part by funds from the Beth Israel Deaconess Medical Center Retina Service and the Grimshaw-Gudewicz Charitable Foundation and a research grant from the Novartis Pharmaceuticals. NR 37 TC 6 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0275-004X J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD MAR PY 2011 VL 31 IS 3 BP 446 EP 452 DI 10.1097/IAE.0b013e3181f6391f PG 7 WC Ophthalmology SC Ophthalmology GA 722YW UT WOS:000287472400004 PM 21336068 ER PT J AU Rouvas, AA Papakostas, TD Ntouraki, A Douvali, M Vergados, I Ladas, ID AF Rouvas, Alexandros A. Papakostas, Thanos D. Ntouraki, Amalia Douvali, Maria Vergados, Ioannis Ladas, Ioannis D. TI PHOTODYNAMIC THERAPY, RANIBIZUMAB, AND RANIBIZUMAB WITH PHOTODYNAMIC THERAPY FOR THE TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article DE polypoidal choroidal vasculopathy (PCV); ranibizumab; PDT; combination ID INTRAVITREAL BEVACIZUMAB INJECTION; PIGMENT EPITHELIAL DETACHMENT; ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; LASER PHOTOCOAGULATION; JAPANESE PATIENTS; CLINICOPATHOLOGICAL CORRELATION; SUBMACULAR HEMORRHAGE; CHINESE PATIENTS; FOLLOW-UP AB Purpose: The purpose of this study was to compare photodynamic therapy (PDT), ranibizumab, and ranibizumab with PDT in polypoidal choroidal vasculopathy. Methods: In this retrospective comparative study, 30 eyes of 30 patients with polypoidal choroidal vasculopathy were assigned to 1 of the 3 groups. The patients in Group 1 (n = 11) received 1 session of PDT. The patients in Group 2 (n = 10) received 3 monthly intravitreal injections of 0.5 mg ranibizumab, and the patients in Group 3 (n = 9) received 1 session of PDT and 3 injections of 0.5 mg ranibizumab. Retreatment, with the same therapeutic scheme in each group, was considered in case of leaking polyps on the indocyanine green angiography in Groups 1 and 3 and persistence or recurrence of subretinal fluid, intraretinal fluid, and/or hemorrhages in Group 2. Results: All the patients completed 12 months of follow-up. The visual acuity in the patients of Group 1 improved by 0.25 logarithm of the minimum angle of resolution units (P< 0.001), whereas the differences in the visual acuity in the other 2 groups were not statistically significant (0.04 logarithm of the minimum angle of resolution, P = 0.8118 in Group 2 and 0.18 logarithm of the minimum angle of resolution, P> 0.05 in Group 3). Of the patients in Group 1, 45.45% gained more than 3 lines (P = 0.0056), whereas no patient in Groups 2 and 3 experienced such a difference. No patient in Group 1 and 11.1% (n = 1) in Group 3 had angiographically evident polyps at 12 months, whereas 90% (n = 9) of the patients in Group 2 had persistent leakage. No extensive submacular hemorrhage or other complications were noted during the follow-up period. Conclusion: Photodynamic therapy resulted in a significantly better outcome at the end of the follow-up, whereas the patients who received ranibizumab or PDT and ranibizumab experienced a stabilization of the disease. RETINA 31: 464-474, 2011 C1 [Rouvas, Alexandros A.; Ntouraki, Amalia; Douvali, Maria; Vergados, Ioannis] Univ Athens, Sch Med, Dept Ophthalmol 2, GR-11527 Athens, Greece. [Papakostas, Thanos D.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. [Ladas, Ioannis D.] Univ Athens, Sch Med, Dept Ophthalmol 1, GR-11527 Athens, Greece. RP Rouvas, AA (reprint author), Univ Athens, Sch Med, Attikon Univ Hosp, Dept Ophthalmol 2, 1 Rimini St, GR-11527 Athens, Greece. EM rallex@hol.gr NR 69 TC 31 Z9 37 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0275-004X J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD MAR PY 2011 VL 31 IS 3 BP 464 EP 474 DI 10.1097/IAE.0b013e3181f274ec PG 11 WC Ophthalmology SC Ophthalmology GA 722YW UT WOS:000287472400006 PM 20948458 ER PT J AU Quan, SF Chan, CS Dement, WC Gevins, A Goodwin, JL Gottlieb, DJ Green, S Guilleminault, C Hirshkowitz, M Hyde, PR Kay, GG Leary, EB Nichols, DA Schweitzer, PK Simon, RD Walsh, JK Kushida, CA AF Quan, Stuart F. Chan, Cynthia S. Dement, William C. Gevins, Alan Goodwin, James L. Gottlieb, Daniel J. Green, Sylvan Guilleminault, Christian Hirshkowitz, Max Hyde, Pamela R. Kay, Gary G. Leary, Eileen B. Nichols, Deborah A. Schweitzer, Paula K. Simon, Richard D. Walsh, James K. Kushida, Clete A. TI The Association between Obstructive Sleep Apnea and Neurocognitive Performance-The Apnea Positive Pressure Long-term Efficacy Study (APPLES) SO SLEEP LA English DT Article DE Obstructive sleep apnea; neurocognition; epidemiology; sleep; oxygen desaturation ID HEART HEALTH; COGNITIVE FUNCTION; AIRWAY PRESSURE; BREATHING DISORDERS; EXECUTIVE FUNCTIONS; DAYTIME SLEEPINESS; CPAP TREATMENT; RISK-FACTOR; DEFICITS; HYPOPNEA AB Study Objectives: To determine associations between obstructive sleep apnea (OSA) and neurocognitive performance in a large cohort of adults. Study Design: Cross-sectional analyses of polysomnographic and neurocognitive data from 1204 adult participants with a clinical diagnosis of obstructive sleep apnea (OSA) in the Apnea Positive Pressure Long-term Efficacy Study (APPLES), assessed at baseline before randomization to either continuous positive airway pressure (CPAP) or sham CPAP. Measurements: Sleep and respiratory indices obtained by laboratory polysomnography and several measures of neurocognitive performance. Results: Weak correlations were found for both the apnea hypopnea index (AHI) and several indices of oxygen desaturation and neurocognitive performance in unadjusted analyses. After adjustment for level of education, ethnicity, and gender, there was no association between the AHI and neurocognitive performance. However, severity of oxygen desaturation was weakly associated with worse neurocognitive performance on some measures of intelligence, attention, and processing speed. Conclusions: The impact of OSA on neurocognitive performance is small for many individuals with this condition and is most related to the severity of hypoxemia. C1 [Quan, Stuart F.] Harvard Univ, Sch Med, Div Sleep Med, Boston, MA 02215 USA. [Quan, Stuart F.] Brigham & Womens Hosp, Div Sleep Med, Boston, MA 02115 USA. [Quan, Stuart F.; Goodwin, James L.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA. [Chan, Cynthia S.; Gevins, Alan] San Francisco Brain Res Inst, San Francisco, CA USA. [Dement, William C.; Guilleminault, Christian; Hyde, Pamela R.; Leary, Eileen B.; Nichols, Deborah A.; Kushida, Clete A.] Stanford Univ, Stanford, CA 94305 USA. [Gottlieb, Daniel J.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Hirshkowitz, Max] Baylor Coll Med, Houston, TX 77030 USA. [Hirshkowitz, Max] VA Med Ctr, Houston, TX USA. [Kay, Gary G.] Cogscreen LLC, Washington, DC USA. [Schweitzer, Paula K.; Walsh, James K.] St Lukes Hosp, Chesterfield, MO USA. [Simon, Richard D.] St Mary Hosp, Walla Walla, WA USA. [Green, Sylvan] Univ Arizona, Coll Publ Hlth, Tucson, AZ USA. [Chan, Cynthia S.; Gevins, Alan] SAM Technol, San Francisco, CA USA. RP Quan, SF (reprint author), Harvard Univ, Sch Med, Div Sleep Med, 401 Pk Dr,2nd Floor E, Boston, MA 02215 USA. EM squan@arc.arizona.edu FU Pfizer; Merck; Somaxon; Evotec; Actelion; Vanda; Neurogen; Sanofi-Aventis; Ventus Medical; Respironics; Jazz; Cephalon; Pacific Medico; GlaxoSmithKline; Xenoport FX Respironics, Inc. supplied the CPAP and sham CPAP devices for this study. There was no other industry support. Dr. Walsh has received research support through grants to his institution from Pfizer, Merck, Somaxon, Evotec, Actelion, Vanda, Neurogen, Sanofi-Aventis, Ventus Medical, Respironics, and Jazz. He has consulted for Pfizer, Sanofi-Aventis, Cephalon, Schering-Plough/Organon, Neurocrine, Takeda, Actelion, Sepracor, Jazz, Respironics, Transcept, Neurogen, GlaxoSmithKline, Somaxon, Eli Lilly, Evotec, Merck, Kingsdown, Vanda, Ventus Medical, and Somnus. Dr. Schweitzer has been the principal investigator by studies sponsored through grants to his institution from Neurogen, Pfizer, Merck, Somnus, and Ventus Medical. Dr. Simon has received research support from Ventus Medical and has participated in speaking engagements for Asante Communications. Dr. Kay has received research support from Cephalon and Merck; he is a 50% owner of CogScreen, which provided licenses and tests to the APPLES study at cost. Dr. Dement has participated in paid speaking engagements. Dr. Kushida Has received research support through grants to Stanford University from Ventus Medical, Merck, Respironics, Jazz, Cephalon, GlaxoSmithKline, Pacific Medico, and Xenoport. Dr. Hirshkowitz has participated in speaking engagements for Cephalon and Takeda and has consulted for Cephalon and Sanofi-Aventis. NR 49 TC 69 Z9 72 U1 3 U2 9 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD MAR 1 PY 2011 VL 34 IS 3 BP 303 EP U207 PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 729AK UT WOS:000287917600010 PM 21358847 ER PT J AU Zariffa, J Kramer, JLK Fawcett, JW Lammertse, DP Blight, AR Guest, J Jones, L Burns, S Schubert, M Bolliger, M Curt, A Steeves, JD AF Zariffa, J. Kramer, J. L. K. Fawcett, J. W. Lammertse, D. P. Blight, A. R. Guest, J. Jones, L. Burns, S. Schubert, M. Bolliger, M. Curt, A. Steeves, J. D. TI Characterization of neurological recovery following traumatic sensorimotor complete thoracic spinal cord injury SO SPINAL CORD LA English DT Article DE thoracic; pin-prick; light touch; motor score; level; safety ID CLINICAL-TRIALS; ICCP PANEL; INTERNATIONAL STANDARDS; INDEPENDENCE MEASURE; OUTCOME MEASURES; MULTICENTER; GUIDELINES; CONDUCT; ASSESSMENTS; VERSION AB Study design: Retrospective, longitudinal analysis of sensory, motor and functional outcomes from individuals with thoracic (T2-T12) sensorimotor complete spinal cord injury (SCI). Objectives: To characterize neurological changes over the first year after traumatic thoracic sensorimotor complete SCI. Methods: A dataset of 399 thoracic complete SCI subjects from the European Multi-center study about SCI (EMSCI) was examined for neurological level, sensory levels and sensory scores (pin-prick and light touch), lower extremity motor score (LEMS), ASIA Impairment Scale (AIS) grade, and Spinal Cord Independence Measure (SCIM) over the first year after SCI. Results: AIS grade conversions were limited. Sensory scores exhibited minimal mean change, but high variability in both rostral and caudal directions. Pin-prick and light touch sensory levels, as well as neurological level, exhibited minor changes (improvement or deterioration), but most subjects remained within one segment of their initial injury level after 1 year. Recovery of LEMS occurred predominantly in subjects with low thoracic SCI. The sensory zone of partial preservation (ZPP) had no prognostic value for subsequent recovery of sensory levels or LEMS. However, after mid or low thoracic SCI, >= 3 segments of sensory ZPP correlated with an increased likelihood for AIS grade conversion. Conclusion: The data suggest that a sustained deterioration of three or more thoracic sensory levels or loss of upper extremity motor function are rare events and may be useful for tracking the safety of a therapeutic intervention in early phase acute SCI clinical trials, if a significant proportion of study subjects exhibit such an ascent. Spinal Cord (2011) 49, 463-471; doi:10.1038/sc.2010.140; published online 12 October 2010 C1 [Zariffa, J.; Kramer, J. L. K.; Steeves, J. D.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, ICORD, Vancouver, BC V5Z 1M9, Canada. [Fawcett, J. W.] Univ Cambridge, Ctr Brain Repair, Cambridge, England. [Lammertse, D. P.] Craig Hosp, Englewood, CO USA. [Blight, A. R.] Acorda Therapeut, Hawthorne, NY USA. [Guest, J.] Neurol Surg & Miami Project Cure Paralysis, Miami, FL USA. [Jones, L.] Geron Corp, Menlo Pk, CA USA. [Burns, S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Schubert, M.; Bolliger, M.; Curt, A.] Balgrist Univ Hosp, Spinal Cord Injury Ctr, Zurich, Switzerland. RP Steeves, JD (reprint author), Univ British Columbia, Vancouver Coastal Hlth Res Inst, ICORD, 818 W 10th Ave, Vancouver, BC V5Z 1M9, Canada. EM steeves@icord.org RI Bolliger, Marc/I-9315-2012; Zariffa, Jose/A-6954-2016; OI Zariffa, Jose/0000-0002-8842-745X; Lammertse, Daniel/0000-0003-4590-2481; Fawcett, James/0000-0002-7990-4568 FU ICCP; SCOPE; International Foundation for Research in Paraplegia, Zurich, Switzerland (IFP-Zurich) FX The authors are grateful for the support of ICCP (www.campaignforcure.org) and SCOPE (www.scopesci.org). EMSCI is supported by the International Foundation for Research in Paraplegia, Zurich, Switzerland (IFP-Zurich). NR 28 TC 38 Z9 38 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD MAR PY 2011 VL 49 IS 3 BP 463 EP 471 DI 10.1038/sc.2010.140 PG 9 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 730ZH UT WOS:000288075600027 PM 20938451 ER PT J AU Hosmer, W Malin, J Wong, M AF Hosmer, Wylie Malin, Jennifer Wong, Mitchell TI Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer SO SUPPORTIVE CARE IN CANCER LA English DT Article DE Elderly patients; Febrile neutropenia; Prediction rule; SEER-Medicare dataset ID NON-HODGKINS-LYMPHOMA; COLONY-STIMULATING FACTOR; COMORBIDITY INDEX; CHOP CHEMOTHERAPY; EARLY LYMPHOPENIA; DOSE-INTENSITY; CLAIMS DATA; MORTALITY; MEDICARE; WOMEN AB Current guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CSF) when febrile neutropenia (FN) risk is greater than 20%. Advanced age is a risk factor for FN; however, little is known about the impact of other factors on the incidence of FN in an older population. We analyzed SEER-Medicare data (1994-2005) to develop and validate a prediction model for hospitalization with fever, infection, or neutropenia occurring after chemotherapy initiation for patients with breast, colorectal, prostate, and lung cancer. In multivariate analysis (N = 58,053) independent predictors of FN included advanced stage at diagnosis [stage 2 (OR 1.29; 95% CI: 1.09-1.53), stage 3 (1.38; 95% CI: 1.19-1.60), and stage 4 (1.57; 95% CI: 1.35-1.83)], number of associated comorbid conditions [one condition (1.13; 95% CI: 1.02-1.28), two conditions (1.39; 95% CI: 1.22-1.57), and three or more conditions (1.81; 95% CI: 1.61-2.04)], receipt of myelosuppressive chemotherapy (1.11; 95% CI: 0.94-1.32), and receipt of chemotherapy within 1 month of diagnosis [1 to 3 months (0.70; 95% CI: 0.62-0.80) and greater than 3 months (0.63; 95% CI: 0.55-0.73)]. We created a prediction model for febrile neutropenia with first cycle of chemotherapy in a large population of elderly patients with common malignancies. C1 [Wong, Mitchell] Univ Calif Los Angeles, Div GIM & HSR, Los Angeles, CA 90024 USA. [Malin, Jennifer] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. [Hosmer, Wylie; Wong, Mitchell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Wong, M (reprint author), Univ Calif Los Angeles, Div GIM & HSR, 911 Broxton Ave, Los Angeles, CA 90024 USA. EM mitchellwong@mednet.ucla.edu RI Lee, Yee Mei/H-1143-2011; OI Wong, Mitchell/0000-0002-4800-8410 FU Amgen, Inc. FX This study was funded by a grant from Amgen, Inc. NR 33 TC 24 Z9 24 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-4355 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD MAR PY 2011 VL 19 IS 3 BP 333 EP 341 DI 10.1007/s00520-010-0821-1 PG 9 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA 728CL UT WOS:000287851500003 PM 20179995 ER PT J AU Figueiredo, JL Nahrendorf, M Vinegoni, C Weissleder, R AF Figueiredo, Jose-Luiz Nahrendorf, Matthias Vinegoni, Claudio Weissleder, Ralph TI Intraoperative Near-infrared Fluorescent Cholangiography (NIRFC) in Mouse Models of Bile Duct Injury: Reply SO WORLD JOURNAL OF SURGERY LA English DT Letter ID INDOCYANINE GREEN C1 [Figueiredo, Jose-Luiz; Nahrendorf, Matthias; Vinegoni, Claudio; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Figueiredo, Jose-Luiz; Nahrendorf, Matthias; Vinegoni, Claudio; Weissleder, Ralph] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Weissleder, R (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Simches Res Bldg,185 Cambridge St, Boston, MA 02114 USA. EM rweissleder@mgh.harvard.edu NR 11 TC 4 Z9 4 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2313 J9 WORLD J SURG JI World J.Surg. PD MAR PY 2011 VL 35 IS 3 BP 694 EP 695 DI 10.1007/s00268-010-0728-5 PG 2 WC Surgery SC Surgery GA 715ZN UT WOS:000286934700036 PM 20645091 ER PT J AU Kerfoot, BP Shaffer, K McMahon, GT Baker, H Kirdar, J Kanter, S Corbett, EC Berkow, R Krupat, E Armstrong, EG AF Kerfoot, B. Price Shaffer, Kitt McMahon, Graham T. Baker, Harley Kirdar, Jamil Kanter, Steven Corbett, Eugene C., Jr. Berkow, Roger Krupat, Edward Armstrong, Elizabeth G. TI Online "Spaced Education Progress-Testing" of Students to Confront Two Upcoming Challenges to Medical Schools SO ACADEMIC MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; USMLE STEP-1 PERFORMANCE; COEFFICIENT ALPHA; MISSING DATA; MCAT SCORES; RETENTION; PREDICTORS; CANCER; CURRICULUM; IMPROVES AB Purpose U.S. medical students will soon complete only one licensure examination sequence, given near the end of medical school. Thus, schools are challenged to identify poorly performing students before this high-stakes test and help them retain knowledge across the duration of medical school. The authors investigated whether online spaced education progress-testing (SEPT) could achieve both aims. Method Participants were 2,648 students from four U.S. medical schools; 120 multiple-choice questions and explanations in preclinical and clinical domains were developed and validated. For 34 weeks, students randomized to longitudinal progress-testing alone (LPTA) received four new questions (with answers/explanations) each week. Students randomized to SEPT received the identical four questions each week, plus two-week and six-week cycled reviews of the questions/explanations. During weeks 31-34, the initial 40 questions were re-sent to students to assess longer-term retention. Results Of the 1,067 students enrolled, the 120-question progress-test was completed by 446 (84%) and 392 (74%) of the LPTA and SEPT students, respectively. Cronbach alpha reliability was 0.87. Scores were 39.9%, 51.9%, 58.7%, and 58.8% for students in years 1-4, respectively. Performance correlated with Step 1 and Step 2 Clinical Knowledge scores (r = 0.52 and 0.57, respectively; P < .001) and prospectively identified students scoring below the mean on Step 1 with 75% sensitivity, 77% specificity, and 41% positive predictive value. Cycled reviews generated a 170% increase in learning retention relative to baseline (P < .001, effect size 0.95). Conclusions SEPT can identify poorly performing students and improve their longer-term knowledge retention. C1 [Kerfoot, B. Price] Harvard Univ, Sch Med, Vet Affairs Boston Healthcare Syst, Surg Serv, Boston, MA USA. [Shaffer, Kitt] Boston Univ, Sch Med, Dept Radiol, Boston, MA 02118 USA. [McMahon, Graham T.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Baker, Harley] Calif State Univ Channel Isl, Dept Psychol, Camarillo, CA USA. [Kirdar, Jamil] Harvard Univ, Sch Med, Vet Affairs Boston Healthcare Syst, Med Serv, Boston, MA USA. [Kanter, Steven] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Corbett, Eugene C., Jr.] Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA. [Berkow, Roger] Univ Alabama, Sch Med, Dept Pediat, Birmingham, AL USA. [Armstrong, Elizabeth G.] Harvard Univ, Sch Med, Educ Programs, Boston, MA USA. RP Kerfoot, BP (reprint author), VA Boston Healthcare Syst, 150 S Huntington Ave,151DIA, Jamaica Plain, MA 02130 USA. EM price.kerfoot@gmail.com RI liu, jing/D-9482-2012; McMahon, Graham/D-3740-2009; OI McMahon, Graham/0000-0003-4288-6535; Shaffer, Kitt/0000-0001-6488-6988 FU Harvard Medical International; Harvard University FX This study was supported by Harvard Medical International, the Harvard University Milton Fund, and the Harvard University Presidential Distance Learning Grant Program. NR 33 TC 10 Z9 10 U1 3 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD MAR PY 2011 VL 86 IS 3 BP 300 EP 306 DI 10.1097/ACM.0b013e3182087bef PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 726AZ UT WOS:000287690700016 PM 21248600 ER PT J AU Cheung, JS Fan, SJ Gao, DS Chow, AM Yang, JA Man, K Wu, EX AF Cheung, Jerry S. Fan, Shu Juan Gao, Darwin S. Chow, April M. Yang, Jian Man, Kwan Wu, Ed X. TI In Vivo Lipid Profiling Using Proton Magnetic Resonance Spectroscopy in an Experimental Liver Fibrosis Model SO ACADEMIC RADIOLOGY LA English DT Article DE Proton magnetic resonance spectroscopy ((1)H MRS); liver fibrosis; lipid; saturated fatty acid; unsaturated fatty acid; carbon tetrachloride (CCl(4)) ID CHRONIC HEPATITIS-C; ISCHEMIA-REPERFUSION INJURY; EXPERIMENTAL RAT MODEL; H-1 MR SPECTROSCOPY; CARBON-TETRACHLORIDE; FATTY-ACIDS; HEPATOCELLULAR-CARCINOMA; SERIAL DEVELOPMENT; CELL-DEATH; DISEASE AB Rationale and Objectives: The aim of this study was to characterize early hepatic lipid changes in an experimental model of liver fibrosis using proton ((1)H) magnetic resonance spectroscopy (MRS) at high magnetic field in vivo. Materials and Methods: Liver fibrosis was induced in 12 Sprague-Dawley rats by twice-weekly carbon tetrachloride (CCl(4)) administration up to 4 weeks. Eight normal rats were used as controls. Single-voxel (1)H MRS experiments were performed at 7 Tesla to measure signal integrals of various lipid peaks including -CH(3), (-CH(2)-)(n), -CH(2)-C=C-CH(2)-, =C-CH(2)-C= and -CH=CH- at 0.9, 1.3, 2.0, 2.8, and 5.3 ppm, respectively, and peak from choline-containing compounds (CCC) at 3.2 ppm. Total lipid, total saturated fatty acid, total unsaturated fatty acid, total unsaturated bond, polyunsaturated bond, and CCC indices were quantified. Results: Significant increases (P < .01) in total lipid and total saturated fatty acid indices were found in animals with CCl(4)-induced fibrosis as compared with normal animals. In addition, total unsaturated bond and polyunsaturated bond indices of animals at 4 weeks after CCl(4) insult were significantly higher than (P < .01 and P < .05, respectively) those of normal animals and animals at 2 weeks following insult; whereas there was only significant increase (P < .01) in total unsaturated fatty acid index in animals with 4-week CCl(4) insult as compared with normal animals. Conclusion: The hepatic lipid changes in CCl(4)-induced experimental fibrosis model were documented in vivo and longitudinally using (1)H MRS at 7 Tesla. The experimental findings suggested that total saturated fatty acid increase contributed mainly to the total lipid increase in animals with CCl(4) insult. This study also demonstrated the potential value of high field MRS to resolve lipid composition and alterations in liver fibrosis. C1 [Cheung, Jerry S.; Fan, Shu Juan; Gao, Darwin S.; Chow, April M.; Yang, Jian; Wu, Ed X.] Univ Hong Kong, Lab Biomed Imaging & Signal Proc, Pokfulam, Hong Kong, Peoples R China. [Cheung, Jerry S.; Fan, Shu Juan; Gao, Darwin S.; Chow, April M.; Yang, Jian; Wu, Ed X.] Univ Hong Kong, Dept Elect & Elect Engn, Pokfulam, Hong Kong, Peoples R China. [Man, Kwan] Univ Hong Kong, Dept Surg, Pokfulam, Hong Kong, Peoples R China. [Wu, Ed X.] Univ Hong Kong, Dept Anat, Pokfulam, Hong Kong, Peoples R China. [Cheung, Jerry S.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA. [Cheung, Jerry S.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Yang, Jian] Xi An Jiao Tong Univ, Dept Diagnost Radiol, Affiliated Hosp 1, Sch Med, Xian 710049, Shannxi Prov, Peoples R China. RP Wu, EX (reprint author), Univ Hong Kong, Lab Biomed Imaging & Signal Proc, Pokfulam, Hong Kong, Peoples R China. EM ewu@eee.hku.hk FU Hong Kong Grant Council [GRF HKU7808/09M] FX From the Laboratory of Biomedical Imaging and Signal Processing (J.S.C., S.J.F., D.S.G., A.M.C., J.Y., E.X.W.), Departments of Electrical and Electronic Engineering (J.S.C., S.J.F., D.S.G., A.M.C., J.Y., E.X.W.), Surgery (KM.), and Anatomy (E.X.W.), The University of Hong Kong, Pokfulam, Hong Kong SAR, China; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA (J.S.C); Department of Diagnostic Radiology of the First Affiliated Hospital, School of Medicine of Xi'an Jiaotong University, Xi'an, Shannxi Province, China (J.Y.). Received September 12, 2010; accepted October 29, 2010. Supported by the Hong Kong Grant Council (GRF HKU7808/09M). Address correspondence to: E.X.W. e-mail: ewu@eee.hku.hk NR 50 TC 12 Z9 14 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1076-6332 J9 ACAD RADIOL JI Acad. Radiol. PD MAR PY 2011 VL 18 IS 3 BP 377 EP 383 DI 10.1016/j.acra.2010.10.012 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 725BR UT WOS:000287620700016 PM 21167757 ER PT J AU Crawford, JM Hoffman, RD Black-Schaffer, WS AF Crawford, James M. Hoffman, Robert D. Black-Schaffer, W. Stephen TI Pathology Subspecialty Fellowship Application Reform, 2007-2010 SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Article DE Subspecialty fellowship; Pathology; Anatomic pathology; Clinical pathology; Exploding market; National Resident Matching Program; Match ID GASTROENTEROLOGY MATCH; RADIOLOGY FELLOWSHIP; SUCCEED; MARKET AB The specialty of pathology and laboratory medicine has entered a phase in which the 4-year sequence of residency training is almost universally followed by 1 or more years of subspecialty fellowship training. Such training may occur in an American Board of Pathology recognized subspecialty or any number of "subspecialty fellowships" that do not lead to subspecialty board certification. Unlike the application process for first-year pathology residency, which is run through the National Resident Matching Program, applications for subspecialty pathology fellowships have no consistent coordination. Responding to widespread dissatisfaction voiced in 2007 by national pathology resident organizations, the Association of Pathology Chairs began evaluation and potential intervention in the fellowship application process. After 3 years of effort, the Council of the Association of Pathology Chairs has recommended implementation of a pathology subspecialty fellowship matching program starting in the 2011-2012 recruiting year for applicants matriculating in fellowship programs in July 2013. We report on the data that informed this decision and discuss the pros and cons that are so keenly felt by the stakeholders in this as-yet-incomplete reform process. C1 [Crawford, James M.] Hofstra Univ, Sch Med, Manhasset, NY USA. [Crawford, James M.] N Shore Long Isl Jewish Hlth Syst, Dept Pathol & Lab Med, Manhasset, NY USA. [Hoffman, Robert D.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA. [Black-Schaffer, W. Stephen] Harvard Univ, Sch Med, Boston, MA USA. [Black-Schaffer, W. Stephen] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Crawford, JM (reprint author), N Shore LIJ Labs, 10 Nevada Dr, Lake Success, NY 11042 USA. EM jcrawford1@nshs.edu NR 28 TC 3 Z9 3 U1 1 U2 3 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD MAR PY 2011 VL 135 IS 3 BP 338 EP 356 DI 10.1309/AJCP16DQXAMQKVNK PG 19 WC Pathology SC Pathology GA 726JT UT WOS:000287718200002 PM 21350087 ER PT J AU Butt, AA Wang, XQ Fried, LF AF Butt, Adeel A. Wang, Xiaoqiang Fried, Linda F. TI HCV Infection and the Incidence of CKD SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Hepatitis C virus (HCV); chronic kidney disease (CKD); renal; liver disease; Electronically Retrieved Cohort of HCV Infected Veteran (ERCHIVES) ID HEPATITIS-C VIRUS; CHRONIC KIDNEY-DISEASE; FATTY LIVER-DISEASE; STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; SUBSTANCE-ABUSE; INCREASED RISK; PREVALENCE; ASSOCIATION; PREDICTORS AB Background: The risk of hepatitis C virus (HCV) infection upon incident chronic kidney disease (CKD) in the presence of traditional risk factors and renal-modifying therapy is not well known. Study Design: National cohort study. Study Design: National cohort study. Setting & Participants: HCV-infected and -uninfected veterans in ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) in 2001-2006. Predictor: HCV infection. Outcomes: Incident CKD stages 3-5 Results: We identified 18,002 patients with HCV infection and 25,137 controls with estimated glomerular filtration rate >60 mL/min/1.73 m(2) at baseline. HCV-infected patients had a lower prevalence of several CKD risk factors, including diabetes (22.9% vs 26.6%), hypertension (52.4% vs 60.8%), and dyslipidemia (39.3% vs 73.9%; P < 0.001). HCV infection was associated with a higher risk of developing CKD stages 3-5 (HR, 1.30; 95% CI, 1.23-1.37). Increasing age, hypertension, and diabetes were associated with significantly higher risks of developing CKD in HCV-infected patients and controls. Decompensated liver disease was a strong predictor of CKD in HCV-infected patients (HR, 3.37; 95% CI, 3.10-3.66) and HCV-uninfected controls (HR, 2.04; 95% CI, 1.84-2.25). In Kaplan-Meier analysis, HCV-infected persons had a shorter time to CKD. Limitations: Lack of proteinuria data; small number of women. Conclusions: HCV infection is associated with higher risk and shorter time to CKD despite having a lower prevalence of many CKD risk factors. HCV-infected persons should have targeted monitoring for the development and progression of CKD. Am J Kidney Dis. 57(3): 396-402. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Butt, Adeel A.] Univ Pittsburgh, Med Ctr, Sch Med, Pittsburgh, PA 15213 USA. [Butt, Adeel A.; Wang, Xiaoqiang; Fried, Linda F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Butt, Adeel A.; Wang, Xiaoqiang; Fried, Linda F.] Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Butt, AA (reprint author), Univ Pittsburgh, Med Ctr, Sch Med, 3601 5th Ave,Ste 3A, Pittsburgh, PA 15213 USA. EM butta@dom.pitt.edu NR 27 TC 37 Z9 38 U1 0 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2011 VL 57 IS 3 BP 396 EP 402 DI 10.1053/j.ajkd.2010.09.023 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 722NR UT WOS:000287439500008 PM 21185632 ER PT J AU Rubin, MF Rosas, SE Chirinos, JA Townsend, RR AF Rubin, Mario F. Rosas, Sylvia E. Chirinos, Julio A. Townsend, Raymond R. TI Surrogate Markers of Cardiovascular Disease in CKD: What's Under the Hood? SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Surrogate markers; chronic kidney disease; cardiovascular disease; review ID LEFT-VENTRICULAR MASS; CHRONIC KIDNEY-DISEASE; INTIMA-MEDIA THICKNESS; PULSE-WAVE VELOCITY; PERIPHERAL ARTERIAL-DISEASE; CORONARY-HEART-DISEASE; CHRONIC-RENAL-FAILURE; ANKLE-BRACHIAL INDEX; POPULATION-BASED ULTRASONOGRAPHY; RISK-FACTORS AB Although clinical cardiovascular outcomes, such as heart attack, stroke, and sudden cardiac death, have a dramatic onset, they result from prolonged exposure to an ever-growing array of risk factors. Several noninvasive procedures are available to assess the cumulative effect of these exposures with the goal of more precisely estimating a person's cardiovascular risk. These include ankle-brachial index, which provides an estimation of obstruction in major-vessel lumen caliber; carotid ultrasound, which evaluates carotid intima-media thickness and plaque, visibly quantifying atherosclerotic burden; aortic pulse wave velocity, which provides a measure of large-artery stiffness; and echocardiography, which measures left ventricular mass, providing a measure of subclinical hypertensive heart disease. In this narrative review, we discuss the role of each of these measures, with a particular emphasis on patients with chronic kidney disease. Am J Kidney Dis. 57(3):488-497. (C) 2011 by the National Kidney Foundation, Inc. C1 [Rubin, Mario F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rosas, Sylvia E.; Chirinos, Julio A.; Townsend, Raymond R.] Philadelphia Vet Adm Med Ctr, Philadelphia, PA USA. [Rosas, Sylvia E.; Chirinos, Julio A.] Univ Penn, Philadelphia, PA 19104 USA. RP Rubin, MF (reprint author), 165 Cambridge St,Ste 302, Boston, MA 02114 USA. EM mfrubin@partners.org RI Rosas, Sylvia/D-1106-2009 FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01DK080033]; Department of Veteran Affairs HSRD [IIR 05-247]; National Institutes of Health [RO1-HL080076]; American Heart Association [0885031N]; National Center for Research Resources [UL1-RR024134]; NIDDK [DK-067390] FX Dr Rosas received salary support in part from award number R01DK080033 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and Department of Veteran Affairs HSR&D IIR 05-247. Dr Chirinos received support from National Institutes of Health grant RO1-HL080076 and American Heart Association grant 0885031N. Dr Townsend received support from National Center for Research Resources grant UL1-RR024134 and NIDDK grant DK-067390. NR 99 TC 12 Z9 13 U1 1 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2011 VL 57 IS 3 BP 488 EP 497 DI 10.1053/j.ajkd.2010.08.030 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 722NR UT WOS:000287439500018 PM 21168944 ER PT J AU Bhargava, P Vaidya, S Dick, AAS Dighe, M AF Bhargava, Puneet Vaidya, Sandeep Dick, Andre A. S. Dighe, Manjiri TI Imaging of Orthotopic Liver Transplantation: Self-Assessment Module SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE liver transplantation; orthotopic liver transplantation ID HEPATIC-ARTERY THROMBOSIS; VASCULAR COMPLICATIONS; SONOGRAPHY; SPECTRUM; CT; US AB The educational objectives for this self-assessment module are for the participant to exercise, self-assess, and improve his or her understanding of imaging of orthotopic liver transplant recipients and to improve familiarity with the complications of orthotopic liver transplantation. C1 [Bhargava, Puneet] Univ Washington, Dept Radiol, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Dick, Andre A. S.] Univ Washington, Dept Surg, Seattle, WA 98195 USA. RP Bhargava, P (reprint author), Univ Washington, Dept Radiol, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-114 Radiol,Mail Stop 35828, Seattle, WA 98108 USA. EM bhargp@u.washington.edu RI Bhargava, Puneet /F-1330-2011; OI Bhargava, Puneet/0000-0002-3849-9666 NR 17 TC 5 Z9 5 U1 0 U2 2 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAR PY 2011 VL 196 IS 3 SU S BP S35 EP S38 DI 10.2214/AJR.10.7296 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 724KU UT WOS:000287575800009 PM 21343534 ER PT J AU Lee, SI Oliva, E Hahn, PF Russell, AH AF Lee, Susanna I. Oliva, Esther Hahn, Peter F. Russell, Anthony H. TI Malignant Tumors of the Female Pelvic Floor: Self-Assessment Module SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE Bartholin gland tumor; endometriosis; fibromatosis; pelvic MRI; PET/CT; radiation therapy planning; vaginal cancer; vulvar cancer ID ENDOMETRIOSIS AB The educational objectives for this self-assessment module are for the participant to exercise, self-assess, and improve his or her understanding of malignant tumors of the female pelvic floor and the imaging features that determine therapy. C1 [Lee, Susanna I.; Hahn, Peter F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA. [Oliva, Esther] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA. [Russell, Anthony H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA. RP Lee, SI (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA. EM slee0@partners.org NR 15 TC 0 Z9 0 U1 0 U2 2 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAR PY 2011 VL 196 IS 3 SU S BP S24 EP S27 DI 10.2214/AJR.09.7210 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 724KU UT WOS:000287575800007 PM 21343532 ER PT J AU Lee, SI Oliva, E Hahn, PF Russell, AH AF Lee, Susanna I. Oliva, Esther Hahn, Peter F. Russell, Anthony H. TI Malignant Tumors of the Female Pelvic Floor: Imaging Features That Determine Therapy: Pictorial Review SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE Bartholin gland tumor; endometriosis; fibromatosis; pelvic MRI; PET/CT; radiation therapy planning; vaginal cancer; vulvar cancer ID LYMPH-NODE METASTASES; FDG PET-CT; PATHOLOGICAL CORRELATION; RECTAL-CANCER; VULVAR CANCER; CASE EXAMPLES; HELICAL CT; CARCINOMA; ENDOMETRIOSIS; ADENOCARCINOMA C1 [Lee, Susanna I.; Hahn, Peter F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA. [Oliva, Esther] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA. [Russell, Anthony H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA. RP Lee, SI (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, 55 Fruit St,White 270, Boston, MA 02114 USA. EM slee0@partners.org NR 47 TC 2 Z9 2 U1 0 U2 3 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAR PY 2011 VL 196 IS 3 SU S BP S15 EP S23 DI 10.2214/AJR.09.7209 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 724KU UT WOS:000287575800006 PM 21343531 ER PT J AU Bhargava, P Vaidya, S Dick, AAS Dighe, M AF Bhargava, Puneet Vaidya, Sandeep Dick, Andre A. S. Dighe, Manjiri TI Imaging of Orthotopic Liver Transplantation: Review SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Review DE liver disease; liver transplantation; liver transplantation complications; orthotopic liver transplantation ID HEPATIC-ARTERY THROMBOSIS; VASCULAR COMPLICATIONS; BILIARY COMPLICATIONS; RANDOMIZED TRIAL; SONOGRAPHY; MANAGEMENT; DIAGNOSIS; US; CT; EXPERIENCE C1 [Bhargava, Puneet] Univ Washington, Dept Radiol, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Dick, Andre A. S.] Univ Washington, Dept Surg, Seattle, WA 98195 USA. RP Bhargava, P (reprint author), Univ Washington, Dept Radiol, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-114 Radiol,Mail Stop 35828, Seattle, WA 98108 USA. EM bhargp@u.washington.edu RI Bhargava, Puneet /F-1330-2011; OI Bhargava, Puneet/0000-0002-3849-9666 NR 43 TC 8 Z9 8 U1 0 U2 4 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAR PY 2011 VL 196 IS 3 SU S BP WS15 EP WS25 DI 10.2214/AJR.09.7221 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 724KU UT WOS:000287575800002 PM 21343537 ER PT J AU Chung, JH Kanne, JP Gilman, MD AF Chung, Jonathan H. Kanne, Jeffrey P. Gilman, Matthew D. TI CT of Diffuse Tracheal Diseases SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Review DE Mounier-Kuhn syndrome; saber-sheath trachea; trachea; tracheal stenosis; tracheomalacia; Wegener granulomatosis ID FORCED EXPIRATION; MANIFESTATIONS; GRANULOMATOSIS; ABNORMALITIES; BRONCHI; WALL C1 [Chung, Jonathan H.; Gilman, Matthew D.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Gilman, MD (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,FND 202, Boston, MA 02114 USA. EM mgilman@partners.org NR 14 TC 9 Z9 9 U1 0 U2 3 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAR PY 2011 VL 196 IS 3 BP W240 EP W246 DI 10.2214/AJR.09.4146 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 724OC UT WOS:000287585100002 PM 21343471 ER PT J AU Varma, MC Kushner, YB Ko, DS Kawai, T Martins, P Kaur, P Markmann, JF Kotton, CN AF Varma, M. C. Kushner, Y. B. Ko, D. S. Kawai, T. Martins, P. Kaur, P. Markmann, J. F. Kotton, C. N. TI Early Onset Adenovirus Infection after Simultaneous Kidney-Pancreas Transplant SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Adenovirus; kidney; pancreas; transplantation ID RENAL-TRANSPLANTATION; RECIPIENTS; GRAFT; MANAGEMENT; HEPATITIS; ALLOGRAFT; RIBAVIRIN; CIDOFOVIR; DNA AB Adenoviruses (AdV) are increasingly recognized as important viral pathogens in immunocompromised hosts. The clinical spectrum ranges from asymptomatic viremia to allograft dysfunction, and death. Most of the medical literature is on AdV infection in children and bone marrow transplant recipients. We report a case of AdV in an adult recipient in the first month after simultaneous kidney-pancreas transplant with thymoglobulin induction. This is a rare report of adenovirus infection after multiorgan transplant, and is unique in that it exhibited tissue invasive disease without any localizing signs or allograft dysfunction, while other cases in medical literature had invasive disease of the allograft with allograft dysfunction, failure, or death. In addition, this is the first report of a radiologic presentation of AdV nephritis. C1 [Kaur, P.; Kotton, C. N.] Massachusetts Gen Hosp, Div Infect Dis, Transplant Infect Dis & Immunocompromised Host Pr, Boston, MA 02114 USA. [Kaur, P.; Kotton, C. N.] Harvard Univ, Sch Med, Boston, MA USA. [Kushner, Y. B.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Varma, M. C.; Ko, D. S.; Kawai, T.; Martins, P.; Markmann, J. F.] Massachusetts Gen Hosp, Div Transplant Surg, Dept Surg, Boston, MA 02114 USA. RP Kotton, CN (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Transplant Infect Dis & Immunocompromised Host Pr, Boston, MA 02114 USA. EM ckotton@partners.org NR 32 TC 4 Z9 5 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAR PY 2011 VL 11 IS 3 BP 623 EP 627 DI 10.1111/j.1600-6143.2010.03408.x PG 5 WC Surgery; Transplantation SC Surgery; Transplantation GA 724LT UT WOS:000287578400034 PM 21342452 ER PT J AU Conhaim, RL Dovi, WF Watson, KE Spiegel, CA Harms, BA AF Conhaim, Robert L. Dovi, William F. Watson, Kal E. Spiegel, Carol A. Harms, Bruce A. TI Bacteremia Does Not Affect Cellular Uptake of Ultrafine Particles in the Lungs of Rats SO ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY LA English DT Article DE ultrafine particles; lung injury; bacteremia; sepsis; alveolar epithelium; alveolar endothelium; neutrophils ID ALVEOLAR; MECHANISMS; TRANSPORT; BARRIER; SEPSIS; INJURY; CELLS; PORE AB To assess the effects of intra-abdominal bacteremia on lung cellular function in vivo, we used electron microscopy to quantify the uptake of 6 nm diameter, albumin-coated colloidal gold particles (overall diam. 20.8 nm) by cells in the lungs of rats made septic by the introduction of live bacteria (E.coli and B. fragilis) into their abdomens. Gold particles were instilled into the trachea 24 hr after bacteremia induction, and lungs were harvested and prepared for electron microscopy 24 hr later. Because bacteremia produces an increase in metabolism, we hypothesized that this might be associated with increased cellular uptake of these particles and also with increased permeability of the alveolar epithelial barrier to them, as bacteremia is also associated with lung injury. We quantified particle uptake by counting particle densities (particles/mu m(2)) within type I and type II epithelial cells, capillary endothelial cells, erythrocytes and neutrophils in the lungs of five septic rats and five sham-sepsis controls. We also counted particle densities within organelles of these cells (nuclei, mitochondria, type II cell lamellar bodies) and within the alveolar interstitium. We found particles to be present within all of these compartments, although we found no differences in particle densities between bacteremic rats and sham-sepsis controls. Our results suggest that these 6 nm particles were able to freely cross cell and organelle membranes, and further suggest that this ability was not altered by bacteremia. Anat Rec, 294:550-557, 2011. (C) 2010 Wiley-Liss, Inc. C1 [Conhaim, Robert L.; Dovi, William F.; Watson, Kal E.; Harms, Bruce A.] William S Middleton Mem Vet Adm Med Ctr, Dept Surg, Madison, WI USA. [Conhaim, Robert L.; Watson, Kal E.; Harms, Bruce A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. RP Conhaim, RL (reprint author), H5-301-BX3236,600 Highland Ave, Madison, WI 53792 USA. EM conhaim@surgery.wisc.edu FU Veterans Health Administration, Office of Research and Development, Department of Veterans Affairs, Biomedical Laboratory Research and Development Service FX Grant sponsor: Veterans Health Administration, Office of Research and Development, Department of Veterans Affairs, Biomedical Laboratory Research and Development Service. NR 22 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1932-8486 J9 ANAT REC JI Anat. Rec. PD MAR PY 2011 VL 294 IS 3 BP 550 EP 557 DI 10.1002/ar.21326 PG 8 WC Anatomy & Morphology SC Anatomy & Morphology GA 725UN UT WOS:000287671700020 PM 21337717 ER PT J AU White, PF Rosow, CE Shafer, SL AF White, Paul F. Rosow, Carl E. Shafer, Steven L. CA Editorial Board Anesthesia & TI The Scott Reuben Saga: One Last Retraction SO ANESTHESIA AND ANALGESIA LA English DT Editorial Material ID INTRAVENOUS REGIONAL ANESTHESIA; ARTHROSCOPIC KNEE SURGERY; POSTOPERATIVE ANALGESIA; DOSE-RESPONSE; INTRAARTICULAR BUPIVACAINE; KETOROLAC; MORPHINE; PAIN; MEPERIDINE; MANAGEMENT C1 [White, Paul F.] White Mt Inst, Los Altos, CA 94022 USA. [White, Paul F.] Cedars Sinai Med Ctr, Dept Anesthesia, Los Angeles, CA 90048 USA. [White, Paul F.] Policlin Abano, Abano Terme, Italy. [Rosow, Carl E.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Management, Boston, MA 02114 USA. [Rosow, Carl E.] Harvard Univ, Sch Med, Boston, MA USA. [Shafer, Steven L.] Columbia Univ, Dept Anesthesiol, New York, NY USA. RP White, PF (reprint author), White Mt Inst, 144 Ashby Lane, Los Altos, CA 94022 USA. EM paul.white@cshs.org NR 24 TC 14 Z9 14 U1 1 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-2999 EI 1526-7598 J9 ANESTH ANALG JI Anesth. Analg. PD MAR PY 2011 VL 112 IS 3 BP 512 EP 515 DI 10.1213/ANE.0b013e318209736f PG 4 WC Anesthesiology SC Anesthesiology GA 726DG UT WOS:000287698400008 PM 21350225 ER PT J AU Kamo, N Dandapani, SV Miksad, RA Houlihan, MJ Kaplan, I Regan, M Greenfield, TK Sanda, MG AF Kamo, N. Dandapani, S. V. Miksad, R. A. Houlihan, M. J. Kaplan, I. Regan, M. Greenfield, T. K. Sanda, M. G. TI Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet SO ANNALS OF ONCOLOGY LA English DT Article DE health care delivery; Internet survey; oncology; patient satisfaction ID QUALITY-OF-LIFE; HEALTH-CARE; QUESTIONNAIRE; ONCOLOGY; PERCEPTIONS; RELIABILITY; VALIDATION; COLLECTION; PENCIL AB Background: Patients' perspectives provide valuable information on quality of care. This study evaluates the feasibility and validity of Internet administration of Service Satisfaction Scale for Cancer Care (SCA) to assess patient satisfaction with outcome, practitioner manner/skill, information, and waiting/access. Patients and methods: Primary data collected from November 2007 to April 2008. Patients receiving cancer care within 1 year were recruited from oncology, surgery, and radiation clinics at a tertiary care hospital. An Internet-based version of the 16-item SCA was developed. Participants were randomised to Internet SCA followed by paper SCA 2 weeks later or vice versa. Seven-point Likert scale responses were converted to a 0-100 scale (minimum-maximum satisfaction). Response distribution, Cronbach's alpha, and test-retest correlations were calculated. Results: Among 122 consenting participants, 78 responded to initial SCA. Mean satisfaction scores for paper/Internet were 91/90 (outcome), 95/94 (practitioner manner/skill), 89/90 (information), and 86/86 (waiting/access). Response rate and item missingness were similar for Internet and paper. Except for practitioner manner/skill, test-retest correlations were robust r = 0.77 (outcome), 0.74 (information), and 0.75 (waiting/access) (all P < 0.001). Conclusions: Internet SCA administration is a feasible and a valid measurement of cancer care satisfaction for a wide range of cancer diagnoses, treatment modalities, and clinic settings. C1 [Miksad, R. A.] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA. [Kamo, N.; Dandapani, S. V.; Miksad, R. A.; Houlihan, M. J.; Kaplan, I.; Regan, M.; Sanda, M. G.] Harvard Univ, Sch Med, Boston, MA USA. [Miksad, R. A.] Massachusetts Gen Hosp, Dept Radiol, Inst Technol Assessment, Boston, MA 02114 USA. [Houlihan, M. J.] Beth Israel Deaconess Med Ctr, Dept Surg, Div Breast Surg, Boston, MA 02215 USA. [Kaplan, I.] Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA. [Regan, M.] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. [Greenfield, T. K.] Inst Publ Hlth, Alcohol Res Grp, Emeryville, CA USA. [Sanda, M. G.] Beth Israel Deaconess Med Ctr, Dept Surg, Div Urol, Boston, MA 02215 USA. RP Miksad, RA (reprint author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, 330 Brookline Ave, Boston, MA 02215 USA. EM rmiksad@bidmc.harvard.edu RI Sanda, Martin/A-6202-2013; Sanda, Martin/B-2023-2015; OI /0000-0002-3108-4812; Miksad, Rebecca/0000-0003-3194-5122 FU National Institutes of Health [R01 CA95662]; Program in Cancer Outcomes Research Training [5R25CA 092203-04]; Department of Medicine; BIDMC; BIDMC-Harvard/MIT Health Sciences and Technology; Pfizer Inc.; Merck Co FX National Institutes of Health (R01 CA95662) to MS and Program in Cancer Outcomes Research Training (5R25CA 092203-04) to RM and the Department of Medicine, BIDMC, and the Clinical Investigator Training Program: BIDMC-Harvard/MIT Health Sciences and Technology, in collaboration with Pfizer Inc. and Merck & Co to RM. NR 44 TC 13 Z9 15 U1 2 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD MAR PY 2011 VL 22 IS 3 BP 723 EP 729 DI 10.1093/annonc/mdq417 PG 7 WC Oncology SC Oncology GA 726UB UT WOS:000287750700031 PM 20716625 ER PT J AU Golshan, M Garber, JE Gelman, R Tung, N Smith, BL Troyan, S Greenberg, CC Winer, EP Ryan, P AF Golshan, M. Garber, J. E. Gelman, R. Tung, Nadine Smith, B. L. Troyan, S. Greenberg, C. C. Winer, E. P. Ryan, P. TI Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery? SO ANNALS OF SURGICAL ONCOLOGY LA English DT Article ID METASTATIC COLORECTAL-CANCER; ENDOTHELIAL GROWTH-FACTOR; PACLITAXEL PLUS BEVACIZUMAB; PREOPERATIVE CHEMOTHERAPY; TRIAL; RECONSTRUCTION; FLUOROURACIL; LEUCOVORIN AB Neoadjuvant chemotherapy is being increasingly used in operable breast cancer. There are limited data on the safety of bevacizumab (bev) in the neoadjuvant setting. We sought to explore the safety of neoadjuvant cisplatin/bev in a protocol for triple negative breast cancer (TNBC). A total of 51 patients with confirmed TNBC were enrolled in a single-arm trial of neoadjuvant cisplatin plus bev. Of the 51 patients, 28 with confirmed TNBC were enrolled in our trial of single-agent neoadjuvant cisplatin. Two-sided Fisher exact test were used for comparing the 2 trials. The 51 patients received neoadjuvant protocol therapy with cisplatin/bev and underwent definitive local therapy. Breast conserving therapy (BCT) was performed in 29 (57%) and mastectomy with or without reconstruction in 22 (43%). Postoperative complications were reported in 22 patients (43%); 4 (8%) required explanation of expanders. Also, 28 patients completed neoadjuvant cisplatin therapy. BCT was performed in 13 (46%) and mastectomy with or without reconstruction in 15 (54%). Postoperative complications were reported in 11 patients (39%). None of the 5 reconstructions were lost. We compared all toxicities between the two trials (P = .81 NS), and wound healing related complications between the two trials (P = .10 NS). Cisplatin/bevacizumab and cisplatin alone neoadjuvant therapy resulted in a significant number of postoperative complications. Specifically, use of expanders/implants may be problematic for patients treated with bev. However, this was a single-arm trial; randomized controlled studies will be needed to determine the optimal use of bevacizumab in the timing of breast cancer surgery. C1 [Golshan, M.; Troyan, S.; Greenberg, C. C.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Garber, J. E.; Gelman, R.; Winer, E. P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Tung, Nadine] Beth Israel Deaconess Med Ctr, Dept Med Oncol, Boston, MA 02215 USA. [Smith, B. L.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Ryan, P.] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA. RP Golshan, M (reprint author), Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA. EM mgolshan@partners.org FU NCI NIH HHS [L30 CA123695] NR 20 TC 16 Z9 17 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD MAR PY 2011 VL 18 IS 3 BP 733 EP 737 DI 10.1245/s10434-010-1366-8 PG 5 WC Oncology; Surgery SC Oncology; Surgery GA 726FB UT WOS:000287703500022 PM 20882415 ER PT J AU de la Cruz, KI Bakaeen, FG Wang, XL Huh, J LeMaire, SA Coselli, JS Chu, D AF de la Cruz, Kim I. Bakaeen, Faisal G. Wang, Xing Li Huh, Joseph LeMaire, Scott A. Coselli, Joseph S. Chu, Danny TI Hypoalbuminemia and Long-Term Survival After Coronary Artery Bypass: A Propensity Score Analysis SO ANNALS OF THORACIC SURGERY LA English DT Article ID LOW SERUM-ALBUMIN; PREOPERATIVE HYPOALBUMINEMIA; CARDIAC-SURGERY; HOSPITAL STAY; RISK-FACTORS; MORTALITY; MORBIDITY; NUTRITION; COMPLICATIONS; INFLAMMATION AB Background. Hypoalbuminemia is associated with increased morbidity in surgical patients. The impact of low albumin level on survival in cardiac surgical patients is unknown. We hypothesized that a low preoperative albumin level negatively affects long-term survival after coronary artery bypass graft (CABG) surgery. Methods. We reviewed prospectively gathered data from the records of 1,164 consecutive patients who underwent primary isolated CABG at our institution between 1997 and 2007. Propensity score analysis of 18 preoperative and intraoperative variables balanced potential confounding factors between the two groups of patients, so that the final study cohort consisted of 588 patients: 294 with a preoperative albumin level less than 3.5 g/dL (ie, hypoalbuminemia) and 294 patients with a preoperative albumin level of 3.5 g/dL or greater. We assessed long-term survival by using Kaplan-Meier curves generated by log rank tests. Results. The two groups of patients were well matched in terms of preoperative and intraoperative covariates. Both groups had similar early outcomes, including 30-day mortality rates (2.0% versus 1.7%; p = 0. 76) and the incidence of major adverse cardiac events (2.7% versus 2.7%; p = 1.0). However, patients with hypoalbuminemia had a significantly worse 8-year survival rate (65% +/- 7% versus 86% +/- 3%; hazard ratio 2.2; 95% confidence interval: 1.4 to 3.6; p = 0.001) than patients without hypoalbuminemia. Conclusions. Although preoperative hypoalbuminemia did not predict increased early postoperative mortality or morbidity in CABG patients, it did independently predict poor long-term survival after CABG. Identifying the mechanism that underlies this relationship is essential in improving overall survival among patients with low serum albumin levels who are undergoing surgical myocardial revascularization. C1 [de la Cruz, Kim I.; Bakaeen, Faisal G.; Wang, Xing Li; Huh, Joseph; LeMaire, Scott A.; Coselli, Joseph S.; Chu, Danny] St Lukes Episcopal Hosp, Texas Heart Inst, Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Chu, D (reprint author), St Lukes Episcopal Hosp, Texas Heart Inst, Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM dchumd@gmail.com NR 29 TC 21 Z9 21 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD MAR PY 2011 VL 91 IS 3 BP 671 EP 676 DI 10.1016/j.athoracsur.2010.09.004 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 726CZ UT WOS:000287697700013 PM 21352977 ER PT J AU Bai, Q Burton, EA AF Bai, Qing Burton, Edward A. TI Zebrafish models of Tauopathy SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE LA English DT Review DE Tau; Tauopathy; Progressive supranuclear palsy; Zebrafish; Alzheimer's disease; Transgenic; Neurodegeneration ID PAIRED HELICAL FILAMENTS; PROGRESSIVE SUPRANUCLEAR PALSY; ALZHEIMER-LIKE PHOSPHORYLATION; REDUCES TAU PHOSPHORYLATION; PROTEIN PHOSPHATASE 2A; NEURONAL CELL-DEATH; TRANSGENIC ZEBRAFISH; IN-VIVO; DANIO-RERIO; NEUROFIBRILLARY TANGLES AB Tauopathies are a group of incurable neurodegenerative diseases, in which loss of neurons is accompanied by intracellular deposition of fibrillar material composed of hyperphosphorylated forms of the microtubule-associated protein Tau. A zebrafish model of Tauopathy could complement existing murine models by providing a platform for genetic and chemical screens, in order to identify novel therapeutic targets and compounds with disease-modifying potential. In addition, Tauopathy zebrafish would be useful for hypothesis-driven experiments, especially those exploiting the potential to deploy in vivo imaging modalities. Several considerations, including conservation of specialized neuronal and other cellular populations, and biochemical pathways implicated in disease pathogenesis, suggest that the zebrafish brain is an appropriate setting in which to model these complex disorders. Novel transgenic zebrafish lines expressing wild-type and mutant forms of human Tau in CNS neurons have recently been reported. These studies show evidence that human Tau undergoes disease-relevant changes in zebrafish neurons, including somato-dendritic relocalization, hyperphosphorylation and aggregation. In addition, preliminary evidence suggests that Tau transgene expression can precipitate neuronal dysfunction and death. These initial studies are encouraging that the zebrafish holds considerable promise as a model in which to study Tauopathies. Further studies are necessary to clarify the phenotypes of transgenic lines and to develop assays and models suitable for unbiased high-throughput screening approaches. This article is part of a Special Issue entitled Zebrafish Models of Neurological Diseases. Published by Elsevier B.V. C1 [Bai, Qing; Burton, Edward A.] Univ Pittsburgh, Sch Med, Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA 15260 USA. [Bai, Qing; Burton, Edward A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15260 USA. [Burton, Edward A.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15260 USA. [Burton, Edward A.] Univ Pittsburgh, Med Ctr, Div Movement Disorders, Pittsburgh, PA 15260 USA. [Burton, Edward A.] VA Pittsburgh Healthcare Syst, Dept Neurol, Pittsburgh, PA USA. [Burton, Edward A.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Burton, EA (reprint author), 7015 BST-3 3501 5th Ave, Pittsburgh, PA 15217 USA. EM eab25@pitt.edu OI Burton, Edward/0000-0002-8072-4636 FU CurePSP - The Society for Progressive Supranuclear Palsy [441-05, 468-08]; NINDS [NS058369] FX We gratefully acknowledge research grant support from CurePSP - The Society for Progressive Supranuclear Palsy (grants #441-05 and #468-08) and NINDS (NS058369). NR 127 TC 5 Z9 5 U1 0 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0925-4439 J9 BBA-MOL BASIS DIS JI Biochim. Biophys. Acta-Mol. Basis Dis. PD MAR PY 2011 VL 1812 IS 3 BP 353 EP 363 DI 10.1016/j.bbadis.2010.09.004 PG 11 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 725CZ UT WOS:000287624100010 PM 20849952 ER PT J AU Qin, GS Jin, XP Zhou, XH AF Qin, Gengsheng Jin, Xiaoping Zhou, Xiao-Hua TI Non-parametric interval estimation for the partial area under the ROC curve SO CANADIAN JOURNAL OF STATISTICS-REVUE CANADIENNE DE STATISTIQUE LA English DT Article DE AUC; diagnostic test; partial AUC; ROC curve ID EMPIRICAL LIKELIHOOD; DIAGNOSTIC-TESTS; METHODOLOGY; REGRESSION AB Accurate diagnosis of disease is a critical part of health care. New diagnostic and screening tests must be evaluated based on their abilities to discriminate diseased conditions from non-diseased conditions. For a continuous-scale diagnostic test, a popular summary index of the receiver operating characteristic (ROC) curve is the area under the curve (AUC). However, when our focus is on a certain region of false positive rates, we often use the partial AUC instead. In this paper we have derived the asymptotic normal distribution for the non-parametric estimator of the partial AUC with an explicit variance formula. The empirical likelihood (EL) ratio for the partial AUC is defined and it is shown that its limiting distribution is a scaled chi-square distribution. Hybrid bootstrap and EL confidence intervals for the partial AUC are proposed by using the newly developed EL theory. We also conduct extensive simulation studies to compare the relative performance of the proposed intervals and existing intervals for the partial AUC. A real example is used to illustrate the application of the recommended intervals. The Canadian Journal of Statistics 39: 17-33; 2011 (C) 2011 Statistical Society of Canada C1 [Qin, Gengsheng; Jin, Xiaoping] Georgia State Univ, Dept Math & Stat, Atlanta, GA 30302 USA. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, NW HSR&D Ctr Excellence, Seattle, WA 98101 USA. [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Qin, GS (reprint author), Georgia State Univ, Dept Math & Stat, Atlanta, GA 30302 USA. EM gqin@gsu.edu FU NSF [DMS 0603913] FX This work is supported in part by NSF DMS 0603913. We would like to thank the editor, associate editor, and referees for their valuable comments which led to substantial improvements in this paper. NR 18 TC 2 Z9 2 U1 2 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0319-5724 J9 CAN J STAT JI Can. J. Stat.-Rev. Can. Stat. PD MAR PY 2011 VL 39 IS 1 BP 17 EP 33 DI 10.1002/cjs.10093 PG 17 WC Statistics & Probability SC Mathematics GA 727GQ UT WOS:000287786500002 ER PT J AU Schnoll, RA Shields, AE AF Schnoll, R. A. Shields, A. E. TI Physician Barriers to Incorporating Pharmacogenetic Treatment Strategies for Nicotine Dependence Into Clinical Practice SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Editorial Material ID GENETIC TEST; SMOKING AB Advances in genomics research may improve health outcomes by tailoring treatment according to patients' genetic profiles. The treatment of nicotine dependence, in particular, may soon encompass pharmacogenetic treatment models. Realizing the benefits of such treatment strategies may depend on physicians' preparedness to incorporate genetic testing into clinical practice. This article describes barriers to clinical integration of pharmacogenetic treatments that will need to be addressed to realize the benefits of individualized smoking-cessation treatment. C1 [Schnoll, R. A.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Shields, A. E.] Harvard Univ, Massachusetts Gen Hosp, Mongan Inst Hlth Policy,Med Sch, Harvard MGH Ctr Genom Vulnerable Populat & Hlth D, Boston, MA USA. [Shields, A. E.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Schnoll, RA (reprint author), Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. EM schnoll@mail.med.upenn.edu FU NCI NIH HHS [CA 126989]; NIDA NIH HHS [DA 026889, R21 DA026404, DA 020830, U01 DA020830, DA 025078, DA 026404, R21 DA026889, R01 DA025078, DA 02585] NR 5 TC 7 Z9 7 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0009-9236 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD MAR PY 2011 VL 89 IS 3 BP 345 EP 347 DI 10.1038/clpt.2010.267 PG 3 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 722NS UT WOS:000287439600010 PM 21326262 ER PT J AU Dabelea, D Dolan, LM D'Agostino, R Hernandez, AM McAteer, JB Hamman, RF Mayer-Davis, EJ Marcovina, S Lawrence, JM Pihoker, C Florez, JC AF Dabelea, D. Dolan, L. M. D'Agostino, R., Jr. Hernandez, A. M. McAteer, J. B. Hamman, R. F. Mayer-Davis, E. J. Marcovina, S. Lawrence, J. M. Pihoker, C. Florez, J. C. TI Association testing of TCF7L2 polymorphisms with type 2 diabetes in multi-ethnic youth SO DIABETOLOGIA LA English DT Article DE TCF7L2; Type 2 diabetes; Youth ID GENE; GLUCOSE AB Common variants in the transcription factor 7-like 2 (TCF7L2) gene have been associated with type 2 diabetes in adults. However, it is not known whether TCF7L2 variation increases the risk of early onset type 2 diabetes. Using a case-control design, we examined whether the reported variants [rs12255372 (T/G) and rs7903146 (T/C)] are associated with type 2 diabetes in SEARCH for Diabetes in Youth study participants. Variants were genotyped in 694 non-Hispanic white (NHW) youth (86 cases, mean age 15.5 years, mean BMI 34.8; and 608 controls, mean age 14.4 years, mean BMI 22.3) and 545 African-American (AA) youth (154 cases, mean age 15.9, mean BMI 37; and 391 controls, mean age 14.8, mean BMI 23.8). Logistic regression adjusted for age, sex, BMI and West African ancestry. The association of the risk T allele with case/control status was different in AA and NHW youth (p = 0.025). Among AA youth, each copy of the T allele (rs7903146) was associated with a 1.97-fold (1.37, 2.82) increased odds for type 2 diabetes (p < 0.0001), after adjustment for age, sex, BMI and African ancestry. No significant association was detected in NHW youth (adjusted OR, 1.14; 0.73, 1.79). TCF7L2 variation is associated with an increased risk of early-onset type 2 diabetes among AA youth, and the association appears to be stronger in AA than NHW youth. This suggests potential different contributions of genetic and environmental factors to early-onset type 2 diabetes by race. C1 [Dabelea, D.; Hamman, R. F.] Univ Colorado Denver, Dept Epidemiol, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. [Dolan, L. M.] Cincinnati Childrens Hosp & Med Ctr, Cincinnati, OH USA. [D'Agostino, R., Jr.] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA. [Hernandez, A. M.; McAteer, J. B.; Florez, J. C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Hernandez, A. M.; McAteer, J. B.; Florez, J. C.] Massachusetts Gen Hosp, Diabet Res Ctr, Diabet Unit, Boston, MA 02114 USA. [McAteer, J. B.; Florez, J. C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Mayer-Davis, E. J.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA. [Marcovina, S.] Univ Washington, Dept Med, Seattle, WA USA. [Lawrence, J. M.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA. [Pihoker, C.] Childrens Hosp & Med Ctr, Seattle, WA 98105 USA. [Florez, J. C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Dabelea, D (reprint author), Univ Colorado Denver, Dept Epidemiol, Colorado Sch Publ Hlth, 13001 17th Pl, Aurora, CO 80045 USA. EM dana.dabelea@ucdenver.edu RI Dagostino Jr, Ralph/C-4060-2017 OI Dagostino Jr, Ralph/0000-0002-3550-8395 FU Centers for Disease Control and Prevention [00097, DP-05-069]; NIDDK [R01DK059184, R01-DK59183]; Massachusetts General Hospital; Doris Duke Charitable Foundation FX SEARCH for Diabetes in Youth is funded by the Centers for Disease Control and Prevention (PA number 00097 and DP-05-069). Kaiser Permanente Southern California (U01 DP000246), University of Colorado Health Sciences Center (U01 DP000247), Pacific Health Research Institute (U01 DP000245), Children's Hospital Medical Center (Cincinnati) (U01 DP000248), University of North Carolina at Chapel Hill (U01 DP000254), University of Washington School of Medicine (U01 DP000244), Wake Forest University School of Medicine (U01 DP000250). The SEARCH for Diabetes in Youth Study is indebted to the many youth and their families, and their healthcare providers, whose participation made this study possible. The project described was also supported by NIDDK R01DK059184 (Defining Diabetes in Youth) and R01-DK59183 (Landmarks in the progression to type 2 diabetes). J. C. Florez is supported by a Physician Scientist Development Award by the Massachusetts General Hospital and a Clinical Scientist Development Award from the Doris Duke Charitable Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIDDK or the National Institutes of Health. The content of this manuscript was presented in abstract form at the American Diabetes Association Annual Scientific Meeting, New Orleans, LA, USA, June 2009. NR 11 TC 20 Z9 20 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD MAR PY 2011 VL 54 IS 3 BP 535 EP 539 DI 10.1007/s00125-010-1982-7 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 716PX UT WOS:000286987000010 PM 21109996 ER PT J AU Ho, SB Aqel, B Dieperink, E Liu, SL Tetrick, L Falck-Ytter, Y DeComarmond, C Smith, CI McKee, DP Boyd, W Kulig, CC Bini, EJ Pedrosa, MC AF Ho, Samuel B. Aqel, Bashar Dieperink, Eric Liu, Shanglei Tetrick, Lori Falck-Ytter, Yngve DeComarmond, Charles Smith, Coleman I. McKee, Daniel P. Boyd, William Kulig, Clark C. Bini, Edmund J. Pedrosa, Marcos C. TI US Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for "Difficult-to-Treat" HCV Genotype 1 Patients SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Consensus interferon; Hepatitis C; Ribavirin; Veterans Affairs ID CHRONIC HEPATITIS-C; PEGINTERFERON ALPHA-2B; VIRUS-INFECTION; NONRESPONDER PATIENTS; TREATMENT DURATION; INDUCTION THERAPY; RANDOMIZED-TRIAL; UNITED-STATES; RETREATMENT; VETERANS AB Patients with chronic hepatitis C genotype 1 (HCV-1) and difficult-to-treat characteristics respond poorly to pegylated interferon alfa and ribavirin (RBV), and could benefit from an interferon with increased activity (consensus interferon or CIFN), favorable viral kinetics from daily dosing, and a longer duration of therapy. The purpose of this pilot study was to determine the efficacy and safety of daily CIFN + RBV for initial treatment of patients with HCV-1 infection. Patients with difficult-to-treat characteristics (92% male, 33% African American, 78% Veterans Affairs [VA]; 67% high viral load, 59% stage 3-4 fibrosis, and mean weight of 204 lbs) were enrolled at seven VA and two community medical centers. They were randomized to daily CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B, n = 31). Intention to treat analysis for treatment groups A and B demonstrated 33% (11/33) and 32% (10/31) sustained virologic response (SVR), respectively. Only 2/31 patients in group B received more than 52 weeks of treatment. The overall group demonstrated a 31% (20/64) rapid virologic response rate (RVR), 54% (34/64) end of treatment virologic response and a 33% (21/64) SVR. Patients with RVR at 4 weeks, early virologic response from 8-12 weeks, and late virologic response from 16-24 weeks demonstrated SVR of 75% (15/20), 31% (4/13), and 22% (2/9), respectively. Overall early non-protocol discontinuation occurred in 26/64 (40%) patients. Daily CIFN and ribavirin for initial treatment of HCV-1 patients has potential for achieving a relatively high RVR rate, but discontinuations are frequent and successful use of this regimen is highly dependent on adequate patient support to maintain adherence. C1 [Ho, Samuel B.; Liu, Shanglei] VA San Diego Healthcare Syst, San Diego, CA 92161 USA. [Ho, Samuel B.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. [Aqel, Bashar] Minneapolis VA Med Ctr, Dept Med, Minneapolis, MN USA. [Dieperink, Eric; Tetrick, Lori] Minneapolis VA Med Ctr, Dept Psychiat, Minneapolis, MN USA. [Dieperink, Eric; Tetrick, Lori] Minneapolis VA Med Ctr, Dept Res, Minneapolis, MN USA. [Falck-Ytter, Yngve] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. [DeComarmond, Charles] WG Hefner VA Med Ctr, Salisbury, NC USA. [Smith, Coleman I.] Minnesota Gastroenterol, Minneapolis, MN USA. [McKee, Daniel P.] Northland Gastroenterol, Duluth, MN USA. [Boyd, William] James A Haley Vet Hosp, Tampa, FL 33612 USA. [Kulig, Clark C.] VA Eastern Colorado Healthcare Syst, Denver, CO USA. [Bini, Edmund J.] VA New York Harbor Healthcare Syst, New York, NY USA. [Pedrosa, Marcos C.] VA Boston Healthcare Syst, Boston, MA USA. RP Ho, SB (reprint author), VA San Diego Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA. EM samuel.ho2@va.gov FU Three Rivers Pharmaceuticals; Valeant Pharmaceuticals International; Human Genome Systems FX Samuel B. Ho, MD, has served as a speaker for Three Rivers Pharmaceuticals, and has received research funding from Three Rivers Pharmaceuticals, Valeant Pharmaceuticals International, and Human Genome Systems. Bashar Aqel, Eric Dieperink, Shanglei Liu and Lori Tetrick have no disclosures. Yngve Falck-Ytter: Research support and speaker's honorarium from Roche Pharmaceuticals. Coleman Smith: Research support and speaker's honorarium from Bristol-Myers Squibb, Novartis Pharmaceuticals, Schering-Plough Corporation, Gilead, and Roche Pharmaceuticals. Edmund J. Bini: Research support and speaker's from Bristol-Myers Squibb, Pharmasset, Schering-Plough Corporation, Gilead, Roche Pharmaceuticals, Valeant, Vertex. Marcos C. Pedrosa: Research support and speaker's honorarium from Schering-Plough Corporation. NR 29 TC 3 Z9 3 U1 0 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD MAR PY 2011 VL 56 IS 3 BP 880 EP 888 DI 10.1007/s10620-010-1504-y PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 723JA UT WOS:000287501500037 PM 21221804 ER PT J AU Wyller, VB Barbieri, R Saul, JP AF Wyller, Vegard Bruun Barbieri, Riccardo Saul, J. Philip TI Blood pressure variability and closed-loop baroreflex assessment in adolescent chronic fatigue syndrome during supine rest and orthostatic stress SO EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE Blood pressure variability; Baroreflex sensitivity; Chronic fatigue syndrome; Autonomic nervous system; Cardiovascular regulation ID HEAD-UP TILT; NEURALLY-MEDIATED HYPOTENSION; BODY NEGATIVE-PRESSURE; CARDIOVASCULAR VARIABILITY; RR-INTERVAL; RESPONSES; INTOLERANCE; EXERCISE; VOLUME; PATHOGENESIS AB Hemodynamic abnormalities have been documented in the chronic fatigue syndrome (CFS), indicating functional disturbances of the autonomic nervous system responsible for cardiovascular regulation. The aim of this study was to explore blood pressure variability and closed-loop baroreflex function at rest and during mild orthostatic stress in adolescents with CFS. We included a consecutive sample of 14 adolescents 12-18 years old with CFS diagnosed according to a thorough and standardized set of investigations and 56 healthy control subjects of equal sex and age distribution. Heart rate and blood pressure were recorded continuously and non-invasively during supine rest and during lower body negative pressure (LBNP) of -20 mmHg to simulate mild orthostatic stress. Indices of blood pressure variability and baroreflex function (alpha-gain) were computed from monovariate and bivariate spectra in the low-frequency (LF) band (0.04-0.15 Hz) and the high-frequency (HF) band (0.15-0.50 Hz), using an autoregressive algorithm. Variability of systolic blood pressure in the HF range was lower among CFS patients as compared to controls both at rest and during LBNP. During LBNP, compared to controls, alpha-gain HF decreased more, and alpha-gain LF and the ratio of alpha-gain LF/alpha-gain HF increased more in CFS patients, all suggesting greater shift from parasympathetic to sympathetic baroreflex control. CFS in adolescents is characterized by reduced systolic blood pressure variability and a sympathetic predominance of baroreflex heart rate control during orthostatic stress. These findings may have implications for the pathophysiology of CFS in adolescents. C1 [Wyller, Vegard Bruun] Rikshosp Univ Hosp, Dept Pediat, N-0027 Oslo, Norway. [Barbieri, Riccardo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, Boston, MA USA. [Saul, J. Philip] Med Univ S Carolina, Charleston, SC USA. RP Wyller, VB (reprint author), Rikshosp Univ Hosp, Dept Pediat, N-0027 Oslo, Norway. EM brwylle@online.no OI Barbieri, Riccardo/0000-0001-9381-3833 FU University of Oslo FX We thank Torun Flatebo, Department of Physiology, University of Oslo, Norway, for technical assistance during the experiments. Vegard Bruun Wyller has received a research grant from the University of Oslo. NR 53 TC 11 Z9 11 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1439-6319 J9 EUR J APPL PHYSIOL JI Eur. J. Appl. Physiol. PD MAR PY 2011 VL 111 IS 3 BP 497 EP 507 DI 10.1007/s00421-010-1670-9 PG 11 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 722TO UT WOS:000287458100018 PM 20890710 ER PT J AU Horesh, Y Katsel, P Haroutunian, V Domany, E AF Horesh, Y. Katsel, P. Haroutunian, V. Domany, E. TI Gene expression signature is shared by patients with Alzheimer's disease and schizophrenia at the superior temporal gyrus SO EUROPEAN JOURNAL OF NEUROLOGY LA English DT Article DE autophagy; Alzheimer's disease; Schizophrenia; Brodmann area 22; superior temporal gyrus; neurodegenerative diseases ID MULTIPLE BRAIN-REGIONS; AUTOPHAGY; PROTEIN; ASSOCIATION; POSTMORTEM; MECHANISMS; PATHOLOGY; DEMENTIA; HOMOLOG AB Background: Alzheimer's disease and Schizophrenia are two common diseases of the brain with significant differences in neuropathology, etiology and symptoms. This dissimilarity in the two diseases makes a comparison of the two ideal for detecting molecular substrates that are common to brain disorders in general. Methods: In this study, we compared gene expression profiles across multiple brain areas, taken postmortem from patients with well-characterized Alzheimer's disease and Schizophrenia, and from cognitively normal control group with no neuro-or psychopathology. Results: Although the totality of gene expression changes in the two diseases is dissimilar, a subset of genes appears to play a role in both diseases in specific brain regions. We find at Brodmann area 22, the superior temporal gyrus, a statistically significant number of genes with apparently disregulated expression in both diseases. Furthermore, we found genes that differentiate the two diseases from the control across multiple brain regions, and note that these genes were usually down-regulated. Brodmann area 8, part of the superior frontal cortex, is relatively abundant with them. Conclusion: We show overwhelming statistical evidence for Alzheimer's and Schizophrenia sharing a specific molecular background at the superior temporal gyrus. We suggest that impairment of the regulation of autophagy pathway is shared, in BA 22, by the two diseases. C1 [Horesh, Y.; Domany, E.] Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel. [Katsel, P.; Haroutunian, V.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Haroutunian, V.] James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY USA. RP Domany, E (reprint author), Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel. EM vahram.har-outunian@mssm.edu; eytan.domany@weiz-mann.ac.il RI DOMANY, EYTAN/K-1560-2012 FU Leir Charitable Foundation; Veterans Administration; [MH066392]; [MH064673] FX This research was supported by a grant from the Leir Charitable Foundation (ED, YH) and MH066392, MH064673 and Veterans Administration Merit and MIRECC programs (VH). We thank Edna Schechtman for statistical advice, and Adi Kimchi for sharing her knowledge of the autophagy pathway. NR 40 TC 13 Z9 13 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-5101 J9 EUR J NEUROL JI Eur. J. Neurol. PD MAR PY 2011 VL 18 IS 3 BP 410 EP 424 DI 10.1111/j.1468-1331.2010.03166.x PG 15 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 722RB UT WOS:000287450900010 PM 20695885 ER PT J AU Tecilazich, F Dinh, T Veves, A AF Tecilazich, Francesco Dinh, Thanh Veves, Aristidis TI Treating diabetic ulcers SO EXPERT OPINION ON PHARMACOTHERAPY LA English DT Review DE chronic inflammation; diabetes mellitus; diabetic foot ulcer; endothelial dysfunction; growth factors; neuropeptides; peripheral neuropathy; peripheral vascular disease; wound healing ID ENDOTHELIAL PROGENITOR CELLS; SHOCK-WAVE THERAPY; RANDOMIZED CLINICAL-TRIAL; GENE-RELATED PEPTIDE; NEUROPEPTIDE-Y; SUBSTANCE-P; FOOT ULCERS; GROWTH-FACTOR; STEM-CELLS; HYPERBARIC-OXYGEN AB Introduction: Diabetic foot ulceration is a serious secondary complication of diabetes mellitus and the most common cause of hospitalization in diabetic patients. The etiology of diabetic foot ulcerations is complex due to their multifactorial nature. Thus, addressing all of the factors involved remains instrumental in wound healing. Areas covered: The first part of this review focuses on the pathophysiology of diabetic foot ulceration and wound-healing impairment. The second part reviews the standard treatments, including advanced wound-care products and new therapeutic approaches currently under investigation. The reader will understand the most up-to-date research regarding the unique pathophysiology of diabetic foot ulceration along with the basic cornerstones of current recommended standard therapy. Expert opinion: Diabetic foot ulceration is a serious complication that can lead -- potentially -- to devastating lower-extremity amputations. Proper adherence to standard treatment strategies can potentially prevent the need for amputation. C1 [Tecilazich, Francesco; Dinh, Thanh; Veves, Aristidis] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Joslin Beth Israel Deaconess Foot Ctr, Boston, MA 02215 USA. RP Veves, A (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Joslin Beth Israel Deaconess Foot Ctr, 330 Brookline Ave, Boston, MA 02215 USA. EM aveves@bidmc.harvard.edu NR 104 TC 7 Z9 9 U1 2 U2 9 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1465-6566 J9 EXPERT OPIN PHARMACO JI Expert Opin. Pharmacother. PD MAR PY 2011 VL 12 IS 4 BP 593 EP 606 DI 10.1517/14656566.2011.530658 PG 14 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 719KR UT WOS:000287204100008 PM 21241210 ER PT J AU Souter, I Baltagi, LM Kuleta, D Meeker, JD Petrozza, JC AF Souter, Irene Baltagi, Lina M. Kuleta, Damien Meeker, John D. Petrozza, John C. TI Women, weight, and fertility: The effect of body mass index on the outcome of superovulation/intrauterine insemination cycles SO FERTILITY AND STERILITY LA English DT Article; Proceedings Paper CT 64th Annual Meeting of the American-Society-for-Reproductive-Medicine CY NOV 08-13, 2008 CL San Francisco, CA SP Amer Soc Reprod Med, Soc Assisted Reprod Technolog DE Obesity; overweight; body mass index; ovulation induction; intrauterine insemination; infertility ID IN-VITRO FERTILIZATION; ASSISTED REPRODUCTIVE TECHNOLOGY; POLYCYSTIC OVARIAN SYNDROME; GROWTH-FACTOR-I; INTRAUTERINE INSEMINATION; OVULATION INDUCTION; OBESITY INCREASES; MATERNAL OBESITY; ADVERSELY AFFECT; INFERTILE WOMEN AB Objective: To determine the fecundity of overweight and obese infertile women treated with gonadotropins and undergoing intrauterine insemination (IUI). Design: Retrospective study. Setting: Academic infertility clinic. Patient(s): Four hundred seventy-seven women undergoing 1,189 ovulation induction (OI)/IUI cycles stratified by body mass index (BMI). Intervention(s): None. Main Outcome Measure(s): BMI groups were compared regarding the following: gonadotropin dose, duration of treatment, peak E(2), number of follicles (total, large, and medium size), E(2)/follicle, endometrial thickness, spontaneous abortion, and clinical and multiple pregnancy rates. Result(s): There was a significant trend toward higher medication requirements and lower E(2) levels with increasing BMI. BMI was inversely associated with [1] the E(2) level per produced preovulatory follicle and [2] the number of medium-size follicles. Furthermore, BMI was inversely associated with the number of medium, large, and total follicles divided by total FSH dose, suggesting that women with a higher BMI develop a lower number of medium and/or large follicles at a given total FSH dose. BMI was positively associated with endometrial thickness, and endometrial thickness was positively associated with pregnancy. Mean number of cycles required to conceive, clinical pregnancy, and spontaneous abortion rates did not differ significantly among the different BMI categories. Conclusion(s): Obese women require higher doses of medication and produce fewer follicles for a given dose, but once medication and response are adjusted to overcome the weight effect, the success of the treatment cycle is comparable to that of normal weight women. (Fertil Steril (R) 2011;95:1042-7. (C) 2011 by American Society for Reproductive Medicine.) C1 [Souter, Irene] Harvard Univ, Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil,Med Sch,Fertil C, Boston, MA 02114 USA. [Meeker, John D.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. RP Souter, I (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil,Med Sch,Fertil C, 55 Fruit St,Yawkey 10A, Boston, MA 02114 USA. EM isouter@partners.org OI Meeker, John/0000-0001-8357-5085 NR 53 TC 21 Z9 21 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD MAR PY 2011 VL 95 IS 3 BP 1042 EP 1047 DI 10.1016/j.fertnstert.2010.11.062 PG 6 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 723BD UT WOS:000287480300037 PM 21195401 ER PT J AU Kwon, JY Diwan, A Susarla, S Chacko, AT Rodriguez, EK AF Kwon, John Y. Diwan, Amna Susarla, Seenu Chacko, Aron T. Rodriguez, Edward K. TI Effect of Surgeon Training, Fracture, and Patient Variables on Calcaneal Fracture Management SO FOOT & ANKLE INTERNATIONAL LA English DT Article DE Calcaneus Fracture; Operative Calcaneus; Nonoperative Calcaneus ID TRIAL AB Background: There appears to he a general lack of consensus in treating calcaneus fractures. Many different patient-based variables such as smoking, diabetes, or occupation, may influence treatment decisions possibly more so than the nature of the injury itself. Indications for operative versus nonoperative treatment are often unclear. The goals of this study were to determine if lack of consensus exists, determine which factors most influence orthopaedic surgeons in choosing operative versus nonoperative treatment and determine if there are differences in treatment based on fellowship training and exposure to these injuries. Materials and Methods: Practicing orthopaedic surgeons of various backgrounds and training were administered an electronic survey. The survey consisted of clinical vignettes and questions regarding fellowship training, demographics and exposure to calcaneus fractures. Orthopaedic surgeons were asked to weigh the importance of patient-based variables in determining operative versus nonoperative treatment. Results: For patients with an uncomplicated medical history, there was a general consensus on treatment as guided by the Sanders classification. For those with a complex medical history, there was less consensus on management despite fracture pattern. Foot & ankle fellowship-trained surgeons (F&AT) ranked calcaneal deformity as more important than trauma fellowship-trained surgeons (NFT), and ranked peripheral vascular disease (PVD)/diabetes mellitus (DM) more important than did both trauma fellowship-trained surgeons (TFT) and NFT surgeons. There was no significant difference in choosing operative versus nonoperative treatment for surgeons treating more calcaneus fractures (more than four per month) versus those who treated fewer (less than one a month). Conclusion: There was general agreement among surgeons regarding the most important variables for determining management of calcaneus fractures. How this information is utilized varies according to practitioner and leads to varying consensus. There was generalized consensus regarding management in cases of anatomic deformity at either end of the spectrum of severity and non-complex medical histories. When additional confounders were added, the agreement between surgeons declined. C1 [Chacko, Aron T.; Rodriguez, Edward K.] Beth Israel Deaconess Med Ctr, Dept Orthopaed Surg, Harvard Combined Orthoped Surg Program, Boston, MA 02215 USA. [Susarla, Seenu] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Kwon, John Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Harvard Combined Orthopaed Re, Boston, MA 02114 USA. RP Kwon, JY (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Harvard Combined Orthopaed Re, 55 Fruit St, Boston, MA 02114 USA. EM jkwon@partners.org OI Susarla, Srinivas/0000-0003-0155-8260 NR 7 TC 4 Z9 4 U1 0 U2 1 PU AMER ORTHOPAEDIC FOOT & ANKLE SOC, INC PI SEATTLE PA 2517 EASTLAKE AVE EAST, STE 200, SEATTLE, WA 98102 USA SN 1071-1007 J9 FOOT ANKLE INT JI Foot Ankle Int. PD MAR PY 2011 VL 32 IS 3 BP 262 EP 271 DI 10.3113/FAI.2011.0262 PG 10 WC Orthopedics SC Orthopedics GA 727SR UT WOS:000287822400007 PM 21477545 ER PT J AU Shi, F Shen, DG Yap, PT Fan, Y Cheng, JZ An, HY Wald, LL Gerig, G Gilmore, JH Lin, WL AF Shi, Feng Shen, Dinggang Yap, Pew-Thian Fan, Yong Cheng, Jie-Zhi An, Hongyu Wald, Lawrence L. Gerig, Guido Gilmore, John H. Lin, Weili TI CENTS: Cortical Enhanced Neonatal Tissue Segmentation SO HUMAN BRAIN MAPPING LA English DT Article DE neonatal segmentation; tissue segmentation; subject-specific atlas; atlas construction ID AUTOMATIC SEGMENTATION; IMAGE SEGMENTATION; PHASED-ARRAY; HUMAN BRAIN; MR-IMAGES; REGISTRATION; RECONSTRUCTION; ALGORITHM AB The acquisition of high-quality magnetic resonance (MR) images of neonatal brains is largely hampered by their characteristically small head size and insufficient tissue contrast. As a result, subsequent image processing and analysis, especially brain tissue segmentation, are often affected. To overcome this problem, a dedicated phased array neonatal head coil is utilized to improve MR image quality by augmenting signal-to-noise ratio and spatial resolution without lengthening data acquisition time. In addition, a specialized hybrid atlas-based tissue segmentation algorithm is developed for the delineation of fine structures in the acquired neonatal brain MR images. The proposed tissue segmentation method first enhances the sheet-like cortical gray matter (GM) structures in the to-be-segmented neonatal image with a Hessian filter for generation of a cortical GM confidence map. A neonatal population atlas is then generated by averaging the presegmented images of a population, weighted by their cortical GM similarity with respect to the to-be-segmented image. Finally, the neonatal population atlas is combined with the GM confidence map, and the resulting enhanced tissue probability maps for each tissue form a hybrid atlas is used for atlas-based segmentation. Various experiments are conducted to compare the segmentations of the proposed method with manual segmentation (on both images acquired with a dedicated phased array coil and a conventional volume coil), as well as with the segmentations of two population-atlas-based methods. Results show the proposed method is capable of segmenting the neonatal brain with the best accuracy, and also preserving the most structural details in the cortical regions. Hum Brain Mapp 32:382-396, 2011. (C) 2010 Wiley-Liss, Inc. C1 [Shi, Feng; Shen, Dinggang; Yap, Pew-Thian; Fan, Yong; Cheng, Jie-Zhi] Univ N Carolina, Dept Radiol, IDEA Lab, Chapel Hill, NC 27599 USA. [Shi, Feng; Shen, Dinggang; Yap, Pew-Thian; Fan, Yong; Cheng, Jie-Zhi; An, Hongyu; Lin, Weili] Univ N Carolina, BRIC, Chapel Hill, NC 27599 USA. [An, Hongyu; Lin, Weili] Univ N Carolina, Dept Radiol, MRI Lab, Chapel Hill, NC 27599 USA. [Wald, Lawrence L.] Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Wald, Lawrence L.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Gerig, Guido] Univ Utah, Sci Comp & Imaging Inst, Salt Lake City, UT USA. [Gilmore, John H.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA. RP Shen, DG (reprint author), Univ N Carolina, Dept Radiol, IDEA Lab, MRI Bldg,106 Mason Farm Rd, Chapel Hill, NC 27599 USA. EM dgshen@med.unc.edu RI Yap, Pew-Thian/G-3292-2012; Shi, Feng/G-3247-2012; Wald, Lawrence/D-4151-2009; OI Shi, Feng/0000-0003-1522-9943; Gerig, Guido/0000-0002-9547-6233; Fan, Yong/0000-0001-9869-4685 FU NIH [EB006733, EB008760, EB008374, EB009634, NS055754, MH064065, MH088520, MH070890, HD053000] FX Contract grant sponsor: NIH; Contract grant number: EB006733, EB008760, EB008374, EB009634, NS055754, MH064065, MH088520, MH070890, HD053000. NR 28 TC 20 Z9 20 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1065-9471 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD MAR PY 2011 VL 32 IS 3 BP 382 EP 396 DI 10.1002/hbm.21023 PG 15 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 721SO UT WOS:000287375500005 PM 20690143 ER PT J AU Artavanis-Tsakonas, K Kasperkovitz, PV Papa, E Cardenas, ML Khan, NS Van der Veen, AG Ploegh, HL Vyas, JM AF Artavanis-Tsakonas, Katerina Kasperkovitz, Pia V. Papa, Eliseo Cardenas, Michael L. Khan, Nida S. Van der Veen, Annemarthe G. Ploegh, Hidde L. Vyas, Jatin M. TI The Tetraspanin CD82 Is Specifically Recruited to Fungal and Bacterial Phagosomes prior to Acidification SO INFECTION AND IMMUNITY LA English DT Article ID CELL-SURFACE DYNAMICS; DENDRITIC CELLS; IMMUNE-SYSTEM; PROTEINS; COMPARTMENTS; MACROPHAGES; COMPLEXES; CRYPTOCOCCOSIS; PHAGOCYTOSIS; TRAFFICKING AB CD82 is a member of the tetraspanin superfamily, whose physiological role is best described in the context of cancer metastasis. However, CD82 also associates with components of the class II major histocompatibility complex (MHC) antigen presentation pathway, including class II MHC molecules and the peptide-loading machinery, as well as CD63, another tetraspanin, suggesting a role for CD82 in antigen presentation. Here, we observe the dynamic rearrangement of CD82 after pathogen uptake by imaging CD82-mRFP1 expressed in primary living dendritic cells. CD82 showed rapid and specific recruitment to Cryptococcus neoformans-containing phagosomes compared to polystyrene-containing phagosomes, similar to CD63. CD82 was also actively recruited to phagosomes containing other pathogenic fungi, including Candida albicans and Aspergillus fumigatus. Recruitment of CD82 to fungal phagosomes occurred independently of Toll-like receptor (TLR) signaling. Recruitment was not limited to fungi, as bacterial organisms, including Escherichia coli and Staphylococcus aureus, also induced CD82 recruitment to the phagosome. CD82 intersected the endocytic pathway used by lipopolysaccharide (LPS), implicating CD82 in trafficking of small, pathogen-associated molecules. Despite its partial overlap with lysosomal compartments, CD82 recruitment to C. neoformans-containing phagosomes occurred independently of phagosome acidification. Kinetic analysis of fluorescence imaging revealed that CD82 and class II MHC simultaneously appear in the phagosome, indicating that the two proteins may be associated. Together, these data show that the CD82 tetraspanin is specifically recruited to pathogen-containing phagosomes prior to fusion with lysosomes. C1 [Kasperkovitz, Pia V.; Cardenas, Michael L.; Khan, Nida S.; Vyas, Jatin M.] Massachusetts Gen Hosp, Div Infect Dis, Dept Med, Boston, MA 02114 USA. [Artavanis-Tsakonas, Katerina; Papa, Eliseo; Van der Veen, Annemarthe G.; Ploegh, Hidde L.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. RP Vyas, JM (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Dept Med, Room 504, Boston, MA 02114 USA. EM jvyas@partners.org RI Vyas, Jatin/Q-1627-2016; OI Vyas, Jatin/0000-0002-9985-9565; Papa, Eliseo/0000-0002-2467-7759 FU NCI [1F32CA105862-01]; MGH Department of Medicine; NIAID [5R01AI034893-17, 5K08AI57999] FX K.A.-T. was supported by a National Research Service Award 1F32CA105862-01 from the NCI. P.V.K., M.L.C., and N.S.K. were supported by DOM start up funds from the MGH Department of Medicine. E.P. was an MIT Poitras Fellow. This work was supported by grant 5R01AI034893-17 from the NIAID awarded to H.L.P. J.M.V. was supported by grant 5K08AI57999 from the NIAID and startup funds from the MGH Department of Medicine. NR 44 TC 14 Z9 15 U1 1 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD MAR PY 2011 VL 79 IS 3 BP 1098 EP 1106 DI 10.1128/IAI.01135-10 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 726DY UT WOS:000287700200012 PM 21149584 ER PT J AU Iovieno, N Tedeschini, E Ameral, VE Rigatelli, M Papakostas, GI AF Iovieno, Nadia Tedeschini, Enrico Ameral, Victoria E. Rigatelli, Marco Papakostas, George I. TI Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials SO INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY LA English DT Review DE antidepressant; major depressive disorder; medical co-morbidity; placebo ID EXCLUSION CRITERIA; CLINICAL-TRIALS; MYOCARDIAL-INFARCTION; DIAGNOSTIC CRITERIA; EFFICACY TRIALS; HIV-INFECTION; PREVALENCE; RISK; ASSOCIATION; SYMPTOMS AB The objective of this study is to assess whether the antidepressants are effective in treating major depressive disorder (MDD) in patients with a co-morbid axis-III disorder, and to compare the relative efficacy (vs. placebo) of antidepressants between these patients and those enrolled in general MDD trials. Medline/Pubmed publication databases were searched. We selected for randomized, double-blind, placebo-controlled trials of antidepressants for MDD, whether conducted in a general population, or in populations with an axis-III disorder. Antidepressants were more effective than placebo in patients with axis-III disorders overall [risk ratio for response (RR) = 1.42, P < 0.0001], as well as specifically for post-stroke (RR = 1.43, P = 0.04), human-immunodeficiency virus positive or acquired immunodeficiency syndrome (RR = 1.66, P = 0.005), but not cancer patients (RR = 1.26, P = 0.19). There was a trend for higher placebo response rates in studies, which did (41.2%) versus those which did not (37.7%) select for axis-III disorders (P = 0.06), and significantly higher antidepressant response rates in studies which did (57.4%) versus those which did not (53.5%) select for axis-III disorders (P = 0.01). Antidepressants are effective for MDD in patients who present with co-morbid axis-III disorders and as effective (vs. placebo) in this population as they are in the general MDD population. Higher general response rates observed in the co-morbid MDD population are intriguing, and require replication. Int Clin Psychopharmacol 26:69-74 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Tedeschini, Enrico] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Iovieno, Nadia; Tedeschini, Enrico; Ameral, Victoria E.; Papakostas, George I.] Harvard Univ, Sch Med, Boston, MA USA. [Iovieno, Nadia] Univ Pisa, I-56100 Pisa, Italy. [Tedeschini, Enrico; Rigatelli, Marco] Univ Modena & Reggio Emilia, Modena, Italy. RP Tedeschini, E (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 50 Staniford St,Suite 401, Boston, MA 02114 USA. EM etedeschini@partners.org RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 FU Bristol-Myers Squibb Company; Forest Pharmaceuticals; National Institute of Mental Health; PAMLAB LLC; Pfizer Inc.; Ridge Diagnostics (formerly known as Precision Human Biolaboratories) FX Conflicts of interests: Dr Iovieno, Ameral, Dr Rigatelli and Dr Tedeschini report no competing interests. Dr Papakostas has served as a consultant for AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly Co., GlaxoSmithKline, Evotec AG, Inflabloc Pharmaceuticals, Jazz Pharmaceuticals, Otsuka Pharmaceuticals, PAMLAB LLC, Pfizer Inc., Pierre Fabre Laboratories, Shire Pharmaceuticals, and Wyeth Inc. Dr Papakostas has received honoraria from Astra Zeneca PLC, Bristol-Myers Squibb Company, Eli Lilly Co., Evotec AG, GlaxoSmithKline, Inflabloc Pharmaceuticals, Jazz Pharmaceuticals, Lundbeck, Otsuka Pharmaceuticals, PAMLAB LLC, Pfizer, Pierre Fabre Laboratories, Shire Pharmaceuticals, Titan Pharmaceuticals, and Wyeth Inc. Dr Papakostas has received research support from Bristol-Myers Squibb Company, Forest Pharmaceuticals, the National Institute of Mental Health, PAMLAB LLC, Pfizer Inc., and Ridge Diagnostics (formerly known as Precision Human Biolaboratories). Dr Papakostas has served on the speaker's bureau for BristolMyersSquibb Co and Pfizer Inc. NR 40 TC 18 Z9 18 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0268-1315 J9 INT CLIN PSYCHOPHARM JI Int. Clin. Psychopharmacol. PD MAR PY 2011 VL 26 IS 2 BP 69 EP 74 DI 10.1097/YIC.0b013e328340775e PG 6 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 712HX UT WOS:000286658300002 PM 20962663 ER PT J AU Ventriglio, A Vincenti, A Centorrino, F Talamo, A Fitzmaurice, G Baldessarini, RJ AF Ventriglio, Antonio Vincenti, Alessio Centorrino, Franca Talamo, Alessandra Fitzmaurice, Garrett Baldessarini, Ross J. TI Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients SO INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE anticonvulsant; bipolar; mood stabilizers; polytherapy schizoaffective; schizophrenia ID SCHIZOPHRENIA; LITHIUM; LAMOTRIGINE; DIVALPROEX; ANTICONVULSANTS; DEPENDENCE; ALCOHOL; TRIALS; RISKS AB Treatments given to patients with primary psychotic disorders include mood stabilizers (MSs) combined with other psychotropics, despite the limited evidence of efficacy, safety, and lack of regulatory approval. We analyzed records of 636 inpatients at the McLean Hospital (2002-2009), who were diagnosed with bipolar disorder (n = 318), a schizoaffective disorder (n = 210), or schizophrenia (n = 108), to evaluate MS-usage, drug-selections, combinations and doses, improvement, adverse-effect risks, associated factors, and secular trends. Between 2002 and 2009, the use of MSs increased from 53 to 94% of patients, MSs per patient increased by 74%, and the total final doses (lithium-equivalents in milligrams/day) increased by 35%. The most commonly prescribed MSs ranked: valproate, lithium, lamtogrine. With the use of MSs, the duration of hospitalization was longer by an average of 18%, Clinical Global Impression ratings improved by 55%, and adverse-effects risk was lower by 22%. In multivariate logistic modeling, treatment with a MS was associated with: (i) most recent year of sampling, (ii) more psychotropics per patient at discharge, (iii) diagnosis (schizophrenia < schizoaffective or bipolar disorders), (iv) longer period of hospitalization, and (v) somewhat younger age. MSs, usually in combination with antipsychotics, were used increasingly for inpatients over the past decade, including for patients with primary psychotic disorders. The effectiveness and safety of this practice remain to be evaluated adequately. Int Clin Psychopharmacol 26:88-95 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Ventriglio, Antonio] Univ Foggia, Inst Psychiat, Dept Psychiat, I-71041 Foggia, Italy. [Vincenti, Alessio; Talamo, Alessandra] Univ Roma La Sapienza, Sch Med 2, Dept Neurosci Mental Hlth & Sensory Funct NESMOS, Rome, Italy. [Vincenti, Alessio; Talamo, Alessandra] St Andrea Hosp, Unit Psychiat, Rome, Italy. [Ventriglio, Antonio; Vincenti, Alessio; Centorrino, Franca; Talamo, Alessandra; Baldessarini, Ross J.] Massachusetts Gen Hosp, Int Consortium Bipolar & Psychot Disorders Res, McLean Div, Boston, MA 02114 USA. [Centorrino, Franca; Fitzmaurice, Garrett; Baldessarini, Ross J.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Ventriglio, A (reprint author), Univ Foggia, Inst Psychiat, Dept Psychiat, Via Guglielmo Marconi 3, I-71041 Foggia, Italy. EM a.ventriglio@libero.it OI Talamo, Alessandra/0000-0001-7321-9247; Ventriglio, Antonio/0000-0002-3934-7007 FU University of Foggia; University of Rome-La Sapienza; Bruce J. Anderson Foundation; McLean Private Donors Psychopharmacology Research Fund FX This study was supported in part by research fellowships from the University of Foggia (Dr Ventriglio) and the University of Rome-La Sapienza (Dr Vincenti), and a Grant from the Bruce J. Anderson Foundation and by the McLean Private Donors Psychopharmacology Research Fund (Dr Baldessarini). NR 30 TC 4 Z9 4 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0268-1315 J9 INT CLIN PSYCHOPHARM JI Int. Clin. Psychopharmacol. PD MAR PY 2011 VL 26 IS 2 BP 88 EP 95 DI 10.1097/YIC.0b013e328340c0de PG 8 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 712HX UT WOS:000286658300005 PM 21030870 ER PT J AU Durand-Heredia, JM Yu, HH De Carlo, S Lesser, CF Janakiraman, A AF Durand-Heredia, Jorge M. Yu, Helen H. De Carlo, Sacha Lesser, Cammie F. Janakiraman, Anuradha TI Identification and Characterization of ZapC, a Stabilizer of the FtsZ Ring in Escherichia coli SO JOURNAL OF BACTERIOLOGY LA English DT Article ID BACTERIAL-CELL-DIVISION; PROTEIN FTSZ; BINDING-PROTEIN; CYTOSKELETAL PROTEIN; ASSEMBLY DYNAMICS; POLYMERIZATION; POLYMERS; TUBULIN; MINC; GTP AB In Escherichia coli, spatiotemporal control of cell division occurs at the level of the assembly/disassembly process of the essential cytoskeletal protein FtsZ. A number of regulators interact with FtsZ and modulate the dynamics of the assembled FtsZ ring at the midcell division site. In this article, we report the identification of an FtsZ stabilizer, ZapC (Z-associated protein C), in a protein localization screen conducted with E. coli. ZapC colocalizes with FtsZ at midcell and interacts directly with FtsZ, as determined by a protein-protein interaction assay in yeast. Cells lacking or overexpressing ZapC are slightly elongated and have aberrant FtsZ ring morphologies indicative of a role for ZapC in FtsZ regulation. We also demonstrate the ability of purified ZapC to promote lateral bundling of FtsZ in a sedimentation reaction visualized by transmission electron microscopy. While ZapC lacks sequence similarity with other nonessential FtsZ regulators, ZapA and ZapB, all three Zap proteins appear to play an important role in FtsZ regulation during rapid growth. Taken together, our results suggest a key role for lateral bundling of the midcell FtsZ polymers in maintaining FtsZ ring stability during division. C1 [Durand-Heredia, Jorge M.; Yu, Helen H.; Janakiraman, Anuradha] CUNY City Coll, Dept Biol, New York, NY 10031 USA. [De Carlo, Sacha] CUNY City Coll, Dept Chem, New York, NY 10031 USA. [De Carlo, Sacha] CUNY City Coll, Inst Macromol Assemblies, New York, NY 10031 USA. [Lesser, Cammie F.] Massachusetts Gen Hosp, Div Infect Dis, Cambridge, MA 02139 USA. [Lesser, Cammie F.] Harvard Univ, Sch Med, Cambridge, MA 02139 USA. [Janakiraman, Anuradha] CUNY, Grad Ctr, New York, NY 10016 USA. RP Janakiraman, A (reprint author), CUNY City Coll, Dept Biol, 160 Convent Ave,MR 616, New York, NY 10031 USA. EM anuj@sci.ccny.cuny.edu FU AHA [SDG 0735538T]; NIH [SC2 GM082336, RO1 AI078445]; NIH/NCRR/RCMI [G12-RR03060] FX This work was supported by the following grants: AHA SDG 0735538T and NIH SC2 GM082336 (to A.J.), RO1 AI078445 (to C.F.L.), and NIH/NCRR/RCMI G12-RR03060 to City College of New York. NR 53 TC 42 Z9 43 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD MAR PY 2011 VL 193 IS 6 BP 1405 EP 1413 DI 10.1128/JB.01258-10 PG 9 WC Microbiology SC Microbiology GA 726CL UT WOS:000287696100014 PM 21216995 ER PT J AU Horvathy, DB Hauck, EF Ogilvy, CS Hopkins, LN Levy, EI Siddiqui, AH AF Horvathy, Denes B. Hauck, Erik F. Ogilvy, Christopher S. Hopkins, L. Nelson Levy, Elad I. Siddiqui, Adnan H. TI Complete preoperative embolization of hemangioblastoma vessels with Onyx 18 SO JOURNAL OF CLINICAL NEUROSCIENCE LA English DT Article DE Brain tumor; Hemangioblastoma; Onyx; Preoperative embolization ID CENTRAL-NERVOUS-SYSTEM; POLYVINYL-ALCOHOL PARTICLES; TUMORS; MENINGIOMAS; LIMITATIONS AB The authors present a preliminary experience with ethyl-enevinylalcohol copolymer (Onyx) for hemangioblastoma vessel embolization before surgical resection. The patient presented with neck pain, dizziness, blurred vision, vomiting, and loss of balance. Diagnostic imaging revealed a posterior fossa cystic mass with a nodular component. Angiography demonstrated a significant vascular blush with arteriovenous shunting that was characteristic of a hemangioblastoma. Tumor vessels originating off the left posterior inferior cerebellar artery were embolized before surgery using Onyx 18 (ev3, Covidien Vascular Therapies, Mansfield, MA, USA). This resulted in complete obliteration of all tumor vessels, transforming a highly vascular tumor into an avascular mass. A safe and uneventful surgical resection was performed the next day. Onyx is a valuable embolic agent for preoperative hemangioblastoma vessel embolization. Because of its low viscosity. Onyx penetrates deeply into the tumor vasculature and allows complete obliteration of tumor vessels. Risks of the intervention have to be carefully weighed against the benefits. If preoperative embolization is indicated, the use of Onyx should be strongly considered. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Horvathy, Denes B.; Hauck, Erik F.; Ogilvy, Christopher S.; Hopkins, L. Nelson; Levy, Elad I.; Siddiqui, Adnan H.] SUNY Buffalo, Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14260 USA. [Horvathy, Denes B.; Hauck, Erik F.; Ogilvy, Christopher S.; Hopkins, L. Nelson; Levy, Elad I.; Siddiqui, Adnan H.] SUNY Buffalo, Sch Med & Biomed Sci, Toshiba Stroke Res Ctr, Buffalo, NY 14260 USA. [Horvathy, Denes B.; Hauck, Erik F.; Ogilvy, Christopher S.; Hopkins, L. Nelson; Levy, Elad I.; Siddiqui, Adnan H.] Millard Fillmore Gates Hosp Kaleida Hlth, Dept Neurosurg, Buffalo, NY 14209 USA. [Ogilvy, Christopher S.] Massachusetts Gen Hosp, Neurovasc Serv, Boston, MA 02114 USA. RP Siddiqui, AH (reprint author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14260 USA. EM asiddiqui@ubns.com RI Horvathy, Denes/F-2587-2013 FU Boston Scientific (CABANA); Cordis (SAPPHIRE WW); ev3/Covidien Vascular Therapies (CREATE); Boston Scientific; Cordis; ev3/Covidien Vascular Therapies FX Dr. Hopkins receives research study grants from Boston Scientific (CABANA), Cordis (SAPPHIRE WW), and ev3/Covidien Vascular Therapies (CREATE); has an ownership/financial interest in Boston Scientific and Cordis; receives honoraria from Boston Scientific, and Cordis; and serves as a consultant to, or on the advisory board for, Boston Scientific and Cordis.; Dr. Levy receives research grant support (principal investigator: Stent-Assisted Recanalization in acute Ischemic Stroke, SARIS), other research support (devices), and honoraria from Boston Scientific and research support from ev3/Covidien Vascular Therapies; serves as a consultant per project and/or per hour for ev3/Covidien Vascular Therapies; and receives fees for carotid stent training from ev3/Covidien Vascular Therapies. Dr Levy receives no consulting salary arrangements. All consulting is per project and/or per hour. NR 15 TC 14 Z9 15 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0967-5868 J9 J CLIN NEUROSCI JI J. Clin. Neurosci. PD MAR PY 2011 VL 18 IS 3 BP 401 EP 403 DI 10.1016/j.jocn.2010.06.016 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 725HT UT WOS:000287636500023 PM 21237650 ER PT J AU Van Dyke, TE AF Van Dyke, Thomas E. TI Proresolving lipid mediators: potential for prevention and treatment of periodontitis SO JOURNAL OF CLINICAL PERIODONTOLOGY LA English DT Article DE anti-inflammatory; lipoxins; P; gingivalis; periodontal disease; resolution agonists; resolvins ID TRIGGERED 15-EPI-LIPOXIN A(4); STABLE ANALOGS; LIPOXIN A(4); RESOLVIN E1; IN-VIVO; APOPTOTIC NEUTROPHILS; ACUTE-INFLAMMATION; ANTI-INFLAMMATION; HUMAN MONOCYTES; FATTY-ACIDS AB P>Aim Periodontitis is an inflammatory disease initiated by microbial biofilm. The host response to the biofilm destroys the periodontium mediated by an overly robust inflammatory response in susceptible individuals. Whether the excessive host response is genetic, epigenetic or mediated by environment is unknown. New pathways of resolution of inflammation have been discovered. Resolution of inflammation is an active, agonist-mediated, programmed return to tissue homeostasis. Materials and Methods Various computer-based search engines were employed to identify papers relevant to resolution of inflammation. Results Recent data suggest that chronic inflammatory periodontal disease may be a failure of resolution pathways as well as overexpression of proinflammatory pathways. In this review, the biology of resolution of inflammation will be examined in normal tissues and periodontal disease. Anti-inflammatory pharmacologic agents [non-steroidal anti-inflammatory drugs (NSAIDs)] have been shown to prevent and slow the progression of periodontitis in animals and humans. However, the side effect profile of NSAIDS or other inhibitors or receptor antagonists preclude their use in periodontal therapy. Conclusion The isolation and characterization of proresolving lipid mediators that are receptor agonists has opened a new area of research for potential therapeutic agents for the management of inflammatory periodontitis. C1 Forsyth Inst, Dept Periodontol, Cambridge, MA 02142 USA. RP Van Dyke, TE (reprint author), Forsyth Inst, Dept Periodontol, Cambridge, MA 02142 USA. EM tvandyke@forsyth.org OI Van Dyke, Thomas/0000-0003-0568-124X FU USPHS [P50-DE16191, DE19938]; Colgate FX Boston University is assigned patents on resolvins that are licensed for clinical development and are subject to consulting agreements for Dr. Van Dyke. This work was supported by USPHS Grants P50-DE16191 and DE19938.; Boston University is assigned patents on resolvins that are licensed for clinical development and are subject to consultant agreement for Thomas E. Van Dyke. This supplement was supported by an unrestricted grant from Colgate. NR 47 TC 15 Z9 17 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0303-6979 J9 J CLIN PERIODONTOL JI J. Clin. Periodontol. PD MAR PY 2011 VL 38 SU 11 BP 119 EP 125 DI 10.1111/j.1600-051X.2010.01662.x PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 722AY UT WOS:000287402800013 PM 21323709 ER PT J AU Gocke, SP Rottier, FJ Havey, RM Renner, SM Patwardhan, AG Carandang, G AF Gocke, Sean P. Rottier, Francis J. Havey, Robert M. Renner, Susan M. Patwardhan, Avinash G. Carandang, Gerard TI Quantitative Analysis of the Long- and Short-arm Crescentic Shelf Bunionectomy Osteotomies in Fresh Cadaveric Matched Pair Specimens SO JOURNAL OF FOOT & ANKLE SURGERY LA English DT Article DE basilar crescentic osteotomy; bunionectomy; crescentic shelf osteotomy ID PROXIMAL METATARSAL OSTEOTOMY; HALLUX-VALGUS CORRECTION; 1ST RAY MOBILITY; FIXATION; STIFFNESS; STRENGTH AB Two variations of crescentic shelf osteotomies have been described for the treatment of moderate to severe hallux abductovalgus: a short arm and a long arm. This study tested the hypothesis that the short-arm osteotomy will have a greater moment to failure and angular stiffness than the long arm. Eighteen first metatarsal specimens were dissected from 9 matched pairs of fresh frozen cadaveric specimens. One metatarsal from each pair received a short-arm osteotomy, whereas the other received a long-arm osteotomy. Each osteotomy was fixed with 2 screws. The short arm was fixed with 1 oblique screw and 1 dorsal-to-plantar screw. The long arm was fixed with 2 dorsal-to-plantar screws: 1 at the proximal aspect and 1 at the distal aspect of the shelf. Each specimen was loaded in a materials testing machine to measure moment to failure and angular stiffness. The base of the first metatarsal was potted and load applied to the plantar aspect of the metatarsal head at a constant rate until failure of the osteotomy. The mean maximum moment to failure of the short arm was significantly greater than the long arm (2.04 +/- 0.96 Newton meter [Nm] vs. 1.48 +/- 0.67 Nm, P = .03). The mean angular stiffness was significantly greater for short arm versus long arm (23.8 +/- 19.11 Nm/radian vs. 0.98 +/- 9.08 Nm/radian, P = .01). We report statistically significant data supporting the short-arm crescentic shelf osteotomy to have a greater moment to failure and angular stiffness compared with the long-arm crescentic shelf osteotomy. (C) 2011 by the American College of Foot and Ankle Surgeons. All rights reserved. C1 [Gocke, Sean P.] Loyola Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, Maguire Ctr, Maywood, IL 60153 USA. [Havey, Robert M.; Renner, Susan M.; Patwardhan, Avinash G.; Carandang, Gerard] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Musculoskeletal Biomech Lab, Hines, IL 60141 USA. RP Gocke, SP (reprint author), Loyola Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, Maguire Ctr, 3rd Year Resident PM&S 36,Suite 1700,2160 S 1st A, Maywood, IL 60153 USA. EM seannddpm@ameritech.net NR 27 TC 0 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1067-2516 J9 J FOOT ANKLE SURG JI J. Foot Ankle Surg. PD MAR-APR PY 2011 VL 50 IS 2 BP 158 EP 164 DI 10.1053/j.jfas.2010.12.006 PG 7 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 726NR UT WOS:000287730300006 PM 21353999 ER PT J AU Lotrich, FE Loftis, JM Ferrell, RE Rabinovitz, M Hauser, P AF Lotrich, Francis E. Loftis, Jennifer M. Ferrell, Robert E. Rabinovitz, Mordechai Hauser, Peter TI IL28B Polymorphism Is Associated with Both Side Effects and Clearance of Hepatitis C During Interferon-Alpha Therapy SO JOURNAL OF INTERFERON AND CYTOKINE RESEARCH LA English DT Article ID VIRAL CLEARANCE; VIROLOGICAL RESPONSE; DEPRESSIVE SYMPTOMS; RIBAVIRIN THERAPY; PLUS RIBAVIRIN; RECEPTOR GENE; MANAGEMENT; TRIAL AB Interferon-alpha (IFN-alpha) treatment for hepatitis C virus (HCV) is complicated by depression and related neurovegetative side effects. Recent genome-wide scans identified IL28B gene polymorphisms that associated with HCV clearance. Whether the IL28B polymorphism is also associated with these adverse effects of IFN-alpha would affect its clinical usefulness. One hundred thirty-three patients were prospectively examined using the Beck Depression Inventory-II and a Structured Clinical Interview for Diagnostic and Statistical Manual-IV (DSM-IV) during IFN-alpha treatment. The candidate C/T single-nucleotide polymorphism upstream from IL28B (rs1297860) was genotyped and assessed for association with individual items from the Beck Depression Inventory-II. We confirmed that the IL28B polymorphism was associated with differences in sustained viral response (F = 3.38; P < 0.05), with the T/T genotype faring worst. However, the T/T genotype was associated with less appetite (P < 0.05), energy (P < 0.05), and sleep complaints (P < 0.05) during treatment. Only 3.1% of patients with T/T developed major appetite complaints, whereas 10.1% and 8.9% of those with the C/T and C/C genotype did, respectively. Only 10.8% of patients with T/T developed major sleep complaints, whereas 16.1% and 20.7% of those with the C/T and C/C genotype did. However, IL28B genotype did not predict development of major depressive disorder (chi(2) = 0.12; P = 0.94). The allele (C) was associated with both better viral clearance and more subjective appetite, energy, and sleep complaints. This has implications for the management of patients with HCV. If genotyping is used to better target therapy, this may co-enrich the population for likelihood of also suffering from these side effects. C1 [Lotrich, Francis E.] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA. [Ferrell, Robert E.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15213 USA. [Rabinovitz, Mordechai] Univ Pittsburgh, Div Gastroenterol & Hepatol, Pittsburgh, PA 15213 USA. [Hauser, Peter] VISN 22 Network Off, Long Beach, CA USA. [Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Dept Psychiat, Res & Dev Serv, Portland, OR 97201 USA. RP Lotrich, FE (reprint author), Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, 3811 Ohara St, Pittsburgh, PA 15213 USA. EM lotrichfe@upmc.edu FU NIMH [K23MH074012]; VA [08-1904] FX This study was funded by NIMH K23MH074012 (to F.E.L.) and VA#08-1904 (to P.H.). NR 31 TC 17 Z9 17 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1079-9907 J9 J INTERF CYTOK RES JI J. Interferon Cytokine Res. PD MAR PY 2011 VL 31 IS 3 BP 331 EP 336 DI 10.1089/jir.2010.0074 PG 6 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA 727KY UT WOS:000287799700006 PM 21133812 ER PT J AU Ogilvy, CS Natarajan, SK Jahshan, S Karmon, Y Yang, XY Snyder, KV Hopkins, LN Siddiqui, AH Levy, EI AF Ogilvy, Christopher S. Natarajan, Sabareesh K. Jahshan, Shady Karmon, Yuval Yang, Xinyu Snyder, Kenneth V. Hopkins, L. Nelson Siddiqui, Adnan H. Levy, Elad I. TI Stent-assisted coiling of paraclinoid aneurysms: risks and effectiveness SO JOURNAL OF NEUROINTERVENTIONAL SURGERY LA English DT Article ID NECKED INTRACRANIAL ANEURYSMS; MIDTERM FOLLOW-UP; INITIAL CLINICAL-EXPERIENCE; CEREBRAL ANEURYSMS; NITINOL STENT; ENDOVASCULAR TREATMENT; ENTERPRISE STENT; NEUROFORM STENT; SYSTEM AB Background Stent assistance for treatment of wide-based aneurysms is becoming rapidly accepted. Methods Cases of aneurysms arising in the paraclinoid location of the internal carotid artery treated with intracranial stents and/or bare platinum coils were analyzed retrospectively from our prospectively collected database. We identified 70 aneurysms treated with stent assistance (including one stenting-alone case) and 24 aneurysms treated with coiling alone. Stenting-assisted coiling was achieved either as a one-time treatment or as a two-step maneuver with the stent placed several weeks before coiling, or stent-assisted coiling was used as a second maneuver in aneurysms that recanalized after previous coiling. Results In aneurysms treated with stent assistance, 60% had >= 95% occlusion at treatment completion, a result comparing favorably with the 54.2% rate of >= 95% occlusion associated with coiling alone. At last follow-up, 60 aneurysms treated with stent assistance had a 66.7% incidence of >= 95% occlusion, with no in-stent stenosis; 75% of patients treated with coiling alone had >= 95% aneurysm occlusion. Thrombus occurred during stent deployment in two patients, one with and one without neurologic sequelae; stent displacement occurred in one patient without neurologic sequelae. At last follow-up, 57 of 62 patients (91.9%) treated with stent-assisted coiling experienced excellent/ good outcomes (modified Rankin scale score <= 2). These results compared favorably with those for the coiling-alone group in which 23 of 24 (95.8%) had good outcomes. Conclusion Stent-assisted coiling of paraclinoid aneurysms did not add significantly to morbidity; overall effectiveness was comparable to that of bare coiling of paraclinoid aneurysms. These results require confirmation by a prospective controlled trial. C1 [Ogilvy, Christopher S.; Natarajan, Sabareesh K.; Jahshan, Shady; Karmon, Yuval; Snyder, Kenneth V.; Hopkins, L. Nelson; Siddiqui, Adnan H.; Levy, Elad I.] SUNY Buffalo, Toshiba Stroke Res Ctr, Sch Med & Biomed Sci, Buffalo, NY 14260 USA. [Hopkins, L. Nelson; Siddiqui, Adnan H.; Levy, Elad I.] SUNY Buffalo, Dept Radiol, Sch Med & Biomed Sci, Buffalo, NY 14260 USA. [Ogilvy, Christopher S.; Natarajan, Sabareesh K.; Jahshan, Shady; Karmon, Yuval; Snyder, Kenneth V.; Hopkins, L. Nelson; Siddiqui, Adnan H.; Levy, Elad I.] Millard Fillmore Gates Hosp, Dept Neurosurg, Buffalo, NY USA. [Ogilvy, Christopher S.; Yang, Xinyu] Massachusetts Gen Hosp, Neurovasc Serv, Boston, MA 02114 USA. [Yang, Xinyu] Tianjin Med Univ Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China. [Ogilvy, Christopher S.; Natarajan, Sabareesh K.; Jahshan, Shady; Karmon, Yuval; Snyder, Kenneth V.; Hopkins, L. Nelson; Siddiqui, Adnan H.; Levy, Elad I.] SUNY Buffalo, Dept Neurosurg, Sch Med & Biomed Sci, Buffalo, NY 14260 USA. RP Levy, EI (reprint author), Univ Buffalo Neurosurg, 3 Gates Circle, Buffalo, NY 14209 USA. EM elevy@ubns.com FU Abbott (ACT 1 Choice); Boston Scientific (CABANA); Cordis (SAPPHIRE WW); ev3/Covidien Vascular Therapies (CREATE); Toshiba; AccessClosure; Boston Scientific; Cordis; Micrus; Valor Medical; American Physicians Fellowship for Medicine in Israel; Stent-Assisted Recanalization in acute Ischemic Stroke, SARIS; Micrus Endovascular; ev3/Covidien Vascular Therapies; Abbott Vascular; Congress of Neurological Surgeons; University at Buffalo; National Institutes of Health [NINDS 1R01NS064592-01A1] FX Dr Hopkins receives research study grants from Abbott (ACT 1 Choice), Boston Scientific (CABANA), Cordis (SAPPHIRE WW) and ev3/Covidien Vascular Therapies (CREATE), and a research grant from Toshiba (for the Toshiba Stroke Research Center); has an ownership/financial interest in AccessClosure, Boston Scientific, Cordis, Micrus and Valor Medical; serves on the Abbott Vascular Speakers' Bureau; receives honoraria from Bard, Boston Scientific, Cordis, and from the following for speaking at conferences: Complete Conference Management, Cleveland Clinic, and SCAI; receives royalties from Cordis (for the AngioGuard device), serves as a consultant to or on the advisory board for Abbott, AccessClosure, Bard, Boston Scientific, Cordis, Gore, Lumen Biomedical, Micrus and Toshiba; and serves as the conference director for Nurcon Conferences/Strategic Medical Seminars LLC. Dr Karmon has received a grant from the American Physicians Fellowship for Medicine in Israel. Dr Levy receives research grant support (principal investigator: Stent-Assisted Recanalization in acute Ischemic Stroke, SARIS), other research support (devices), and honoraria from Boston Scientific and research support from Micrus Endovascular and ev3/Covidien Vascular Therapies; has ownership interests in Intratech Medical Ltd and Mynx/Access Closure; serves as a consultant on the board of Scientific Advisors to Codman & Shurtleff, Inc.; serves as a consultant per project and/or per hour for Micrus Endovascular, ev3/Covidien Vascular Therapies and TheraSyn Sensors, Inc.; and receives fees for carotid stent training from Abbott Vascular and ev3/Covidien Vascular Therapies. Dr Levy receives no consulting salary arrangements. All consulting is per project and/or per hour. Dr Natarajan is the recipient of the 2010-2011 Cushing Award of the Congress of Neurological Surgeons (eligible to receive research support after 1 July 2010). Dr Ogilvy serves as a consultant to Mizuho America. Dr Siddiqui has received research grants from the University at Buffalo and from the National Institutes of Health (NINDS 1R01NS064592-01A1, Hemodynamic induction of pathologic remodeling leading to intracranial aneurysms); is a consultant to Codman & Shurtleff, Inc. Concentric Medical, ev3/Covidien Vascular Therapies and Micrus Endovascular; serves on speakers' bureaus for Codman & Shurtleff, Inc. and Genentech; and has received honoraria from Genentech, Neocure Group LLC, American Association of Neurological Surgeons' courses, and an Emergency Medicine Conference and from Codman & Shurtleff, Inc. for training other neurointerventionists. Dr Siddiqui receives no consulting salary arrangements. All consulting is per project and/or per hour. Dr Jahshan, Dr Snyder and Dr Yang have nothing to disclose. NR 16 TC 17 Z9 21 U1 1 U2 3 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1759-8478 J9 J NEUROINTERV SURG JI J. NeuroInterventional Surg. PD MAR PY 2011 VL 3 IS 1 BP 14 EP 20 DI 10.1136/jnis.2010.002303 PG 7 WC Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA 718MQ UT WOS:000287127500004 PM 21990780 ER PT J AU Leslie-Mazwi, TM Sims, JR Hirsch, JA Nogueira, RG AF Leslie-Mazwi, Thabele M. Sims, John R. Hirsch, Joshua A. Nogueira, Raul G. TI Periprocedural blood pressure management in neurointerventional surgery SO JOURNAL OF NEUROINTERVENTIONAL SURGERY LA English DT Article ID ACUTE ISCHEMIC-STROKE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; CEREBRAL PERFUSION-PRESSURE; CAROTID-ENDARTERECTOMY; INTRACEREBRAL HEMORRHAGE; ARTERIOVENOUS-MALFORMATIONS; INTRACRANIAL HEMORRHAGE; HYPERPERFUSION SYNDROME; NEUROLOGIC MORBIDITY; PREDICTIVE FACTORS AB With the increasing range of conditions currently amenable to endovascular therapies, the knowledge of periprocedural blood pressure management is essential for the neurointerventional surgeon. This review discusses the physiology of cerebral blood flow and blood pressure, monitoring options for neurointerventional patients, useful agents for blood pressure elevation and reduction and neuroanesthetic considerations during procedures with an emphasis on practical decision-making. Also included are parameters for conditions typically encountered in the neurointerventional suite based on best available evidence, with reference to blood pressure management before, during and after neurointerventional therapy. C1 [Nogueira, Raul G.] Massachusetts Gen Hosp, Dept Intervent Neuroradiol, Dept Neurol Crit Care, Boston, MA 02114 USA. RP Nogueira, RG (reprint author), Emory Fac Off Bldg 80 Jesse Hill Dr SE,Room 398, Atlanta, GA 30303 USA. EM rnoguei@emory.edu NR 47 TC 2 Z9 2 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1759-8478 J9 J NEUROINTERV SURG JI J. NeuroInterventional Surg. PD MAR PY 2011 VL 3 IS 1 BP 66 EP 73 DI 10.1136/jnis.2009.001206 PG 8 WC Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA 718MQ UT WOS:000287127500017 PM 21990793 ER PT J AU Walcott, BP Gerrard, JL Nogueira, RG Nahed, BV Terry, AR Ogilvy, CS AF Walcott, Brian P. Gerrard, Jason L. Nogueira, Raul G. Nahed, Brian V. Terry, Anna R. Ogilvy, Christopher S. TI Microsurgical retrieval of an endovascular microcatheter trapped during Onyx embolization of a cerebral arteriovenous malformation SO JOURNAL OF NEUROINTERVENTIONAL SURGERY LA English DT Article ID PREOPERATIVE EMBOLIZATION; AVM EMBOLIZATION; BRAIN; MANAGEMENT; COMPLICATIONS; MULTICENTER; EXPERIENCE; SYSTEM AB Objective Cerebral arteriovenous malformations (AVMs) are vascular lesions that are amenable to various treatment modalities including stereotactic radiosurgery, fractionated radiotherapy, endovascular embolization, microsurgical obliteration or combined modality treatment. A potential complication of endovascular therapy with embolization material is microcatheter entrapment. We report on a patient for whom surgery was combined with endovascular embolization to obliterate an AVM and retrieve an entrapped endovascular microcatheter. Participant A 52-year-old woman suffered a left parietal hemorrhage from an AVM. She underwent staged endovascular embolization of the lesion using Onyx material. During the second stage of the embolization, the microcatheter (Marathon Flow Directed Microcatheter; eV3 Neurovascular, Inc., Irvine, CA, USA) was retained in the Onyx plug. It was decided to section the microcatheter at the groin and proceed with microsurgical obliteration of the AVM, with removal of the entrapped microcatheter remnant. Intervention The AVM was dissected circumferentially allowing the meticulous obliteration of the feeding vessels. A single remaining feeding vessel originating from the distal anterior cerebral artery was identified and suspected to contain the entrapped microcatheter. The location was confirmed using stereotactic guidance (BrainLab, Munich, Germany) and the vessel was then sectioned allowing complete removal of the AVM. The microcatheter (102 cm) was then extracted cranially using gentle traction. Conclusion This demonstrates the first incidence of microcatheter removal after procedural entrapment in Onyx embolization material. C1 [Walcott, Brian P.; Gerrard, Jason L.; Nahed, Brian V.; Terry, Anna R.; Ogilvy, Christopher S.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Walcott, Brian P.; Gerrard, Jason L.; Nogueira, Raul G.; Nahed, Brian V.; Terry, Anna R.; Ogilvy, Christopher S.] Harvard Univ, Sch Med, Boston, MA USA. [Nogueira, Raul G.] Massachusetts Gen Hosp, Dept Vasc & Crit Care Neurol, Boston, MA 02114 USA. [Nogueira, Raul G.] Massachusetts Gen Hosp, Dept Intervent Neuroradiol, Boston, MA 02114 USA. RP Walcott, BP (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St,White Bldg,Room 502, Boston, MA 02114 USA. EM walcott.brian@mgh.harvard.edu NR 26 TC 9 Z9 10 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1759-8478 J9 J NEUROINTERV SURG JI J. NeuroInterventional Surg. PD MAR PY 2011 VL 3 IS 1 BP 77 EP 79 DI 10.1136/jnis.2010.002733 PG 3 WC Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA 718MQ UT WOS:000287127500019 PM 21990795 ER PT J AU Kang, GA Heath, S Rothlind, J Starr, PA AF Kang, Gail A. Heath, Susan Rothlind, Johannes Starr, Philip A. TI Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington's disease SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Article ID PRIMARY GENERALIZED DYSTONIA; GLOBUS-PALLIDUS; SUBTHALAMIC NUCLEUS; PARKINSONS-DISEASE; TECHNICAL APPROACH; IMPLANTATION; LOCATIONS; INTERNUS AB Background Deep brain stimulator (DBS) implantation has been shown to be effective in the treatment of various movement disorders including Parkinson's disease, essential tremor and dystonia. However, there is limited information regarding the potential use of DBS in Huntington's disease (HD). In this study, the authors present their findings on the long-term motor and neurocognitive results of two HD patients (patient 1: 57 years, 42 cytosine-adenine guanine (CAG) repeats; patient 2: 50 years, 41 CAG repeats) who underwent staged bilateral globus pallidus interna DBS surgery. Methods The patients were evaluated at baseline and at five timepoints throughout a 2-year postoperative during which motoric ratings ((Unified Huntington's Disease Rating Scale), Activities of Daily Living scores (HD-ADL) and neurocognitive testing) were obtained. Results Both patients had a sustained decline in chorea 2 years after initial DBS surgery. Despite this improvement in chorea, one patient has had continuing deterioration in gait, bradykinesia and dystonia scores, which has caused his ability to perform activities of daily living to return to his baseline level of functioning prior to DBS surgery. Both patients have experienced further gradual decline in neurocognitive functioning, which appears to be independent of DBS and most likely related to disease progression. Conclusion DBS implantation may be a potential treatment option for a subset of HD patients who have significant functional deficits due to chorea. However, appropriate selection of the best candidates for DBS appears to be challenging, given the difficulty in predicting disease course in HD due to its variable nature. C1 [Kang, Gail A.; Heath, Susan; Starr, Philip A.] Parkinsons Dis Res Educ & Clin Ctr, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Kang, Gail A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Rothlind, Johannes] San Francisco VA Med Ctr, Dept Mental Hlth Serv, San Francisco, CA USA. [Starr, Philip A.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA. RP Kang, GA (reprint author), Parkinsons Dis Res Educ & Clin Ctr, San Francisco Vet Affairs Med Ctr, 4150 Clement St 127P, San Francisco, CA 94121 USA. EM gakang@comcast.net FU Parkinson's Disease Research Education Clinical Center FX Parkinson's Disease Research Education Clinical Center NR 32 TC 29 Z9 29 U1 1 U2 5 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD MAR PY 2011 VL 82 IS 3 BP 272 EP 277 DI 10.1136/jnnp.2009.202903 PG 6 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA 721KK UT WOS:000287351900009 PM 20974647 ER PT J AU Sanchez, CE Tierney, TS Gale, JT Alavian, KN Sahin, A Lee, JS Mulligan, RC Carter, BS AF Sanchez, Carlos E. Tierney, Travis S. Gale, John T. Alavian, Kambiz N. Sahin, Ayguen Lee, Jeng-Shin Mulligan, Richard C. Carter, Bob S. TI Recombinant adeno-associated virus type 2 pseudotypes: comparing safety, specificity, and transduction efficiency in the primate striatum Laboratory investigation SO JOURNAL OF NEUROSURGERY LA English DT Article DE adeno-associated virus; apoptosis; convection-enhanced delivery; gene therapy; nonhuman primate ID CONVECTION-ENHANCED DELIVERY; PHASE-I TRIAL; GENE-THERAPY; PARKINSONIAN MONKEYS; NIGROSTRIATAL SYSTEM; NONHUMAN-PRIMATES; VIRAL VECTORS; MOUSE-BRAIN; OPEN-LABEL; AAV-HAADC AB Object. Although several clinical trials utilizing the adeno-associated virus (AAV) type 2 serotype 2 (2/2) are now underway, it is unclear whether this particular serotype offers any advantage over others in terms of safety or efficiency when delivered directly to the CNS. Methods. Recombinant AAV2-green fluorescent protein (GFP) serotypes 2/1, 2/2, 2/5, and 2/8 were generated following standard triple transfection protocols (final yield 5.4 x 10(12) particles/ml). A total of 180 mu l of each solution was stereotactically infused, covering the entire rostrocaudal extent of the caudoputamen in 4 rhesus monkeys (Macaca mulatto) (3.0 +/- 0.5 kg). After 6 weeks' survival, the brain was formalin fixed, cut at 40 mu m, and stained with standard immunohistochemistry for anti-GFP, anticaspase-2, and cell-specific markers (anti-microtubule-associated protein-2 for neurons and anti glial fibrillary acidic protein for glia). Unbiased stereological counting methods were used to determine cell number and striatal volume. Results. The entire striatum of each animal contained GFP-positive cells with significant labeling extending beyond the borders of the basal ganglia. No ischemic/necrotic, hemorrhagic, or neoplastic change was observed in any brain. Total infusate volumes were similar across the 4 serotypes. However, GFP-labeled cell density was markedly different. Adeno-associated virus 2/1,2/2, and 2/5 each labeled < 8000 cells/mm(3), whereas serotype 8 labeled > 21,000 cells. a 3- to 4-fold higher transduction efficiency. On the other hand, serotype 8 also labeled neurons and glia with equal affinity compared with neuronal specificities > 89% for the other serotypes. Moderate caspase-2 colabeling was noted in neurons immediately around the AAV2/1 injection tracts, but was not seen above the background anywhere in the brain following injections with serotypes 2, 5, or 8. Conclusions. Intrastriatal delivery of AAV2 yields the highest cell transduction efficiencies but lowest neuronal specificity for serotype 8 when compared with serotypes 1, 2. and 5. Only AAV2/1 revealed significant caspase-2 activation. Careful consideration of serotype-specific differences in AAV2 neurotropism, transduction efficiency, and potential toxicity may affect future human trials. (DOI:10.3171/2010.8.JNS091583) C1 [Sanchez, Carlos E.; Tierney, Travis S.; Gale, John T.; Sahin, Ayguen; Carter, Bob S.] Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA 02115 USA. [Sanchez, Carlos E.; Tierney, Travis S.; Gale, John T.; Sahin, Ayguen; Carter, Bob S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Nayef Al Rodhan Labs Cellular Neurosurg & Neuosur, Boston, MA 02115 USA. [Lee, Jeng-Shin; Mulligan, Richard C.] Harvard Univ, Sch Med, Dept Genet, Harvard Gene Therapy Initiat, Boston, MA 02115 USA. [Alavian, Kambiz N.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. RP Carter, BS (reprint author), Univ Calif San Diego, Dept Neurosurg, 200 W Arbor Dr,Mail Code 8893, San Diego, CA 92103 USA. EM bobcarter@ucsd.edu RI Alavian, Kambiz/D-7720-2012; OI Alavian, Kambiz/0000-0002-0653-3057 FU NIH/National Cancer Institute [2T32CA071345-11]; CHDI Foundation FX Vector stocks were kindly donated by the Harvard Gene Therapy Initiative at Harvard Medical School. Dr. Sanchez was supported by an NIH/National Cancer Institute T-32 Training Program in Cancer Biology grant (no. 2T32CA071345-11; Surgical Oncology). Material costs for the research were provided by a grant from the HighQ Foundation (now known as the CHDI Foundation). NR 37 TC 15 Z9 16 U1 0 U2 0 PU AMER ASSOC NEUROLOGICAL SURGEONS PI ROLLING MEADOWS PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA SN 0022-3085 J9 J NEUROSURG JI J. Neurosurg. PD MAR PY 2011 VL 114 IS 3 BP 672 EP 680 DI 10.3171/2010.8.JNS091583 PG 9 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 725WD UT WOS:000287676700022 PM 20950087 ER PT J AU Harolds, JA Novelline, RA Guiberteau, MJ Metter, D Oates, ME AF Harolds, Jay A. Novelline, Robert A. Guiberteau, Milton J. Metter, Darlene Oates, M. Elizabeth TI COMMENTARY Jobs and New Initiatives in Nuclear Medicine Education SO JOURNAL OF NUCLEAR MEDICINE LA English DT Editorial Material ID BREAST-CANCER; MAMMOGRAPHY; RADIOLOGY; SPECT/CT C1 [Harolds, Jay A.] Michigan State Univ, Grand Rapids, MI 49503 USA. [Novelline, Robert A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Guiberteau, Milton J.] Univ Texas Med Sch Houston, Houston, TX USA. [Metter, Darlene] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Oates, M. Elizabeth] Univ Kentucky, Lexington, KY 40506 USA. RP Harolds, JA (reprint author), Michigan State Univ, Grand Rapids, MI 49503 USA. NR 25 TC 5 Z9 5 U1 0 U2 1 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD MAR 1 PY 2011 VL 52 IS 3 BP 17N EP 23N PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 724LR UT WOS:000287578200001 PM 21345784 ER PT J AU El Fakhri, G Surti, S Trott, CM Scheuermann, J Karp, JS AF El Fakhri, Georges Surti, Suleman Trott, Cathryn M. Scheuermann, Joshua Karp, Joel S. TI Improvement in Lesion Detection with Whole-Body Oncologic Time-of-Flight PET SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE WB-(18)FDG; TOF-PET; lesion detection ID OBSERVER PERFORMANCE; RECONSTRUCTION; ATTENUATION; TOMOGRAPHY; SCANNER; BENEFIT; IMPACT AB Time-of-flight (TOF) PET has great potential in whole-body oncologic applications, and recent work has demonstrated qualitatively in patient studies the improvement that can be achieved in lesion visibility. The aim of this work was to objectively quantify the improvement in lesion detectability that can be achieved in lung and liver lesions with whole-body F-18-FDG TOF PET in a cohort of 100 patients as a function of body mass index, lesion location and contrast, and scanning time. Methods: One hundred patients with BMIs ranging from 16 to 45 were included in this study. Artificial 1-cm spheric lesions were imaged separately in air at variable locations of each patient's lung and liver, appropriately attenuated, and incorporated in the patient list-mode data with 4 different lesion-to-background contrast ranges. The fused studies with artificial lesion present or absent were reconstructed using a list-mode unrelaxed ordered-subsets expectation maximization with chronologically ordered subsets and a gaussian TOF kernel for TOF reconstruction. Conditions were compared on the basis of performance of a 3-channel Hotelling observer signal-to-noise ratio in detecting the presence of a sphere of unknown size on an anatomic background while modeling observer noise. Results: TOF PET yielded an improvement in lesion detection performance (3-channel Hotelling observer signal-to-noise ratio) over non-TOF PET of 8.3% in the liver and 15.1% in the lungs. The improvement in all lesions was 20.3%, 12.0%, 9.2%, and 7.5% for mean contrast values of 2.0:1, 3.2:1, 4.4:1, and 5.7:1, respectively. Furthermore, this improvement was 9.8% in patients with a BMI of less than 30 and 11.1% in patients with a BMI of 30 or more. Performance plateaued faster as a function of number of iterations with TOF than non-TOF. Conclusion: Over all contrasts and body mass indexes, oncologic TOF PET yielded a significant improvement in lesion detection that was greater for lower lesion contrasts. This improvement was achieved without compromising other aspects of PET imaging. C1 [Karp, Joel S.] Univ Penn, Sch Med, Dept Radiol, Philadelphia, PA 19104 USA. [El Fakhri, Georges; Trott, Cathryn M.] Harvard Univ, Sch Med, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02115 USA. [El Fakhri, Georges; Trott, Cathryn M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Karp, JS (reprint author), Univ Penn, Sch Med, Dept Radiol, 423 Guardian Dr,Blockley Hall,Room 425, Philadelphia, PA 19104 USA. EM joelkarp@mail.med.upenn.edu RI Trott, Cathryn/B-5325-2013 OI Trott, Cathryn/0000-0001-6324-1766 FU National Institutes of Health (NIH) [RO1-CA113941, R01-EB009056, EB005876, R21-CA134812] FX This work was supported in part by grants RO1-CA113941, R01-EB009056, EB005876, and R21-CA134812 from the National Institutes of Health (NIH). The contents of this paper are solely the responsibility of the authors and do not represent the official views of the NIH. NR 19 TC 69 Z9 69 U1 1 U2 12 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD MAR 1 PY 2011 VL 52 IS 3 BP 347 EP 353 DI 10.2967/jnumed.110.080382 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 724LR UT WOS:000287578200014 PM 21321265 ER PT J AU Prieto-Jimenez, CA Cardenas, VM Fischbach, LA Mulla, ZD Rivera, JO Dominguez, DC Graham, DY Ortiz, M AF Prieto-Jimenez, Carmen A. Cardenas, Victor M. Fischbach, Lori A. Mulla, Zuber D. Rivera, Jose O. Dominguez, Delfina C. Graham, David Y. Ortiz, Melchor TI Double-blind Randomized Trial of Quadruple Sequential Helicobacter pylori Eradication Therapy in Asymptomatic Infected Children in El Paso, Texas SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION LA English DT Article DE child; drug therapy; Helicobacter infections; preschool; United States ID UNITED-STATES; TRIPLE THERAPY; BREATH TEST; METAANALYSIS; EFFICACY; CARE; RESIDENTS; PURCHASE; MEXICO; BORDER AB Objectives: We assessed the efficacy of a novel quadruple sequential 10-day eradication therapy, its compliance, and reported adverse events in a sample of asymptomatically Helicobacter pylori-infected children in El Paso, Texas, as part of a study aiming to assess the influence of this infection on the levels of markers of iron stores. Patients and Methods: Using a double-blind randomized trial design, 110 asymptomatic children ages 3 to 11 with H pylori infection were randomly assigned to receive either a 10-day course of sequential eradication therapy plus 6 weeks of iron supplementation, eradication therapy plus placebo, iron supplementation plus placebo, or placebo only. H pylori infection status was assessed >= 45 days after treatment using the urea breath test. Analyses compared the proportion of subjects cured according to assignment to and completion of the sequential eradication therapy. Results: Intent-to-treat and per-protocol analyses indicated that 44.3% and 52.9%, respectively, of the children receiving the novel quadruple sequential therapy had their infection eradicated compared with 12.2% and 15.4% in the arms receiving iron or placebo only, respectively (P < 0.001 in both analyses). Study medications were taken with no or only mild adverse events in most children. Conclusions: A quadruple sequential regimen eradicated H pylori in only half the asymptomatic children receiving this treatment. There was no difference in the cure rates of those receiving iron supplementation and those receiving placebo. C1 [Prieto-Jimenez, Carmen A.] Dept Pediat, El Paso, TX USA. [Mulla, Zuber D.] Dept Obstet & Gynecol, El Paso, TX USA. [Ortiz, Melchor] Dept Biomed Sci, Div Biostat & Epidemiol, El Paso, TX USA. [Cardenas, Victor M.] Houston Sch Publ Hlth, UT HSC, El Paso, TX USA. [Fischbach, Lori A.] Univ N Texas, HSC Sch Publ Hlth, Ft Worth, TX USA. [Rivera, Jose O.] Univ Texas El Paso, UTEP UT Austin Collaborat Pharm Program, El Paso, TX USA. [Dominguez, Delfina C.] Univ Texas El Paso, Clin Sci Lab, Coll Hlth Sci, El Paso, TX USA. [Graham, David Y.] Baylor Coll Med, DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Cardenas, VM (reprint author), UT Sch Publ Hlth, El Paso Reg Campus,1100 Stanton Ave,Suite 110F, El Paso, TX 79902 USA. EM victor.cardenas@uth.tmc.edu FU Thrasher Research Fund, Salt Lake City, UT [02823-9]; Meretek Diagnostics; Takeda Pharmaceuticals North America, Deerfield, IL [MA-L-185] FX The present study was funded through an award (number 02823-9) of the Thrasher Research Fund, Salt Lake City, UT. We received an in-kind donation of lansoprazole (Prevacid Solutab) and its placebo (contract MA-L-185) from Takeda Pharmaceuticals North America, Deerfield, IL.; D.Y.G. is a member of the board of and has received funding from Meretek Diagnostics. The other authors report no conflicts of interest. NR 26 TC 5 Z9 5 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-2116 J9 J PEDIATR GASTR NUTR JI J. Pediatr. Gastroenterol. Nutr. PD MAR PY 2011 VL 52 IS 3 BP 319 EP 325 DI 10.1097/MPG.0b013e318206870e PG 7 WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics GA 723AH UT WOS:000287477100012 PM 21336156 ER PT J AU Cardenas, VM Prieto-Jimenez, CA Mulla, ZD Rivera, JO Dominguez, DC Graham, DY Ortiz, M AF Cardenas, Victor M. Prieto-Jimenez, Carmen A. Mulla, Zuber D. Rivera, Jose O. Dominguez, Delfina C. Graham, David Y. Ortiz, Melchor TI Helicobacter pylori Eradication and Change in Markers of Iron Stores Among Non-iron-deficient Children in El Paso, Texas: An Etiologic Intervention Study SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION LA English DT Article DE Helicobacter infections; child; ferritins/blood; iron deficiency; preschool; United States/epidemiology ID SERUM FERRITIN; UNITED-STATES; ANEMIA; INFECTION; POPULATION; TRIAL; SUPPLEMENTATION; METAANALYSIS; ASSOCIATION AB Objectives: We assessed whether Helicobacter pylori eradication was followed by changes in iron stores among non-iron-deficient children. Materials and Methods: Double-blind randomized intervention trial on 110 asymptomatic 3-to 10-year-olds with H pylori infection assigned to any of the following 4 arms: both quadruple eradication and iron supplementation, either quadruple sequential eradication or iron supplementation, or placebo only. Hemoglobin, transferrin saturation, and serum ferritin were measured at baseline and 8 months later to assess changes according to study arm, H pylori infection status at >= 45 days, and cytotoxin-associated gene product A status. Results: Intent-to-treat (n = 110) and per-protocol (n 90) analyses revealed no differences across study arms in changes of iron stores. However, we found that those who had their infection eradicated had a 3-fold increased average change from baseline serum ferritin compared with that of children who remained infected (P < 0.05). Eradication of infection by cytotoxin-associated gene product A negative strains was associated with a larger ferritin increase. Conclusions: In this double-blind randomized trial, the first among non-iron-deficient, asymptomatic H pylori-infected children living in the contiguous United States, we found no effect of H pylori eradication regarding changes in iron stores. However, those who had their infection eradicated at follow-up had a significantly larger increase in serum ferritin from baseline. C1 [Cardenas, Victor M.] Houston Sch Publ Hlth, UT HSC, Houston, TX USA. [Prieto-Jimenez, Carmen A.; Mulla, Zuber D.; Ortiz, Melchor] TTU HSC Paul L Foster Sch Med, Dept Pediat, El Paso, TX USA. [Mulla, Zuber D.] Dept Obstet & Gynecol, Lubbock, TX USA. [Ortiz, Melchor] Dept Obstet & Gynecol, Lubbock, TX USA. [Rivera, Jose O.] Dept Surg, Galveston, TX USA. [Rivera, Jose O.; Dominguez, Delfina C.] Univ Texas El Paso, El Paso, TX USA. [Rivera, Jose O.] UTEP UT Austin Collaborat Pharm Program, El Paso, TX USA. [Dominguez, Delfina C.] Coll Hlth Sci, Clin Sci Lab, El Paso, TX USA. [Graham, David Y.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Cardenas, VM (reprint author), UT Sch Publ Hlth, El Paso Reg Campus,1100 Stanton Ave,Suite 110F, El Paso, TX 79902 USA. EM victor.cardenas@uth.tmc.edu RI Gough, Ethan/B-8633-2012 FU Thrasher Research Fund, Salt Lake City UT [02823-9]; Takeda Pharmaceuticals North America, Deerfield, IL [MA-L-185] FX The present study was funded through an award (no. 02823-9) of the Thrasher Research Fund, Salt Lake City UT). We received an in-kind donation of lansoprazole (Prevacid Solutab) and its placebo (contract MA-L-185) from Takeda Pharmaceuticals North America, Deerfield, IL.; D.Y.G. is a member of the board of and has received funding from Meretek NR 35 TC 19 Z9 20 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-2116 J9 J PEDIATR GASTR NUTR JI J. Pediatr. Gastroenterol. Nutr. PD MAR PY 2011 VL 52 IS 3 BP 326 EP 332 DI 10.1097/MPG.0b013e3182054123 PG 7 WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics GA 723AH UT WOS:000287477100013 PM 21336159 ER PT J AU Kim, DS Park, SH Jeong, YM Kwon, SB Miller, AJ Fisher, DE Park, KC AF Kim, Dong-Seok Park, Seo-Hyoung Jeong, Yun-Mi Kwon, Sun-Bang Miller, Arlo J. Fisher, David E. Park, Kyoung-Chan TI Sphingosine-1-phosphate decreases melanin synthesis via microphthalmia-associated transcription factor phosphorylation through the S1P(3) receptor subtype SO JOURNAL OF PHARMACY AND PHARMACOLOGY LA English DT Article DE extracellular signal-regulated kinase; melanogenesis; microphthalmia-associated transcription factor; S1P receptor; sphingosine-1-phosphate ID SPHINGOSINE 1-PHOSPHATE; MAP KINASE; CELL-PROLIFERATION; DOWN-REGULATION; ERK ACTIVATION; IN-VITRO; MITF; DIFFERENTIATION; MELANOCYTES; MELANOGENESIS AB Objectives Previously, we reported that sphingosine-1-phosphate (S1P) reduced melanin synthesis. In this study we have investigated S1P receptor-mediated extracellular signal-regulated protein kinase (ERK) activation and microphthalmia-associated transcription factor (MITF) phosphorylation. Methods To examine S1P-induced signalling pathways, electron and confocal microscopic studies, reverse transcription-polymerase chain reaction and Western blot analysis were performed. Key findings S1P phosphorylated MITF at Ser73, which may have resulted in a MITF mobility shift. Furthermore, 90 kDa ribosomal S6 kinase-1 (RSK-1) phosphorylation was observed after S1P treatment. In addition, PD98059 abrogated the S1P-induced MITF mobility shift and RSK-1 activation. In experiments with MITF mutants, it was shown that dual phosphorylation at Ser73 and Ser409 was indispensable for MITF degradation. We investigated further the actions of S1P on its specific receptors. The results showed that pertussis toxin completely abolished the hypopigmentary effects and ERK pathway activation by S1P, suggesting that S1P regulated melanogenesis via its receptor. The use of specific receptor antagonists indicated that the S1P(3) receptor was dominantly involved in S1P-induced ERK activation and hypopigmentation. Conclusions The results suggested that S1P reduced melanin synthesis via S1P(3) receptor-mediated ERK and RSK-1 activation, and subsequent MITF dual phosphorylation and degradation. C1 [Park, Seo-Hyoung; Kwon, Sun-Bang; Park, Kyoung-Chan] Seoul Natl Univ, Bundang Hosp, Dept Dermatol, Songnam 463707, Kyoungki Do, South Korea. [Kim, Dong-Seok; Jeong, Yun-Mi] Chung Ang Univ, Coll Med, Dept Biochem, Seoul 156756, South Korea. [Miller, Arlo J.; Fisher, David E.] Harvard Univ, Sch Med, Charlestown, MA USA. [Miller, Arlo J.; Fisher, David E.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Dept Dermatol, Charlestown, MA USA. RP Park, KC (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Dermatol, 300 Gumi Dong, Songnam 463707, Kyoungki Do, South Korea. EM gcpark@snu.ac.kr RI Park, Kyoung Chan/J-5474-2012 FU Ministry of Education, Science and Technology [2009-0052816]; Ministry of Health and Welfare, Republic of Korea [A050432] FX This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0052816) and by the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (grant no. A050432). NR 43 TC 6 Z9 6 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3573 J9 J PHARM PHARMACOL JI J. Pharm. Pharmacol. PD MAR PY 2011 VL 63 IS 3 BP 409 EP 416 DI 10.1111/j.2042-7158.2010.01223.x PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 726ES UT WOS:000287702500012 PM 21749389 ER PT J AU Sweetenham, JW Freedman, AS AF Sweetenham, John W. Freedman, Arnold S. TI Early initial therapy of advanced follicular lymphoma: the need for vigilance SO LEUKEMIA & LYMPHOMA LA English DT Editorial Material ID PHASE-III; FREE SURVIVAL; RITUXIMAB; FLUDARABINE; CYCLOPHOSPHAMIDE; VINCRISTINE; PREDNISONE; COMBINATION C1 [Sweetenham, John W.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA. [Freedman, Arnold S.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Sweetenham, JW (reprint author), Cleveland Clin, Taussig Canc Inst, 9500 Euclid Ave,Desk R-35, Cleveland, OH 44195 USA. EM sweetej@ccf.org NR 16 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PD MAR PY 2011 VL 52 IS 3 BP 355 EP 357 DI 10.3109/10428194.2010.551574 PG 3 WC Oncology; Hematology SC Oncology; Hematology GA 722BK UT WOS:000287404300004 PM 21323517 ER PT J AU Vela-Chavez, T Adam, P Kremer, M Bink, K Bacon, CM Menon, G Ferry, JA Fend, F Jaffe, ES Quintanilla-Martinez, L AF Vela-Chavez, Teresa Adam, Patrick Kremer, Marcus Bink, Karin Bacon, Christopher M. Menon, Geetha Ferry, Judith A. Fend, Falko Jaffe, Elaine S. Quintanilla-Martinez, Leticia TI Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus SO LEUKEMIA & LYMPHOMA LA English DT Article ID MULTIPLE-MYELOMA; PROTEIN EXPRESSION; OVEREXPRESSION; PROGRESSION; ACTIVATION; BINDING; G(1); BCL6 AB The aims of this study were to analyze the incidence and morphology of cyclin D1++ DLBCL and cases of Richter transformation (RT), and to elucidate possible molecular mechanisms of cyclin D1 overexpression. Seventy-two cases of de novo DLBCL and 12 cases of RT were included in this study. Cyclin D1 positivity was found in 10/66 (15%%) cases of unselected de novo DLBCL and in 2/11 (18%%) cases of RT. Seven independently identified cases of cyclin D1++ DLBCL, including one RT, were added to the study. Centroblastic morphology was found in 17/19 (89%%) cases of cyclin D1++, most with a post-germinal center phenotype (CD10--, BCL6++, MUM1++). No alterations in the CCND1 gene indicative for a translocation t(11;14) were identified by FISH. Analysis of the MYC locus yielded gene copy alterations in five cases and no disruption of the gene locus in any case, suggesting an alternative mechanism of cyclin D1 deregulation.= 50%), and the remission rate was 45% (final MADRS score of <= 7). Responders had significantly lower pretreatment docosahexaenoic acid levels than nonresponders did (P = 0.03). Hot flashes were present in 15 (75%) participants. Among those with hot flashes at baseline, the number of hot flashes per day improved significantly from baseline (P = 0.02) and Hot Flash Related Daily Interference Scale scores decreased significantly (P = 0.006). Conclusions: These data support further study of omega-3 fatty acids for major depressive disorder and hot flashes in women during the menopausal transition. C1 [Freeman, Marlene P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Perinatal & Reprod Psychiat Program, Boston, MA 02114 USA. [Hibbeln, Joseph R.] NIAAA, Bethesda, MD USA. [Silver, Michael; Hirschberg, April M.; Pascuillo, Erica; Economou, Nicole I.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Freeman, MP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Perinatal & Reprod Psychiat Program, 185 Cambridge St, Boston, MA 02114 USA. EM mfreeman@partners.org FU GlaxoSmithKline (GSK); Forest; Lilly; Astra-Zeneca Pharmaceuticals; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb; Forest Laboratories, Inc.; National Institute on Aging, National Institutes of Health, National Institute of Mental Health; Ortho-McNeil Janssen; Pfizer Inc. FX This study was funded by an investigator-initiated grant from GlaxoSmithKline (GSK). GSK had no input on the study implementation, data analysis, or manuscript preparation. This work was completed at Massachusetts General Hospital.; Marlene P. Freeman, MD- research support from investigator-initiated trials: Forest, GSK, and Lilly. CME support of program: Pam Lab. Stipend for medical editing: DSM Nutritionals. Speaking: none. Consulting: none. Stock: none. Hadine Joffe, MD, MSc-research support to the Perinatal and Reproductive Psychiatry Program: Bayer HealthCare Pharmaceuticals, Forest Laboratories, Inc., and GSK. Speaking/honoraria: none. Advisory/consulting: Sanofi-Aventis and Pfizer. Royalty/patent, other income: None. Lee S. Cohen, MD-research support: Astra-Zeneca Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Forest Laboratories, Inc., GSK, National Institute on Aging, National Institutes of Health, National Institute of Mental Health, Ortho-McNeil Janssen, and Pfizer Inc. Advisory/consulting: Eli Lilly & Company and Noven. Honoraria: none. Royalty/patent, other income: None. Michael Silver, Joseph Hibbeln, Amy Yule, April Hirschberg, Betty Wang, Laura Petrillo, Erica Pascuillo, Nicole Economou-nothing to disclose. NR 30 TC 19 Z9 19 U1 3 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD MAR PY 2011 VL 18 IS 3 BP 279 EP 284 DI 10.1097/gme.0b013e3181f2ea2e PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 725PT UT WOS:000287658600010 PM 21037490 ER PT J AU Haigis, KM Sweet-Cordero, A AF Haigis, Kevin M. Sweet-Cordero, Alejandro TI New insights into oncogenic stress SO NATURE GENETICS LA English DT Editorial Material ID DNA-DAMAGE RESPONSE; TUMOR SUPPRESSION; P53; APOPTOSIS; JNK AB xpression of oncogenes in otherwise normal cells often leads to the activation of anti-oncogenic pathways through a poorly understood process described as 'oncogenic stress'. A new study implicates the Jnk pathway signaling in the activation of p53 in response to both K-Ras and Neu oncogene expression. C1 [Haigis, Kevin M.] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA USA. [Haigis, Kevin M.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA USA. [Haigis, Kevin M.] Harvard Univ, Dept Pathol, Sch Med, Charlestown, MA USA. [Sweet-Cordero, Alejandro] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA. RP Haigis, KM (reprint author), Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA USA. EM khaigis@partners.org; ascor@stanford.edu NR 15 TC 16 Z9 16 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD MAR PY 2011 VL 43 IS 3 BP 177 EP 178 DI 10.1038/ng0311-177 PG 2 WC Genetics & Heredity SC Genetics & Heredity GA 726BR UT WOS:000287693800004 PM 21350495 ER PT J AU Bellot, G McClintock, MA Lin, CX Shih, WM AF Bellot, Gaetan McClintock, Mark A. Lin, Chenxiang Shih, William M. TI Recovery of intact DNA nanostructures after agarose gel-based separation SO NATURE METHODS LA English DT Letter ID NANOSCALE SHAPES; FOLDING DNA C1 [Bellot, Gaetan; McClintock, Mark A.; Lin, Chenxiang; Shih, William M.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Bellot, Gaetan; McClintock, Mark A.; Lin, Chenxiang; Shih, William M.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Lin, Chenxiang; Shih, William M.] Wyss Inst Biologically Inspired Engn Harvard, Cambridge, MA USA. RP Bellot, G (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. EM william_shih@dfci.harvard.edu RI Lin, Chenxiang/G-2303-2010; OI Lin, Chenxiang/0000-0001-7041-1946 FU NIGMS NIH HHS [1U54GM094608-01, U54 GM094608]; NIH HHS [1DP2OD004641-01, DP2 OD004641] NR 9 TC 29 Z9 30 U1 2 U2 43 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1548-7091 J9 NAT METHODS JI Nat. Methods PD MAR PY 2011 VL 8 IS 3 BP 192 EP 194 DI 10.1038/nmeth0311-192 PG 4 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 726OT UT WOS:000287734800008 PM 21358621 ER PT J AU Ruff, CT Braunwald, E AF Ruff, Christian T. Braunwald, Eugene TI The evolving epidemiology of acute coronary syndromes SO NATURE REVIEWS CARDIOLOGY LA English DT Review ID ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR RISK-FACTORS; UNITED-STATES COMMUNITIES; HEART-DISEASE MORTALITY; LONG-TERM TRENDS; ST-ELEVATION; EUROPEAN COUNTRIES; NATIONAL REGISTRY; DEVELOPING-WORLD; GLOBAL REGISTRY AB The clinical entities that comprise acute coronary syndromes (ACS)-ST-segment elevation myocardial infarction (STEMI), non-STEMI, and unstable angina-have been recognized as widespread causes of death and disability for more than a century. Seminal research in the past 50 years has led to important scientific and medical advances in our understanding of ACS. Rapid modernization of the developing world has led to a pandemic of coronary artery disease and its manifestation as ACS, with profound implications for personal, societal, and global health. Epidemiological studies have provided insight into the changing demographics of ACS, and highlighted the importance of modifiable risk factors and adherence to guideline-recommended therapy. C1 [Ruff, Christian T.; Braunwald, Eugene] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA. [Ruff, Christian T.; Braunwald, Eugene] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Ruff, CT (reprint author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, 350 Longwood Ave,1st Floor Off, Boston, MA 02115 USA. EM cruff@partners.org NR 81 TC 33 Z9 37 U1 0 U2 9 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5002 J9 NAT REV CARDIOL JI Nat. Rev. Cardiol. PD MAR PY 2011 VL 8 IS 3 BP 140 EP 147 DI 10.1038/nrcardio.2010.199 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 726OB UT WOS:000287731700005 PM 21173793 ER PT J AU Mandal, PK Blanpain, C Rossi, DJ AF Mandal, Pankaj K. Blanpain, Cedric Rossi, Derrick J. TI DNA damage response in adult stem cells: pathways and consequences SO NATURE REVIEWS MOLECULAR CELL BIOLOGY LA English DT Article ID STRAND BREAK REPAIR; HEMATOPOIETIC STEM; OXIDATIVE STRESS; INDUCED APOPTOSIS; SELF-RENEWAL; OXYGEN; P53; DIFFERENTIATION; MAINTENANCE; RESISTANCE AB In contrast to postmitotic or short-lived somatic cells, tissue-specific stem cells must persist and function throughout life to ensure tissue homeostasis and repair. The enormous functional demands and longevity of stem cells raises the possibility that stem cells might be uniquely equipped to maintain genomic integrity in ways different than somatic cells. Indeed, evidence suggests that stem cell compartments possess unique properties that combine to either limit or, in some instances, accelerate DNA damage accrual. C1 [Mandal, Pankaj K.; Rossi, Derrick J.] Childrens Hosp, Immune Dis Inst, Program Cellular & Mol Med, Boston, MA 02115 USA. [Rossi, Derrick J.] Harvard Univ, Sch Med, Stem Cell & Regenerat Biol Dept, Cambridge, MA 02138 USA. [Rossi, Derrick J.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Blanpain, Cedric] Univ Libre Bruxelles, IRIBHM, B-1070 Brussels, Belgium. RP Rossi, DJ (reprint author), Childrens Hosp, Immune Dis Inst, Program Cellular & Mol Med, 200 Longwood Ave, Boston, MA 02115 USA. EM rossi@idi.harvard.edu RI mandal, pankaj/B-4885-2016 FU European Research Council; Wallonia Region; Fondation contre le Cancer; EMBO; US National Institutes of Health; US National Institutes of Aging [AG029760-01] FX C. B. is a researcher of the Fonds National de la Recherche Scientifique and is supported by grants from the European Research Council, the Wallonia Region, Fondation contre le Cancer and the EMBO Young Investigator Programme. D.J.R. is supported by grants from the US National Institutes of Health and the US National Institutes of Aging (grant no. AG029760-01). The authors thank I. Beerman for critical comments on the manuscript. NR 49 TC 68 Z9 71 U1 2 U2 11 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-0072 J9 NAT REV MOL CELL BIO JI Nat. Rev. Mol. Cell Biol. PD MAR PY 2011 VL 12 IS 3 BP 198 EP 202 DI 10.1038/nrm3060 PG 5 WC Cell Biology SC Cell Biology GA 725NX UT WOS:000287653400006 PM 21304553 ER PT J AU Shahlaie, K Larson, PS Starr, PA AF Shahlaie, Kiarash Larson, Paul S. Starr, Philip A. TI Intraoperative Computed Tomography for Deep Brain Stimulation Surgery: Technique and Accuracy Assessment SO NEUROSURGERY LA English DT Article DE Computed tomography; Deep brain stimulation; Intraoperative imaging; Lead location; Neuronavigation ID GLOBUS-PALLIDUS INTERNUS; SUBTHALAMIC NUCLEUS; ELECTRODE PLACEMENT; PARKINSONS-DISEASE; IMPLANTATION; LOCALIZATION; MRI; CANCER; SHIFT; EXPERIENCE AB BACKGROUND: The efficacy of deep brain stimulation (DBS) is highly dependent on the accuracy of lead placement. OBJECTIVE: To describe the use of intraoperative computed tomography (iCT) to confirm lead location before surgical closure and to study the accuracy of this technique. METHODS: Fifteen patients underwent awake microelectrode-guided DBS surgery in a stereotactic frame. A portable iCT scanner (Medtronic O-arm) was positioned around the patient's head throughout the procedure and was used to confirm lead location before fixation of the lead to the skull. Images were computationally fused with preoperative magnetic resonance imaging (MRI), and lead tip coordinates with respect to the midpoint of the anterior commissure-posterior commissure line were measured. Tip coordinates were compared with those obtained from postoperative MRI. RESULTS: iCT was integrated into standard frame-based microelectrode-guided DBS surgery with a minimal increase in surgical time or complexity. Technically adequate 2-dimensional and 3-dimensional images were obtained in all cases. Head positioning and fixation techniques that allow unobstructed imaging are described. Lead tip measurements on iCT fused with preoperative MRI were statistically indistinguishable from those obtained with postoperative MRI. CONCLUSION: iCT can be easily incorporated into standard DBS surgery, replaces the need for C-arm fluoroscopy, and provides accurate intraoperative 3-dimensional confirmation of electrode tip locations relative to preoperative images and surgical plans. iCT fused to preoperative MRI may obviate the need for routine postoperative MRI in DBS surgery. Technical nuances that must be mastered for the efficient use of iCT during DBS implantation are described. C1 [Starr, Philip A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Care Ctr, San Francisco, CA USA. RP Starr, PA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 533 Parnassus Ave,Box 0445, San Francisco, CA 94143 USA. EM starrp@neurosurg.ucsf.edu NR 28 TC 35 Z9 36 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-396X J9 NEUROSURGERY JI Neurosurgery PD MAR PY 2011 VL 68 IS 3 SU 3 BP 114 EP 124 DI 10.1227/NEU.0b013e31820781bc PG 11 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 726OR UT WOS:000287734500017 PM 21206322 ER PT J AU Kang, JX AF Kang, Jing X. TI Effect of omega-3 fatty acids on life span SO NUTRITION LA English DT Editorial Material C1 [Kang, Jing X.] Massachusetts Gen Hosp, Lab Lipid Med & Technol, Charlestown, MA USA. [Kang, Jing X.] Harvard Univ, Sch Med, Charlestown, MA USA. RP Kang, JX (reprint author), Massachusetts Gen Hosp, Lab Lipid Med & Technol, Charlestown, MA USA. NR 3 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0899-9007 J9 NUTRITION JI Nutrition PD MAR PY 2011 VL 27 IS 3 BP 333 EP 333 DI 10.1016/j.nut.2010.07.011 PG 1 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 725ZF UT WOS:000287684700012 PM 20934849 ER PT J AU Riley, LE Celi, AC Onderdonk, AB Roberts, DJ Johnson, LC Tsen, LC Leffert, L Pian-Smith, MCM Heffner, LJ Haas, ST Lieberman, ES AF Riley, Laura E. Celi, Ann C. Onderdonk, Andrew B. Roberts, Drucilla J. Johnson, Lise C. Tsen, Lawrence C. Leffert, Lisa Pian-Smith, May C. M. Heffner, Linda J. Haas, Susan T. Lieberman, Ellice S. TI Association of Epidural-Related Fever and Noninfectious Inflammation in Term Labor SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID MATERNAL TEMPERATURE REGULATION; INTRAPARTUM FEVER; MEPERIDINE ANALGESIA; CONTROLLED-TRIAL; INTERLEUKIN-8; HYPERTHERMIA; INFECTION; DELIVERY; SERUM; CHORIOAMNIONITIS AB OBJECTIVE: To investigate the role of infection and noninfectious inflammation in epidural analgesia-related fever. METHODS: This was an observational analysis of placental cultures and serum admission and postpartum cytokine levels obtained from 200 women at low risk recruited during the prenatal period. RESULTS: Women receiving labor epidural analgesia had fever develop more frequently (22.7% compared with 6% no epidural; P=.009) but were not more likely to have placental infection (4.7% epidural, 4.0% no epidural; P>.99). Infection was similar regardless of maternal fever (5.4% febrile, 4.3% afebrile; P=.7). Median admission interleukin (IL)-6 levels did not differ according to later epidural (3.2 pg/mL compared with 1.6 pg/mL no epidural; P=.2), but admission IL-6 levels greater than 11 pg/mL were associated with an increase in fever among epidural users (36.4% compared with 15.7% for 11 pg/mL or less; P=.008). At delivery, both febrile and afebrile women receiving epidural had higher IL-6 levels than women not receiving analgesia. CONCLUSION: Epidural-related fever is rarely attributable to infection but is associated with an inflammatory state. (Obstet Gynecol 2011;117:588-95) DOI:10.1097/AOG.0b013e31820b0503 C1 [Riley, Laura E.] Harvard Univ, Massachusetts Gen Hosp, Dept Obstet & Gynecol, Sch Med, Boston, MA 02114 USA. Brigham & Womens Hosp, Dept Obstet, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Gynecol, Boston, MA 02115 USA. Harvard Univ, Dept Med, Clin Microbiol Lab, Sch Med, Boston, MA 02114 USA. Harvard Univ, Dept Obstet & Gynecol, Brigham & Womens Hosp, Sch Med, Boston, MA 02114 USA. Harvard Univ, Dept Pathol, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. Brigham & Womens Hosp, Dept Newborn Med, Boston, MA 02115 USA. Harvard Univ, Dept Anesthesiol Perioperat & Pain Med, Brigham & Womens Hosp, Sch Med, Boston, MA 02114 USA. Harvard Univ, Dept Anesthesia Crit Care & Pain Med, Div Obstetr Anesthesia, Massachusetts Gen Hosp,Med Sch, Boston, MA 02114 USA. Boston Univ, Dept Obstet & Gynecol, Boston Med Ctr, Sch Med, Boston, MA 02215 USA. RP Riley, LE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Obstet & Gynecol, Sch Med, 55 Fruit St, Boston, MA 02114 USA. EM lriley@partners.org OI Tsen, Lawrence/0000-0002-1964-723X FU Maternal Child Health Bureau, Health Resources and Services Administration [R40 MC00248]; NHLBI [RO1HL081663] FX Funding provided by the Maternal Child Health Bureau, Health Resources and Services Administration (R40 MC00248). Also supported by an NHLBI reentry award RO1HL081663 (ACC). NR 32 TC 34 Z9 36 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD MAR PY 2011 VL 117 IS 3 BP 588 EP 595 DI 10.1097/AOG.0b013e31820b0503 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 725MR UT WOS:000287649400011 PM 21343762 ER PT J AU Saman, M Etebari, P Pakdaman, MN Urken, ML AF Saman, M. Etebari, P. Pakdaman, M. N. Urken, M. L. TI Anatomic relationship between the spinal accessory nerve and the jugular vein: a cadaveric study SO SURGICAL AND RADIOLOGIC ANATOMY LA English DT Article DE IJV; San; Neck dissection; Accessory nerve; Jugular foramen; Jugular vein; Neck anatomy; Neck surgery ID MICROSURGICAL ANATOMY; SURGICAL IMPLICATIONS; HIGH DUPLICATION; FORAMEN; NECK AB Previous studies of the course of the Spinal Accessory Nerve (SAN) and its relationship to the Internal Jugular Vein (IJV) have yielded conflicting results because of the small number of anatomic specimens and anatomic variability. Classic teaching in Head and Neck Surgery is that the SAN almost always crosses the IJV anteriorly in the upper neck. However, because of the morbidity associated with the injury to the IJV during nerve dissection, it is imperative that the surgeon is wary of the posteriorly crossing nerve. In order to further elucidate the anatomy of the SAN in relation to its surrounding structures, we have studied its anatomy at various points. Specifically, we have aimed to: (1) characterize the anatomic relationship of the SAN to the IJV at three major points: (a) within jugular foramen (JF), (b) at base of skull (BoS), and (c) at the posterior belly of the digastric muscle, (2) record the distance travelled by the SAN from the BoS to its medial to lateral crossing of the IJV, and (3) characterize the anatomy of the JF by with respect to greatest length, width, and partitioning. Sixty-one cadavers, 27 male, and 34 female (84 necks) were dissected and the course of the SAN was followed from the BoS to the crossing the IJV. Data recorded included the relationship of the SAN to the IJV (a) within the JF from an intracranial view, (b) exiting the JF at BoS, and (c) in the neck at the level of the posterior belly of the digastric muscle where anterior versus posterior positioning of the crossing nerve with respect to the IJV was noted. The distance travelled by the SAN from BoS until crossing the IJV, the length and width of the JF within the cranial fossa, and JF partitioning were also recorded. Within the JF, the SAN travelled anteromedial to the IJV in 73/84 (87%) necks. While exiting the JF, the SAN was found lateral to the IJV in 56/84 (67%) of necks. In the anterior triangle of the neck the SAN crossed the IJV anteriorly in 67/84 (80%) necks, posteriorly in 16/84 (19%) and in the one case of IJV bifurcation, the nerve pierced the vein. The average distance travelled by SAN from BoS to crossing the IJV was 2.38 cm. The average length and width of the JF were, respectively, 1.42 and 0.78 cm, and the IJV was partitioned in 36/84 necks, with 3 of the partitions being bony and the remainder fibrinous. No relationship was found between JF dimensions/partitioning and the anatomic relationship of the structures exiting it. In this study, the dimensions and relationship of the IJV and SAN are described in detail. This relationship is specifically noted at three major points, namely within the cranium, at the BoS, and in the anterior neck triangle. In its medial to lateral path in the anterior neck triangle, the SAN crossed the IJV anteriorly in a majority of the cases. However, a posteriorly crossing nerve was not uncommon. These findings support results in previous literature in that the SAN is located anterior to the IJV in the majority of the cases, however, it is imperative for the surgeon to be mindful to the anatomic variability and possible posterior crossing of the IJV by the SAN in the neck to avoid injury to the IJV during the dissection of the nerve. The distance travelled by the nerve prior to crossing the IJV was measured and can be used as a helpful tool for the surgeon in finding the nerve during dissections. We were not able to demonstrate a correlation between the relationship of the SAN and IJV at other recorded points and their crossing relationship. Similarly, no correlation was found between the anatomy of JF and the relationship of the SAN and IJV at any point. C1 [Saman, M.] New York Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, New York, NY 10003 USA. [Pakdaman, M. N.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. [Etebari, P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Dev Dent, San Antonio, TX 78229 USA. [Saman, M.; Urken, M. L.] Beth Israel Deaconess Med Ctr, Dept Otolaryngol Head & Neck Surg, New York, NY 10003 USA. RP Saman, M (reprint author), New York Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, New York, NY 10003 USA. EM m.saman@live.com NR 21 TC 10 Z9 10 U1 0 U2 0 PU SPRINGER FRANCE PI PARIS PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE SN 1279-8517 J9 SURG RADIOL ANAT JI Surg. Radiol. Anat. PD MAR PY 2011 VL 33 IS 2 BP 175 EP 179 DI 10.1007/s00276-010-0737-y PG 5 WC Anatomy & Morphology; Radiology, Nuclear Medicine & Medical Imaging; Surgery SC Anatomy & Morphology; Radiology, Nuclear Medicine & Medical Imaging; Surgery GA 724QT UT WOS:000287592000014 PM 20959982 ER PT J AU Bokhari, MB Patel, CB Ramos-Valadez, DI Ragupathi, M Haas, EM AF Bokhari, Malak B. Patel, Chirag B. Ramos-Valadez, Diego I. Ragupathi, Madhu Haas, Eric M. TI Learning curve for robotic-assisted laparoscopic colorectal surgery SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES LA English DT Article DE Cumulative sum analysis; Learning curve; Rectosigmoid; Robotic-assisted laparoscopic surgery ID CANCER; CUSUM AB Robotic-assisted laparoscopic surgery (RALS) is evolving as an important surgical approach in the field of colorectal surgery. We aimed to evaluate the learning curve for RALS procedures involving resections of the rectum and rectosigmoid. A series of 50 consecutive RALS procedures were performed between August 2008 and September 2009. Data were entered into a retrospective database and later abstracted for analysis. The surgical procedures included abdominoperineal resection (APR), anterior rectosigmoidectomy (AR), low anterior resection (LAR), and rectopexy (RP). Demographic data and intraoperative parameters including docking time (DT), surgeon console time (SCT), and total operative time (OT) were analyzed. The learning curve was evaluated using the cumulative sum (CUSUM) method. The procedures performed for 50 patients (54% male) included 25 AR (50%), 15 LAR (30%), 6 APR (12%), and 4 RP (8%). The mean age of the patients was 54.4 years, the mean BMI was 27.8 kg/m(2), and the median American Society of Anesthesiologists (ASA) classification was 2. The series had a mean DT of 14 min, a mean SCT of 115.1 min, and a mean OT of 246.1 min. The DT and SCT accounted for 6.3% and 46.8% of the OT, respectively. The SCT learning curve was analyzed. The CUSUM(SCT) learning curve was best modeled as a parabola, with equation CUSUM(SCT) in minutes equal to 0.73 x case number(2) - 31.54 x case number - 107.72 (R = 0.93). The learning curve consisted of three unique phases: phase 1 (the initial 15 cases), phase 2 (the middle 10 cases), and phase 3 (the subsequent cases). Phase 1 represented the initial learning curve, which spanned 15 cases. The phase 2 plateau represented increased competence with the robotic technology. Phase 3 was achieved after 25 cases and represented the mastery phase in which more challenging cases were managed. The three phases identified with CUSUM analysis of surgeon console time represented characteristic stages of the learning curve for robotic colorectal procedures. The data suggest that the learning phase was achieved after 15 to 25 cases. C1 [Haas, Eric M.] Univ Texas Houston, Div Minimally Invas Colon & Rectal Surg, Dept Surg, Colorectal Surg Associates Ltd LLP,Med Sch Housto, Houston, TX 77054 USA. [Bokhari, Malak B.] VA Pittsburgh Healthcare Syst, Dept Surg, Pittsburgh, PA 15240 USA. RP Haas, EM (reprint author), Univ Texas Houston, Div Minimally Invas Colon & Rectal Surg, Dept Surg, Colorectal Surg Associates Ltd LLP,Med Sch Housto, 7900 Fannin St,Suite 2700, Houston, TX 77054 USA. EM ehaasmd@houstoncolon.com OI Ragupathi, Madhu/0000-0002-1371-2926 NR 14 TC 104 Z9 108 U1 2 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0930-2794 J9 SURG ENDOSC JI Surg. Endosc. PD MAR PY 2011 VL 25 IS 3 BP 855 EP 860 DI 10.1007/s00464-010-1281-x PG 6 WC Surgery SC Surgery GA 726TU UT WOS:000287749900027 PM 20734081 ER PT J AU Turner, BG Cizginer, S Kim, MC Mino-Kenudson, M Ducharme, RW Surti, VC Sylla, P Brugge, WR Rattner, DW Gee, DW AF Turner, Brian G. Cizginer, Sevdenur Kim, Min-Chan Mino-Kenudson, Mari Ducharme, Richard W. Surti, Vihar C. Sylla, Patricia Brugge, William R. Rattner, David W. Gee, Denise W. TI Stent placement provides safe esophageal closure in thoracic NOTESTM procedures SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES LA English DT Article; Proceedings Paper CT 12th World Congress of Endoscopic Surgery (WCES) CY APR 14-17, 2010 CL Natl Harbor, MD DE NOTES; Natural orifice surgery; Transesophageal; Endoscopic; Thoracic; Esophageal stent ID ORIFICE TRANSESOPHAGEAL MEDIASTINOSCOPY; ENDOSCOPIC SURGERY NOTES; HERNIA REPAIR; MANAGEMENT; THORACOSCOPY; PERFORATIONS; ACCESS; LEAKS AB Safe esophageal closure remains a challenge in transesophageal Natural Orifice Transluminal Endoscopic Surgery (NOTES). Previously described methods, such as suturing devices, clips, or submucosal tunneling, all have weaknesses. In this survival animal series, we demonstrate safe esophageal closure with a prototype retrievable, antimigration stent. Nine Yorkshire swine underwent thoracic NOTES procedures. A double-channel gastroscope equipped with a mucosectomy device was used to create an esophageal mucosal defect. A 5-cm submucosal tunnel was created and the muscular esophageal wall was incised with a needle-knife. Mediastinoscopy and thoracoscopy were performed in all swine; lymphadenectomy was performed in seven swine. A prototype small intestinal submucosal (SurgiSIS(A (R))) covered stent was deployed over the mucosectomy site and tunnel. Three versions of the prototype stent were developed. Prenecropsy endoscopy confirmed stent location and permitted stent retrieval. Explanted esophagi were sent to pathology. Esophageal stenting was successful in all animals. Stent placement took 15.8 +/- A 4.8 minuted and no stent migration occurred. Prenecropsy endoscopy revealed proximal ingrowth of esophageal mucosa and erosion with Stent A. Mucosal inflammation and erosion was observed proximally with Stent B. No esophageal erosion or pressure damage from proximal radial forces was seen with Stent C. On necropsy, swine 5 had a 0.5-cm periesophageal abscess. Histology revealed a localized inflammatory lesion at the esophageal exit site in swine 1, 3, and 9. The mucosectomy site was partially healed in three swine and poorly healed in six. All swine thrived clinically, except for a brief period of mild lethargy in swine 9 who improved with short-term antibiotic therapy. The submucosal tunnels were completely healed and no esophageal bleeding or stricture formation was observed. All swine survived 13.8 +/- A 0.4 days and gained weight in the postoperative period. Esophageal stenting provides safe closure for NOTES thoracic procedures but may impede healing of the mucosectomy site. C1 [Sylla, Patricia; Rattner, David W.; Gee, Denise W.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Turner, Brian G.; Cizginer, Sevdenur; Brugge, William R.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Kim, Min-Chan] Dong A Univ, Dept Surg, Coll Med, Minimally Invas & Robot Ctr, Pusan 602715, South Korea. [Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Ducharme, Richard W.; Surti, Vihar C.] Cook Med Inc, Winston Salem, NC 27105 USA. RP Gee, DW (reprint author), Massachusetts Gen Hosp, Dept Surg, 15 Parkman St,WACC 460, Boston, MA 02114 USA. EM dgee@partners.org FU NIBIB NIH HHS [R01 EB009362, R01 EB005807, R01 EB009362-01A2, R01 EB009362-02, R01 EB010037] NR 17 TC 5 Z9 7 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0930-2794 J9 SURG ENDOSC JI Surg. Endosc. PD MAR PY 2011 VL 25 IS 3 BP 913 EP 918 DI 10.1007/s00464-010-1297-2 PG 6 WC Surgery SC Surgery GA 726TU UT WOS:000287749900037 PM 20820811 ER PT J AU Esakoff, TF Sparks, TN Kaimal, AJ Kim, LH Feldstein, VA Goldstein, RB Cheng, YW Caughey, AB AF Esakoff, T. F. Sparks, T. N. Kaimal, A. J. Kim, L. H. Feldstein, V. A. Goldstein, R. B. Cheng, Y. W. Caughey, A. B. TI Diagnosis and morbidity of placenta accreta SO ULTRASOUND IN OBSTETRICS & GYNECOLOGY LA English DT Article DE placenta accreta; placenta previa; ultrasound ID PRIOR CESAREAN-SECTION; PREVIA-ACCRETA; COLOR DOPPLER; CONSERVATIVE MANAGEMENT; PRENATAL-DIAGNOSIS; RISK-FACTORS; ULTRASOUND AB Objective To examine the diagnostic precision of ultrasound examination for placenta accreta in women with placenta previa and to compare the morbidity associated with accreta to that of previa alone. Methods This was a retrospective cohort study of all women with previa with/without accreta examined at the University of California, San Francisco (UCSF) between 2002 and 2008. The sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) of ultrasound examination for the diagnosis of accreta were calculated and compared with results from similar studies in the literature. Univariable analysis was used to compare clinical outcomes. Results The PPV of an ultrasound diagnosis of accreta was 68% and NPV was 98%. Ultrasound had a sensitivity of 89.5%. Compared with previa alone, accreta had an odds ratio (OR) of 89.6 (95% CI, 19.44-412.95) for estimated blood loss > 2 L, an OR of 29.6 (95% CI, 8.20-107.00) for transfusion and an OR of 8.52 (95% CI, 2.58-28.11) for length of hospital stay > 4 days. Conclusion Placenta accreta is associated with greater morbidity than is placenta previa alone. Ultrasound examination is a good diagnostic test for accreta in women with placenta previa. This is consistent with most other studies in the literature. Copyright (C) 2011 ISUOG. Published by John Wiley & Sons, Ltd. C1 [Esakoff, T. F.; Kim, L. H.] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Los Angeles, CA 90048 USA. [Sparks, T. N.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA. [Kaimal, A. J.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Kim, L. H.; Cheng, Y. W.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Feldstein, V. A.; Goldstein, R. B.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. [Caughey, A. B.] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA. RP Esakoff, TF (reprint author), Cedars Sinai Med Ctr, Dept Obstet & Gynecol, 8635 W 3rd St,Suite 160, Los Angeles, CA 90048 USA. EM esakofft@gmail.com FU Robert Wood Johnson Foundation [RWJF-61535] FX This study was presented as the Frank Lynch Memorial Essay at the 2009 Pacific Coast Obstetrical and Gynecological Society Meeting. A.B.C. is supported by the Robert Wood Johnson Foundation as a Physician Faculty Scholar, Grant # RWJF-61535. NR 23 TC 37 Z9 45 U1 2 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0960-7692 J9 ULTRASOUND OBST GYN JI Ultrasound Obstet. Gynecol. PD MAR PY 2011 VL 37 IS 3 BP 324 EP 327 DI 10.1002/uog.8827 PG 4 WC Acoustics; Obstetrics & Gynecology; Radiology, Nuclear Medicine & Medical Imaging SC Acoustics; Obstetrics & Gynecology; Radiology, Nuclear Medicine & Medical Imaging GA 724WH UT WOS:000287606600012 PM 20812377 ER PT J AU Schindler, G Capper, D Meyer, J Janzarik, W Omran, H Herold-Mende, C Schmieder, K Wesseling, P Mawrin, C Hasselblatt, M Louis, DN Korshunov, A Pfister, S Hartmann, C Paulus, W Reifenberger, G von Deimling, A AF Schindler, Genevieve Capper, David Meyer, Jochen Janzarik, Wibke Omran, Heymut Herold-Mende, Christel Schmieder, Kirsten Wesseling, Pieter Mawrin, Christian Hasselblatt, Martin Louis, David N. Korshunov, Andrey Pfister, Stefan Hartmann, Christian Paulus, Werner Reifenberger, Guido von Deimling, Andreas TI Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma SO ACTA NEUROPATHOLOGICA LA English DT Article DE BRAF; V600E mutation; Brain tumor; Pleomorphic xanthoastrocytoma; Ganglioglioma ID ATYPICAL TERATOID/RHABDOID TUMOR; B-RAF GENE; PATHWAY ACTIVATION; MAPK PATHWAY; COMPONENT; DUPLICATION; EXPRESSION; GLIOMAS; CANCER; INHIBITOR AB Missense mutations of the V600E type constitute the vast majority of tumor-associated somatic alterations in the v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) gene. Initially described in melanoma, colon and papillary thyroid carcinoma, these alterations have also been observed in primary nervous system tumors albeit at a low frequency. We analyzed exon 15 of BRAF spanning the V600 locus by direct sequencing in 1,320 adult and pediatric tumors of the nervous system including various types of glial, embryonal, neuronal and glioneuronal, meningeal, adenohypophyseal/sellar, and peripheral nervous system tumors. A total of 96 BRAF mutations were detected; 93 of the V600E type and 3 cases with a three base pair insertion between codons 599 and 600. The highest frequencies of BRAF (V600E) mutations were found in WHO grade II pleomorphic xanthoastrocytomas (42/64; 66%) and pleomorphic xanthoastrocytomas with anaplasia (15/23; 65%), as well as WHO grade I gangliogliomas (14/77; 18%), WHO grade III anaplastic gangliogliomas (3/6) and pilocytic astrocytomas (9/97; 9%). In pilocytic astrocytomas BRAF (V600E) mutation was strongly associated with extra-cerebellar location (p = 0.009) and was most frequent in diencephalic tumors (4/12; 33%). Glioblastomas and other gliomas were characterized by a low frequency or absence of mutations. No mutations were detected in non-glial tumors, including embryonal tumors, meningiomas, nerve sheath tumors and pituitary adenomas. The high mutation frequencies in pleomorphic xanthoastrocytomas, gangliogliomas and extra-cerebellar pilocytic astrocytomas implicate BRAF (V600E) mutation as a valuable diagnostic marker for these rare tumor entities. Future clinical trials should address whether BRAF (V600E) mutant brain tumor patients will benefit from BRAF (V600E)-directed targeted therapies. C1 [Capper, David; Hartmann, Christian; von Deimling, Andreas] Univ Heidelberg, Inst Pathol, Dept Neuropathol, D-69120 Heidelberg, Germany. [Capper, David; Meyer, Jochen; Korshunov, Andrey; Hartmann, Christian; von Deimling, Andreas] German Canc Res Ctr, Clin Cooperat Unit Neuropathol G380, D-6900 Heidelberg, Germany. [Schindler, Genevieve; Schmieder, Kirsten] Ruprecht Karls Univ Heidelberg, Dept Neurosurg, Fac Med, Mannheim, Germany. [Herold-Mende, Christel] Univ Heidelberg, Div Neurosurg Res, Dept Neurosurg, D-69120 Heidelberg, Germany. [Wesseling, Pieter] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NCMLS, NL-6525 ED Nijmegen, Netherlands. [Mawrin, Christian] Otto VonGuericke Univ Magdegurg, Dept Neuropathol, D-39016 Magdeburg, Germany. [Hasselblatt, Martin; Paulus, Werner] Univ Hosp Munster, Inst Neuropathol, Munster, Germany. [Louis, David N.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Louis, David N.] Harvard Univ, Sch Med, Boston, MA USA. [Pfister, Stefan] German Canc Res Ctr, Div Mol Genet, D-6900 Heidelberg, Germany. [Pfister, Stefan] Univ Heidelberg Hosp, Heidelberg, Germany. [Reifenberger, Guido] Univ Dusseldorf, Dept Neuropathol, Dusseldorf, Germany. RP von Deimling, A (reprint author), Univ Heidelberg, Inst Pathol, Dept Neuropathol, Neuenheimer Feld 220-221, D-69120 Heidelberg, Germany. EM andreas.vondeimling@med.uni-heidelberg.de RI Capper, David/I-8500-2014; von Deimling, Andreas/F-7774-2013; Wesseling, P./H-8114-2014; Pfister, Stefan/F-6860-2013; Hartmann, Christian/D-1882-2010; OI von Deimling, Andreas/0000-0002-5863-540X; Wesseling, P./0000-0001-5453-5201; Pfister, Stefan/0000-0002-5447-5322; Hasselblatt, Martin/0000-0003-2707-8484 FU Bundesministerium fur Bildung und Forschung [BMBF-01ES0730, 01GS0883] FX We would like to thank Kerstin Lindenberg and Britta Friedensdorf for excellent technical assistance. We thank the tissuebank of the National Center of Tumor Diseases Heidelberg for supplying us with tumor material. This work was supported by the Bundesministerium fur Bildung und Forschung (BMBF-01ES0730 and 01GS0883). NR 40 TC 328 Z9 335 U1 1 U2 22 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-6322 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD MAR PY 2011 VL 121 IS 3 BP 397 EP 405 DI 10.1007/s00401-011-0802-6 PG 9 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 720YG UT WOS:000287318000009 PM 21274720 ER PT J AU Forquer, MR Hashimoto, JG Roberts, ML Wiren, KM AF Forquer, Melissa R. Hashimoto, Joel G. Roberts, Melissa L. Wiren, Kristine M. TI Elevated testosterone in females reveals a robust sex difference in altered androgen levels during chronic alcohol withdrawal SO ALCOHOL LA English DT Article DE Ethanol; Androgen; Estrogen; Withdrawal; Sexually dimorphic; Abstinence ID PITUITARY-ADRENAL AXIS; SEIZURE-RESISTANT MICE; ETHANOL WITHDRAWAL; POSTMENOPAUSAL WOMEN; REPRODUCTIVE FUNCTION; INDUCED HYPOGONADISM; PREMENOPAUSAL WOMEN; INDUCED CONVULSIONS; GENDER-DIFFERENCES; GONADAL AXIS AB The endocrine disruption associated with alcohol (ethanol) abuse in both males and females is widely recognized. Ethanol intoxication and withdrawal in males results in significant reductions in androgen levels. Less is known about female alcoholics, and because the changes in testosterone concentrations remain controversial, we systematically characterized changes in sex steroids after chronic ethanol exposure and withdrawal in both sexes. Testosterone and 17 beta-estradiol concentrations were determined during chronic high intoxication, over a withdrawal time course, and following a period of abstinence using a genetic model of withdrawal vulnerability, the Withdrawal Seizure-Resistant (WSR) and -Prone (WSP) selected lines. In males, testosterone concentrations were significantly lower in intoxicated WSP mice after chronic ethanol exposure, and were dramatically and transiently reduced during the withdrawal period in both WSR and WSP lines. In contrast, testosterone levels were increased in intoxicated WSP females and in both WSR and WSP mice during withdrawal. Chronic ethanol exposure disrupted normal estrous cycling in WSP mice, associated with hyperandrogenemia while intoxicated. In abstinence, elevated testosterone was observed in both sexes but only in WSR mice. Estrogen levels were modestly reduced during withdrawal in both WSR and WSP lines, predominantly in males. These findings identify a mechanism based on altered androgen signaling that likely contributes to sex-specific responses during withdrawal. However, only WSR mice showed similar elevations in androgen long after withdrawal in both sexes, suggesting that genotype is an important determinant of steroid responses after abstinence. Increased androgen signaling in females as a consequence of chronic ethanol exposure may play an important and relatively uncharacterized role in sexually dimorphic responses to alcohol abuse. Published by Elsevier Inc. C1 [Forquer, Melissa R.; Hashimoto, Joel G.; Roberts, Melissa L.; Wiren, Kristine M.] Portland VA Med Ctr, Res Serv P3 R&D39, Portland, OR 97239 USA. [Hashimoto, Joel G.; Wiren, Kristine M.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. RP Wiren, KM (reprint author), Portland VA Med Ctr, Res Serv P3 R&D39, 3710 SW Vet Hosp Rd, Portland, OR 97239 USA. EM wirenk@ohsu.edu OI Wiren, Kristine/0000-0002-6159-4450 FU Department of Veterans Affairs; National Institute of Alcoholism and Alcohol Abuse [R01 AA013194] FX The authors would like to thank Dr. Deborah Finn for advice on alcohol exposure paradigms and careful reading of the article. They also thank Drs. John Crabbe and Pamela Metten for providing the WSP and WSR mice and help with the chamber studies. This publication was made possible by grants from the Department of Veterans Affairs Merit Review program (K. M. W.) and the National Institute of Alcoholism and Alcohol Abuse R01 AA013194 (K. M. W.). All work was performed in facilities provided by the Department of Veterans Affairs. NR 68 TC 9 Z9 9 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-8329 J9 ALCOHOL JI Alcohol PD MAR PY 2011 VL 45 IS 2 BP 161 EP 171 DI 10.1016/j.alcohol.2010.08.013 PG 11 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA 722GZ UT WOS:000287421900007 PM 20843636 ER PT J AU Pereira, ACP McQuillin, A Puri, V Anjorin, A Bass, N Kandaswamy, R Lawrence, J Curtis, D Sklar, P Purcell, SM Gurling, HMD AF Pereira, Ana C. Parente McQuillin, Andrew Puri, Vinay Anjorin, Adebayo Bass, Nicholas Kandaswamy, Radhika Lawrence, Jacob Curtis, David Sklar, Pamela Purcell, Shaun M. Gurling, Hugh M. D. TI Genetic Association and Sequencing of the Insulin-Like Growth Factor 1 Gene in Bipolar Affective Disorder SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE insulin-like growth factor 1; bipolar disorder; association studies; GWAS; chromosome 12 ID SINGLE NUCLEOTIDE POLYMORPHISMS; CHROMOSOME 12Q24.31 REGION; FACTOR-I GENE; IGF-I; HIPPOCAMPAL NEUROGENESIS; DEPRESSIVE-DISORDERS; SUSCEPTIBILITY LOCUS; SIGNIFICANT LINKAGE; MAJOR DEPRESSION; RAT HIPPOCAMPUS AB Insulin-like growth factor 1 (IGF1) has been shown to have an important role in brain development and function. Studies of IGF1 administration in rodents have shown that it has an anxiolytic and antidepressant effect. A genome-wide association study (GWAS) of the first University College London (UCL) cohort of 506 bipolar affective disorder subjects and 510 controls was carried out. The exons and flanking regions of IGF1 were resequenced, any new polymorphisms found were genotyped in an enlarged UCL sample of 937 cases and 941 controls. GWAS data gave good evidence of allelic and haplotypic association between multiple IGF1 SNP's and bipolar disorder (BD). New polymorphisms were found by resequencing IGF1 region. Data from GWAS and the new markers showed that twelve out of 43 SNPs showed association with BD with the four most significant SNP shaving values of 3.7 x 10(-5), 8.4 x 10(-4), 2.6 x 10(-4), and 2.5 x 10(-4). A 5' promoter microsatellite polymorphism previously correlated with plasma lipoprotein concentration was also associated with BD (P = 0.013). Haplotypic association confirmed association with BD with significance values similar to the single marker SNP values. The marker rs12426318 has also been found to be associated with BD in a second sample. A test of gene wide significance with permutation testing for all markers genotyped at IGF1 was also significant. These data implicate IGF1 as a candidate gene to cause genetic susceptibility to BD. (C) 2011 Wiley-Liss, Inc. C1 [Pereira, Ana C. Parente; McQuillin, Andrew; Puri, Vinay; Anjorin, Adebayo; Bass, Nicholas; Kandaswamy, Radhika; Lawrence, Jacob; Gurling, Hugh M. D.] UCL, Mol Psychiat Lab, Dept Mental Hlth Sci, Windeyer Inst Med Sci, London W1T 4JF, England. [Curtis, David] Univ London, Ctr Psychiat, Barts & London Sch Med & Dent, London, England. [Sklar, Pamela; Purcell, Shaun M.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Sklar, Pamela; Purcell, Shaun M.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Sklar, Pamela; Purcell, Shaun M.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Sklar, Pamela; Purcell, Shaun M.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Sklar, Pamela; Purcell, Shaun M.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Sklar, Pamela; Purcell, Shaun M.] Broad Inst Harvard & MIT, Cambridge, MA USA. RP Gurling, HMD (reprint author), UCL, Mol Psychiat Lab, Res Dept Mental Hlth Sci, Med Sch,Windeyer Inst Med Sci, 46 Cleveland St, London W1T 4JF, England. EM h.gurling@ucl.ac.uk RI Gurling, Hugh/A-5029-2010; McQuillin, Andrew/C-1623-2008 OI McQuillin, Andrew/0000-0003-1567-2240 FU UK Medical Research Council [G9623693N, G0500791]; Stanley Foundation; Stanley Center for Psychiatric Research; Fundacao Para a Ciencia e Tecnologia (FCT); Stanley Psychiatric Research Center at the Broad Institute, Boston USA FX Grant sponsor: UK Medical Research Council; Grant number: G9623693N, G0500791; Grant sponsor: Stanley Foundation and The Stanley Center for Psychiatric Research; Grant sponsor: Fundacao Para a Ciencia e Tecnologia (FCT).; The UCL clinical and control samples were collected with the support from the MDF the Bipolar Organization (formerly the UK Manic Depression Fellowship), the Neuroscience Research Charitable Trust, the Central London NHS Blood Transfusion Service, the Camden and Islington NHS Foundation Trust and by a research lectureship from the Priory Hospitals. Genetic analysis of the UCL cohort has been supported by UK Medical Research Council project grants G9623693N and G0500791. The Stanley Foundation and the Stanley Psychiatric Research Center at the Broad Institute, Boston USA, funded the genome-wide association genotyping. Ana Pereira's PhD research was supported by Fundacao Para a Ciencia e Tecnologia (FCT), a governmental foundation from Portugal. NR 66 TC 15 Z9 15 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4841 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD MAR PY 2011 VL 156B IS 2 BP 177 EP 187 DI 10.1002/ajmg.b.31153 PG 11 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 718VQ UT WOS:000287154900007 PM 21302346 ER PT J AU Saetre, P Vares, M Werge, T Andreassen, OA Arinami, T Ishiguro, H Nanko, S Tan, EC Han, DH Roffman, JL Muntjewerff, JW Jagodzinski, PP Kempisty, B Hauser, J Vilella, E Betcheva, E Nakamura, Y Regland, B Agartz, I Hall, H Terenius, L Jonsson, EG AF Saetre, Peter Vares, Maria Werge, Thomas Andreassen, Ole A. Arinami, Tadao Ishiguro, Hiroki Nanko, Shinichiro Tan, Ene Choo Han, Doug Hyun Roffman, Joshua L. Muntjewerff, Jan-Willem Jagodzinski, Pawel P. Kempisty, Bartosz Hauser, Joanna Vilella, Elisabet Betcheva, Elitza Nakamura, Yusuke Regland, Bjorn Agartz, Ingrid Hall, Hakan Terenius, Lars Jonsson, Erik G. TI Methylenetetrahydrofolate Reductase (MTHFR) C677T and A1298C Polymorphisms and Age of Onset in Schizophrenia: A Combined Analysis of Independent Samples SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE methylenetetrahydrofolate reductase gene (MTHFR); schizophrenia; age of onset ID GENETIC POLYMORPHISMS; PLASMA HOMOCYSTEINE; BIPOLAR-DISORDER; NO ASSOCIATION; RISK-FACTOR; EXECUTIVE FUNCTION; VASCULAR-DISEASE; COMMON VARIANTS; CANDIDATE GENES; ENZYME-ACTIVITY AB Methylenetetrahydrofolate reductase (MTHFR) is involved in the one-carbon cycle, which is of importance for nucleotide synthesis and methylation of DNA, membranes, proteins and lipids. The MTHFR gene includes two common polymorphisms (rs1801133 or C677T; rs1801131 or A1298C) which both alter enzyme activity. The T-allele of the C677T polymorphism has recently been associated with earlier age at onset of schizophrenia. In the present study we examined the association between the MTHFR C677T and A1298C polymorphisms and age at onset of schizophrenia in twelve samples consisting of 3,213 unrelated schizophrenia patients, including the original Scandinavian sample. There was no consistent relationship between MTHFR C677T, A1298C or combined 677T/1298C carriers and age of onset in schizophrenia when the results of each study were combined using meta-analysis. The present results suggest that the investigated MTHFR polymorphisms do not influence age of onset in schizophrenia. (C) 2011 Wiley-Liss, Inc. C1 [Saetre, Peter; Vares, Maria; Hall, Hakan; Terenius, Lars; Jonsson, Erik G.] Karolinska Hosp & Inst, Dept Clin Neurosci, HUBIN Project, SE-17176 Stockholm, Sweden. [Werge, Thomas] Copenhagen Univ Hosp, Res Inst Biol Psychiat, Mental Hlth Ctr Sct Hans, Roskilde, Denmark. [Andreassen, Ole A.; Agartz, Ingrid] Univ Oslo, Inst Psychiat, Oslo, Norway. [Andreassen, Ole A.] Oslo Univ Hosp, Dept Psychiat, Oslo, Norway. [Arinami, Tadao; Ishiguro, Hiroki] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Med Genet, Tsukuba, Ibaraki, Japan. [Nanko, Shinichiro] Teikyo Univ, Sch Med, Dept Psychiat, Tokyo 173, Japan. [Tan, Ene Choo] KK Womens & Childrens Hosp, KK Res Ctr, Singapore, Singapore. [Tan, Ene Choo] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Psychol Med, Singapore 117595, Singapore. [Han, Doug Hyun] Chung Ang Univ Hosp, Dept Psychiat, Seoul, South Korea. [Roffman, Joshua L.] Massachusetts Gen Hosp, Dept Psychiat, Schizophrenia Res Program, Boston, MA 02114 USA. [Roffman, Joshua L.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Muntjewerff, Jan-Willem] Radboud Univ Nijmegen Med Ctr, Dept Psychiat, Nijmegen, Netherlands. [Jagodzinski, Pawel P.; Kempisty, Bartosz] Univ Med Sci, Dept Biochem & Mol Biol, Poznan, Poland. [Hauser, Joanna] Karol Marcinkowski Univ Med Sci, Dept Psychiat, Lab Psychiat Genet, Poznan, Poland. [Vilella, Elisabet] Univ Rovira & Virgili, Inst Pere Mata, IISPV, Psychiat Univ Hosp, E-43201 Reus, Spain. [Betcheva, Elitza] Med Univ, Dept Med Genet, Sofia, Bulgaria. [Nakamura, Yusuke] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo, Japan. [Regland, Bjorn] Gothenburg Univ, Inst Clin Neurosci, Gothenburg, Sweden. [Agartz, Ingrid] Diakonhjemmet Hosp, Dept Psychiat Res, Oslo, Norway. [Hall, Hakan] Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden. RP Jonsson, EG (reprint author), Karolinska Hosp & Inst, Dept Clin Neurosci, HUBIN Project, R5 00, SE-17176 Stockholm, Sweden. EM erik.jonsson@ki.se RI Muntjewerff, Jan-Willem/J-6361-2012; Muntjewerff, J.W./L-4537-2015; OI Agartz, Ingrid/0000-0002-9839-5391; Jonsson, Erik/0000-0001-8368-6332; Andreassen, Ole A./0000-0002-4461-3568 FU Pozan University Medical Sciences [502-01-01124182-07474]; Copenhagen Hospital; Danish National Psychiatric Research Foundation; Danish Agency for Science, and Technology and Innovation (Centre for Pharmacogenetics); Research Council of Norway [163070/V50, 167153/V50]; South-Eastern Norway Health Authority [123/2004]; Oslo University Hospital; University of Oslo; Swedish Research Council [2006-2992, 2006-986, 2008-2167]; Stockholm County Council; Karolinska Institutet; Knut and Alice Wallenberg Foundation; HUBIN project FX Grant sponsor: Pozan University Medical Sciences; Grant number: 502-01-01124182-07474; Grant sponsor: Copenhagen Hospital Corporation Research Fund; Grant sponsor: Danish National Psychiatric Research Foundation; Grant sponsor: Danish Agency for Science, and Technology and Innovation (Centre for Pharmacogenetics); Grant sponsor: Research Council of Norway; Grant numbers: 163070/V50, 167153/V50; Grant sponsor: South-Eastern Norway Health Authority; Grant number: 123/2004; Grant sponsor: Oslo University Hospital; Grant sponsor: University of Oslo; Grant sponsor: Swedish Research Council; Grant numbers: 2006-2992, 2006-986, 2008-2167; Grant sponsor: Regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet; Grant sponsor: Knut and Alice Wallenberg Foundation.; This study was financed in Polen by Poznan University Medical Sciences (502-01-01124182-07474), in Denmark from the Copenhagen Hospital Corporation Research Fund, the Danish National Psychiatric Research Foundation, the Danish Agency for Science, and Technology and Innovation (Centre for Pharmacogenetics), in Norway from the Research Council of Norway (163070/V50, 167153/V50), the South-Eastern Norway Health Authority (123/2004), Oslo University Hospital, and University of Oslo, and in Sweden from the Swedish Research Council (2006-2992, 2006-986, 2008-2167), the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet, the Knut and Alice Wallenberg Foundation, and the HUBIN project. The funding sources had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 71 TC 12 Z9 12 U1 1 U2 6 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4841 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD MAR PY 2011 VL 156B IS 2 BP 215 EP 224 DI 10.1002/ajmg.b.31160 PG 10 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 718VQ UT WOS:000287154900011 PM 21302350 ER PT J AU Shen, YP Chen, XL Wang, LW Guo, J Shen, JL An, Y Zhu, HT Zhu, YL Xin, RL Bao, YH Gusella, JF Zhang, T Wu, BL AF Shen, Yiping Chen, Xiaoli Wang, Liwen Guo, Jin Shen, Jianliang An, Yu Zhu, Haitao Zhu, Yanli Xin, Ruolei Bao, Yihua Gusella, James F. Zhang, Ting Wu, Bai-Lin TI Intra-Family Phenotypic Heterogeneity of 16p11.2 Deletion Carriers in a Three-Generation Chinese Family SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE 16p11.2 microdeletion; phenotypic heterogeneity; autism spectrum disorders (ASD); Chinese ID MENTAL-RETARDATION; CANDIDATE GENES; MICRODELETION; AUTISM; REARRANGEMENTS; INDIVIDUALS; DISORDER; OBESITY AB The 16p11.2 deletion is a recurrent genomic event and a significant risk factor for autism spectrum disorders (ASD). This genomic disorder also exhibits extensive phenotypic variability and diverse clinical phenotypes. The full extent of phenotypic heterogeneity associated with the 16p11.2 deletion disorder and the factors that modify the clinical phenotypes are currently unknown. Multiplex families with deletion offer unique opportunities for exploring the degree of heterogeneity and implicating modifiers. Here we reported the clinical and genomic characteristics of three 16p11.2 deletion carriers in a Chinese family. The father carries a de novo 16p11.2 deletion, and it was transmitted to the proband and sib. The proband presented with ASD, intellectual disability, learning difficulty, congenital malformations such as atrial septal defect, scoliosis. His dysmorphic features included myopia and strabismus, flat and broad nasal bridge, etc. While the father shared same neurodevelopmental problems as the proband, the younger brother did not show many of the proband's phenotypes. The possible unmasked mutation of TBX6 and MVP gene in this deleted region and the differential distribution of other genomic CNVs were explored to explain the phenotypic heterogeneity in these carriers. This report demonstrated the different developmental trajectory and discordant phenotypes among family members with the same 16p11.2 deletion, thus further illustrated the phenotypic complexity and heterogeneity of the 16p11.2 deletion. (C) 2010 Wiley-Liss, Inc. C1 [Shen, Yiping; Chen, Xiaoli; Wu, Bai-Lin] Childrens Hosp Boston, Dept Lab Med, Boston, MA USA. [Shen, Yiping; Chen, Xiaoli; Gusella, James F.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Shen, Yiping; Gusella, James F.; Wu, Bai-Lin] Harvard Univ, Sch Med, Boston, MA USA. [Shen, Yiping; Gusella, James F.; Wu, Bai-Lin] Autism Consortium, Boston, MA USA. [Chen, Xiaoli; Guo, Jin; Bao, Yihua; Zhang, Ting] Capital Inst Pediat, Dept Mol Immunol, Beijing, Peoples R China. [Wang, Liwen; Zhu, Yanli] Capital Inst Pediat, Dept Neurol, Affiliated Childrens Hosp, Beijing, Peoples R China. [Shen, Jianliang] Navy Gen Hosp PLA, Dept Hematol, Beijing, Peoples R China. [An, Yu; Zhu, Haitao; Zhang, Ting; Wu, Bai-Lin] Fudan Univ, Childrens Hosp, Shanghai 200433, Peoples R China. [An, Yu; Zhu, Haitao; Wu, Bai-Lin] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China. [Xin, Ruolei] Beijing Ctr Dis Control & Prevent, Inst STD AIDS Prevent & Control, Beijing, Peoples R China. RP Zhang, T (reprint author), Fudan Univ, Childrens Hosp, Shanghai 200433, Peoples R China. EM zhangtingcv@yahoo.com.cn; Bai-Lin.Wu@childrens.harvard.edu FU Chinese National "973" project on Population and Health [2010CB529601, 2007CB511901]; Science and Technology Council of Shanghai [09JC1402400, 09ZR1404500]; Ministry of Science and Technology of the P.R. China; Simons Foundation Autism Research Initiative; Autism Speaks; NIH; NIH [GM061354] FX Grant sponsor: Chinese National "973" project on Population and Health; Grant Number: 2010CB529601 (Wu B-L) and 2007CB511901 (Zhang T); Grant sponsor: Science and Technology Council of Shanghai; Grant Number: 09JC1402400 (Wu B-L) and 09ZR1404500 (An Y).; We appreciated the patient and his parents for their collaboration and permission, which make detailed clinical information and photography available here. This work was jointly supported by the Ministry of Science and Technology of the P.R. China, National "973" project on Population and Health (2010CB529601 to B.L.W.; 2007CB511901 to T.Z.); the Science and Technology Council of Shanghai (09JC1402400 to B.L.W.; 09ZR1404500 to YA.) J.F.G. is supported by Simons Foundation Autism Research Initiative, Autism Speaks and NIH grant (GM061354). NR 21 TC 14 Z9 16 U1 0 U2 10 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4841 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD MAR PY 2011 VL 156B IS 2 BP 225 EP 232 DI 10.1002/ajmg.b.31147 PG 8 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 718VQ UT WOS:000287154900012 PM 21302351 ER PT J AU Chang, SC Pauls, DL Lange, C Sasanfar, R Santangelo, SL AF Chang, Shun-Chiao Pauls, David L. Lange, Christoph Sasanfar, Roksana Santangelo, Susan L. TI Common Genetic Variation in the GAD1 Gene and the Entire Family of DLX Homeobox Genes and Autism Spectrum Disorders SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE autism spectrum disorder; genetic association; candidate gene study; DLX homeobox; GAD1 ID RECEPTOR SUBUNIT GENES; SINGLE-NUCLEOTIDE POLYMORPHISMS; GLUTAMIC-ACID DECARBOXYLASE; CHROMOSOME 7Q; GLUTAMATE-RECEPTOR-6 GENE; CANDIDATE GENES; ASSOCIATION; LINKAGE; SUSCEPTIBILITY; TWIN AB Biological and positional evidence supports the involvement of the GAD1 and distal-less homeobox genes (DLXs) in the etiology of autism. We investigated 42 single nucleotide polymorphisms in these genes as risk factors for autism spectrum disorders (ASD) in a large family-based association study of 715 nuclear families. No single marker showed significant association after correction for multiple testing. A rare haplotype in the DLX1 promoter was associated with ASD (P-value = 0.001). Given the importance of rare variants to the etiology of autism revealed in recent studies, the observed rare haplotype may be relevant to future investigations. Our observations, when taken together with previous findings, suggest that common genetic variation in the GAD1 and DLX genes is unlikely to play a critical role in ASD susceptibility. (C) 2010 Wiley-Liss, Inc. C1 [Pauls, David L.; Sasanfar, Roksana; Santangelo, Susan L.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Boston, MA 02114 USA. [Chang, Shun-Chiao; Pauls, David L.; Santangelo, Susan L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Lange, Christoph] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Pauls, David L.; Sasanfar, Roksana; Santangelo, Susan L.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Lange, Christoph] Brigham & Womens Hosp, Channing Labs, Boston, MA 02115 USA. RP Santangelo, SL (reprint author), Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, MGH Simches Res Bldg,185 Cambridge St,CPZN 6-256, Boston, MA 02114 USA. EM ssantangelo@pngu.mgh.harvard.edu FU National Alliance for Autism Research Pre-Doctoral Mentor-based Training Fellowship; Autism Speaks; AGRE consortium; National Institute of Mental Health [1U24MH081810] FX Grant sponsor: National Alliance for Autism Research Pre-Doctoral Mentor-based Training Fellowship.; This work was supported by National Alliance for Autism Research (now merged with Autism Speaks) Pre-doctoral Mentor-based Training Fellowship. We gratefully acknowledge support from Autism Speaks and the resources provided by the AGRE consortium and the participating AGRE families. The Autism Genetic Resource Exchange (AGRE) is a program of Autism Speaks and is supported, in part, by grant 1U24MH081810 from the National Institute of Mental Health to Clara M. Lajonchere (PI). NR 54 TC 8 Z9 8 U1 3 U2 12 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4841 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD MAR PY 2011 VL 156B IS 2 BP 233 EP 239 DI 10.1002/ajmg.b.31148 PG 7 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 718VQ UT WOS:000287154900013 PM 21302352 ER PT J AU Crepel, A Steyaert, J De la Marche, W De Wolf, V Fryns, JP Noens, I Devriendt, K Peeters, H AF Crepel, An Steyaert, Jean De la Marche, Wouter De Wolf, Veerle Fryns, Jean-Pierre Noens, Ilse Devriendt, Koen Peeters, Hilde TI Narrowing the Critical Deletion Region for Autism Spectrum Disorders on 16p11.2 SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Letter ID PTEN; INDIVIDUALS; PARTICLES; PROTEIN C1 [Crepel, An; De Wolf, Veerle; Fryns, Jean-Pierre; Devriendt, Koen; Peeters, Hilde] Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium. [Steyaert, Jean; De la Marche, Wouter] UPC KU Leuven, Dept Child & Adolescent Psychiat, Louvain, Belgium. [Steyaert, Jean] Maastricht Univ, Res Inst Growth & Dev GROW, Maastricht, Netherlands. [Steyaert, Jean] Univ Limburg, Acad Hosp Maastricht, Dept Clin Genet, Maastricht, Netherlands. [Noens, Ilse] Univ Leuven, Dept Educ Sci, Ctr Parenting Child Welf & Disabil, B-3000 Louvain, Belgium. [Noens, Ilse] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. RP Peeters, H (reprint author), Univ Leuven, Ctr Human Genet, Herestr 49, B-3000 Louvain, Belgium. EM hilde.peeters@med.kuleuven.be RI Steyaert, Jean/B-5326-2015 OI Steyaert, Jean/0000-0003-2512-4694 NR 13 TC 16 Z9 17 U1 0 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4841 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD MAR PY 2011 VL 156B IS 2 BP 243 EP 245 DI 10.1002/ajmg.b.31163 PG 3 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 718VQ UT WOS:000287154900015 PM 21302354 ER PT J AU Atassi, N Cook, A Pineda, CME Yerramilli-Rao, P Pulley, D Cudkowicz, M AF Atassi, Nazem Cook, Amanda Pineda, Cristiana M. E. Yerramilli-Rao, Padmaja Pulley, Darlene Cudkowicz, Merit TI Depression in amyotrophic lateral sclerosis SO AMYOTROPHIC LATERAL SCLEROSIS LA English DT Article DE ALS; depression; management; symptomatic; enrollment ID QUALITY-OF-LIFE; CLINICAL-TRIALS; ALS; PREVALENCE; RECRUITMENT; EXPERIENCE; ENROLLMENT; DISORDERS; CANCER AB Depression is an under-recognized comorbidity associated with amyotrophic lateral sclerosis (ALS). The goals of this study were to prospectively estimate the prevalence of depression and other ALS related symptoms and to study the impact of depression on enrollment in research studies. One hundred and twenty-seven people with ALS completed the ALS Depression Inventory (ADI-12) and answered questions about ALS related symptoms and research study enrollment preferences. Demographics, ALS symptoms, medications, functional status, and research enrollment were compared between depressed and non-depressed patients. Results showed that the prevalence of mild and severe depression was 29% and 6%, respectively. More than one-third of our ALS patients were receiving anti-depressants to treat depression, sialorrhea, and pseudobulbar affect. Depression prevalence was not correlated with disease duration or progression. Except for anxiety, none of the ALS related symptoms predicted depression. The presence of depression did not have an effect on the decision to enroll in research studies. In conclusion, major depression is less common in our ALS cohort than in the general population. The diagnosis of depression can be masked by some ALS related symptoms and it has no impact on enrollment in ALS clinical trials. C1 [Atassi, Nazem; Cook, Amanda; Pineda, Cristiana M. E.; Yerramilli-Rao, Padmaja; Pulley, Darlene; Cudkowicz, Merit] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Atassi, N (reprint author), Massachusetts Gen Hosp, NCTU, 13th St,Bldg 149,Room 2274, Charlestown, MA 02129 USA. EM NATASSI@PARTNERS.ORG FU DiGiovanni MGH ALS; Scholars in Clinical Science Program (SCSP) of Harvard Catalyst; Harvard Clinical and Translational Science Center; Harvard University; affiliated academic health centers; [NIH-T32NS0498005] FX We would like to thank the participants in this study and DiGiovanni MGH ALS research fund. This work was conducted with support from NIH-T32NS0498005 and the Scholars in Clinical Science Program (SCSP) of Harvard Catalyst, the Harvard Clinical and Translational Science Center and financial contributions from Harvard University and its affiliated academic health centers. NR 17 TC 29 Z9 30 U1 0 U2 6 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1748-2968 J9 AMYOTROPH LATERAL SC JI Amyotroph. Lateral. Scler. PD MAR PY 2011 VL 12 IS 2 BP 109 EP 112 DI 10.3109/17482968.2010.536839 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 722AU UT WOS:000287402100005 PM 21091399 ER PT J AU Korcheva, VB Levine, J Beadling, C Warrick, A Countryman, G Olson, NR Heinrich, MC Corless, CL Troxell, ML AF Korcheva, Veselina B. Levine, Judith Beadling, Carol Warrick, Andrea Countryman, Gayle Olson, Neal R. Heinrich, Michael C. Corless, Christopher L. Troxell, Megan L. TI Immunohistochemical and Molecular Markers in Breast Phyllodes Tumors SO APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY LA English DT Article DE breast; phyllodes; MDM2; TP53; phospho-H3; KIT; FBX4; cyclin D1 ID COMPARATIVE GENOMIC HYBRIDIZATION; P53 PROTEIN EXPRESSION; SPINDLE-CELL CARCINOMA; F-BOX PROTEINS; C-KIT; FIBROEPITHELIAL LESIONS; CYSTOSARCOMA-PHYLLODES; COPY NUMBER; MUTATIONS; FEATURES AB Phyllodes tumors of the breast are diagnostically and managerially enigmatic, as their malignant potential is difficult to predict based on the standard morphologic criteria. Thus, there is a need for additional markers of biologic potential. Although a number of ancillary tests have been reported, consensus in the literature is lacking. We studied 38 cellular fibroadenomas and phyllodes tumors of various grade (World Health Organization benign, borderline, and malignant) with a panel of immunohistochemical stains (p53, CD117, phospho-Histone3, mdm2, cdk4) and screened 26 of the tumors for mutations across 30 cancer-related genes using PCR and mass-spectrometry based methods. p53 and phospho-Histone3 (mitotic marker) showed increased staining in higher grade phyllodes tumors. CD117, mdm2, and cdk4 showed no difference in expression across different grades of phyllodes tumors. Mutational analysis revealed an S8R substitution in FBX4 (an E3 ubiquitin ligase) in 3 cases: 1 benign and 2 borderline. The S8R substitution seems to be more common in phyllodes tumors (11.5%) as compared with other cancers. FBX4 S8R cases had high cyclin D1 expression, but this finding was not specific. Our data support earlier studies showing that p53 has potential use in pathologic assessment of phyllodes tumors, and we newly characterized phospho-Histone3 for this application. Further studies are needed to characterize the molecular pathogenesis of the phyllodes tumors, as we were unable to identify activating mutations despite screening for a large panel of activating hotspot mutations. The significance of the FBX4 substitution deserves further investigation. C1 [Korcheva, Veselina B.; Corless, Christopher L.; Troxell, Megan L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA. [Levine, Judith; Beadling, Carol; Warrick, Andrea; Countryman, Gayle; Heinrich, Michael C.; Corless, Christopher L.; Troxell, Megan L.] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Portland, OR 97239 USA. [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA. [Olson, Neal R.] Kaiser Permanente NW, Dept Pathol, Portland, OR USA. [Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA. RP Troxell, ML (reprint author), Oregon Hlth & Sci Univ, Dept Pathol, L471,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM troxellm@ohsu.edu FU Department of Veteran's Affairs; Oregon Health & Science University Medical Research Foundation; Sequenom, Inc. FX Supported in part by a VA Merit Review Grant from the Department of Veteran's Affairs (M.C.H.) and by a grant from the Oregon Health & Science University Medical Research Foundation (M.L.T). C.L.C. has received honoraria and research support from Sequenom, Inc. NR 43 TC 17 Z9 17 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1062-3345 J9 APPL IMMUNOHISTO M M JI Appl. Immunohistochem. PD MAR PY 2011 VL 19 IS 2 BP 119 EP 125 DI 10.1097/PAI.0b013e3181f5349a PG 7 WC Anatomy & Morphology; Medical Laboratory Technology; Pathology SC Anatomy & Morphology; Medical Laboratory Technology; Pathology GA 719GO UT WOS:000287190000006 PM 21030860 ER PT J AU Shin, JM Vagin, O Munson, K Kidd, M Modlin, IM Sachs, G AF Shin, J. M. Vagin, O. Munson, K. Kidd, M. Modlin, I. M. Sachs, G. TI Molecular mechanisms in therapy of acid-related diseases (vol 65, pg 264, 2008) SO CELLULAR AND MOLECULAR LIFE SCIENCES LA English DT Correction C1 [Shin, J. M.; Vagin, O.; Munson, K.; Sachs, G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. [Shin, J. M.; Vagin, O.; Munson, K.; Sachs, G.] VA Greater Los Angeles Healthcare Syst, W LA Med Ctr, Los Angeles, CA 90073 USA. [Kidd, M.; Modlin, I. M.] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA. RP Sachs, G (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. EM gsachs@ucla.edu NR 1 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER BASEL AG PI BASEL PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND SN 1420-682X EI 1420-9071 J9 CELL MOL LIFE SCI JI Cell. Mol. Life Sci. PD MAR PY 2011 VL 68 IS 5 BP 921 EP 921 DI 10.1007/s00018-010-0621-2 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 719WY UT WOS:000287243400014 ER PT J AU Kim, SJ Giugliano, RP Jang, IK AF Kim, Soo-Joong Giugliano, Robert P. Jang, Ik-Kyung TI Adjunctive pharmacologic therapy in percutaneous coronary intervention: Part II anticoagulant therapy SO CORONARY ARTERY DISEASE LA English DT Article DE angioplasty; anticoagulant; antiplatelet therapy; antithrombotic therapy; platelet; thrombin ID FACTOR XA INHIBITOR; LOW-DOSE HEPARIN; ELEVATION MYOCARDIAL-INFARCTION; GLYCOPROTEIN-IIB/IIIA BLOCKADE; MOLECULAR-WEIGHT HEPARIN; 7TH ACCP CONFERENCE; UNFRACTIONATED HEPARIN; RANDOMIZED-TRIAL; DOUBLE-BLIND; INDUCED THROMBOCYTOPENIA AB Pharmacological adjuvant therapies to protect against procedure-related thrombotic complication are indispensable during percutaneous coronary intervention. In addition to antiplatelet therapy, use of anticoagulants to prevent acute thrombotic complication during percutaneous coronary intervention is essential. Besides unfractionated heparin (UFH), new anticoagulants have been developed and compared with UFH. Low-molecular weight heparins, direct thrombin inhibitors (e. g. bivalirudin), and recently developed agents such as fondaparinux (a factor Xa inhibitor) provide new alternatives to conventional UFH. Coron Artery Dis 22:113-121 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02114 USA. [Kim, Soo-Joong] Kyung Hee Univ, Med Ctr, Coll Med, Dept Cardiol, Seoul, South Korea. [Giugliano, Robert P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02114 USA. RP Jang, IK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, 55 Fruit St, Boston, MA 02114 USA. EM ijang@partners.org NR 54 TC 0 Z9 0 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0954-6928 J9 CORONARY ARTERY DIS JI Coronary Artery Dis. PD MAR PY 2011 VL 22 IS 2 BP 113 EP 121 DI 10.1097/01.mca.0000394697.74220.cd PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 719GD UT WOS:000287188700011 PM 21304293 ER PT J AU Shazly, TA AF Shazly, Tarek A. TI Ocular acid burn due to 20% concentrated salicylic acid SO CUTANEOUS AND OCULAR TOXICOLOGY LA English DT Article DE Ocular; trauma; salicylic acid; burn AB This is a case report of severe conjunctival and corneal epithelial defects resulting from accidental exposure to salicylic acid that was mistakenly used instead of artificial tears (eye drops). The patient was treated with tobramycin 0.3%--dexamethasone 1% 3 times a day, cyclopentolate 1% twice a day, and artificial tears 6 times a day and underwent daily examinations until the corneal and conjunctival epithelial defects resolved. The corneal and conjunctival epithelial defects slowly resolved over 14 days. Visual acuity improved to its preinjury level of 20/40 in the affected eye. No residual corneal scarring was evident. Slowly resolving corneal and conjunctival epithelial defects can occur from direct contact with salicylic acid; therefore, this medication should be packaged and labeled differently from eye drops.6 visits) nephrology care during this time period. Results: There were 8022 patients meeting inclusion criteria: 37% received no predialysis nephrology care, while 24% received low, 16% moderate, and 23% high-intensity predialysis nephrology care. During the year after dialysis initiation, patients in these groups spent an average of 52, 40, 31, and 27 days in the hospital (P < 0.001), respectively, and accounted for an average of $103,772, $96,390, $93,336, and $89,961 in total healthcare costs (P < 0.001), respectively. Greater intensity of predialysis nephrology care was associated with lower costs even among patients whose first predialysis nephrology visit was <= 3 months before dialysis initiation. Patients with greater predialysis nephrology care also had lower mortality rates during the year after dialysis initiation (43%, 38%, 28%, and 25%, respectively, P < 0.001). Conclusions: Greater intensity of predialysis nephrology care was associated with fewer hospital days and lower total healthcare costs during the year after dialysis initiation, even though patients survived longer. C1 [Stroupe, Kevin T.; Fischer, Michael J.; Sohn, Min-Woong; Browning, Margaret M.; Huo, Zhiping; Hynes, Denise M.] Hines VA Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA. [Stroupe, Kevin T.] Loyola Univ Chicago, Program Hlth Serv Res, Stritch Sch Med, Maywood, IL USA. [Stroupe, Kevin T.; Browning, Margaret M.; Hynes, Denise M.] VA Informat Resource Ctr, Hines, IL USA. [Fischer, Michael J.] Jesse Brown VA Med Ctr, Chicago, IL USA. [Fischer, Michael J.; Hynes, Denise M.] Univ Illinois, Dept Med, Chicago, IL USA. [Kaufman, James S.] VA Boston Healthcare Syst, Boston, MA USA. [Kaufman, James S.] Boston Univ, Dept Med, Boston, MA 02215 USA. [O'Hare, Ann M.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [O'Hare, Ann M.] Univ Washington, Dept Med, Seattle, WA USA. [O'Hare, Ann M.] Grp Hlth Res Inst, Seattle, WA USA. [Sohn, Min-Woong] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA. RP Stroupe, KT (reprint author), Hines VA Hosp, Ctr Management Complex Chron Care, 5000 S 5th Ave,151 H,Bldg 1B260, Hines, IL 60141 USA. EM kevin.stroupe@va.gov RI Sohn, Min-Woong/C-3560-2015 OI Sohn, Min-Woong/0000-0002-9474-2907 FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [VA HSRD IIR 02-244, IIR 20-016]; VA HSR&D Research Career Scientist Award; VA HSR&D Career Development Award; National Kidney Foundation of Illinois; NIH [K23AG28980] FX Supported by Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (VA HSR&D IIR 02-244 and IIR 20-016 [to K. T. S., D. M. H., and M. M. B.]; VA HSR&D Research Career Scientist Award [to D. M. H.]; VA HSR&D Career Development Award [to M. J. F.]) and the National Kidney Foundation of Illinois (to M. J. F.); NIH K23AG28980 (to A. M. O'H.). NR 47 TC 9 Z9 10 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD MAR PY 2011 VL 49 IS 3 BP 248 EP 256 DI 10.1097/MLR.0b013e31820192ba PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 719VT UT WOS:000287240300005 PM 21224743 ER PT J AU Ghogawala, Z Martin, B Benzel, EC Dziura, J Magge, SN Abbed, KM Bisson, EF Shahid, J Coumans, JVCE Choudhri, TF Steinmetz, MP Krishnaney, AA King, JT Butler, WE Barker, FG Heary, RF AF Ghogawala, Zoher Martin, Brook Benzel, Edward C. Dziura, James Magge, Subu N. Abbed, Khalid M. Bisson, Erica F. Shahid, Javed Coumans, Jean-Valery C. E. Choudhri, Tanvir F. Steinmetz, Michael P. Krishnaney, Ajit A. King, Joseph T., Jr. Butler, William E. Barker, Fred G., II Heary, Robert F. TI Comparative Effectiveness of Ventral vs Dorsal Surgery for Cervical Spondylotic Myelopathy SO NEUROSURGERY LA English DT Article DE Cervical spondylotic myelopathy; Clinical trial; Cost-effectiveness analysis; Outcomes ID SURGICAL-TREATMENT; HEALTH-CARE; CONTROLLED-TRIAL; NATIONAL TRENDS; SPINAL-FUSION; CORPECTOMY; COMPLICATIONS; DECOMPRESSION; OUTCOMES; GRAFT AB BACKGROUND: Cervical spondylotic myelopathy (CSM) is the most common cause of spinal cord dysfunction. OBJECTIVE: To determine the feasibility of a randomized clinical trial comparing the clinical effectiveness and costs of ventral vs dorsal decompression with fusion surgery for treating CSM. METHODS: A nonrandomized, prospective, clinical pilot trial was conducted. Patients ages 40 to 85 years with degenerative CSM were enrolled at 7 sites over 2 years (2007-2009). Outcome assessments were obtained preoperatively and at 3 months, 6 months, and 1 year postoperatively. A hospital-based economic analysis used costs derived from hospital charges and Medicare cost-to-charge ratios. RESULTS: The pilot study enrolled 50 patients. Twenty-eight were treated with ventral fusion surgery and 22 with dorsal fusion surgery. The average age was 61.6 years. Baseline demographics and health-related quality of life (HR-QOL) scores were comparable between groups; however, dorsal surgery patients had significantly more severe myelopathy (P<.01). Comprehensive 1-year follow-up was obtained in 46 of 50 patients (92%). Greater HR-QOL improvement (Short-Form 36 Physical Component Summary) was observed after ventral surgery (P =.05). The complication rate (16.6% overall) was comparable between groups. Significant improvement in the modified Japanese Orthopedic Association scale score was observed in both groups (P<.01). Dorsal fusion surgery had significantly greater mean hospital costs ($ 29 465 vs $ 19 245; P<.01) and longer average length of hospital stay (4.0 vs 2.6 days; P<.01) compared with ventral fusion surgery. CONCLUSION: Surgery for treating CSM was followed by significant improvement in disease-specific symptoms and in HR-QOL. Greater improvement in HR-QOL was observed after ventral surgery. Dorsal fusion surgery was associated with longer length of hospital stay and higher hospital costs. The pilot study demonstrated feasibility for a larger randomized clinical trial. C1 [Ghogawala, Zoher] Yale Univ, Wallace Clin Trials Ctr, Sch Med, Greenwich Hosp, Greenwich, CT 06830 USA. [Ghogawala, Zoher; Abbed, Khalid M.] Connecticut Spine Inst, Greenwich, CT USA. [Ghogawala, Zoher; Abbed, Khalid M.] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA. [Dziura, James] Yale Univ, Sch Med, Yale Ctr Clin Invest, New Haven, CT USA. [Martin, Brook] Dartmouth Coll, Hanover, NH 03755 USA. [Benzel, Edward C.; Steinmetz, Michael P.; Krishnaney, Ajit A.] Cleveland Clin Fdn, Ctr Spine Hlth, Cleveland, OH 44195 USA. [Benzel, Edward C.; Steinmetz, Michael P.; Krishnaney, Ajit A.] Cleveland Clin Fdn, Dept Neurosurg, Cleveland, OH 44195 USA. [Magge, Subu N.] Lahey Clin Fdn, Dept Neurosurg, Burlington, MA USA. [Bisson, Erica F.] Univ Utah, Hlth Sci Ctr, Dept Neurosurg, Salt Lake City, UT USA. [Shahid, Javed] Danbury Hosp, Dept Neurosurg, Danbury, CT USA. [Coumans, Jean-Valery C. E.; Butler, William E.; Barker, Fred G., II] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Choudhri, Tanvir F.] Mt Sinai Hosp, Dept Neurosurg, New York, NY 10029 USA. [King, Joseph T., Jr.] VA Connecticut Healthcare Syst, Neurosurg Sect, West Haven, CT USA. [Heary, Robert F.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosurg, Newark, NJ 07103 USA. RP Ghogawala, Z (reprint author), Yale Univ, Wallace Clin Trials Ctr, Sch Med, Greenwich Hosp, 5 Perryridge Rd, Greenwich, CT 06830 USA. EM zoher.ghogawala@yale.edu FU Jean and David Wallace Foundation [GH-382]; National Center for Research Resources, a component of the National Institutes of Health (NIH) [UL1 RR024146]; NIH Roadmap for Medical Research FX The study was supported by a research grant (GH-382) from the Jean and David Wallace Foundation (to Z.G., Greenwich Hospital). This study was additionally supported by Clinical and Translational Science Award grant number UL1 RR024146 (to Z.G., Yale University) from the National Center for Research Resources, a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article. NR 43 TC 36 Z9 40 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-396X J9 NEUROSURGERY JI Neurosurgery PD MAR PY 2011 VL 68 IS 3 BP 622 EP 630 DI 10.1227/NEU.0b013e31820777cf PG 9 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 719WN UT WOS:000287242300026 PM 21164373 ER PT J AU Lennerz, JKM Fernandez-Del Castillo, C Pitman, MB AF Lennerz, Jochen K. M. Fernandez-Del Castillo, Carlos Pitman, Martha B. TI Mixed Ductal-Endocrine Carcinoma of the Pancreas Metastatic to the Liver SO PANCREAS LA English DT Letter ID TUMORS; EXOCRINE C1 [Lennerz, Jochen K. M.; Pitman, Martha B.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Fernandez-Del Castillo, Carlos] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Lennerz, JKM (reprint author), Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. EM JLennerz@partners.org NR 9 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD MAR PY 2011 VL 40 IS 2 BP 319 EP 321 DI 10.1097/MPA.0b013e3181f891e7 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 719VN UT WOS:000287239700030 PM 21311316 ER PT J AU Chan, JA Ryan, DP Fuchs, CS Zhu, AX Abrams, TA Wolpin, BM Casey, C Regan, E Cavanaugh, K Kulke, MH AF Chan, Jennifer A. Ryan, David P. Fuchs, Charles S. Zhu, Andrew X. Abrams, Thomas A. Wolpin, Brian M. Casey, Carolyn Regan, Eileen Cavanaugh, Kristen Kulke, Matthew H. TI Phase I Study of Pasireotide (SOM230) in Combination With Everolimus (RAD001) in Patients With Advanced Neuroendocrine Tumors (NET) SO PANCREAS LA English DT Meeting Abstract C1 [Chan, Jennifer A.; Fuchs, Charles S.; Abrams, Thomas A.; Wolpin, Brian M.; Casey, Carolyn; Regan, Eileen; Cavanaugh, Kristen; Kulke, Matthew H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Chan, Jennifer A.; Fuchs, Charles S.; Abrams, Thomas A.; Wolpin, Brian M.; Kulke, Matthew H.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Ryan, David P.; Zhu, Andrew X.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD MAR PY 2011 VL 40 IS 2 BP 325 EP 325 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 719VN UT WOS:000287239700036 ER PT J AU Chan, JA Mayer, RJ Jackson, N Malinowski, P Regan, E Kulke, MH AF Chan, Jennifer A. Mayer, Robert J. Jackson, Nadine Malinowski, Paige Regan, Eileen Kulke, Matthew H. TI Phase I Study of Sorafenib in Combination With Everolimus (RAD001) in Patients With Advanced Neuroendocrine Tumors (NET) SO PANCREAS LA English DT Meeting Abstract C1 [Chan, Jennifer A.; Mayer, Robert J.; Jackson, Nadine; Malinowski, Paige; Regan, Eileen; Kulke, Matthew H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Chan, Jennifer A.; Mayer, Robert J.; Jackson, Nadine; Kulke, Matthew H.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD MAR PY 2011 VL 40 IS 2 BP 326 EP 326 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 719VN UT WOS:000287239700037 ER EF